<SEC-DOCUMENT>0001104659-15-033863.txt : 20150505
<SEC-HEADER>0001104659-15-033863.hdr.sgml : 20150505
<ACCEPTANCE-DATETIME>20150505060100
ACCESSION NUMBER:		0001104659-15-033863
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		11
CONFORMED PERIOD OF REPORT:	20150331
FILED AS OF DATE:		20150505
DATE AS OF CHANGE:		20150505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PTC THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001070081
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043416587
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35969
		FILM NUMBER:		15830337

	BUSINESS ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449
		BUSINESS PHONE:		9082227000

	MAIL ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTC THERAPEUTICS INC
		DATE OF NAME CHANGE:	19980909
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>a15-7157_110q.htm
<DESCRIPTION>10-Q
<TEXT>


<html>
<head>


  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;10-Q</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:3.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(Mark One)</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:3.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:12.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><b><font size="3" face="Wingdings" style="font-size:12.0pt;font-weight:bold;">x</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160; </font>QUARTERLY REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">For the quarterly period ended March&nbsp;31, 2015</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OR</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:12.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><b><font size="3" face="Wingdings" style="font-size:12.0pt;font-weight:bold;">o</font>&#160; TRANSITION REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160; </font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Commission file number: 001-35969</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">PTC Therapeutics,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of registrant as specified in its charter)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">04-3416587</font></b></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or other jurisdiction of incorporation or organization)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(I.R.S. Employer Identification <br>   Number)</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">100 Corporate Court<br>   South Plainfield, NJ</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">07080</font></b></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal executive offices)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Zip Code)</font></p>    </td>   </tr>  </table>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(908) 222-7000</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Registrant&#146;s telephone number, including area code)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d)&nbsp;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90 days.&#160; Yes </font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font><font size="2" style="font-size:10.0pt;">&#160;&#160; No </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&nbsp;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160; Yes </font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160; No </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer&#148;, &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule&nbsp;12b-2 of the Exchange Act.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Large accelerated filer </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accelerated filer </font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Non-accelerated filer </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;"><br> &nbsp;(Do not check if a smaller reporting   company)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Smaller reporting company </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>    </td>   </tr>  </table>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2 of the Exchange Act).&#160; Yes </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160; No </font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of April&nbsp;30, 2015 there were 33,848,276 shares of Common Stock, $0.001 par value per share, outstanding.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105733\15-7157-1\task7388916\7157-1-ba.htm',USER='105733',CD='May  5 00:13 2015' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><a name="TableOfContents"></a><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TABLE OF CONTENTS</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="94%" valign="bottom" style="padding:0in 0in 0in 0in;width:94.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;"><a href="#PartifinancialInformation_112559" title="Click to goto ">PART&nbsp;I&#151;FINANCIAL&nbsp;INFORMATION</a></font></b></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.38%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.62%;">
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1_FinancialStatements__112626" title="Click to goto ">Item   1. Financial Statements</a></font></u></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item2_ManagementsDiscussionAndAna_123154" title="Click to goto ">Item 2. Management&#146;s Discussion and Analysis of   Financial Condition and Results of Operations</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item3_QuantitativeAndQualitativeD_124213" title="Click to goto ">Item 3. Quantitative and Qualitative Disclosures About   Market Risk</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item4_ControlsAndProcedures__124214" title="Click to goto ">Item 4. Controls and Procedures</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;"><a href="#PartiiotherInformation_124548" title="Click to goto ">PART&nbsp;II&#151;OTHER INFORMATION</a></font></b></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1_LegalProceedings__124549" title="Click to goto ">Item   1. Legal Proceedings</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1a_RiskFactors_124550" title="Click to goto ">Item   1A. Risk Factors</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item2_UnregisteredSalesOfEquitySe_130744" title="Click to goto ">Item 2. Unregistered Sales of Equity Securities and   Use of Proceeds</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">71</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item6_Exhibits__130851" title="Click to goto ">Item 6.   Exhibits</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">72</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_111543_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\108224\15-7157-1\task7384386\7157-1-bg.htm',USER='108224',CD='May  1 21:11 2015' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FORWARD-LOOKING STATEMENTS</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Quarterly Report on Form10-Q contains forward looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Quarterly Report on Form10-Q, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward looking statements. The words &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;might,&#148; &#147;plan,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;target,&#148; &#147;potential,&#148; &#147;will,&#148; &#147;would,&#148; &#147;could,&#148; &#147;should,&#148; &#147;continue,&#148; and similar expressions are intended to identify forward looking statements, although not all forward looking statements contain these identifying words.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The forward looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the timing and conduct of our clinical trials and studies of Translarna&#153; (ataluren) for the treatment of Duchenne muscular dystrophy, cystic fibrosis, mucopolysaccharidosis type I, or MPS I, and aniridia, caused by nonsense mutations, as well as our studies in spinal muscular atrophy and our cancer stem cell program, including statements regarding the timing of initiation, enrollment and completion of the trials and the period during which the results of the trials will become available;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the rate and degree of market acceptance and clinical utility of Translarna;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to commercialize Translarna in general, and specifically as a treatment for Duchenne muscular dystrophy caused by nonsense mutations, or nmDMD, including the timing of such commercialization and our ability to successfully negotiate adequate pricing and reimbursement processes on a timely basis, or at all, in the countries in which we may obtain regulatory approval, including the countries in the European Economic Area;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the timing of and our ability to obtain additional marketing authorization of Translarna and our other product candidates, and the ability of Translarna and our other product candidates to meet existing or future regulatory standards;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to obtain additional and maintain existing reimbursed named patient and cohort early access programs on adequate terms;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our estimates regarding the potential market opportunity for Translarna, including the size of eligible patient populations and our ability to identify such patients;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to expand the approved product label of Translarna for the treatment of nmDMD;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the timing and scope of our commercial infrastructure expansion, including the growth of our international presence in Europe and in other territories;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the potential receipt of revenues from future sales of Translarna and other product candidates, including our ability to earn a profit from sales or licenses of Translarna for the treatment of nmDMD;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our sales, marketing and distribution capabilities and strategy, including the ability of our third party manufacturers to manufacture and deliver Translarna in commercially sufficient quantities and the ability of distributors to process orders in a timely manner and satisfy its other obligations to us;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to establish and maintain arrangements for the manufacture of Translarna and our other product candidates that are sufficient to meet clinical trial and commercial launch requirements;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our plans to pursue development of Translarna for additional indications other than Duchenne muscular dystrophy, cystic fibrosis, MPS I, and aniridia, caused by nonsense mutations;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_111833_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\108699\15-7157-1\task7385496\7157-1-bi.htm',USER='108699',CD='May  2 04:15 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to maintain the marketing authorization of Translarna for the treatment of nmDMD in the European Economic Area, which is conditioned upon completion of our Phase 3 confirmatory trial in nmDMD, among other things, and subject to annual review and renewal by the EMA following its reassessment of the risk benefit balance of the authorization;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to advance our earlier stage programs, including our antibacterial program;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our plans to pursue research and development of other product candidates;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the potential advantages of Translarna;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our estimates regarding expenses, future revenues, capital requirements and needs for additional financing, including our ability to maintain the level of our expenses consistent with our internal budgets and forecasts and to secure additional funds on favorable terms or at all;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our intellectual property position;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the impact of government laws and regulations;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our competitive position; and</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our expectations with respect to the development and regulatory status of our product candidate and program directed against spinal muscular atrophy in collaboration with F. Hoffmann La Roche Ltd and Hoffmann La Roche Inc., which we refer to collectively as Roche, and the Spinal Muscular Atrophy Foundation, or the SMA Foundation, and our estimates regarding future revenues from achievement of milestones in that program.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may not actually achieve the plans, intentions or expectations disclosed in our forward looking statements, and you should not place undue reliance on our forward looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report on Form&nbsp;10-Q, particularly in Part&nbsp;II,&nbsp;Item 1A. Risk Factors that we believe could cause actual results or events to differ materially from the forward looking statements that we make. Our forward looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You should read this Quarterly Report on Form&nbsp;10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form&nbsp;10-Q and our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2014 completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In this Quarterly Report on Form&nbsp;10-Q, unless otherwise stated or the context otherwise requires, references to &#147;PTC,&#148; &#147;PTC Therapeutics,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; and similar references refer to PTC Therapeutics,&nbsp;Inc. and, where appropriate, its subsidiaries. The trademarks, trade names and service marks appearing in this Quarterly Report on Form&nbsp;10-Q are the property of their respective owners.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="PB_4_111912_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\108699\15-7157-1\task7385496\7157-1-bi.htm',USER='108699',CD='May  2 04:15 2015' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PART&nbsp;I&#151;FINANCIAL INFORMATION</font></b><a name="PartifinancialInformation_112559"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 1. Financial Statements.</font></b><a name="Item1_FinancialStatements__112626"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PTC Therapeutics,&nbsp;Inc.</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Consolidated Balance Sheets (unaudited)</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">In thousands (except per share data)</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">March</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">31,&nbsp;2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">December&nbsp;<br>   31,<br>   2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Assets</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Current assets:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash equivalents </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36,825</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">49,748</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Marketable securities </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">243,642</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">265,493</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prepaid expenses and other   current assets </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,116</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,885</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Receivables, net </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,178</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,445</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total current assets </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">289,761</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">323,571</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fixed assets, net </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,408</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,159</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Deposits and other assets </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">351</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">489</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total assets </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">299,520</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">333,219</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Liabilities   and stockholders&#146; equity</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Current liabilities:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accounts payable and accrued   expenses </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23,532</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29,121</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Deferred revenue </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">373</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,354</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total current liabilities </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23,905</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32,475</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other long-term liabilities </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,295</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,277</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total liabilities </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26,200</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">34,752</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common stock, $0.001 par   value. Authorized 125,000,000 shares; issued and outstanding </font><font size="2" style="font-size:10.0pt;">33,483,306 </font><font size="2" style="font-size:10.0pt;">shares at   March&nbsp;31, 2015. Authorized 125,000,000 shares; issued and outstanding   32,898,392 shares at December&nbsp;31, 2014 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Additional paid-in capital </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">734,489</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">721,722</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accumulated other   comprehensive loss </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(736</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(737</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accumulated deficit </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(460,466</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(422,551</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total stockholders&#146; equity </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">273,320</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">298,467</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total liabilities and   stockholders&#146; equity </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">299,520</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">333,219</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">See accompanying unaudited notes.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5<a name="PB_5_112152_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\108699\15-7157-1\task7385496\7157-1-fa.htm',USER='108699',CD='May  2 04:28 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PTC Therapeutics,&nbsp;Inc.</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Consolidated Statements of Operations (unaudited)</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">In thousands (except per share data)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="66%" valign="bottom" style="padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="30%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:30.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>   March&nbsp;31</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="66%" valign="bottom" style="padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="66%" valign="bottom" style="padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="66%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Revenues:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="66%" valign="bottom" style="padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net product revenue </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,069</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="66%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Collaboration revenue</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">338</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,147</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="66%" valign="bottom" style="padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Grant revenue </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,075</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">70</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="66%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total revenues </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7,482</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,217</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="66%" valign="bottom" style="padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Operating expenses:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="66%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27,938</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15,889</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="66%" valign="bottom" style="padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Selling, general and administrative   </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17,615</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7,540</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="66%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total operating expenses </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">45,553</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23,429</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="66%" valign="bottom" style="padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Loss from operations </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(38,071</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(14,212</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="66%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest income </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">524</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">171</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="66%" valign="bottom" style="padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other (expense) income, net </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(368</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(57</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="66%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(37,915</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(14,098</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="66%" valign="bottom" style="padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="66%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Weighted-average shares   outstanding:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="66%" valign="bottom" style="padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Basic and diluted (in   shares) </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33,067,752</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24,492,487</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="66%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss per share&#151;basic and   diluted (in dollars per share) </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1.15</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(0.58</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">See accompanying unaudited notes.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6<a name="PB_6_112320_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='6',FILE='C:\JMS\108699\15-7157-1\task7385496\7157-1-fa.htm',USER='108699',CD='May  2 04:28 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PTC Therapeutics,&nbsp;Inc.</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Consolidated Statements of Comprehensive Loss (unaudited)</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">In thousands</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(37,915</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(14,098</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other comprehensive loss:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unrealized gain on   marketable securities </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">125</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Foreign currency translation   loss</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(124</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Comprehensive loss </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(37,914</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(14,088</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">See accompanying unaudited notes.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7<a name="PB_7_112410_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='7',FILE='C:\JMS\108699\15-7157-1\task7385496\7157-1-fa.htm',USER='108699',CD='May  2 04:28 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PTC Therapeutics,&nbsp;Inc.</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Consolidated Statements of Cash Flows (unaudited)</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">In thousands</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;<br>   31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Cash   flows from operating activities</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(37,915</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(14,098</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adjustments to reconcile net   loss to net cash used in operating activities:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Depreciation </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">634</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">588</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Change in valuation of   warrant liability </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">41</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">55</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amortization of premiums on   investments </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">486</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">414</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Share-based compensation   expense </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,748</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,705</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Changes in operating assets   and liabilities:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prepaid expenses and other   current assets </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2,231</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(358</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Receivables </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,267</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">120</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Deposits and other assets </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">138</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accounts payable and accrued   expenses </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5,589</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,472</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other long-term liabilities </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(23</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(23</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Deferred revenue </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2,981</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(386</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash used in operating   activities </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(36,425</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(13,438</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Cash   flows from investing activities</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Purchases of fixed assets </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(883</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(186</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Purchases of marketable   securities </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(19,108</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(25,354</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sale&nbsp;&amp; redemption   of marketable securities </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40,598</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21,273</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash provided/(used in)   investing activities </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20,607</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4,267</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Cash   flows from financing activities</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Payments on long-term debt </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(37</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proceeds from exercise of   options </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,019</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net proceeds from public   offerings </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">118,183</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash provided by   financing activities </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,019</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">118,146</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Effect of exchange rate changes   on cash</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(124</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net increase/(decrease) in   cash and cash equivalents </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(12,923</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">100,441</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash equivalents,   beginning of period </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">49,748</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15,414</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash equivalents,   end of period </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36,825</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">115,855</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Supplemental   disclosure of cash information</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash paid for interest </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Supplemental   disclosures of non-cash information related to investing and financing   activities</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Change in unrealized gain   (loss) on marketable securities </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">125</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">See accompanying unaudited notes.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8<a name="PB_8_112546_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='8',FILE='C:\JMS\108699\15-7157-1\task7385496\7157-1-fa.htm',USER='108699',CD='May  2 04:28 2015' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PTC Therapeutics,&nbsp;Inc.</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Notes to Consolidated Financial Statements (unaudited) </font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">March&nbsp;31, 2015</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">In thousands (except per share data unless otherwise noted)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">The Company</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">PTC Therapeutics,&nbsp;Inc. (the Company or PTC) was incorporated as a Delaware corporation on March&nbsp;31, 1998. PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics targeting an area of RNA biology referred to as post-transcriptional control. The letters &#147;PTC&#148; in the corporate name are an acronym for post-transcriptional control processes, which are the regulatory events that occur in cells during and after a messenger RNA is copied from DNA through the transcription process. The Company has discovered all of its compounds currently under development using its proprietary technologies. The Company plans to continue to develop these compounds both on its own and through selective collaboration arrangements with leading pharmaceutical and biotechnology companies. The Company believes that systematically targeting post-transcriptional control processes represents an unexploited approach to drug discovery and development. The Company&#146;s internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company&#146;s lead product, Translarna&#153; (ataluren) received marketing authorization from the European Commission, or EC, in August&nbsp;2014 for the treatment of nonsense mutation Duchenne muscular dystrophy, or nmDMD, in ambulatory patients age 5 years and over in the 31 member states of the European Economic Area, or EEA. This marketing authorization is subject to annual review and renewal by the European Medicines Agency, or EMA following its reassessment of the risk-benefit balance of the authorization and is further conditioned on the Company&#146;s ability to complete its global, confirmatory Phase 3 clinical trial in nmDMD, which it refers to as ACT DMD, and submit the final report, including additional efficacy and safety data from the trial, during 2015. See &#147;Risk Factors&#151;Risks Related to Regulatory Approval of our Product Candidates&#148; for further detail regarding the EMA&#146;s approval process, including a description of the risk-benefit balance.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company launched Translarna on a commercial basis in Germany in December&nbsp;2014 and expects to expand its launch activities across the EEA throughout 2015 and future years, subject to successful completion of pricing and reimbursement negotiations. Concurrently, the Company has been pursuing reimbursed early access programs in selected countries where those mechanisms exist, both within Europe and in those countries outside of Europe that will reference the marketing authorization described above.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company has not generated significant product revenue to date and is subject to a number of risks similar to those of other early stage companies, including dependence on key individuals, the difficulties inherent in the development of commercially usable products, the potential need to obtain additional capital necessary to fund the development of its products, and competition from other companies. As of March&nbsp;31, 2015, the Company had an accumulated deficit of approximately $460.4 million. The Company has financed its operations to date primarily through public offerings of common stock in February&nbsp;2014 and October&nbsp;2014, its initial public offering of common stock in June&nbsp;2013, private placements of its convertible preferred stock, collaborations, bank debt, convertible debt financings, grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease area addressed by the Company&#146;s product candidates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Summary of significant accounting policies</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company&#146;s complete listing of significant accounting policies are described in Note 2 of the notes to the Company&#146;s audited financial statements as of December&nbsp;31, 2014 included in the Company&#146;s Annual Report on Form&nbsp;10-K filed with the Securities and Exchange Commission (SEC) on March&nbsp;2, 2015 (2014 Form&nbsp;10-K).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Basis of Presentation</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The accompanying financial information as of March&nbsp;31, 2015 and for the three months ended March&nbsp;31, 2015 and 2014 has been prepared by the Company, without audit, pursuant to the rules&nbsp;and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9<a name="PB_9_113548_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='9',FILE='C:\JMS\105733\15-7157-1\task7388916\7157-1-fn.htm',USER='105733',CD='May  5 00:14 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">generally accepted accounting principles in the United States (GAAP) have been condensed or omitted pursuant to such rules&nbsp;and regulations. These interim financial statements should be read in conjunction with the Company&#146;s audited financial statements as of December&nbsp;31, 2014 and notes thereto included in the 2014 Form&nbsp;10-K.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the opinion of management, the unaudited financial information as of March&nbsp;31, 2015 and for the three months ended March&nbsp;31, 2015 and 2014 reflects all adjustments, which are normal recurring adjustments, necessary to present a fair statement of financial position, results of operations and cash flows. The results of operations for the three month period ended March&nbsp;31, 2015 are not necessarily indicative of the results to be expected for the year ended December&nbsp;31, 2015 or for any other interim period or for any other future year.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Use of estimates</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Inventories and cost of product revenue</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On August&nbsp;4, 2014, the Company was notified that the European Commission, or EC, granted marketing authorization for Translarna for the treatment of Duchenne muscular dystrophy caused by nonsense mutations, or nmDMD, in ambulatory patients aged five years and older. The marketing authorization allows the Company to market Translarna in the European Economic Area, or EEA, which is comprised of the 28 member states of the European Union plus Norway,&nbsp;Iceland and Liechtenstein. This marketing authorization is subject to annual review and renewal by the European Medicines Agency, or EMA following its reassessment of the risk-benefit balance of the authorization and is further conditioned on the Company&#146;s ability to complete its global, confirmatory Phase 3 clinical trial in nm DMD, which it refers to as ACT DMD, and submit the final report, including additional efficacy and safety data from the trial during 2015.&#160; The launch in these countries is on a country by country basis. The Company does do not have sufficient history or experience from which to accurately forecast product sales or demand generation. As such, the Company has not capitalized inventory and will not capitalize inventory until the completion of ACT DMD and satisfaction of the EMA conditions or until the Company can reasonably predict future product sales. The costs incurred related to the manufacturing of Translarna have been recorded as research and development expense in the statements of operations. The Company&#146;s cost of product sales includes royalties and other miscellaneous selling costs, which were not material and therefore included as a component of research and development costs in the current year presentation. The time period over which this inventory is consumed will depend on a number of factors, including the amount of future Translarna sales, and the ability to utilize inventory prior to its expiration date.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Recently issued accounting standard</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In May&nbsp;2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No.&nbsp;2014-09, Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for annual reporting periods beginning after December&nbsp;15, 2016. Early application is not permitted. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. Presently, the Company is assessing what effect the adoption of ASU 2014-09 will have on its financial statements and accompanying notes.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In August&nbsp;2014, the FASB issued ASU 2014-15, &#147;Presentation of Financial Statements&#151;Going Concern&#151;Disclosures of Uncertainties about an entity&#146;s Ability to Continue as a Going Concern.&#148; ASU 2014-15 provides new guidance related to management&#146;s responsibility to evaluate whether there is substantial doubt about an entity&#146;s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10<a name="PB_10_113643_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='10',FILE='C:\JMS\105733\15-7157-1\task7388916\7157-1-fn.htm',USER='105733',CD='May  5 00:14 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">U.S. auditing standards and to provide related footnote disclosures. This new guidance is effective for the annual period ending after December&nbsp;15, 2016, and for annual periods and interim periods thereafter. The requirements of ASU 2014-15 are not expected to have a significant impact on the Condensed Consolidated Financial Statements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Revenue Recognition</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company recognizes revenue when amounts are realized or realizable and earned. Revenue is considered realizable and earned when the following criteria are met: (1)&nbsp;persuasive evidence of an arrangement exists; (2)&nbsp;delivery has occurred or services have been rendered; (3)&nbsp;the price is fixed or determinable; and (4)&nbsp;collection of the amounts due are reasonably assured.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Net Product Sales</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">PTC&#146;S net product sales have consisted solely of sales of Translarna for the treatment of nmDMD in territories outside of the U.S. The Company applies the revenue recognition guidance in accordance with Financial Accounting Standards Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) Subtopic 605-15, Revenue Recognition&#151;Products. The Company recognizes revenue from product sales when there is persuasive evidence that an arrangement exists, title to product and associated risk of loss has passed to the customer, the price is fixed or determinable, collectability is reasonably assured and the Company has no further performance obligations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company records revenue on sales where Translarna is available either on a commercial basis or through a reimbursed early access program and typically paid for by a government authority or institution. Prior to January&nbsp;1, 2015, the Company recognized revenue for commercial and reimbursed early access program sales on a cash basis once the product was shipped on behalf of the government authority or institution and payment had been received, if all other revenue recognition criteria were met. Beginning in the first quarter of 2015, the Company is recognizing revenue for Translarna as product is shipped, as the Company has established a pattern of collectability.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company records revenue net of estimated discounts and rebates. Allowances are recorded as a reduction of revenue at the time revenues from product sales are recognized. Allowances for government rebates and discounts are established at the time of delivery. These allowances are adjusted to reflect known changes in factors that may impact such allowances in the quarter those changes are known.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Collaboration and Grant Revenue</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The terms of these agreements typically include payments to the Company of one or more of the following: nonrefundable, upfront license fees; milestone payments; research funding and royalties on future product sales. In addition, the Company generates service revenue through agreements that generally provide for fees for research and development services and may include additional payments upon achievement of specified events.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company evaluates all contingent consideration earned, such as a milestone payment, using the criteria as provided by the Financial Accounting Standards Board (FASB), guidance on the milestone method of revenue recognition. At the inception of a collaboration arrangement, the Company evaluates if a milestone payment is substantive. The criteria requires that (1)&nbsp;the Company determines if the milestone is commensurate with either its performance to achieve the milestone or the enhancement of value resulting from our activities to achieve the milestone; (2)&nbsp;the milestone be related to past performance; and (3)&nbsp;the milestone be reasonable relative to all deliverable and payment terms of the collaboration arrangement. If these criteria are met then the contingent milestones can be considered a substantive milestone and will be recognized as revenue in the period that the milestone is achieved. The Company recognizes royalties as earned in accordance with the terms of various research and collaboration agreements. If not substantive, the contingent consideration is allocated to the existing units of accounting based on relative selling price and recognized following the same basis previously established for the associated unit of accounting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company has the risks and rewards as the principal in the research and development activities.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11<a name="PB_11_113702_455"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='11',FILE='C:\JMS\105733\15-7157-1\task7388916\7157-1-fn.htm',USER='105733',CD='May  5 00:14 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Fair value of financial instruments and marketable securities</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company follows the fair value measurement rules, which provides guidance on the use of fair value in accounting and disclosure for assets and liabilities when such accounting and disclosure is called for by other accounting literature. These rules&nbsp;establish a fair value hierarchy for inputs to be used to measure fair value of financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Level 1&#151;Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the balance sheet date.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Level 2&#151;Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves,&nbsp;etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Level 3&#151;Inputs are unobservable and reflect the Company&#146;s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash equivalents are reflected in the accompanying financial statements at fair value. The carrying amount of grant and collaboration receivables, accounts payable and accrued expenses, and debt approximates fair value due to the short-term nature of those instruments.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fair value of certain marketable securities is based upon market prices using quoted prices in active markets for identical assets quoted on the last day of the period. In establishing the estimated fair value of the remaining investments, the Company used the fair value as determined by its investment advisors using observable inputs other than quoted prices.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company reviews its investments on a periodic basis for other-than-temporary impairments. This review is subjective, as it requires management to evaluate whether an event or change in circumstances has occurred in that period that may have a significant adverse effect on the fair value of the investment.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12<a name="PB_12_113817_4141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='12',FILE='C:\JMS\105733\15-7157-1\task7388916\7157-1-fn.htm',USER='105733',CD='May  5 00:14 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following represents the fair value using the hierarchy described in Note 3 for the Company&#146;s financial assets and liabilities that are required to be measured at fair value on a recurring basis as of March&nbsp;31, 2015 and December&nbsp;31, 2014:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="55%" colspan="11" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:55.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">March&nbsp;31,&nbsp;2015</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Total</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Quoted&nbsp;prices<br>   in&nbsp;active<br>   markets&nbsp;for<br>   identical&nbsp;assets<br>   (level&nbsp;1)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Significant<br>   other<br>   observable<br>   inputs<br>   (level&nbsp;2)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Significant<br>   unobservable<br>   inputs<br>   (level&nbsp;3)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Marketable securities </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">243,642</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">243,642</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Warrant liability </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">229</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">229</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr height="0">
<td width="307" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="80" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="80" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="80" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="80" style="border:none;"></td>
<td width="7" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="55%" colspan="11" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:55.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">December&nbsp;31,&nbsp;2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Total</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Quoted&nbsp;<br>   prices<br>   in&nbsp;active<br>   markets&nbsp;for<br>   identical&nbsp;<br>   assets<br>   (level&nbsp;1)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Significant<br>   other<br>   observable<br>   inputs<br>   (level&nbsp;2)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Significant<br>   unobservable<br>   inputs<br>   (level&nbsp;3)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Marketable securities </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">265,493</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">265,493</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Warrant Liability </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">188</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">188</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr height="0">
<td width="307" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="80" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="80" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="80" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="80" style="border:none;"></td>
<td width="7" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following is a summary of marketable securities accounted for as available-for-sale securities at March&nbsp;31, 2015 and December&nbsp;31, 2014:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="55%" colspan="11" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:55.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">March&nbsp;31,&nbsp;2015</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Amortized</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Gross&nbsp;Unrealized</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Fair</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Cost</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Gains</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Losses</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Value</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Commercial paper </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19,748</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19,774</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Corporate debt securities </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">186,810</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">44</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(320</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">186,534</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Government obligations </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">37,346</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(33</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">37,334</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">243,904</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">91</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(353</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 2.25pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">243,642</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="55%" colspan="11" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:55.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">December&nbsp;31,&nbsp;2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Amortized</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Gross&nbsp;Unrealized</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Fair</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Cost</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Gains</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Losses</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Value</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Corporate debt securities </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">230,379</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">80</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(428</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">230,031</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Government obligations </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">35,501</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(46</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">35,462</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">265,880</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">87</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(474</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">265,493</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">At March&nbsp;31, 2015 and December&nbsp;31, 2014, the Company held securities with an unrealized loss position that were not considered to be other-than-temporarily impaired as the Company has the ability to hold such investments until recovery of their fair value.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13<a name="PB_13_114406_8627"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='13',FILE='C:\JMS\105733\15-7157-1\task7388916\7157-1-fn.htm',USER='105733',CD='May  5 00:14 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Marketable securities on the balance sheet at March&nbsp;31, 2015 and December&nbsp;31, 2014 mature as follows:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">March&nbsp;31,&nbsp;2015</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Less&nbsp;Than<br>   12&nbsp;Months</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">More&nbsp;Than<br>   12&nbsp;Months</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Commercial paper </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19,774</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Corporate debt securities </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">138,306</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">48,228</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Government obligations </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11,312</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26,022</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total Marketable securities </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">169,392</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">74,250</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">December&nbsp;31,&nbsp;2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Less&nbsp;Than<br>   12&nbsp;Months</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">More&nbsp;Than<br>   12&nbsp;Months</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Corporate debt securities </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">157,758</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">72,273</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Government obligations </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,003</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29,459</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total Marketable securities </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">163,761</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101,732</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Level 3 valuation</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The warrant liability is classified in Other long-term liabilities on the Company&#146;s balance sheet. The warrant liability is marked-to-market each reporting period with the change in fair value recorded as a gain or loss within Other income (expense), net on the Company&#146;s statement of operations until the warrants are exercised, expire or other facts and circumstances lead the warrant liability to be reclassified as an equity instrument. The fair value of the warrant liability is determined at each reporting period by utilizing the Black-Scholes option pricing model.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The table presented below is a summary of changes in the fair value of the Company&#146;s Level 3 valuation for warrant liability for the period ended March&nbsp;31, 2015:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="81%" valign="bottom" style="padding:0in 0in 0in 0in;width:81.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Level&nbsp;3&nbsp;assets</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="81%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:81.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Beginning balance as of December&nbsp;31, 2014 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">188</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Change in fair value of warrant liability </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">41</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="81%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:81.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ending balance as of March&nbsp;31, 2015 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">229</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fair value of the warrant liability is estimated using an option-pricing model, which includes variables such as the expected volatility based on guideline public companies, the stock fair value, and the estimated time to a liquidity event. The significant assumptions used in preparing the option pricing model for valuing the Company&#146;s warrants as of March&nbsp;31, 2015 include (i)&nbsp;volatility (68%&#151;70%), (ii)&nbsp;risk free interest rate (0.56%&#151;1.13%), (iii)&nbsp;strike price ($128-$2,520), (iv)&nbsp;fair value of common stock ($60.85), and (v)&nbsp;expected life (2.21&#151;4.48 years). The significant assumptions used in preparing the option pricing model for valuing the Company&#146;s warrants as of December&nbsp;31, 2014 include (i)&nbsp;volatility (68%-70%), (ii)&nbsp;risk free interest rate (0.89%&#151;1.65%), (iii)&nbsp;strike price ($128&#151;$2,520), (iv)&nbsp;fair value of common stock ($51.77), and (v)&nbsp;expected life (2.50&#151;4.70 years). See Note 6 for a description of the warrants issued in connection with the convertible notes.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Other comprehensive income (loss) and accumulated other comprehensive items</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other comprehensive income (loss) includes changes in equity that are excluded from net income (loss), such as unrealized gains and losses on marketable securities.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following tables summarize other comprehensive income (loss) and the changes in accumulated other comprehensive items for the three months ended March&nbsp;31, 2015:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14<a name="PB_14_114545_7906"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='14',FILE='C:\JMS\105733\15-7157-1\task7388916\7157-1-fn.htm',USER='105733',CD='May  5 00:14 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Unrealized<br>   Gains/(Losses)<br>   On<br>   Marketable<br>   Securities</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Foreign<br>   Currency<br>   Translation</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Total<br>   Accumulated<br>   Other<br>   Comprehensive<br>   Items</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Balance at December&nbsp;31, 2014 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(387</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(350</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(737</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other comprehensive income/(loss) before   reclassifications </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">125</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(124</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amounts reclassified from other comprehensive   items </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other comprehensive income/(loss) </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">125</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(124</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Balance at March&nbsp;31, 2015 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(262</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(474</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(736</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Accounts payable and accrued expenses</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accounts payable and accrued expenses at March&nbsp;31, 2015 and December&nbsp;31, 2014 consist of the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="66%" valign="bottom" style="padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">March&nbsp;31,</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">December&nbsp;31,<br>   2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Employee compensation, benefits, and related accruals </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,365</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,312</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="66%" valign="top" style="padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Consulting and contracted research </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11,691</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,349</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Professional fees </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,382</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,334</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="66%" valign="top" style="padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accounts payable </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,139</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,128</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,955</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,998</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="66%" valign="bottom" style="padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23,532</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29,121</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Warrants</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All of the Company&#146;s outstanding warrants were classified as liabilities as of March&nbsp;31, 2015 and December&nbsp;31, 2014 because they contained non-standard antidilution provisions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following is a summary of the Company&#146;s outstanding warrants as of March&nbsp;31, 2015:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Warrant<br>   shares</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exercise<br>   price</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Expiration</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common stock </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,250</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">128.00</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2017</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common stock </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7,030</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">128.00</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2019 and   2020</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common stock </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">130</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,520.00</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2019</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following is a summary of the Company&#146;s outstanding warrants as of December&nbsp;31, 2014:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Warrant<br>   shares</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exercise<br>   price</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Expiration</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common stock </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,250</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">128.00</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2017</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common stock </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7,030</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">128.00</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2019 and   2020</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common stock </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">130</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,520.00</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2019</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15<a name="PB_15_114937_3736"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='15',FILE='C:\JMS\105733\15-7157-1\task7388916\7157-1-fn.htm',USER='105733',CD='May  5 00:14 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Net loss per share</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Basic earnings per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding. Diluted earnings per share is computed by dividing net income (loss) by the weighted-average number of common shares plus the effect of dilutive potential common shares outstanding during the period.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following tables set forth the computation of basic and diluted net loss per share:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="66%" valign="bottom" style="padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="29%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:29.28%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;<br>   31,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="66%" valign="bottom" style="padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Numerator</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.78%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="66%" valign="top" style="padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(37,915</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:11.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(14,098</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Denominator</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.78%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="66%" valign="top" style="padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Denominator for basic and diluted net loss per share </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33,067,752</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.78%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24,492,487</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Net loss per share:</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.78%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="66%" valign="top" style="padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Basic and diluted </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1.15</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 2.25pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)*</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:11.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(0.58</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 2.25pt 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font><font size="2" style="font-size:10.0pt;">*</font></p>    </td>   </tr>  </table>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">*</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">In the three months ended March&nbsp;31, 2015 and 2014, the Company experienced a net loss and therefore did not report any dilutive share impact.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table shows historical dilutive common share equivalents outstanding, which are not included in the above historical calculation, as the effect of their inclusion is anti-dilutive during each period.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="3" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">As&nbsp;of&nbsp;March&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stock Options </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,627,833</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,133,830</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unvested restricted stock </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">364,970</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">748,456</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,992,803</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,882,286</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Stock award plan</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On March&nbsp;5, 2013, the Company&#146;s Board of Directors approved the 2013 Stock Incentive Plan, which provides for the granting of stock option awards, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards in the aggregate of 739,937 shares of common stock. On March&nbsp;5, 2013, the Board approved a grant of 735,324 shares of restricted stock and 4,613 stock options. There are no additional shares available for issuance under this plan.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In May&nbsp;2013, the Company&#146;s Board of Directors and stockholders increased by 2,500,000 the number of shares authorized under the 2009 Equity and Long Term Incentive Plan, which provides for the granting of stock option awards, restricted stock awards, and other stock-based and cash-based awards.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In May&nbsp;2013, the Company&#146;s Board of Directors and stockholders approved the 2013 Long Term Incentive Plan, which became effective upon the closing of the Company&#146;s IPO.&#160; The 2013 Long Term Incentive Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards and other stock-based awards. The number of shares of common stock reserved for issuance under the 2013 Long Term Incentive Plan is the sum of (1)&nbsp;245,000 shares of common stock available for issuance under the Company&#146;s 2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan, (2)&nbsp;the number of shares (up to 3,040,444 shares) equal to the sum of the number of shares of common stock subject to outstanding awards under the Company&#146;s 1998 Employee, Director and Consultant Stock Option Plan, 2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right plus (3)&nbsp;an annual increase, to be added on the first </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16<a name="PB_16_115219_9621"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='16',FILE='C:\JMS\105733\15-7157-1\task7388916\7157-1-fn.htm',USER='105733',CD='May  5 00:14 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">day of each fiscal year until the expiration of the 2013 Long Term Incentive Plan, equal to the lowest of 2,500,000 shares of common stock, 4% of the number of shares of common stock outstanding on the first day of the fiscal year and an amount determined by the Company&#146;s Board of Directors.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">From January&nbsp;1, 2015 through March&nbsp;31, 2015, the Company issued a total of 1,456,550 stock options to various employees.&#160; Of those, 93,350 were inducement grants for non-statutory stock options. The inducement grant awards were made pursuant to the NASDAQ inducement grant exception as a material component of our new hires&#146; employment compensation.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A summary of stock option activity is as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Number&nbsp;of<br>   options</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Weighted-<br>   average<br>   exercise<br>   price</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Weighted-<br>   average<br>   remaining<br>   contractual<br>   term</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Aggregate<br>   intrinsic<br>   value</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(in&nbsp;<br>   thousands)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Outstanding at   December&nbsp;31, 2014 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,432,972</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25.00</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Granted </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,456,550</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">51.02</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exercised </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(234,830</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.86</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Forfeited </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(26,265</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">47.52</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expired </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(594</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">388.53</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Outstanding at   March&nbsp;31, 2015 </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,627,833</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33.60</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.9 years</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">140,399</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vested or Expected to   vest at March&nbsp;31, 2015 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,332,726</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32.74</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.9 years</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">133,232</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exercisable at   March&nbsp;31, 2015 </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,037,262</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30.98</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.2 years</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">45,137</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The fair value of grants made in the three months ended March&nbsp;31, 2015 was contemporaneously estimated on the date of grant using the following assumptions:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="53%" style="border-collapse:collapse;margin-left:1.75in;width:53.34%;">
<tr>
<td width="53%" valign="bottom" style="padding:0in 0in 0in 0in;width:53.46%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.66%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="40%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:40.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;months&nbsp;<br>   ended&nbsp;March&nbsp;<br>   31,&nbsp;2015</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="53%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:53.46%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Risk-free interest rate </font></p>    </td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:40.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.54% &#151; 1.77%</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="53%" valign="top" style="padding:0in 0in 0in 0in;width:53.46%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expected volatility </font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="bottom" style="padding:0in 0in 0in 0in;width:40.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">67%-69%</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="53%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:53.46%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expected term </font></p>    </td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:40.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.50 - 6.11 years</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company assumed no expected dividends for all grants. The weighted average grant date fair value of options granted during the three month period ended March&nbsp;31, 2015 was $31.82 per share.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company uses the &#147;simplified method&#148; to determine the expected term of options. Under this method, the expected term represents the average of the vesting period and the contractual term. The expected volatility of share options was estimated based on a historical volatility analysis of peers that were similar to the Company with respect to industry, stage of life cycle, size, and financial leverage. The risk-free rate of the option is based on U.S. Government Securities Treasury Constant Maturities yields at the date of grant for a term similar to the expected term of the option.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Restricted Stock Awards</font></i><font size="2" style="font-size:10.0pt;">&#151;Restricted stock awards are granted subject to certain restrictions, including in some cases service or time conditions (restricted stock). The grant-date fair value of restricted stock awards, which has been determined based upon the market value of the Company&#146;s shares on the grant date, is expensed over the vesting period.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17<a name="PB_17_115521_8715"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='17',FILE='C:\JMS\105733\15-7157-1\task7388916\7157-1-fn.htm',USER='105733',CD='May  5 00:14 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table summarizes information on the Company&#146;s restricted stock:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="64%" valign="bottom" style="padding:0in 0in 0in 0in;width:64.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="32%" colspan="4" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:32.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Restricted&nbsp;Stock</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="64%" valign="bottom" style="padding:0in 0in 0in 0in;width:64.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Number&nbsp;of<br>   Shares</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Weighted<br>   Average&nbsp;<br>   Grant<br>   Date&nbsp;Fair&nbsp;<br>   Value</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="64%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:64.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">January&nbsp;1, 2015 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">718,400</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.72</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Granted </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="64%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:64.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vested </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(350,084</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.59</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Forfeited </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,346</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.82</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="64%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:64.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unvested at March&nbsp;31, 2015 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">364,970</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.85</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company recorded share-based compensation expense in the statement of operations as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="64%" valign="bottom" style="padding:0in 0in 0in 0in;width:64.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="32%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:32.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;<br>   31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="64%" valign="bottom" style="padding:0in 0in 0in 0in;width:64.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="64%" valign="bottom" style="padding:0in 0in 0in 0in;width:64.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="64%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:64.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,667</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,944</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Selling, general and administrative </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,081</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,761</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="64%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:64.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,748</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,705</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of March&nbsp;31, 2015 there was approximately $70.6 million of total unrecognized compensation cost related to unvested share-based compensation arrangements granted under the 2009 Equity and Long Term Incentive Plan, 2013 Long Term Incentive Plan and equity awards made pursuant to the NASDAQ inducement grant exception for new hires. This cost is expected to be recognized as share-based compensation expense over the weighted average remaining service period of approximately 3.0 years.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9. Commitments and contingencies</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Operating leases</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company leases office space under a noncancelable operating lease through February&nbsp;2019. Rent expense was approximately $0.3 million for the three months ended March&nbsp;31, 2015. The Company also leases certain office equipment under operating leases. Future minimum lease payments as of March&nbsp;31, 2015 are as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="80%" style="border-collapse:collapse;margin-left:.75in;width:80.0%;">
<tr>
<td width="80%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:80.62%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2015 </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,016</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.62%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2016 </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">946</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:80.62%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2017 </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">923</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.62%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2018 </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,035</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:80.62%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2019 </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">176</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="bottom" style="padding:0in 0in 0in 0in;width:80.62%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,096</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Other contingencies</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under various agreements, the Company will be required to pay royalties and milestone payments upon the successful development and commercialization of products. The Company has entered into funding agreements with The Wellcome Trust Limited (Wellcome Trust) for the research and development of small molecule compounds. To the extent that the Company develops and commercializes program intellectual property on a for-profit basis, it may become obligated to pay to Wellcome Trust development and regulatory milestone payments of up to an aggregate of $68.9 million and single-digit royalties on sales of any research program product. The Company&#146;s obligation to pay such royalties would continue on a country-by-country basis until the longer of the expiration of the last patent </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18<a name="PB_18_122129_563"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='18',FILE='C:\JMS\105733\15-7157-1\task7388916\7157-1-fn.htm',USER='105733',CD='May  5 00:14 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">in the program intellectual property in such country covering the research program product and the expiration of market exclusivity of such product in such country.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company has also entered into a collaboration agreement with the SMA Foundation. The Company may become obligated to pay the SMA Foundation single-digit royalties on worldwide net product sales of any collaboration product that we successfully develop and subsequently commercialize or, if the Company outlicenses rights to a collaboration product, a specified percentage of certain payments the Company receives from the licensee. The Company is not obligated to make such payments unless and until annual sales of a collaboration product exceed a designated threshold. The Company&#146;s obligation to make such payments would end upon its payment to the SMA Foundation of a specified amount.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company has employment agreements with certain employees that require the funding of a specific level of payments, if certain events, such as a change in control or termination without cause, occur.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Collaboration Revenue</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In January&nbsp;2014, the Company announced the initiation of a Phase 1 clinical program in its spinal muscular atrophy collaboration with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc. (Roche) and the Spinal Muscular Atrophy Foundation which triggered a $7.5 million milestone payment from Roche. The Company considered this milestone event substantive because the applicable criteria of its revenue recognition policy would be satisfied and recorded it as collaboration revenue for the three months ended March&nbsp;31, 2014.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19<a name="PB_19_122224_9497"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='19',FILE='C:\JMS\105733\15-7157-1\task7388916\7157-1-fn.htm',USER='105733',CD='May  5 00:14 2015' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item</font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;"> 2.</font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;"> Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.</font></b><a name="Item2_ManagementsDiscussionAndAna_123154"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and the notes to those financial statements appearing elsewhere in this </font></i><i><font size="2" style="font-size:10.0pt;font-style:italic;">Quarterly Report on Form&nbsp;10-Q and the audited consolidated financial statements and notes thereto and management&#146;s discussion and analysis of financial condition and results of operations for the year ended December&nbsp;31, 2014 included in our </font></i><i><font size="2" style="font-size:10.0pt;font-style:italic;">Annual Report on Form&nbsp;10</font></i><i><font size="2" style="font-size:10.0pt;font-style:italic;">-</font></i><i><font size="2" style="font-size:10.0pt;font-style:italic;">K</font></i><i><font size="2" style="font-size:10.0pt;font-style:italic;"> filed with the Securities and Exchange Commission on March&nbsp;2, 2015.</font></i><i><font size="2" style="font-size:10.0pt;font-style:italic;"> This discussion contains forward</font></i><i><font size="2" style="font-size:10.0pt;font-style:italic;">-</font></i><i><font size="2" style="font-size:10.0pt;font-style:italic;">looking statements that involve significant risks and uncertainties. As a result of many factors, such as those set forth in Part&nbsp;</font></i><i><font size="2" style="font-size:10.0pt;font-style:italic;">II</font></i><i><font size="2" style="font-size:10.0pt;font-style:italic;">,&nbsp;Item 1A.</font></i><i><font size="2" style="font-size:10.0pt;font-style:italic;"> (</font></i><i><font size="2" style="font-size:10.0pt;font-style:italic;">Risk Factors</font></i><i><font size="2" style="font-size:10.0pt;font-style:italic;">)</font></i><i><font size="2" style="font-size:10.0pt;font-style:italic;"> of this </font></i><i><font size="2" style="font-size:10.0pt;font-style:italic;">Quarterly</font></i><i><font size="2" style="font-size:10.0pt;font-style:italic;"> Report on Form&nbsp;10</font></i><i><font size="2" style="font-size:10.0pt;font-style:italic;">-Q</font></i><i><font size="2" style="font-size:10.0pt;font-style:italic;">, our actual results may differ materially from those anticipated in these forward</font></i><i><font size="2" style="font-size:10.0pt;font-style:italic;">-</font></i><i><font size="2" style="font-size:10.0pt;font-style:italic;">looking statements.</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Overview and Corporate Update</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. Post-transcriptional control processes are the regulatory events that occur in cells during and after a messenger RNA molecule is copied from DNA through the transcription process. Our internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. We have discovered all of our compounds currently under development using our proprietary technologies. We plan to continue to develop these compounds both on our own and through selective collaboration arrangements with leading pharmaceutical and biotechnology companies.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our lead product candidate is ataluren, an investigational new drug in the US, for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense mutation. We hold worldwide commercialization rights to ataluren for all indications in all territories. The brand name of ataluren is Translarna&#153;.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Translarna&#153; for nonsense mutation Duchenne muscular dystrophy</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Translarna&#153; (ataluren), received marketing authorization from the European Commission, or EC, in August&nbsp;2014 for the treatment of nonsense mutation Duchenne muscular dystrophy, or nmDMD, in ambulatory patients age 5 years and over in the 31 member states of the European Economic Area, or EEA. Our authorization in the EEA is subject to annual review and renewal by the European Medicines Agency, or EMA, following its reassessment of the risk benefit balance of the authorization, which we refer to as the annual EMA reassessment. This marketing authorization is further conditioned on our ability to complete our global, confirmatory Phase 3 clinical trial in nmDMD, which we refer to as ACT DMD, and submit the final report, including additional efficacy and safety data from the trial, during 2015. We completed enrollment for ACT DMD in September&nbsp;2014 and we expect to receive top-line data in the fourth quarter of 2015. See &#147;Risk Factors&#151;Risks Related to Regulatory Approval of our Product and Product Candidates&#148; on page&nbsp;59 for further detail regarding the annual EMA reassessment process, including a description of the risk benefit balance.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We launched Translarna on a commercial basis in Germany in December&nbsp;2014 and in Austria in April 2015. We expect to expand our launch activities across the European Economic Area, or EEA, throughout 2015 and future years, subject to successful completion of pricing and reimbursement negotiations. The market access process, including pricing and reimbursement negotiations, varies from country to country and can take over 18 months in certain circumstances.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Concurrently, we have been pursuing reimbursed early access programs, or EAP programs, in selected countries where funded named patient or cohort programs exist, both within the European Economic Area and in those countries outside of the EEA that will reference the marketing authorization in the EEA. Translarna is authorized under EAP programs in Columbia, France, Greece,&nbsp;Italy,&nbsp;Israel, Spain, and Turkey.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">During the fourth quarter of 2014 we initiated a rolling new drug application, or NDA, with the U.S. Food and Drug Administration, or FDA, for Translarna as a treatment for nmDMD. We believe this process gives the FDA an opportunity to conduct a meaningful review of most of the segments of our NDA, ahead of reviewing our ACT DMD data. Assuming positive data from ACT DMD, we expect that the submission of the data will complete our rolling NDA and allow for FDA review. If granted priority review and approval by the FDA, we believe we have the potential to begin commercialization in the U.S. in the first half of 2016. In preparation for a potential U.S. launch, </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20<a name="PB_20_122510_3641"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='20',FILE='C:\JMS\C901937\15-7157-1\task7389716\7157-1-ga.htm',USER='C901937',CD='May  5 05:27 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">subject to positive ACT DMD data and receipt of FDA approval, we have begun building out our commercial team and infrastructure in the U.S.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We ultimately intend to market Translarna in all markets in the EEA where market access is possible. We currently expect Translarna to be priced at levels consistent with the pricing for other therapies for the treatment of rare disorders where high unmet medical need exists.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Translarna&#153; for nonsense mutation cystic fibrosis</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are currently enrolling a global, confirmatory Phase 3 clinical trial of Translarna for the treatment of cystic fibrosis caused by nonsense mutations, or nmCF. We refer to this trial as ACT CF. We anticipate completing enrollment in this trial by the end of 2015 with top line data about a year later.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the second half of 2015, we intend to submit a request for a variation to our marketing authorization of Translarna in the European Economic Area, described above, to include approval for the treatment of nmCF. Our variation submission will use the clinical results achieved in our prior Phase 3 clinical trial in nmCF. We believe that the EMA&#146;s Committee for Medicinal Products for Human Use will consider the status of ACT CF enrollment important at the time of our submission and we are planning to submit once ACT CF enrollment is well underway. Approval of the marketing authorization variation will depend on the EMA&#146;s assessment of the relative benefits and risks of approval. We may not be able to demonstrate the required relative risk-benefit profile and there is substantial risk that the EMA will not grant us a variation approving Translarna for the treatment of nmCF. If approved, we expect that the EMA will require us, as a post-approval measure, to provide comprehensive clinical data from ACT CF to the EMA. In addition, unless and until we satisfy the conditions of our primary marketing authorization in the EEA for Translarna, such authorization will continue to be subject to annual review and renewal by the EMA. See &#147;Risk Factors&#151;Risks Related to Regulatory Approval of our Product and Product Candidates&#148; on page&nbsp;59 for further detail regarding the annual EMA reassessment process, including a description of the risk benefit balance.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Translarna&#153; for additional indications</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We recently announced that we intend to initiate a Phase 2 proof-of-concept study for Translarna for the treatment of aniridia prior to the end of 2015. Aniridia is a genetic disorder due to mutations in the PAX6 gene associated with loss of eyesight and other symptoms.&#160; We estimate that approximately one-third of all aniridia cases are due to a nonsense mutation. In a prior study conducted by an independent investigator, Translarna treated mice with nonsense mutation aniridia showed a significant increase in the PAX6 protein in a nonsense mutation PAX6 gene, but not in a PAX6 gene harboring a splice-site mutation. The investigators in this study found that Translarna not only inhibited disease progression, but also reversed corneal, lens and retinal malformation defects and restored electrical responses of the retina.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are also pursuing the development of Translarna for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, or nmMPS I. We are initiating our Phase 2 proof-of-concept clinical study in nmMPS I and expect some data by the end of 2015.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Over the last six years multiple independent investigators have conducted preclinical studies in which Translarna enabled readthrough of the premature stop codons from a large set of nonsense mutations across a diverse group of experimental models exhibiting various genetic disorders. The studies evaluated Translarna&#146;s ability to read through premature stop codons in mRNA in cell-free systems, transfected cell lines, mouse models and patient cells. Based on these studies by independent investigators in addition to our own trials and studies, we expect to continue to pursue additional indications for Translarna.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Spinal muscular atrophy program</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">RG7800, an investigational oral therapy for spinal muscular atrophy, or SMA, is our product candidate under our joint development SMA program with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., which we refer to collectively as Roche, and the Spinal Muscular Atrophy Foundation, or SMA Foundation.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21<a name="PB_21_122619_5250"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='21',FILE='C:\JMS\C901937\15-7157-1\task7389716\7157-1-ga.htm',USER='C901937',CD='May  5 05:27 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Recently, results from the Phase 1 study of RG7800, completed in the first half of 2014, were presented at the emerging science session at the annual meeting of the American Academy of Neurology. The Phase 1 study was a single ascending dose, placebo-controlled clinical study in 48 healthy volunteers. Preliminary findings from the Phase 1 study indicated that RG7800 showed a favorable safety profile and was well tolerated at all dose levels studied. In addition, proof of mechanism was demonstrated by a dose-dependent effect on Survival Motor Neuron 2 (SMN2) mRNA splicing towards the production of full length SMN2 mRNA.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">MOONFISH, a Phase 2, multiple-dose clinical study investigating the safety and tolerability of RG7800 was initiated in November&nbsp;2014. This study is enrolling up to 64 SMA patients, with once daily oral dosing over 12 weeks of treatment.&#160; Secondary outcome measures include pharmacokinetics and pharmacodynamics as well as exploratory efficacy endpoints.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dosing of the first cohort of the Phase 2 MOONFISH study was recently completed. RG7800 was well tolerated and preliminary review of the blinded data in the first cohort indicates substantial increases in full length SMN2 mRNA.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Data from a longer term non-clinical safety and toxicology study of RG7800 in cynomolgus monkeys have recently shown an eye finding at exposures above those explored in SMA patients and healthy volunteers. As a precautionary measure, the collaboration partners decided in April&nbsp;2015 to temporarily suspend dosing of additional patients to evaluate this finding and confirm next steps for MOONFISH.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Cancer stem cell program</font></i></p>
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In April&nbsp;2015, we initiated a Phase 1 first-in-human, dose-escalation safety and pharmacokinetic open-label clinical study for our product candidate, PTC596, in advanced cancer patients with solid tumors. PTC596 is a first-in-class, oral, potent and selective inhibitor that targets tumor stem cell populations by reducing the function, activity and amount of a protein called BMI1. Elevated levels of BMI1 are associated with more aggressive tumors and a poor prognosis in a wide variety of cancers, including glioblastoma.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Antibacterial program</font></i></p>
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our compound PTC672 is an orally bioavailable, new chemical entity with a novel mechanism of action distinct from all approved antibiotics. We have commenced IND-enabling preclinical safety studies for PTC672 to allow submission of an investigational new drug application, or IND supporting initiation of clinical assessment. PTC672 is derived from a novel chemical scaffold and has the potential to address the significant need for new treatment options to combat multi-drug resistant Gram-negative Neisseria gonorrhea. PTC672 acts selectively, inhibiting only Neisseria and sparing beneficial bacteria, which we believe may be a significant advantage in treating gonorrhea compared to using broad-acting antibiotics.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Funding</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">During 2015, we expect that our revenues will be primarily generated from sales of Translarna in counties in the EEA where we are able to obtain pricing and reimbursement approval at acceptable levels and in other territories where we are permitted to distribute Translarna under our EAPs.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Historically, we have financed our operations primarily through our public offerings of common stock in February&nbsp;2014 and in October&nbsp;2014, our initial public offering of common stock in June&nbsp;2013, private placements of our preferred stock, collaborations, bank debt and convertible debt financings and grants and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease areas addressed by our product candidates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of March&nbsp;31, 2015, we had an accumulated deficit of $460.5 million. We had a net loss of $37.9 million for the three months ended March&nbsp;31, 2015 and a net loss of $14.1 million for the three months ended March&nbsp;31, 2014.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We anticipate that our expenses will increase substantially in connection with the expansion of our commercial infrastructure as we continue to establish an international presence, particularly throughout Europe and in the U.S., and our efforts to commercialize Translarna for the treatment of nmDMD, including significant sales and marketing, legal and regulatory, and distribution and manufacturing expenses. In addition, we expect to continue to incur significant costs in connection with our ongoing ACT DMD and ACT CF trials as well as our Phase 2 proof-of-concept studies for nmMPS I and nonsense mutation aniridia. We also expect to incur ongoing research and development expenses for our other product candidates, including the ongoing Phase 1 clinical study under our cancer stem cell program and IND-enabling studies under our antibacterial program. In addition, we may incur substantial costs in connection with our ongoing rolling NDA submission with the FDA for Translarna for the treatment of nmDMD and our currently anticipated submission of a marketing authorization variation with the EMA to seek to include Translarna for the treatment of nmCF in the second half of 2015. We have begun seeking and intend to continue to seek marketing approval for Translarna for the treatment of nmDMD in territories outside of </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22<a name="PB_22_122739_536"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='22',FILE='C:\JMS\C901937\15-7157-1\task7389716\7157-1-ga.htm',USER='C901937',CD='May  5 05:27 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">the EEA and we may also seek marketing approval for Translarna for other indications, and these efforts may significantly impact the timing and extent of our commercialization expenses.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Furthermore, as a result of our initial public offering in June&nbsp;2013, we have incurred and expect to continue to incur additional costs associated with operating as a public company. These costs include significant legal, accounting, investor relations and other expenses that we did not incur as a private company. Accordingly, we may need to obtain substantial additional funding in connection with our continuing operations. Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or our commercialization efforts. We will need to generate significant revenues to achieve and sustain profitability, and we may never do so.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Financial operations overview</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To date, our net product sales have consisted solely of sales of Translarna for the treatment of nmDMD in territories outside of the U.S. Our process for recognizing revenue is described below under &#147;Critical accounting policies and significant judgments and estimates&#151;Revenue recognition&#148;.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Roche and the SMA Foundation Collaboration.</font></i><font size="2" style="font-size:10.0pt;">&#160; In November&nbsp;2011, we entered into a license and collaboration agreement, or licensing agreement, with Roche and the SMA Foundation pursuant to which we are collaborating with Roche and the SMA Foundation to further develop and commercialize compounds identified under our spinal muscular atrophy program with the SMA Foundation. The research component of this agreement terminated effective December&nbsp;31, 2014. The licensing agreement included a $30 million upfront payment made in 2011 which was recognized on a deferred basis over the research term, and the potential for up to $460 million in milestone payments and royalties on net sales.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In August&nbsp;2013, we announced the selection of a development candidate. The achievement of this milestone triggered a $10.0 million payment to us from Roche, which we recorded as collaboration revenue for the year ended December&nbsp;31, 2013.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In January&nbsp;2014, we initiated a Phase 1 clinical program, which triggered a $7.5 million milestone payment to us from Roche which we recorded as collaboration revenue for the year ended December&nbsp;31, 2014.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In November&nbsp;2014, we announced that our joint development program in Spinal Muscular Atrophy (SMA) with Roche and the SMA Foundation (SMAF) has started a Phase 2 study in adult and pediatric patients. The achievement of this milestone triggered a $10.0 million payment to us from Roche which we recorded as collaboration revenue for the year ended December&nbsp;31, 2014.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Grant revenue.</font></i><font size="2" style="font-size:10.0pt;">&#160; From time to time, we receive grant funding from various institutions and governmental bodies. The grants are typically for early discovery research, and generally such grant programs last from two to five years.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Research and development expense</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development expenses consist of the costs associated with our research activities, as well as the costs associated with our drug discovery efforts, conducting preclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings. Our research and development expenses consist of:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">employee-related expenses, which include salaries and benefits, including share-based compensation, for the personnel involved in our drug discovery and development activities; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation of leasehold improvements and equipment, and laboratory and other supplies.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23<a name="PB_23_122821_5926"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='23',FILE='C:\JMS\C901937\15-7157-1\task7389716\7157-1-ga.htm',USER='C901937',CD='May  5 05:27 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We use our employee and infrastructure resources across multiple research projects, including our drug development programs. We track expenses related to our clinical programs and certain preclinical programs on a per project basis.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We expect our research and development expenses to increase in connection with our ongoing activities, particularly as we continue our confirmatory Phase 3 clinical trials of Translarna for the treatment of nmDMD and nmCF, our Phase 2 proof-of-concept study of Translarna in nmMPS I and nonsense mutation aniridia, and our IND-enabling studies under our antibacterial program, and as we prepare to commence our Phase 1 clinical study for PTC596 under our cancer stem cell program. The timing and amount of these expenses will depend upon the outcome of our ongoing clinical trials and the costs associated with our planned clinical trials. The timing and amount of these expenses will also depend on the costs associated with potential future clinical trials of our product candidates and the related expansion of our research and development organization, regulatory requirements, advancement of our preclinical programs and product candidate manufacturing costs.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table provides research and development expense for our most advanced principal product development programs, for the three months ended March&nbsp;31, 2015 and March&nbsp;31, 2014.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="80%" style="border-collapse:collapse;margin-left:.75in;width:80.0%;">
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="33%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:33.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;months<br>   March&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="33%" colspan="5" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:33.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(in&nbsp;thousands)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Translarna (nmDMD, nmCF and nmMPS I) </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17,991</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7,797</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" style="padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Antibacterial </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,440</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,223</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cancer stem cell </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">506</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">672</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" style="padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Spinal muscular atrophy </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">324</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">708</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Next generation nonsense readthrough </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,063</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,464</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" style="padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other research and preclinical </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,614</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,025</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total research and development </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27,938</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15,889</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr height="0">
<td width="374" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="8" style="border:none;"></td>
<td width="82" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="8" style="border:none;"></td>
<td width="82" style="border:none;"></td>
<td width="8" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The successful development of our product and product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the scope, rate of progress and expense of our clinical trials and other research and development activities;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the potential benefits of our products and product candidate over other therapies;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to market, commercialize and achieve market acceptance for any of our product candidates that we are developing or may develop in the future;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">clinical trial results;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the terms and timing of regulatory approvals; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the expense of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A change in the outcome of any of these variables with respect to the development of Translarna or any other product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the EMA or FDA or other regulatory authority were to require us to conduct clinical trials beyond those which we currently anticipate will be required for the completion of clinical development of Translarna or any other product candidate or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24<a name="PB_24_122932_4688"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='24',FILE='C:\JMS\C901937\15-7157-1\task7389716\7157-1-ga.htm',USER='C901937',CD='May  5 05:27 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Selling, general and administrative expense</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Selling, general and administrative expenses consist primarily of salaries and other related costs for personnel, including share-based compensation expenses, in our executive, legal, business development, finance, accounting, information technology and human resource functions. Other selling, general and administrative expenses include facility-related costs not otherwise included in research and development expense; advertising and promotional expenses; costs associated with industry and trade shows; and professional fees for legal services, including patent-related expenses, and accounting services.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We expect that selling, general and administrative expenses will increase in future periods as a result of our continued efforts to establish an expanded international presence in Europe and other territories and our continued efforts to commercialize Translarna for the treatment of nmDMD, including increased payroll, expanded infrastructure, commercial operations, increased consulting, legal, accounting and investor relations expenses.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Interest income</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest income consists of interest income earned on investments.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Critical accounting policies and significant judgments and estimates</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our management&#146;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with generally accepted accounting principles in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. Actual results may differ from these estimates under different assumptions or conditions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As an emerging growth company under the Jumpstart Our Business Startups Act of 2012, we have elected to delay the adoption of new or revised accounting standards until those standards would otherwise apply to private companies. As a result of this election, our financial statements may not be comparable to the financial statements of other public companies.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Revenue recognition</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We recognize revenue when amounts are realized or realizable and earned. Revenue is considered realizable and earned when the following criteria are met: (1)&nbsp;persuasive evidence of an arrangement exists; (2)&nbsp;delivery has occurred or services have been rendered; (3)&nbsp;the price is fixed or determinable; and (4)&nbsp;collection of the amounts due are reasonably assured.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Net Product Sales</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To date, our net product sales have consisted solely of sales of Translarna for the treatment of nmDMD in territories outside of the U.S. We began recognizing revenue for payments received under the reimbursed EAPs for Translarna in nmDMD patients in selected countries in the third quarter of 2014.&#160; We have now established a pattern of collectability and, beginning in January&nbsp;2015, we recognize revenue from product sales when there is persuasive evidence that an arrangement exists, title to product and associated risk of loss has passed to the customer, the price is fixed or determinable, collectability is reasonably assured and we have no further performance obligations in accordance with Financial Accounting Standards Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) Subtopic 605-15, Revenue Recognition&#151;Products.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have recorded revenue on sales where Translarna is available either on a commercial basis or through a reimbursed EAP program and typically paid for by a government authority or institution. Prior to January&nbsp;1, 2015, we generally recognized revenue for these reimbursed EAP programs once the product was shipped on behalf of the government authority or institution on a cash basis if all other revenue recognition criteria had been met. Beginning in the first quarter of 2015, the Company is recognizing revenue for Translarna as product is shipped, as the Company has established a pattern of collectability.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25<a name="PB_25_122958_2983"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='25',FILE='C:\JMS\C901937\15-7157-1\task7389716\7157-1-ga.htm',USER='C901937',CD='May  5 05:27 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We record revenue net of estimated third party discounts and rebates. Allowances are recorded as a reduction of revenue at the time revenues from product sales are recognized. Allowances for government and other third-party rebates and discounts are established or estimated at the time of delivery. These allowances are adjusted to reflect known changes in factors and may impact such allowances in the quarter those changes are known.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Collaboration and Grant Revenue</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The terms of collaboration agreements typically include payments of one or more of the following: nonrefundable, upfront license fees; milestone payments; research funding; and royalties on future product sales. In addition, if applicable, we generate service revenue through collaboration and grant agreements that provide for fees for research and development services or additional payments upon achievement of specified events.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We evaluate all contingent consideration earned, such as a milestone payment, using the criteria as provided by the Financial Accounting Standards Board, or FASB, guidance on the milestone method of revenue recognition. At the inception of a collaboration arrangement, we evaluate if milestone payments are substantive. The criteria requires that (1)&nbsp;we determine if the milestone is commensurate with either its performance to achieve the milestone or the enhancement of value resulting from our activities to achieve the milestone; (2)&nbsp;the milestone be related to past performance; and (3)&nbsp;the milestone be reasonable relative to all deliverable and payment terms of the collaboration arrangement. If these criteria are met then the contingent milestones can be considered as substantive milestones and will be recognized as revenue in the period that the milestone is achieved. We recognize royalties as earned in accordance with the terms of various research and collaboration agreements. If not substantive, the contingent consideration is allocated to the existing units of accounting based on relative selling price and recognized following the same basis previously established for the associated unit of accounting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We recognize reimbursements for research and development costs under collaboration agreements as revenue as the services are performed. We record these reimbursements as revenue and not as a reduction of research and development expenses as we have the risks and rewards as the principal in the research and development activities.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our principal obligation under our grant agreements is to conduct the internal or external research in the specific field funded by the grant. We determine, through the grant&#146;s normal research process, which research and development projects to pursue. We recognize grant revenues as the research activities are performed. If the grant includes an upfront payment, we defer the amount and recognize it as revenue as the expenditures are incurred.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Inventories and Cost of Product Revenues</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In 2014, we were notified that the European Commission, or EC, granted marketing authorization for Translarna for the treatment of nmDMD, in ambulatory patients aged five years and older. This marketing authorization is subject to annual review and renewal by the EMA following its reassessment of the risk-benefit balance of the authorization, which we refer to as the annual EMA reassessment, and is further conditioned on our ability to complete ACT DMD and submit the final report, including additional efficacy and safety data from the trial, in 2015 and implement measures, including pharmacovigilance plans, that are detailed in the risk management plan for Translarna that was submitted to EMA. We submitted a marketing authorization renewal request to the EMA in February&nbsp;2015. We plan to seek to renew the approval on an annual basis until our obligations have been fulfilled and the approval is converted from a conditional approval into a full approval. The conditional marketing authorization allows us to market Translarna in the 31 member states of European Economic Area. Our launch in these countries is on a country by country basis.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We do not have sufficient history or experience from which to accurately forecast product sales or demand generation. As such, we have not capitalized inventory and will not capitalize inventory until full approval has been obtained or until we can reasonably predict future product sales and demand generation. The costs incurred related to Translarna have been recorded as research and development expense in the statements of operations. We do not separately present a cost of product revenues in our statement of operations since the cost of product sales has been insignificant to date.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26<a name="PB_26_123014_6228"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='26',FILE='C:\JMS\C901937\15-7157-1\task7389716\7157-1-ga.htm',USER='C901937',CD='May  5 05:27 2015' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Accrued expenses</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As part of the process of preparing our financial statements, we are required to estimate accrued expenses. This process involves communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual cost. The majority of our service providers invoice us monthly in arrears for services performed. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us. Examples of estimated accrued expenses include:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">fees paid to contract research organizations in connection with preclinical and toxicology studies and clinical trials;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">fees paid to investigative sites in connection with clinical trials;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">fees paid to contract manufacturers in connection with the production of clinical trial materials; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">professional service fees.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Share-based compensation</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We expect to grant additional stock options that will result in additional share-based compensation expense. We measure the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of the award. For service type awards, share-based compensation expense is recognized on a straight-line basis over the period during which the employee is required to provide service in exchange for the entire award. For awards that vest or begin vesting upon achievement of a performance condition, we estimate the likelihood of satisfaction of the performance condition and recognize compensation expense when achievement of the performance condition is deemed probable using an accelerated attribution model.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In 2015, we issued a total of </font><font size="2" style="font-size:10.0pt;">1,456,550 </font><font size="2" style="font-size:10.0pt;">stock options to various employees. Of those, 93,350 were non-statutory stock option inducement grants made pursuant to the NASDAQ inducement grant exception as a material component of our new hires&#146; employment compensation. All other stock option grants were made under our 2013 Long Term Incentive Plan.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The fair value of options is calculated using the Black-Scholes option pricing model to determine the fair value of stock options on the date of grant based on key assumptions, such as expected volatility and expected term. As a new public company, we do not have sufficient history to estimate the volatility of our common stock price or the expected life of the options. We calculate expected volatility based on reported data for similar publicly traded companies for which historical information is available and will continue to do so until the historical volatility of our common stock is sufficient to measure expected volatility for future option grants.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The fair value of grants made in the three months ended March&nbsp;31, 2015 was contemporaneously estimated on the date of grant using the following assumptions:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="46%" style="border-collapse:collapse;margin-left:2.0in;width:46.66%;">
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.36%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="30%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:30.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Risk-free interest rate </font></p>    </td>
<td width="5%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:5.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:30.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.54 &#150; 1.77%</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" style="padding:0in 0in 0in 0in;width:62.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expected volatility </font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="bottom" style="padding:0in 0in 0in 0in;width:30.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">67-69%</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expected term </font></p>    </td>
<td width="5%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:5.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:30.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.50 - 6.11 years</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We assumed no expected dividends for all grants. The weighted average grant date fair value of options granted during the three months ended March&nbsp;31, 2015 was $31.82 per share.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We use the &#147;simplified method&#148; to determine the expected term of options. Under this method, the expected term represents the average of the vesting period and the contractual term. The expected volatility of share options was estimated based on a historical volatility analysis of peers that were similar to us with respect to industry, stage of</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27<a name="PB_27_123537_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='27',FILE='C:\JMS\105590\15-7157-1\task7388950\7157-1-gc.htm',USER='105590',CD='May  5 00:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">life cycle, size, and financial leverage. The risk-free rate of the option is based on U.S. Government Securities Treasury Constant Maturities yields at the date of grant for a term similar to the expected term of the option.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Restricted Stock Awards</font></i><font size="2" style="font-size:10.0pt;">&#151;Restricted stock awards are granted subject to certain restrictions, including service conditions. The grant-date fair value of restricted stock awards, which has been determined based upon the market value of our common stock on the grant date, is expensed over the vesting period.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table summarizes information on our restricted stock:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="86%" style="border-collapse:collapse;margin-left:.5in;width:86.66%;">
<tr>
<td width="65%" valign="bottom" style="padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="30%" colspan="4" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:30.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Restricted&nbsp;Stock</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" style="padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Number&nbsp;of<br>   Shares</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Weighted<br>   Average&nbsp;Grant<br>   Date&nbsp;Fair&nbsp;Value</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="65%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">January&nbsp;1, 2015</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">718,400</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.72</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Granted </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vested </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(350,084</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.59</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Forfeited </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,346</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.82</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unvested at March&nbsp;31, 2015 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">364,970</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.85</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We recorded share-based compensation expense in the statement of operations as follows for the three months ended March&nbsp;31,</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="73%" style="border-collapse:collapse;margin-left:1.0in;width:73.34%;">
<tr>
<td width="59%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:59.1%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(in&nbsp;thousands)</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.36%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.36%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.38%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="59%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:59.1%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.06%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,667</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.06%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,944</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.1%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Selling, general and administrative </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,081</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,761</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="59%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:59.1%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.06%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,748</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.06%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,705</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of March&nbsp;31, 2015 there was approximately $70.6 million of total unrecognized compensation cost related to unvested share-based compensation arrangements granted under the 2009 Equity and Long Term Incentive Plan, 2013 Long Term Incentive Plan and equity award plans made pursuant to the NASDAQ inducement grant exception for new hires. This cost is expected to be recognized as share-based compensation expense over the weighted average remaining service period of approximately 3.0 years.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Results of operations</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Three months ended March&nbsp;31, 2015 compared to three months ended March&nbsp;31, 2014</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table summarizes revenues and selected expense and other income data for the three months ended March&nbsp;31, 2015 and 2014.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;months&nbsp;ended<br>   March&nbsp;31,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(in&nbsp;thousands)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Change&nbsp;2015&nbsp;vs.<br>   2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net product revenue </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,069</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,069</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Collaboration and grant revenue</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,413</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,217</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6,804</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development expense </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27,938</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15,889</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12,049</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Selling, general and administrative expense </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17,615</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7,540</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10,075</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest income</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">524</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">171</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">353</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr height="0">
<td width="415" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="80" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="80" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="80" style="border:none;"></td>
<td width="7" style="border:none;"></td>   </tr> </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28<a name="PB_28_123824_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='28',FILE='C:\JMS\105590\15-7157-1\task7388950\7157-1-gc.htm',USER='105590',CD='May  5 00:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Net product revenues.</font></i><font size="2" style="font-size:10.0pt;"> Net product revenues were $5.1 million for the three months ended March&nbsp;31, 2015. We have recorded revenue on sales where Translarna is available either on a commercial basis or through a reimbursed EAP program and typically paid for by a government authority or institution.&#160; This includes $1.4 million of revenue which was deferred during 2014 when recognized revenue on a cash basis. As of January&nbsp;1, 2015, we recognized revenue for Translarna as product is shipped, given we have established a pattern of collectability.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Collaboration and grant revenues.</font></i><font size="2" style="font-size:10.0pt;"> Collaboration and grant revenues were $2.4 million for the three months ended March&nbsp;31, 2015, a decrease of $6.8 million, or 74%, from $9.2 million for the three months ended March&nbsp;31, 2014. The decrease was primarily due to recognition of a $7.5 million milestone in our spinal muscular atrophy collaboration with Roche in the first quarter of 2014.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Research and development expense.</font></i><font size="2" style="font-size:10.0pt;"> Research and development expense was $27.9 million for the three months ended March&nbsp;31, 2015, an increase of $12.0 million, or 76%, from $15.9 million for the three months ended March&nbsp;31, 2014. The increase resulted primarily from an increase in clinical trial related expenses associated with our ongoing clinical trials, supply chain activities in support of the launch of Translarna as well as in conjunction with our expanding clinical-stage pipeline and an increase in non-cash, share-based compensation expense of approximately $2.7 million.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Selling, general and administrative expense.</font></i><font size="2" style="font-size:10.0pt;"> Selling, general and administrative expense was $17.6 million for the three months ended March&nbsp;31, 2015, an increase of $10.1 million, or 134%, from $7.5 million for the three months ended March&nbsp;31, 2014. The increase resulted primarily from additional costs associated with commercial activities in support of the launch of Translarna across Europe and other regions and an increase in non-cash, share-based compensation expense of approximately $3.3 million.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Interest income. </font></i><font size="2" style="font-size:10.0pt;">&#160;Interest income was $0.5 million for the three months ended March&nbsp;31, 2015, an increase of $0.3 million, or 206%, from $0.2 million for the three months ended March&nbsp;31, 2014.&#160; The increase was due to interest income related to investments.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Liquidity and capital resources</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Sources of liquidity</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Since inception, we have incurred significant operating losses. As a growing commercial stage biopharmaceutical company, we are engaging in significant commercialization efforts for Translarna for nmDMD while also devoting a substantial portion of our efforts on research and development programs related to Translarna and our other product candidates. During 2015, we expect that our revenues will be primarily generated from sales of Translarna in counties in the EEA where we are able to obtain pricing and reimbursement approval at acceptable levels and in other territories where we are permitted to distribute Translarna under our early access programs, or EAP.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have historically financed our operations primarily through the issuance and sale of our common stock in public offerings, the private placements of our preferred stock, collaborations, bank debt, convertible debt financings and grants and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease areas addressed by our product candidates. We expect to continue to incur significant expenses and operating losses for at least the next several years. The net losses we incur may fluctuate significantly from quarter to quarter.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In February&nbsp;2014, we closed a public offering of 5,163,265 shares of common stock at a public offering price of $24.50 per share, including 673,469 shares pursuant to the exercise by the underwriters of an overallotment option. We received net proceeds from the public offering of approximately $118.4 million after deducting underwriting discounts and commissions and other offering expenses payable by us.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In October&nbsp;2014, we closed a public offering of 3,450,000 shares of common stock at a public offering price of $36.25 per share, including 450,000 shares pursuant to the exercise by the underwriters of their option to purchase additional shares. We received net proceeds from the public offering of approximately $117.6 million after deducting underwriting discounts and commissions and other offering expenses payable by us.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29<a name="PB_29_123853_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='29',FILE='C:\JMS\105590\15-7157-1\task7388950\7157-1-gc.htm',USER='105590',CD='May  5 00:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Cash flows</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of March&nbsp;31, 2015, we had cash, cash equivalents and marketable securities of $280.5 million.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table provides information regarding our cash flows and our capital expenditures for the periods indicated.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="86%" style="border-collapse:collapse;margin-left:.5in;width:86.66%;">
<tr>
<td width="69%" valign="bottom" style="padding:0in 0in 0in 0in;width:69.98%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="25%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:25.96%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;months&nbsp;ended<br>   March&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="69%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:69.98%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(in&nbsp;thousands)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="11%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.54%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="11%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.54%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="69%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:69.98%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash provided by (used in):</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="11%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:11.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="11%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:11.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="69%" valign="bottom" style="padding:0in 0in 0in 0in;width:69.98%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Operating activities </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(36,425</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(13,438</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="69%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:69.98%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Investing activities </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="11%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20,607</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="11%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4,267</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="69%" valign="bottom" style="padding:0in 0in 0in 0in;width:69.98%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Financing activities </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="11%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:11.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,019</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="11%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:11.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">118,146</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr height="0">
<td width="454" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="8" style="border:none;"></td>
<td width="66" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="8" style="border:none;"></td>
<td width="66" style="border:none;"></td>
<td width="8" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash used in operating activities was $36.4 million for the three months ended March&nbsp;31, 2015 and $13.4 million for the three months ended March&nbsp;31, 2014. The change in net cash used in operating activities primarily related to supporting clinical development and pre-commercial activities.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash provided by investing activities was $20.6 million for the three months ended March&nbsp;31, 2015 and net cash used in investing activities was $4.3 million for the three months ended March&nbsp;31, 2014. Cash provided by investing activities was related to the sale&nbsp;&amp; redemption of marketable securities for the three months ended March&nbsp;31, 2015.&#160; Cash used in investing activities was related to net purchases of investments for the three months ended March&nbsp;31, 2014.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash provided by financing activities was $3.0 million for the three months ended March&nbsp;31, 2015 and $118.1 million for the three months ended March&nbsp;31, 2014. Net cash provided by financing activities was primarily attributable to the exercise of options for the three months ended March&nbsp;31, 2015. Net cash provided by financing activities in 2014 was primarily attributable to approximately $118.4 million in net proceeds from the February&nbsp;2014 public offering for the three months ended March&nbsp;31, 2014.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Funding requirements</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We anticipate that our expenses will increase substantially in connection with the expansion of our commercial infrastructure as we continue to establish an international presence, particularly throughout Europe and in the U.S., and our efforts to commercialize Translarna for the treatment of nmDMD, including significant sales and marketing, legal and regulatory, and distribution and manufacturing expenses. In addition, we expect to continue to incur significant costs in connection with our ongoing ACT DMD and ACT CF trials as well as our Phase 2 proof-of-concept studies for nmMPS I and nonsense mutation aniridia. We also expect to incur ongoing research and development expenses for our other product candidates, including the ongoing Phase 1 clinical study under our cancer stem cell program and IND-enabling studies under our antibacterial program. In addition, we may incur substantial costs in connection with our ongoing rolling NDA submission with the FDA for Translarna for the treatment of nmDMD and our currently anticipated submission of a marketing authorization variation with the EMA to seek to include Translarna for the treatment of nmCF in the second half of 2015. We have begun seeking and intend to continue to seek marketing approval for Translarna for the treatment of nmDMD in territories outside of the EEA and we may also seek marketing approval for Translarna for other indications, and these efforts may significantly impact the timing and extent of our commercialization expenses.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, our expenses will increase if and as we:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">initiate or continue the research and development of Translarna for additional indications and of our other product candidates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">seek to discover and develop additional product candidates;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30<a name="PB_30_124010_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='30',FILE='C:\JMS\105590\15-7157-1\task7388950\7157-1-gc.htm',USER='105590',CD='May  5 00:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">maintain, expand and protect our intellectual property portfolio; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">add operational, financial and management information systems and personnel, including personnel to support our product development and commercialization efforts.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We believe that our existing cash and cash equivalents, including the net proceeds from our public offerings of common stock, marketable securities and research funding that we expect to receive under our collaborations, will be sufficient to enable us to fund our operating expenses and capital expenditure requirements through late 2017. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our future capital requirements will depend on many factors, including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the progress and results of confirmatory Phase 3 clinical trials of Translarna for nmDMD and nmCF as well as our Phase 2 proof&#160; of concept studies for nmMPS I and nonsense mutation aniridia and our ongoing Phase 1 clinical study under our cancer stem cell program and IND-enabling studies under our antibacterial program;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the scope, costs and timing of the expansion of our commercial infrastructure, including in connection with the growth of our international presence in Europe and in other territories;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the scope, costs and timing of our commercialization activities, including product sales, marketing, legal, regulatory, distribution and manufacturing, in the European Economic Area for nmDMD and any of our other product candidates that may receive marketing approval or any additional indications or territories in which we receive authorization to market Translarna;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the timing and costs related to our rolling NDA submission with the FDA for Translarna for the treatment of nmDMD and our currently anticipated submission of a marketing authorization variation with the EMA to seek to include Translarna for the treatment of nmCF in the second half of 2015;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the timing and scope of growth in our employee base;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for Translarna for additional indications and for our other product candidates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the number and development requirements of other product candidates that we pursue;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the costs, timing and outcome of regulatory review of Translarna and our other product candidates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">revenue received from commercial sales of Translarna or any of our other product candidates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the costs of preparing, filing and prosecuting patent applications, maintaining, and protecting our intellectual property rights and defending against intellectual property related claims;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the extent to which we acquire or invest in other businesses, products and technologies; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to establish and maintain collaborations, including our collaborations with Roche and the SMA Foundation, and our ability to obtain research funding and achieve milestones under these agreements.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs primarily through a combination of equity offerings, debt financings, collaborations, strategic alliances, grants and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease areas addressed by our product and product candidates and marketing, distribution or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our shareholders ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31<a name="PB_31_124125_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='31',FILE='C:\JMS\105590\15-7157-1\task7388950\7157-1-gc.htm',USER='105590',CD='May  5 00:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">adversely affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Contractual obligations</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">During the period ending March&nbsp;31, 2015, there were no material changes to our contractual obligations and commitments outside the ordinary course of business from those disclosed under the heading &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations-Contractual Obligations&#148; in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2014.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</font></b><a name="Item3_QuantitativeAndQualitativeD_124213"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">During the period ending March&nbsp;31, 2015, there were no material changes in our market risk or how our market risk is managed, compared to those disclosed under the heading &#147;Quantitative and Qualitative Disclosures about Market Risk&#148; in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2014.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 4. Controls and Procedures.</font></b><a name="Item4_ControlsAndProcedures__124214"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March&nbsp;31, 2015. The term &#147;disclosure controls and procedures&#148;, as defined in Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)&nbsp;under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission&#146;s rules&nbsp;and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#146;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March&nbsp;31, 2015, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No change in our internal control over financial reporting occurred during the quarter ended March&nbsp;31, 2015 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32<a name="PB_32_124225_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='32',FILE='C:\JMS\105590\15-7157-1\task7388950\7157-1-gc.htm',USER='105590',CD='May  5 00:23 2015' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PART&nbsp;II&#151;OTHER INFORMATION</font></b><a name="PartiiotherInformation_124548"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 1. Legal Proceedings.</font></b><a name="Item1_LegalProceedings__124549"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">From time to time in the ordinary course of our business, we are subject to claims, legal proceedings and disputes as a result of patients seeking to participate in our clinical trials or otherwise gain access to our product candidates. We are not currently subject to any material legal proceedings.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 1A.&#160; Risk Factors</font></b><a name="Item1a_RiskFactors_124550"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following risk factors and other information included in this Quarterly Report on Form&nbsp;10-Q should be carefully considered. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we presently deem less significant may also impair our business operations. Please see page&nbsp;1 of this Quarterly Report on Form&nbsp;10-Q for a discussion of some of the forward-looking statements that are qualified by these risk factors. If any of the following risks occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to Our Financial Position and Need for Additional Capital</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We have incurred significant losses since our inception. We expect to incur significant expenses in connection with the continued expansion of our global operations and execution of our commercial strategy for Translarna</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">&#153;<i> (ataluren) in European Economic Area and other territories, our efforts to obtain broader and additional regulatory approvals for Translarna, and the development of our product pipeline. We expect to continue to incur operating losses for at least the next several years and may never generate profits from operations or maintain profitability.</i></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Since inception, we have incurred significant operating losses. As of March&nbsp;31, 2015, we had an accumulated deficit of $460.5 million. We have historically financed our operations primarily through the issuance and sale of our common stock in public offerings, the private placements of our preferred stock, collaborations, bank debt, convertible debt financings, and grants and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease areas addressed by our product candidates. We expect to continue to incur significant expenses and operating losses for at least the next several years. The net losses we incur may fluctuate significantly from quarter to quarter.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are a growing commercial-stage biopharmaceutical company, but prior to 2014 we devoted substantially all of our efforts on research and development, including clinical trials. In August&nbsp;2014, the European Commission granted marketing authorization for Translarna&#153; (ataluren) for the treatment of Duchenne muscular dystrophy caused by nonsense mutations, or nmDMD, in ambulatory patients aged five years and older. The marketing is subject to annual review and renewal by the EMA following its reassessment of the risk-benefit balance of the authorization, which we refer to as the annual EMA reassessment, and is further conditioned on our ability to complete ACT DMD and submit the final report, including additional efficacy and safety data from the trial, during 2015. See &#147;Risk Factors&#151;Risks Related to Regulatory Approval of our Product Candidates&#148; on page&nbsp;59 for further detail regarding the annual EMA reassessment process, including a description of the risk benefit balance.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The marketing authorization described above allows us to market Translarna in the 31 member states of the European Economic Area, or EEA. We commenced our commercial launch of Translarna in Germany in December&nbsp;2014 and we expect to commercially launch in other key countries in the EEA throughout 2015 and beyond, subject to completion of pricing and reimbursement negotiations. Concurrently, in preparation for a potential U.S. launch in the first half of 2016, we have begun building out our commercial team and infrastructure in the U.S. We anticipate that our expenses will increase substantially in connection with the expansion of our global infrastructure as we continue to establish an international presence and our efforts to commercialize Translarna for the treatment of nmDMD, including significant sales and marketing, legal and regulatory, and distribution and manufacturing expenses.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, we expect to continue to incur significant costs in connection with our ongoing confirmatory Phase 3 clinical trials for Translarna for the treatment of nmDMD and nmCF as well as our Phase 2 proof-of-concept studies for nmMPS I and aniridia. We also expect to incur ongoing research and development expenses for Translarna in</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33<a name="PB_33_125030_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='33',FILE='C:\JMS\C901937\15-7157-1\task7389716\7157-1-ge.htm',USER='C901937',CD='May  5 05:08 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">additional indications as well as for our other product candidates, including the ongoing Phase 1 clinical study under our cancer stem cell program and IND-enabling studies under our antibacterial program. In addition, we may incur substantial costs in connection with our rolling NDA submission with the FDA for Translarna for the treatment of nmDMD and our currently anticipated submission of a marketing authorization variation with the EMA to seek to include Translarna for the treatment of nmCF in the second half of 2015. We have begun seeking and intend to continue to seek marketing approval for Translarna for the treatment of nmDMD in territories outside of the EEA and we may also seek marketing approval for Translarna for other indications. These efforts may significantly impact the timing and extent of our commercialization expenses.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, our expenses will increase if and as we:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">initiate or continue the research and development of Translarna for additional indications and of our other product candidates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">seek to discover and develop additional product candidates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">maintain, expand and protect our intellectual property portfolio; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">add operational, financial and management information systems and personnel, including personnel to support our product development and commercialization efforts.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our ability to generate profits from operations and become and remain profitable depends on our ability to successfully develop and commercialize drugs that generate significant revenue. This will require us to be successful in a range of challenging activities, including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">successfully completing confirmatory Phase 3 clinical trials of Translarna for the treatment of either or both of nmDMD and nmCF and successfully initiating clinical studies of Translarna for the treatment of additional indications, including nmMPS I and nonsense mutation aniridia, and successfully advancing our other programs and collaborations, including our cancer stem cell, antibacterial and SMA programs;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">establishing a global commercial infrastructure, including the sales, marketing and distribution capabilities to effectively market and sell Translarna in Europe, the United States, and other parts of the world;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">successfully implementing marketing and distribution relationships with third parties in territories where we do not pursue direct commercialization;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">negotiating and securing adequate pricing and reimbursement terms on a timely basis, or at all, in the countries in which we have and may obtain regulatory approval;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">negotiating and securing adequate reimbursement from other third-party payors for Translarna;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">launching commercial sales of Translarna for the treatment of nmDMD in accordance with our estimated timeline;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">maintaining the marketing authorization of Translarna for the treatment of nmDMD in the EEA and satisfying all related conditions and ongoing requirements;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">identifying patients eligible for treatment with Translarna;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">obtaining approval to market Translarna for the treatment of other indications, and expanding the territories in which we are approved to market Translarna for the treatment of nmDMD;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">expanding the approved product label of Translarna for the treatment of nmDMD;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">protecting our rights to our intellectual property portfolio related to Translarna; and</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">34<a name="PB_34_125053_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='34',FILE='C:\JMS\C901937\15-7157-1\task7389716\7157-1-ge.htm',USER='C901937',CD='May  5 05:08 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">contracting for the manufacture and distribution of commercial quantities of Translarna;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to generate profits from operations. Even if we do generate profits from operations, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to generate profits from operations and remain profitable would decrease the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product offerings or continue our operations. A decline in the value of our company could also cause our stockholders to lose all or part of their investment in our company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We expect to incur significant expenses related to the establishment of an expanded international presence and the commercialization of Translarna, including costs related to product sales and marketing, legal and regulatory, and distribution and manufacturing, which may further increase as we expand the geographic area covered by our commercial launch and in the event we receive additional approvals for the use of Translarna or any of our other product candidates. In addition, we expect our research and development expenses to increase in connection with our ongoing activities, particularly as we continue our confirmatory Phase 3 clinical trials of Translarna for the treatment of nmDMD and nmCF, our Phase 2 proof-of-concept study of Translarna in nmMPS, and our Phase 1 clinical study under our cancer stem cell program and IND-enabling studies under our antibacterial program. We also expect to initiate a proof-of- concept study for Translarna in nonsense mutation aniridia during 2015. Furthermore, since the closing of our initial public offering in June&nbsp;2013, we have begun to incur additional costs associated with operating as a public company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We believe that our existing cash and cash equivalents, including the net proceeds from our public offerings of common stock, marketable securities and research funding that we expect to receive under our collaborations, will be sufficient to enable us to fund our operating expenses and capital expenditure requirements through late 2017. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our future capital requirements will depend on many factors, including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the progress and results of our confirmatory Phase 3 clinical trials of Translarna for nmDMD and nmCF as well as our Phase 2 proof-of-concept studies for nmMPS I and nonsense mutation aniridia and our Phase 1 clinical study under our cancer stem cell program and IND-enabling studies under our antibacterial program;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the scope, costs and timing of the expansion of our commercial infrastructure, including in connection with the growth of our international presence, in Europe and in other territories;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the scope, costs and timing of our commercialization activities, including product sales, marketing, legal, regulatory, distribution and manufacturing, in the European Economic Area for nmDMD and any of our other product candidates that may receive marketing approval or any additional indications or territories in which we receive authorization to market Translarna;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the timing and costs related to our rolling NDA submission with the FDA for Translarna for the treatment of nmDMD and our currently anticipated submission of a marketing authorization variation with the EMA to seek to include Translarna for the treatment of nmCF in the second half of 2015;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the timing and scope of growth in our employee base;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for Translarna for additional indications and for our other product candidates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the number and development requirements of other product candidates that we pursue;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the costs, timing and outcome of regulatory review of Translarna and our other product candidates;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">35<a name="PB_35_125113_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='35',FILE='C:\JMS\C901937\15-7157-1\task7389716\7157-1-ge.htm',USER='C901937',CD='May  5 05:08 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">revenue received from commercial sales of Translarna or any of our other product candidates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the costs of preparing, filing and prosecuting patent applications, maintaining, and protecting our intellectual property rights and defending against intellectual property-related claims;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the extent to which we acquire or invest in other businesses, products and technologies; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to establish and maintain collaborations, including our collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche,&nbsp;Inc., which we refer to collectively as Roche, and the Spinal Muscular Atrophy Foundation, or the SMA Foundation, and our ability to obtain research funding and achieve milestones under these agreements.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales for certain product candidates or indications. In addition, our product candidates, if approved, may not achieve commercial success, including Translarna for the treatment of nmDMD.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are continuing to engage in significant commercialization efforts for Translarna for nmDMD throughout the EEA. We commenced our commercial launch of Translarna in Germany in December&nbsp;2014 and we expect to commercially launch in other key countries in the EEA throughout 2015 and in future years, subject to completion of pricing and reimbursement negotiations. In the third quarter of 2014, we began to recognize revenue for payments received under reimbursed early access programs for Translarna for nmDMD patients in selected countries. We expect that our commercial revenue generated in the next several years will be derived exclusively from sales of Translarna for the treatment of nmDMD and other indications, if any, that may receive marketing authorization and that commercial sales will generally be limited to countries in the European Economic Area and other territories in which we have obtained marketing authorization and reimbursement approval or are permitted to initiate treatment under reimbursed early access programs or pursuant to other procedures. Other commercial revenue, if any, would be derived from sales of products that we are not planning to have commercially available for several years, if at all.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accordingly, we will need to continue to rely on additional financing in connection with our continuing operations and to achieve our business objectives. In addition, we may seek additional capital due to favorable market conditions or based on strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. Additional financing may not be available to us on acceptable terms or at all. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or our commercialization efforts.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings; debt financings; collaborations; strategic alliances; grants and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease areas addressed by our product candidates; and marketing, distribution or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our shareholders ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates; or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36<a name="PB_36_125144_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='36',FILE='C:\JMS\C901937\15-7157-1\task7389716\7157-1-ge.htm',USER='C901937',CD='May  5 05:08 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our limited operating history may make it difficult for our stockholders to evaluate the success of our business to date and to assess our future viability.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We commenced our commercial launch of Translarna in Germany in December&nbsp;2014 and in the third quarter of 2014 we began to recognize revenue for payments received under reimbursed early access programs for Translarna for nmDMD patients in selected countries. Prior to such time, our operations were limited to organizing and staffing our company, developing and securing our technology, raising capital, undertaking preclinical studies and clinical trials of our product candidates, and preparing for the commercial launch of Translarna for nmDMD in Europe. We are in the process of transitioning from a company with a research and development focus to a company capable of supporting global commercial activities. We may not be successful in such a transition. Other than with respect to the marketing authorization granted by the European Commission in August&nbsp;2014 for Translarna for the treatment of nmDMD, which is subject to annual EMA reassessment until we fulfill certain obligations, we have not proven our ability to successfully obtain marketing approvals to sell our product or product candidates. In addition, we have not yet demonstrated our ability to complete development of product candidates, manufacture a commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for a successful full scale product commercialization. Consequently, any predictions our stockholders make about our future success or viability may not be as accurate as they could be if we had a longer operating history. In addition, as a new business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our ability to use our net operating losses and certain other tax attributes may be subject to annual limitations under federal and state tax law that could materially affect our ability to utilize such losses and attributes.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If a corporation undergoes an &#147;ownership change&#148; within the meaning of Section&nbsp;382 of the Internal Revenue Code, or Section&nbsp;382, the corporation&#146;s ability to utilize any net operating losses, or NOLs, and certain tax credits and other attributes generated before such an ownership change, is limited. We believe that we have in the past experienced ownership changes within the meaning of Section&nbsp;382 that have resulted in limitations under Section&nbsp;382 (and similar state provisions) on the use of our NOLs and other tax attributes. Future changes in ownership could result in additional ownership changes within the meaning of Section&nbsp;382 that could further limit our ability to utilize our NOLs and certain other tax attributes.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Changes in our effective income tax rate could adversely affect our results of operations.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are subject to income taxes in the Unites States and various foreign jurisdictions. Taxes will be incurred as income is earned among these different jurisdictions. Various factors may have favorable or unfavorable effects on our effective income tax rate. These factors include, but are not limited to, interpretations of existing tax laws, changes in tax laws and rates, the accounting for stock options and other share-based compensation, changes in accounting standards, future levels of research and development spending, changes in the mix and level of pre-tax earnings by taxing jurisdiction, the outcome of examinations by the U.S. Internal Revenue Service and other jurisdictions, the accuracy of our estimates for unrecognized tax benefits, the realization of deferred tax assets, or by changes to our ownership or capital structure. The impact on our income tax provision resulting from the above- mentioned factors and others may be significant and could adversely affect our results of operations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to the Development and Commercialization of our Product and Product Candidates</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We depend heavily on the success of our lead product, Translarna, which we are developing for nmDMD, nmCF, nmMPS I and nonsense mutation aniridia. All of our other product candidates, including those under our collaborations with Roche and the SMA Foundation, are still in early clinical or preclinical development. If we are unable to execute our commercial strategy for Translarna for the treatment of nmDMD in the European Economic Area, fail to receive regulatory approval in the United States and other territories, fail to maintain or satisfy the conditions of our marketing authorization in the European Economic Area, or if we experience significant delays in accomplishing such goals, our business will be materially harmed.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have invested a significant portion of our efforts and financial resources in the development of Translarna for nmDMD and nmCF. Additionally, we are initiating a Phase 2 proof-of-concept study in nmMPS I and plan to initiate a Phase 2 proof-of-concept study in nonsense mutation aniridia during 2015. Our ability to generate product revenues will depend heavily on the successful development and commercialization of Translarna. In August&nbsp;2014,</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">37<a name="PB_37_125226_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='37',FILE='C:\JMS\C901937\15-7157-1\task7389716\7157-1-ge.htm',USER='C901937',CD='May  5 05:08 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Translarna was granted marketing authorization in the EEA for the treatment of nmDMD in ambulatory patients aged 5 years and older, which is subject to annual EMA reassessment and is further conditioned on our ability to complete ACT DMD and submit the final report in 2015. Translarna is still under investigation for the treatment of nmDMD in the United States and has not been approved by the FDA. If we do not successfully commercialize Translarna in the EEA or receive regulatory approval in the United States for Translarna for the treatment of nmDMD and subsequently successfully commercialize Translarna in the United States, our ability to generate additional revenue will be jeopardized and, consequently, our business will be materially harmed.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The success of Translarna will depend on a number of additional factors, including the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">successful completion of confirmatory Phase 3 clinical trials of Translarna in nmDMD and nmCF and the successful advancement of Translarna in additional indications, in particular, nmMPS I and nonsense mutation aniridia;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the establishment of an expanded international commercial infrastructure capable of supporting product sales, marketing and distribution of Translarna;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">implementing marketing and distribution relationships with third parties in territories where we do not pursue direct commercialization;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the continued maintenance of, and satisfaction of the conditions under, the marketing authorization of Translarna for the treatment of nmDMD in the European Economic Area;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to obtain additional and maintain existing reimbursed named patient and cohort early access programs on adequate terms;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">whether and when we obtain marketing approval of Translarna in additional territories and for additional or expanded indications;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">successful negotiation of adequate pricing and reimbursement terms on a timely basis, or at all, in the countries which require such negotiation and in which we obtain regulatory approval;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the timing and scope of the commercial launch of Translarna in nmDMD;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">establishing and maintaining commercial manufacturing arrangements with third party manufacturers;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the ability of our third-party manufacturers to successfully produce commercial and clinical supplies of Translarna on a timely basis sufficient to meet the needs of our commercial and clinical activities;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">successful identification of eligible patients;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">acceptance of Translarna in nmDMD by patients, the medical community and third-party payors;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">effectively competing with other therapies;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">a continued acceptable safety profile of Translarna;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">protecting our rights in our intellectual property portfolio.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to continue to commercialize Translarna, which would materially harm our business.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The marketing authorization granted by the European Commission for Translarna for the treatment of nmDMD is subject to the satisfaction of specific conditions and is limited to ambulatory patients aged five years and older located in the European Economic Area, which significantly limits an already small treatable patient population,</font></i></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">38<a name="PB_38_125310_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='38',FILE='C:\JMS\C901937\15-7157-1\task7389716\7157-1-ge.htm',USER='C901937',CD='May  5 05:08 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">&nbsp;</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">reduces our commercial opportunities, and is subject to an annual reassessment of the risk-benefit balance by the EMA.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have obtained orphan drug designations from the EMA and from the FDA for Translarna for the treatment of nmDMD because the number of patients who could benefit from treatment with Translarna is small. The marketing label approved by the European Commission further limits the currently treatable patient population to ambulatory nmDMD patients aged five years and older who have been identified through genetic testing. Overall, we estimate that the potential opportunity for a treatment for nmDMD is approximately 7,000 patients worldwide including 2,000 patients in the United States, 2,500 patients in the European Union and 2,500 patients in the rest-of-world including Latin America, Japan and Australia. We estimate that approximately 40% of nmDMD patients are ambulatory and at least five years old. Our estimates of both the number of people who have DMD caused by a nonsense mutation, as well as the subset of people with nmDMD who are ambulatory and at least five years old, are based on our beliefs and estimates derived from a variety of sources and may prove to be incorrect. Information concerning the eligible patient population is generally limited to certain geographies and may not employ definitive measures capable of establishing with precision the actual number of nmDMD patients in such geography. If the market opportunities for Translarna for the treatment of nmDMD are smaller than we believe they are, our business and anticipated revenues will be negatively impacted. Although we intend to seek to expand the approved product label of Translarna for the treatment of nmDMD in the future, the timing of, and our ability to generate, the necessary data or results required to obtain expanded regulatory approval is currently uncertain. Given the small number of patients who have nmDMD, and the smaller number of patients who meet the criteria for treatment under our current marketing authorization, our commercial opportunity is limited. It is critical to the commercial success of Translarna for nmDMD that we successfully identify and treat these patients.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, the marketing authorization granted by the European Commission is subject to annual review and renewal by the EMA following its reassessment of the risk-benefit balance of the authorization, which we refer to as the annul EMA reassessment, and is further conditioned on our ability to complete ACT DMD and submit the final report, which must include additional efficacy and safety data from the trial in 2015, and implement measures, including pharmacovigilance plans, that are detailed in the risk management plan. We submitted a marketing authorization renewal request to the EMA in February&nbsp;2015. We plan to seek to renew the marketing authorization on an annual basis until we have satisfied the conditions of the marketing authorization and a full marketing authorization is granted. If we fail to satisfy such requirements, or if it is determined that the balance of risks and benefits of using Translarna changes materially, the European Commission could, at the EMA&#146;s recommendation, vary, suspend, withdraw or refuse to renew the marketing authorization for Translarna or require additional clinical trials, any of which would negatively impact our anticipated revenue from Translarna and materially harm our business. See &#147;Risk Factors&#151;Risks Related to Regulatory Approval of our Product Candidates&#148; on page&nbsp;59 for further detail regarding the annual EMA reassessment process, including a description of the risk benefit balance.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If clinical trials of our product or product </font></i></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">candidates, such as</font></i></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;"> our confirmatory Phase 3 clinical trials of Translarna, fail to demonstrate safety and efficacy to the satisfaction of the EMA or FDA, or do not otherwise produce favorable results, we may experience delays in completing, or ultimately be unable to complete, the development and commercialization of Translarna or any other product candidate.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with seeking marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For example, we did not achieve the primary efficacy endpoint with the pre-specified level of statistical significance in a Phase 2b clinical trial of Translarna for the treatment of nmDMD that we completed in 2010 or in a Phase 3 clinical trial of Translarna for the treatment of nmCF that we completed in 2011. Although we believe that the collective data from these trials, including retrospective and subgroup analyses that we have performed, provide</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">39<a name="PB_39_125353_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='39',FILE='C:\JMS\C901937\15-7157-1\task7389716\7157-1-ge.htm',USER='C901937',CD='May  5 05:08 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">strong support for concluding that Translarna was active and showed clinically meaningful improvements over placebo in these trials, we may similarly fail to achieve the primary efficacy endpoint in ACT DMD and ACT CF, our confirmatory Phase 3 clinical trials of Translarna for these indications. If the results of our confirmatory Phase 3 clinical trials are not favorable, we may need to conduct additional clinical trials at significant cost or altogether abandon development of Translarna for either or both of nmDMD and nmCF. We also did not achieve the primary objective in one of four prior Phase 2 clinical trials that we conducted for Translarna for the treatment of nmCF in which we measured change in chloride conductance in nasal cells over the course of treatment.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Further, the marketing authorization granted by the European Commission is subject to an annual EMA reassessment and is further conditioned on our ability to complete ACT DMD and submit the final report, including additional efficacy and safety data from the trial, during 2015. If the results of ACT DMD are not favorable, if we fail to satisfy the conditions of the marketing authorization, or if it is determined that the balance of risks and benefits of using Translarna changes materially, the European Commission could, at the EMA&#146;s recommendation, vary, suspend, withdraw or refuse to renew the marketing authorization for Translarna or require additional clinical trials. See &#147;Risk Factors&#151;Risks Related to Regulatory Approval of our Product Candidates&#148; on page&nbsp;61 for further detail regarding the annual EMA reassessment process, including a description of the risk benefit balance. We also sell Translarna under reimbursed early access programs in a limited number of countries and there is no assurance that such sales will continue to be authorized in any particular country. If any of these events were to occur, they would negatively impact our anticipated revenue from Translarna and could materially harm our business.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we are required to conduct additional clinical trials or other testing of Translarna or any other product candidate that we develop beyond those that we contemplate; if we are unable to successfully complete our clinical trials or other testing; if the results of these trials or tests are not positive or are only modestly positive; or if there are safety concerns, we may:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">be unable to successfully renew our marketing authorization in the EEA for Translarna for the treatment of nmDMD;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">be delayed in obtaining marketing approval for our product candidates or additional authorizations for our product;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">not obtain marketing approval at all;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">obtain approval for indications or patient populations that are not as broad as intended or desired;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">be subject to additional post-marketing testing requirements or restrictions; or</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">have the product removed from the market after obtaining marketing approval.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we or our collaborators experience any of a number of possible unforeseen events in connection with clinical trials related to our product or product candidates, including those under our collaboration with Roche and the SMA Foundation, potential marketing approval or commercialization of our product</font></i></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;"> or</font></i></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;"> product candidates could be delayed or prevented.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We or our collaborators may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product or product candidates, including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 45.0pt;text-indent:-27.0pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">clinical trials of our product or product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40<a name="PB_40_125415_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='40',FILE='C:\JMS\C901937\15-7157-1\task7389716\7157-1-ge.htm',USER='C901937',CD='May  5 05:08 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 45.0pt;text-indent:-27.0pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate;</font></p>
<p style="margin:0in 0in .0001pt 45.0pt;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 45.0pt;text-indent:-27.0pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">we may be unable to enroll a sufficient number of patients in our trials to ensure adequate statistical power to detect any statistically significant treatment effects;</font></p>
<p style="margin:0in 0in .0001pt 45.0pt;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 45.0pt;text-indent:-27.0pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</font></p>
<p style="margin:0in 0in .0001pt 45.0pt;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 45.0pt;text-indent:-27.0pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">regulators, institutional review boards or independent ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</font></p>
<p style="margin:0in 0in .0001pt 45.0pt;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 45.0pt;text-indent:-27.0pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">we may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</font></p>
<p style="margin:0in 0in .0001pt 45.0pt;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 45.0pt;text-indent:-27.0pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">we may have to suspend or terminate clinical trials of our product or product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks;</font></p>
<p style="margin:0in 0in .0001pt 45.0pt;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 45.0pt;text-indent:-27.0pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">regulators, institutional review boards or independent ethics committees may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</font></p>
<p style="margin:0in 0in .0001pt 45.0pt;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 45.0pt;text-indent:-27.0pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the cost of clinical trials of our product or product candidates may be greater than we anticipate;</font></p>
<p style="margin:0in 0in .0001pt 45.0pt;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 45.0pt;text-indent:-27.0pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the supply or quality of our product or product candidates or other materials necessary to conduct clinical trials of our product or product candidates may be insufficient or inadequate; or</font></p>
<p style="margin:0in 0in .0001pt 45.0pt;text-indent:-27.0pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 45.0pt;text-indent:-27.0pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our product or product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators, institutional review boards or independent ethics committees to suspend or terminate the trials.</font></p>
<p style="margin:0in 0in .0001pt 45.0pt;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our product development costs will increase if we experience delays in testing or marketing approvals. We do not know whether any preclinical tests or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product or product candidates, allow our competitors to bring products to market before we do, or impair our ability to successfully commercialize our product or product candidates, and so may harm our business and results of operations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our conclusions regarding the activity and potential efficacy of Translarna in our completed Phase 2b clinical trial of Translarna for the treatment of nmDMD and in our completed Phase 3 clinical trial of Translarna for nmCF are based on retrospective analyses of the results of these trials and nominal p-values, which are generally considered less reliable indicators of efficacy than pre-specified analyses and adjusted p-values.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">After determining that we did not achieve the primary efficacy endpoint with the pre-specified level of statistical significance in our completed Phase 2b clinical trial of Translarna for the treatment of nmDMD and in our completed Phase 3 clinical trial of Translarna for nmCF, we performed retrospective and subgroup analyses that we believe provide strong support for concluding that Translarna was active and showed clinically meaningful improvements over placebo in these trials. Although we believe that these additional analyses of the results of these trials were warranted, a retrospective analysis performed after unblinding trial results can result in the introduction of bias if the analysis is inappropriately tailored or influenced by knowledge of the data and actual results. Some of our favorable statistical data from these trials also are based on nominal p-values that reflect only one particular comparison when more than one comparison is possible, such as when two active treatments are compared to placebo or when two or more subgroups are analyzed. Nominal p-values cannot be compared to the benchmark p-value of 0.05 to determine statistical significance without being adjusted for the testing of multiple dose groups or analyses of subgroups.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">41<a name="PB_41_125433_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='41',FILE='C:\JMS\C901937\15-7157-1\task7389716\7157-1-ge.htm',USER='C901937',CD='May  5 05:08 2015' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Because of these limitations, regulatory authorities typically give greater weight to results from pre-specified analyses and adjusted p-values and less weight to results from post-hoc, retrospective analyses and nominal p-values. This diminishes the likelihood that the EMA will approve our request of a variation to our marketing authorization for Translarna to include Translarna for nmCF on a conditional basis, and, even if we successfully complete our confirmatory Phase 3 clinical trials, could negatively impact the evaluation by the EMA or the FDA of our anticipated applications for full marketing approval for Translarna for the applicable indication.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our confirmatory Phase 3 clinical trials of Translarna for nmDMD and nmCF, even if successfully completed, may not be sufficient for approval of Translarna for the applicable indication.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">It is possible that the EMA or the FDA may not consider the results of our confirmatory Phase 3 clinical trials of Translarna for nmDMD or nmCF, once completed and even if successful, to be sufficient for approval of Translarna for such indication. The FDA typically requires two adequate and well-controlled pivotal clinical trials to support marketing approval of a product candidate for a particular indication. The EMA or the FDA could determine that the results of our trials are not sufficiently robust, are subject to confounding factors or are not adequately supported by other trial endpoints. In addition, although we have had discussions with the FDA regarding our confirmatory Phase 3 clinical trial of Translarna for the treatment of nmCF, the FDA may not consider our proposed trial design acceptable. For example, in 2012, the FDA indicated that in its view the data from our completed Phase 3 clinical trial and other data from our development program in cystic fibrosis do not by themselves support an NDA submission and, consequently, the FDA informed us that additional clinical data would be required to establish the evidence necessary to support eventual filing of an NDA for the use of Translarna to treat nmCF. We had additional interactions with the FDA in 2013 regarding the clinical development design which would have the potential to support an NDA, but we did not achieve a consensus between the EMA and FDA views. While we have incorporated feedback from the FDA into our ACT CF trial design, we believe that certain key recommendations from the FDA are not appropriate. Two of the key recommendations that we are in disagreement with are the designation of FEV</font><font size="1" style="font-size:6.5pt;position:relative;top:1.0pt;">1</font><font size="2" style="font-size:10.0pt;">, CF pulmonary exacerbations and body mass index as three co-primary endpoints for the trial and a suggested three-year trial duration. FEV</font><font size="1" style="font-size:6.5pt;position:relative;top:1.0pt;">1</font><font size="2" style="font-size:10.0pt;">&#160;is the primary endpoint in ACT CF, with CF pulmonary exacerbations and body mass index key secondary endpoints, which is consistent with other clinical trials currently ongoing in cystic fibrosis and FDA&#146;s earlier recommendation. Additionally, we believe that extending the study duration to three years would result in a number of complications that would ultimately limit the robustness of the data and conclusions that could be drawn from the results. Based on these interactions, we nonetheless initiated ACT CF in the first half of 2014 consistent with feedback from the EMA on our trial design. If the FDA does not consider our trial designs acceptable, we may need to conduct more than one confirmatory clinical trial and our ability to receive marketing approval for this indication could be delayed or prevented.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Because we are developing our product and product candidates for the treatment of diseases in which there is little clinical experience and, in some cases, using new endpoints or methodologies, there is increased risk that the outcome of our clinical trials will not be favorable.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There are no marketed therapies approved to treat the underlying cause of nmDMD or nmCF. In addition, there has been limited historical clinical trial experience generally for the development of drugs to treat either of these diseases. As a result, the design and conduct of clinical trials for these diseases, particularly for drugs to address the underlying nonsense mutations causing these diseases in some subsets of patients, is subject to increased risk.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prior to our conducting the Phase 2b clinical trial of Translarna for nmDMD, there was no established precedent for an appropriate trial design to evaluate the efficacy of Translarna for nmDMD, and little clinical experience in the methodologies used to analyze the resulting data. Although we believe that we now understand the issues of concern with the pre-specified statistical analyses of our Phase 2b clinical trial results, and that we have designed our confirmatory Phase 3 ACT DMD clinical trial of Translarna in an appropriate fashion, we may nonetheless experience similar or other unknown complications with ACT DMD because of the limited clinical experience in this indication. As a result, we may not achieve the pre-specified endpoint with statistical significance in ACT DMD, which would make approval of Translarna for this indication unlikely. Among other endpoints in ACT DMD, the trial protocol includes two secondary endpoints that have not been used previously as outcome measures in published therapeutic clinical trials of nmDMD. These endpoints, in particular, may produce results that are unpredictable or inconsistent with other trial results.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">42<a name="PB_42_123900_5753"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='42',FILE='C:\JMS\105538\15-7157-1\task7389728\7157-1-gg.htm',USER='105538',CD='May  5 05:11 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">With regard to nmCF, we believe that we now understand subgroup effects that we observed in our completed Phase 3 clinical trial and that we have designed our confirmatory Phase 3 ACT CF clinical trial of Translarna to take these effects into account. However, we may nonetheless experience unknown complications with ACT CF. As a result, we may not achieve the pre-specified endpoint with statistical significance in ACT CF, which would make approval of Translarna for this indication unlikely.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are faced with similar challenges in connection with the design of our Phase 2 proof-of-concept study of Translarna in nmMPS I because there is also limited historical clinical trial experience for the development of drugs to treat the underlying cause of this disorder. While clinical trials of enzyme replacement therapies conducted by third parties have provided some insight into the disorder, enzyme replacement therapies do not sufficiently address the central nervous system, skeletal or cardiac symptoms associated with the disorder. In addition, our own pre-clinical and early stage clinical trials targeting nmMPS I have been limited in duration and, as a result, it is substantially uncertain whether our clinical design will optimize the duration or level of dosing or that we will be able to demonstrate a statistically significant biochemical or clinical effect in the primary or secondary pre-specified endpoints selected for the study.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we experience delays or difficulties in the enrollment of patients in our clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may not be able to initiate or continue clinical trials for our product candidates, including our confirmatory Phase 3 ACT CF clinical trial of Translarna or our Phase 2 proof-of-concept study of Translarna in nmMPS I, if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials. For example, nmCF and nmMPS I are characterized by relatively small patient populations, which could result in slow enrollment of clinical trial participants. In addition, our competitors have ongoing clinical trials for product candidates that could be competitive with our product candidates. As a result, potential clinical trial sites may elect to dedicate their limited resources to participation in our competitors&#146; clinical trials and not ours, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#146; product candidates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Patient enrollment is affected by other factors including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">severity of the disease under investigation;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">eligibility criteria for the study in question;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">perceived risks and benefits of the product candidate under study;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">efforts to facilitate timely enrollment in clinical trials;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">patient referral practices of physicians;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the ability to monitor patients adequately during and after treatment; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">proximity and availability of clinical trial sites for prospective patients.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Enrollment delays in our clinical trials may result in increased development costs for our product candidates. Our inability to enroll a sufficient number of patients in our confirmatory Phase 3 clinical trial of Translarna in nmCF, our Phase 2 proof-of-concept study of Translarna in nmMPS I or any of our other clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. In addition, we intend to submit a variation to our marketing authorization for Translarna in the EEA in the second half of 2015 to seek approval for the treatment of nmCF. Although we plan to submit the variation with the clinical results achieved in our prior Phase 3 clinical trial in nmCF, we believe that the CHMP will consider it important that ACT CF be well underway prior to our submission. As a result, enrollment delays in ACT CF could also delay the timeline for our planned submission with the EMA. In addition, we expect that even if the EMA approves a variance to include Translarna for nmCF, the EMA will require us, as a post-approval measure, to provide it with comprehensive clinical data from ACT CF. In addition, unless and until we satisfy the conditions of our primary marketing authorization in the EEA for Translarna, such authorization will continue to be subject to annual review and renewal by the EMA. See &#147;Risk Factors&#151;Risks Related to Regulatory Approval of our Product and Product Candidates&#148; on </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">43<a name="PB_43_123900_1002"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='43',FILE='C:\JMS\105538\15-7157-1\task7389728\7157-1-gg.htm',USER='105538',CD='May  5 05:11 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">page&nbsp;59 for further detail regarding the annual EMA reassessment process, including a description of the risk benefit balance. As a result, ACT CF enrollment delays could have a negative impact on our ability to obtain and maintain any marketing authorization for nmCF that may be granted in the future, if any.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If serious adverse or inappropriate side effects are identified during the development of Translarna or any other product candidate, we may need to abandon or limit our development of that product or product candidate.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All of our products and product candidates are in clinical or preclinical development and their risk of failure is high. It is impossible to predict when or if any of our product candidates will prove effective or safe in humans or will receive regulatory approval. If our product or product candidates are associated with undesirable side effects or have characteristics that are unexpected, we may need to abandon their development or limit development to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk benefit perspective. Many compounds that initially showed promise in clinical or earlier stage testing have later been found to cause side effects that prevented further development of the compound.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For example, although we did not observe a pattern of liver enzyme elevations in our Phase 2 or Phase 3 clinical trials of Translarna, we did observe modest elevations of liver enzymes in some subjects in one of our Phase 1 clinical trials. These elevated enzyme levels did not require cessation of Translarna administration, and enzyme levels typically normalized after completion of the treatment phase. We did not observe any increases in bilirubin, which can be associated with serious harm to the liver, in the Phase 1 clinical trial.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, in our completed Phase 3 clinical trial of Translarna for the treatment of nmCF, five adverse events in the Translarna arm of the trial that involved the renal system led to discontinuation. As compared to the placebo group, the Translarna treatment arm also had a higher incidence of adverse events of creatinine elevations, which can be an indication of impaired kidney function. In the Translarna treatment arm, more severe clinically meaningful creatinine elevations were reported in conjunction with cystic fibrosis pulmonary exacerbations. These creatinine elevations were associated with concomitant treatment with antibiotics associated with impaired kidney functions, such as aminoglycosides or vancomycin. This led to the subsequent prohibition of concomitant use of Translarna and these antibiotics, which was successful in addressing this issue in the clinical trial. If patients in the Translarna arm of a confirmatory Phase 3 clinical trial for the treatment of nmCF exhibit clinically meaningful creatinine elevations, the EMA or the FDA might not approve Translarna for this indication or could require that we instruct physicians to frequently monitor patients for these abnormalities or impose other conditions, which may be an impediment to the use of Translarna because of concerns related to its safety and convenience.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our focus on the discovery and development of product candidates that target post-transcriptional control processes is unproven, and we do not know whether we will be able to develop any products of commercial value.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our scientific approach focuses on the discovery and development of product candidates that target post-transcriptional control processes. While a number of commonly used drugs and a growing body of research validate the importance of post-transcriptional control processes in the origin and progression of a number of diseases, no existing drugs have been specifically designed to alter post-transcriptional control processes in the same manner as Translarna or our other product candidates. As a result, our focus on targeting these processes may not result in the discovery and development of commercially viable drugs that safely and effectively treat genetic disorders or other diseases. In addition, although we have received marketing authorization by the European Commission for Translarna for the treatment of nmDMD, such marketing authorization is subject to annual EMA reassessment, and is further conditioned on our ability to complete ACT DMD and submit the final report, including additional efficacy and safety data from the trial, in 2015. We may not be successful in developing and receiving full regulatory approval for such use and we may not receive regulatory approval for additional indications for Translarna or any other potentially commercially viable drug that treats an approved indication by targeting a particular post-transcriptional control process. Furthermore, we may not receive regulatory approval for product candidates that target different post-transcriptional control processes. If we fail to develop and commercialize viable drugs, we will not achieve commercial success.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">44<a name="PB_44_123900_1031"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='44',FILE='C:\JMS\105538\15-7157-1\task7389728\7157-1-gg.htm',USER='105538',CD='May  5 05:11 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Translarna for the treatment of nmDMD, or any other product candidate that receives marketing approval, if any, may fail to achieve the degree of market acceptance by physicians, patients, third party payors and others in the medical community necessary for commercial success.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Although Translarna is currently authorized by the EMA for marketing for the treatment of nmDMD, Translarna and any of our other product candidates that may receive marketing approval may nonetheless fail to gain sufficient market acceptance by physicians, patients, third party payors and others in the medical community. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenues or any profits from operations. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the efficacy and potential advantages compared to alternative treatments;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the prevalence and severity of any side effects;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the ability to offer our product candidates for sale at competitive prices;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">convenience and ease of administration compared to alternative treatments;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the strength of marketing and distribution support;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">sufficient third-party coverage or reimbursement; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any restrictions on concomitant use of other medications, such as a restriction that nmCF patients taking Translarna not also use chronic inhaled aminoglycoside antibiotics.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our ability to negotiate, secure and maintain third-party coverage and reimbursement may be affected by political, economic and regulatory developments in the United States, the European Union and other jurisdictions. Governments continue to impose cost containment measures, and third-party payors are increasingly challenging prices charged for medicines and examining their cost effectiveness, in addition to their safety and efficacy. These and other similar developments could significantly limit the degree of market acceptance of Translarna or any of our other product candidates that receive marketing approval.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product or product candidates, we may not be successful in our continuing efforts to commercialize Translarna or commercializing any other product candidate if and when they are approved.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have limited experience in the sale and marketing of pharmaceutical products, and we may be unable to successfully execute our commercial strategy in the EEA or, if approved, in the U.S. or other territories. Our commercial strategy for Translarna involves the development of a commercial infrastructure that spans multiple jurisdictions. In preparation for a potential U.S. launch in the first half of 2016, we are evaluating our commercial strategy and have begun building out our commercial team and infrastructure in the U.S. Our ability to successfully commercialize Translarna for the treatment of nmDMD in the EEA and other territories, including the U.S., if approved, is heavily dependent upon our ability to continue to build an infrastructure that is capable of implementing our global commercial strategy. International operations are subject to inherent risks. The establishment and development of our commercial infrastructure will continue to be expensive and time consuming, and we may not be able to develop our commercial organizations in all intended territories in a timely manner or at all. Doing so will require a high degree of coordination and compliance with laws and regulations in numerous jurisdictions, including restrictions on advertising practices, enforcement of intellectual property rights, restrictions on pricing or discounts, and unexpected changes in international regulatory requirements and tariffs. If we are unable to effectively coordinate such activities or comply with such laws and regulations, our ability to commercialize Translarna in those jurisdictions in which it is or may be approved will be adversely affected. If we are unable to establish and maintain adequate sales, marketing and distribution capabilities, whether independently </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">45<a name="PB_45_123900_7990"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='45',FILE='C:\JMS\105538\15-7157-1\task7389728\7157-1-gg.htm',USER='105538',CD='May  5 05:11 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">or with third parties, we may not be able to generate product revenue consistent with our expectations and may not become profitable.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have evaluated markets outside of the EEA to determine in which geographies we might, if approved, choose to commercialize Translarna ourselves and in which geographies we might choose to collaborate with third parties. We intend to continue to promote Translarna in the EEA and in other permitted territories using both internal and external resources. There are risks involved with establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training an internal commercial team is expensive and time consuming and could delay our commercialization efforts for Translarna for the treatment of nmDMD or any other product launch. If the commercial launch of Translarna or any other product candidate for which we recruit a commercial team and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition such personnel.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The arrangements that we have entered into, or may enter into, with third parties to perform sales and marketing services will generate lower product revenues or profitability of product revenues to us than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. We have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Factors that may inhibit our efforts to commercialize our products on our own include:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our inability to implement third party marketing and distribution relationships in territories where we do not pursue direct commercialization;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the inability of our commercial team to obtain access to or persuade adequate numbers of physicians to prescribe Translarna or any future products;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the lack of complementary products to be offered by our commercial team, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">unforeseen costs and expenses associated with creating an independent commercial organization.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We plan to develop our commercial strategy for additional indications for Translarna or other product candidates, if and when such drugs are approved in the applicable region.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We expect that during 2015 all of our sales of Translarna for the treatment of nmDMD will occur in territories outside of the U.S., which subjects us to additional business risks that could adversely affect our revenue and results of operations.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We expect that during 2015, all of our revenue from sales of Translarna will be generated from countries other than the United States. Additionally, we have operations in several European countries and other territories. We expect that we will continue to expand our international operations in the future. International operations inherently subject us to a number of risks and uncertainties, including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">changes in international regulatory and compliance requirements that could restrict our ability to manufacture, market and sell our products;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">financial risks such as longer payment cycles, difficulty collecting accounts receivable and exposure to fluctuations in foreign currency exchange rates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">difficulty in staffing and managing international operations;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">46<a name="PB_46_123900_2846"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='46',FILE='C:\JMS\105538\15-7157-1\task7389728\7157-1-gg.htm',USER='105538',CD='May  5 05:11 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">potentially negative consequences from changes in or interpretations of tax laws;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">changes in international medical reimbursement policies and programs;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">trade protection measures, including import or export licensing requirements and tariffs;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to develop relationships with qualified local distributors and trading companies;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">political and economic instability in particular foreign economies and markets;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">diminished protection of intellectual property in some countries outside of the U.S.;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">differing labor regulations and business practices; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">regulatory and compliance risks that relate to maintaining accurate information and control over sales and distributors&#146; and service providers&#146; activities that may fall within the purview of the Foreign Corrupt Practices Act, UK Bribery Act or similar local regulation.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any of these factors may, individually or as a group, have a material adverse effect on our business and results of operations. As we continue to expand our existing international operations, we may encounter new risks.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The development and commercialization of new drug products is highly competitive. We face competition with respect to our current product candidates and any products we may seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There is currently no marketed therapy, other than Translarna in the EEA, which has received approval for the treatment of the underlying cause of Duchenne muscular dystrophy. Other currently available treatments for Duchenne muscular dystrophy are only palliative. However, there are other biopharmaceutical companies, including BioMarin Pharmaceutical Inc. (following its acquisition of Prosensa Therapeutic in early 2015) and Sarepta Therapeutics, that are developing treatments for Duchenne muscular dystrophy based on a different scientific approach known as exon-skipping. Summit Corporation also has a product candidate in early clinical development designed to increase the production of the protein utrophin, which is functionally similar to dystrophin, to treat Duchenne muscular dystrophy. Nobelpharma, a Japanese company, is currently sponsoring a Phase 2 clinical trial in Japan of its product candidate NPC-14 (arbekacin sulfate), which is a generically available aminoglycoside antibiotic, in boys with nmDMD.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There are a number of large pharmaceutical and biotechnology companies that currently market and sell products to manage the symptoms and side effects of cystic fibrosis. These products include Chiron Corporation&#146;s TOBI and Genentech,&nbsp;Inc.&#146;s Pulmozyme. Although there are currently no marketed products approved to treat the underlying cause of nmCF, Vertex Pharmaceuticals&#146; CFTR potentiator drug Kalydeco is approved by the FDA and in other territories as a treatment for cystic fibrosis in patients six years of age and older who have a type of mutation in the CFTR gene known as a gating mutation. Vertex Pharmaceuticals also is developing two other product candidates for the treatment of cystic fibrosis in patients who have a type of mutation in the CFTR gene known as a process block mutation. We believe that Translarna is the only product candidate in clinical trials that is designed to treat the underlying cause of nmCF by restoring CFTR activity.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, Aldurazyme, which is manufactured by BioMarin Pharmaceutical Inc. and sold by Genzyme Corporation, is an enzyme replacement therapy for the treatment of mucopolysaccharidosis I. Our SMA collaboration with Roche and the SMA Foundation also faces competition. For example,&nbsp;Isis Pharmaceuticals,&nbsp;Inc. is evaluating its antisense drug as a treatment for SMA in two Phase 3 studies that were initiated in SMA patients in 2014. Other companies are also pursuing product candidates for the treatment of SMA, including Novartis Pharmaceuticals Corporation.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">47<a name="PB_47_123900_457"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='47',FILE='C:\JMS\105538\15-7157-1\task7389728\7157-1-gg.htm',USER='105538',CD='May  5 05:11 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our competitors may develop products that are more effective, safer, more convenient or less costly than any that we are developing or that would render our product candidates obsolete or non-competitive. Our competitors may also obtain marketing approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We believe that many competitors are attempting to develop therapeutics for the target indications of our product candidates, including academic institutions, government agencies, public and private research organizations, large pharmaceutical companies and smaller more focused companies.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Many of our competitors may have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to or necessary for our programs.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Even if we are able to commercialize Translarna for the treatment of nmDMD on a broad scale or commercialize Translarna for other indications or any other product candidate that we develop, the product may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We currently expect that Translarna will be priced at levels consistent with the pricing for other therapies for the treatment of rare disorders where high unmet medical need exists.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The regulations and practices that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries, including almost all of the member states of the European Economic Area, require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, including the European market, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our ability to commercialize Translarna or any other product candidate successfully also will depend in part on the extent to which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the E.U. and U.S. healthcare industries and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Prices at which we or our customers seek reimbursement for our products can be subject to challenge, reduction or denial by the government and other payers. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that coverage and reimbursement will be available for Translarna or any other product that we commercialize and, if coverage and reimbursement are available, the level of reimbursement. Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. Obtaining reimbursement for Translarna may be particularly difficult because of the higher prices typically associated with drugs directed at smaller populations of patients. In addition, third-party payors are likely to impose strict requirements for reimbursement of a higher priced drug. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">48<a name="PB_48_123900_2959"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='48',FILE='C:\JMS\105538\15-7157-1\task7389728\7157-1-gg.htm',USER='105538',CD='May  5 05:11 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the applicable regulatory authority. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs, and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. In the United States, third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. In the European Union, reference pricing systems and other measures may lead to cost containment and reduced prices. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. In addition, in the European Union, for medicines authorized by the centralized authorization procedure, an authorized trader, such as a wholesaler, can purchase a medicine in one European Union member state and import the product into another EU member state. This process is called &#147;parallel distribution&#148;. As a result, a purchaser in one EU member state may seek to import Translarna from another European Union member state where Translarna is sold at a lower price. This could have a negative impact on our business, financial condition, results of operations and growth.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We face an inherent risk of product liability exposure related to the commercialization of Translarna, any other product that we may commercialize, and in connection with the testing of our product candidates in human clinical trials for Translarna and any other product that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">reduced resources of our management to pursue our business strategy;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">decreased demand for any product candidates or products that we may develop;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">injury to our reputation and significant negative media attention;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">withdrawal of clinical trial participants;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">significant costs to defend the related litigation;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">increased insurance costs, or an inability to maintain appropriate insurance coverage;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">substantial monetary awards to trial participants or patients;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">loss of revenue; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the inability to commercialize any products that we may develop.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have product liability insurance that covers our commercial sales, sales pursuant to reimbursed early access programs and clinical trials up to a $25.0 million annual aggregate limit, and subject to a per claim deductible. The amount of insurance we currently hold may not be adequate to cover all liabilities and defense costs that we may incur. We may need to further increase our insurance coverage as we continue commercializing Translarna or as and when we begin commercializing any other product candidate that receives marketing approval. The cost of insurance coverage is highly variable, based on a wide range of factors and is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability or defense costs that may arise.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">49<a name="PB_49_123900_3821"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='49',FILE='C:\JMS\105538\15-7157-1\task7389728\7157-1-gg.htm',USER='105538',CD='May  5 05:11 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations currently, and may in the future, involve the use of hazardous and flammable materials, including chemicals and medical and biological materials, and produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and wastes, we cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials or disposal of hazardous wastes, we could be held liable for any resulting damages, and any liability could exceed our resources.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We also maintain liability insurance for some of these risks, but our policy excludes pollution and has a coverage limit of $10.0 million.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Because we have limited financial and managerial resources, we focus on research programs and product candidates for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. For example, we initiated separate Phase 2 clinical trials of Translarna for the treatment of hemophilia in 2009 and the metabolic disorder methylmalomic acidemia in 2010, but then suspended these clinical trials to focus on the development of Translarna for nmDMD and nmCF when we found variability in the assays used in these trials and preliminary data from these trials did not indicate definitive evidence of activity. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have based our research and development efforts on small-molecule drugs that target post-transcriptional control processes. Notwithstanding our large investment to date and anticipated future expenditures in proprietary technologies, including GEMS and our alternative splicing technology, which we use in the discovery of these molecules, to date we have only been granted marketing authorization to treat nmDMD under a restricted label, and subject to the fulfillment of certain conditions, in the European Economic Area. We may not be able to satisfy the conditions of our current marketing authorization for nmDMD, including the completion of ACT DMD, and we may never successfully develop any other marketable drugs or indications using our scientific approach. As a result of pursuing the development of product candidates using our proprietary technologies, we may fail to develop product candidates or address indications based on other scientific approaches that may offer greater commercial potential or for which there is a greater likelihood of success. Research programs to identify new product candidates require substantial technical, financial and human resources. These research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">50<a name="PB_50_123900_3011"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='50',FILE='C:\JMS\105538\15-7157-1\task7389728\7157-1-gg.htm',USER='105538',CD='May  5 05:11 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to our Dependence on Third Parties</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We contract with third parties for the manufacture and distribution of our product and product candidates, which may increase the risk that we will not have sufficient quantities of our products or product candidates or such quantities at an acceptable cost, which could delay, prevent or impair our commercialization or development efforts.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We do not own or operate manufacturing or distribution facilities for the production or distribution of clinical or commercial supplies of our product candidates. We have limited personnel with experience in drug manufacturing and lack the resources and the capabilities to manufacture any of our product candidates on a clinical or commercial scale. We currently rely on third parties for supply of the active pharmaceutical ingredients in Translarna and all of our product candidates. We outsource all manufacturing, packaging, labeling and distribution of our products and product candidates to third parties, including our commercial supply of Translarna.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We currently have a contract with a pharmacy and hospital distributor in the EU that distributes Translarna for clinical programs and certain commercial programs. We recently engaged a third party logistics provider in the EU and we expect that this provider will distribute all of our commercial product by the end of 2015.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We currently rely on a single source for the production of some of our raw materials and we obtain our supply of the bulk drug substance for Translarna from two third-party manufacturers and the bulk drug substance for our antibacterial and oncology programs through another third-party manufacturer. We engage a separate manufacturer to provide bulk drug product and expect to finalize our validation of another bulk drug manufacturer in late 2015. We engage a separate manufacturer to provide fill and finish services for our finished commercial and clinical product and are in the process of completing arrangements with two additional providers to provide these services, initially for our clinical product, in early to mid-2015, with commercial product services expected to commence for at least one provider in late 2015. We do not currently have any agreements with third-party manufacturers for the long-term commercial supply of Translarna or any of our product candidates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may be unable to conclude agreements for commercial or clinical supply with third-party manufacturers, or may be unable to do so on acceptable terms.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Even if we are able to establish and maintain arrangements with third-party manufacturers and distributors, reliance on such service providers entails additional risks, including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">reliance on the third party for regulatory compliance and quality assurance;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the possible breach of the manufacturing agreement by the third party;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the possible misappropriation of our proprietary information, including our trade secrets and know-how;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the possibility of commercial supplies of Translarna not being distributed to commercial vendors or end users in a timely manner, resulting in lost sales;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the possibility of clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Many additional factors could cause production or distribution interruptions with the manufacture and distribution of Translarna and any of our product candidates, including human error, natural disasters, labor disputes, acts of terrorism or war, equipment malfunctions, contamination, or raw material shortages.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, third-party manufacturers or distributors may not be able to comply with current good manufacturing practice, or cGMP, or good distribution practice, or GDP, or similar regulatory requirements outside the European Union and the United States. Our failure, or the failure of our third-party manufacturers or distributors, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">51<a name="PB_51_123900_9487"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='51',FILE='C:\JMS\105538\15-7157-1\task7389728\7157-1-gg.htm',USER='105538',CD='May  5 05:11 2015' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">candidates or product, operating restrictions, criminal prosecutions or debarment, any of which could significantly and adversely affect supplies of Translarna or our product candidates.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our product and product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If the third parties that we engage to manufacture product for our commercial sales, preclinical tests and clinical trials should, prior to the time that we have validated alternative providers, cease to continue to do so for any reason, we likely would experience delays in our ability to supply Translarna to patients or in advancing our clinical trials while we identify and qualify replacement suppliers and we may be unable to obtain replacement supplies on terms that are favorable to us. In addition, if we are not able to obtain adequate supplies of Translarna or our product candidates or the drug substances used to manufacture them, we will lose commercial sales revenue and it will be more difficult for us to develop our product candidates and compete effectively.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our current and anticipated future dependence upon others for the manufacture and distribution of Translarna and our product candidates may adversely affect our business, financial condition, results of operations and growth including our ability to develop product candidates and commercialize our products that receive regulatory approval on a timely and competitive basis.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We rely on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We do not independently conduct clinical trials for our product or product candidates. We rely on third parties, such as contract research organizations, clinical data management organizations, medical institutions and clinical investigators, to perform this function. Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it would delay our product development activities.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our reliance on these third parties for clinical development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with standards, commonly referred to as Good Clinical Practices, or GCP, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. Similar GCP and transparency requirements apply in the European Union. Failure to comply with such requirements, including with respect to clinical trials conducted outside the European Union and United States, can also lead regulatory authorities to refuse to take into account clinical trial data submitted as part of a marketing application.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For example, in the first half of 2013 inspectors acting at the request of the EMA conducted GCP inspections of selected clinical sites from our completed Phase 2b clinical trial of Translarna for the treatment of nmDMD and our clinical trial site relating to our then pending MAA for approval of Translarna for the treatment of nmDMD. Following these inspections, we received inspection reports containing a combination of critical and major findings. These findings related to waivers we granted to admit patients to our Phase 2b clinical trial of Translarna for the treatment of nmDMD in advance of formal approval of protocol amendments that would have established their eligibility for the trial, as well as our oversight of our trial sites and the completeness or sufficiency of clinical trial documentation. In response to these findings, we described to the EMA the enhanced internal procedures and controls we have implemented, and the internal quality assurance department we have established, since the conclusion of our Phase 2b clinical trial of Translarna for the treatment of nmDMD. In addition, we proposed corrective action plans to address the inspectors&#146; specific findings. If we do not meet our commitment to the corrective actions we proposed to the EMA, we may face additional consequences, including rejection of data or other direct action by national regulatory authorities, which could require us to conduct additional clinical trials or other supportive studies to maintain our marketing authorization in the EEA for Translarna for the treatment of nmDMD or to obtain full approval from the EMA.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">52<a name="PB_52_124010_4015"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='52',FILE='C:\JMS\C901892\15-7157-1\task7383387\7157-1-gi.htm',USER='C901892',CD='May  1 13:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Furthermore, third parties that we rely on for our clinical development activities may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. Our product development costs will increase if we experience delays in testing or obtaining marketing approvals.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We also rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approvals of our product or product candidates or commercialization of our products, producing additional losses and depriving us of potential product revenue.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We currently depend, and expect to continue to depend, on collaborations with third parties for the development and commercialization of some of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For each of our product candidates, we plan to evaluate the merits of retaining commercialization rights for ourselves or entering into selective collaboration arrangements with leading pharmaceutical or biotechnology companies, such as our collaborations with Roche and the SMA Foundation, for our spinal muscular atrophy program. We have entered into arrangements with certain third parties to market or distribute Translarna for the treatment of nmDMD in certain countries and, as we continue to implement our commercialization plans for Translarna, we anticipate that we will engage additional third parties to perform these functions for us in other countries. We generally plan to seek collaborators for the development and commercialization of product candidates that have high anticipated development costs, are directed at indications for which a potential collaborator has a particular expertise, or involve markets that require a large sales and marketing organization to serve effectively. Our likely collaborator(s)&nbsp;for any marketing, distribution, development, licensing or broader collaboration arrangements may include: large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and/or biotechnology companies.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We will have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on our collaborators&#146; desire and abilities to successfully perform the functions assigned to them in these arrangements. In particular, the successful development of a product candidate from our spinal muscular atrophy program will initially depend on the success of our collaborations with the SMA Foundation and Roche, including whether Roche continues clinical development of the current clinical candidate or pursues clinical development of any other compounds identified under the collaborations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Collaborations involving our product candidates, including our collaborations with the SMA Foundation and Roche, pose the following risks to us:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs, based on clinical trial results, changes in the collaborators&#146; strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">53<a name="PB_53_124010_2784"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='53',FILE='C:\JMS\C901892\15-7157-1\task7383387\7157-1-gi.htm',USER='C901892',CD='May  1 13:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">disputes may arise between the collaborator and us as to the ownership of intellectual property arising during the collaboration;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">we may grant exclusive rights to our collaborators, which would prevent us from collaborating with others;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our products or product candidates or that result in costly litigation or arbitration that diverts management attention and resources; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Collaborators have terminated collaborations with us in the past. For example, in 2008, we entered into a collaboration with Genzyme Corporation for the development and commercialization of Translarna under which we granted to Genzyme rights to commercialize Translarna in all countries other than the United States and Canada. In 2011, we restructured the collaboration and regained worldwide rights to Translarna, with Genzyme obtaining an option to commercialize Translarna in indications other than nmDMD outside the United States and Canada. In 2012, this option expired without being exercised by Genzyme and the collaboration terminated.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we are not able to establish additional collaborations, we may have to alter our development and commercialization plans.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our product development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. For some of our product candidates, we may decide to collaborate further with pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborators&#146; resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborators&#146; evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge; and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under future license agreements from entering into agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">54<a name="PB_54_124010_1605"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='54',FILE='C:\JMS\C901892\15-7157-1\task7383387\7157-1-gi.htm',USER='C901892',CD='May  1 13:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we fail to comply with our obligations in our intellectual property licenses and funding arrangements with third parties, we could lose rights that are important to our business.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are a party to a number of license agreements and expect to enter into additional licenses in the future. Our existing licenses impose, and we expect that future licenses will impose, various diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these obligations, the licensor may have the right to terminate the license, in which event we might not be able to market any product that is covered by these agreements, which could materially adversely affect the value of the product candidate being developed under such license agreement. Termination of these license agreements or reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms, or cause us to lose rights in important intellectual property or technology.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have also received grant funding for some of our development programs from philanthropic organizations and patient advocacy groups pursuant to agreements that impose development and commercialization diligence obligations on us. If we fail to comply with these obligations, the applicable organization could require us to grant to the organization exclusive rights under certain of our intellectual property, which could materially adversely affect the value to us of product candidates covered by that intellectual property even if we are entitled to a share of any consideration received by such organization in connection with any subsequent development or commercialization of the product candidates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Some of our patented technology was developed with U.S. federal government funding. When new technologies are developed with U.S. government funding, the government obtains certain rights in any resulting patents, including a nonexclusive license authorizing the government to use the invention for non-commercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise &#147;march-in&#148; rights to use or allow third parties to use our patented technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the U.S. government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations or to give preference to U.S. industry. In addition, U.S. government-funded inventions must be reported to the government and U.S. government funding must be disclosed in any resulting patent applications. Furthermore, our rights in such inventions are subject to government license rights and certain restrictions on manufacturing products outside the United States.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to our Intellectual Property</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be adversely affected.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our proprietary technology and products. We seek to protect our proprietary position by filing patent applications in the United States and in certain foreign jurisdictions related to our novel technologies and product candidates that are important to our business. This process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, if we license technology or product candidates from third parties in the future, these license agreements may not permit us to control the preparation, filing and prosecution of patent applications, or to maintain or enforce the patents, covering this intellectual property. These agreements could </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">55<a name="PB_55_124010_1629"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='55',FILE='C:\JMS\C901892\15-7157-1\task7383387\7157-1-gi.htm',USER='C901892',CD='May  1 13:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">also give our licensors the right to enforce the licensed patents without our involvement, or to decide not to enforce the patents at all. Therefore, in these circumstances, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, patent law in many countries restricts the patentability of methods of treatment of the human body more than U.S. law does. In addition, we may not pursue or obtain patent protection in all major markets. Assuming the other requirements for patentability are met, currently, the first to file a patent application is generally entitled to the patent. However, prior to March&nbsp;16, 2013, in the United States, the first to invent was entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Moreover, we may be subject to a third party submission of prior art to a patent office or become involved in opposition, derivation, reexamination, inter partes review, post grant review, interference proceedings or other patent office proceedings or litigation, in the United States or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. In addition, other companies may attempt to circumvent any regulatory data protection or market exclusivity that we obtain under applicable legislation, which may require us to allocate significant resources to preventing such circumvention. Legal and regulatory developments in the European Union and elsewhere may also result in clinical trial data submitted as part of an MAA becoming publicly available. Such developments could enable other companies to circumvent our intellectual property rights and use our clinical trial data to obtain marketing authorizations in the European Union and in other jurisdictions. Such developments may also require us to allocate significant resources to prevent other companies from circumventing or violating our intellectual property rights. Our attempts to prevent third parties from circumventing our intellectual property and other rights may ultimately be unsuccessful. We may also fail to take the required actions or pay the necessary fees to maintain our patents.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">56<a name="PB_56_124010_6467"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='56',FILE='C:\JMS\C901892\15-7157-1\task7383387\7157-1-gi.htm',USER='C901892',CD='May  1 13:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Competitors may infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file claims, which can be expensive and time consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent&#146;s claims narrowly or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the intellectual property and other proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and technology, including interference, derivation, inter partes review or post-grant review proceedings before the U.S. Patent and Trademark Office. The risks of being involved in such litigation and proceedings may also increase as our product candidates approach commercialization, and as we gain greater visibility as a public company. Third parties may assert infringement claims against us based on existing or future intellectual property rights. We may not be aware of all such intellectual property rights potentially relating to our product candidates. For example, we have not conducted a recent freedom-to-operate search or analysis for Translarna&#153; (brand name of ataluren). Any freedom-to-operate search or analysis previously conducted may not have uncovered all relevant patents and patent applications, and there may be pending or future patent applications that, if issued, would block us from commercializing Translarna. Thus, we do not know with certainty whether Translarna, any other product candidate, or our commercialization thereof, does not and will not infringe any third party&#146;s intellectual property.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we are found to infringe a third party&#146;s intellectual property rights, or in order to avoid or settle litigation, we could be required to obtain a license to continue developing and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us, and could require us to make substantial payments. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#146; fees if we are found to have willfully infringed a patent or other intellectual property right. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For example, it is possible that one or more third parties might bring a patent infringement or other legal proceeding against us regarding Translarna. We are aware of an issued U.S. patent and international patent applications that purport to disclose or contain claims to chemical scaffolds that are sufficiently broad that they could be read to encompass Translarna, even though neither the issued U.S. patent nor any of the international patent applications specifically discloses Translarna. In order to successfully challenge the validity of any issued U.S. patent, we would need to overcome a presumption of validity. This burden is a high one requiring us to present clear and convincing evidence as to the invalidity of these claims. There is no assurance that a court would find these claims to be invalid. In addition, we believe that our testing of Translarna in clinical trials for the purpose of seeking FDA approval would be a valid defense against any infringement claims in the United States based on the availability of a statutory exemption. However, there can be no assurance that our interpretation of the statutory exemption would be upheld, and the statutory exemption would only cover our preclinical research activities, and not the commercialization of Translarna.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may be subject to claims by third parties asserting that we or our employees have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</font></i></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">57<a name="PB_57_124010_4102"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='57',FILE='C:\JMS\C901892\15-7157-1\task7383387\7157-1-gi.htm',USER='C901892',CD='May  1 13:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#146;s former employer. Litigation may be necessary to defend against these claims.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, while we typically require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Intellectual property litigation could cause us to spend substantial resources and could distract our personnel from their normal responsibilities.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development, sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition to seeking patents for some of our technology and products, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. However, we cannot guarantee that we have executed these agreements with each party that may have or have had access to our trade secrets or that the agreements we have executed will provide adequate protection. Any party with whom we have executed such an agreement may breach that agreement and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be obtained or independently developed by a competitor, our competitive position would be harmed.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We have not yet registered our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our trademark applications may not be allowed for registration, and our registered trademarks may not be maintained or enforced. During trademark registration proceedings, we may receive rejections. Although we are </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">58<a name="PB_58_124010_4129"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='58',FILE='C:\JMS\C901892\15-7157-1\task7383387\7157-1-gi.htm',USER='C901892',CD='May  1 13:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the U.S. Patent and Trademark Office and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we are not able to obtain adequate trademark protection or regulatory approval for our brand names, including Translarna, we may be required to re-brand affected products, which could cause delays in getting such products to market and substantially increase our costs.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any trademark we intend to use for our product candidates, including Translarna, will require that we seek trademark registration worldwide. Trademark registration is a territory-specific and we must apply for registration in the US as well as any other country where we intend to commercialize product. Failure to obtain the appropriate registrations may place our use of the trademark at risk or make if subject to legal challenges, which could force us to choose an alternative name for our product candidates. In addition, the FDA, and other regulatory authorities outside the United States, typically conduct a separate review of proposed product names for pharmaceuticals, including an evaluation of potential for confusion with other product names or medication or prescribing errors. These regulatory authorities may also object to any product name we submit if they believe the name inappropriately implies medical claims. If the FDA or other competent regulatory authority outside the United States objects to any of our proposed product names, we may be required to adopt an alternative name for our product candidates. If we adopt an alternative name, either because of our inability to obtain a trademark registration or approval or related legal challenges or because of objections from regulatory authorities, we would lose the benefit of our existing trademark applications for such product candidate, and may be required to expend significant additional resources in an effort to identify a suitable product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA or applicable other regulatory authority, which could cause delays in getting our products to market and substantially increase our costs. We may be unable to build a successful brand identity for a new trademark in a timely manner or at all, which would limit our ability to commercialize our product candidates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to Regulatory Approval of our Product and Product Candidates</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to continue to commercialize Translarna for nmDMD or other indications or commercialize our other product candidates, and our ability to generate revenue will be materially impaired.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Translarna and our other product candidates, and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and EMA and by comparable authorities in other countries. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have received marketing authorization to market Translarna for nmDMD in the European Economic Area, which is subject to annual EMA reassessment and is further conditioned on our ability to complete ACT DMD and submit the final report, including additional efficacy and safety data from the trial, during 2015. We have not otherwise received marketing approval for Translarna or any of our other product candidates from regulatory authorities in any jurisdiction. We intend to submit a variation to our marketing authorization application with the EMA to seek to include Translarna for the treatment of nmCF in the second half of 2015. There is substantial risk that the EMA will not grant us approval of Translarna for the treatment of nmCF. We expect that even if the EMA approves a variance to include Translarna for nmCF, the EMA will require us, as a post-approval measure, to provide it with comprehensive clinical data from ACT CF. In addition, unless and until we satisfy the conditions of our primary marketing authorization in the EEA for Translarna, such authorization will continue to be subject to annual review and renewal by the EMA.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have begun seeking and intend to continue to seek marketing approval for Translarna for the treatment of nmDMD in territories outside of the EEA. In December&nbsp;2014, we commenced a rolling basis submission of a new drug application, or NDA, to the FDA for approval of Translarna for the treatment of nmDMD. We may not receive </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">59<a name="PB_59_124010_7128"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='59',FILE='C:\JMS\C901892\15-7157-1\task7383387\7157-1-gi.htm',USER='C901892',CD='May  1 13:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">necessary approvals from the FDA or other regulators to further commercialize Translarna or any product candidate in any market.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have only limited experience in filing and supporting the applications necessary to obtain marketing approvals for product candidates and expect to continue to rely on third-party contract research organizations to assist us in this process. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#146;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Regulatory authorities may determine that Translarna or any of our other product candidates are not effective or only moderately effective, or have undesirable or unintended side effects, toxicities, safety profiles or other characteristics that preclude us from obtaining marketing approval or that prevent or limit commercial use.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The process of obtaining marketing approvals is expensive, may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For example, our ability to obtain and maintain marketing authorizations granted on a conditional basis in the European Union is limited to specific circumstances and subject to several conditions and obligations. Conditional marketing authorizations based on incomplete clinical data may be granted for a limited number of listed medicinal products for human use, including products designated as orphan medicinal products under E.U. law, if (1)&nbsp;the risk- benefit balance of the product is positive, (2)&nbsp;it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data, (3)&nbsp;unmet medical needs will be fulfilled and (4)&nbsp;the benefit to public health of the immediate availability on the market of the medicinal product outweighs the risk inherent in the fact that additional data are still required. Specific obligations, including with respect to the completion of ongoing or new studies, and with respect to the collection of pharmacovigilance data, may be specified in the conditional marketing authorization. Marketing authorizations subject to conditions are only valid for one year, and must be renewed annually by the EMA after an assessment of the risk-benefit balance and need for additional or modified conditions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, marketing approvals in countries outside the United States do not ensure pricing approvals in those countries or in any other countries, and marketing approvals and pricing approvals do not ensure that reimbursement will be obtained.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may not be able to obtain orphan drug exclusivity for our product candidates. If our competitors are able to obtain orphan drug exclusivity for their products that are the same drug as our product candidates, or can be classified as a similar medicinal product within the meaning of E.U. law, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Regulatory authorities in some jurisdictions, including the European Union and the United States, may designate drugs for relatively small patient populations as orphan drugs. We have obtained orphan drug designations from the EMA and from the FDA for Translarna for the treatment of nmDMD, nmCF, and nmMPS I. Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of market exclusivity, which, subject to certain exceptions, precludes the EMA from accepting another marketing application for a similar medicinal product or the FDA from approving another marketing application for the same drug for the same indication for that time period. The applicable market exclusivity period is ten years in the European Union and seven years in the United States. The E.U. exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation, including if the drug is sufficiently profitable so that market exclusivity is no longer justified.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">60<a name="PB_60_124010_3263"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='60',FILE='C:\JMS\C901892\15-7157-1\task7383387\7157-1-gi.htm',USER='C901892',CD='May  1 13:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the European Union, a &#147;similar medicinal product&#148; is a medicinal product containing a similar active substance or substances as contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic indication. For a drug such as Translarna, which is composed of small molecules, the FDA defines &#147;same drug&#148; as a drug that contains the same active moiety and is intended for the same use. Obtaining orphan drug exclusivity for Translarna for these indications, both in the European Union and in the United States, may be important to the product candidate&#146;s success. If a competitor obtains orphan drug exclusivity for and approval of a product with the same indication as Translarna before we do and if the competitor&#146;s product is the same drug or a similar medicinal product as ours, we could be excluded from the market. Even if we obtain orphan drug exclusivity for Translarna for these indications, we may not be able to maintain it. For example, if a competitive product that is the same drug or a similar medicinal product as Translarna is shown to be clinically superior to our product candidate, any orphan drug exclusivity we have obtained will not block the approval of such competitive product. In addition, orphan drug exclusivity will not prevent the approval of a product that is the same drug as Translarna if the FDA finds that we cannot assure the availability of sufficient quantities of the drug to meet the needs of the persons with the disease or condition for which the drug was designated. The same considerations would apply to any of our product candidates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The fast track designation for Translarna may not actually lead to a faster development or regulatory review or approval process.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for FDA fast track designation. We have obtained a fast track designation from the FDA for Translarna for the treatment of nmDMD. However, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw our fast track designation if the FDA believes that the designation is no longer supported by data from our clinical development program. Our fast track designation does not guarantee that we will qualify for or be able to take advantage of the FDA&#146;s expedited review procedures, nor does it increase the likelihood of FDA approval.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Marketed pharmaceutical products, including Translarna for the treatment of nmDMD, are subject to extensive and rigorous governmental regulation and could be subject to restrictions or withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The company, Translarna, our product candidates, our operations, our facilities, our suppliers, and our contract manufacturers, distributors, and contract testing laboratories are subject to extensive regulation by governmental authorities in the EEA, the United States, and other territories, with regulations differing from country to country.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are not permitted to market our product candidates in the EEA, the United States, or other territories until we have received requisite regulatory approvals. In order to receive and maintain such approvals, we and our third-party service providers must comply on a continuous basis with a broad array of regulations related to establishment registration and product listing, manufacturing processes, risk management measures, quality and pharmacovigilance systems, pre- and post-approval clinical data, labeling, advertising and promotional activities, record keeping, distribution, and import and export of pharmaceutical products for any product for which we obtain marketing approval. Any regulatory approval of any of our products or product candidates, once obtained, may be withdrawn. For example, our marketing authorization in the EEA is subject to annual EMA reassessment and is further conditioned on our ability to complete ACT DMD and submit the final report, including additional efficacy and safety data from the trial, during 2015. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing and distribution.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are required to submit safety and other post-market information and reports, implement pharmacovigilance plans, and comply with cGMP requirements related to manufacturing including, quality control, quality assurance and complaints and corresponding maintenance of records and documents, requirements regarding the distribution of samples to healthcare professionals and recordkeeping, among other things, in connection with the marketing authorization for Translarna for the treatment of nmDMD described above. Regulatory authorities, including the EMA and local regulatory authorities in EEA member states, subject a marketed product, its manufacturer and the manufacturing facilities to ongoing review and periodic inspections and the EMA is responsible for coordinating inspections, undertaken by the competent authorities of applicable member states, of our manufacturing facilities to</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">61<a name="PB_61_124010_6333"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='61',FILE='C:\JMS\C901892\15-7157-1\task7383387\7157-1-gi.htm',USER='C901892',CD='May  1 13:23 2015' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">assess whether our manufacturing, and other procedures, comply with cGMP. Similar regulatory and inspection requirements apply in other jurisdictions including those imposed by the FDA in the United States.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or may be subject to significant conditions of approval, including the requirement of risk evaluation and mitigation strategy, or REMS. A regulatory authority also may impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product. In addition, the competent authorities of each EU member state and the FDA closely regulate the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling and regulatory requirements. Such regulatory authorities can impose stringent restrictions on manufacturers&#146; communications regarding off-label use and if we do not comply with the laws governing promotion of approved drugs, we may be subject to enforcement action for off-label promotion. Violations of the Federal Food, Drug, and Cosmetic Act relating to the promotion of prescription drugs may lead to civil and criminal penalties, investigations alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results which could negatively affect our business, including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">restrictions on such products, manufacturers or manufacturing processes;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">changes to or restrictions on the labeling or marketing of a product;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">restrictions on product distribution or use;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">requirements to implement a REMS;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">requirements to conduct post-marketing studies or clinical trials;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">warning or untitled letters;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">withdrawal of the products from the market;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">refusal to approve pending applications or supplements to approved applications that we submit;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">recall of products;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">fines, restitution or disgorgement of profits or revenues;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">suspension or withdrawal of marketing approvals;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">refusal to permit the import or export of our products;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">product seizure;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">injunctions;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the imposition of civil or criminal penalties; or</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">debarment.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Non-compliance with E.U. requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the European Union&#146;s requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">62<a name="PB_62_124105_1861"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='62',FILE='C:\JMS\C901892\15-7157-1\task7383387\7157-1-gk.htm',USER='C901892',CD='May  1 13:24 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are also subject to laws and license and registration requirements covering the distribution of marketed products. If we fail to comply with any of these requirements, we may be subject to action by regulatory agencies, which could negatively affect our business. Regulatory agencies may also change existing requirements or adopt new requirements or policies. We may be slow to adapt or may not be able to adapt to these changes or new requirements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our initial commercial launch of Translarna has begun in, and is expected to continue to take place in, countries that tend to impose strict price controls, which may adversely affect our revenues, if any. Failure to obtain and maintain acceptable pricing and reimbursement terms for Translarna in the European Economic Area and other jurisdictions would prevent us from marketing our products in such regions.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In some countries, particularly the member states of the EEA, the pricing of prescription pharmaceuticals is subject to strict governmental control. Each country in the EEA has its own pricing and reimbursement regulations and may have other regulations related to the marketing and sale of pharmaceutical products in the country. We generally will not be able to commence commercial sales of Translarna for the treatment of nmDMD pursuant to the marketing authorization granted by the European Commission in any particular member state of the EEA until we conclude the applicable pricing and reimbursement negotiations and comply with any licensing, employment or related regulatory requirements in that country. In some countries we may be required to conduct additional clinical trials or other studies of our product including trials that compare the cost-effectiveness of our product to other available therapies in order to obtain reimbursement or pricing approval. We may not be able to conclude pricing and reimbursement negotiations or comply with additional regulatory requirements in the countries in which we seek to commercialize Translarna on a timely basis, or at all.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The pricing and reimbursement process varies from country to country and can take over 18 months to complete. Pricing negotiations may continue after reimbursement has been obtained. Since December&nbsp;2014, Translarna for the treatment of nmDMD has been commercially available in Germany, but we are still in the process of finalizing our pricing negotiations with relevant German authorities. We cannot predict the timing of Translarna&#146;s commercial launch in countries where we are awaiting pricing and reimbursement guidelines. While we have submitted pricing and reimbursement dossiers with respect to Translarna for the treatment of nmDMD in key EEA countries, we have not received both pricing and reimbursement approval in any country, and there is no assurance that we will receive such approval or, if we do, that the price, level of reimbursement and other terms will be acceptable to us. In addition, the price that is approved by local governmental authorities pursuant to commercial pricing and reimbursement processes may be significantly lower than the price we are able to charge for sales under our reimbursed early access programs. In some instances, reimbursement may be subject to challenge, reduction or denial by the government and other payers. In some countries, such as France, EAP and commercial sales of a product can begin while pricing and reimbursement rates are under discussion with the applicable government health programs. In the event that the negotiated price of the product is lower than the amount reimbursed for sales made prior to the conclusion of price negotiations, the company may become obligated to repay such excess amount to the applicable government health program. We will make such retroactive reimbursement, if any, following the conclusion of price negotiations with the applicable government health authority.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Political, economic and regulatory developments may further complicate pricing and reimbursement negotiations and there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. For example, during the fourth quarter of 2014, the publicly funded health care system in the UK determined to reconsider how it assesses certain new treatments and postponed certain pricing and reimbursement meetings, including meetings related to Translarna.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Reference pricing used by various E.U. member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. Publication of discounts by third-party payors or authorities may lead to further pressure on prices or reimbursement levels within the country of publication and other countries.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we fail to successfully secure and maintain pricing and reimbursement coverage for Translarna or are significantly delayed in doing so or if burdensome conditions are imposed by private payers, government authorities or other third-party payers on such reimbursement, planned launches in the affected countries will be delayed and our anticipated revenue and growth prospects could be negatively affected and our business could be adversely affected.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">63<a name="PB_63_124105_5835"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='63',FILE='C:\JMS\C901892\15-7157-1\task7383387\7157-1-gk.htm',USER='C901892',CD='May  1 13:24 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our relationships with customers, healthcare providers and professionals and third-party payors are or will be subject to applicable anti-kickback, fraud and abuse, transparency and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Healthcare providers, physicians and third-party payors play a primary role in the recommendation and prescription of any products or product candidates, including Translarna. Our arrangements with customers, healthcare providers and professionals and third-party payors may expose us to broadly applicable fraud and abuse, transparency and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Failure to maintain a comprehensive and effective compliance program, and to integrate the operations of any acquired businesses into a combined comprehensive and effective compliance program on a timely basis, could subject us to a range of regulatory actions that could affect our ability to commercialize our products and could harm or prevent sales of the affected products, or could substantially increase the costs and expenses of commercializing and marketing our products.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Restrictions and reporting requirements under applicable federal and state healthcare laws and regulations, and equivalent laws and regulations in the European Union, include, and are not limited to, the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Anti-corruption and anti-bribery statutes, including the U.S. Foreign Corrupt Practices Act, or FCPA, and the UK Bribery Act of 2010, or Bribery Act. These statutes are generally broad in scope and will require us to make and keep books and records that accurately and fairly reflect the transactions of the company and to devise and maintain an adequate system of internal accounting controls. The FCPA prohibits the offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to improperly influence any act or decision, secure any other improper advantage, or obtain or retain business. Under the UK Bribery Act, companies which carry on a business or part of a business in the United Kingdom may be held liable for bribes given, offered or promised to any person, including non-UK government officials and private persons, by employees and persons associated with the company in order to obtain or retain business or a business advantage for the company.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Anti-kickback statutes, which generally prohibit, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under government funded healthcare programs. The U.S. federal statute has been broadly interpreted to apply to manufacturer arrangements with prescribers, purchasers and formulary managers, among others and many states have enacted equivalent state laws that apply not only to government payors but commercial payors. Several other countries, including the United Kingdom, have enacted similar anti-kickback, fraud and abuse, and healthcare laws and regulations.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively the Affordable Care Act), amended the intent requirement of the federal anti-kickback statute such that a person no longer needs to have actual knowledge of the statue or specific intent to violate it.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Laws and regulations, including the U.S. False Claims Act, which impose civil and criminal liability on individuals and entities who submit, or cause to be submitted, false or fraudulent claims for payment to the government. The U.S. government has brought False Claims Act actions against pharmaceutical companies on the theory that their practices have caused false claims to be submitted to the government. The U.S. Attorneys&#146; Offices and the main Department of Justice have taken broad interpretations of what constitutes falsity or false claims. A wide range of pharmaceutical manufacturers&#146; commercial activity, marketing practices and price reporting practices have been scrutinized as potential violations of the False Claims Act.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">64<a name="PB_64_124105_808"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='64',FILE='C:\JMS\C901892\15-7157-1\task7383387\7157-1-gk.htm',USER='C901892',CD='May  1 13:24 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program and also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information. In addition, international data protection laws including the European Union Data Protection Directive and member state implementing legislation may apply to some or all of the clinical data obtained outside of the U.S. Furthermore, certain privacy laws and genetic testing laws may apply directly to our operations and/or those of our collaborators and may impose restrictions on our use and dissemination of individuals&#146; health information.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">HIPAA also imposes criminal liability for knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Laws and regulations regulating off-label promotion. Off-label promotion of medicinal products is prohibited in the European Union. The applicable laws at European Union level and in the individual European Union member states also prohibit the direct-to-consumer advertising of prescription- only medicinal products. Violations of the rules&nbsp;governing the promotion of medicinal products in the European Union could be penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising and promotion of our products to the general public and may also impose limitations on our promotional activities with health care professionals. Under the Federal Food, Drug and Cosmetic Act and other laws, if any of our product candidates are approved, we would be prohibited from promoting our products for off-label uses. This means, for example, that we would not be able to make claims about the use of our marketed products outside of their approved indications, and we would not be able to proactively discuss or provide information on off-label uses of such products, with very specific and limited exceptions. The FDA does not, however, restrict physicians from prescribing products for off-label uses in the practice of medicine. Should the FDA determine that our activities constituted the promotion of off-label use, the FDA could bring action to prevent us from distributing those products for the off-label use and could impose fines and penalties on us and our executives. In addition, failure to follow FDA rules&nbsp;and guidelines relating to promotion and advertising can result in, among other things, the FDA&#146;s refusal to approve a product, the suspension or withdrawal of an approved product from the market, product recalls, fines, disgorgement of money, operating restrictions, injunctions or criminal prosecutions.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Statutory requirements to disclose publicly payments made to physicians, including in certain European Union member states and the U.S. For example, under federal Physician Sunshine Act requirements, manufacturers of drugs, devices, biologics and medical supplies must report information related to payments and other transfers of value made to or at the request of covered recipients, such as physicians and teaching hospitals, and physician ownership and investment interests in such manufacturers. A number of states have enacted their own transparency requirements that obligate manufacturers to report different types of spending related to physicians and other covered recipients.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Laws governing the advertising and promotion of medicinal products, interactions with physicians and patients, misleading and comparative advertising and unfair commercial practices. For example, legislation adopted by individual EU member states that may apply to the advertising and promotion of medicinal products require that promotional materials and advertising in relation to medicinal products comply with the product&#146;s Summary of Product Characteristics, or SmPC, as approved by the competent authorities. The SmPC is the document that provides information to physicians concerning the safe and effective use of the medicinal product. Promotion of indications not covered by the SmPC is specifically prohibited.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Analogous state laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">65<a name="PB_65_124105_4581"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='65',FILE='C:\JMS\C901892\15-7157-1\task7383387\7157-1-gk.htm',USER='C901892',CD='May  1 13:24 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">requiring drug manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, interactions between pharmaceutical companies and physicians are also governed by industry self-regulation codes of conduct and physicians&#146; codes of professional conduct. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the EU. The provision of benefits or advantages to physicians is also governed by the national laws of the EU member states, as well as codes of conduct issued by self-regulatory industry bodies. Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician&#146;s employer, their competent professional organization, and the competent authorities of the individual EU member states. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the EU member states.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws, regulations, transparency requirements and self-regulatory codes will involve substantial costs. We cannot guarantee that we, our employees, our consultants or our third-party contractors are or will be in compliance with all federal, state and foreign regulations and codes. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs, such as Medicare and Medicaid, reputational harm, and the curtailment or restructuring of our operations. Exclusion, suspension and debarment from government funded healthcare programs would significantly impact our ability to commercialize, sell or distribute any drug. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could also have an adverse effect on our business, financial condition and results of operations. If any of the physicians or other providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of Translarna or any of our other product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates, including Translarna, for which we obtain marketing approval.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the United States, the Medicare Prescription Drug,&nbsp;Improvement, and Modernization Act of 2003, or Medicare Modernization Act, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average sales prices for physician administered drugs. In addition, this legislation provided authority for limiting the number of drugs that will be covered in any therapeutic class. Cost reduction initiatives and other provisions of this legislation could decrease the coverage and price that we receive for any approved products. While the Medicare Modernization Act applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the Medicare Modernization Act may result in a similar reduction in payments from private payors.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In March&nbsp;2010, President Obama signed into law the Affordable Care Act, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for health care and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. Effective October&nbsp;1, 2010, the Affordable Care Act revised the definition of &#147;average manufacturer price&#148; for reporting purposes, which could increase the amount of Medicaid drug rebates to states. Further, the new law imposes a significant annual fee on companies that manufacture or import branded prescription drug products.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">66<a name="PB_66_124105_9058"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='66',FILE='C:\JMS\C901892\15-7157-1\task7383387\7157-1-gk.htm',USER='C901892',CD='May  1 13:24 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">While the U.S. Supreme Court upheld the constitutionality of most elements of the Affordable Care Act in June&nbsp;2012, other legal challenges are still pending final adjudication in several jurisdictions. In addition, Congress has in the past proposed and likely will continue to propose a number of legislative initiatives challenging various aspects of the Affordable Care Act. At this time, it remains unclear whether there will be any changes made to the Affordable Care Act, whether to certain provisions or its entirety. We cannot assure that the Affordable Care Act, as currently enacted or as amended in the future, will not adversely affect our business and financial results and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, the Budget Control Act of 2011, among other things, created the Joint Select Committee on Deficit Reduction to recommend proposals in spending reductions to Congress. The Joint Select Committee did not achieve a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, which triggered the legislation&#146;s automatic reduction to several government programs, including aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, starting in 2013. In January&nbsp;2013, President Obama signed into law the American Taxpayer Relief Act of 2012, or the ATRA, which delayed for another two months the budget cuts mandated by the sequestration provisions of the Budget Control Act of 2011. The ATRA, among other things, also reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. In March&nbsp;2013, the President signed an executive order implementing sequestration, and in April&nbsp;2013, the 2% Medicare reductions went into effect. In December&nbsp;2013, Congress amended the Budget Control Act to provide greater discretionary spending in 2014 and 2015 than originally budgeted and provide relief from the FDA user fee for two years; this legislation also extended the prohibition against reducing payments to Medicare providers by more than 2% for two years (i.e., until 2023). In December&nbsp;2014, Congress passed an omnibus funding bill (the Consolidated and Further Continuing Appropriations Act, 2015) and a tax extenders bill, both of which may negatively impact coverage and reimbursement of healthcare items and services.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#146;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize Translarna and our product candidates. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state level may result in significant additional requirements or obstacles that may increase our operating costs.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to Employee Matters and Managing Growth</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our future success depends on our ability to retain our chief executive officer and other key executives and to attract, retain and motivate qualified personnel.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are highly dependent on Dr.&nbsp;Stuart W. Peltz, our co-founder and Chief Executive Officer, and the other principal members of our executive and scientific teams. Although we have formal employment agreements with each of our executive officers, these agreements do not prevent our executives from terminating their employment with us at any time. We do not maintain &#147;key person&#148; insurance on any of our executive officers. The loss of the services of any of these persons might impede the achievement of our research, development and commercialization objectives.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">67<a name="PB_67_124105_2615"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='67',FILE='C:\JMS\C901892\15-7157-1\task7383387\7157-1-gk.htm',USER='C901892',CD='May  1 13:24 2015' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We are in the process of expanding our development, regulatory and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with our commercialization plans and business strategy, including our commercial launch of Translarna, we have experienced and plan to continue to experience significant growth in our employee base for sales, marketing, operational, managerial, financial, human resources, drug development, quality, regulatory and medical affairs and other areas. This growth has and will continue to impose significant added responsibilities on members of management, including the need to recruit, hire, retain, motivate and integrate additional employees. Also, our management may have to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. To manage our recent and anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to our Common Stock</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">provide for a classified board of directors such that not all members of the board are elected at one time;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">allow the authorized number of our directors to be changed only by resolution of our board of directors;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">limit the manner in which stockholders can remove directors from the board;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">limit who may call stockholder meetings;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#147;poison pill&#148; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">68<a name="PB_68_124216_3790"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='68',FILE='C:\JMS\105538\15-7157-1\task7389728\7157-1-gm.htm',USER='105538',CD='May  5 05:12 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">An active trading market for our common stock may not be sustained.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our shares of common stock began trading on The NASDAQ Global Select Market on June&nbsp;20, 2013. Given the limited trading history of our common stock, there is a risk that an active trading market for our common stock will not be sustained, which could put downward pressure on the market price of our common stock and thereby affect the ability of our stockholders to sell their shares.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our stock price may be volatile. The stock market in general and the market for smaller pharmaceutical and biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, our stockholders may not be able to sell their common stock at or above the price at which they purchased it. The market price for our common stock may be influenced by many factors, including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to advance the commercialization of Translarna for the treatment of nmDMD;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the success of competitive products or technologies;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">results of clinical trials of Translarna and any other product candidate that we develop;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the development and regulatory status of our SMA program with Roche and the SMA Foundation;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">results of clinical trials of product candidates of our competitors;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">regulatory or legal developments in the United States and other countries;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the recruitment or departure of key personnel;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the level of expenses related to any of our product candidates or clinical development programs;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">variations in our financial results or those of companies that are perceived to be similar to us;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">changes in the structure of healthcare payment systems;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">market conditions in the pharmaceutical and biotechnology sectors;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">general economic, industry and market conditions; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the other factors described in this &#147;Risk Factors&#148; section.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We are an &#147;emerging growth company,&#148; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are an &#147;emerging growth company&#148;, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and may remain an emerging growth company until December&nbsp;31, 2018, provided that, if the market value of our common stock that is held by non-affiliates exceeds $700 million as of any June&nbsp;30 before that time or if we </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">69<a name="PB_69_124216_2898"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='69',FILE='C:\JMS\105538\15-7157-1\task7389728\7157-1-gm.htm',USER='105538',CD='May  5 05:12 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">have annual gross revenues of $1 billion or more in any fiscal year, we would cease to be an emerging growth company as of December&nbsp;31 of the applicable year. We also would cease to be an emerging growth company if we issue more than $1 billion of non-convertible debt over a three-year period. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include: not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements; reduced disclosure obligations regarding executive compensation; and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may choose to take advantage of some, but not all, of the available exemptions. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, the JOBS Act also provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to delay such adoption of new or revised accounting standards, and as a result, we may not comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for public companies that are not emerging growth companies. As a result of such election, our financial statements may not be comparable to the financial statements of other public companies.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If the market value of our common stock that is held by non-affiliates exceeds $700 million as of June&nbsp;30, 2015, we will cease to be an emerging growth company as of December&nbsp;31, 2015.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We are currently incurring and expect to continue to incur increased costs as a result of operating as a public company, and our management is and will continue to be required to devote substantial time to new compliance initiatives.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As a public company, and particularly after we are no longer an &#147;emerging growth company,&#148; we incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002, the Dodd-Frank Act, the listing requirements of The NASDAQ Global Select Market and other applicable securities rules&nbsp;and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules&nbsp;and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules&nbsp;and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">However, for as long as we remain an emerging growth company, we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies as described in the preceding risk factor. Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or Section&nbsp;404, we will be required to furnish a report by our management on our internal control over financial reporting. However, as an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm until we are no longer an emerging growth company. To achieve compliance with Section&nbsp;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section&nbsp;404. This could result </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">70<a name="PB_70_124216_9195"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='70',FILE='C:\JMS\105538\15-7157-1\task7389728\7157-1-gm.htm',USER='105538',CD='May  5 05:12 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Because we do not anticipate paying any cash dividends on our capital in the foreseeable future, capital appreciation, if any, will be our stockholders sole source of gain.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the development and growth of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be our stockholders sole source of gain for the foreseeable future.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Sales of a substantial number of shares of our common stock in the public market by our existing stockholders could significantly reduce the market price of our common stock.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. A significant number of our shares are currently &#147;restricted&#148; securities as a result of securities laws, but are able to be sold, subject to any applicable volume limitations under federal laws with respect to affiliate sales. Moreover, certain holders of an aggregate of 1,894,327 shares of our common stock have rights, subject to some conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have a significant number of restricted stock awards and shares that are subject to outstanding options under our equity compensation plans or as inducement grants to new hire employees pursuant to Nasdaq rules. These shares underlying these awards are or, with respect to certain option grants, will be registered on a Form&nbsp;S-8 registration statement. As a result, upon vesting these shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates. The exercise of options and the subsequent sale of the underlying common stock or the sale of restricted stock upon vesting could cause a decline in our stock price. These sales also might make it difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certain of our employees, executive officers and directors have entered or may enter into Rule&nbsp;10b5-1 plans providing for sales of shares of our common stock from time to time. Under a Rule&nbsp;10b5-1 plan, a broker executes trades pursuant to parameters established by the employee, director or officer when entering into the plan, without further direction from the employee, officer or director. A Rule&nbsp;10b5-1 plan may be amended or terminated in some circumstances. Our employees, executive officers and directors may also buy or sell additional shares outside of a Rule&nbsp;10b5-1 plan when they are not in possession of material, nonpublic information.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</font></b><a name="Item2_UnregisteredSalesOfEquitySe_130744"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Use of Proceeds from Registered Securities</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On June&nbsp;25, 2013, we closed our initial public offering of 9,627,800 shares of our common stock, including 1,255,800 shares of our common stock pursuant to the exercise by the underwriters of an over-allotment option, at a public offering price of $15.00 per share for an aggregate offering price of approximately $144.4 million. The offer and sale of all of the shares in the offering were registered under the Securities Act pursuant to a registration statement on Form&nbsp;S-1 (File No.&nbsp;333-188657), which was declared effective by the SEC on June&nbsp;19, 2013.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We received aggregate net proceeds from the offering of approximately $131.6 million, after deducting underwriting discounts and commissions and other offering expenses payable by us. None of the underwriting discounts and commissions or other offering expenses were incurred or paid to directors or officers of ours or their associates or to persons owning 10 percent or more of our common stock or to any affiliates of ours.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of March&nbsp;31, 2015, we have used approximately $114.7 million of the net offering proceeds primarily to fund the clinical development of Translarna for the treatment of nmDMD, nmCF and nmMPS I, to seek marketing approval in the European Union, the United States and other territories for Translarna for nmDMD, for commercial efforts for Translarna, to fund research and development of Translarna for additional indications and for our earlier stage programs, and for working capital and other general corporate purposes. We are holding a significant portion </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">71<a name="PB_71_124216_6318"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='71',FILE='C:\JMS\105538\15-7157-1\task7389728\7157-1-gm.htm',USER='105538',CD='May  5 05:12 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">of the balance of the net proceeds from the offering in a variety of capital preservation investments, including short term, investment grade, interest bearing instruments and U.S. government securities. There has been no material change in our planned use of the net proceeds from the offering as described in our final prospectus filed with the SEC pursuant to Rule&nbsp;424(b)&nbsp;under the Securities Act.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Recent Sales of Unregistered Securities</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Inducement stock option awards. </font></i><font size="2" style="font-size:10.0pt;">Pursuant to the NASDAQ inducement grant exception, during the quarter ended March&nbsp;31, 2015, we issued options to purchase an aggregate of 93,350 shares of common stock to certain new hire employees at a weighted-average exercise price of $51.35 per share. The shares underlying these option awards will be registered on a Form&nbsp;S-8 registration statement prior to the first vesting event applicable to each such award.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 6. Exhibits.</font></b><a name="Item6_Exhibits__130851"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Those exhibits required to be filed by Item 601 of Regulation S-K are listed in the Exhibit&nbsp;Index immediately preceding the exhibits hereto and such listing is incorporated herein by reference.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="24%" valign="top" style="padding:0in 0in 0in 0in;width:24.02%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PTC THERAPEUTICS,&nbsp;INC.</font></b></p>    </td>   </tr>
<tr>
<td width="24%" valign="top" style="padding:0in 0in 0in 0in;width:24.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="24%" valign="top" style="padding:0in 0in 0in 0in;width:24.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="24%" valign="top" style="padding:0in 0in 0in 0in;width:24.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:   May&nbsp;5, 2015</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Shane Kovacs</font></p>    </td>   </tr>
<tr>
<td width="24%" valign="top" style="padding:0in 0in 0in 0in;width:24.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:45.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Shane   Kovacs</font></p>    </td>   </tr>
<tr>
<td width="24%" valign="top" style="padding:0in 0in 0in 0in;width:24.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief   Financial Officer</font></p>    </td>   </tr>
<tr>
<td width="24%" valign="top" style="padding:0in 0in 0in 0in;width:24.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Principal   Financial and Accounting Officer and Duly Authorized Signatory)</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;INDEX</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="15%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.2%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;Number</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="82%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:82.66%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description&nbsp;of&nbsp;Exhibit</font></b></p>    </td>   </tr>
<tr>
<td width="15%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:15.2%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="82%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:82.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification   of Principal Executive Officer pursuant to Rule&nbsp;13a-14(a)&nbsp;or   Rule&nbsp;15d-14(a)&nbsp;of the Securities Exchange Act of 1934, as adopted   pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002</font></p>    </td>   </tr>
<tr>
<td width="15%" valign="top" style="padding:0in 0in 0in 0in;width:15.2%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31.2</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification   of Principal Financial Officer pursuant to Rule&nbsp;13a-14(a)&nbsp;or   Rule&nbsp;15d-14(a)&nbsp;of the Securities Exchange Act of 1934, as adopted   pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002</font></p>    </td>   </tr>
<tr>
<td width="15%" valign="top" style="padding:0in 0in 0in 0in;width:15.2%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification   of Principal Executive Officer pursuant to 18 U.S.C. Section&nbsp;1350, as   adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002</font></p>    </td>   </tr>
<tr>
<td width="15%" valign="top" style="padding:0in 0in 0in 0in;width:15.2%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32.2</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification   of Principal Financial Officer pursuant to 18 U.S.C. Section&nbsp;1350, as   adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002</font></p>    </td>   </tr>
<tr>
<td width="15%" valign="top" style="padding:0in 0in 0in 0in;width:15.2%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.INS</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL   Instance Document*</font></p>    </td>   </tr>
<tr>
<td width="15%" valign="top" style="padding:0in 0in 0in 0in;width:15.2%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.SCH</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL   Taxonomy Extension Schema Document*</font></p>    </td>   </tr>
<tr>
<td width="15%" valign="top" style="padding:0in 0in 0in 0in;width:15.2%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.CAL</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL   Taxonomy Extension Calculation Linkbase Document*</font></p>    </td>   </tr>
<tr>
<td width="15%" valign="top" style="padding:0in 0in 0in 0in;width:15.2%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.LAB</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL   Taxonomy Extension Label Linkbase Database*</font></p>    </td>   </tr>
<tr>
<td width="15%" valign="top" style="padding:0in 0in 0in 0in;width:15.2%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.PRE</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL   Taxonomy Extension Presentation Linkbase Document*</font></p>    </td>   </tr>
<tr>
<td width="15%" valign="top" style="padding:0in 0in 0in 0in;width:15.2%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.DEF</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL   Taxonomy Extension Definition Linkbase Document*</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">* Submitted electronically herewith.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">72<a name="PB_72_124216_6277"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='72',FILE='C:\JMS\105538\15-7157-1\task7389728\7157-1-gm.htm',USER='105538',CD='May  5 05:12 2015' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a15-7157_1ex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>


<html>
<head>


  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;31.1</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CERTIFICATIONS</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I, Stuart W. Peltz, certify that:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">I have reviewed this Quarterly Report on Form&nbsp;10-Q of PTC Therapeutics,&nbsp;Inc.;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)) for the registrant and have:</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions):</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:   May&nbsp;5, 2015</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="51%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:51.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   STUART W. PELTZ </font></p>    </td>   </tr>
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="51%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:51.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stuart   W. Peltz </font></p>    </td>   </tr>
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.5%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Chief Executive Officer </font></i></p>    </td>   </tr>
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.5%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">(Principal Executive Officer)</font></i></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1<a name="PB_1_124354_4286"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\JMS\105538\15-7157-1\task7389728\7157-1-ma.htm',USER='105538',CD='May  5 05:15 2015' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a15-7157_1ex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>


<html>
<head>


  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;31.2</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CERTIFICATIONS</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I, Shane Kovacs, certify that:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">I have reviewed this Quarterly Report on Form&nbsp;10-Q of PTC Therapeutics,&nbsp;Inc.;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)) for the registrant and have:</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions):</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:   May&nbsp;5, 2015</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   SHANE KOVACS </font></p>    </td>   </tr>
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Shane   Kovacs </font></p>    </td>   </tr>
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Chief Financial Officer </font></i></p>    </td>   </tr>
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">(Principal Financial and Accounting Officer)</font></i></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1<a name="PB_1_124441_981"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\JMS\105538\15-7157-1\task7389728\7157-1-mc.htm',USER='105538',CD='May  5 05:13 2015' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a15-7157_1ex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>


<html>
<head>


  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;32.1</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION&nbsp;1350,</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT OF 2002</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with the Quarterly Report on Form&nbsp;10-Q of PTC Therapeutics,&nbsp;Inc. (the &#147;Company&#148;) for the period ended March&nbsp;31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), the undersigned, Stuart W. Peltz, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&nbsp;1350, that to his knowledge:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the Report fully complies with the requirements of Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Securities Exchange Act of 1934; and</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:   May&nbsp;5, 2015</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   STUART W. PELTZ </font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:45.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stuart   W. Peltz </font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.42%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Chief Executive Officer </font></i></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.42%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">(Principal Executive Officer)</font></i></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1<a name="PB_1_124515_5611"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\JMS\105538\15-7157-1\task7389728\7157-1-me.htm',USER='105538',CD='May  5 05:15 2015' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>a15-7157_1ex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>


<html>
<head>


  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;32.2</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION&nbsp;1350,</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT OF 2002</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with the Quarterly Report on Form&nbsp;10-Q of PTC Therapeutics,&nbsp;Inc. (the &#147;Company&#148;) for the period ended March&nbsp;31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), the undersigned, Shane Kovacs, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&nbsp;1350, that to his knowledge:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the Report fully complies with the requirements of Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Securities Exchange Act of 1934; and</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:   May&nbsp;5, 2015</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   SHANE KOVACS </font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:45.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Shane   Kovacs</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:1.0pt;font-style:italic;">&nbsp;</font></i></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.84%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:1.0pt;font-style:italic;">&nbsp;</font></i></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.16%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Chief Financial Officer</font></i></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.16%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">(Principal Financial and Accounting Officer)</font></i></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1<a name="PB_1_124547_6946"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\JMS\105538\15-7157-1\task7389728\7157-1-mg.htm',USER='105538',CD='May  5 05:14 2015' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>ptct-20150331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  5.12.31.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/4/2015 1:50:49 PM-->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ptct="http://www.ptcbio.com/20150331" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31">
  <link:schemaRef xlink:type="simple" xlink:href="ptct-20150331.xsd" />
  <!--Context Section-->
  <context id="As_Of_3_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_5_31_2013_us-gaap_PlanNameAxis_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-05-31</instant>
    </period>
  </context>
  <context id="As_Of_3_5_2013_us-gaap_PlanNameAxis_ptct_StockIncentivePlan2013Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:StockIncentivePlan2013Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-03-05</instant>
    </period>
  </context>
  <context id="As_Of_3_5_2013_us-gaap_PlanNameAxis_ptct_StockIncentivePlan2013Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:StockIncentivePlan2013Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-03-05</instant>
    </period>
  </context>
  <context id="Duration_5_1_2013_To_5_31_2013_us-gaap_PlanNameAxis_ptct_EquityAndLongTermIncentivePlan2009Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:EquityAndLongTermIncentivePlan2009Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-05-01</startDate>
      <endDate>2013-05-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="Duration_3_5_2013_To_3_5_2013_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember_us-gaap_PlanNameAxis_ptct_StockIncentivePlan2013Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:StockIncentivePlan2013Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-03-05</startDate>
      <endDate>2013-03-05</endDate>
    </period>
  </context>
  <context id="Duration_3_5_2013_To_3_5_2013_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_ptct_StockIncentivePlan2013Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:StockIncentivePlan2013Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-03-05</startDate>
      <endDate>2013-03-05</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_ForeignCurrencyGainLossMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ForeignCurrencyGainLossMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_OtherDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_OtherDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_3_31_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_3_31_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_3_31_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_3_31_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_ForeignCurrencyGainLossMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ForeignCurrencyGainLossMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_ForeignCurrencyGainLossMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ForeignCurrencyGainLossMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="As_Of_5_31_2013_us-gaap_PlanNameAxis_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-05-31</instant>
    </period>
  </context>
  <context id="Duration_5_1_2013_To_5_31_2013_us-gaap_PlanNameAxis_ptct_LongTermIncentivePlan2013Member_us-gaap_RangeAxis_us-gaap_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:LongTermIncentivePlan2013Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-05-01</startDate>
      <endDate>2013-05-31</endDate>
    </period>
  </context>
  <context id="Duration_8_4_2014_To_8_4_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
    </entity>
    <period>
      <startDate>2014-08-04</startDate>
      <endDate>2014-08-04</endDate>
    </period>
  </context>
  <context id="Duration_1_21_2014_To_1_22_2014_dei_LegalEntityAxis_ptct_RocheAndSMAFoundationMember_ptct_MilestoneAxis_ptct_ClinicalDevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ptct:RocheAndSMAFoundationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ptct:MilestoneAxis">ptct:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-21</startDate>
      <endDate>2014-01-22</endDate>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_CounterpartyNameAxis_ptct_WellcomeTrustLimitedMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementProductAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ptct:WellcomeTrustLimitedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementProductAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_3_31_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_InvestmentTypeAxis_us-gaap_OtherDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_InvestmentTypeAxis_us-gaap_OtherDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_4_30_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
    </entity>
    <period>
      <instant>2015-04-30</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <!--Unit Section-->
  <unit id="Unit15">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Unit14">
    <measure>xbrli:pure</measure>
  </unit>
  <unit id="Unit13">
    <measure>ptct:state</measure>
  </unit>
  <unit id="Unit12">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="Unit1">
    <measure>xbrli:shares</measure>
  </unit>
  <!--Tuple Section-->
  <!--Element Section-->
  <dei:AmendmentFlag contextRef="Duration_1_1_2015_To_3_31_2015">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="Duration_1_1_2015_To_3_31_2015">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="Duration_1_1_2015_To_3_31_2015">Q1</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="Duration_1_1_2015_To_3_31_2015">2015</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="Duration_1_1_2015_To_3_31_2015">2015-03-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="Duration_1_1_2015_To_3_31_2015">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="Duration_1_1_2015_To_3_31_2015">0001070081</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="As_Of_4_30_2015" unitRef="Unit1" decimals="INF">33848276</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="Duration_1_1_2015_To_3_31_2015">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="Duration_1_1_2015_To_3_31_2015">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName contextRef="Duration_1_1_2015_To_3_31_2015">PTC THERAPEUTICS, INC.</dei:EntityRegistrantName>
  <ptct:AccruedConsultingAndContractedResearchCurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">9349000</ptct:AccruedConsultingAndContractedResearchCurrent>
  <ptct:AccruedConsultingAndContractedResearchCurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">11691000</ptct:AccruedConsultingAndContractedResearchCurrent>
  <ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">101732000</ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue>
  <ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue contextRef="As_Of_12_31_2014_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3">72273000</ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue>
  <ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue contextRef="As_Of_12_31_2014_us-gaap_InvestmentTypeAxis_us-gaap_OtherDebtSecuritiesMember" unitRef="Unit12" decimals="-3">29459000</ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue>
  <ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">74250000</ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue>
  <ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue contextRef="As_Of_3_31_2015_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3">48228000</ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue>
  <ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue contextRef="As_Of_3_31_2015_us-gaap_InvestmentTypeAxis_us-gaap_OtherDebtSecuritiesMember" unitRef="Unit12" decimals="-3">26022000</ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue>
  <ptct:ChangeInUnrealizedGainLossOnMarketableSecurities contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">10000</ptct:ChangeInUnrealizedGainLossOnMarketableSecurities>
  <ptct:ChangeInUnrealizedGainLossOnMarketableSecurities contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">125000</ptct:ChangeInUnrealizedGainLossOnMarketableSecurities>
  <ptct:CollaborationRevenue contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">9147000</ptct:CollaborationRevenue>
  <ptct:CollaborationRevenue contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">338000</ptct:CollaborationRevenue>
  <ptct:CollaborationRevenuesDisclosureTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="text-indent:0pt;margin-left:0pt; padding-right:23pt;"&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;10.&lt;/font&gt;&lt;/font&gt;&lt;font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"&gt;&lt;font style="display: inline;font-weight:bold;font-size:3pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Collaboration Revenue&lt;/font&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;In January&amp;nbsp;2014, the Company announced the initiation of a Phase 1 clinical program in its spinal muscular atrophy collaboration with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc. (Roche) and the Spinal Muscular Atrophy Foundation which triggered a $7.5 million milestone payment from Roche. The Company considered this milestone event substantive because the applicable criteria of its revenue recognition policy would be satisfied and recorded it as collaboration revenue for the three months ended March&amp;nbsp;31, 2014.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</ptct:CollaborationRevenuesDisclosureTextBlock>
  <ptct:DepositsAndOtherAssetsNoncurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">489000</ptct:DepositsAndOtherAssetsNoncurrent>
  <ptct:DepositsAndOtherAssetsNoncurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">351000</ptct:DepositsAndOtherAssetsNoncurrent>
  <ptct:DevelopmentAndRegulatoryMilestonePaymentObligations contextRef="As_Of_3_31_2015_us-gaap_CounterpartyNameAxis_ptct_WellcomeTrustLimitedMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementProductAgreementMember" unitRef="Unit12" decimals="-5">68900000</ptct:DevelopmentAndRegulatoryMilestonePaymentObligations>
  <ptct:InventoriesAndCostOfRevenuePolicyTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Inventories and cost of product revenue&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;On August&amp;nbsp;4, 2014, the Company was notified that the European Commission, or EC, granted marketing authorization for Translarna for the treatment of Duchenne muscular dystrophy caused by nonsense mutations, or nmDMD, in ambulatory patients aged five years and older. The marketing authorization allows the Company to market Translarna in the European Economic Area, or EEA, which is comprised of the 28 member states of the European Union plus Norway,&amp;nbsp;Iceland and Liechtenstein. This marketing authorization is subject to annual review and renewal by the European Medicines Agency, or EMA following its reassessment of the risk-benefit balance of the authorization and is further conditioned on the Company&amp;#x2019;s ability to complete its global, confirmatory Phase 3 clinical trial in nm DMD, which it refers to as ACT DMD, and submit the final report, including additional efficacy and safety data from the trial during 2015.&amp;nbsp;&amp;nbsp;The launch in these countries is on a country by country basis. The Company does do not have sufficient history or experience from which to accurately forecast product sales or demand generation. As such, the Company has not capitalized inventory and will not capitalize inventory until the completion of ACT DMD and satisfaction of the EMA conditions or until the Company can reasonably predict future product sales. The costs incurred related to the manufacturing of Translarna have been recorded as research and development expense in the statements of operations. The Company&amp;#x2019;s cost of product sales includes royalties and other miscellaneous selling costs, which were not material and therefore included as a component of research and development costs in the current year presentation. The time period over which this inventory is consumed will depend on a number of factors, including the amount of future Translarna sales, and the ability to utilize inventory prior to its expiration date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</ptct:InventoriesAndCostOfRevenuePolicyTextBlock>
  <ptct:MilestonePaymentsReceived contextRef="Duration_1_21_2014_To_1_22_2014_dei_LegalEntityAxis_ptct_RocheAndSMAFoundationMember_ptct_MilestoneAxis_ptct_ClinicalDevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="Unit12" decimals="-5">7500000</ptct:MilestonePaymentsReceived>
  <ptct:MinimumAgeOfAmbulatoryPatient contextRef="Duration_8_4_2014_To_8_4_2014">P5Y</ptct:MinimumAgeOfAmbulatoryPatient>
  <ptct:NetProductSales contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">5069000</ptct:NetProductSales>
  <ptct:NumberOfStates contextRef="Duration_8_4_2014_To_8_4_2014" unitRef="Unit13" decimals="INF">31</ptct:NumberOfStates>
  <ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding contextRef="Duration_5_1_2013_To_5_31_2013_us-gaap_PlanNameAxis_ptct_LongTermIncentivePlan2013Member_us-gaap_RangeAxis_us-gaap_MinimumMember" unitRef="Unit14" decimals="2">0.04</ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding>
  <ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber contextRef="Duration_5_1_2013_To_5_31_2013_us-gaap_PlanNameAxis_ptct_LongTermIncentivePlan2013Member_us-gaap_RangeAxis_us-gaap_MinimumMember" unitRef="Unit1" decimals="INF">2500000</ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber>
  <ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards contextRef="As_Of_5_31_2013_us-gaap_PlanNameAxis_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">3040444</ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards>
  <ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="Unit1" decimals="INF">93350</ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions>
  <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="text-indent:0pt;margin-left:0pt; padding-right:28pt;"&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;5.&lt;/font&gt;&lt;/font&gt;&lt;font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"&gt;&lt;font style="display: inline;font-weight:bold;font-size:3pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Accounts payable and accrued expenses&lt;/font&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Accounts payable and accrued expenses at March&amp;nbsp;31, 2015 and December&amp;nbsp;31, 2014 consist of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;March&amp;nbsp;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:66.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Employee compensation, benefits, and related accruals &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,365&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,312&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:66.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Consulting and contracted research &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11,691&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,349&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:66.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Professional fees &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,382&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,334&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:66.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Accounts payable &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,139&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,128&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:66.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Other &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,955&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,998&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;23,532&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;29,121&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">29121000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">23532000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">4128000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">3139000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">-414000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-486000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">3334000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">3382000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">-737000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="Unit12" decimals="-3">-387000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_ForeignCurrencyGainLossMember" unitRef="Unit12" decimals="-3">-350000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">-736000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="As_Of_3_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="Unit12" decimals="-3">-262000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="As_Of_3_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_ForeignCurrencyGainLossMember" unitRef="Unit12" decimals="-3">-474000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AdditionalPaidInCapital contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">721722000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">734489000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">3705000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2014_To_3_31_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3">1944000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2014_To_3_31_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="Unit12" decimals="-3">1761000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">9748000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3">4667000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="Unit12" decimals="-3">5081000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit1" decimals="0">3882286</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2014_To_3_31_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="0">3133830</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2014_To_3_31_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" unitRef="Unit1" decimals="0">748456</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit1" decimals="0">4992803</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="0">4627833</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" unitRef="Unit1" decimals="0">364970</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">333219000</us-gaap:Assets>
  <us-gaap:Assets contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">299520000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">323571000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">289761000</us-gaap:AssetsCurrent>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">265493000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3">230031000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_OtherDebtSecuritiesMember" unitRef="Unit12" decimals="-3">35462000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_12_31_2014_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit12" decimals="-3">265493000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_12_31_2014_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit12" decimals="-3">265493000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">243642000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_3_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3">19774000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_3_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3">186534000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_3_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_OtherDebtSecuritiesMember" unitRef="Unit12" decimals="-3">37334000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_3_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit12" decimals="-3">243642000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_3_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit12" decimals="-3">243642000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">87000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3">80000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_OtherDebtSecuritiesMember" unitRef="Unit12" decimals="-3">7000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">91000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="As_Of_3_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3">26000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="As_Of_3_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3">44000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="As_Of_3_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_OtherDebtSecuritiesMember" unitRef="Unit12" decimals="-3">21000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">474000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3">428000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_OtherDebtSecuritiesMember" unitRef="Unit12" decimals="-3">46000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">353000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="As_Of_3_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3">320000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="As_Of_3_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_OtherDebtSecuritiesMember" unitRef="Unit12" decimals="-3">33000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">265880000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3">230379000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_OtherDebtSecuritiesMember" unitRef="Unit12" decimals="-3">35501000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">243904000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="As_Of_3_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3">19748000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="As_Of_3_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3">186810000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="As_Of_3_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_OtherDebtSecuritiesMember" unitRef="Unit12" decimals="-3">37346000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">163761000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="As_Of_12_31_2014_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3">157758000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="As_Of_12_31_2014_us-gaap_InvestmentTypeAxis_us-gaap_OtherDebtSecuritiesMember" unitRef="Unit12" decimals="-3">6003000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">169392000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="As_Of_3_31_2015_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3">19774000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="As_Of_3_31_2015_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3">138306000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="As_Of_3_31_2015_us-gaap_InvestmentTypeAxis_us-gaap_OtherDebtSecuritiesMember" unitRef="Unit12" decimals="-3">11312000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Basis of Presentation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The accompanying financial information as of March&amp;nbsp;31, 2015 and for the three months ended March&amp;nbsp;31, 2015 and 2014 has been prepared by the Company, without audit, pursuant to the rules&amp;nbsp;and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP) have been condensed or omitted pursuant to such rules&amp;nbsp;and regulations. These interim financial statements should be read in conjunction with the Company&amp;#x2019;s audited financial statements as of December&amp;nbsp;31, 2014 and notes thereto included in the 2014 Form&amp;nbsp;10-K.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;In the opinion of management, the unaudited financial information as of March&amp;nbsp;31, 2015 and for the three months ended March&amp;nbsp;31, 2015 and 2014 reflects all adjustments, which are normal recurring adjustments, necessary to present a fair statement of financial position, results of operations and cash flows. The results of operations for the three month period ended March&amp;nbsp;31, 2015 are not necessarily indicative of the results to be expected for the year ended December&amp;nbsp;31, 2015 or for any other interim period or for any other future year.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="text-indent:0pt;margin-left:0pt; padding-right:28pt;"&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;2.&lt;/font&gt;&lt;/font&gt;&lt;font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"&gt;&lt;font style="display: inline;font-weight:bold;font-size:3pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Summary of significant accounting policies&lt;/font&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company&amp;#x2019;s complete listing of significant accounting policies are described in Note 2 of the notes to the Company&amp;#x2019;s audited financial statements as of December&amp;nbsp;31, 2014 included in the Company&amp;#x2019;s Annual Report on Form&amp;nbsp;10-K filed with the Securities and Exchange Commission (SEC) on March&amp;nbsp;2, 2015 (2014 Form&amp;nbsp;10-K).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Basis of Presentation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The accompanying financial information as of March&amp;nbsp;31, 2015 and for the three months ended March&amp;nbsp;31, 2015 and 2014 has been prepared by the Company, without audit, pursuant to the rules&amp;nbsp;and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP) have been condensed or omitted pursuant to such rules&amp;nbsp;and regulations. These interim financial statements should be read in conjunction with the Company&amp;#x2019;s audited financial statements as of December&amp;nbsp;31, 2014 and notes thereto included in the 2014 Form&amp;nbsp;10-K.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;In the opinion of management, the unaudited financial information as of March&amp;nbsp;31, 2015 and for the three months ended March&amp;nbsp;31, 2015 and 2014 reflects all adjustments, which are normal recurring adjustments, necessary to present a fair statement of financial position, results of operations and cash flows. The results of operations for the three month period ended March&amp;nbsp;31, 2015 are not necessarily indicative of the results to be expected for the year ended December&amp;nbsp;31, 2015 or for any other interim period or for any other future year.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Use of estimates&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Inventories and cost of product revenue&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;On August&amp;nbsp;4, 2014, the Company was notified that the European Commission, or EC, granted marketing authorization for Translarna for the treatment of Duchenne muscular dystrophy caused by nonsense mutations, or nmDMD, in ambulatory patients aged five years and older. The marketing authorization allows the Company to market Translarna in the European Economic Area, or EEA, which is comprised of the 28 member states of the European Union plus Norway,&amp;nbsp;Iceland and Liechtenstein. This marketing authorization is subject to annual review and renewal by the European Medicines Agency, or EMA following its reassessment of the risk-benefit balance of the authorization and is further conditioned on the Company&amp;#x2019;s ability to complete its global, confirmatory Phase 3 clinical trial in nm DMD, which it refers to as ACT DMD, and submit the final report, including additional efficacy and safety data from the trial during 2015.&amp;nbsp;&amp;nbsp;The launch in these countries is on a country by country basis. The Company does do not have sufficient history or experience from which to accurately forecast product sales or demand generation. As such, the Company has not capitalized inventory and will not capitalize inventory until the completion of ACT DMD and satisfaction of the EMA conditions or until the Company can reasonably predict future product sales. The costs incurred related to the manufacturing of Translarna have been recorded as research and development expense in the statements of operations. The Company&amp;#x2019;s cost of product sales includes royalties and other miscellaneous selling costs, which were not material and therefore included as a component of research and development costs in the current year presentation. The time period over which this inventory is consumed will depend on a number of factors, including the amount of future Translarna sales, and the ability to utilize inventory prior to its expiration date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Recently issued accounting standard&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;In May&amp;nbsp;2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No.&amp;nbsp;2014-09, Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for annual reporting periods beginning after December&amp;nbsp;15, 2016. Early application is not permitted. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. Presently, the Company is assessing what effect the adoption of ASU 2014-09 will have on its financial statements and accompanying notes.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;In August&amp;nbsp;2014, the FASB issued ASU 2014-15, &amp;#x201C;Presentation of Financial Statements&amp;#x2014;Going Concern&amp;#x2014;Disclosures of Uncertainties about an entity&amp;#x2019;s Ability to Continue as a Going Concern.&amp;#x201D; ASU 2014-15 provides new guidance related to management&amp;#x2019;s responsibility to evaluate whether there is substantial doubt about an entity&amp;#x2019;s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards and to provide related footnote disclosures. This new guidance is effective for the annual period ending after December&amp;nbsp;15, 2016, and for annual periods and interim periods thereafter. The requirements of ASU 2014-15 are not expected to have a significant impact on the Condensed Consolidated Financial Statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Revenue Recognition&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company recognizes revenue when amounts are realized or realizable and earned. Revenue is considered realizable and earned when the following criteria are met: (1)&amp;nbsp;persuasive evidence of an arrangement exists; (2)&amp;nbsp;delivery has occurred or services have been rendered; (3)&amp;nbsp;the price is fixed or determinable; and (4)&amp;nbsp;collection of the amounts due are reasonably assured.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;font-size:10pt;"&gt;Net Product Sales&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;PTC&amp;#x2019;S net product sales have consisted solely of sales of Translarna for the treatment of nmDMD in territories outside of the U.S. The Company applies the revenue recognition guidance in accordance with Financial Accounting Standards Board (&amp;#x201C;FASB&amp;#x201D;) Accounting Standards Codification (&amp;#x201C;ASC&amp;#x201D;) Subtopic 605-15, Revenue Recognition&amp;#x2014;Products. The Company recognizes revenue from product sales when there is persuasive evidence that an arrangement exists, title to product and associated risk of loss has passed to the customer, the price is fixed or determinable, collectability is reasonably assured and the Company has no further performance obligations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company records revenue on sales where Translarna is available either on a commercial basis or through a reimbursed early access program and typically paid for by a government authority or institution. Prior to January&amp;nbsp;1, 2015, the Company recognized revenue for commercial and reimbursed early access program sales on a cash basis once the product was shipped on behalf of the government authority or institution and payment had been received, if all other revenue recognition criteria were met. Beginning in the first quarter of 2015, the Company is recognizing revenue for Translarna as product is shipped, as the Company has established a pattern of collectability.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company records revenue net of estimated discounts and rebates. Allowances are recorded as a reduction of revenue at the time revenues from product sales are recognized. Allowances for government rebates and discounts are established at the time of delivery. These allowances are adjusted to reflect known changes in factors that may impact such allowances in the quarter those changes are known.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;font-size:10pt;"&gt;Collaboration and Grant Revenue&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The terms of these agreements typically include payments to the Company of one or more of the following: nonrefundable, upfront license fees; milestone payments; research funding and royalties on future product sales. In addition, the Company generates service revenue through agreements that generally provide for fees for research and development services and may include additional payments upon achievement of specified events.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company evaluates all contingent consideration earned, such as a milestone payment, using the criteria as provided by the Financial Accounting Standards Board (FASB), guidance on the milestone method of revenue recognition. At the inception of a collaboration arrangement, the Company evaluates if a milestone payment is substantive. The criteria requires that (1)&amp;nbsp;the Company determines if the milestone is commensurate with either its performance to achieve the milestone or the enhancement of value resulting from our activities to achieve the milestone; (2)&amp;nbsp;the milestone be related to past performance; and (3)&amp;nbsp;the milestone be reasonable relative to all deliverable and payment terms of the collaboration arrangement. If these criteria are met then the contingent milestones can be considered a substantive milestone and will be recognized as revenue in the period that the milestone is achieved. The Company recognizes royalties as earned in accordance with the terms of various research and collaboration agreements. If not substantive, the contingent consideration is allocated to the existing units of accounting based on relative selling price and recognized following the same basis previously established for the associated unit of accounting.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company has the risks and rewards as the principal in the research and development activities.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2013" unitRef="Unit12" decimals="-3">15414000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_3_31_2014" unitRef="Unit12" decimals="-3">115855000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">49748000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">36825000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_12_31_2014_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit15" decimals="2">2520.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_12_31_2014_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit15" decimals="2">128.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_12_31_2014_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit15" decimals="2">128.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_31_2015_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit15" decimals="2">2520.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_31_2015_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit15" decimals="2">128.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_31_2015_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit15" decimals="2">128.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="As_Of_12_31_2014_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">130</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="As_Of_12_31_2014_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">7030</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="As_Of_12_31_2014_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">6250</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="As_Of_3_31_2015_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">130</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="As_Of_3_31_2015_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">7030</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="As_Of_3_31_2015_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">6250</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;9. Commitments and contingencies&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Operating leases&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company leases office space under a noncancelable operating lease through February&amp;nbsp;2019. Rent expense was approximately $0.3 million for the three months ended March&amp;nbsp;31, 2015. The Company also leases certain office equipment under operating leases. Future minimum lease payments as of March&amp;nbsp;31, 2015 are as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.62%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;2015 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,016&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.62%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;2016 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;946&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.62%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;2017 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;923&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.62%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;2018 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,035&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.62%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;2019 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;176&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.62%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,096&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Other contingencies&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Under various agreements, the Company will be required to pay royalties and milestone payments upon the successful development and commercialization of products. The Company has entered into funding agreements with The Wellcome Trust Limited (Wellcome Trust) for the research and development of small molecule compounds. To the extent that the Company develops and commercializes program intellectual property on a for-profit basis, it may become obligated to pay to Wellcome Trust development and regulatory milestone payments of up to an aggregate of $68.9 million and single-digit royalties on sales of any research program product. The Company&amp;#x2019;s obligation to pay such royalties would continue on a country-by-country basis until the longer of the expiration of the last patent &lt;/font&gt;&lt;a name="mrllPB12"&gt;&lt;/a&gt;&lt;font style="display: inline;font-size:10pt;"&gt;in the program intellectual property in such country covering the research program product and the expiration of market exclusivity of such product in such country.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company has also entered into a collaboration agreement with the SMA Foundation. The Company may become obligated to pay the SMA Foundation single-digit royalties on worldwide net product sales of any collaboration product that we successfully develop and subsequently commercialize or, if the Company outlicenses rights to a collaboration product, a specified percentage of certain payments the Company receives from the licensee. The Company is not obligated to make such payments unless and until annual sales of a collaboration product exceed a designated threshold. The Company&amp;#x2019;s obligation to make such payments would end upon its payment to the SMA Foundation of a specified amount.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company has employment agreements with certain employees that require the funding of a specific level of payments, if certain events, such as a change in control or termination without cause, occur.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_12_31_2014" unitRef="Unit15" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_3_31_2015" unitRef="Unit15" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="INF">125000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_3_31_2015" unitRef="Unit1" decimals="INF">125000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="INF">32898392</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_3_31_2015" unitRef="Unit1" decimals="INF">33483306</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="INF">32898392</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_3_31_2015" unitRef="Unit1" decimals="INF">33483306</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">33000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">33000</us-gaap:CommonStockValue>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">-14088000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-37914000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="text-indent:0pt;margin-left:0pt; padding-right:28pt;"&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;4.&lt;/font&gt;&lt;/font&gt;&lt;font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"&gt;&lt;font style="display: inline;font-weight:bold;font-size:3pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Other comprehensive income (loss) and accumulated other comprehensive items&lt;/font&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Other comprehensive income (loss) includes changes in equity that are excluded from net income (loss), such as unrealized gains and losses on marketable securities.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The following tables summarize other comprehensive income (loss) and the changes in accumulated other comprehensive items for the three months ended March&amp;nbsp;31, 2015:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:55.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Unrealized&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Gains/(Losses)&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;On&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Marketable&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Foreign&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Currency&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Translation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Accumulated&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Other&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Comprehensive&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Items&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:55.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Balance at December&amp;nbsp;31, 2014 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(387
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(350
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(737
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:55.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Other comprehensive income/(loss) before reclassifications &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;125
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(124
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:55.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Amounts reclassified from other comprehensive items &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:55.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Other comprehensive income/(loss) &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;125
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(124
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:55.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Balance at March&amp;nbsp;31, 2015 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(262
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(474
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(736
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
  <us-gaap:DeferredRevenueCurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">3354000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">373000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:Depreciation contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">588000</us-gaap:Depreciation>
  <us-gaap:Depreciation contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">634000</us-gaap:Depreciation>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="text-indent:0pt;margin-left:0pt; padding-right:28pt;"&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;8.&lt;/font&gt;&lt;/font&gt;&lt;font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"&gt;&lt;font style="display: inline;font-weight:bold;font-size:3pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Stock award plan&lt;/font&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;On March&amp;nbsp;5, 2013, the Company&amp;#x2019;s Board of Directors approved the 2013 Stock Incentive Plan, which provides for the granting of stock option awards, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards in the aggregate of 739,937 shares of common stock. On March&amp;nbsp;5, 2013, the Board approved a grant of 735,324 shares of restricted stock and 4,613 stock options. There are no additional shares available for issuance under this plan.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;In May&amp;nbsp;2013, the Company&amp;#x2019;s Board of Directors and stockholders increased by 2,500,000 the number of shares authorized under the 2009 Equity and Long Term Incentive Plan, which provides for the granting of stock option awards, restricted stock awards, and other stock-based and cash-based awards.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;In May&amp;nbsp;2013, the Company&amp;#x2019;s Board of Directors and stockholders approved the 2013 Long Term Incentive Plan, which became effective upon the closing of the Company&amp;#x2019;s IPO.&amp;nbsp;&amp;nbsp;The 2013 Long Term Incentive Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards and other stock-based awards. The number of shares of common stock reserved for issuance under the 2013 Long Term Incentive Plan is the sum of (1)&amp;nbsp;245,000 shares of common stock available for issuance under the Company&amp;#x2019;s 2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan, (2)&amp;nbsp;the number of shares (up to 3,040,444 shares) equal to the sum of the number of shares of common stock subject to outstanding awards under the Company&amp;#x2019;s 1998 Employee, Director and Consultant Stock Option Plan, 2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right plus (3)&amp;nbsp;an annual increase, to be added on the first day of each fiscal year until the expiration of the 2013 Long Term Incentive Plan, equal to the lowest of 2,500,000 shares of common stock, 4% of the number of shares of common stock outstanding on the first day of the fiscal year and an amount determined by the Company&amp;#x2019;s Board of Directors.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;From January&amp;nbsp;1, 2015 through March&amp;nbsp;31, 2015, the Company issued a total of 1,456,550 stock options to various employees.&amp;nbsp;&amp;nbsp;Of those, 93,350 were inducement grants for non-statutory stock options. The inducement grant awards were made pursuant to the NASDAQ inducement grant exception as a material component of our new hires&amp;#x2019; employment compensation.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;A summary of stock option activity is as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Number&amp;nbsp;of&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Weighted-&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;average&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;exercise&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Weighted-&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;average&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;remaining&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;contractual&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;term&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Aggregate&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;intrinsic&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;(in&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Outstanding at December&amp;nbsp;31, 2014 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,432,972
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;25.00
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Granted &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,456,550
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;51.02
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Exercised &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(234,830
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12.86
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Forfeited &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(26,265
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;47.52
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Expired &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(594
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;388.53
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Outstanding at March&amp;nbsp;31, 2015 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,627,833
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;33.60
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;8.9 years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;140,399
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Vested or Expected to vest at March&amp;nbsp;31, 2015 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,332,726
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;32.74
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;8.9 years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;133,232
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Exercisable at March&amp;nbsp;31, 2015 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,037,262
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;30.98
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;8.2 years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;45,137
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The fair value of grants made in the three months ended March&amp;nbsp;31, 2015 was contemporaneously estimated on the date of grant using the following assumptions:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 53.00%;margin-left:126pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:53.46%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.66%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Three&amp;nbsp;months&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;ended&amp;nbsp;March&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;31,&amp;nbsp;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:53.46%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Risk-free interest rate &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.66%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;1.54% &amp;#x2014; 1.77%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:53.46%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Expected volatility &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.66%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;67%-69%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:53.46%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Expected term &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.66%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;5.50 - 6.11 years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company assumed no expected dividends for all grants. The weighted average grant date fair value of options granted during the three month period ended March&amp;nbsp;31, 2015 was $31.82 per share.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company uses the &amp;#x201C;simplified method&amp;#x201D; to determine the expected term of options. Under this method, the expected term represents the average of the vesting period and the contractual term. The expected volatility of share options was estimated based on a historical volatility analysis of peers that were similar to the Company with respect to industry, stage of life cycle, size, and financial leverage. The risk-free rate of the option is based on U.S. Government Securities Treasury Constant Maturities yields at the date of grant for a term similar to the expected term of the option.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;font-size:10pt;"&gt;Restricted Stock Awards&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#x2014;Restricted stock awards are granted subject to certain restrictions, including in some cases service or time conditions (restricted stock). The grant-date fair value of restricted stock awards, which has been determined based upon the market value of the Company&amp;#x2019;s shares on the grant date, is expensed over the vesting period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The following table summarizes information on the Company&amp;#x2019;s restricted stock:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="4" valign="bottom" style="width:32.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Restricted&amp;nbsp;Stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Number&amp;nbsp;of&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Average&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Grant&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Date&amp;nbsp;Fair&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;January&amp;nbsp;1, 2015 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;718,400
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10.72
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:64.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Granted &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Vested &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(350,084
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10.59
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:64.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Forfeited &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,346
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10.82
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Unvested at March&amp;nbsp;31, 2015 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;364,970
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10.85
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company recorded share-based compensation expense in the statement of operations as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:32.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Three&amp;nbsp;Months&amp;nbsp;Ended&amp;nbsp;March&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Research and development &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,667&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,944&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:64.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Selling, general and administrative &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,081&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,761&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Total &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,748&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,705&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;As of March&amp;nbsp;31, 2015 there was approximately $70.6 million of total unrecognized compensation cost related to unvested share-based compensation arrangements granted under the 2009 Equity and Long Term Incentive Plan, 2013 Long Term Incentive Plan and equity awards made pursuant to the NASDAQ inducement grant exception for new hires. This cost is expected to be recognized as share-based compensation expense over the weighted average remaining service period of approximately 3.0 years.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit15" decimals="2">-0.58</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit15" decimals="2">-1.15</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="text-indent:0pt;margin-left:0pt; padding-right:28pt;"&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;7.&lt;/font&gt;&lt;/font&gt;&lt;font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"&gt;&lt;font style="display: inline;font-weight:bold;font-size:3pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Net loss per share&lt;/font&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Basic earnings per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding. Diluted earnings per share is computed by dividing net income (loss) by the weighted-average number of common shares plus the effect of dilutive potential common shares outstanding during the period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The following tables set forth the computation of basic and diluted net loss per share:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:29.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Three&amp;nbsp;months&amp;nbsp;ended&amp;nbsp;March&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:66.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Numerator&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.78%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:66.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Net loss &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(37,915
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(14,098
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:66.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Denominator&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.78%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:66.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Denominator for basic and diluted net loss per share &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;33,067,752
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.78%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;24,492,487
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:66.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Net loss per share:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.78%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:66.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Basic and diluted &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1.15
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)*&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.58
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;*&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:3pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;In the three months ended March&amp;nbsp;31, 2015 and 2014, the Company experienced a net loss and therefore did not report any dilutive share impact.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The following table shows historical dilutive common share equivalents outstanding, which are not included in the above historical calculation, as the effect of their inclusion is anti-dilutive during each period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;As&amp;nbsp;of&amp;nbsp;March&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Stock Options &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,627,833&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,133,830&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Unvested restricted stock &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;364,970&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;748,456&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Total &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,992,803&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,882,286&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:EffectOfExchangeRateOnCash contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-124000</us-gaap:EffectOfExchangeRateOnCash>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">9312000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">3365000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-5">70600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="Duration_1_1_2015_To_3_31_2015">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">55000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">41000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAssumptionsExercisePrice contextRef="As_Of_12_31_2014_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_RangeAxis_us-gaap_MaximumMember" unitRef="Unit15" decimals="0">2520</us-gaap:FairValueAssumptionsExercisePrice>
  <us-gaap:FairValueAssumptionsExercisePrice contextRef="As_Of_12_31_2014_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_RangeAxis_us-gaap_MinimumMember" unitRef="Unit15" decimals="0">128</us-gaap:FairValueAssumptionsExercisePrice>
  <us-gaap:FairValueAssumptionsExercisePrice contextRef="As_Of_3_31_2015_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_RangeAxis_us-gaap_MaximumMember" unitRef="Unit15" decimals="0">2520</us-gaap:FairValueAssumptionsExercisePrice>
  <us-gaap:FairValueAssumptionsExercisePrice contextRef="As_Of_3_31_2015_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_RangeAxis_us-gaap_MinimumMember" unitRef="Unit15" decimals="0">128</us-gaap:FairValueAssumptionsExercisePrice>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_RangeAxis_us-gaap_MaximumMember">P4Y8M12D</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_RangeAxis_us-gaap_MinimumMember">P2Y6M</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_RangeAxis_us-gaap_MaximumMember">P4Y5M23D</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_RangeAxis_us-gaap_MinimumMember">P2Y2M16D</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_RangeAxis_us-gaap_MaximumMember" unitRef="Unit14" decimals="2">0.70</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_RangeAxis_us-gaap_MinimumMember" unitRef="Unit14" decimals="2">0.68</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_RangeAxis_us-gaap_MaximumMember" unitRef="Unit14" decimals="2">0.70</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_RangeAxis_us-gaap_MinimumMember" unitRef="Unit14" decimals="2">0.68</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_RangeAxis_us-gaap_MaximumMember" unitRef="Unit14" decimals="4">0.0165</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_RangeAxis_us-gaap_MinimumMember" unitRef="Unit14" decimals="4">0.0089</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_RangeAxis_us-gaap_MaximumMember" unitRef="Unit14" decimals="4">0.0113</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_RangeAxis_us-gaap_MinimumMember" unitRef="Unit14" decimals="4">0.0056</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="text-indent:0pt;margin-left:0pt; padding-right:28pt;"&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;3.&lt;/font&gt;&lt;/font&gt;&lt;font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"&gt;&lt;font style="display: inline;font-weight:bold;font-size:3pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Fair value of financial instruments and marketable securities&lt;/font&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company follows the fair value measurement rules, which provides guidance on the use of fair value in accounting and disclosure for assets and liabilities when such accounting and disclosure is called for by other accounting literature. These rules&amp;nbsp;establish a fair value hierarchy for inputs to be used to measure fair value of financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 00.00pt; display: inline;"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt;font-family:Symbol;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;Level 1&amp;#x2014;Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the balance sheet date.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 00.00pt; display: inline;"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt;font-family:Symbol;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;Level 2&amp;#x2014;Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves,&amp;nbsp;etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 00.00pt; display: inline;"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt;font-family:Symbol;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;Level 3&amp;#x2014;Inputs are unobservable and reflect the Company&amp;#x2019;s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;Cash equivalents are reflected in the accompanying financial statements at fair value. The carrying amount of grant and collaboration receivables, accounts payable and accrued expenses, and debt approximates fair value due to the short-term nature of those instruments.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;Fair value of certain marketable securities is based upon market prices using quoted prices in active markets for identical assets quoted on the last day of the period. In establishing the estimated fair value of the remaining investments, the Company used the fair value as determined by its investment advisors using observable inputs other than quoted prices.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;The Company reviews its investments on a periodic basis for other-than-temporary impairments. This review is subjective, as it requires management to evaluate whether an event or change in circumstances has occurred in that period that may have a significant adverse effect on the fair value of the investment.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;The following represents the fair value using the hierarchy described in Note 3 for the Company&amp;#x2019;s financial assets and liabilities that are required to be measured at fair value on a recurring basis as of March&amp;nbsp;31, 2015 and December&amp;nbsp;31, 2014:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:55.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;March&amp;nbsp;31,&amp;nbsp;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Quoted&amp;nbsp;prices&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;in&amp;nbsp;active&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;markets&amp;nbsp;for&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;identical&amp;nbsp;assets&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;(level&amp;nbsp;1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Significant&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;other&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;observable&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;inputs&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;(level&amp;nbsp;2)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Significant&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;unobservable&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;inputs&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;(level&amp;nbsp;3)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;Marketable securities &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;243,642&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;243,642&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;Warrant liability &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;229&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;229&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:55.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;December&amp;nbsp;31,&amp;nbsp;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Quoted&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;prices&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;in&amp;nbsp;active&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;markets&amp;nbsp;for&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;identical&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;assets&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;(level&amp;nbsp;1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Significant&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;other&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;observable&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;inputs&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;(level&amp;nbsp;2)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Significant&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;unobservable&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;inputs&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;(level&amp;nbsp;3)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;Marketable securities &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;265,493&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;265,493&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;Warrant Liability &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;188&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;188&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;The following is a summary of marketable securities accounted for as available-for-sale securities at March&amp;nbsp;31, 2015 and December&amp;nbsp;31, 2014:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:55.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;March&amp;nbsp;31,&amp;nbsp;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Amortized&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Gross&amp;nbsp;Unrealized&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Fair&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Cost&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Gains&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Losses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;Commercial paper &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;19,748
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;26
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;19,774
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;Corporate debt securities &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;186,810
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;44
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(320
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;186,534
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;Government obligations &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;37,346
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;21
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(33
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;37,334
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;243,904
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;91
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(353
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;243,642
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:55.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;December&amp;nbsp;31,&amp;nbsp;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Amortized&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Gross&amp;nbsp;Unrealized&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Fair&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Cost&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Gains&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Losses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;Corporate debt securities &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;230,379
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;80
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(428
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;230,031
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;Government obligations &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;35,501
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(46
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;35,462
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;265,880
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;87
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(474
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;265,493
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;At March&amp;nbsp;31, 2015 and December&amp;nbsp;31, 2014, the Company held securities with an unrealized loss position that were not considered to be other-than-temporarily impaired as the Company has the ability to hold such investments until recovery of their fair value.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;Marketable securities on the balance sheet at March&amp;nbsp;31, 2015 and December&amp;nbsp;31, 2014 mature as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;March&amp;nbsp;31,&amp;nbsp;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Less&amp;nbsp;Than&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;12&amp;nbsp;Months&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;More&amp;nbsp;Than&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;12&amp;nbsp;Months&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;Commercial paper &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;19,774&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;Corporate debt securities &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;138,306&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;48,228&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;Government obligations &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11,312&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;26,022&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;Total Marketable securities &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;169,392&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;74,250&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;December&amp;nbsp;31,&amp;nbsp;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Less&amp;nbsp;Than&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;12&amp;nbsp;Months&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;More&amp;nbsp;Than&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;12&amp;nbsp;Months&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;Corporate debt securities &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;157,758&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;72,273&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;Government obligations &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,003&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;29,459&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;Total Marketable securities &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;163,761&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;101,732&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;color:#000000;"&gt;Level 3 valuation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;The warrant liability is classified in Other long-term liabilities on the Company&amp;#x2019;s balance sheet. The warrant liability is marked-to-market each reporting period with the change in fair value recorded as a gain or loss within Other income (expense), net on the Company&amp;#x2019;s statement of operations until the warrants are exercised, expire or other facts and circumstances lead the warrant liability to be reclassified as an equity instrument. The fair value of the warrant liability is determined at each reporting period by utilizing the Black-Scholes option pricing model.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;The table presented below is a summary of changes in the fair value of the Company&amp;#x2019;s Level 3 valuation for warrant liability for the period ended March&amp;nbsp;31, 2015:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:81.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Level&amp;nbsp;3&amp;nbsp;assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:81.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;Beginning balance as of December&amp;nbsp;31, 2014 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;188&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:81.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;Change in fair value of warrant liability &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;41&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:81.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;Ending balance as of March&amp;nbsp;31, 2015 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;229&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;color:#000000;"&gt;Fair value of the warrant liability is estimated using an option-pricing model, which includes variables such as the expected volatility based on guideline public companies, the stock fair value, and the estimated time to a liquidity event. The significant assumptions used in preparing the option pricing model for valuing the Company&amp;#x2019;s warrants as of March&amp;nbsp;31, 2015 include (i)&amp;nbsp;volatility (68%&amp;#x2014;70%), (ii)&amp;nbsp;risk free interest rate (0.56%&amp;#x2014;1.13%), (iii)&amp;nbsp;strike price ($128-$2,520), (iv)&amp;nbsp;fair value of common stock ($60.85), and (v)&amp;nbsp;expected life (2.21&amp;#x2014;4.48 years). The significant assumptions used in preparing the option pricing model for valuing the Company&amp;#x2019;s warrants as of December&amp;nbsp;31, 2014 include (i)&amp;nbsp;volatility (68%-70%), (ii)&amp;nbsp;risk free interest rate (0.89%&amp;#x2014;1.65%), (iii)&amp;nbsp;strike price ($128&amp;#x2014;$2,520), (iv)&amp;nbsp;fair value of common stock ($51.77), and (v)&amp;nbsp;expected life (2.50&amp;#x2014;4.70 years). See Note 6 for a description of the warrants issued in connection with the convertible notes.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:81.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Level&amp;nbsp;3&amp;nbsp;assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:81.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Beginning balance as of December&amp;nbsp;31, 2014 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;188&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:81.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Change in fair value of warrant liability &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;41&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:81.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Ending balance as of March&amp;nbsp;31, 2015 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;229&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember" unitRef="Unit12" decimals="-3">41000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="As_Of_12_31_2014_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember" unitRef="Unit12" decimals="-3">188000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="As_Of_3_31_2015_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember" unitRef="Unit12" decimals="-3">229000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">7540000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">17615000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">-3472000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-5589000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">-386000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-2981000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDepositOtherAssets contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">-17000</us-gaap:IncreaseDecreaseInDepositOtherAssets>
  <us-gaap:IncreaseDecreaseInDepositOtherAssets contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-138000</us-gaap:IncreaseDecreaseInDepositOtherAssets>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">-23000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-23000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">358000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">2231000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInReceivables contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">-120000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInReceivables contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-1267000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">171000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">524000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:InterestPaid contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">1000</us-gaap:InterestPaid>
  <us-gaap:Liabilities contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">34752000</us-gaap:Liabilities>
  <us-gaap:Liabilities contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">26200000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">333219000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">299520000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">32475000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">23905000</us-gaap:LiabilitiesCurrent>
  <us-gaap:MarketableSecuritiesCurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">265493000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:MarketableSecuritiesCurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">243642000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:MarketableSecuritiesTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;March&amp;nbsp;31,&amp;nbsp;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;height:21.10pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;height:21.10pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:21.10pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Less&amp;nbsp;Than&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;12&amp;nbsp;Months&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;height:21.10pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:21.10pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;More&amp;nbsp;Than&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;12&amp;nbsp;Months&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;height:21.10pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Commercial paper &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;19,774&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Corporate debt securities &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;138,306&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;48,228&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Government obligations &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11,312&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;26,022&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Total Marketable securities &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;169,392&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;74,250&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Less&amp;nbsp;Than&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;12&amp;nbsp;Months&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;More&amp;nbsp;Than&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;12&amp;nbsp;Months&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Corporate debt securities &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;157,758&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;72,273&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Government obligations &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,003&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;29,459&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Total Marketable securities &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;163,761&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;101,732&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
  <us-gaap:NatureOfOperations contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="text-indent:0pt;margin-left:0pt; padding-right:28pt;"&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;1.&lt;/font&gt;&lt;/font&gt;&lt;font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"&gt;&lt;font style="display: inline;font-weight:bold;font-size:3pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;The Company&lt;/font&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;PTC Therapeutics,&amp;nbsp;Inc. (the Company or PTC) was incorporated as a Delaware corporation on March&amp;nbsp;31, 1998. PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics targeting an area of RNA biology referred to as post-transcriptional control. The letters &amp;#x201C;PTC&amp;#x201D; in the corporate name are an acronym for post-transcriptional control processes, which are the regulatory events that occur in cells during and after a messenger RNA is copied from DNA through the transcription process. The Company has discovered all of its compounds currently under development using its proprietary technologies. The Company plans to continue to develop these compounds both on its own and through selective collaboration arrangements with leading pharmaceutical and biotechnology companies. The Company believes that systematically targeting post-transcriptional control processes represents an unexploited approach to drug discovery and development. The Company&amp;#x2019;s internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company&amp;#x2019;s lead product, Translarna&amp;#x2122; (ataluren) received marketing authorization from the European Commission, or EC, in August&amp;nbsp;2014 for the treatment of nonsense mutation Duchenne muscular dystrophy, or nmDMD, in ambulatory patients age 5 years and over in the 31 member states of the European Economic Area, or EEA. This marketing authorization is subject to annual review and renewal by the European Medicines Agency, or EMA following its reassessment of the risk-benefit balance of the authorization and is further conditioned on the Company&amp;#x2019;s ability to complete its global, confirmatory Phase 3 clinical trial in nmDMD, which it refers to as ACT DMD, and submit the final report, including additional efficacy and safety data from the trial, during 2015. See &amp;#x201C;Risk Factors&amp;#x2014;Risks Related to Regulatory Approval of our Product Candidates&amp;#x201D; for further detail regarding the EMA&amp;#x2019;s approval process, including a description of the risk-benefit balance.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company launched Translarna on a commercial basis in Germany in December&amp;nbsp;2014 and expects to expand its launch activities across the EEA throughout 2015 and future years, subject to successful completion of pricing and reimbursement negotiations. Concurrently, the Company has been pursuing reimbursed early access programs in selected countries where those mechanisms exist, both within Europe and in those countries outside of Europe that will reference the marketing authorization described above.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company has not generated significant product revenue to date and is subject to a number of risks similar to those of other early stage companies, including dependence on key individuals, the difficulties inherent in the development of commercially usable products, the potential need to obtain additional capital necessary to fund the development of its products, and competition from other companies. As of March&amp;nbsp;31, 2015, the Company had an accumulated deficit of approximately $460.4 million. The Company has financed its operations to date primarily through public offerings of common stock in February&amp;nbsp;2014 and October&amp;nbsp;2014, its initial public offering of common stock in June&amp;nbsp;2013, private placements of its convertible preferred stock, collaborations, bank debt, convertible debt financings, grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease area addressed by the Company&amp;#x2019;s product candidates.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:NatureOfOperations>
  <us-gaap:NetCashProvidedByUsedInContinuingOperations contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">100441000</us-gaap:NetCashProvidedByUsedInContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInContinuingOperations contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-12923000</us-gaap:NetCashProvidedByUsedInContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">118146000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">3019000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">-4267000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">20607000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">-13438000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-36425000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">-14098000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-37915000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">-14098000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-37915000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Recently issued accounting standard&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;In May&amp;nbsp;2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No.&amp;nbsp;2014-09, Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for annual reporting periods beginning after December&amp;nbsp;15, 2016. Early application is not permitted. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. Presently, the Company is assessing what effect the adoption of ASU 2014-09 will have on its financial statements and accompanying notes.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;In August&amp;nbsp;2014, the FASB issued ASU 2014-15, &amp;#x201C;Presentation of Financial Statements&amp;#x2014;Going Concern&amp;#x2014;Disclosures of Uncertainties about an entity&amp;#x2019;s Ability to Continue as a Going Concern.&amp;#x201D; ASU 2014-15 provides new guidance related to management&amp;#x2019;s responsibility to evaluate whether there is substantial doubt about an entity&amp;#x2019;s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards and to provide related footnote disclosures. This new guidance is effective for the annual period ending after December&amp;nbsp;15, 2016, and for annual periods and interim periods thereafter. The requirements of ASU 2014-15 are not expected to have a significant impact on the Condensed Consolidated Financial Statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="4" valign="bottom" style="width:32.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Restricted&amp;nbsp;Stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Number&amp;nbsp;of&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Average&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Grant&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Date&amp;nbsp;Fair&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;January&amp;nbsp;1, 2015 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;718,400
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10.72
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:64.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Granted &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Vested &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(350,084
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10.59
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:64.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Forfeited &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,346
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10.82
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Unvested at March&amp;nbsp;31, 2015 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;364,970
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10.85
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
  <us-gaap:OperatingExpenses contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">23429000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">45553000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">-14212000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-38071000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">4096000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">1016000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">176000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">1035000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">923000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">946000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-5">300000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">2998000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">1955000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">10000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">125000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-124000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">1000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="Unit12" decimals="-3">125000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_ForeignCurrencyGainLossMember" unitRef="Unit12" decimals="-3">-124000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">1000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="Unit12" decimals="-3">125000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_ForeignCurrencyGainLossMember" unitRef="Unit12" decimals="-3">-124000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">2277000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">2295000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">-57000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-368000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">25354000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">19108000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">186000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">883000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">3885000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">6116000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">118183000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">21273000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">40598000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">3019000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">9159000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">9408000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ReceivablesNetCurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">4445000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">3178000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:RepaymentsOfLongTermDebt contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">37000</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">15889000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">27938000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">-422551000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">-460466000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RevenueFromGrants contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">70000</us-gaap:RevenueFromGrants>
  <us-gaap:RevenueFromGrants contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">2075000</us-gaap:RevenueFromGrants>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Revenue Recognition&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company recognizes revenue when amounts are realized or realizable and earned. Revenue is considered realizable and earned when the following criteria are met: (1)&amp;nbsp;persuasive evidence of an arrangement exists; (2)&amp;nbsp;delivery has occurred or services have been rendered; (3)&amp;nbsp;the price is fixed or determinable; and (4)&amp;nbsp;collection of the amounts due are reasonably assured.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;font-size:10pt;"&gt;Net Product Sales&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;PTC&amp;#x2019;S net product sales have consisted solely of sales of Translarna for the treatment of nmDMD in territories outside of the U.S. The Company applies the revenue recognition guidance in accordance with Financial Accounting Standards Board (&amp;#x201C;FASB&amp;#x201D;) Accounting Standards Codification (&amp;#x201C;ASC&amp;#x201D;) Subtopic 605-15, Revenue Recognition&amp;#x2014;Products. The Company recognizes revenue from product sales when there is persuasive evidence that an arrangement exists, title to product and associated risk of loss has passed to the customer, the price is fixed or determinable, collectability is reasonably assured and the Company has no further performance obligations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company records revenue on sales where Translarna is available either on a commercial basis or through a reimbursed early access program and typically paid for by a government authority or institution. Prior to January&amp;nbsp;1, 2015, the Company recognized revenue for commercial and reimbursed early access program sales on a cash basis once the product was shipped on behalf of the government authority or institution and payment had been received, if all other revenue recognition criteria were met. Beginning in the first quarter of 2015, the Company is recognizing revenue for Translarna as product is shipped, as the Company has established a pattern of collectability.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company records revenue net of estimated discounts and rebates. Allowances are recorded as a reduction of revenue at the time revenues from product sales are recognized. Allowances for government rebates and discounts are established at the time of delivery. These allowances are adjusted to reflect known changes in factors that may impact such allowances in the quarter those changes are known.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;font-size:10pt;"&gt;Collaboration and Grant Revenue&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The terms of these agreements typically include payments to the Company of one or more of the following: nonrefundable, upfront license fees; milestone payments; research funding and royalties on future product sales. In addition, the Company generates service revenue through agreements that generally provide for fees for research and development services and may include additional payments upon achievement of specified events.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company evaluates all contingent consideration earned, such as a milestone payment, using the criteria as provided by the Financial Accounting Standards Board (FASB), guidance on the milestone method of revenue recognition. At the inception of a collaboration arrangement, the Company evaluates if a milestone payment is substantive. The criteria requires that (1)&amp;nbsp;the Company determines if the milestone is commensurate with either its performance to achieve the milestone or the enhancement of value resulting from our activities to achieve the milestone; (2)&amp;nbsp;the milestone be related to past performance; and (3)&amp;nbsp;the milestone be reasonable relative to all deliverable and payment terms of the collaboration arrangement. If these criteria are met then the contingent milestones can be considered a substantive milestone and will be recognized as revenue in the period that the milestone is achieved. The Company recognizes royalties as earned in accordance with the terms of various research and collaboration agreements. If not substantive, the contingent consideration is allocated to the existing units of accounting based on relative selling price and recognized following the same basis previously established for the associated unit of accounting.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company has the risks and rewards as the principal in the research and development activities.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:SalesRevenueNet contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">9217000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">7482000</us-gaap:SalesRevenueNet>
  <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;March&amp;nbsp;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:66.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Employee compensation, benefits, and related accruals &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,365&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,312&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:66.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Consulting and contracted research &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11,691&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,349&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:66.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Professional fees &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,382&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,334&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:66.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Accounts payable &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,139&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,128&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:66.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Other &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,955&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,998&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;23,532&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;29,121&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:55.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Unrealized&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Gains/(Losses)&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;On&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Marketable&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Foreign&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Currency&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Translation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Accumulated&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Other&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Comprehensive&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Items&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:55.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Balance at December&amp;nbsp;31, 2014 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(387
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(350
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(737
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:55.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Other comprehensive income/(loss) before reclassifications &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;125
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(124
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:55.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Amounts reclassified from other comprehensive items &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:55.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Other comprehensive income/(loss) &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;125
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(124
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:55.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Balance at March&amp;nbsp;31, 2015 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(262
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(474
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(736
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;As&amp;nbsp;of&amp;nbsp;March&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Stock Options &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,627,833&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,133,830&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Unvested restricted stock &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;364,970&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;748,456&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Total &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,992,803&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,882,286&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:55.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;March&amp;nbsp;31,&amp;nbsp;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Amortized&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Gross&amp;nbsp;Unrealized&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Fair&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Cost&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Gains&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Losses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Commercial paper &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;19,748
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;26
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;19,774
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Corporate debt securities &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.98%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;186,810
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;44
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(320
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;186,534
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Government obligations &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;37,346
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;21
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(33
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;37,334
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;243,904
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;91
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(353
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;243,642
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="text-indent:0pt;margin-left:0pt; padding-right:34pt;"&gt;&lt;/font&gt;&lt;font style="text-indent:0pt;margin-left:0pt; padding-right:34pt;text-align:left"&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;/font&gt;&lt;font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:55.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Amortized&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Gross&amp;nbsp;Unrealized&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Fair&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Cost&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Gains&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Losses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Corporate debt securities &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;230,379
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;80
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(428
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;230,031
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Government obligations &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;35,501
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(46
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;35,462
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;265,880
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;87
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(474
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;265,493
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:29.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Three&amp;nbsp;months&amp;nbsp;ended&amp;nbsp;March&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:66.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Numerator&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.78%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:66.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Net loss &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(37,915
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(14,098
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:66.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Denominator&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.78%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:66.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Denominator for basic and diluted net loss per share &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;33,067,752
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.78%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;24,492,487
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:66.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Net loss per share:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.78%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:66.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Basic and diluted &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1.15
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)*&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.58
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;*&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:3pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;In the three months ended March&amp;nbsp;31, 2015 and 2014, the Company experienced a net loss and therefore did not report any dilutive share impact.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:32.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Three&amp;nbsp;Months&amp;nbsp;Ended&amp;nbsp;March&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Research and development &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,667&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,944&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:64.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Selling, general and administrative &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,081&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,761&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Total &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,748&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,705&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:55.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;March&amp;nbsp;31,&amp;nbsp;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Quoted&amp;nbsp;prices&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;in&amp;nbsp;active&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;markets&amp;nbsp;for&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;identical&amp;nbsp;assets&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;(level&amp;nbsp;1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Significant&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;other&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;observable&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;inputs&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;(level&amp;nbsp;2)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Significant&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;unobservable&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;inputs&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;(level&amp;nbsp;3)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Marketable securities &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;243,642&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;243,642&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Warrant liability &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.98%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;229&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;229&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:55.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Quoted&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;prices&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;in&amp;nbsp;active&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;markets&amp;nbsp;for&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;identical&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;assets&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;(level&amp;nbsp;1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Significant&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;other&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;observable&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;inputs&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;(level&amp;nbsp;2)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Significant&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;unobservable&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;inputs&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;(level&amp;nbsp;3)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Marketable securities &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;265,493&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;265,493&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Warrant Liability &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.98%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;188&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;188&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.60%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;2015 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.68%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,016&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.60%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;2016 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.02%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;946&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.60%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;2017 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.02%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;923&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.60%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;2018 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.02%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,035&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.60%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;2019 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;176&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.60%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,096&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Number&amp;nbsp;of&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Weighted-&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;average&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;exercise&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Weighted-&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;average&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;remaining&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;contractual&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;term&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Aggregate&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;intrinsic&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;(in&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Outstanding at December&amp;nbsp;31, 2014 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,432,972
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;25.00
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Granted &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,456,550
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;51.02
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Exercised &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(234,830
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12.86
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Forfeited &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(26,265
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;47.52
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Expired &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(594
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;388.53
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Outstanding at March&amp;nbsp;31, 2015 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,627,833
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;33.60
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;8.9 years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;140,399
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Vested or Expected to vest at March&amp;nbsp;31, 2015 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,332,726
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;32.74
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;8.9 years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;133,232
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Exercisable at March&amp;nbsp;31, 2015 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,037,262
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;30.98
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;8.2 years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;45,137
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:53.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.66%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Three&amp;nbsp;months&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;ended&amp;nbsp;March&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;31,&amp;nbsp;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:53.48%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Risk-free interest rate &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.66%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;1.54% &amp;#x2014; 1.77%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:53.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Expected volatility &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.66%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;67%-69%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:53.48%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Expected term &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.66%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:40.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;5.50 - 6.11 years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The following is a summary of the Company&amp;#x2019;s outstanding warrants as of March&amp;nbsp;31, 2015:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:49.60%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Warrant&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.92%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Expiration&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:49.60%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Common stock &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,250&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.62%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;128.00&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.92%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2017&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:49.60%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Common stock &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.08%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7,030&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.62%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.68%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;128.00&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.92%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.14%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;2019 and 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:49.60%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Common stock &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.08%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;130&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.62%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.68%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,520.00&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.92%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.14%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The following is a summary of the Company&amp;#x2019;s outstanding warrants as of December&amp;nbsp;31, 2014:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:49.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Warrant&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.98%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.98%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Expiration&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.92%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:49.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Common stock &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,250&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;128.00&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2017&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.92%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:49.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Common stock &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7,030&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.98%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.56%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;128.00&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.98%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.14%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;2019 and 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.92%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:49.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Common stock &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;130&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.56%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,520.00&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.14%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.92%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">3705000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">9748000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit1" decimals="INF">3346</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit15" decimals="2">10.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Duration_3_5_2013_To_3_5_2013_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_ptct_StockIncentivePlan2013Member" unitRef="Unit1" decimals="INF">735324</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Duration_3_5_2013_To_3_5_2013_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember_us-gaap_PlanNameAxis_ptct_StockIncentivePlan2013Member" unitRef="Unit1" decimals="INF">4613</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="As_Of_12_31_2014_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit1" decimals="INF">718400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="As_Of_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit1" decimals="INF">364970</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="As_Of_12_31_2014_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit15" decimals="2">10.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="As_Of_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit15" decimals="2">10.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit1" decimals="INF">350084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit15" decimals="2">10.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember_us-gaap_RangeAxis_us-gaap_MaximumMember">P6Y1M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember_us-gaap_RangeAxis_us-gaap_MinimumMember">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember_us-gaap_RangeAxis_us-gaap_MaximumMember" unitRef="Unit14" decimals="4">0.6900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember_us-gaap_RangeAxis_us-gaap_MinimumMember" unitRef="Unit14" decimals="4">0.6700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember_us-gaap_RangeAxis_us-gaap_MaximumMember" unitRef="Unit14" decimals="4">0.0177</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember_us-gaap_RangeAxis_us-gaap_MinimumMember" unitRef="Unit14" decimals="4">0.0154</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="Duration_5_1_2013_To_5_31_2013_us-gaap_PlanNameAxis_ptct_EquityAndLongTermIncentivePlan2009Member" unitRef="Unit1" decimals="INF">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="As_Of_3_5_2013_us-gaap_PlanNameAxis_ptct_StockIncentivePlan2013Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">739937</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="As_Of_3_5_2013_us-gaap_PlanNameAxis_ptct_StockIncentivePlan2013Member" unitRef="Unit1" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="As_Of_5_31_2013_us-gaap_PlanNameAxis_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">245000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="As_Of_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="Unit12" decimals="-3">45137000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="As_Of_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="Unit1" decimals="INF">1037262</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="As_Of_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="Unit15" decimals="INF">30.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="Unit1" decimals="INF">594</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="Unit1" decimals="INF">26265</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="Unit1" decimals="INF">1456550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="Unit15" decimals="2">31.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="As_Of_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="Unit12" decimals="-3">140399000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2014_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="Unit1" decimals="INF">3432972</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="Unit1" decimals="INF">4627833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2014_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="Unit15" decimals="INF">25.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="Unit15" decimals="INF">33.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember">P8Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="As_Of_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="Unit12" decimals="-3">133232000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="As_Of_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="Unit1" decimals="INF">4332726</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="As_Of_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="Unit15" decimals="INF">32.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember">P8Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="Unit15" decimals="INF">12.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="Unit15" decimals="INF">388.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="Unit15" decimals="INF">47.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="Unit15" decimals="INF">51.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:SharePrice contextRef="As_Of_12_31_2014_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit15" decimals="2">51.77</us-gaap:SharePrice>
  <us-gaap:SharePrice contextRef="As_Of_3_31_2015_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit15" decimals="2">60.85</us-gaap:SharePrice>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">298467000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">273320000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="text-indent:0pt;margin-left:0pt; padding-right:28pt;"&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;6.&lt;/font&gt;&lt;/font&gt;&lt;font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"&gt;&lt;font style="display: inline;font-weight:bold;font-size:3pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Warrants&lt;/font&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;All of the Company&amp;#x2019;s outstanding warrants were classified as liabilities as of March&amp;nbsp;31, 2015 and December&amp;nbsp;31, 2014 because they contained non-standard antidilution provisions.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The following is a summary of the Company&amp;#x2019;s outstanding warrants as of March&amp;nbsp;31, 2015:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:55.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Warrant&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.08%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Expiration&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:55.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Common stock &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,250&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;128.00&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2017&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:55.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Common stock &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7,030&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;128.00&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.08%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.42%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;2019 and 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:55.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Common stock &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;130&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,520.00&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.42%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The following is a summary of the Company&amp;#x2019;s outstanding warrants as of December&amp;nbsp;31, 2014:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:55.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Warrant&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.08%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Expiration&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:55.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Common stock &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,250&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;128.00&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2017&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:55.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Common stock &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7,030&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;128.00&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.08%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.42%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;2019 and 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:55.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Common stock &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;130&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,520.00&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.42%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="Unit1" decimals="INF">234830</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:UseOfEstimates contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Use of estimates&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="As_Of_12_31_2014_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit12" decimals="-3">188000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="As_Of_12_31_2014_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit12" decimals="-3">188000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="As_Of_3_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit12" decimals="-3">229000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="As_Of_3_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit12" decimals="-3">229000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit1" decimals="0">24492487</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit1" decimals="0">33067752</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <!--Footnote Section-->
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ptct-20150331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  5.12.31.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/4/2015 1:50:54 PM-->
<!--Modified on: 5/4/2015 1:50:54 PM-->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ptcbio.com/20150331" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ptct="http://www.ptcbio.com/20150331" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-roles="http://fasb.org/us-roles/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" id="StatementConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>00300 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" id="DisclosureAccountsPayableAndAccruedExpensesDetails">
        <link:definition>40501 - Disclosure - Accounts payable and accrued expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>40901 - Disclosure - Commitments and contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureCompanys" id="DisclosureCompanys">
        <link:definition>10101 - Disclosure - The Company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecurities" id="DisclosureFairValueOfFinancialInstrumentsAndMarketableSecurities">
        <link:definition>10301 - Disclosure - Fair value of financial instruments and marketable securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureOtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItems" id="DisclosureOtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItems">
        <link:definition>10401 - Disclosure - Other comprehensive income (loss) and accumulated other comprehensive items</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpenses" id="DisclosureAccountsPayableAndAccruedExpenses">
        <link:definition>10501 - Disclosure - Accounts payable and accrued expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureWarrants" id="DisclosureWarrants">
        <link:definition>10601 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>10701 - Disclosure - Net loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureStockAwardPlan" id="DisclosureStockAwardPlan">
        <link:definition>10801 - Disclosure - Stock award plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>10901 - Disclosure - Commitments and contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureCollaborationRevenue" id="DisclosureCollaborationRevenue">
        <link:definition>11001 - Disclosure - Collaboration Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesTables" id="DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesTables">
        <link:definition>30303 - Disclosure - Fair value of financial instruments and marketable securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureOtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsTables" id="DisclosureOtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsTables">
        <link:definition>30403 - Disclosure - Other comprehensive income (loss) and accumulated other comprehensive items (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesTables" id="DisclosureAccountsPayableAndAccruedExpensesTables">
        <link:definition>30503 - Disclosure - Accounts payable and accrued expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureWarrantsTables" id="DisclosureWarrantsTables">
        <link:definition>30603 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>30703 - Disclosure - Net loss per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureStockAwardPlanTables" id="DisclosureStockAwardPlanTables">
        <link:definition>30803 - Disclosure - Stock award plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>30903 - Disclosure - Commitments and contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureCompany" id="DisclosureCompany">
        <link:definition>40101 - Disclosure - The Company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails" id="DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails">
        <link:definition>40301 - Disclosure - Fair value of financial instruments and marketable securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails2" id="DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails2">
        <link:definition>40302 - Disclosure - Fair value of financial instruments and marketable securities (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails3" id="DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails3">
        <link:definition>40303 - Disclosure - Fair value of financial instruments and marketable securities (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails4" id="DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails4">
        <link:definition>40304 - Disclosure - Fair value of financial instruments and marketable securities (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureOtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsDetails" id="DisclosureOtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsDetails">
        <link:definition>40401 - Disclosure - Other comprehensive income (loss) and accumulated other comprehensive items (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureWarrantsDetails" id="DisclosureWarrantsDetails">
        <link:definition>40601 - Disclosure - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureNetLossPerShareDetails" id="DisclosureNetLossPerShareDetails">
        <link:definition>40701 - Disclosure - Net loss per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureNetLossPerShareDetails2" id="DisclosureNetLossPerShareDetails2">
        <link:definition>40702 - Disclosure - Net loss per share (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureStockAwardPlanDetails" id="DisclosureStockAwardPlanDetails">
        <link:definition>40801 - Disclosure - Stock award plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureStockAwardPlanDetails2" id="DisclosureStockAwardPlanDetails2">
        <link:definition>40802 - Disclosure - Stock award plan - (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureStockAwardPlanDetails3" id="DisclosureStockAwardPlanDetails3">
        <link:definition>40803 - Disclosure - Stock award plan (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureCollaborationRevenueDetails" id="DisclosureCollaborationRevenueDetails">
        <link:definition>41001 - Disclosure - Collaboration Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ptct-20150331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ptct-20150331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ptct-20150331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ptct-20150331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://fasb.org/us-gaap/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element abstract="false" id="ptct_DepositsAndOtherAssetsNoncurrent" name="DepositsAndOtherAssetsNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="false" id="ptct_CollaborationRevenue" name="CollaborationRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="false" id="ptct_AccruedConsultingAndContractedResearchCurrent" name="AccruedConsultingAndContractedResearchCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="ptct_StockIncentivePlan2013Member" name="StockIncentivePlan2013Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_EquityAndLongTermIncentivePlan2009Member" name="EquityAndLongTermIncentivePlan2009Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_RocheAndSMAFoundationMember" name="RocheAndSMAFoundationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_MilestoneAxis" name="MilestoneAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_MilestoneDomain" name="MilestoneDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <element id="ptct_MilestonePaymentsReceived" name="MilestonePaymentsReceived" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element abstract="true" id="ptct_LongTermIncentivePlan2013Member" name="LongTermIncentivePlan2013Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member" name="Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_CollaborationRevenuesDisclosureAbstract" name="CollaborationRevenuesDisclosureAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="false" id="ptct_CollaborationRevenuesDisclosureTextBlock" name="CollaborationRevenuesDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_ClinicalDevelopmentMilestonesMember" name="ClinicalDevelopmentMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <element id="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ptct_MinimumAgeOfAmbulatoryPatient" name="MinimumAgeOfAmbulatoryPatient" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ptct_NumberOfStates" name="NumberOfStates" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ptct_ChangeInUnrealizedGainLossOnMarketableSecurities" name="ChangeInUnrealizedGainLossOnMarketableSecurities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ptct_NetProductSales" name="NetProductSales" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ptct_WellcomeTrustLimitedMember" name="WellcomeTrustLimitedMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ptct_DevelopmentAndRegulatoryMilestonePaymentObligations" name="DevelopmentAndRegulatoryMilestonePaymentObligations" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ptct_InventoriesAndCostOfRevenuePolicyTextBlock" name="InventoriesAndCostOfRevenuePolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>ptct-20150331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  5.12.31.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/4/2015 1:50:54 PM-->
<!--Modified on: 5/4/2015 1:50:54 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#StatementConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.ptcbio.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureAccountsPayableAndAccruedExpensesDetails" roleURI="http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_635663442529957864" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_635663442529957864" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_635663442529957864" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_635663442529957864" xlink:to="us-gaap_MarketableSecuritiesCurrent_635663442529957864" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_635663442529957864" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_635663442529957864" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_635663442529957864" xlink:to="us-gaap_ReceivablesNetCurrent_635663442529957864" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_635663442529957864" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_DepositsAndOtherAssetsNoncurrent" xlink:label="ptct_DepositsAndOtherAssetsNoncurrent_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="ptct_DepositsAndOtherAssetsNoncurrent_635663442529957864" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_635663442529957864" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_635663442529957864" xlink:to="us-gaap_LiabilitiesCurrent_635663442529957864" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_635663442529957864" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_635663442529957864" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_635663442529957864" xlink:to="us-gaap_DeferredRevenueCurrent_635663442529957864" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_635663442529957864" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_635663442529957864" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_635663442529957864" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_635663442529957864" xlink:to="us-gaap_CommonStockValue_635663442529957864" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_635663442529957864" xlink:to="us-gaap_AdditionalPaidInCapital_635663442529957864" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_635663442529957864" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_635663442529957864" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_635663442529957864" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_635663442529957864" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_635521864192661224" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_635521864192661224" xlink:to="us-gaap_OperatingIncomeLoss_635663442529957864" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_635663442529957864" xlink:to="us-gaap_SalesRevenueNet_635663442529957864" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_NetProductSales" xlink:label="ptct_NetProductSales_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet_635663442529957864" xlink:to="ptct_NetProductSales_635663442529957864" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_CollaborationRevenue" xlink:label="ptct_CollaborationRevenue_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet_635663442529957864" xlink:to="ptct_CollaborationRevenue_635663442529957864" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet_635663442529957864" xlink:to="us-gaap_RevenueFromGrants_635663442529957864" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_635663442529957864" xlink:to="us-gaap_OperatingExpenses_635663442529957864" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_635663442529957864" xlink:to="us-gaap_ResearchAndDevelopmentExpense_635663442529957864" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_635663442529957864" xlink:to="us-gaap_GeneralAndAdministrativeExpense_635663442529957864" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_635521864192661224" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_635663442529957864" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_635521864192661224" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_635663442529957864" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ptcbio.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_635663442529957864" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_635663442529957864" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_635663442529957864" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInContinuingOperations" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635663442529957864" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635663442529957864" xlink:to="us-gaap_NetIncomeLoss_635663442529957864" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635663442529957864" xlink:to="us-gaap_Depreciation_635663442529957864" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635663442529957864" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_635663442529957864" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635663442529957864" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_635663442529957864" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635663442529957864" xlink:to="us-gaap_ShareBasedCompensation_635663442529957864" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635663442529957864" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_635663442529957864" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635663442529957864" xlink:to="us-gaap_IncreaseDecreaseInReceivables_635663442529957864" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635663442529957864" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets_635663442529957864" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635663442529957864" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_635663442529957864" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635663442529957864" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_635663442529957864" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635663442529957864" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_635663442529957864" order="11" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635663442529957864" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635663442529957864" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_635663442529957864" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635663442529957864" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_635663442529957864" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635663442529957864" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_635663442529957864" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635663442529957864" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635663442529957864" xlink:to="us-gaap_RepaymentsOfLongTermDebt_635663442529957864" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635663442529957864" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_635663442529957864" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635663442529957864" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_635663442529957864" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectOfExchangeRateOnCash" xlink:label="us-gaap_EffectOfExchangeRateOnCash_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCash_635663442529957864" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Accounts payable and accrued expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_635663442529957864" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_AccruedConsultingAndContractedResearchCurrent" xlink:label="ptct_AccruedConsultingAndContractedResearchCurrent_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="ptct_AccruedConsultingAndContractedResearchCurrent_635663442529957864" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_635663442529957864" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent_635663442529957864" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_635663442529957864" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Commitments and contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_635663442529957864" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_635663442529957864" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_635663442529957864" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_635663442529957864" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_635663442529957864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_635663442529957864" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>ptct-20150331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  5.12.31.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/4/2015 1:50:54 PM-->
<!--Modified on: 5/4/2015 1:50:54 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails" roleURI="http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails2" roleURI="http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails3" roleURI="http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails3" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails4" roleURI="http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails4" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureOtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsDetails" roleURI="http://www.ptcbio.com/role/DisclosureOtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureWarrantsDetails" roleURI="http://www.ptcbio.com/role/DisclosureWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureNetLossPerShareDetails2" roleURI="http://www.ptcbio.com/role/DisclosureNetLossPerShareDetails2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureStockAwardPlanDetails" roleURI="http://www.ptcbio.com/role/DisclosureStockAwardPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureStockAwardPlanDetails2" roleURI="http://www.ptcbio.com/role/DisclosureStockAwardPlanDetails2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureStockAwardPlanDetails3" roleURI="http://www.ptcbio.com/role/DisclosureStockAwardPlanDetails3" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureCollaborationRevenueDetails" roleURI="http://www.ptcbio.com/role/DisclosureCollaborationRevenueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <definitionLink xlink:role="http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Fair value of financial instruments and marketable securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_635663442529957864" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_635663442529957864" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635663442529957864" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635663442529957864" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails2" xlink:type="extended" xlink:title="40302 - Disclosure - Fair value of financial instruments and marketable securities (Details 2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_635663442529957864" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_635663442529957864" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherDebtSecuritiesMember" xlink:label="us-gaap_OtherDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_OtherDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails3" xlink:type="extended" xlink:title="40303 - Disclosure - Fair value of financial instruments and marketable securities (Details 3)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentHoldingsTable" xlink:label="us-gaap_InvestmentHoldingsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_InvestmentHoldingsTable" xlink:to="us-gaap_InvestmentTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_635663442529957864" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_635663442529957864" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherDebtSecuritiesMember" xlink:label="us-gaap_OtherDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_OtherDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentHoldingsLineItems" xlink:label="us-gaap_InvestmentHoldingsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_InvestmentHoldingsLineItems" xlink:to="us-gaap_InvestmentHoldingsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_InvestmentHoldingsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" xlink:label="ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_InvestmentHoldingsLineItems" xlink:to="ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails4" xlink:type="extended" xlink:title="40304 - Disclosure - Fair value of financial instruments and marketable securities (Details 4)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_635663442530057864" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_635663442530057864" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635663442530057864" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_635663442530057864" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_635663442530057864" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_635663442530057864" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="us-gaap_FairValueAssumptionsExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_FairValueAssumptionsExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ptcbio.com/role/DisclosureOtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Other comprehensive income (loss) and accumulated other comprehensive items (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_635663442530057864" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_635663442530057864" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyGainLossMember" xlink:label="us-gaap_ForeignCurrencyGainLossMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ForeignCurrencyGainLossMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ptcbio.com/role/DisclosureWarrantsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_635663442530057864" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_635663442530057864" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_635663442530057864" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_635663442530057864" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ptcbio.com/role/DisclosureNetLossPerShareDetails2" xlink:type="extended" xlink:title="40702 - Disclosure - Net loss per share (Details 2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_635663442530057864" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_635663442530057864" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ptcbio.com/role/DisclosureStockAwardPlanDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Stock award plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_635663442530057864" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_635663442530057864" use="optional" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_EquityAndLongTermIncentivePlan2009Member" xlink:label="ptct_EquityAndLongTermIncentivePlan2009Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="ptct_EquityAndLongTermIncentivePlan2009Member" use="optional" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_StockIncentivePlan2013Member" xlink:label="ptct_StockIncentivePlan2013Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="ptct_StockIncentivePlan2013Member" use="optional" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member" xlink:label="ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member" use="optional" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_LongTermIncentivePlan2013Member" xlink:label="ptct_LongTermIncentivePlan2013Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PlanNameDomain" xlink:to="ptct_LongTermIncentivePlan2013Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635663442530057864" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635663442530057864" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards" xlink:label="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber" xlink:label="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding" xlink:label="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions" xlink:label="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward" xlink:label="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ptcbio.com/role/DisclosureStockAwardPlanDetails2" xlink:type="extended" xlink:title="40802 - Disclosure - Stock award plan - (Details 2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ptcbio.com/role/DisclosureStockAwardPlanDetails3" xlink:type="extended" xlink:title="40803 - Disclosure - Stock award plan (Details 3)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_635663442530157864" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_635663442530157864" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Commitments and contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_635663442530157864" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_635663442530157864" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementProductAgreementMember" xlink:label="us-gaap_CollaborativeArrangementProductAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementProductAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635663442530157864" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635663442530157864" use="optional" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_WellcomeTrustLimitedMember" xlink:label="ptct_WellcomeTrustLimitedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ptct_WellcomeTrustLimitedMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_DevelopmentAndRegulatoryMilestonePaymentObligations" xlink:label="ptct_DevelopmentAndRegulatoryMilestonePaymentObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ptct_DevelopmentAndRegulatoryMilestonePaymentObligations" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ptcbio.com/role/DisclosureCollaborationRevenueDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Collaboration Revenue (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_635663442530257864" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_635663442530257864" use="optional" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_RocheAndSMAFoundationMember" xlink:label="ptct_RocheAndSMAFoundationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="ptct_RocheAndSMAFoundationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_MilestoneAxis" xlink:label="ptct_MilestoneAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="ptct_MilestoneAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_MilestoneDomain" xlink:label="ptct_MilestoneDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ptct_MilestoneAxis" xlink:to="ptct_MilestoneDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_MilestoneDomain" xlink:label="ptct_MilestoneDomain_635663442530257864" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ptct_MilestoneAxis" xlink:to="ptct_MilestoneDomain_635663442530257864" use="optional" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_ClinicalDevelopmentMilestonesMember" xlink:label="ptct_ClinicalDevelopmentMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ptct_MilestoneDomain" xlink:to="ptct_ClinicalDevelopmentMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_MilestonePaymentsReceived" xlink:label="ptct_MilestonePaymentsReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="ptct_MilestonePaymentsReceived" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>ptct-20150331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  5.12.31.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/4/2015 1:50:54 PM-->
<!--Modified on: 5/4/2015 1:50:54 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_DocumentAndEntityInformationAbstract" xlink:label="ptct_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptct_DocumentAndEntityInformationAbstract" xlink:to="ptct_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptct_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed assets, net</label>
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_DepositsAndOtherAssetsNoncurrent" xlink:label="ptct_DepositsAndOtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptct_DepositsAndOtherAssetsNoncurrent" xlink:to="ptct_DepositsAndOtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptct_DepositsAndOtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the carrying value of amounts transferred to third parties for security purposes and other noncurrent assets that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptct_DepositsAndOtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposits and Other Assets Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptct_DepositsAndOtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposits and other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Revenue, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other long-term liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.001 par value. Authorized 125,000,000 shares; issued and outstanding 33,483,306 shares at March 31, 2015. Authorized 125,000,000 shares; issued and outstanding 32,898,392 shares at December 31, 2014</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, authorized shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, issued shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, outstanding shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="us-gaap_SalesRevenueNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetAbstract" xlink:to="us-gaap_SalesRevenueNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues:</label>
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_NetProductSales" xlink:label="ptct_NetProductSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptct_NetProductSales" xlink:to="ptct_NetProductSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptct_NetProductSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of revenue earned from product sales during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptct_NetProductSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Product Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptct_NetProductSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net product revenue</label>
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_CollaborationRevenue" xlink:label="ptct_CollaborationRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptct_CollaborationRevenue" xlink:to="ptct_CollaborationRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptct_CollaborationRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of revenue earned from collaborative research and development and licensing agreements during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptct_CollaborationRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptct_CollaborationRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromGrants" xlink:to="us-gaap_RevenueFromGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Income (Expense), Nonoperating, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other (expense) income, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average shares outstanding:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator for basic and diluted net loss per share (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and diluted (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and diluted (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share - basic and diluted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive loss:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain on marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation of warrant liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion (Amortization) of Discounts and Premiums, Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of premiums on investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Deposit Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposits and other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Noncurrent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other long-term liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of fixed assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale and Maturity of Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale &amp; redemption of marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided/ used in investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments on long-term debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from public offerings</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectOfExchangeRateOnCash" xlink:label="us-gaap_EffectOfExchangeRateOnCash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCash" xlink:to="us-gaap_EffectOfExchangeRateOnCash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of Exchange Rate on Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of exchange rate changes on cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase/(decrease) in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of cash information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosures of non-cash information related to investing and financing activities</label>
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_ChangeInUnrealizedGainLossOnMarketableSecurities" xlink:label="ptct_ChangeInUnrealizedGainLossOnMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptct_ChangeInUnrealizedGainLossOnMarketableSecurities" xlink:to="ptct_ChangeInUnrealizedGainLossOnMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptct_ChangeInUnrealizedGainLossOnMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents change in the unrealized gain (loss) on marketable securities in noncash investing and financing activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptct_ChangeInUnrealizedGainLossOnMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in Unrealized Gain (Loss) on Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptct_ChangeInUnrealizedGainLossOnMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in unrealized gain (loss) on marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The Company</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The Company</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of significant accounting policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of significant accounting policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of financial instruments and marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of financial instruments and marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income (loss) and accumulated other comprehensive items</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="us-gaap_ComprehensiveIncomeNoteTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="us-gaap_ComprehensiveIncomeNoteTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNoteTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss) Note [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomeNoteTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income (loss) and accumulated other comprehensive items</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (loss) income attributable to common stockholders per share:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock award plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock award plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_CollaborationRevenuesDisclosureAbstract" xlink:label="ptct_CollaborationRevenuesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptct_CollaborationRevenuesDisclosureAbstract" xlink:to="ptct_CollaborationRevenuesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptct_CollaborationRevenuesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Revenue</label>
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_CollaborationRevenuesDisclosureTextBlock" xlink:label="ptct_CollaborationRevenuesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptct_CollaborationRevenuesDisclosureTextBlock" xlink:to="ptct_CollaborationRevenuesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptct_CollaborationRevenuesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the entire disclosure pertaining to collaboration revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptct_CollaborationRevenuesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Revenues Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptct_CollaborationRevenuesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of estimates</label>
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_InventoriesAndCostOfRevenuePolicyTextBlock" xlink:label="ptct_InventoriesAndCostOfRevenuePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptct_InventoriesAndCostOfRevenuePolicyTextBlock" xlink:to="ptct_InventoriesAndCostOfRevenuePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptct_InventoriesAndCostOfRevenuePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for inventories and cost of revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptct_InventoriesAndCostOfRevenuePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories And Cost Of Revenue Policy Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptct_InventoriesAndCostOfRevenuePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories and cost of product revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently issued accounting standard</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of financial assets and liabilities that are required to be measured at fair value on a recurring basis</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of marketable securities accounted for as available-for-sale securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of marketable securities on the balance sheet</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of changes in the fair value of the Company's Level 3 valuation for warrant liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of other comprehensive income (loss) and the changes in accumulated other comprehensive items</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of the Company's outstanding warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of computation of basic and diluted net loss per share for common stockholders</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of historical dilutive common share equivalents outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of stock option activity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of assumptions used to estimate fair value of grants made on the date of grant</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonvested Restricted Stock Shares Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of information on the Company's restricted stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of share-based compensation expense recorded in the statement of operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of future minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_MinimumAgeOfAmbulatoryPatient" xlink:label="ptct_MinimumAgeOfAmbulatoryPatient" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptct_MinimumAgeOfAmbulatoryPatient" xlink:to="ptct_MinimumAgeOfAmbulatoryPatient_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptct_MinimumAgeOfAmbulatoryPatient_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the minimum age of ambulatory patient.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptct_MinimumAgeOfAmbulatoryPatient_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum age of Ambulatory Patient</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptct_MinimumAgeOfAmbulatoryPatient_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum age of ambulatory patient</label>
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_NumberOfStates" xlink:label="ptct_NumberOfStates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptct_NumberOfStates" xlink:to="ptct_NumberOfStates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptct_NumberOfStates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of states of european union</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptct_NumberOfStates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of States</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptct_NumberOfStates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of member states of the European Union</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Frequency [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring basis</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Hierarchy [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimate Of Fair Value Fair Value Disclosure [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs Level2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant other observable inputs (level 2)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs Level3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant unobservable inputs (level 3)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets and liabilities measured at fair value on recurring basis</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Available-for-sale Securities [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major Types of Debt and Equity Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major Types Of Debt And Equity Securities [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major Types of Debt and Equity Securities [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Paper Not Included With Cash And Cash Equivalents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial paper</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate debt securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherDebtSecuritiesMember" xlink:label="us-gaap_OtherDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDebtSecuritiesMember" xlink:to="us-gaap_OtherDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government obligations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Available-for-sale Securities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities accounted for as available-for-sale securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized Cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available for Sale Securities Accumulated Gross Unrealized Gain Before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Unrealized Gains</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available for Sale Securities Accumulated Gross Unrealized Loss Before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Unrealized Losses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentHoldingsTable" xlink:label="us-gaap_InvestmentHoldingsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentHoldingsTable" xlink:to="us-gaap_InvestmentHoldingsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentHoldingsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Holdings [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Type Categorization [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentHoldingsLineItems" xlink:label="us-gaap_InvestmentHoldingsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentHoldingsLineItems" xlink:to="us-gaap_InvestmentHoldingsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentHoldingsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Holdings [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentHoldingsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities on the balance sheet</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Marketable securities, Less Than 12 Months</label>
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" xlink:label="ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" xlink:to="ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of available-for-sale debt securities at fair value maturing after the next fiscal year following the latest fiscal year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available For Sale Securities Debt Maturities Over One Year Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Marketable securities, More Than 12 Months</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value by Liability Class [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of warrant liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in the fair value of warrant liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of warrant liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assumption used to estimate the fair value of warrant liability by utilizing the Black-Scholes option-pricing model</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="us-gaap_FairValueAssumptionsExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExercisePrice" xlink:to="us-gaap_FairValueAssumptionsExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assumptions, Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Strike price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of shares (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected life</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss) [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Net Unrealized Investment Gain Loss [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized Gains/(Losses) On Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss) [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income and accumulated other comprehensive items</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income/(loss) before reclassifications</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income/(loss)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee compensation, benefits, and related accruals</label>
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_AccruedConsultingAndContractedResearchCurrent" xlink:label="ptct_AccruedConsultingAndContractedResearchCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptct_AccruedConsultingAndContractedResearchCurrent" xlink:to="ptct_AccruedConsultingAndContractedResearchCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptct_AccruedConsultingAndContractedResearchCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for consulting and contracted research.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptct_AccruedConsultingAndContractedResearchCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Consulting and Contracted Research Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptct_AccruedConsultingAndContractedResearchCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consulting and contracted research</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional fees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Redemption, Period [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Redemption Period [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Redemption, Period [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Redemption Period Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2017</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Redemption Period Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019 and 2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total shares excluded from calculation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_EquityAndLongTermIncentivePlan2009Member" xlink:label="ptct_EquityAndLongTermIncentivePlan2009Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptct_EquityAndLongTermIncentivePlan2009Member" xlink:to="ptct_EquityAndLongTermIncentivePlan2009Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptct_EquityAndLongTermIncentivePlan2009Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the 2009 Equity and Long-Term Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptct_EquityAndLongTermIncentivePlan2009Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity And Long Term Incentive Plan2009 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptct_EquityAndLongTermIncentivePlan2009Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2009 Equity and Long Term Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_StockIncentivePlan2013Member" xlink:label="ptct_StockIncentivePlan2013Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptct_StockIncentivePlan2013Member" xlink:to="ptct_StockIncentivePlan2013Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptct_StockIncentivePlan2013Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the 2013 Stock Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptct_StockIncentivePlan2013Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Incentive Plan2013 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptct_StockIncentivePlan2013Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2013 Stock Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member" xlink:label="ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member" xlink:to="ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the 2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity2009 And Long Term Incentive Plan And Stock Incentive Plan2013 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_LongTermIncentivePlan2013Member" xlink:label="ptct_LongTermIncentivePlan2013Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptct_LongTermIncentivePlan2013Member" xlink:to="ptct_LongTermIncentivePlan2013Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptct_LongTermIncentivePlan2013Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the 2013 Long Term Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptct_LongTermIncentivePlan2013Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Incentive Plan2013 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptct_LongTermIncentivePlan2013Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2013 Long Term Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock option</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock option plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Awards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares of restricted stock granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares available for issuance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of additional shares authorized</label>
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards" xlink:label="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards" xlink:to="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of shares subject to outstanding awards used to calculate authorized shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share based Compensation Arrangement by Share based Payment Award Number of Shares Authorized Shares Subject to Outstanding Awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares subject to outstanding awards</label>
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber" xlink:label="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber" xlink:to="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of shares to be added annually on the first day of each fiscal year in the number of shares authorized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share based Compensation Arrangement by Share based Payment Award Number of Shares Authorized Annual Increase Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual increase in the number of shares on the first day of the fiscal year</label>
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding" xlink:label="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding" xlink:to="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of shares outstanding to be added annually on the first day of each fiscal year in the number of shares authorized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share based Compensation Arrangement by Share based Payment Award Number of Shares Authorized Annual Increase as Percentage of Stock Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual increase in the number of shares outstanding on the first day of the fiscal year (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end of the period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning of the period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expired (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested or expected to vest at the end of the period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at the end of the period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average exercise price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end of the period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning of the period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expired (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested or expected to vest at the end of the period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at the end of the period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average remaining contractual term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning of the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested or expected to vest at the end of the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at the end of the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation assumptions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term</label>
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions" xlink:label="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions" xlink:to="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the inducement grants for non-statutory stock options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inducement grants for non-statutory stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant date fair value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward" xlink:label="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward" xlink:to="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement by Share Based Payment Award Options Intrinsic Value [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end of the period (in dollars)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested or expected to vest at the end of the period (in dollars)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at the end of the period (in dollars)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end of the period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning of the period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end of the period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning of the period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expense recorded in the statement of operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining service period for recognition of unrecognized compensation cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Rent Expense, Net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2015</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Two Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2016</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Three Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2017</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Four Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2018</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Five Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total future minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other contingencies</label>
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_DevelopmentAndRegulatoryMilestonePaymentObligations" xlink:label="ptct_DevelopmentAndRegulatoryMilestonePaymentObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptct_DevelopmentAndRegulatoryMilestonePaymentObligations" xlink:to="ptct_DevelopmentAndRegulatoryMilestonePaymentObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptct_DevelopmentAndRegulatoryMilestonePaymentObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the development and regulatory milestones payments which the entity may be obligated to pay under certain contractual agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptct_DevelopmentAndRegulatoryMilestonePaymentObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development and regulatory milestone payments which the entity may be obligated to pay</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition, Multiple-deliverable Arrangements [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_RocheAndSMAFoundationMember" xlink:label="ptct_RocheAndSMAFoundationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptct_RocheAndSMAFoundationMember" xlink:to="ptct_RocheAndSMAFoundationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptct_RocheAndSMAFoundationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Roche and SMA Foundation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptct_RocheAndSMAFoundationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Roche And S M A Foundation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptct_RocheAndSMAFoundationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Roche and SMA Foundation</label>
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_MilestoneAxis" xlink:label="ptct_MilestoneAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptct_MilestoneAxis" xlink:to="ptct_MilestoneAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptct_MilestoneAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by categories of milestones achieved.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptct_MilestoneAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone [Axis]</label>
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_MilestoneDomain" xlink:label="ptct_MilestoneDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptct_MilestoneDomain" xlink:to="ptct_MilestoneDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptct_MilestoneDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Different categories of milestones defined by agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptct_MilestoneDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptct_MilestoneDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone [Domain]</label>
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_ClinicalDevelopmentMilestonesMember" xlink:label="ptct_ClinicalDevelopmentMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptct_ClinicalDevelopmentMilestonesMember" xlink:to="ptct_ClinicalDevelopmentMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptct_ClinicalDevelopmentMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to certain clinical development events on the basis of which certain milestones are achieved.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptct_ClinicalDevelopmentMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical Development Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptct_ClinicalDevelopmentMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical development milestones</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Revenue</label>
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_MilestonePaymentsReceived" xlink:label="ptct_MilestonePaymentsReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptct_MilestonePaymentsReceived" xlink:to="ptct_MilestonePaymentsReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptct_MilestonePaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments received during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptct_MilestonePaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Payments Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptct_MilestonePaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payment received from Roche</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyGainLossMember" xlink:label="us-gaap_ForeignCurrencyGainLossMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyGainLossMember" xlink:to="us-gaap_ForeignCurrencyGainLossMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyGainLossMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Gain Loss [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyGainLossMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Translation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFiveMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Redemption Period Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling General And Administrative Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementProductAgreementMember" xlink:label="us-gaap_CollaborativeArrangementProductAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementProductAgreementMember" xlink:to="us-gaap_CollaborativeArrangementProductAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementProductAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Product Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementProductAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Funding agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repurchase Agreement Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_WellcomeTrustLimitedMember" xlink:label="ptct_WellcomeTrustLimitedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptct_WellcomeTrustLimitedMember" xlink:to="ptct_WellcomeTrustLimitedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptct_WellcomeTrustLimitedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to The Wellcome Trust Limited.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptct_WellcomeTrustLimitedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Wellcome Trust Limited [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptct_WellcomeTrustLimitedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Wellcome trust</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>ptct-20150331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  5.12.31.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/4/2015 1:50:54 PM-->
<!--Modified on: 5/4/2015 1:50:54 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.ptcbio.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#StatementConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.ptcbio.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureCompanys" roleURI="http://www.ptcbio.com/role/DisclosureCompanys" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureFairValueOfFinancialInstrumentsAndMarketableSecurities" roleURI="http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureOtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItems" roleURI="http://www.ptcbio.com/role/DisclosureOtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItems" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureAccountsPayableAndAccruedExpenses" roleURI="http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureWarrants" roleURI="http://www.ptcbio.com/role/DisclosureWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureNetLossPerShare" roleURI="http://www.ptcbio.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureStockAwardPlan" roleURI="http://www.ptcbio.com/role/DisclosureStockAwardPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.ptcbio.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureCollaborationRevenue" roleURI="http://www.ptcbio.com/role/DisclosureCollaborationRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesTables" roleURI="http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureOtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsTables" roleURI="http://www.ptcbio.com/role/DisclosureOtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureAccountsPayableAndAccruedExpensesTables" roleURI="http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureWarrantsTables" roleURI="http://www.ptcbio.com/role/DisclosureWarrantsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.ptcbio.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureStockAwardPlanTables" roleURI="http://www.ptcbio.com/role/DisclosureStockAwardPlanTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureCompany" roleURI="http://www.ptcbio.com/role/DisclosureCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails" roleURI="http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails2" roleURI="http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails3" roleURI="http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails3" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails4" roleURI="http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails4" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureOtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsDetails" roleURI="http://www.ptcbio.com/role/DisclosureOtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureAccountsPayableAndAccruedExpensesDetails" roleURI="http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureWarrantsDetails" roleURI="http://www.ptcbio.com/role/DisclosureWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.ptcbio.com/role/DisclosureNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureNetLossPerShareDetails2" roleURI="http://www.ptcbio.com/role/DisclosureNetLossPerShareDetails2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureStockAwardPlanDetails" roleURI="http://www.ptcbio.com/role/DisclosureStockAwardPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureStockAwardPlanDetails2" roleURI="http://www.ptcbio.com/role/DisclosureStockAwardPlanDetails2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureStockAwardPlanDetails3" roleURI="http://www.ptcbio.com/role/DisclosureStockAwardPlanDetails3" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ptct-20150331.xsd#DisclosureCollaborationRevenueDetails" roleURI="http://www.ptcbio.com/role/DisclosureCollaborationRevenueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_DocumentAndEntityInformationAbstract" xlink:label="ptct_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptct_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_635663442530257864" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptct_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_635663442530257864" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptct_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_635663442530257864" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptct_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_635663442530257864" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptct_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_635663442530257864" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptct_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate_635663442530257864" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptct_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus_635663442530257864" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptct_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory_635663442530257864" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptct_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_635663442530257864" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptct_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus_635663442530257864" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptct_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_635663442530257864" order="11" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_635663442530257864" xlink:to="us-gaap_AssetsCurrentAbstract_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_635663442530257864" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_635663442530257864" xlink:to="us-gaap_MarketableSecuritiesCurrent_635663442530257864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_635663442530257864" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_635663442530257864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_635663442530257864" xlink:to="us-gaap_ReceivablesNetCurrent_635663442530257864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_635663442530257864" xlink:to="us-gaap_AssetsCurrent_635663442530257864" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_635663442530257864" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_635663442530257864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_DepositsAndOtherAssetsNoncurrent" xlink:label="ptct_DepositsAndOtherAssetsNoncurrent_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_635663442530257864" xlink:to="ptct_DepositsAndOtherAssetsNoncurrent_635663442530257864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_635663442530257864" xlink:to="us-gaap_Assets_635663442530257864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635663442530257864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635663442530257864" xlink:to="us-gaap_LiabilitiesCurrentAbstract_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635663442530257864" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635663442530257864" xlink:to="us-gaap_DeferredRevenueCurrent_635663442530257864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635663442530257864" xlink:to="us-gaap_LiabilitiesCurrent_635663442530257864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635663442530257864" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_635663442530257864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635663442530257864" xlink:to="us-gaap_Liabilities_635663442530257864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635663442530257864" xlink:to="us-gaap_CommonStockValue_635663442530257864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635663442530257864" xlink:to="us-gaap_AdditionalPaidInCapital_635663442530257864" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635663442530257864" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_635663442530257864" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635663442530257864" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_635663442530257864" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635663442530257864" xlink:to="us-gaap_StockholdersEquity_635663442530257864" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635663442530257864" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_635663442530257864" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Consolidated Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_635663442530257864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_635663442530257864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_635663442530257864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract_635521864192505224" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="us-gaap_SalesRevenueNetAbstract_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_635521864192505224" xlink:to="us-gaap_SalesRevenueNetAbstract_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_NetProductSales" xlink:label="ptct_NetProductSales_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueNetAbstract_635663442530257864" xlink:to="ptct_NetProductSales_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_CollaborationRevenue" xlink:label="ptct_CollaborationRevenue_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueNetAbstract_635663442530257864" xlink:to="ptct_CollaborationRevenue_635663442530257864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueNetAbstract_635663442530257864" xlink:to="us-gaap_RevenueFromGrants_635663442530257864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueNetAbstract_635663442530257864" xlink:to="us-gaap_SalesRevenueNet_635663442530257864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_635521864192505224" xlink:to="us-gaap_OperatingExpensesAbstract_635663442530257864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_635663442530257864" xlink:to="us-gaap_ResearchAndDevelopmentExpense_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_635663442530257864" xlink:to="us-gaap_GeneralAndAdministrativeExpense_635663442530257864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_635663442530257864" xlink:to="us-gaap_OperatingExpenses_635663442530257864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_635521864192505224" xlink:to="us-gaap_OperatingIncomeLoss_635663442530257864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_635521864192505224" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_635663442530257864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_635521864192505224" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_635663442530257864" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_635521864192505224" xlink:to="us-gaap_NetIncomeLoss_635663442530257864" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_635521864192505224" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_635663442530257864" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_635663442530257864" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_635521864192505224" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_635663442530257864" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_635521857964077224" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_635521857964077224" xlink:to="us-gaap_NetIncomeLoss_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_635521857964077224" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_635663442530257864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_635663442530257864" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_635663442530257864" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_635663442530257864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_635521857964077224" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_635663442530257864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract_635521874935319224" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635521874935319224" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635663442530257864" xlink:to="us-gaap_NetIncomeLoss_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635663442530257864" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635663442530257864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635663442530257864" xlink:to="us-gaap_Depreciation_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635663442530257864" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_635663442530257864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635663442530257864" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_635663442530257864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635663442530257864" xlink:to="us-gaap_ShareBasedCompensation_635663442530257864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635663442530257864" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635663442530257864" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635663442530257864" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635663442530257864" xlink:to="us-gaap_IncreaseDecreaseInReceivables_635663442530257864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635663442530257864" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets_635663442530257864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635663442530257864" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_635663442530257864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635663442530257864" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_635663442530257864" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635663442530257864" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_635663442530257864" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635663442530257864" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635663442530257864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635521874935319224" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635663442530257864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635663442530257864" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635663442530257864" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_635663442530257864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635663442530257864" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_635663442530257864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635663442530257864" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635663442530257864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635521874935319224" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635663442530257864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635663442530257864" xlink:to="us-gaap_RepaymentsOfLongTermDebt_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635663442530257864" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_635663442530257864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635663442530257864" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_635663442530257864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635663442530257864" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635663442530257864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectOfExchangeRateOnCash" xlink:label="us-gaap_EffectOfExchangeRateOnCash_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635521874935319224" xlink:to="us-gaap_EffectOfExchangeRateOnCash_635663442530257864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInContinuingOperations_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635521874935319224" xlink:to="us-gaap_NetCashProvidedByUsedInContinuingOperations_635663442530257864" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635521874935319224" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_635663442530257864" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_6356634425302578641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635521874935319224" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_6356634425302578641" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635521874935319224" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_635663442530257864" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_635663442530257864" xlink:to="us-gaap_InterestPaid_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635521874935319224" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_635663442530257864" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_ChangeInUnrealizedGainLossOnMarketableSecurities" xlink:label="ptct_ChangeInUnrealizedGainLossOnMarketableSecurities_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_635663442530257864" xlink:to="ptct_ChangeInUnrealizedGainLossOnMarketableSecurities_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureCompanys" xlink:type="extended" xlink:title="10101 - Disclosure - The Company" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of significant accounting policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecurities" xlink:type="extended" xlink:title="10301 - Disclosure - Fair value of financial instruments and marketable securities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureOtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItems" xlink:type="extended" xlink:title="10401 - Disclosure - Other comprehensive income (loss) and accumulated other comprehensive items" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="us-gaap_ComprehensiveIncomeNoteTextBlock_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNoteTextBlock_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpenses" xlink:type="extended" xlink:title="10501 - Disclosure - Accounts payable and accrued expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureWarrants" xlink:type="extended" xlink:title="10601 - Disclosure - Warrants" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="10701 - Disclosure - Net loss per share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureStockAwardPlan" xlink:type="extended" xlink:title="10801 - Disclosure - Stock award plan" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10901 - Disclosure - Commitments and contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureCollaborationRevenue" xlink:type="extended" xlink:title="11001 - Disclosure - Collaboration Revenue" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_CollaborationRevenuesDisclosureAbstract" xlink:label="ptct_CollaborationRevenuesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_CollaborationRevenuesDisclosureTextBlock" xlink:label="ptct_CollaborationRevenuesDisclosureTextBlock_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptct_CollaborationRevenuesDisclosureAbstract" xlink:to="ptct_CollaborationRevenuesDisclosureTextBlock_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of significant accounting policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_635663442530257864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_InventoriesAndCostOfRevenuePolicyTextBlock" xlink:label="ptct_InventoriesAndCostOfRevenuePolicyTextBlock_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ptct_InventoriesAndCostOfRevenuePolicyTextBlock_635663442530257864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_635663442530257864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_635663442530257864" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesTables" xlink:type="extended" xlink:title="30303 - Disclosure - Fair value of financial instruments and marketable securities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_635663442530257864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock_635663442530257864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_635663442530257864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureOtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsTables" xlink:type="extended" xlink:title="30403 - Disclosure - Other comprehensive income (loss) and accumulated other comprehensive items (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesTables" xlink:type="extended" xlink:title="30503 - Disclosure - Accounts payable and accrued expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureWarrantsTables" xlink:type="extended" xlink:title="30603 - Disclosure - Warrants (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="30703 - Disclosure - Net loss per share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_635663442530257864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_635663442530257864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_635663442530257864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureStockAwardPlanTables" xlink:type="extended" xlink:title="30803 - Disclosure - Stock award plan (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_635663442530357864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_635663442530357864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="30903 - Disclosure - Commitments and contingencies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureCompany" xlink:type="extended" xlink:title="40101 - Disclosure - The Company" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_MinimumAgeOfAmbulatoryPatient" xlink:label="ptct_MinimumAgeOfAmbulatoryPatient_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ptct_MinimumAgeOfAmbulatoryPatient_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_NumberOfStates" xlink:label="ptct_NumberOfStates_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ptct_NumberOfStates_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_635663442530357864" order="3" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Fair value of financial instruments and marketable securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635663442530357864" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635663442530357864" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_635663442530357864" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_635663442530357864" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_635663442530357864" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635663442530357864" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_635663442530357864" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_635663442530357864" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635663442530357864" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember_635663442530357864" xlink:to="us-gaap_FairValueInputsLevel2Member_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember_635663442530357864" xlink:to="us-gaap_FairValueInputsLevel3Member_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635663442530357864" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_635663442530357864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_635663442530357864" xlink:to="us-gaap_AvailableForSaleSecurities_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_635663442530357864" xlink:to="us-gaap_WarrantsAndRightsOutstanding_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails2" xlink:type="extended" xlink:title="40302 - Disclosure - Fair value of financial instruments and marketable securities (Details 2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_635663442530357864" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_635663442530357864" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_635663442530357864" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_635663442530357864" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_635663442530357864" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_635663442530357864" xlink:to="us-gaap_CorporateDebtSecuritiesMember_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherDebtSecuritiesMember" xlink:label="us-gaap_OtherDebtSecuritiesMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_635663442530357864" xlink:to="us-gaap_OtherDebtSecuritiesMember_635663442530357864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_635663442530357864" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_635663442530357864" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_635663442530357864" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_635663442530357864" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_635663442530357864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_635663442530357864" xlink:to="us-gaap_AvailableForSaleSecurities_635663442530357864" order="4" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails3" xlink:type="extended" xlink:title="40303 - Disclosure - Fair value of financial instruments and marketable securities (Details 3)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentHoldingsTable" xlink:label="us-gaap_InvestmentHoldingsTable_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_InvestmentHoldingsTable_635663442530357864" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentHoldingsTable_635663442530357864" xlink:to="us-gaap_InvestmentTypeAxis_635663442530357864" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis_635663442530357864" xlink:to="us-gaap_InvestmentTypeCategorizationMember_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_635663442530357864" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_635663442530357864" xlink:to="us-gaap_CorporateDebtSecuritiesMember_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherDebtSecuritiesMember" xlink:label="us-gaap_OtherDebtSecuritiesMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_635663442530357864" xlink:to="us-gaap_OtherDebtSecuritiesMember_635663442530357864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentHoldingsLineItems" xlink:label="us-gaap_InvestmentHoldingsLineItems_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentHoldingsTable_635663442530357864" xlink:to="us-gaap_InvestmentHoldingsLineItems_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentHoldingsLineItems_635663442530357864" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" xlink:label="ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentHoldingsLineItems_635663442530357864" xlink:to="ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails4" xlink:type="extended" xlink:title="40304 - Disclosure - Fair value of financial instruments and marketable securities (Details 4)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_635663442530357864" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_635663442530357864" xlink:to="us-gaap_FairValueByLiabilityClassAxis_635663442530357864" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis_635663442530357864" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_635663442530357864" xlink:to="us-gaap_WarrantMember_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_635663442530357864" xlink:to="us-gaap_StatementClassOfStockAxis_635663442530357864" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635663442530357864" xlink:to="us-gaap_ClassOfStockDomain_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635663442530357864" xlink:to="us-gaap_CommonStockMember_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_635663442530357864" xlink:to="us-gaap_RangeAxis_635663442530357864" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_635663442530357864" xlink:to="us-gaap_RangeMember_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_635663442530357864" xlink:to="us-gaap_MinimumMember_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_635663442530357864" xlink:to="us-gaap_MaximumMember_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_635663442530357864" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_635663442530357864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_635663442530357864" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_635663442530357864" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_635663442530357864" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6356634425303578641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_635663442530357864" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6356634425303578641" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_635663442530357864" xlink:to="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_635663442530357864" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_635663442530357864" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="us-gaap_FairValueAssumptionsExercisePrice_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_635663442530357864" xlink:to="us-gaap_FairValueAssumptionsExercisePrice_635663442530357864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_635663442530357864" xlink:to="us-gaap_SharePrice_635663442530357864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_635663442530357864" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm_635663442530357864" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureOtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Other comprehensive income (loss) and accumulated other comprehensive items (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_635663442530357864" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_635663442530357864" xlink:to="us-gaap_StatementEquityComponentsAxis_635663442530357864" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_635663442530357864" xlink:to="us-gaap_EquityComponentDomain_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_635663442530357864" xlink:to="us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyGainLossMember" xlink:label="us-gaap_ForeignCurrencyGainLossMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_635663442530357864" xlink:to="us-gaap_ForeignCurrencyGainLossMember_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_635663442530357864" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_635663442530357864" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_635663442530357864" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_635663442530357864" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_635663442530357864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6356634425303578641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_635663442530357864" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6356634425303578641" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Accounts payable and accrued expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_AccruedConsultingAndContractedResearchCurrent" xlink:label="ptct_AccruedConsultingAndContractedResearchCurrent_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="ptct_AccruedConsultingAndContractedResearchCurrent_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_635663442530357864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableCurrent_635663442530357864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_635663442530357864" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_635663442530357864" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureWarrantsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_635663442530357864" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_635663442530357864" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_635663442530357864" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_635663442530357864" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_635663442530357864" xlink:to="us-gaap_WarrantMember_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_635663442530357864" xlink:to="us-gaap_StatementClassOfStockAxis_635663442530357864" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635663442530357864" xlink:to="us-gaap_ClassOfStockDomain_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635663442530357864" xlink:to="us-gaap_CommonStockMember_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_635663442530357864" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis_635663442530357864" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis_635663442530357864" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain_635663442530357864" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain_635663442530357864" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain_635663442530357864" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFiveMember_635663442530357864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_635663442530357864" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_635663442530357864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_635663442530357864" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_635663442530357864" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Net loss per share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_635663442530357864" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_635663442530357864" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_635663442530357864" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_635663442530357864" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_635663442530357864" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_635663442530357864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_635663442530357864" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureNetLossPerShareDetails2" xlink:type="extended" xlink:title="40702 - Disclosure - Net loss per share (Details 2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_635663442530357864" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_635663442530357864" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_635663442530357864" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_635663442530357864" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_635663442530357864" xlink:to="us-gaap_EmployeeStockOptionMember_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_635663442530357864" xlink:to="us-gaap_RestrictedStockMember_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_635663442530357864" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_635663442530357864" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureStockAwardPlanDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Stock award plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635524268476679386" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635524268476679386" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635663442530357864" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635663442530357864" xlink:to="us-gaap_PlanNameAxis_635663442530357864" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_635663442530357864" xlink:to="us-gaap_PlanNameDomain_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_EquityAndLongTermIncentivePlan2009Member" xlink:label="ptct_EquityAndLongTermIncentivePlan2009Member_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_635663442530357864" xlink:to="ptct_EquityAndLongTermIncentivePlan2009Member_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_StockIncentivePlan2013Member" xlink:label="ptct_StockIncentivePlan2013Member_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_635663442530357864" xlink:to="ptct_StockIncentivePlan2013Member_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member" xlink:label="ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_635663442530357864" xlink:to="ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_635663442530357864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_LongTermIncentivePlan2013Member" xlink:label="ptct_LongTermIncentivePlan2013Member_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_635663442530357864" xlink:to="ptct_LongTermIncentivePlan2013Member_635663442530357864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635663442530357864" xlink:to="us-gaap_StatementClassOfStockAxis_635663442530357864" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635663442530357864" xlink:to="us-gaap_ClassOfStockDomain_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635663442530357864" xlink:to="us-gaap_CommonStockMember_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635663442530357864" xlink:to="us-gaap_AwardTypeAxis_635663442530357864" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635663442530357864" xlink:to="us-gaap_StockOptionMember_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635663442530357864" xlink:to="us-gaap_RestrictedStockMember_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635663442530357864" xlink:to="us-gaap_RangeAxis_635663442530357864" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_635663442530357864" xlink:to="us-gaap_RangeMember_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_635663442530357864" xlink:to="us-gaap_MinimumMember_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_635663442530357864" xlink:to="us-gaap_MaximumMember_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635663442530357864" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_635663442530357864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_635663442530357864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards" xlink:label="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635663442530357864" xlink:to="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards_635663442530357864" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber" xlink:label="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635663442530357864" xlink:to="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_635663442530357864" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding" xlink:label="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635663442530357864" xlink:to="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding_635663442530357864" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635663442530357864" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635663442530357864" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_635663442530357864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_635663442530357864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_635663442530357864" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6356634425303578641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6356634425303578641" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_635663442530357864" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_635663442530357864" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635663442530357864" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_635663442530357864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_635663442530357864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_635663442530357864" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6356634425303578641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6356634425303578641" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_635663442530357864" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_635663442530357864" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_635663442530357864" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_635663442530357864" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_635663442530357864" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_635663442530357864" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_635663442530357864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635663442530357864" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635663442530357864" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_635663442530357864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions" xlink:label="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635663442530357864" xlink:to="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions_635663442530357864" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_635663442530357864" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward" xlink:label="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635663442530357864" xlink:to="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_635663442530357864" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_635663442530357864" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_635663442530357864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureStockAwardPlanDetails2" xlink:type="extended" xlink:title="40802 - Disclosure - Stock award plan - (Details 2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635527762611451754" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635527762611451754" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635663442530357864" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635663442530357864" xlink:to="us-gaap_AwardTypeAxis_635663442530357864" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635663442530357864" xlink:to="us-gaap_RestrictedStockMember_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_635663442530357864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_635663442530357864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_635663442530357864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_635663442530357864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_635663442530357864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6356634425303578641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6356634425303578641" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635663442530357864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_635663442530457864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_635663442530457864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_635663442530457864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_635663442530457864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_635663442530457864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_635663442530457864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_635663442530457864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6356634425304578641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_635663442530457864" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6356634425304578641" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureStockAwardPlanDetails3" xlink:type="extended" xlink:title="40803 - Disclosure - Stock award plan (Details 3)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_635663442530457864" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_635663442530457864" xlink:to="us-gaap_IncomeStatementLocationAxis_635663442530457864" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_635663442530457864" xlink:to="us-gaap_IncomeStatementLocationDomain_635663442530457864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_635663442530457864" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_635663442530457864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_635663442530457864" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_635663442530457864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_635663442530457864" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_635663442530457864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_635663442530457864" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_635663442530457864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_635663442530457864" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_635663442530457864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_635663442530457864" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_635663442530457864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Commitments and contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_635663442530457864" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635663442530457864" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635663442530457864" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_635663442530457864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635663442530457864" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_635663442530457864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635663442530457864" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_635663442530457864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635663442530457864" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_635663442530457864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635663442530457864" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_635663442530457864" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635663442530457864" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_635663442530457864" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_635663442530457864" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_635663442530457864" xlink:to="us-gaap_TypeOfArrangementAxis_635663442530457864" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_635663442530457864" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_635663442530457864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementProductAgreementMember" xlink:label="us-gaap_CollaborativeArrangementProductAgreementMember_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_635663442530457864" xlink:to="us-gaap_CollaborativeArrangementProductAgreementMember_635663442530457864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_635663442530457864" xlink:to="us-gaap_CounterpartyNameAxis_635663442530457864" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis_635663442530457864" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635663442530457864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_WellcomeTrustLimitedMember" xlink:label="ptct_WellcomeTrustLimitedMember_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635663442530457864" xlink:to="ptct_WellcomeTrustLimitedMember_635663442530457864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_635663442530457864" xlink:to="us-gaap_RangeAxis_635663442530457864" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_635663442530457864" xlink:to="us-gaap_RangeMember_635663442530457864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_635663442530457864" xlink:to="us-gaap_MaximumMember_635663442530457864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_635663442530457864" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_635663442530457864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_DevelopmentAndRegulatoryMilestonePaymentObligations" xlink:label="ptct_DevelopmentAndRegulatoryMilestonePaymentObligations_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_635663442530457864" xlink:to="ptct_DevelopmentAndRegulatoryMilestonePaymentObligations_635663442530457864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ptcbio.com/role/DisclosureCollaborationRevenueDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Collaboration Revenue (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_CollaborationRevenuesDisclosureAbstract" xlink:label="ptct_CollaborationRevenuesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptct_CollaborationRevenuesDisclosureAbstract" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_635663442530457864" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_635663442530457864" xlink:to="us-gaap_TypeOfArrangementAxis_635663442530457864" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_635663442530457864" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_635663442530457864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_635663442530457864" xlink:to="us-gaap_CollaborativeArrangementMember_635663442530457864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_635663442530457864" xlink:to="dei_LegalEntityAxis_635663442530457864" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_635663442530457864" xlink:to="dei_EntityDomain_635663442530457864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_RocheAndSMAFoundationMember" xlink:label="ptct_RocheAndSMAFoundationMember_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_635663442530457864" xlink:to="ptct_RocheAndSMAFoundationMember_635663442530457864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_MilestoneAxis" xlink:label="ptct_MilestoneAxis_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_635663442530457864" xlink:to="ptct_MilestoneAxis_635663442530457864" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_MilestoneDomain" xlink:label="ptct_MilestoneDomain_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptct_MilestoneAxis_635663442530457864" xlink:to="ptct_MilestoneDomain_635663442530457864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_ClinicalDevelopmentMilestonesMember" xlink:label="ptct_ClinicalDevelopmentMilestonesMember_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptct_MilestoneDomain_635663442530457864" xlink:to="ptct_ClinicalDevelopmentMilestonesMember_635663442530457864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_635663442530457864" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_635663442530457864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptct-20150331.xsd#ptct_MilestonePaymentsReceived" xlink:label="ptct_MilestonePaymentsReceived_635663442530457864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_635663442530457864" xlink:to="ptct_MilestonePaymentsReceived_635663442530457864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EICAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Collaboration Revenue (Details) (Collaboration agreement, Roche and SMA Foundation, Clinical development milestones, USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 22, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Collaboration agreement | Roche and SMA Foundation | Clinical development milestones</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Collaboration Revenue</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_MilestonePaymentsReceived', window );">Milestone payment received from Roche</a></td>
        <td class="nump"><a title="ptct_MilestonePaymentsReceived[dei_LegalEntityAxis=ptct_RocheAndSMAFoundationMember;ptct_MilestoneAxis=ptct_ClinicalDevelopmentMilestonesMember;us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember]" onclick="toggleNextSibling(this);">$ 7.5</a><span style="display:none;white-space:normal;text-align:left;">ptct_MilestonePaymentsReceived<br>/ dei_LegalEntityAxis<br>= ptct_RocheAndSMAFoundationMember<br>/ ptct_MilestoneAxis<br>= ptct_ClinicalDevelopmentMilestonesMember<br>/ us-gaap_TypeOfArrangementAxis<br>= us-gaap_CollaborativeArrangementMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_MilestonePaymentsReceived">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Milestone payments received during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">ptct_MilestonePaymentsReceived</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>ptct_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0`^R@)E^@$``%X9```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F4%OVC`8AN^3]A\B7RMB
M;'==5Q%ZZ-;C5FG=#_"2#Q+AV);M=O#OYX06314#H2'MO1!![.]]\.$YO)[=
MKGM3/%.(G;,5$^64%61KUW1V6;$?C_>3:U;$I&VCC;-4L0U%=CM__V[VN/$4
MB[S;QHJU*?D;SF/=4J]CZ3S9_&;A0J]3_AJ6W.MZI9?$Y71ZQ6MG$]DT2<,,
M-I]]IH5^,JGXLLX_;TD"F<B*N^W"(:MBVGO3U3IE4OYLFS<IDY>$,N\<U\2V
M\_$B8S"^-V%X\_>`EWW?\M&$KJ'B08?T5?<9@Z\-_^7"ZJ=SJ_+PD#V4;K'H
M:FI<_=3G$RBC#Z2;V!*EWI3CL^QU9U^Y#^2/BR,?'^+,(,/_&P>?R"%!.!0(
MQR4(QP<0CBL0CH\@'-<@')]`.,04!03%J`)%J0+%J0)%J@+%J@)%JP+%JP)%
MK`+%K!+%K!+%K!+%K!+%K!+%K!+%K!+%K!+%K!+%K!+%K`K%K`K%K`K%K`K%
MK`K%K`K%K`K%K`K%K`K%K.I_F37E]ICX^/GO*AO''*DO8]H8BF>N'+9#CR6W
M.E#S/87<LY\=X,_91SAJ;>J[-A?.9SZ$W=Q#^;D%?PC.QWP?$.AT@-?"?]@]
M\7D0A=31KO+?5YWO$O-=PNF!;[I[&FXK&FKV9//Q=F3^&P``__\#`%!+`P04
M``8`"````"$`M54P(_4```!,`@``"P`(`E]R96QS+RYR96QS(*($`BB@``(`
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````(R2ST[#,`S&[TB\0^3[ZFY("*&ENTQ(NR%4'L`D
M[A^UC:,D0/?VA`."2F/;T?;GSS];WN[F:50?'&(O3L.Z*$&Q,V)[UVIXK9]6
M#Z!B(F=I%,<:CAQA5]W>;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+\>QRI9$P
M4<IA:-&3&:AEW)3E/8:_'E`M/-7!:@@'>P>J/OH\^;*W-$UO>"_F?6*73HQ`
MGA,[RW;E0V8+J<_;J)I"RTF#%?.<TQ')^R)C`YXFVEQ/]/^V.'$B2XG02.#S
M/-^*<T#KZX$NGVBI^+W./.*GA.%-9/AAP<4/5%\```#__P,`4$L#!!0`!@`(
M````(0"-7SRC$0(``&T8```:``@!>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;',@H@0!**```0``````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````````"\F<V*
MVS`4A?>%OH/1OE%TKR<S4\:914MAMNWT`82MQ&8<V4CJ3]Z^(@Q.`YW3+,3=
M!"03Z>-:YYPK_/#X^S!6/UV(P^0;959K53G?3MW@]XWZ_OSEPYVJ8K*^L^/D
M7:..+JK'[?MW#U_=:%/^4^R'.59Y%1\;U:<T?]0ZMKT[V+B:9N?SD]T4#C;E
M8=CKV;8O=N\TK=<;'?Y>0VTOUJR>ND:%I\ZPJIZ/<][Z_XM/N]W0NL]3^^/@
M?/K''OK7%%YB[US*B]JP=ZE1RU34IR>&5YE9Z3=P<CUD<>X0#FV$<6B#</A>
M&(?O$0X981PR"(=K81RN$4Y-)7%B;X/KOJ60G2/FA5_5=3&-:&Y+PBR:/H,L
M4Z\ROT4P12NS[/PV#"$8(ZUQ`S5..2)$'9#6J#HD;3D$+:<N:CDQ'<<<N&<U
MG<:H'$6WO^+D0L.3/KCPW!KQTL#:D'08$`P#EK8\AI['TG'`,`_JHIZ7<G?L
MSJ(^#?7I%YZ8&V'?O8$^(TUC(`Y)WQ((WA)(^I9`\);`TD;,V(F+JNF:D((=
MA)'N(`SL(%@ZIQBZCG1,P922?E/P11GITAA8&Y).<(()3M()3C#!6=IS&'H.
M2\<GP_BLB\9G:\?V4V\'?^YQEBG44TB')LY,X6X+]A-&6ML&:MM(:]M`;9.T
MF`B*B8N*Z8KVAN'986E9\:(K??&18/L'``#__P,`4$L#!!0`!@`(````(0"9
M1CO?NP,``+H,```/````>&PO=V]R:V)O;VLN>&ULE)=-<]HP$(;OG>E_<#VY
MMOZ$)AF@4])VFDN:*6ERU"BVP)K(DD>20_CW79MBUA;Q-">S-KS[]>Q:S+Z\
ME,)[9MIP)>=^]"GT/28SE7.YF?M_[GY\//<]8ZG,J5"2S?T=,_Z7Q?MWLZW2
M3X]*/7D@(,W<+ZRM+H/`9`4KJ?FD*B;AR5KIDEHP]28PE68T-P5CMA1!'(;3
MH*1<^GN%2_T_&FJ]YAG[IK*Z9-+N1303U$+XIN"5\1>S-1?L?I^11ZOJAI80
M]XOP/4&-_9YSR_*Y/P%3;5GOAJZK9<T%/+U(PL0/%EV2M]K+V9K6PMY!>@=U
MJ%><QO&T^693BGO.MN;XH\;T7AZXS-6V^2J4=M=9"02P;1\]\-P6\#P,P^[>
M3\8WA3W<!/D`Z;<5!#_MU9-M>H>*$.@4^2XMMSMR+??5YPI:V%3]&C*+?$]?
M<OB@K_.H"1RK7$$1E>`YA1*1)1549HRLFI\:))%"(IU&_`8-<DN13()4VF*_
M&LG*0D!-OPU1:_*K8D@E12KI:"Q]E2M5(A4H?)?1Y"TJ%!=FBE1:*'!&``X!
MIQ65.^0XQ?WX//2\JLN2ZEV3M>$;R8%]*BVA6:9J:;%,C%R?#V5^4*[),Q4U
M:Y367$)?.16$2V-UC65P3RZ&,K]LP33)(`?-"B8-?V8@`38C0N$ZI+@I43C4
M^;H/WY"*[NBC8"VSD).N@;I>;W%;(H?6!ZHUE*/G&;<@<MB\8;8)%3Q#(J:@
MNN?M,ZIAY!"YLBI[(G1+=4XJF`Q<-MB1'3[1"0K+DML]O\UX9@KF4VY@S7)8
MIL?13"^PS`D,A:"/2K>[COQFSTS6./X)'LO(X6^<)<"PA;59$1/,9.1`.4Y3
M3PA3&3E8CO/4$\)<1@Z8XT#UA#"9L)`'^^]`%+EKN,2]F6`48P=%%ZP3$IC-
MV&%SR-<)`0QH[``*R^5US`CN+\8U=G!%BZI7.DQG[-`Y3@6`T.$UQ9SN7YYX
M3XX+`0A'(0BO&[OXC9P""$<AS&GL<#H>$8#1"<6]&CF<C@./:Y3@&H$QX'0<
M>"PTQ9.3.-QVP']CEG*!B4]P4<`8A'""^!,:/>\.L:]K$)Q#@H<6C$$DSN"<
MB`-/+YR\_E.A'P4>W\1=KX/7`_D7!<'$)GB"P1C$,3[!>!@3/,)@.$(G7A6'
MB!"O">85#)`)6ICA=`GG72Y9WIR>^]:_$V>IA;A=PCL6SM$9%:ON@)GZB]%$
M/IPMS^)P%B`'X!99X`X$,SAS-Y?VT)I.IONE&QS^=BS^`@``__\#`%!+`P04
M``8`"````"$`A8;-]A<$``#R#0``&````'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;)1776^C1A1]K]3_@'BW8?C&LKU:B-*NU)6JJMT^8QC;*,`@!L?)O^^=
MN1B889/:>4@,]W#FW`\?;K9?WNK*>*4=+UFS,\G:-@W:Y*PHF]/._.?OYU5D
M&KS/FB*K6$-WYCOEYI?]K[]LKZQ[X6=*>P,8&KXSSWW?;BR+YV=:9WS-6MI`
MY,BZ.NOALCM9O.UH5LB'ZLIR;#NPZJQL3&38=/=PL..QS.D3RR\U;7HDZ6B5
M]:"?G\N6W]CJ_!ZZ.NM>+NTJ9W4+%(>R*OMW26H:=;[Y=FI8EQTJR/N->%E^
MXY87"_JZS#O&V;%?`YV%0I<YQU9L`=-^6Y20@2B[T='CSOQ*-BF)3&N_E07Z
M4=(KGWTV^)E=?^O*XH^RH5!MZ)/HP(&Q%P']5HA;\+"U>/I9=N#/SBCH,;M4
M_5_L^CLM3^<>VNU#1B*Q3?'^1'D.%06:M>,+IIQ5(`!^&W4I1@,JDKW)O]>R
MZ,\[TPW6?FB[!.#&@?+^N124II%?>,_J?Q%$!BHD<082%]0/<>=>$@L%R?R>
MLC[;;SMV-6!HX$C>9F($R0:(;XFAC#'5CS*%%`7)5\$BN2`)#NUYW?OVUGJ%
MBN8#)$%(:!HCA*B(](80C0!UHT3(6Y?H0@=_7ON;(O&0ID@[+UE"'$W1$N%/
M$$4CE&ZN\7-M`@P3,"N%[ZHG)PCQ9/]%A=/9#>5@[Y&#!7AG0E9C#WQ/.Q@A
MT=##(%;#*8:E+D4&3/']^0NP)L-7STD0XDD9KANIT12C@8S&Q`O'L*(I>$23
M`&N:@I%6#GF"$#S5L4--<HIAE!Q.TZ](@O&_OTP"K$F:,D5)"$%)H1=-PRG#
MZ3P<.V1Z6A$E7E(S"_A\=@58FUVM.PE"9K,[NZ$<'#]RL`!KU="&,T'(T*`P
M7HS-/$[\*)J>5V01,)?["R+1JK!@ZCZV:<"@,A(&1)\=!1#ZWD2@*M/<^O-6
M$334^=<]T#UPP*`RS_=U(TH5@.-ZSD=%$UYY]Q01=%9%FC:\R8!!:2LWLD--
M?*HBB.>0B4.MFW#/^\6AURKB='\F-S^6[SI'<]%4"9.9<%760^9-ENX=:.<F
M`P9-:.4&VE<S5>/^!X8@-IL'RK6T\T";[T0R[DQ\K:S<,%Y^`Y!E0!#/CB?M
M:M$>LG6"K@S=&E]Y@>[K`V9F6/,[ZN$/&3A9.G@PE7RPAKE'NZX=A.%LQT`;
M'W@&8_.\V/&BB4<5J)FYV.?^?UF"U5DW5WUTD@$3RY?NBJR)%RL_ZLM2;.."
M<H#;L*<JZ'AJ`NK'U1M7TYIV)YK2JN)&SBYBK29PZG@75_Y$K/QR:1\#L'&W
MV8E^S[I3V7"CHD=XU%Z',%H=[NQXT;-6KH8'UL.N+3^>X7\K"GL6"#6-(V/]
M[4(LH^-_:_O_````__\#`%!+`P04``8`"````"$`JPPBZ/("```,"```&0``
M`'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6R455UOVC`4?9^T_V#YO?F&$`14
MA:K;I$V:IGT\F\1)K"9Q9)O2_OM=VY#&8>L8#X"=XW///??F>G7[W#;HB0K)
M>+?&H1=@1+N<%ZRKUOC']X>;!492D:X@#>_H&K]0B6\W[]^MCEP\RII2A8"A
MDVM<*]4O?5_F-6V)]'A/.WA2<M$2!4M1^;(7E!3F4-OX41#,_9:P#EN&I;B&
M@Y<ER^D]SP\M[90E$;0A"O3+FO7RS-;FU]"U1#P>^IN<MSU0[%G#U(LAQ:C-
MEY^JC@NR;R#OYS`A^9G;+"[H6Y8++GFI/*#SK=#+G#,_\X%ILRH89*!M1X*6
M:WP7+G<+[&]6QI^?C![EZ#^2-3]^$*SXS#H*9D.9=`'VG#]JZ*=";\%A_^+T
M@RG`5X$*6I)#H[[QXT?*JEI!M6>0D,YK6;S<4YF#H4#C13/-E/,&!,`W:IGN
M##"$/)O?(RM4O<;QW)NE01P"'.VI5`],4V*4'Z3B[2\+"D]4EB0ZD<2@_O0\
MNI;$MX),?O=$D<U*\"."GH&0LB>Z`\,E$)\3LS*&5/^6*:2H2>XTB^&")"14
MYVF3+&8K_PDLS4^8K<6D&`V8T$7LS@A="9`W:(3$IQIC*.&?S3]+TH=<2;-)
MO.TE))HHND3,7B&.1O!NK/%M;1H,+3"R(LH"-_368A+3`=KCW6C#B9S\3V0-
M7F-(:RC"?%HG"UF8*M[$:19.`#L'$"9!MABD.\*@LZ^W1(.GEB0#K^FRK<6,
M+!EM.)'G;F3=U/]N&'W(M299S"<*+&9NO(GC8)ZFHWXP(G=C2)0D690LTH'%
M40FOPO7^:/#4GZDZBQGY,]IP(NM;:?32O]VL&CSUY34C6QF+R6S/A%Z89,YG
MR-]:Y*`#&&$..'M-RXJV4]E.K9:*BNYHTTB4\X.>N"$$'7;M9;"%R\",3G]X
M`,.X)Q7]0D3%.HD:6L+1P$NA@X0=YW:A>&^&QIXK&,/F;PVW+H47$(1B5'*N
MS@L]IH9[?/,;``#__P,`4$L#!!0`!@`(````(0!!H:><'`,``',*```9````
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;)16R6[;,!"]%^@_"+Q'F^45MH/$
M0=H"+5`47<ZT1%E$)%$@Z3CY^\Z02B+*D6-?+(OS^.;-HB&7UT]5Z3TRJ;BH
M5R3R0^*Q.A49KW<K\N?W_=6,>$K3.J.EJ-F*/#-%KM>?/RT/0CZH@C'M`4.M
M5J30NED$@4H+5E'EBX;58,F%K*B&5[D+5",9S<RFJ@SB,)P$%>4UL0P+>0Z'
MR'.>LCN1[BM6:TLB64DUZ%<%;]0+6Y6>0U=1^;!OKE)1-4"QY277SX:4>%6Z
M^+:KA:3;$N)^BA*:OG";ER/ZBJ=2*)%K'^@"*_0XYGDP#X!IO<PX1(!I]R3+
M5^0F6FRB$0G62Y.@OYP=5.>_IPIQ^")Y]IW7#+(-=<(*;(5X0.BW#)=@<W"T
M^]Y4X*?T,I;3?:E_B<-7QG>%AG*/(2(,;)$]WS&50D:!QH_'R)2*$@3`KU=Q
M;`W("'TRSP//=+$BHXD_GH:C".#>EBE]SY&2>.E>:5']LZ"HI;(D<4L"SY8D
MBB\F&;4D\'PCB6?C:#SY6$I@PS)9NJ.:KI=2'#QH/1"N&HJ-'"V`&=,S@B2_
MGQ[("^ZYP4UF*Z`5U/1QG<SB9?`(=4A;S.TQIH?8O(-X@P2@[U4DY*TK\K0X
M!*](;&3%833MZ;+FQ-0'@]ET%ARGD(WSG2(8,D>\UXS$DW'/L\5T/'<6',_)
M)9X1C.&^>4YFHYYGBYF8E$"SA*YY,VAV5$&[GY\/!/=5):[;6XN9&551/'.M
MFR&KHVERB28$NYKBZ=SU>FLQG1IU%AS/TTL\(_BC[K"8CN?.@N,93Z;.%WOZ
M8T"P&_-Q=UB,[0X8;/WN&#0[JN:7J$)P7U6_.RQFJ#N&K(ZF"`;9^:DR:%2%
M\PP&1[\U6GNG0MT5UW%OJIZN460'X>GAT8*ZWNTVL^)ZQXEV=H=$=OZ='B`M
M*+'?ZE&+#)I=73COSM=EIZ.KJ]\D<'/`3K)=$H_C?N\.VZTR>VVP!V)#=^P'
ME3M>*Z]D.0SRT)_"%)+VTF!?M&C,P;<5&@Y[\[>`RQV#@R3T`9P+H5]>\%KR
M>EU<_P<``/__`P!02P,$%``&``@````A`-&$Z6P7`P``_0@``!D```!X;"]W
M;W)K<VAE971S+W-H965T,S$N>&ULG%9=;YLP%'V?M/^`_-X0,"0A2E(U5-TJ
M;=(T[>/9`1.L`D:VT[3_?M=V0C#INF0O(?8]]^CXW(LOB]N7NO*>J9",-TL4
MC,;(HTW&<]9LE^CGCX>;&?*D(DU.*M[0)7JE$MVN/GY8[+EXDB6ER@.&1BY1
MJ50[]WV9E;0F<L1;VD"DX*(F"I9BZ\M64)*;I+KRP_%XXM>$-<@RS,4E'+PH
M6$;O>;:K::,LB:`54:!?EJR51[8ZNX2N)N)IU]YDO&Z!8L,JIEX-*?+J;/ZX
M;;@@FPK._1)$)#MRF\49?<TRP24OU`CH?"OT_,R)G_C`M%KD#$Z@;?<$+9;H
M+IBG"?)7"^//+T;WLO??DR7??Q(L_\(:"F9#F70!-IP_:>ACKK<@V3_+?C`%
M^":\G!9D5ZGO?/^9LFVIH-HQ'$B?:YZ_WE.9@:%`,PICS93Q"@3`KU<SW1E@
M"'DQSSW+5;E$>#**IV,<`-S;4*D>F*9$7K:3BM>_+2@X4%F2\$`"SP-)$%Y-
M@@\D\#R1A+,XB"?_EN+;8QF7[HDBJX7@>P\Z#X3+EN@^#N;`K.W!8/+;]H`O
M.N=.)YE40$LHZ?,JFDX7_C/4(3M@UA8S15Z'"5U$^@;B!/%!7R<2?+M>I$YR
M18:!JV!M(5-3*WVPM+?A"`!GKA>@D\#-G@,8#P182'02T-MP!$3_(T`G+1&<
MJ2M!-)T-%%C,S!01XTGLAM-^.(&>[\*..G@3^O:\WSP:/%25=+RFP=86,S&J
M@F"2#`J7]N,)CD[ICJS)-;(T>"!K-A[(LA@K"^/9R0VC.G7#..JR'57P2EQN
ME@8/50W,6%O,056`3V985?UP%(2G!G!4Z7'7NP?>+Z$&NZI"//3*8@XE3.)A
M8_7#89+\157BJKKL=M))KKJS]\Y";->'.,;#2CKQ).A='-8T.V[L15I3L:4I
MK2KI97RG1TD(?=OMVBFW#N9PV\!X&>RG,/W,OM\%8/JT9$N_$K%EC?0J6@#E
M>#2%GA=V?MF%XJVYWC9<P=PQ?TOXS*!PCXU'`"XX5\>%GI#=A\OJ#P```/__
M`P!02P,$%``&``@````A`'%L(?M?`P``&PP``!D```!X;"]W;W)K<VAE971S
M+W-H965T,S`N>&ULE%9=CZ(P%'W?9/\#X5VP@*)&G<QD,KN;[":;S7X\5RC2
M#%!"ZSCS[_>V19""HB^CC.>><S].+UT_O.>9]48J3EFQL9$SM2U21"RFQ7YC
M__G],EG8%A>XB''&"K*Q/PBW'[:?/ZV/K'KE*2'"`H:";^Q4B'+ENCQ*28ZY
MPTI2P"\)JW(LX+':N[RL"(Y54)ZYWG0Z=W-,"ULSK*I;.%B2T(@\L^B0DT)H
MDHID6$#^/*4E/['ET2UT.:Y>#^4D8GD)%#N:4?&A2&TKCU;?]@6K\"Z#NM]1
M@*,3MWKHT><TJAAGB7"`SM6)]FM>NDL7F+;KF$(%LNU619*-_8A63VAIN]NU
M:M!?2H[\[+O%4W;\4M'X.RT(=!OF)">P8^Q50K_%\E\0[/:B7]0$?E963!)\
MR,0O=OQ*Z#X5,.X95"0+6\4?SX1'T%&@<;R99(I8!@G`7RNGTAK0$?RN/H\T
M%NG&]N?.+)SZ".#6CG#Q0B6E;44'+EC^3X-03:5)O)H$/FL2-',";Q8N;F!Q
M=4:JP&<L\'9=L:,%K@%-7F+I0;0"9EE9<+$R*$G&/,H@%0IH#N-XVP;SY=I]
M@Q9&->:ICT$-P@7Q)@-0-3/P84+#O3UE((.Z&7@MO4KR:0`RG(#?3V"\!3((
MQFA;;0O":<.O,]"80%GKO.*@*WB]4@G>V%#,F9!9JL8LU"0FH1\V>70:#6.]
MO]$RR)3W&GY=I\8$2KY-K:,][VI?+UF"34W?T-28JYKA/9H2;&H&AJ;&:$UH
M\[SYN5.J7/K&B1KWLPPRY6<-OVZSQO3MM.P+COM7!HWY5V/Z@@B.YWF)UZ>I
MT&9MK4UT;36H[JV_N&!A-+"NQINKHLP,3!/7H-I17MO\SG"1L:U&2M<[J'MX
M32<K2MBZ^OA<%#:VU(BP7CU=8=/.Z+2?Y`*?>/.V(]V2[UI7:&A?M2>EGK8&
M#3AK8$>->UF^BD?-7(,&-._:36AH.?7<?+Z=)OZL?3%T.VML*/GRO<'-0ZNJ
MG5W=X<ZN0EX[^VX&QK(:<=70ENK9^;2FE*LN*QM;:T19KZ(1/VM0_1H,0K-F
M?;W3MY\2[\D/7.UIP:V,)-#XJ1."C2I]N=,/@I7JCK%C`BYEZFL*EW`"5Z"I
M`^"$,7%ZD-?'YEJ__0\``/__`P!02P,$%``&``@````A`&_)FRH&!```60\`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,CDN>&ULE%==;ZLX$'U?:?\#XKV`
M"=`D2G)UH;>[5[HKK5;[\4S`2:P"1MAMVG^_8QN*;;CYR$,+]IGQF?',,=Y\
M>:\KYPUWC-!FZR(O<!W<%+0DS7'K_O/W\\/2=1C/FS*O:(.W[@=F[I?=K[]L
MSK1[82>,N0,>&K9U3YRW:]]GQ0G7.?-HBQN8.="NSCF\=D>?M1W.2VE45WX8
M!(E?YZ1QE8=U=XL/>CB0`C_1XK7&#5=..ESE'/BS$VG9X*TN;G%7Y]W+:_M0
MT+H%%WM2$?XAG;I.7:R_'QO:Y?L*XGY'45X,ON7+Q'U-BHXR>N`>N/,5T6G,
M*W_E@Z?=IB00@4B[T^'#UOV*UEF(7'^WD0GZE^`STYX==J+GWSI2_B`-AFS#
M/HD=V%/Z(J#?2S$$QO[$^EGNP)^=4^)#_EKQO^CY=TR.)P[;'4-$(K!U^?&$
M60$9!3=>&`M/!:V``/QU:B)*`S*2O\O_9U+RT]9=)%[\&"P0P)T]9OR9")>N
M4[PR3NO_%$A&].DD[)TL@+V:#^'QLK&OB,BXGG*>[S8=/3M0++`4:W-1>F@-
M7D1`T4\#@DB$S5=A)$T!S6`7WG91M-KX;Y"YHL>D4PPR$=D4$<4CQ@>"GRPA
M9)OE`C9O/NT#2V%DL8P#DT,ZQ80F(IM!C!"#)*3O?I+""*K`=<94QJ-_F>Y4
M82)93R+_F39@,(A,!I?3(\!;%\+35EZ8P:<*LY1;C)9+<S93LY*700/J1T_$
M91H";-.(S(52A8E4I8TE(K.3#9.B;_6:2>YA(<`VB]ABH3`J&6%HU7NF9J?)
M>+R'A@#;-!*+AL)HU:`-&`D0A\[=K2V,['I\M!@HC,9`&S`8K$P&EPM!@.W8
MK8I+%0:%*UD*@9=8@.P"P&"&0#WTY%RF)M$V-ZL`TAXTD(N]>&7^OCU8[959
M)DMO:5JL=!.3OZ7;5_@KJ35Z/;&E$"E0W^RAG=F?3IN\A%QJ17>%EQ)7DY?5
MWRE2(!";4:@22R*S6="8;I.CD,_;.2JQ-3G:`H4T15:JI(^8JPO5U%:_\<15
M6@O+C$F([;Y$FB#W++01D\5=&BT^<:[V9@\:ZC_P+'K9!8#)[2[E1G/2/>E-
M!1JX(0^>C-^WATE%V29)'.@_I)N8_.^2?#2C^=/>5*#^[(E#JW>SWLG,O,G,
M.A*N=*>2=;/R)]TY:+]6F(EU<F9H#C2>:R;'NPX--'-J)%;AI3U(.[#T$6/U
MT#H7;NM.:77MU.Q!&@M]Q&1AJ;M@<</W[IS*6S*>A@JD#M`D\);V7AF`&'F/
M8S851W4Y4I>(-C_B/_+N2!KF5/@`-*'M02PZ=352+YRV\C-\3SE<:>3C":ZP
M&+YD`P_`!TKY\"(^XCXOQ;O_`0``__\#`%!+`P04``8`"````"$`B/^9>+H#
M``#.#```&0```'AL+W=O<FMS:&5E=',O<VAE970R."YX;6R<5UUOXC@4?5]I
M_T.4]Y(XGX"`JJ3JSD@[TFJU._-L$@-1DSBR36G__5S;*;%-6TI?@-R<>W+N
MAV\NB]OGMO&>".,U[98^FH2^1[J25G6W6_K___=P,_4]+G!7X89V9.F_$.[?
MKO[\8W&D[)'O"1$>,'1\Z>^%Z.=!P,L]:3&?T)YT<&=+68L%7+)=P'M&<*6<
MVB:(PC`+6EQWOF:8L\]PT.VV+LD]+0\MZ80F8:3!`O3S?=WS5[:V_`Q=B]GC
MH;\I:=L#Q:9N:O&B2'VO+>??=QUE>--`W,\HP>4KM[HXHV_KDE%.MV("=($6
M>A[S+)@%P+1:5#5$(-/N,;)=^G=H7J#,#U8+E:"?-3ERX[?']_3X%ZNKO^N.
M0+:A3K("&TH?)?1[)4W@')QY/Z@*_,.\BFSQH1'_TN,W4N_V`LJ=0D0RL'GU
M<D]X"1D%FDF42J:2-B``/KVVEJT!&<'/ZOM85V*_].-LDN9AC`#N;0@7#[6D
M]+WRP`5M?VD0&J@T2320P/=`@J*K2>*!!+Y'DFB:HC2[+"708:DLW6.!5PM&
MCQZT'@CG/9:-C.;`+-.3O)L>R(OTN9-.RA70'&KZM$J2=!$\01W*`;/6F-SW
M3IC(1A1O($9(`/I.(B%OKL@8.N'M&KZ*E$ZVR`C9"M8:DJM:R<`*PV`)@,Q<
M+T`Z0;L8&4B2S%&@,<FHP#!8"I*O*)!.2Q^".M4@27)'@<9,5151-HMG8PU4
ML0L;$.?9F$5+(73-]3F23J["J:-08S*E,$^B-+3O%^9]%*(\'B.P!&:VP(^[
M1X)=82.ORLQ:8XSB&0;KR7`*KD^-=+K4/AIC*#`,E@+Y.G..^>43))W<'+CM
MHS&Z.&B6YXE3''U?*;0$S6Q!'Q=#@ETAL?V@M<88J3`,UI,13([K<Z&\+I5C
M`!DB3(NMXHW!>[DB2,_,CT_T`!IJ$D_CT)DZA8U(\SP=SYRM4@[$J_L&Z3%J
MJQR?H`_/`-(JDVD4.8#"`N11E(\5MS7*D6EH_+B5D!ZPMC:G:=<#R*SC>W,9
M?6DP*Z^+W:0GKZG"L-@Y^-+PE7O0V;ER#_@`&KH)P=YC'[S"`F1A^%Z9G/$K
M-XU/-/Q;<]CIE#7LCS(._0Z+LC`ZDV@!9DDZ.\6@TZC71[T8M83M2$&:AGLE
M/<C5,()7S\FJU]8UFL/V`.NB8R]@G57VX'0#MLD>[\@/S'9UQ[V&;($RG.20
M?*;W47TA:*_6E0T5L$>JGWOXWT!@+PDG`-Y2*EXOY,9[^B>R^@T``/__`P!0
M2P,$%``&``@````A``\BH222!```/A$``!D```!X;"]W;W)K<VAE971S+W-H
M965T,C<N>&ULE%A=;ZLX$'U?:?\#XKT!@R$?2G)UH>KNE?9*J]5^/!/B)*B`
M(Z!-^^]W[''`-FD^7IK&/AX?GYDYX"R_?52E\\Z:MN#URB43WW58G?-M4>]7
M[C]_OSS-7*?MLGJ;E;QF*_>3M>ZW]:^_+$^\>6T/C'4.1*C;E7OHNN/"\]K\
MP*JLG?`CJV%FQYLJZ^!KL_?:8\.RK5Q4E5[@^[%7947M8H1%<T\,OML5.7OF
M^5O%Z@Z#-*S,.N#?'HIC>XY6Y?>$J[+F]>WXE//J""$V15ETGS*HZU3YXL>^
MYDVV*>'<'X1F^3FV_#(*7Q5YPUN^ZR80SD.BXS//O;D'D=;+;0$G$+([#=NM
MW.]DD0;4]=9+*="_!3NUVO].>^"GWYIB^T=1,U`;\B0RL.'\54!_;,40+/9&
MJU]D!OYLG"W;96]E]Q<__<Z*_:&#=$=P(G&PQ?;SF;4Y*`IA)D$D(N6\!`+P
MUZD*41J@2/8A/T_%MCNLW#">1%,_)`!W-JSM7@H1TG7RM[;CU7\((BH4!@E4
M$/A404CP<)!0!8'/(4@PBT@4WZ;BX;&D2L]9EZV7#3\Y4'I`O#UFHI#)`B(+
M>>B7\H`N8LUWL4@N!70+.7U?TS!>>N^0AUQA$L1,7:?'!"8BO8`8(![PZTF"
M;C;)$"KA<@[/),4BDV1`3`8)0J8R5^)@J39@$`!E'B<@%D&Y:`K0<&HQ0(RL
M?REMJ@T8#*C)X/K1!7CEPF%Z[6DXLW9&S$QF+Z#AW*<F(#4`<32;^3W`8`;5
MHFMSG9D`V\SF?5PI08(8*IG-K92E^N1L4--@%#_"2(`M1G0X*3)"##)Z"J/0
M))P:TW0Z"&FP@E:X7R<!MEE94B2(B<\9C.G0/5A+!B".Z'P@;C`3SSK-`ZYG
M4(!M9M;&"6*TJM8&C)WGYL["?6XWMEATJZ\0HS'0!@P&!'SD_L-+M'7Z46<I
M$":&S*?4:KU4`20[DXSEQM<S0=!`S3:WFTF!L'8#RZ33?E8\0G7')<()[ZX)
MB;9DH7:Y*E`OB]8G6*X*<$$688KWDT$+-62A0^5C1Q/-9]7NVH@IA66]]Q4I
M0?N$H)H'#WZE6"!(*U.U[((&#]FL>,.QNW1<IPA2"9G%,V+Y7JK"*(L)_7`Z
ME)>IT4.62RYX;CA$5MKHKDH'3U79TF>_>C*1ARQ7HNTBMA1)%.C\*`BL^=2<
MI\'0^J9>#UDNN>2YH_9"4)_-*!QIIB."T(=WV/Y!9K*S;/F&#:&UFOUF[9T0
MS7]5!K418_?`<N3[^DVNNO544""MW_01D\5#5AQ<LN(A]UC1"H09"J<AM=W8
M!$21_T5^@H?,6:*MNAYUFP*IQ\2P+^;*F!U,S!1,^.?=)AV@VYI%8S53HD#G
M9K,\/#6G-35-7I9]7R]FN(J.C'/T)%,@?'>&1(XZS01$-!Y>D)`;7E?Q(E:Q
M9L]25I:MD_,W<14-X)6N'\5K<D(622#N*=9X*J[/8MSK)^#V>LSV[&?6[(NZ
M=4JV@Y#^9`INW^#]%[]T_"BO1QO>P;U5_GN`WRD8W(/\"8!WG'?G+V*#_I>/
M]?\```#__P,`4$L#!!0`!@`(````(0`[8LWZFP,``'4+```8````>&PO=V]R
M:W-H965T<R]S:&5E=#$N>&ULE%;;CJ,X$'U?:?X!^3V`(7>%C#JT>G>D'6FU
M<]EG!TR"&C"#G4[WWT^5#30XO6KZA>OAU/&I<E&[S\]EX3SQ1N:BB@AU?>+P
M*A%I7ITB\N/[PVQ-'*E8E;)"5#PB+UR2S_M/?^RNHGF49\Z5`PR5C,A9J7KK
M>3(Y\Y))5]2\@C>9:$JFX+8Y>;)N.$OU1V7A!;Z_]$J65\0P;)LI'"++\H3?
MB^12\DH9DH873(%^><YKV;&5R12ZDC6/EWJ6B+(&BF->Y.I%DQ*G3+9?3I5H
MV+&`=3_3.4LZ;GUS0U_F22.DR)0+=)X1>KOFC;?Q@&F_2W-8`=KN-#R+R!W=
MQG1.O/U.&_0SYU<YN';D65S_;/+T[[SBX#;D2;'C-U[P1/$4,D<<S,A1B$?\
M]`L\\B&(U``,(G]U8>X"C.+U88;77<@'G;9_&B?E&;L4ZE]Q_8OGI[."2`NP
M`=W8IB_W7":0!HCE!@MD340!%'!TRASK"6QDST9=GJIS1,*ENUCY(06X<^12
M/>1(29SD(I4H_S,@VE(9DJ`E@?/5O`\"=T7]3;B:3A*V)'!N26C@TKF_?%^(
M9Q:E_;IGBNUWC;@Z4*T@6]8,:Y]N@?=M4\`-Q-XA."(K2%M$)&3F:>_OO"?P
M/FD1!X.`8X^@8T3<(3!]H*$7`LY,%X)@%(+90F4'\V`8-[#BWB+"'C$2`BY,
M%X)@*(C!>FU'#$)O"BTU'CP8Q9U_)"Z"(P)KZGV>]ZLQCA@$''O$8HR(.X2=
M"2C(Z08@>"QD.0YS,(BY+A?JKWQ_;9=$A["%+#\B!,%C(2M+B$$,'5F/$7&'
ML(5`Q4]W!,%C(9MQF(-!++0C\\#?6*F+S7M=,J,*P=_8Y+V*X+$,:I>F@1A#
MCF]MY[A#V(9L/J($P982JP(.!H(UDNUG,QK,0D!DV&!FU'(O[K"V)@J_D^GV
M:+2ERFH9AQ8SK!CZVC3,;NXQ-W*PT4W.%C5M<;BAJ546AQ8SDF/OZ1YS(P?[
MWT`._@5#<.R=AF^ZYDB6O;^IP0PZ7/MDJ4LJ#-?S=;!Z_6I4TA2[X4#6.W),
M[QS)L7>Y9HR(Z3>!3V\<^K_^"X/+1Z0@VJH?JYT<-"-*>>W!-]7<8_J$F:'&
M_*1+WIQXS(M".HFXX)!"P=3^:3]UM>-0_P+FEYJ=^%?6G/)*.@7/X%/?Q5FC
M,1.0N5&BUB/`42B87/3E&<9;#K]4WP5P)H3J;E!@/S#O?P,``/__`P!02P,$
M%``&``@````A`%,-$LX-`P``X0@``!D```!X;"]W;W)K<VAE971S+W-H965T
M,S0N>&ULE%;;CILP$'VOU']`?E_N22`*66VRVG:E5JJJ7IX=,,%:P,AV-KM_
MWQF<L%S:;O*2P'`X<\Z,[6%U^U*5UC.3BHLZ(9[M$HO5J<AXO4_(SQ\/-Q&Q
ME*9U1DM1LX2\,D5NUQ\_K(Y"/JF",6T!0ZT24FC=+!U'I06KJ+)%PVIXD@M9
M40VW<N^H1C*:M2]5I>.[[MRI**^)85C*2SA$GO.4W8OT4+%:&Q+)2JI!ORIX
MH\YL57H)747ETZ&Y2475`,6.EUR_MJ3$JM+EX[X6DNY*\/WBA30]<[<W$_J*
MIU(HD6L;Z!PC=.HY=F('F-:KC(,#++LE69Z0.V^Y]5SBK%=M@7YQ=E2]:TL5
MXOA)\NP+KQE4&_J$'=@)\830QPQ#\+(S>?NA[<`W:64LIX=2?Q?'SXSO"PWM
MGH$C-+;,7N^92J&B0&/[,V1*10D"X->J."X-J`A]:?^//--%0H*9O?#<.%@`
MRXXI_<"1DECI06E1_38@[T1E2/P320#J3\]]>[9P`P]ROD/B&$&MOWNJZ7HE
MQ=&"10,I54-Q"7I+(#X;,S(ZJ_]R"A:1Y`Y9$K(@%IA0T)[G=1A%*^<92IJ>
M,)LIQALBMF<$=@+D=1K!>%_CWXM^EH)@E()-0&T;$P#N3IL_RCM%S-X@`R50
MH<N5(!@:W4\<A</4&X,).[7;7F"0.;PF,X(3`K8ZRV$4CS(;S-PT*X[]R`V&
MB&T?$421[T?S#C'0!JOO\JH@>*0M=CM>TS*#Z56E%QADGE^3&<'O]<-@>IE[
M@4%F6.N7>T;PR/.D'P9SZL?<7T3!N!]]1.`%012\U6V@#:=.;T__?[\@>*0M
M'FW,C<'TJM(+##+'UV1&\'O],)A>YEY@D!E._RM,M^B1ZTE'3B#3DF`>QHNW
M>K?K%$<.6C"(11B%L_$.,1/%G+@5DWNV966IK%0<<%KXL/NZ:#?)[GP\#D;Q
M#4XXC#O=`Q@P#=VSKU3N>:VLDN5`Z=HX4:094>9&BZ8]YW="PVAI+POXE&!P
M.+HV@',A]/D&$W0?)^L_````__\#`%!+`P04``8`"````"$`"^57$.<(``#(
M+```&0```'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6R<6EUOXS@2?%_@_H/A
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MRE7433/)<C_3JMXZ`>[_H]W&+PU7D>6/\.?[9MV^/8Y5,<EGB4H=??1<->V7
MC9]R/%I]:]IZ]W\@I3@53)+A).Y/G"33@P<K'.Q&X.`TG^@LG\T'2)C"[83J
MV&6[?'HXUN\CM^2<X.:P]`LXO7<S]Y?#U<%S?_/D,,3=:>-Z^/U)+[*'Z7=7
M]Q5RRIB3<H:)&7JA.,?V<#)]YDR=^/,=N&+2._"-56YY7+X3/XC?22YDEC%%
MW*I!AKM:*$7JFG&6&`IFXSGTXH/;<.VEMW%9OB<_CMWLI!'BVB5P=%B`OGM&
M`I8`K*)N'0R7XLFNXDQ*P<M0`H=(D8`E`)/B]A:5,JRY?I"LSDQ(`DX1.J>T
MRA8SV5U@=*(M`9C&@FN\W#E/EMKF0AMP0%NJ\R+/$\XPP"#:","TS6[1YLE2
MVX)?N00.:+O+E)XKJ0T81!L!F#8?K8.MQY.YMCP15RZ!<])69(78$@8(1!H!
MF+3%+=(\64J39@(<'9;;74X\(/B$.?W:YX[?JY8`3%CJG(T6;=B&"*.D1+'>
M2R1!^721S>9*N+)!"BD@1;A0[^"DNP.%@N]38\L3H:),@81"E<IFF3`<@Q0J
M%`8%A`OU'GV[4'!V+K1S]M#$,@42"$T3Y72*HAND4*$PJ$>HMVLB]++/I&#N
MU)?S1.R'$DG=U4V$6(KPPGG/)GH&=AB<GA=.M*],@30/VT6&JL'?=JHM1;A&
M[]E$XY6:@<-S;3(X_*'1;?=%T):[)X:HI20G8#/CD)Z6>ML>+@],GLN3V9$"
M">2EV60N:FN00*OW47BDWKF'RP.?Y_)D?(0I3]73LTD>58^D!5:/(+RYWKV'
MRP.O9_)2F2`ID&#AJ;E0;_#7M'8?)4CJ'9R(&[@[P/>Y2)DE8>I3#96:1!TF
MX8$E)`@K8?:I.`FC1)RDHI$EDF`AJFPR$^YHD$"*21$N\U-ADO6$22K#!$DH
M,YDLQ(8R2*`R/XJ2S/7M]IZ'4?P$G:>B6"62.A4F0BQ%>/E$<@Q;BQDD"%^+
M,D&0Y/SZ_"22IW)!GDGGXPU%N-1/A8I_BI9'L%0:-Y*N2(69NCK;\S#_=H$]
M=]Z4+?XM0211K+4225RB-*$SJ:LF21PN\:9\R2`'V)$ADPZ)I*Y`)D(L1;@>
M$2@#%V)/L&32%#,@P5EKH53TR(2$3KBE")<I@F6@S)Z`R2)7!!+:33J9"X+)
M2*"`>5.$RQ01<_EPDT$&\.Y&;DB"(ES=X#!:-L)A>OQ;E]OM+XP284)>]005
M)9(@EU.=J(7<%<@@.BG"=7XJ351/FLBC:8DD//&[1Q,E^XL,JO.C.%&?BI,P
M2M93.'*))*BGSE,ES-(@@<KT:A['`>'E%.ER>1FJGE3)Q-5+)'57-Q%B*<+U
M>`LG)Z\K>L#P^;:0IJ=D*I@(L13A>F[*"17GA,[%8B^1E+K-Z=\\II-<__TN
M6FDD%<!)<%A/"V_*"04YP0X&F8PR))TD)I-"--D@HVNRI0@OH<B-*RWMRXNH
MA$!B41N]RE(GTCEJ*<(EBLRX(K$G*Y2,-"6CP$2(I0C7<U,XJ+YPB'8!,7X(
M!QQ&6T@X3(\6X7"Y/H'-32S>!4@Z+;%T,IO%NP!)1")%N$21"U<D]N6!W`4:
M2">);A>(=6B00?5]E`=:Y,$5?>#7?)>*JY=A2F_JY/@>1=:9=-X%%.$E%%DP
M[.2D>S)!OGLLD=05RD2(I0C7Y0U\<"9HL'N6"4H^D2&)ZH%A'6(IA^L1F3"P
M3G$VY$H^D6EI^P81.)1D[K6Y^X^_U;=T$!=Z4S+HGF10\NR!I*Y,)D(L1;B>
MFY)`@W]?::0T>8/#.H66(ER/L/V!C>RS?Y&/I8[L/T+L&?''@*ZI7*)(@H$2
MP<B9?:C(WHC;0R)HB5B*,%WY38D0V.(M2;0GD=0USD2(I0C7(^Q_6)WRGAA0
MTF:11'41DX?#&7)@E^J"O*CB*D4(#%39$P:Z6R]!09D#B:J4B*4<KDLX_^5P
MRL'Q+V],)%$],*Q#+.5P/<+Q!]8)+-S==O<Z*^ZF]'F32\0B`MV<J5R11UJN
M\U-)D/<D@9;G1R1UU3(18BG"==UD_#D8_Y5^`HGJD8C%B0*'Z[G)^'/P=-9'
M+1Z02B11/3(*+').?5PLR),RU]<3!#Y5K^R#GB#0\J5,'@5!A%B*<%W"_:_H
M`?N^TD?I\2:7B*4(TU,(UQ^V+\,H_CR0DTZ`?R&)]!,1//EH?_01!Q\ZANOL
M28/K_2QZTD#+DR.2J,XH#2B'Z_*6//@D6X"!7^XGDJ@>&-8AEG*X'F_)1,_`
M?OI1HI]:GF0+('4J#"+03Y7H1,OB6CJ("_U4(!0]@:#EB19)5&@4")3#=8D`
MN+Q!"S#^*PT%$M4C$8L3!0[7(XQ_8$/!R;GARA-M(>W>(((;M/?1A`[B0D4B
M>*$#=FA?,LASK?L0]?RN$\ZUB'0/\HG8U?[CU?,8T`G?HL+7EH?E:_7/Y?%U
MLV]&V^K%24TF,]>4(WR)"C^T]2%\D_A<M^X+TO#7-_?%<.4^"$HFCOQ2U^WI
M!_^O4>=OD)_^`@``__\#`%!+`P04``8`"````"$`X\>QC"X#``"1"0``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6R<5MMNFT`0?:_4?T#['F`-^";C
M*&F4-E(K554OSVM8S"K`HMUUG/Q]9QD;,'9<NR_&P-ESYLR,9[RX?2T+YX4K
M+605$^KZQ.%5(E-1K6/RZ^?CS90XVK`J986L>$S>N":WRX\?%ENIGG7.N7&`
MH=(QR8VIYYZGDYR73+NRYA6\R:0JF8%;M?9TK3A+FT-EX8U\?^R53%0$&>;J
M$@Z992+A#S+9E+PR2*)XP0S$KW-1ZSU;F5Q"5S+UO*EO$EG60+$2A3!O#2EQ
MRF3^M*ZD8JL"?+_2D"5[[N;FB+X4B9):9L8%.@\#/?8\\V8>,"T7J0`'-NV.
MXEE,[NC\G@;$6RZ:!/T6?*M[WQV=R^UG)=*OHN*0;:B3K<!*RF<+?4KM(SCL
M'9U^;"KP73DIS]BF,#_D]@L7Z]Q`N2-P9(W-T[<'KA/(*-"XH\@R);*``.#3
M*85M#<@(>VVN6Y&:/";!V(TF?D`![JRX-H_"4A(GV6@CRS\(HCLJ)!GM2."Z
M(Z&1&XZBR?0"%@\C:@P^,,.6"R6W#G0-:.J:V1ZD<V#>.\,X6J_O606/EN3.
MLL1D0AQPH:$^+\LHG"V\%\AILL/<(P8^6PQM$1Y$TX8$8?1#.IWDO;(%6V6;
M=!O*/3[HRXQ.RP37R%AP3("[#3Z<=>&C,F+"II/Z?L)KA"P8VJ,G%$5^:P"%
M$',L!+W43YRM90"]?CZ!]M"ALR@:.D/,N"GLA$Y#OXOHH'+CPP#."UOP4+@K
M%3I%#`K?!)'O3\,V%P?*T'I]Z^>5+7B@W'.$RHC9*P?A^+2NG?"#G\^_4VX/
M#?2CH.5'?<2@?C`.9Y-W4C[[GP#LH6&3=8G%`!!SW&04.NIZR\VIH>=HX'D'
MFC5]1GUWTK7#0;&I'26]K)^O=H,>2G?E1+<[4"L===/K4/JJX41Q&/7'1N1W
MS#MI!+72T_=<#P;693]O6(O'S389)AY!70A=9=`];D9<'"57:_Z)%X5V$KFQ
M6X]"P=JG[4:^&S63L'T!"[%F:_Z-J;6HM%/P#(Y"D6&X*%RI>&-DW:REE32P
M"INO.?SUX3#<?1?`F91F?V.7=OMG:OD7``#__P,`4$L#!!0`!@`(````(0"F
M2#V)J`0``%X1```8````>&PO=V]R:W-H965T<R]S:&5E=#(N>&ULG%A=C^(V
M%'VOU/\0Y7T(_L@7`E:;C*9=J96JJKM]#L%`-$F,DC#,_/M>QQ[\D6$6^@+$
M/KX^/O?Z.&;YY;6IO1?6]15O5SZ:S7V/M27?5NU^Y7__Y^DA\;U^*-IM4?.6
MK?PWUOM?UK_^LCSS[KD_,#9X$*'M5_YA&(Z+(.C+`VN*?L:/K(6>'>^:8H#'
M;A_TQXX5VW%04P=X/H^"IJA:7T98=+?$X+M=5;)'7IX:U@XR2,?J8@#^_:$Z
M]N_1FO*6<$W1/9^.#R5OCA!B4]75\#8&];VF7'S;M[PK-C6L^Q71HGR//3Y,
MPC=5V?&>[X89A`LDT>F:TR`-(-)ZN:U@!4)VKV.[E?\5+7),_&"]'`7Z4;%S
M;_SV^@,__]95VS^JEH':D">1@0WGSP+Z;2N:8'`P&?TT9N"OSMNR77&JA[_Y
M^7=6[0\#I#N$%8F%+;9OCZPO05$(,\.AB%3R&@C`I]=4HC1`D>)U_#Y7V^&P
M\DDT"^,Y00#W-JP?GBH1TO?*4S_PYE\)0BJ4#()5$/A601"^.PA10>!;!\%)
MB,+HYU0"N:Q1I<=B*-;+CI\]*#T@WA\+4<AH`9$_E@7T$-BO`CP.@17WD,N7
M-9XO@Q>0OU203$)BW],0&Y%_@,`72`"T+MQ`+I.;2!V!`OB<HQCD<$27\.,R
M,@F)QQ2)=>5&@T4`!#$)?#ZQ``-!<^7$F5A"J)[8:+`FIO=,+,`K']:@):?.
MQ!*2C"DC48)#NS\W^VD:T^32;]&"BK]=#P%V:#G39A(2R4JB)**Z$,9,Y18@
M"FFJ%;6(13:QVRI%#'((1I=URTJ1$$DP0LCISLUNDB1Z>18YV`RWJR;`#JG8
M(24ADA1!L<Z5U,SLII1>(27.MYOWO0`[I)Q9,PE1J4S2.'(V76X"""9AK`&6
M6ND]Q`38(98Z:DF());2N<,[M[I1J$=;I!#8SNURC6B;%IGXI(BX\JG<DJ$6
M0R91A9#=-+E&ZS[WELYK&@5QYLV0Q*@\IFGH&GQN(0@A&%TC)USUYA)#TH--
M^R2.&V0*8_BGV6(G3#BK,?EMCH"D'UL*:<>1EJ`P2B$2NBQS&Y`BK#6V*=YE
M\FCJ\L1U>851-14[S'/5+9D3$NKA-J^[7%Z\2SE;D&C+49)9-D[2N0/(51#%
M#--8`VQJCL]_?B"CJ<$3Q\$SA5'9Q*F>6.U#T^(QCK47V\3N\G@T-7FB`RO-
M3!O'$=P:;%_+51"E&4BF=XM-S7%ZL1/2G[Y%H:GE$\<Z,X51Y3:I-AEATFN3
MN\OMT=3NB38?I9MIZ#&AIG>JE%H(C&)\13GLF/YM'C*.LLV?.KG+%$9J\Q"[
M59F[_;HX+/7P7?8_HAUBVIJD>@HCB^J!1G,:.3LF=R`8A\;A9=.[ZP#`\@`P
MO==]'<P41NW6&`X?1]G<1J0)C:YI][\."+BINFY'G<+/%$:^;../CE`+\>$1
M*J^S\J+6L&[/<E;7O5?RD[BJ8GAIN+3*:W2&%AD6]PJG/1?7:]$>7#K@=GLL
M]NS/HMM7;>_5;`<AY[,83+J3]V/Y,/#C>(_:\`'NM>//`_R/P>#"-)\!>,?Y
M\/X@)KC\,[+^#P``__\#`%!+`P04``8`"````"$`,A+/&Y("````!P``&```
M`'AL+W=O<FMS:&5E=',O<VAE970S+GAM;)1576_;(!1]G[3_@'BO\4?L)E&<
MJDG7;=(F3=,^G@G&,:HQ%I"F_?>[0-K$29NU>0C&G'LX]]P+GET]R!;=<VV$
MZDJ<1#%&O&.J$MVZQ+]_W5Z,,3*6=A5M5<=+_,@-OII__##;*GUG&LXM`H;.
ME+BQMI\28EC#)361ZGD'*[72DEJ8ZC4QO>:T\D&R)6D<%T12T>'`,-5OX5!U
M+1B_46PC>6<#B>8MM:#?-*(W3VR2O85.4GVWZ2^8DCU0K$0K[*,GQ4BRZ==U
MIS1=M9#W0S*B[(G;3T[HI6!:&57;".A($'J:\X1,"##-9Y6`#)SM2/.ZQ-?)
M=%E@,I]Y?_X(OC4'S\@T:OM9B^J;Z#B8#65R!5@I=>>@7ROW"H+)2?2M+\`/
MC2I>TTUK?ZKM%R[6C85JYY"0RVM:/=YPP\!0H(G2W#$QU8(`^$=2N,X`0^B#
M'[>BLDV)LR+*+^,L`3A:<6-OA:/$B&V,5?)O`"4[JD"2[DA@W)$DZ;M)LAT)
MC'N2=)PG>?%_*22DY5VZH9;.9UIM$70>"#<]=7V<3('9V9.!R2_;`[ZXF&L7
MY$,!;:"D]_/1:$;NH0QL!UF<0M(A8OD"8@\A(.]9(]AVJ/&\-@>&'##::\N'
M.R\"9.1+Y/)9'KP8;`PLAQN_S1P75&*@W`LHC@0$R,0[EWRZR(;+RU>7!^)&
M0W'G77'@(U&7PUT7`5($46D>^]\0LSR/&<B#TW'HW7EY#GPD;SS<>A$@05Z6
MC<99%A_9NAQ`TO%DG$U>Z:CB/>(<^$C<Y$A<@)P5-X"\+"Y<8N%X]G3-OU.]
M%IU!+:^AE^+H$A+4X0H+$ZMZ?PQ7RL+5XQ\;^-)PZ.DX`G"ME'V:N$OR^=LU
M_P<``/__`P!02P,$%``&``@````A``E0>2*V/0``^\D``!0```!X;"]S:&%R
M9613=')I;F=S+GAM;.R=VVX<V96F[P>8=P@(Y6FJD4SQ?"B7V6!14K6Z2R59
MI&ST93(S2*8K3\[(E(K&7/AB'F%N#$P#PKS$W.M1_"3S_6OM'8<=D13+79Z^
M&<`'*C)BQ]KK?-HKOOFGGZ:3[$.^+,;SV6^>[/9WGF3Y;#@?C6>WOWGR_NKE
M]LF3K%@-9J/!9#[+?_/D/B^>_-/9?_TOWQ3%*N/96?&;)W>KU>+K9\^*X5T^
M'13]^2*?\<O-?#D=K/CG\O99L5CF@U%QE^>KZ>39WL[.T;/I8#Q[D@WGZ]F*
M]Q[L[CW)UK/Q']?YA5\Z/#YX<O9-,3[[9G7V?#Y<3_/9*@..[,5L-5[=9Z]F
M_@+@_N;9ZNR;9[K5;]_/7L]GJ[N"6T?Y*/WU]6#9S_9W>]G>SNYA^N/Y0C_N
M=/\8WOPNOQT7J^4`>'X83/-TB;=7%]G5/[]X=_[VQ?NK5Q>7O>S5#Q?]]*ZP
MU@6[6@XF[&:4_Y3]:WZ?WE=N_>I^T7K5[L[V;S<^\#9?CN="URA[/EBUGCT'
MH2-#ZLO)X#9=Y6*]7`):]G)<#`'OW_+!<N-*<2OAD7?Y8KY<P3_9Y6JP6A?I
MTO^6MRZ%%5Z.)_DRNP#8V_FRA8GSX3#G=WX=`19_I0M'..;3Z7S&R^?#'WO9
MY=U@F1?9F_7*N!BPTL=*#-?W^A*.:X&9WADPW'GO;W?3]US,9\5\,A[9!KX=
M3`:S80YXB$21;;V_?)Y]]31]Y-4LN[J;KPO8ON@A'I.\*++YZBY??AP7>58L
M\N'X9MQF\>?YL&3Q@W312-I!4?#JKUL_#XH[D[.A_LC_N!Y_&$Q@A18VD*,?
M\]7@>@(@^7"]'*_&;<J^7>:+P7B4Y3^A%`H((0FV'60\8BSF<*1@O,N'.6]F
M=78^RU?I[U?S%7SY\!HOQS_!*[Y^YR+/8=5B#/XKJ+JA\;=U_Q;Q.1D/KL<3
MPT(+J?"NM%J1+0;WAC&]<#`<+M<`&'&3;O%Y?I.#HE&VS#_DLW5+@ILHJ+T^
M7>B-."9#?]]NK_+E-'O@5E_S@1LN7+H*EZZO=OH[.[OL:IG!)>N\GYVO5W?S
MY?A/@+V[=]C;V=G1?[/"Q/#7V;@HM&7#=R62V?Y^[^!DO[>_<Q3NS`:K#`8;
MWI6:^F]>>J]W<GK2VS_=JRV-@.33:Y`2[$!+2,Y'(R@YG\%CXM_M\2P;#A9C
M>"Y%+J1=3]<3D^K`V/,IYNX.?A]_R$%[T1*=^C.C_&8\'&_@;T/SW7PRPD#_
M@PGCJJ476R0S[#[FR0<UTEOT)D8T7XTQ`$\W::@'ED@1U>2<DF6R+7`[FD\F
M@R7B`4F,55JJL/GTH.(RYZR'7Q:X[C&WSFM<N>G^FAZ7B<ME1='+-]D;X!^(
M;1ZIT?.?AOEBY38JPS`,?HZ2K_LQ+?Y]YRJCK=Y_R%?98CD?K8>K37KE0L2X
MGOM.-MWTG?D_#VJF\&.+^P.6<!"BYFOIRW=Y@<>!]$M1C-C+9+X0EE,R7^:3
M"2:]E]WF,U`_L?L'H^EX9A[:"@%,'W%QP4?5_FHPI/=]C]QF-\OY-`OW0M7T
MGE<S]&F.(SS&96Y[@JYWM\(NGX:[.BV1R-*E*7Z?CV_O\'BV!_CH@UM,K?LS
M-39M(>_;03$>.N;&D[7<)8F8/]B2J_CB2O2R[>RZ<X7'".E&T4!^:TK1D+O!
MZ6FHE*9\M1=)*>(HAQBUEPFO+22]GQ&13,Q.W1*)9'B,T\<X-"_G2TB"-3#O
M97B?*1`H4/](?2<%FS!WT?BA#<L'>SF9?]RH4"YTQXW=46=6&'LPA/T[G;+S
MT1_6Q<JUUFJ.A`_GLR$>M?PLVT/&5?UM+N"Z@(.$H5)DJI5;:,6C8KFQH2.E
MS<7=8`8'LY1\!<<82O/C8&FZ)#H=+0-W/E4\\:?R`=XP':^G:-P9BWU`_FPK
MZ>LN)2G;L#+@BR&PQ[Y$D,?T?@>O2+9J3K()4X0/+[>U[9JWFBXK`?LB'M.'
M4JKZ-J6N*MRGS[Q=HS#9K5FBFYKK^^"-CV+Z2R*`[+\-IHM?PRRC?+HP;H=V
MCWJZQ`!VY\.8B/Q9%GGJ,?M*<7$SGA$Z?0$7@_M@E"64T>\=Y=<M"_)V.1_F
M^2BH^ORG?#E4:,7>YK;+EL[7;MA([:'%^GJ"PIW?X*X#5N<3Q@%Q_]GU??:8
M7;Q@1<PTL.`HN/`H_,W\;^-_K9O25Q!BD-!O1?YL:Y3[7S(_SHBRJ0;/`\&=
M(;WKQEYV3?IC-A/^`0R=0)(AA>"!ITDZ;'[N<KU83,R=PI2/2#V@+M=+HX8!
M/-Z<\[%76JA)6HBMNF%.`=OP`A.9V7RVG;X%=G?/'H58XU7V\!CZN481WM>)
MM=F2'7CZ:*-S=9=GLB.#64LY[O8?^-%24<1^@T6^QH\O>I\_O9J1&MC"KX\+
M9J"+^YZBAZ7[AO,EZ1N+9OCW('L.`M#0,%WX07:._^!]#N\^?U+\M'MZ>M+7
M&D1W/'$[F5]#ONOQ?($&G@Z&]FZN2`FS@^Q&N164,JL(#M%YCG=SWZM[>J9R
M>6(J@92A+M4_T$TF]UGT\G#`1KVLF'(QF\XG9"+05:Q;;CI;#9:WA#%2GK.,
MK0S$@.]^.!>(D_GM/40.@3949M/D!%;;9M:'R[$I`0.>1-U\TB<A0TR7K^"O
M(OOKG_\7V_[KG_]=--9>(I(PI60&]3)[YW`YG]U/V?CRP<5=KV!QBE[V\6XL
M]Y<%M.XROU6(258LDV-/M+&Z(T*>$WN*V3,R8Y,B&Y&$L5T28-\`(,28DC'*
ML;I+VS#T&<X7)(S<L7T.#E9WR_GZ]L[>TMAS!,9W'+@OP\"4!&,9(1UD*H4B
MZI+C0).Z:[2"1OR3-]?\=Q2_(-3]*,/%<DP"B3VM\N'=3+3`MC;?MR!-QF;G
M+$_:ER2(_@X+"F94=?7B:^)O<PI8?OX16B.G<7\%N4,Y1+J_'MZ8\W$;0KB/
M8Q:8D*D6D`GW:C$8I@3UWEX\F+5`OLXG8X@42%3<%P2(,"]1-!BI>/$A+HNX
M9Q'R9T081G*X=SW#>9G,QW+J!PM0.(!)A)'E^K:D"[(!K#6L-U#ZUS__17(.
M>Y#<`*(H?JRX&"^`?0;/CD:\5*X$F8W5&)TL7$>),AF"15$6D[6A:BD^9:'Y
M$GKS"^ZD2Y8`06D+\Z0Q=8N,4M'*AE_!XX'%##[10$A0F-K+KMS%!N"__H__
MG6T1)T^P"K.G($=)0B!W/\28/V0&7%V82RP!>K&&W7(PR%NFI`/08H!)3OM"
M^R!K=8M'_/D3)8$#$U,]LT)5F&LI%L<Z0`78;;HFY)<2?+ZFWC$#6]-U@=(A
M!3:"UKSF#DW&TK/I\]?/;?7!]#I*[X)GG9AXPH?9/5%NR#ZB`06)7KR_B]Q:
M>HJ<]0HJ\/[&)EX@#?,I/L<Y(/H^7IR+R@CX)E3P4[&^_H,<"JFYV6P]F(#`
M#^/\H_$+",T_<@G?I/&NU_F(_-0,*,X)LH>^MQ>OST'3A+`CBK.\#2A;R.V*
M\"['Q8_;UZQ[,UX14WK&.^PE9G`<E\8G^&#K)>]>2M@]_09I@Y6H<X?G68%3
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M!OD46A7##2$Y&.%/71$#^`MJ,1)_+I7'L7V^**T=V1.K_AF%;M8K^9@FBC@2
ME8P4:RI.17&S=M<%-C/?!Z=W*8F0.Z'<_!CI7A9F00B:;^<KCWXQ9!?H02]R
M3!`;P1"XV,SH=9[/L@6/KK56N0Y[&RSEW]C+18S;Y8!@%SRX#0-_5DS`>!:X
M"?@_+#V79L**8H\*;LY_(O^%JRZ#**/&PZX!#6;^Y4]4ZRB?1&@FTH8;S<'X
M.,;`FUP@^F8$-NH79Y!KH"-W^"%_D!'D1<SFJY"U$V<7Y%0H90U55&7+]?2D
M:(SXR)."RDTMELW6IB<!6\J&'\?3L50QS_@6)1M@?AFPBD)%\4IKF.6N\_@H
M)T4PLGW"E#_F8KT1&901BA)A$/E&8XFV3"*H'\^$>^`U=/)CE:84&BN>EB-4
M6-4G["RLML"9P*E!XF9$H`)Y?HU\(A"5+@E%!^X0*YJO-$=-@@F#I_G*X%8)
M>;Q"Z-)&85MC7$\/&2[*_5-4,>M2\^:EC5)FA:9`52MTA**%]FEJXZ<QVC9G
MHU\='.WT#S*(,$%8&HZ',;V'3>Q6L%:)U9+&B!8&;,Q*T7%+H^N(6VAD-0ZA
M_V5^O5R#G)J">(,&I<#C5R`SKT/_&[:3%;L6_!<<+7MTOR=I_R#VPQ6E:&3&
MFVUK0>P,5GLU5@ET4081!I6,4,W-A!S7@]F/\,@U8EE_3E>J8)+[D'9X2B2.
M*B:Q7`5!,L;'K<FM(J>9H!IX\GMQ!_]3M\$/44YB>0N?>^SD?D9P0."Q#W,S
M4K?X_PM3+\[AYJ&9BU>Z@3B^[A1<F-S<F[F(4HK(!FO3$OG+]11BW@O!=?F&
MD50,U?86%,2'"%,:I^_U__9GKRH]:X"*V<U%F*`3]=(O@V-Q5Z70X+`?D-5L
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M8_(8GH%M<G<!BB?@7LD*@C=VQ"O_@,-GQJ=DTCIO&ST`HW.]C=(B.@4!E`&&
MB'4\BV0),[=X^96+&1IR%CPZ/$W\`HFIF[[UK`U;@_:_*`=C.I2<0$'C;0VJ
MXDP]"^1,!6[E49IEJ-_7<`_@*B4,\*MO!F/JZ>((;4U"5Z':.E_8?H\U"UP:
MVU'-(IO[4!:7W))WW]DAM"$OO$ET<5FA8.G4R-S+UQJB5.#7H&3CRR`P3.4.
MOY@EJ`CYZV']EDH]5/RM&Q5`N/L7>=<3UNW?:U%`BU_>P_L`1:')W)R6M9+:
M`^F(LD>S#3R7Z#=)12:`"_&[=[TM,84`=%FQ77SKR(;23=/!C^P[OM3T(S'V
MVJLOBFG(``Z\1""N!P#<`C`TF'JO$6!XQY(]6BM?V;^5]ZFEURV]ALYA2>)X
M\2)BUG@&?<E;S!,/%*J8J=JD^YV;X(DM`;:Z2&H]82$.KAXRU\`J"SBHPY5G
M*IQ)<1W0,G+$\>E#>D?!3XFG%O5>X:3-"*?ELQM3D]X5.:,#LZ&'X4V5%3HP
M*\G_"L*@P"Q=#A-;_YW30K\^E&<RSP[ZX!/1.&<RW$Q6P;!5JJMD]$8:ZH&D
M$S6=M?0[UJ^5K,*O9/$O9J2DBA'`6E9*G4<N^YN@1F>I/%U'C?&N]EC?#@:A
M@:#.'%;4>+@:\B*(Z=A0X+:]DR]DQ;"`>#:+R;K`75M^'-RKW$%F7$37?[\?
M$R`3<I&0'5MHPELV[2J),_]_M@SF\7S8?U:ZK)$M^_SI\Z<KQ"TD?)RWT`)5
M0D/.JJ>6UA1N[B45_B-_RI5MAJ:C.<IA1-,#5LE\IF*M2%^IVHRDJB42$2!I
M+/2(4B&F>AP7L#N>V5I%,PP9ZCVGC%BE,0J*YP"C.@CZ?123'O"J1=_RNYJ:
M)69'0NQO/2HJ/DJ)>5+1TC*"M;H%`QKO8,,D^21LDJ$J;152FB8+:H4H;M1,
M`):"@"FI*S?1T@4&<;52U'I$>QB:04%GY#6;Q>IAME>$JY9#BRK5MNP8'J)M
M9?DL$:9TV00T6;)#`(*0M:#P1"APU/1?Y;N"4%46D&+50[H[PXPVRL\'/5-9
M)&VO\FL:=`_Q8=,>.+V"3\D+Y_<#3_B(>.Y,$$ZIXC:8Y:IJD)93$QJX8ZM1
M@WU47DXD4F+$,LYZG#WC[,$APHC'?.S)$J`+CE>XC[9QBQ&73EO/+)JR%AWD
M\IG[X3O$5<$I,1N:*4<0"HJD`D6-R"K\`XKC4X!<8RI/@KGH5+DUD8A\=#U;
M)NJYHR'\!OK7J&=8K)R!6LI^#7?"TS4HT/.(!V*DI`HR-@Y^E'R-ECE_1R9L
MIN)B;"6NL@G0G',JRU8[`O[^ZT%(#KFHO2PCF//J\<OP>)%].V>5;.OE^>6W
M3^-[.F]\OQ",V=;YY?NG&)V^IYNV=TY[).I!,O5*4Q07N%=+D$C"5B7&"XI-
M]`LNT4(\:?$*SS@%J,#1OJA5>8*6)1/1;1-:?&0>7-YOA\;_(=+@+Y&$D$`U
M:;Y=D_R7BB*%!-U#!CK[3IZF>!`_49DLD.W`#.`>N%'!9.B6*BN+<J&I&9")
M)U*"PSM>U[&#X,["I3BH4D&6:N5A@Q'*QV6\-PL%)&923YC[_MHVWITB^=OY
M?&2:J,B7'\:D0*4"N!NO/I:^]2P\;.AUUA=*2=G.'9\1FEI2M>;ZDJLF,:`U
M0/EZF<.QYCW#)B*#Y_@)8CW^QVN'V2/X0J8UC'C['6E+*VX;P>EP,`J7H#6$
MIYX-^\-Z=!OR0UK/VGPL5&C^$+SR$HFX:NI-C2HAJ%=D*.20H1R%"S)$1)0E
M$$UB(?R4J@@\Y?.)U&514(&$-N_Z0^F5V/+C?055P*5<,>'V43][X54+&G@L
MCH.JK"\%R"*>;N`>+)/ESF5&C+V=90%;)(CRF^4(":Q+<$_U1H4>($3B!:)I
M2V^XY^*V;Z`6-.L.:*3E3#3Y>S#R5BYZ5%Q-IM48`!5ZJ0JSYX_BVK"L5HE/
M:]66L)J-TE:1[*YHR`1.:9LR(P9&.NK?:*AZ"3HH*=1/J7VBFA#"U7924_B"
MK%)H:#$/]U4^_&ZN+:%]8.`9_WY>!GV&I?<E8UMP9+(`9="O!*AF',_M2(N5
M6J7#K`/#:-!8N:]"8XF<W4/%5NKT@P&H+I<*J6;\JTC77L-NL'_%N'I;+GT@
M+4B%RYA!_X/2PMRNK\4HELH?S=>DSUV(FX#7#(ZT0P7XK:&$:T*)W$)T7VQM
M"O*."4*VA;DU4-%<X\F_4DW&V!MX@G:5.9IE[_N7?4\RZMG(S3"7+/\\(@6V
M=A^H*WDH#2:YJ:.-?S?EU-C20Y)@X4F1ZI6;I-/M<$W$HV`+LF9FQ-0K'I[Z
MAUR=!@7J.JHN!-"9=*O)N!SC8?#K3"8&C8S_&/;'2PR:'D8*J4C^*LHC<5TL
MW&']W>#A!42#]TUR^O,*H8WN:JDNY3CZD_`3<4%(D0A^-NM]X*@7_[L\H46*
M:9:/^J4MAQ(PC@JE,DZ=-XM?W:!5_1$4SL'F>&#HFN:KK[.MW:>?/T$$\M!V
M2(@V#%""49:Z`CQU1'L^$G^(^*/X-2EZ'AGA'>#,W5LMS4R@``'P(MK'NM<L
M^Y^/>'2?1\4T<+`,OW253L;Q7+3NVO*OC5&W#KA9Q2NI72@&1,9O`6,CC'3`
M6A&"`'0GEG/4HI7Z4-^&6NZE@J"44M8[]Y=+N#V-EFP7AFJ"=:K#]/5)_U-'
M\F#JIAXHB*\%8B-18KD."268!_V>_JE5N?6`R>M5C5UP?.C=\F1&Y)?`0DW7
MBG6EU>OY^HI].SW%X%*BNN55HB^?DMDJZV`H;?-<"SB7W%:TH%O<?GZI!L.G
MV26:SFIZ1SN'V[("[P)#UT0!#1\07KCL/B`'YCZ@IZW4[FB-K.MZMHL]/>?8
MQ:!RF%;J$S,]9XM*N<`;<QT'D+BHLP42JO75^'<AHUN&@M%C<MOW,*=Z=14&
MC5H>ED8:$X9TO5LCKP?6^$7>9<0&81TLD>2.%NY;"Y\>;$[C+:)ZI4T0D!)W
MH.U*OBO]![.!I&SP@6X;4R;!H>'NCF878U_OPASP@M!/TMT'XGNZI[9K%::R
MX1D[1N=M60S&"E'R@N_-:1J3\AJOB+N4<G@;@ZU_(?:VFGDX"N^(;W&,]%R(
M9``43R9VZHB\7X(VB*MM6[4$2[U@!\"X!#"RGUJ/B[OQ8B&EA%'.[P83@G;7
M/(_8E6&%H[56Y;BC^F0E+VAEW8&$K6A5'&$/WN-VZH)=:F@+VU'1_>S;TN>5
M$@%86LI(%/P1G*%2!!Q^+V*HGR+2C`T]RI$YCF^2@JIQ!IN-&^>!L&],M.N=
MN):8E:0V[#-F;@*2Q$%4=1V;1@[Z.;!_2_/6=5K*L5*V`,_25LQ0+KTP/>1^
MRC*_1EI1'^?*ZTHVN&Y6LLK!B$LEX<$\Q&WB-PL9EGD(U\*QBKA=9X>X'`$K
MQX0;;Q*F:O0.P!AY:V`"3@,SM?>RLV@C30,66*OF1KR^YGHG%-ZR'V=J%Z[%
M7B'AP7[8U'2`=^<>C!5):PL&UHA,$;JJ0@RG?=K*+?I<U'M#;'=^G/*=2UIJ
M)T5.**\33R82VM0M!7)WR5:E-@@Y)1TR#S]Y7!59BJ=),LGL<Z+*8VWQ-<!8
M'^?7N'*<4U#KB9069U$7&`ER4D1TUOIZD^<X(O3V@'TM%-^C4T$A*U?O6ZDR
M9\AT=X;P%9HA-#LU)<FKW^JR")Y-*4RQ+ZB.`5&IJI?#;7*G+*05R/9'":'4
M5KU5J_2<](.1VC-S)6`#'0$/"+5X@)YK-7B;L@&EY12&T)K?HG9=&F-8@U"A
MD/!PB$RLZF;.SH@>:Y,J=SS5C:A#`-S<QCKDL7A5(E>J+U<MVGW9!?$XO\12
M730?Q=P1%-/"%:W1B7=,$V&_4=QK^A,9=AF$`VE5"'I!IJ[6`U7W:IO$KI`B
M15U[:53I4I,QZJ.UT,Y@E'LNJZ<FK.99"_3(]-'#A0]8O;DIUAW*H)$!5?;>
M\V'!5BNDKWL(.#:!\,DBB)-6S6>(O3>("4N>SH+KU"V(+3!W2UVZ2NCYL4SY
M2IU+!F>_">NU(I6)>5+RL:S"4#DPP7>/CGY%-WLL>$9A!:5[]&H8,.A*\U'$
M_Q'A=6VSF8K][%741R4UI/3@%:'$6:C&XR54H)TH!]`BUYM]JY&XQ@,"RU+3
MMI.00I1C63)B4,(02_-NC`N:J(/,`<]8FZL:;P06_A.\42DKV5V+^Q0]I%Z^
M%BZ1\X&4GPH`#=V2\'RIIPU99'_JG.QB4,-0Q(=K`<&-;J8MPLV57F[AH!B*
M84EP*)PF$->F1^1><2>R:YPB.L?:A/O3PF6Y9[52!,UO#%SHQ)([:`MD7#LC
MYJH;VAAHU9QZ0=$$XD'U5[Z\HIX6+=U(-UNF9#:4>3SA&5+;3?52HCJZ4I5J
MARF#+,OA2%E`#CVXQ:PF@-283*@3];C4<G\V@*JDB/4W\(Q(%S62/#O]6P$1
MJQE-.&('$.$'B*5\/(8GL':#P>K&JU(F+;2_5.]/F52_*0L>"@:6%'QTB$SO
M]@JX:8#-8WSV^[_H<G4".!,Z1JQ?R6&>$LZ153`C:UUIL;`6K#NG/1);M89^
M<$YMC2"_03BTV5KF7WRG`#2@H=[J8G&PF]Y*MI+'93H03L1-"Q%^>7!1$T9&
M`<F<LPGC.'&7-QJ6(@4GU:#%J>`<U?#.2LA0?D%+OO0T>H^MH=CH"'*DU)_2
MCDO:=N]'KP?<:GWX2[$AWK>CO7J7)UUEOU?T2M@XMN*AMY,[E(N)+YI-<(DF
MQ=?9]_K_;#?;NF-R!5M5TLDBT:>]\!M-IT*FW[B?<1;V8^.^%BM__C^I1QQ>
M0K[C_:QTZ/^X)K>.#5.2RRHH)ATJ,JL7Q=U`I=GL+%ZD/<2KD[ZT'JFPQDR#
M#*>?S`CA3CS71)"&V5/-H06_0[L'M*^<JLXKO&M&/-D$.E2%52:$?2,R#2R9
MUOFUE)I):TT;*Z2K]L%9D^##C.@J&ZI6RJ]JL/-_]2,=(I/%N*$)B]:/QRFZ
M&4OJJ8GC7K(?K5&AO+T@5^K89[U(K'+'IG3E,Q&0!$;=B+[RH4>AB;$H_;RO
M51%4<:!\0.IT]^.<%C,R^QSB['W^E*^&?7A7+!L%1?&&J#'"Y=#QPU)A@VIW
M])0I62[G-D6'&Z0?*LKY'L4K`^]+H=8Y<9,/0GQWB+JF"(5;&XLY%.T6[2!0
M%9L)Q/6L]F+M(<:\-8ODK>NUUD+9(<JG'OQ:(]>"K`?],`OJ+M2PK0=/^A:"
M2=SDCV@]8Y,&*S:-;3!=IG7L:=-QI=>B):Y%B$:K[8>01&N)E1WYK\TP"'D*
MZZ4%Y\!F,*'"R^I;I2K)K(0R608Q*S7L``_)P-]K5U6+@Y_+$`:;'AXR50VJ
M"^J?R.&!.6_.2W;PHW9X!OU466QEV4VSXL&1Q^,X.N%_*%'+R'FBH6;*6\AY
M62W&_<-0PG)V2HR]4I5.`PMO`\L%->I!9E,SM,3>;&`EYT%;A(="*#E1Q#(B
ME6+@FS^&NXY73+TQIKDB'W$A)*=J.`G/X1/0B:\[U<829K\TXTDWES!3[6E8
MNHP$31[E/5<K$.U_T/EE63NM71.:+RB=%N:O>'&T'O*C<[HCFR_#;5=&U`,6
M3NFXTRU=:;*_+<,`Q3E/CT/@N2>.L\IC"Z;<EPW%4!WI->W(%NT4:V<S<8RQ
MRWHJMD?9)K,<GOF2Q`S'RR&C=2A'R(;*4RVK3"9/R$H]SE*^I*/>!S*I;1&L
MA`$F+HDU:@1:5OCOQ&(5G]"S(A_8!Q\TZ%HE02K_AL(S\>BUZX`?=#QCWSA4
MZB!0QE1>I0TVV+?2GH0<@SEA^&/!#R,*K:L.IRKZ('3H.UF%PN[#+E4713P)
MU)HK]+J<LF&=18>I'V3#S-*+OS67@OJB.4+IK^/9YT]NM--?7/`Y"0,GIK^5
MPLW#YC2G-VQ-Y/=Q,*DU8>RR.MJ9/F3LWKI8&LKT%Y?$]&I\\U[KS77;M^FI
M_?0I#37^NEC0(?6;)\9TN`%/SB!$>]AIEB[Z57IA[V"_=W2P]_E3^@-&.KG4
M_=[?I\.Q6N_<VSMM+]]@+6]*2UYW%KDDO;Z!:Z+?W'Y7-S_L'1WV#D[W6[<_
MO,WOPPS5^]8V=T].6FN=2=562D+I$K(KY9E#Y^?4V`43C7*0PD4ZRRK=-A>V
M5:(@:X(,>Z<2$EX)H95\S!-L(-@:^%JR>^YCR]K3>;_3D?3/GZH)="D)9+O3
M:Q<TEZ;7OL,0MHKJW[-XN]3^.W77)<]WDP(%&2M\"^8&+5-*;'HJC`W"RM*1
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MI,9$*IYCH%M#!XJ5`%$_3,CW./3D8^@.S\K!L38QM@OZ,HB5D%9G'(($:Z]A
M,U@Y<@%QNN&(!)&Z[%$A,=V@@K?G@YL1@`UBJBU40[TK(=1$A7]94\(*`A`:
M3ZKHU/%:0T1P_SLQ78O24!7=:":=XJ<(8L#X+1WM/VY?#E%HA"W>[EMF)J9S
MREPME74%=GQZO7EYY(#4-D(NTCIWZGY$K2]`F&COHQY3M/C8W(SV3N5\:+7`
M.#1P\GZD/0[54W-)A[XS'QM!['2ZNA5)U<@2F=U#DK8+DYK2[O4N4+<^QK6)
MB?8>4Q$^:"N$[E>\\';6)KP)<E)@SUXV,A[=/(NZJ'(+'CK"L,XOVS&39?P2
MRPTA-UJ@F.C@U.<(W&""0[VB;'S],)^0P2/G;^?+H"7*1A4*'Z@61HX@UF30
MZ#!TQX`NBN&/-7[RQ)`M6R9`K)L&41L@><C52"^PN-V%JGZ2`)XH#P=;"@3]
M`F^3NHMBTB48QI_*^\>;ZMQ<J8_.*#8FCK?&](S6,+!U=/(K(ISCG5^1.-T:
MZU?K_KM1H:"1;LVV=OJ'1[IYM[^['V[7_12IQAQ_MF@DV_IJ=^]D^ZN]WN'>
MCJWX@3N:W`=J]=4/1^G65TRA.3D,6=LMW5T2:C*^0;7N]?=V>>E!_^#$C[L^
M_<_`9X<(/H32[4<B].34$7IT^"!"V?_/0>GA;O_X^$&4'NX82H]W2I1JJ-D/
M2L`<>;1%=-`:(U;R6#C0!=?BZC+1P/I(*HM:&[8S8\EVGZ8;3\E8]?6%:$IE
M9)]:Y$;\]^#W&JC:35M!U4'_[[CXEY<NE5#-%`4K6Z:H&!'L!PJM`*$NO\;>
MJUZB6K@A%\2MOO`CRQD+,$G4W&D]J\C;[*@4HV)OG>V;H\2L6?1!4DC3U7;T
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M#GT)T3N2`MV`7,"UH7'0*XY^OI6WEJU`R8;.2#H<G;8=[#->>W#:@J;[M6^7
M\QL=@[3O'EGK;/H6]G;2$;US>;^=.>E^28M3VN_8W6]#?';0PPE\Y$9<O-*%
M=WNGAQV$V>LQP+RU\-G>?N^P*U-!SF-WKP/1O_?D1,MW..IO^N5<9Q*\)U4J
MFF%%EI/0*26=!Y)#7CI'E@:L*2'BCY@%L;.;G?[Y!MFZ9D"%JO>H,$W%8&X`
M\WW5WC;;MA?K\+L.6([T^1@U`UG/E=BB[71=88I+X6R%SC+47]R:AZ.5'%N6
MO27G`8DI30O['DYZ]<5/_AV']+J%$^G%%^7$@>27;OYE/U6DD3Q!GJP[W[9W
MPH?2.GAL9_>X??6XM[/???.I::"]G78*?;?S"05,FU[<(6*_&#$;JK>[/*+3
M@9;Z4HW!J)CB\KC_Y7N^M2\5J5\7:;&&;5]+G"@E;I\_(ETTTB!7"53+,58'
MCMCT8_JEI6K\!0L9Q5N?7NIGS\,7EOZ?0F`CC@1SK*]SZ,5$E8;?!:$1HDOO
MZ$:HXR0=K>#IIT>Z]U",M!7S*_2D8S=T+=U8#\/0N--`D3II$;@ETU?J'/S\
M">0RYY$874DP\O:>!4O9@2)Y>ND'^EAIVFJ5J[L%M^2F=)FM_>/>:?M;L%N[
M![V=TU:1Z'FNV>N,BWCD:VOW6_"BMH`O8:KE4Y2PE]*2(K-[SRX?L@.1+*W-
MDWAI]14\_<?6;>1I6JCXQU>>4?]R+!;T%A@UYKEP<V?I,Q^HA,6I.$;PPF.T
MJNF<$N-EK?7:L^VL)'&695)_NV0RG,YZ#!>KG8I^'/IA=228#MYJJ;J\U+][
MRFSUTA['K*!>.J,;/`3F5;.91E_75^<-P[4R@_,9WF/(&8:N&+/\U-5L$5E7
M,Y\([W:YO1%E:)269<$WB.HY@C._*:6F+27=C'%IN<<W=EBG[<(>]([VCGLG
M^QTEG_W>+E_K/.DP-]TO>F]=6NZYDM.S*0&>I4M9;/_HH'=ZW&'XCBFT'1RV
M"W#=+_3"6;HX2Y_R)="N(A:[.:'L==)^P9EC21_`H<F3>4_IJB?]+]WQIIRU
MRUE1DOK[#0$P?\^/AN,(/K<&736A65^@.DNE:?44<UV5*WY%6Q8,`H^]!9K(
MC65+?"PJ6*^B&(=%'=<A\VL[(8[QBWI+_%A;MM2'!OE)G;!U,K6O4%Y2/YN$
M="XI]=7B["#ARKJO!?K@ED,9G*LF(W23'>^?]D[WCUUFS5^-(J>]];,-J'+T
ME!BA<&8U0%OPL+>_=U!;,`7>@(2906`=#X4E>Y%AE^/Z43_W)ZNF$%/9RDS:
M,7$_=V)#M,0.+8V#/HR3IAY):)!HD(6/O$H9Z"0[I,<O(>$=OI\K9%8.200R
MC(_DY@B8N&7G-'OA)3B1Z'L^?Y9=J7WTEV*>-I*-YAX==W`$0&A,4H-!_@Z8
M*SFDE)DO;5UQ$'76:KB*];_J<4U&#?*C?P9S9=+ZZNT;QGRI@R!(YJ:W>-1$
MPMM82,N4C`N1@Q@WN)(Z+R$6C<EKC--]DV,[Q-"%^4$Y]*)&BW&0G;KH65*!
M-C=OB6HQ^Y?VB:NMW9']E93;`<R]`_OT<TTR&^\K6ZZZI:N)\,<RM"'B`5UI
M`U0$:`L=6^N%6FKV>SL'.[V#@ZA0GLH+&$S*1FS?7^<**4(YRAB_M%/S'K)`
ML4I8ZXRESZAE,0/5*XV!;2OD@]3[<%DSW,$*_#(8@H@JN%MC`$9*4[ML#)VZ
MY%"5)MC^V7G+6'/V01]>XR"G1B'J3ZS/#0=/8",>P5D+WZ,T32:LA<TJ"<@_
M<7SPP)@K!H9+EO-R7WTL>36\S*<`QU7=7OFT5YMO0QTWS"^+*I1-6)\4)\P%
M4VA"MBD.H0_=_*H;YA\`@\V3)MD;1F<:'LKH1N`;:VT2=CHJZKP2CC3!%I4*
M#TH[895>=O`KB<VCV*K.2UW[T2+U[4C_"R^6Q4[ZWW5OG?W:7DA+1[_4Q+ET
M;`B0^^R2)('3\'.,PA!A`$GTI0HVO"N7KG=XR+?AC:/=0T&5S*W4KG.U=,!;
M.K8PA?LF''OH9:>D&WG.4F*:B1A.79MZ=6T;4EE=BM158OI8%$V?_S$8$1G7
M9N,+5S^<7SX__RWVN?D^!"8>><>]Y_`ZSHZ-^T3A+<J1GCKXK9E>=WAXS&7[
M2]B:G6[4C3'7W$+Y>;T1I8XH/WAE?3:\=G.+'"&R?09E?I/ZK@'AZ>7RB]/I
M#^$+U.GEV%247B_/::0_*.&H69C(<_J3E$YZ[3RZD.D/]!$0'!%+IS^HF2'M
M=3WC$]CM1!O':/@R#]\L3$M^W9'%FRH0E!)K)[G2L+U[F>_DOR(,"=S=-\=,
M9NOVLZV]_0/%88]:YF6IFY/;68:<Y5&:`=@$C+K&.D`Y/'U</2W!8*(R4HR<
MG?1/O94@`;H;NM\1N4C1\U6_VC@ZG1'JJCL]:LF`?:N&=]2NDC6`=Z\3WK,K
M*>9&?U)05E.I&CH>I&$>D471H"3)#YJ1LT$V?MC/Z(?C4L$HC$+$Y0YG=42F
M2M37>H721!+`-K)RZ2:_F*7K/*K23;)W'('?[N@*2M^YVS_$3-)=DJD)Y5?)
MS]UKETSPH6K-2AX\.SK^U?;1Z<]<3UJJQ:J'?2S2=G;4W]W=S`*E!Z1.+5AU
M9E^OH].%ORU##6[=@'&TW,,%#U7+[#2!*1E/VN^<M$;H)F-%.VHW:%U/(24,
M]F#?H7W;X*O]W?[)GNYS+[YEFL33<4-4DSP(8&`=9X87-%GI*[,^-$;#0;'J
M96.G,3O^E>_;L(D_$.#N9^\UMI![""O\>?<DF@_@7F))":+\M1$KP9&2S"M\
M\Y29>=#:?\WRF'_KKD"Y<(U/6,<SBQ&;$CPM*O..0QOG;`SJN;[:\WS'8W(?
M/IBTR#D+QW[0'^9=Q#/5H$1`111:HQ-[$EJ$+CD:&O:L9(T(#DC6NC:\'VHV
M4T&;C4?<U2DV'<$2<_B^U''GLF6S;0)J?$/*-):;L#&(M<,550L+4\MLXL`]
M4"HP)?QXK:9\/QICYZ1Q/LR=+Z?M.F,J$X6S)TE)]ENB.Q)>2'"H$A9;GGVS
M.GL'UD,ZRB.?<TLVN"!SA_[SEO\I_J36\=\\V=UY\NSL&X[H`@`K3SG%M:LK
MRY>H3;_EBM'H?"("=^S=G.E_^O5FP&R:^[""+CRS15=GJ)P:!.Z`Q;B;H"@*
M62W>BT=M(:4!KJJISIBK.TL\B;(OU-U-2@0HPH@2&2WK](1%:?'4,]E67`&&
MLQ>'%D5[YW:'Y*?W!Y\V9@EUF/-:WYPL!3$R<IGVF%I;D]#`^>/`,($_+?<1
M0QBW5TYI`<+^$`\?=X(!A@N-M9MB&*@+K9X58PC&?U=N&*LQ--YV%MO(E$:$
MD9`Y)<>#;:O#D^ZX9<K>E=SS^9.Q3VH`+CO+Q]$'3N\^=_EJ.Y+?R:5+[WX.
M9CY_4EMRZX%NB]4*K9(5NY\*;D]R+\>@#G=Z.R>I7\9U&D+2KI_NE<O4_2-<
MGZN:*B.I[-]K,'X)>;]A+<R)O")AD/@KY^6C7F"ZVCF&!^*:X*2\#J7#%P^5
M#KMW!V]0M=5\-:+D^E"=%)/DCX\ZJO1TDQP\MN?ETC\1P8`U6HF6!,`6F8\T
M5A\M`7^3T4]?2P;MI*/-A/,S70=K.+MTT-'$PC&<G8Z6E_/.=A%(@4Z3J;-<
M:O51S^.=_I%&<NF;GJ87+(A7(VDYCZM!7@UI(@,T,6.)+5O'&M!&AK#>F?@9
M]JA5U\$3^#E)[0>S-(;VT#@;M+@YX#\_UI=]*P-ZV5L4H.TZ*$)SZ=CYM69*
ME4@"LQLQ$-1GI3UC0T+I\I41=6DU@G^#T#0)MM\/+=B)15V=H3T9QE]-?Y)+
MA%5B]C1=1"D'GO+APY]S_QO@@9<Q<AP;ZCB$6M<1?@?,Q+!C%(#.6X<B!G5@
M!L1:6M',0=`'<544AN>;&A]]!=1W>(.E8NE@XIW^?LG#(I\4SY=#+O>E0,-"
M=6?[K$0`/1KZL`6QU<(2.LZV"=CX\2_](SD2^BFY9%LF3MRS'`YT3"-B95X?
MT(*[/;Z]T+(N9Z<'71?W.JJY++#?H1]VCSL64#=$Q^4W4AOF6V]D)'?IX[B\
M:G)G,T=83?D#E4HS(#^TH&:UT7QHZG*(8(6ZTG]A9M>0_D5]L;NNT*5LT4_A
M6'/X'*[T&(53S;$-,58DLDW>M9E`JNL#1#G4M)HP9]ZZ^/GW:';6UNAGW'6^
M,89X`?I6\_K3L@:$R])M=0"GT&=#F<W*Z'4FA0GD!8VX(X'GL4+^DYI[X-K@
M<T>(R[DZZ4[Q,-DC^G2JG2A/[U_3XR*RJNG0&D2"-'#X:7[#]!`UI\A=79'(
MY"03JHNMA=/6%47`27-_+713]57;@\I8'01CKUYR&?#ZF-\30;XZ4LHG6AKM
M1F4X/DPSHE*`22F_Q03<.JEO9DR"6:(U;I?_%VD;XFL^;'5T//*737JKEO;I
M1JX8Y08+0]80S8=WKN^WPY^.*516+!A,J+,B!VQ"B@5M'K]B%*[8_)L%%A$"
M!K<GPMI-&@4*&O\:7VC'L:5<M?ZF_9J%:P,0''L[(\('!Y0V!BQ;/B!*,-5?
MU[(<8O;(;Y(04X5L1F4@%Y/6O-<H+CY755!=\HFQE^)I<^D;Q'F8X5K//L`8
M'^?+R>@C1^^LH2CNK\$NS1%.\980HPL/08T0$P;9,L1J0BEZGEWS`Z)1:A38
M9(G4..TCEJC6A,G)'""P[@IQ7(JE\')B^=HD8813%>(0]T=+$Z:S>LHCO@7W
M0E/.21NI.B,DAY>&-$"\#\=D1L=20Y;M"Z/.!>6$XQE2!741O;7Q=BBJ5>AC
MX_6IOA%YJH/`"0,0ID.)[OJ12:3A:M*<N=DAAAV`N!CF@H,ZBDU0"OL7%MO,
M)(:NH]"+7E]D8Z\QF=VN[)(S;$1[68;BK2C>^$$I@1`M0_W=0Q^%*'@BP8PU
MRN4T=0D=:WB7((4S4))`:9WEG/H8[DDHP,KEEK6!F\@9D&CK^4BFULXN&F1Y
MIT.B[3+([D[_4?>]FE6%/ESJI&T/GD"(AS(((`%_AH93C]%%@[>HAYP)D.5W
MZV&18(*,C,7"BK[3=:'6./)$;'G!V,LF7YF%?=G/_AG_BBS-]O<#TC5#7O?]
M2D7-4?L'^EOZV9;=Y$?]C$G\9:_CR\[#RRHMQ$2L,6J69,TM"MQ8^*OC_F%I
MA5KVRR7-WM/48%`O?AO&TY?EI'0[L0O%PY>+B/8PK;$'7\Z[/IK%X>)JDC?<
MHR8K)GW95^1"$&%(7O#)G"'?#X[?V_9O.2K?*K3H3ALR@+V$NYI(C<L]VO\]
M:+'9935@IW'XN)J4:O#I4,+66T'*7VEY[4QMJ6:[%S)DX<.%:?@16-AV%#YN
ME]ZBY$J5KJHRH=7L`5=E;O\\NU0>T,NVKG2E#1US!/B^`=2`"-6:?N3><%P_
M>6$Z06[ZWSXC+-U5#<7=@'/T2">TH+@(*1WR(0Q)[)IAU%J^MKWN]5$YDIUX
M_MY&F[96J?A@:!,!RJ:_9CU""P4;]`]%F#RZ;S1SE:$=D-*UGKZ(U]9AR!AC
MU,XQHG:&-B5#APA^QM'>S52O-C0'Z+_/\=44BZW#4!)A.UD&<4-*`$%Z!*."
M#.RD3(M9PK_E#-_OPPFFS>^K4-0D*\9)Y0%+<`=BMK()[1;VS>^I<:CVM28_
M&%)/"E"&)H36)`V6VN<,3"IXKCRF$YHK4^37Y?QO[0AOK6G-+)9<LH[AS7NL
M<.EEA5"9L=E\..BMA6LXJ55OR^G,9+JM.O5`G3F(-<ZWJ39+L[5>4X&U.?F.
M(*.W8UW&P&^M4P/WBSFORF8]F`].WW'Q4')J,^)KD(6ODG2G9-+7756:+-MZ
M?_D\^ZIEUW8R3TCSI<M1>_`;GWCL9SOX4O*HTM4M!YY>?!UR12$0&$RO8U1-
M)*FO4Z</''87G[T+2(IAFJL?R#/NIBDDR.57Z^T3ZNF:_T$C^SSG?.$$%;T!
M9R_Q!DD_*BG>/8Y]\[1-^*8^:S,%_%WSY^R_DT>A^RR]+:@]XJ8P52J]H;U.
M;:9EZ(%O#XSUN919>RSEP\O5AU9BXVQ"<EBJ-:LRF7E3^2J/]'\":8!Q$W%>
MEX,.ZI/K_F/^!X?J&9K%IY_P"SJ&&FHZ(DT`5)[]LXR=4PYMAF+]+A_=D%+.
M6/=W7?U@TATZ(PK;+33F,'WR(GP35$.^&P,-TQMKA?,JM=0R?K^,#&7[/Y-0
MCW'D'A@TIXG]$.,*_R[;W0NZ+47`@\]KVMX7GO^%4',`:J(#T\NZU3-1[55L
M^=,,-'5N9F]1AY=VC`S#.."S2IX!,1_0^YUIR;!^EG3G)4JZU?W%0VYQ\)(V
M*YW6V*[T[;X\*B*Q^%]<&=ND-&+P[M-E@\E)+Y^7PZ7:'H=,R$TC$FO!H-,L
M7Q[9]G]9NY;>*&(8_%?FV$-+V2U4G)`0VT650*JHA,2QO$[5]K`M@G_/9SM.
M,D[B9*9<=Q/'B?/PX[,'7F@I)L\EN"P+7Q*.ZX3])L%+5KS"+529W^L6^DRJ
M.(5E_4$.%4!W,(R$[8J!KA3$1,@<RVZ``DY;>/0IOW7:7%+]\^)JT':(L'([
M2^?3'0*Q3P4N]I6\]!,<%4)^>U$EK^W>:#OLVAH;="'BNJ@J<_,CRNH<C)*A
M)?JOEEM/E7`&"W;5\M)/68D5VN??XF<AH4S1#]@=J&-OA=;FI%>L9C$EV\$P
M3!Y4EU7[U)YK&:20D*=UKQ,LS(ZXE\I&DY8R0BSLCCZ#2C:;;3MH\/8D?;6F
M4HOEY3W\=7Z5%=OCQA9(L0WL].S_^D)-)VF&^MLI1]OU#+;>L-!:;J3B,E&X
M.,)^%%<?.Z,URSRQ5W]*5V6U$SMR>Q17*7D$YW;]LWFOJ-ZBJX0+C*-A,-/$
MGXL<(,W4MD)CY)@"5.V?GWN&<.$0Z"WMQC4BH9'#B'PMR<26F9Q3^U^R`0.H
MU38PX'SGMN-]U1#D!_+D85$=6>LF=1OA4@G99"XE24APFE1F55R)'K,!7@<O
M);GC%-=#T$9%OBXB9S(*:)$7]5=HXIE"GG_^D5(W<N*?*=.^RI.+M]]Z+NE^
M^[G0^^VA@#%29.RN&-X*_8'7[HH^Y>$-TB=5[)6$(.-`HR1A<:1Q_;ZQ/4,]
MU6GS4A5.9.C7%,X52VC'&EDKVT?Y2VIY71\FKX%XG3-OJR5V;;(!N]F'EH"*
M*(+\V"F+]8*+-C.IQO9W3)6#40ACAG+C)#AF1UUZ$(K7>H7L<EVDH#<B2)=`
M_O#!S]<P8J.]EJ5J^$9A[$'A>+N,P=F*XK9UR\TR53?D+H,AMQ$J='!JQV4T
MR=LR.6.B5L,DZ07Z*6[XQ(**=!<K3%BRC+,5VHB[PQ.M14ELPT1>:?X.L4H.
MTVCJM^W6I`_IYE.R_8KA8/O86(6F;=B^WI@]-<_KZYG6!;_>DH]5]N#HV%I^
M1K?9HD'H1-8W?S']+)/F(0LJ"EJ[*K!62G[[&GAW.%`Q`020N=0*N=!(#SMP
MJC09RV&G!N_IK[QD`#7,4NPM1\.DL[D-##/YMY0<B"SH>!;M2_;MV\W;LBV3
M-&ZK>3'&M=#PA0QHTXZ^;L98I1Q/(5%G8FUUVM%KRCZL:BC`C.C-JJ]SR<MH
MMX49HCZI/O%"SNI%<`(#+$DO!P=!M``86A1\);=13&SXCB"]UC``Y*B,ZA1Z
M3E)%C_B@+?DJQ)'&CT*@K#%_/]'$KO5%/01*EW`S\R$>EV9\)>4V?.3<AE/)
M-R#]`-_X/D4Z81&++;N$#`"-ZMXHZ'+W!`I[J4/R%?!PS;+\:^<F_HM%4>O]
MD[C[([H1]V($;^-+X+!CF[?S#NBS^P?):A!LF8?J#C@ZMF@?"6(L$/(YY!20
M2#NI*B`QE\B\09P(1,"`0.)L#BR&)^T>D7.X=!2^RP#/B.0[MB[`:]3ODC0G
M-!D/!"%Q[\6TQ7>M\>H6@?T&]UCU%OOXJ\._74(P#8<$X#\*.270',&"@W.+
M1TJ=SH_'Q[?_````__\#`%!+`P04``8`"````"$`;@.%C-T.``!0E0``#0``
M`'AL+W-T>6QE<RYX;6SL76UOX[@1_EZ@_T'0MD4/:"*_R'&<BW/8>*-V@>WV
M<)NB!7I%H=ARHJY>7$G>3:[H?^]0KT-+%"F9,E/T&O36EJWAP^>9&0Y)6;K^
M[MGWM"].%+MAL-3'YR-=<X)UN'&#QZ7^YWOK[%+7XL0.-K87!LY2?W%B_;N;
M7_[B.DY>/.?3D^,D&I@(XJ7^E"2[*\.(UT^.;\?GX<X)X)-M&/EV`F^C1R/>
M18Z]B<E)OF=,1J,+P[?=0,\L7/EK$2.^'7W>[\[6H;^S$_?!]=SD);6E:_[Z
MZOUC$$;V@P=0G\>FO2YLIV]JYGUW'85QN$W.P9P1;K?NVJFC7!@+`RS=7`=[
MW_*36%N'^R!9ZI/RD)9]\GZSU"]T+>OR*MP`B-_\:Q\FW_XJ^^?-[]Z\&?WC
MFV__]H.S^?N/OZU_]N,WNE$T@VR"!NTVST>M9N'CS+*1]^#F>AL&J",+H(FP
M=?4Y"+\&%OD,G`&Z1[YV<QW_I'VQ/3@R)O#6H1=&6@(J0__2(X'M.]DW5K;G
M/D0N^=K6]EWO)3L\(0=2Q\B_Y[L@$SEH9"V<MIT'@J;HTR6!0?5I2H[@/OG0
M)9L<;.^3_<^&/E%MS?AM'<,?U5;:B_9^26NK[A<U#H]IJ]0*M1,]/BQURX(<
M,AZ-"*U8L($:6ZQ&T-[)&KN8G:QG4VMJS:7VC/+%NFZDP:DEDTI.@];;^;N3
MT2F_,5;O\C1\J@@@`2>711="MR6^YQ;Y.X6?G'A`&T:Q=*"EDGX:>E5NO'=]
M)]8^.E^U'T+?#@BQ>%!+O]T\)J>`I9JF?%J^^<*KYN?U8?>`E>/*%LJ%A^O'
M&)DN1[]Z./97&#F/3/M89E1L#=7$4#0QNM&<-OJ+@(;*HTVG@1Q#A+N>5\Y:
MIB:IZ^'(S35,H!(G"BQXH^6O[U]V4-4',-<CJ<'(OL?Y]F-DOXPG:9")G1"'
MGKLA*!Y7Z5PB=X75Q9VUNDO;1<A$43",6M9J/H#1N]O%2C[2U6(AV^C$@C_)
M1M_.R)]DHQ;\;R6-TSQV3%D@2WM:XI*Y_^A\OE@L+L<7EY>7"W,Z-LV4Y(?<
MH]U@XSP[9#E`&DUU!#-`L)A>+BXF`&1D7J9-G13!%`#,9[/+V7@Q,>'_:?(:
M'H%L3F>Z:E41`D6J(@2*5$VGGX:$S)]'"JS$*8Y5A$"1J@B!(E7GDC/P7+FJ
M"($B51$"1:JF=;S$6(45;L6QBA`H4A4A4*2JM.(SS\"PK:!8581`D:H(P:E5
M+:95J[L[*UU"JU=F[/HXG<G!W/$AC#:P/5CL>8TO8-Z6';NY]IQM`K/$R'U\
M(O\FX0[^^Q`F"6RFW5QO7/LQ#&P/7AK%&<6_+6?"=B/L+"[UY,E=?X;&J"6G
M#&_6Q%`ME#YKD@K?G)NCN3F;7&23*$E-^\[&W?OUWI5M-_H*T$BXY7<<<1B4
MC>3N4*VH&D2%7#[!,U*I4Z4%3P"?*%Q"\`P9?:QV%T3[B,X0ZR,Z0;"/Z`S1
M/D+H-`57P>0FW,-.]Z'`EG4Y&F4+N:+MM!M$P!L\IAD$.J?.)_>4!D:YYW3M
M*^276FS<3LA?6K$V])1S1KV?G!,:>LDY0[2/M-\4ZE+&R^4$DIX;D!SP37V]
M'PQH*#NQP'.0!//\1%:TLRTFX737W%VN^89><\_IUW7A'B-(T*EN(VB?1HIS
M#M26)45-\H':$>X&G]^\5('*9^UXWB=2B_QU6Y8_L,IW<_V\1=?FP`53Y.(5
M<ND/>0E+Z?G+K-3)W@`/K),FS),T>[?S7C[N_0<GLM*KJ-(FTJ-DR;YZ=YO6
M:-7[MY[[&/A.NDZI9V:^C\+$62?I55[I/A(+SY2!9YP;$L%S3/LFHWW@29B/
M8]J'=;!&$8$7I>V#<PFW+],?R/5LN5.#!-BIV_#(1`"K'04"$$$%`G+]7<X!
MN*<*!#"++!"`@U8(`$Z+5QP3!["-6C8)/E`U">T/U23DF**75),#]I*5?J']
MEEY:5/H]BF:4;\'1*YKA30N`HYIDI5A5*0;)#I%640!O6BBP8-25,^2-63E?
M&2$HZ0*&BA%(`VV,R/-*E'.AS0I`.R.W$NL0Y!0D%:F&`'"40$!"C!6-OV.,
M0=$(C+U!T1",(5!C\`EC`BM!C9"*,``>)5%1U0EC:L0X(0T(@JH,B;QAHBI%
M8@RJ<F0EQ415BD005&5(K(2J%(DQJ,J12`I5*1)!`$:49$BLA*H4B3&HRI&5
M%%-5*1)!4)4AD1+3@5.D@9=-LT54M'XZGI)?%;+6'D&A8OY_*-;SEKN2"EO3
MW-.SZ5,V=00QTLD4FDL3<':Q>*H]A9'[$\PRR4\?U[":ZD0Z^:ELXJ[QD:^1
MO;MWGF$NFNVY/6^/ZB`'4]4^+&7K6I?&I?-S!!8!I3E$<'N>SNJY*_-:X5A9
M<_3J-M=#N"#(ZHYJ#(3K'(-T%Y`4(B1R5=,$HZ1R#%@J@B=?=(;#5!%!^ZP%
MS)'D<VS`H,;)=$)9XV.H%90U/@$>E34NS#ISR#HB)9.YD[*>2]<<)R9R*0<>
MN3N/G!.T2"\E%E\W.NZHAC-%RV;"X&F*+/Y(=5FL2U'Q=6&#%<!D!9MFXS9?
M*I>;MI&?3@_7(>CVZ4'#2G<.N%@P/=R@TLAOH+*1"2Y_,-K*8JSC$+B[2(AC
MG<9"UM_%21Q$8)PF3P(.*YY>WY9>&]>FY<GYJT/L-"O">$^?V[L$B>RRJ$X<
M+T[A-[[-^;:>W^C\(AP,&%.?!#SY>3C"@S-3+TXJ.YU>+(2U`5.10^&AB4H/
MO-'@U5/(G$,<&X/$`9LFKO4D(<Q1EP$<CY&48AR7$N*C^Q@X$(1.8QQ+D1HC
M3`ZX`J"%+BP`KTAI7F^C8YTN3H5]!KMQBVP,X.VRB<!F<BD(C(B6KXGA&H5F
MM*9@&W5"B+*Z'NO-JU$8#'*`BE!(*R\$OT5I1"C;1>43>BRB>MILTUAV>"#2
MAO9"['.\2I0Y+'/T$_*A[B&`69)=@>)T<1PR$JB-`S-\T#:Q%?8IKH*,5`'T
M/:3K(62/;UQ#(Y(JA#%B.KN')@<I'9D#8F+/Q&`11XJ6F"?AF9B(OK4(%9%7
M*&Y;Y&0`H\>H>J85@48/4@-JSAZTZL!I1U0"D0Z5FNHTPB%I0XO$M-X<3#1K
M0AYX7'Y&(\?K!DJB*1](:*#UW$W+3%,J+'K?<84'[G\EO&LCHA16<8;OGCHY
MX2U"K;#^@D@!TK:XT(&U6,I+E4-B0HF(8H^3AYB9AQL6B)#_XQU]E%:ET(Z]
ML27A9S>I$]TJD8*LDT,,28MPP8@]5/;E>YW84'G9QP1=GBG%#["']I*"!6B0
M[-D'(;L6!@+;YC]T!<),K9C!+,9;KJSA+9`A)V?CYNTGT,"%AZDN0<`&)X?4
MOEBDQX2XHNEC+-JO74"5!EUORB&MGR=VPTT1#`]Y:8T@8=?#R%OJ2VB\J6JC
MN>2!4AH=`X'KSM_/`TEZC7[?/'/@<IWB]XBHZ+25AW/T:PQ;"A.'0:6C+P64
MMVXAK*X<U^/P1B<[(1:[YU^*'PZ@#A`Z.3LSG_$RKK!>.,?VJ4/QM)I.'QS*
M>F@H7K7P?XB$]\^&QIWY7B?AV5D.9JUMY;VP\'T#E0J+L2PTV`W%0O7UAP;;
MQ0::ZM1)[.9S:'F.#@GR2[(VIZ-C6=@%!\,K/_7T"6%$)QTT0UQ[V`,@.X*&
M`-AG<,$11%'($7BHX1AGY8,(X2#J&2&=DC3RMY.`ZQ.^C&UH2MQZ;?-J]U)D
MK11TTAFMMW!XHW?)!LW+#&$/'+'&EXBR/6.G[I[<:ZH0LSS@-+72(/(';`;1
MM"?4$K@(ST?X1Q=F.4AI8H4QR8F@&F\]T1SG>\,P5,?$=S9`LBTVE-'P0@&$
M-VVUH;""&%^?8N'G<N8IZ7@_#':^XP2"A'S71V)<?W7Q0:%Z\%A`](C!B0J:
MP)/@DTY8CRD'%I#FB[<`21,FG%0Z#0NL#,>;K@NCP2FN!WNOY@8%!](-GRSZ
MD,7:PN=$9B\Q7WON:+E*A[]4.F'%!8=)9E;K$I32&\<QV$<V)J!!LH0P0G)A
M2E&JD9=-/W.HZ=4\*^BO&[[CE/B=EII1T)4W$U.3G-65*FWTI?=I@SNSH>=<
MT$^Y*._CII&GQR_UR>C7VIGV=DV,EA-9,J(][%T/'O-&?KM![K&WWL?PC*K;
M[&!^4[0V6V7Z)+\OPK9@<;VK+;"0%>.D&L:V((:[VBK7]N&6==@6/`*DLZUR
M`7D*KQ`N$ZYYZXH+3LGZ.*6YGPER;S;IF-X_%ND(71;!A6U5.@)SJ(^DRUUM
M53J"<-@6=+FKK4I'0(ALF=!(5UN5CJ`"M@7NUM56J:,)PB%;,T'N+QIUI'V5
MW.Q1!!>V5>E(^^I4T%>QK4I'VE=)E[OBJG0$JX@O$S[H:JO2D<X3IF">P'VL
M=*2YGPER?YA1:8^?"'I\9J72#EXACDC%*L)19J52C?;RJ:"79U8JO6C_-@7]
M.[-2*07V4(],^$"\1Z5&4YI=4Y#=6WM39%W:8<@X(P)C97OKO6>3YR\5AL@Z
M/^H0F=T(67IRUI^U%3R;JC1$QP,91D4,W3WO/#NPDS!ZT<C]2TMSM.@S07._
M#\.2(]K"!-Z*`/J#8V_<X%$#7O)!G"*(5%1=S)2Q0--#GF;0Q0R<G:&A_8_L
MS74Q`V=G9NBD2NHG$3/O@]V^5(C.I63H%C'QP0T^.QO:<^@L06Z>(V+IH[-/
M(KOT/SJDR`1!R`AYHEEI@TX1Z0/*#FO&C_``LX)$4FFCV"'5OTB;?]HGB$9R
M%C)"[OPH8N3>3>"9F[F:=`P36$(F0KBG<&GB(*,(VOB+'04D6JC0/?!11H^J
M6S1#];]YKIYNE_*>V/!,T?2Y=^5\`(C:.%M[[R7WY8=+O7K]Q_1IMN!,^;>^
M=[^$26IBJ5>O/Y#'!$,4PVX)I)L/,3QZ%O[5]I&[U/]]=SM?O+NS)F>7H]O+
M,W/JS,X6L]MW9S-S=?ONG;4834:K_P!EOA?$5\]C<ZD_)<GNRC#B]9/CV_&Y
M[ZZC,`ZWR?D:GCX<;K?NVC'B701))7YRG,3WC,EHM#`6AF^G#_X$(U>Q!]^*
M\L[FX#]5QY8Z>I/!3^]_!K#ACG9%)XR8/"3P$VGDYK\```#__P,`4$L#!!0`
M!@`(````(0#[8J5ME`8``*<;```3````>&PO=&AE;64O=&AE;64Q+GAM;.Q9
M3V_;-A2_#]AW('1O;2>V&P=UBMBQFZU-&\1NAQYIF9984Z)`TDE]&]KC@`'#
MNF&7`;OM,&PKT`*[=)\F6X>M`_H5]DA*LAC+2](&&];5AT0B?WS_W^,C=?7:
M@XBA0R(DY7';JUVN>HC$/A_3.&A[=X;]2QL>D@K'8\QX3-K>G$COVM;[[UW%
MFRHD$4&P/I:;N.V%2B6;E8KT81C+RSPA,<Q-N(BP@E<15,8"'P'=B%76JM5F
M)<(T]E",(R![>S*A/D%#3=+;RHCW&+S&2NH!GXF!)DV<%08[GM8T0LYEEPET
MB%G;`SYC?C0D#Y2'&)8*)MI>U?R\RM;5"MY,%S&U8FUA7=_\TG7I@O%TS?`4
MP2AG6NO76U=V<OH&P-0RKM?K=7NUG)X!8-\'3:TL19KU_D:MD]$L@.SC,NUN
MM5&MN_@"_?4EF5N=3J?12F6Q1`W(/M:7\!O59GU[S<$;D,4WEO#USG:WVW3P
M!F3QS25\_TJK67?Q!A0R&D^7T-JA_7Y*/8=,.-LMA6\`?*.:PA<HB(8\NC2+
M"8_5JEB+\'TN^@#00(85C9&:)V2"?8CB+HY&@F+-`&\27)BQ0[Y<&M*\D/0%
M353;^S#!D!$+>J^>?__J^5/TZOF3XX?/CA_^=/SHT?'#'RTM9^$NCH/BPI??
M?O;GUQ^C/YY^\_+Q%^5X6<3_^L,GO_S\>3D0,F@AT8LOG_SV[,F+KS[]_;O'
M)?!M@4=%^)!&1*);Y`@=\`AT,X9Q)2<C<;X5PQ!39P4.@78)Z9X*'>"M.69E
MN`YQC7=70/$H`UZ?W7=D'81BIF@)YQMAY`#W.&<=+DH-<$/S*EAX.(N#<N9B
M5L0=8'Q8QKN+8\>UO5D"53,+2L?VW9`X8NXS'"L<D)@HI.?XE)`2[>Y1ZMAU
MC_J"2SY1Z!Y%'4Q+33*D(R>0%HMV:01^F9?I#*YV;+-W%W4X*]-ZAQRZ2$@(
MS$J$'Q+FF/$ZGBD<E9$<XH@5#7X3J[!,R,%<^$5<3RKP=$`81[TQD;)LS6T!
M^A:<?@-#O2IU^QZ;1RY2*#HMHWD3<UY$[O!I-\114H8=T#@L8C^04PA1C/:Y
M*H/O<3=#]#OX`<<KW7V7$L?=IQ>".S1P1%H$B)Z9B1)?7B?<B=_!G$TP,54&
M2KI3J2,:_UW99A3JMN7PKFRWO6W8Q,J29_=$L5Z%^P^6Z!T\B_<)9,7R%O6N
M0K^KT-Y;7Z%7Y?+%U^5%*88JK1L2VVN;SCM:V7A/*&,#-6?DIC2]MX0-:-R'
M0;W.'#I)?A!+0GC4F0P,'%P@L%F#!%<?414.0IQ`WU[S-)%`IJ0#B1(NX;QH
MADMI:SST_LJ>-AOZ'&(KA\1JCX_M\+H>SHX;.1DC56#.M!FC=4W@K,S6KZ1$
M0;?785;30IV96\V(9HJBPRU769O8G,O!Y+EJ,)A;$SH;!/T06+D)QW[-&LX[
MF)&QMKOU4>86XX6+=)$,\9BD/M)Z+_NH9IR4Q<J2(EH/&PSZ['B*U0K<6IKL
M&W`[BY.*[.HKV&7>>Q,O91&\\!)0.YF.+"XF)XO14=MK-=8:'O)QTO8F<%2&
MQR@!KTO=3&(6P'V3KX0-^U.3V63YPINM3#$W"6IP^V'MOJ2P4P<2(=4.EJ$-
M#3.5A@"+-2<K_UH#S'I1"I14H[-)L;X!P?"O20%V=%U+)A/BJZ*S"R/:=O8U
M+:5\IH@8A.,C-&(S<8#!_3I409\QE7#C82J"?H'K.6UM,^46YS3IBI=B!F?'
M,4M"G)9;G:)9)ENX*4BY#.:M(![H5BJ[4>[\JIB4OR!5BF'\/U-%[R=P!;$^
MUA[PX7988*0SI>UQH4(.52@)J=\7T#B8V@'1`E>\,`U!!7?4YK\@A_J_S3E+
MPZ0UG"35`0V0H+`?J5`0L@]ER43?*<1JZ=YE2;*4D(FH@K@RL6*/R"%A0UT#
MFWIO]U`(H6ZJ25H&#.YD_+GO:0:-`MWD%//-J63YWFMSX)_N?&PR@U)N'38-
M36;_7,2\/5CLJG:]69[MO45%],2BS:IG60',"EM!*TW[UQ3AG%NMK5A+&J\U
M,N'`B\L:PV#>$"5PD83T']C_J/"9_>"A-]0A/X#:BN#[A28&80-1?<DV'D@7
M2#LX@L;)#MI@TJ2L:=/625LMVZPON-/-^9XPMI;L+/X^I['SYLQEY^3B11H[
MM;!C:SNVTM3@V9,I"D.3["!C'&.^E!4_9O'1?7#T#GPVF#$E33#!IRJ!H8<>
MF#R`Y+<<S=*MOP```/__`P!02P,$%``&``@````A`*^68;A5`@``@`4``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,SDN>&ULC%3;CMHP$'VOU'^P_+YQ`@DL
M$6&U"-&NU$I5U<NS<1QB$<>1;2[[]QW;D'+9;GDA,3ES+C.33)\.LD$[KHU0
M;8&3*,:(MTR5HET7^.>/Y<,C1L;2MJ2-:GF!7[G!3[./'Z9[I3>FYMPB8&A-
M@6MKNYP0PVHNJ8E4QUMX4BDMJ86C7A/3:4Y+7R0;,HCC$9%4M#@PY/H>#E55
M@O&%8EO)6QM(-&^H!?^F%ITYL4EV#YVD>K/M'IB2'5"L1"/LJR?%2++\9=TJ
M35<-Y#XD*64G;G^XH9>":65492.@(\'H;>8)F1!@FDU+`0E<VY'F58&?DWR>
M83*;^O[\$GQOSNZ1J=7^DQ;E%]%R:#:,R0U@I=3&05]*]Q<4DYOJI1_`-XU*
M7M%M8[^K_6<NUK6%:6<0R.7*R]<%-PP:"C31P-M@J@$#\(ND<)L!#:$'?]V+
MTM8%'HZB;!P/$X"C%3=V*1PE1FQKK)*_`RAQIGJ2P9$$KD>2)(O2039^O(.%
M!$<^X():.IMJM4>P-*!I.NI6,,F!V24;07_>3@9N7,VS*_*E@#8PC=TL&TVF
M9`<M9$?,_!:3#M(>0T"^]P"ZYQ[>UW;@*^UQW/-Z?_.W,$F/N=`>7FJ[_.D_
M)WO*[XH*#"I_\X\'/7_P$#"IWZOSL.FEX/MA'1B6Y4QH.!E="07,K1"D..^J
M2S;\[V1=T76RX95@P$S\W,=1UC\-?0TO4=BQCJ[Y5ZK7HC6HX14XB*,QE.OP
M"H6#59V?YTI96'U_6\.7CL.BQ1&`*Z7LZ>!>TO[;.?L#``#__P,`4$L#!!0`
M!@`(````(0!!N@@U.P,``-T)```9````>&PO=V]R:W-H965T<R]S:&5E=#,X
M+GAM;)1676^;,!1]G[3_@/Q>P!!(B$*J=E6W29LT3?MX=L`$JX"1[33MO]^]
MF#!"FBC-0Q+PX9Q[[KWV977[4E?.,U=:R"8EU/6)PYM,YJ+9IN3WK\>;!7&T
M84W.*MGPE+QR36[7'S^L]E(]Z9)SXP!#HU-2&M,N/4]G):^9=F7+&U@II*J9
M@4NU]72K.,N[A^K*"WP_]FHF&F(9ENH:#ED4(N,/,MO5O#&61/&*&8A?EZ+5
M![8ZNX:N9NIIU]YDLFZ!8B,J85X[4N+4V?+KMI&*;2KP_4)G+#MP=Q<G]+7(
ME-2R,"[0>3;04\^)EWC`M%[E`AQ@VAW%BY3<T>4]G1%OO>H2]$?PO1[]=W0I
M]Y^5R+^)AD.VH4Y8@8V43PC]FN,M>-@[>?JQJ\`/Y>2\8+O*_)3[+UQL2P/E
MCL`1&EOFKP]<9Y!1H'&#")DR64$`\.W4`EL#,L)>NM^]R$V9DC!VH[D?4H`[
M&Z[-HT!*XF0[;63]UX)H3V5)@IX$?GL2&KFS()HOKF#Q;$2=P0=FV'JEY-Z!
MK@%-W3+L0;H$YH,S&\?@]9Q5\(@D=\B2DCEQP(6&^CROHSA<><^0TZS'W%L,
M?`\8.B`\B&8("<(8A_1VD@_*"$9E3#J&<F]OC&6"MV7"]\@@&*HV"CY<_.>U
MRA;3M>&1G]E[A!"<$C`Q9"F*9X,!*V0QBR[/H8^?`7`D#+TU3B36-H3>OYQ0
M?.C8:11'`[\-P&).G<;'@I>%$(Q.L5L"GTXU['+<+5.?QF==0M>-75X61?!(
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MO@O@0DISN,`7@.'%;/T/``#__P,`4$L#!!0`!@`(````(0`K!A8^30,``!\*
M```9````>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;)1676^;,!1]G[3_@/S>
M``F0#X543:INDS9IFO;Q[(`)5@$CVVG:?[]K.U`;UC1[:8,Y/C[WW,N]7M\^
MUY7W1+B@K$E1.`F01YJ,Y;0YI.C7SX>;!?*$Q$V.*]:0%+T0@6XW'S^L3XP_
MBI(0Z0%#(U)42MFN?%]D):FQF+"6-/"F8+S&$A[YP1<M)SC7F^K*GP9!XM>8
M-L@PK/@U'*PH:$;N67:L22,-"2<5EJ!?E+05'5N=74-78_YX;&\R5K=`L:<5
ME2^:%'EUMOIR:!C'^PKB?@XCG'7<^F%$7].,,\$*.0$ZWP@=Q[STESXP;=8Y
MA0B4[1XG18KNPM4NG")_L]8&_:;D)*S?GBC9Z1.G^5?:$'`;\J0RL&?L44&_
MY&H)-ONCW0\Z`]^YEY,"'ROY@YT^$WHH):0[AHA48*O\Y9Z(#!P%FLDT5DP9
MJT``_/5JJDH#','/^O^)YK),T2R9Q/-@%@+<VQ,A'ZBB1%YV%)+5?PPH/%,9
MDNF99`;JS^^GUY+X1I".[QY+O%ES=O*@:.!(T6)5@N$*B+O`C(P^U+<BA1`5
MR9UB2=$<>1"$@/0\;>)XL?:?P-+LC-F.,:&+V'4(E0F0UVN$P&V-_S:]DZ+`
M2HI*@M*V-0O`W6N;#LX=(^)7B*,$'+*5*+>B-\N@4Z0V0<(M`7&\="5L#2;J
M5>^L!4=!Y"JX[(4"IPC"ZT-?##S?&LA"YVPYCQ9!$+C2=C9B-@]B&^%(`R-L
M<RY+4V!76IP,3MX:3**US8,$#AZ),Q#MFZ,E<;5<ERBU::AIZ)?!@">]I7'R
M6BRZXG8=9EC'\'U<;Y`"#\0,B\9`K**Q%APWU!@:?.3OEZW:]%[9&HREP%IP
M%"Q=!9=K0X'=T$=E:R"F-*(DF8\KPT:$RRBR$8ZT$*:![<YE;1KMBAO5[1EC
MV6*ON(>KGO??J0E-I[S<4LX@6X79IE=<%:H#6BK>L<#TRXMM!8:QRJ'I*W&P
M"&W[S5?B0,)YXD",/#./S;RJ"3^0':DJX67LJ&;M%!I#O]K?`^[T-6"POE7W
M`]5<_?X%C.<6'\@WS`^T$5Y%"J`,)G/H*-P,>/,@6:NGY)Y)&,SZ9PD7,0*C
M)9@`N&!,=@_J@/YJM_D+``#__P,`4$L#!!0`!@`(````(0`)W&EX`0,``&L(
M```9````>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;)1676^;,!1]G[3_8/%>
M#`XD*4I2-:!NE39IFO;Q[(`)5@$CVVG:?[]K'`B0JDM?8K@<'\X]]_J2U=U+
M5:)G)A47]=KQ7<]!K$Y%QNO]VOG]Z^%FZ2"E:9W14M1L[;PRY=QM/G]:'85\
M4@5C&@%#K=9.H7438:S2@E54N:)A-3S)A:RHAENYQZJ1C&;MIJK$Q//FN**\
M=BQ#)*_A$'G.4Y:(]%"Q6EL2R4JJ0;\J>*,ZMBJ]AJZB\NG0W*2B:H!BQTNN
M7UM2!U5I]+BOA:2[$O)^\0.:=MSMS05]Q5,IE,BU"W38"KW,^1;?8F#:K#(.
M&1C;D63YVKGWHV3AX,VJ]></9T<UN$:J$,<ODF??>,W`;"B3*<!.B"<#?<Q,
M"#;CB]T/;0%^2)2QG!Y*_5,<OS*^+S14.X2$3%Y1]IHPE8*A0..2T#"EH@0!
M\(LJ;CH##*$O[7KDF2[6SFSNA@MOY@,<[9C2#]Q0.B@]*"VJOQ;DGZ@L"3F1
MP'HB\4,W(.%B^1&6V8D%UHZ%?%A*<"*!]4Q"EJ$?SO^?$+;FM%XG5-/-2HHC
M@OZ%]%5#S6GP(V!^VUQPU6#O#;C=`KXI:(CG34!F*_P,54Q/F.U;F&",B3N,
M*9HA3@8!#,)Z=6#[4)UI@1DTTOLJS::Q2N*/!6PO(5#3,2:VF(6#^F3)&)&\
M@3A#1GE`X8=YO*_?@(W^SIUM%S@K"<A\K"6VF/8X6DL'@9$4*/+U4@P8+!]X
MX'O3@EM,T,N-IX%D$!A)@6-XO10#7CM@>5^.@"S&)FPM!EXWP"S'F+C#=.XF
M@\!(W7RL[KK>,YNF*F_'"K86$[3G9S;IS+A[V,L;!$;RH#&O-\^`)[(F+]Y:
MR*",-K!L9=X$<R^83WH.AK]A[1"$A.&9U&JUP]T.G(K)/8M962J4BH,9W`2X
M^ZC]IL0D@E:&Y"?QA$1)&\?]`YCU#=VS[U3N>:U0R7*@]-P%U%/:KX6]T:)I
MI\%.:)CR[64!'W4&<\=S`9P+H;L;>#'N_R9L_@$``/__`P!02P,$%``&``@`
M```A``!3TC]U`P``=`L``!D```!X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
ME%9=;YLP%'V?M/^`>&^(@:1)%%(UJ;I-VJ1IVL>S`R98!8QLIVG__:YM0FS2
MDO0E!'/NX?C<Z\M=WKU4I?=,N*"L3GPT&OL>J5.6T7J7^']^/][,?$](7&>X
M9#5)_%<B_+O5YT_+`^-/HB!$>L!0B\0OI&P602#2@E18C%A#:GB2,UYA";=\
M%XB&$YSIH*H,PO%X&E28UKYA6/!K.%B>TY0\L'1?D5H:$DY*+$&_*&@CCFQ5
M>@U=A?G3OKE)6=4`Q9:65+YJ4M^KTL6W7<TXWI:P[Q<4X_3(K6_.Z"N:<B98
M+D=`%QBAYWN>!_,`F%;+C,(.E.T>)WGBWZ/%!L5^L%IJ@_Y2<A#6?T\4[/"%
MT^P[K0FX#7E2&=@R]J2@WS*U!,'!6?2CSL!/[F4DQ_M2_F*'KX3N"@GIGL".
MU,86V>L#$2DX"C2C<**84E:"`/CU*JI*`QS!+_IZH)DL$C^:CB:WXP@!W-L2
M(1^IHO2]="\DJ_X9$&JI#$G8DL"U)4'AATFBE@2N)Y)P-D&3Z64I@=F6=ND!
M2[Q:<G;PH/1`N&BP*F2T`&9E3P0FOVT/^*)B[E60#@6T@)P^K^)HO`R>(0]I
MBUD;S*WO=9C016S>0)P@`>CK1()O'Q>I@ER1(7(5K`WD5N=*;6QC+3@"P)F^
M@/C=(CJZI(+`3<N!..HK,!A=_]K:C;7@*(A=!</Y4>#$A\V<O)_TMFX@,YV\
M,(ZF\<EZ(\0!3"?Q/.H8'&%@@VW-L#`%=H7%4>_%:X.Q++$6G#=/W3>KTKV<
M%!5T*2D&8RFP%AP%4-W7[UV!W;V'_:08R/3]I#B`@:2HKY=UJH>3HL"NL#@Z
M)5M7P]I@8J,LG'>E8&K%?HIFL^ZI8];<U71=IU%!?6UQQV^T&8R5+FO!48"@
ML=FV7%<Q.NI2R;0@2X2]XJKHM=SAY"#3)0?/<HL9J!L7,5`X2'5`JW*NRY*.
MZJ>I7]PMR+;(M%N]XEJDNF!/Q>6CC4SOA-^N[9TWW!9DJWBOY<)8XJBXD*CS
MIGM^C#1EXK=M]^P<.8_/#Y(9<LSGNR)\1S:D+(67LKT:8$(XG-VJ&:[6:`'?
M.!AJ>NL;&+KT>M`]@)FGP3OR`_,=K857DAPHQZ-;:+[<3$WF1K)&?U2W3,*T
MH_\6,-T2^'J.1P#.&9/'&S67=?/RZC\```#__P,`4$L#!!0`!@`(````(0#2
M8A%5K@\``*)+```9````>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;*R<2V\C
M.0Z`[POL?S!\']OU\J.09!#7V^4"%HO9W;/;<1*CDSBPW=TS_WZH$E4EDNHD
MSO:EW?E$4A)%293*Y:O?_WQ^&GS?'4_[P\OUT!M-AH/=R_9PMW]YN![^YX_\
MM_EP<#IO7NXV3X>7W?7PK]UI^/O-/_]Q]>-P_'IZW.W.`[#P<KH>/I[/K_%X
M?-H^[IXWI]'A=?<")?>'X_/F#'\>'\:GU^-N<]<J/3^-_<ED.G[>[%^&VD)\
M_(B-P_W]?KM+#]MOS[N7LS9RW#UMSM#^T^/^]62L/6\_8NYY<_SZ[?6W[>'Y
M%4Q\V3_MSW^U1H>#YVU</;P<CILO3]#O/[UPLS6VVS^$^>?]]G@X'>[/(S`W
MU@V5?5Z,%V.P='-UMX<>*+</CKO[Z^&M%S=1,!S?7+4.^N]^]^-D_7]P>CS\
M*([[N_7^90?>AG%2(_#E</BJ1*L[A4!Y++3S=@3^=1S<[>XWWY[._S[\*'?[
MA\<S#'<$/5(=B^_^2G>G+7@4S(S\2%G:'IZ@`?#OX'FO0@,\LOGS>NA#Q?N[
M\^/U,)B.HMDD\$!\\&5W.N=[97(XV'X[G0_/_]-"'IK21D(T`I]HQ`M&7CB9
M7F`#:FL;`I]H(QKY\\B++C$R12/PB4:@7V\T?(;R\(GR5N??T(/9TS86/C_?
MV`4:@4\TLAB%?C2;7^)ZSPR@^@^:\4;S*`JG\QGX\HU.>.";MA?J/Z@*CI`:
M8QTS;0BFF_/FYNIX^#&`>0U5GEXW:I7P8B\8#DSP:1-=./XL&B$,E95;9>9Z
M"%5#H)U@"GV_";WIU?@[A/T69992QJ,2B9%0,:[,IAQD'.0<%!R4'%0<K#BH
M.5AST%A@#)[LW`G#\"O<J<PH=QI'+`WH_>LSWQD)HY)RD'&0<U!P4')0<;#B
MH.9@S4%C`>([B#[B._?Z9R).2<-*9T5<X`74)TN4671^3`1)!<D$R04I!"D%
MJ019"5(+LA:DL0EQ&*S5%SA,2<,LAP]KCLZ8Q[30-.P]IDF@=XMV4FHR@V'L
M#`7^A!K*A%JNR9RJL2@N.B$3QJ4P5&G"ZF>&5D*M[DS;S9[39J\[(5-_8QLB
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M[3%-;(\AL:)1R.1"IA"D%%J5D%D)F5H3C^S`0<!6\W4O92*]L4T1GWEPUKS`
M::TX]1HBVVV(;+\913@@F$9E4BQWB!4.5DK5RB&VDF(U(K)6!`%;*]:]E&EM
M0VQ1'ZI4_B<S^.T85,<U%H2(9I`T]#,G8!MF@E)^[\T44:C6A.\W01CX"[X$
M9E(M-_7!$M_5YT4LJ2F,\;`U[K.-II1V*T0+OQOOE92JC=2\DUI+U!!%ZGIU
M$OB<Z_49`J:2&>&E.@'#:,QM5P0!VYT3E()P,(HIHM!KO>.%T32*V*::2;7<
M(#N?=;A>M\J?M\8CN,5CP5H:.WV+J@[U2_NJ8UW#:X/@KLAT9NU@C6'Z%LH^
MK:H#_R<'0!]*R`!HQ&*?!5O25@EW57;L:\603AJV;V>H.+/'UYLS;^9.*3DA
MNAK5;//\T9S55LIF5HC(G-!VK,[41LJ>$UIJT:.&F*=S0ITW/C<G]$F%#(E&
M;$ZPC3Q1&Y):Q_H(3!%!V/;K2A"P=24SBF0*R"%!\T1*#HF6PHD2SD81&]K2
MU-8WL^J0/5%$;VHC1B8*BEFL,7*.B:*.)F)4X*(1_//A+$_=Z?+]0B,V9]A)
M*4%%*\Q21*%J@+EQ"T*Q;*'Y=^8,MFORS@AI,:BRW:+F\U'$-K92-K0RG9[T
M$WXEQ6I$UAQ92]0013IMH(O__P`I(RP_THC.H)#E;(F'BGUHIAW2FVXX]6=S
MG@ADG5"W@.<=LD?6L:_H&F<+/1C!2"Q@HDE59QJ*K*!A\VS5B76-J@UZ,T#6
M*-5MI)-@P2*Y,88<,TR=L/@,\Z?JB<<E4TR?TV`BFQUQZ6E$IUC((C=!*3+%
MT-9DUOHXA#QSYC,W9U(O1S2'W+SSLF,`M?6YSCH"?S1CJ4HI35>(O`E9ET,Q
M@MJVU9D:->GNR1?A-4IA%NI!CWENW9!6T2FHCG9\!+VH/0J_DTCK0R$9-8W8
MO&,N2CQ4M.>=07IF>),`!HTY*)-ZN4'JH/#6L*%Y2&K;57`R6K!=L326^D95
M!JE,K#,>A"PW6AFQ7K,VR%84P;1&*9QY8>0%;(]OC!W'Q%.GR\\-&QY5[<FF
M$3E."I1Z`F42Y1(5$I4251*M)*HE6DO4$$3"W;_L[-V*T[T%T:Q/7A*)4HDR
MB7*)"HE*B2J)5A+5$JTE:@BBSOKT(1NNMW!/[F=.Z+$YMT0I.^XD2B7*),HE
M*B0J):HD6DE42[26J"&(NA*6`C)?WUY;?27.XDXCXBR-[#L?5*2WJ2%;5S*4
MTHJTG>K48Z\K[[13'Y+L/0#V+]5TTDZ-2#LU8NUD`9*A+5<[U4'`;J=^`G[A
M#:Z/QPEK+41$FJ^E2/,UHG>M(<N;,K3E:K[*RG_2_'<\KO-YXG&-:*[$+T,2
ME9+!N%CI18K(4_E=O\%%+$_.B":-%I6N?JX;F.C:GM>()@_\/)GXJ-COMJE!
M*LFQNL&2Q<R(R<W45YG7Y[JA<S8R&AJQT>`Y4%LE&PVTI39]JQLLW<B()AT-
ME>5\KAN8']FCH1&9!P*EZJJ!3O9,HERB0J)2HDJBE42U1&N)&H*HWU1B8_OM
MG1FH\R`RYAJ1G$"@U!<HDRB7J)"HE*B2:"51+=%:HH8@XJR`)U#6PONVWUK-
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M.&DOK6;>/)R(Y5E79VGEICH8U&Y=%W=/A:E./Q;P)B/^W+HT$NT3`.H=E?39
ML_KC*8!.%\D$UXAF_>(!<("*]OZ%BI!4]?V4^Y=0S(TM=4GT<\W"$NLCQK9&
M?:)RN\_Y1&>%Q"<:L8AAA_@DT%+6V*>(Z#/9*9L*&4K16V7Q`-`IQ>^>B[[&
M]IGL9!2QA*Y$"=U,XC,(;(?/+LQ_6B/TI@01"RGN/J-HA12B"):=+C""*>M0
M9A0AX^BDY"-MIY1P'TK!V03=QX>A-';:9E+W_8KT$2Z?>?J(B$;?C*T\"4K9
MT8=HJM>K8!HNN%8FM7)3G>UTN5ZA%$2V<13;V$IBFCJ*)YSM>M7'V1^'5PB@
M]]Z5"&4>BLC>Q21*)<HDRB4J)"HEJB1:251+M):H(8CZ\++L%9Y%B;#2R#XC
MHY2%4HDRB7*)"HE*B2J)5A+5$JTE:@BBSE()XZ<V`[5R0R(+FT&_MH3\6_I+
ME")QIQ4ME$JI3*)<HD*B4J)*HI5$M41KB1J"J"M5;FJ[\NT,6WVS0OO/[-E+
M1)9G$D16$IDBHLDSSXFR7LJ8SR4J)"HEJA#I1M`^J[37[K.57WT\ZPYU\FSG
M%8B(*[04<85&))_VYV(7[*1Z5PA48(U@RTB5$E6(7*YP)N+]TOVA[VF',B<W
MJ-_\$T3V%0FBA4Z2_8G']IRL%S#=RZ69HI=2>Q>886?.LA<P9BIBAD:'RD%_
M$AWO3`[,7OMCY#+4"&HS-2>([.^5&60?Q!PL-ZSW:F&0I5HZ6&68(\WY=&8=
MRLP:$<MMV!U'@E(DM\&4'$*\3_IX.I>AHEK..JF`?T4DE^8+TZXWS9=N\RPH
M*V*>A$[T*Q+NU@A-N!'1A'O&3[A&L8^.%-$44@/+7RQ3SWHI$Z2YM%7T4K8M
M=O8I>RECJR*VJ+]^188=R0P;$8U"CV?8*&5'H;&E'MEW#A/)<H9B4ZBYDPIF
M;`7/I?WB8_9+I_TY:W]%[%.__I*$/)().2)[@Y,HE2B3*)>HD*B4J))H)5$M
MT5JBAB#JP\L2<O@E!)X8(;*R[T2B5*),HERB0J)2HDJBE42U1&N)U*\]J#[J
M#FEGZ5]OT*_./^^.#[MD]_1T&FP/W]0O,\`-R,U5A_%G(\(PO@5+L#RP$DB[
M8Y6I.DHB'WYKHGWK@NM$@?D5"E9RZWOQ+3QF<UB#$O5-$E?)'$K:+Z0S:TM_
M`24N:[?!)+Z%HXK#&I2HIU..DA#Z`V=!5PGTQVD-?F[CUJD!G7'W!1KLJ@$J
M<+7V%H9%YV:\ZQYT'>[R'(WUH8-.'4B^8Y5U2ITTG,4JK9,ED,;%*E.3)6DX
M!QW7L$#Z`SJN$MCZ8K6Q26NPD<5JFY(E\`0C5L\G7"41E+0OE##OP.TXE+AZ
M"H^J8G4%[K(V!QU7J^$P%2^=?H,S59PX2^!H!3YPM2T-IU#B:@%\L3Q6WR27
M;5OZ?KR$[]7(D@1*$F<)?-TI5M_%D3KP$!1ZZ@Q/\,[2Z9T$2A)G208EZ@&%
MK`>>*$(]KG"'IVY0X@IX>&L.?."*@T8%O*L`7NT"%5=WX*TC*'$U`%Y]@1)W
M`T(H<;FM@870&1Z+>.EL6+*($V=!NHA39T&VB-6[B@Y7+F+U=J(L*!>Q>D51
M%E2+6+VH*`M6BUB]K2@+ZD4,+W1*7H8QO'8K^2J,X;U:R6MPH,M_-42W*[CK
M:0PO@COLS&)XN=G!YS&\JROY,HR7+IZ$<>+B61C#2\C23@[KC:O].:PVKO;G
ML-:XVI_/8G@3W&$?UIFVWG&W:L$O)+UN'G;-YOBP?SD-GG;WL$_#TRFXUSGJ
MWUC2?YSQSO;+X0R_C=1>WS[";V'MX.=GX!G$<'!_.)S-'U#QN/MUK9N_`0``
M__\#`%!+`P04``8`"````"$`'-81;B@$``"2#0``&0```'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6RL5UN/JS80?J_4_X!X/^$6"$%)CA(N[9%:J:K.:9]9
M<!*T@"-,-KO_OF.,'5_2GNVV+^OE8^;S?#.#/=E\?NU:ZP4-I,']UO86KFVA
MOL)UTY^V]K>OQ:?8MLA8]G79XAYM[3=$[,^['W_8W/#P3,X(C18P]&1KG\?Q
MDC@.J<ZH*\D"7U`/;XYXZ,H1'H>30RX#*NO)J6L=WW4CIRN;WF8,R?`>#GP\
M-A7*<'7M4#\RD@&UY0CQDW-S(9RMJ]Y#UY7#\_7RJ<+=!2B>FK89WR92V^JJ
MY,NIQT/YU(+N5V]95IQ[>C#HNZ8:,,''<0%T#@O4U+QVU@XP[39U`PIHVJT!
M';?VWDL*S[.=W69*T!\-NA'I?XN<\>VGH:E_:7H$V88ZT0H\8?Q,3;_4%`)G
MQ_`NI@K\-E@U.I;7=OP=WWY&S>D\0KE#4$2%)?5;AD@%&06:A1]2I@JW$`#\
MM;J&M@9DI'R=UEM3C^>M'42+<.4&'IA;3XB,14,I;:NZDA%W?S*C29$@\6<2
M6&>2<+'RW'6P>C_'<N:`=>;P%G$8+J/X7Y#`=I,:6$4@?AQZ8?1]-0[+S)3H
MK!S+W6;`-PNZ%[232TF_!2^);(MGF.5#Y/SO4@ZYIB1[RK*U5[8%V230)R^[
MI>]MG!>H;37;'$P;S2+E%K20E#;3@5P'"@EP0)&0!<7Z'V11%BJ+!W3@P%VG
MKZI,N05WR70@UX%"`A0-@:KA<=/S"E!C:&^I`D&LQ7:8;=9"3VH@F8'D!E+(
MB!(QM+>9]05M\7\.GOI!`\(B]8\>/3-:+:?V\ETOU#+/WON!4)?-'M#6@M8+
M8]4M9T9+6(11$$>J42%S*XI!VH<44[]),>^3`T/BB,O30DAGC^G`9%\'0P+Y
MJPOBE1IY+HSX1H5,I&B!/'U("_53M3#D7BHMJ)2]ETO%D!@N;JD*>JF$D=`B
M$RE:("D?TD+]5"T,N==%"RJ=/:2Z,$2KRUJKBS`26F0B10N=9O0C&JXQ2-6Y
MJ9X/&#(&Q^"#+RR`7F+G,Z5093'D7B(MOI2]ETO$D)#NRP_Y8.UJLH21D"43
M*;+6_UT6I5!E,61Y/[+3V4:J#T=D)>:YP*Q6L$ARM1NKX%3TS%'$>3#K&$6#
MN0'V?%`HN+]YI29'5=,,14MQLJ4FE)E0;D*%`JD1TZM4:K/OA,DN7CBR>:$/
M,`C2:JS8]$3O[]2$,A/*38@.E7<N%B8;$MGLTJ'AA%+4ML2J\)4.@."PVPB8
M3:<0$1]/M3=9F,#!")'K>)3DT2-\E>132^GV<9+'#^QA+M[[#_`##>@1[B<P
M!9CQ'(($+EL3WR^3/2@V7QP\%W9@0[6(%2;B2WE"OY;#J>F)U:(C),R=>G%@
M,S5[&/$%$@ES,1YA%I[^/<-O'P25=.EQ<\1XY`^PM2-^3>W^`@``__\#`%!+
M`P04``8`"````"$`3I*QF7\&``#2&0``&0```'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6RL65N/XC84?J_4_X#ROD`"@1`-K`9RE5JIJK;M<R:$(1H@*,E<
M]M_W<QPGMD^&LJN^K)?/YWSVN?CXQ//P]>-\&KUE9947E[5ACJ?&*+NDQ3Z_
M/*^-O[X%7QQC5-7)99^<BDNV-KYGE?%U\^LO#^]%^5(=LZP>@>%2K8UC75_=
MR:1*C]DYJ<;%-;M@YE"4YZ3&S_)Y4EW++-DW2N?3Q)I.%Y-SDE\,SN"6]W`4
MAT.>9EZ1OIZS2\U)RNR4U-A_=<ROE6`[I_?0G9/RY?7Z)2W.5U`\Y:>\_MZ0
M&J-SZL;/EZ),GDZP^\.<)ZG@;GX0^G.>ED55'.HQZ"9\H]3FU60U`=/F89_#
M`N;V49D=UL:CZ<:F8TPV#XV#_LZS]TKZ_Z@Z%N]AF>]_RR\9O(TXL0@\%<4+
M$XWW#(+RA&@'303^*$?[[)"\GNH_B_<HRY^/-<)MPR)FF+O_[F55"H^"9FS9
MC"DM3M@`_AV=<Y8:\$CRL38L+)SOZ^/:F"W&]G(Z,R$^>LJJ.L@9I3%*7ZNZ
M./_#A<R6BI/,6A*,+<FJY[BA-V_U,+9ZYMBQ[?G"66+Q&XJ8;7:-L55<C.>6
MO72:7=]07+2*&']HI\M6#V.K9]VW(,Y9LU.,K:(SMAS;M!?,OS=VNFH5,=ZS
MTPF/:Y,F7E(GFX>R>!_A["%RU35A)]ETP27R@Z_<9<QG"8-,822/C&5MP'KD
M0H4L?]O,9@^3-R1FVHILJ8BI2NR$!,M"QNKI@*\#@0Z$.A#I0"P!$_B@<P0R
M_']P!&-ACA`V;`70>\;2S!820L73`5\'`AT(=2#2@5@"%+-Q)G6S9Z@RP_5!
MA)LIH1+<"G<KLNH\L2.(1Q"?(`%!0H)$!(EE1#$7I40WU[3'K)S<MICIX8A@
M^#S#N<QBWIM,$(\@/D$"@H0$B0@2RXAB,FR33;YM)Q-N[!39N.7(`D-GN36?
M:SG<"0DUCR`^00*"A`2)"!++B&(HBK9L*"]E=\26Z:DV<T2.)$$\@O@$"0@2
M$B0B2"PCBH&HK[*!MR/)A%6K.+(`O11)6XMD)]1%DB`^00*"A`2)"!++B&(H
MZS[)I71'))F>:C-'Y$@2Q".(3Y"`("%!(H+$,J(8B)M6-O!V))FP:A5'9*LX
M,N-]5W-Y<L1!W9>BO5"C[7="(MH!(0H[&9EHJ1)%G9`@BF4BQ783UXMLO'1.
MZV.>OFP+;!BW](!39F@MVH:#D:A.:7C7ANR5%I+=TD(.HWK;6%-3.P!^+R!,
M"2A-V$NU-%I%C'H!01,K-*I+6%.B);QECU'I!IR`QK#S`F]F<"V)1;9FV]_@
M.I#B[JCAVK52UJQ3](0B%NT435M3](6B+&7-5RI](*1Z^O`N^D@H*O3V5*6/
MA51#KSJ2M3F:(^^ZWTW>'RF>Y)"CU$N;-*VM8O,9UK:M')JAO'6>M&RM[?/;
M%2$E8A>(3?1<82\E<VF]==1+":Y8X5)]Q)JCG_(1[ZH4'W%HJ62;K9V%G<FE
ME&SCD(,**?F(G,5.2M@54*ZPA30NK=1%O93@BA4NU4>LF_HI'_$V3/$1A[0\
MT@KH#AI-0>MC[[60ED?D1')%)8\(5SC,I9W;J)?J?21SJ3["(24^PN,`(GI_
M&6<<6AGGD)I2"ZT$[-@;!A25E.*0C:%/J85V7OU6$5+"Q(!RA;V4S*4=X:B7
M$ERQPJ6ZB[5U>DK]J+MX:X@PB06W)H?F?1G9M1"N&R'EM9`CEZ2!XLZY;%PA
MD@>U8A-0^O`N^JB5TNBU8A$K]*H'6;_XN0>_%=?/^@;YRN1-I^)"#BF-`X$\
MDT`^A0(*A12**!0KD&HVZR(EL_^C)>`]IV(?AY9]<[C#DR,[/A+D4<BG4$"A
MD$(1A=@C9[\BMX\_6O+7J'-6/F>[['2J1FGQRAXD+0=M3@?SU]+MTL5'`[):
MQQT7O?8`;D(!GAV:@0KV1&<\TW99E:`SJ`HN._-T!J^XC]8`OF6ONT.XY>)!
MAO)L9RZ>+BC^.'<?!S>[G;OX\*<*6]O%=_(`OG#Q>4GQ>(6--O5"\ZQG6O#&
MT%[1FL`;0S.>.8/.D!VXJJ$S-(/+#CI#IN#J@L[0S';E;@<WO5NYN\$);^7B
MDX>:[YE3K#YD?[!R6?M/5<*5BX^>`1Q4K/G'S*3S)5[4K\ES]GM2/N>7:G3*
M#DCP:?-!6_(W>?ZC;DO84U'C+;VI9D?\[23#8^B47:R'HJC%#[9`]]>8S;\`
M``#__P,`4$L#!!0`!@`(````(0`"[$.9T`@``%$G```9````>&PO=V]R:W-H
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MN6F;Y^X&<A/>47K-=Y.["90>[W=[7`&S?72NGQ_&7[RP\H/QY/&^-^A_^_JC
MU?X_:E^;C_2\WU7[4PVW<9_8'7AJFJ\L--\QA,H34COI[\!_SJ-=_;QY/W3_
M;3ZR>O_RVN%VW^**V(6%NQ]1W6[A*&1N_%NFM&T.Z`#^'1WW+#7@R.;[P]A'
MP_M=]_HP#N8WMXMIX"%\]%2W7;)GDN/1]KWMFN/_>9`GI+A(($3P*T3\V8TW
MF\Z9QH5Z,U$/OZ+>[&;A3>^"Q>5Z*.T[C5]1S[O<P;FH@%_9T,6.+40\?F7\
M51W#J.H[AM_K.G8G*N!7-G2Q8QX2I&^!_4?6N*IKS"%>$_^YKG,>DH)74=F!
M6T5OZ(0G59^CT:;;/-Z?FX\1!CZ::M\V;!KQ0J;&LC-`S[G$D*\_2U?D*5/Y
MPF0>QK@9J-YBC'U[]+W%_>0;QL56Q*QHC&=&K&4$&P1,-K)!;(/$!JD-,AOD
M-BAL4-J@TL`$Q@WNP3#B'AO;GW2/R3#WY'6O)-#LM*R2$;)*9(/8!HD-4AMD
M-LAM4-B@M$&E`<,JS#S$JAFL<D^#,J]8+23DQ;P2,7>#?6M"(D)B0A)"4D(R
M0G)""D)*0BJ=&#9A]!*;O-L;-MU>=HI5Q"#&SX4AR(/F,V45(1$A,2$)(2DA
M&2$Y(04A)2&53@RK8,F_LXI5[*V2@V?%B>X+(1$A,2$)(2DA&2$Y(04A)2&5
M3@Q?\`@U?+F<-RS:-(.3.?2U3%I:\\\0)#V,"(D)20A)"<D(R0DI""D)J71B
M^(.GE.$/7Y!=,<181=,J3O2\(20B)"8D(20E)",D)Z0@I"2DTHGA"]MPV$L!
M__8&>?#)QQD3,GWB9(Y;HJ74G9520]"04H3$A"2$I(1DA.2$%(24A%0Z,:S#
MXI!8=]6LS2J:5G&BIQ0A$2$Q(0DA*2$9(3DA!2$E(95.#%_8&I@8\Z]RJE<R
MG1+(S"I_:F65BAK2BJ*8HH2BE**,HIRB@J*2HLI`IH]L`6J/S:L2C&TJK`P3
M2$\QBB**8HH2BE**,HIRB@J*2HHJ`YDFL:6G;M+E!Q_;[=C.<&0XPU'`M]-\
M4\+1$C]J-O.MO4PLY!$E\RX12--*592N-3=S.%-14BNG6H6*4EK>;&9JE2I*
M:E6&EFDI6Z=^PE*^K,4B5&JO/(X,2\7B5[>4(\M2W^QZ++0,2XE6JJ*4#;YO
M;48S%26[F@NDW9Y"1>E:UH.K5%%2JS*T3$O9>O83EO+EKV&IOB+N]\EKMNQ'
M+FM=CP2R+`UL2WE%PU*BE;JUK"5AIJ*D#3GM5Z&B-$L#:]8N5934J@PMTU*V
M%/Z$I7SE##VIO6)[=OAG9"E'AJ4<699:`RP66H:E1"L548':M684Y1*IH5(H
M>=T_:_8I592\QLK0,OUC2V7=/VU%W+WNMU]7#28Z/$@<$VJ`PQYQ!,07W(:M
M8@VNG%Y['!FV<K3$4-;FTUL[4X<H>44)U4HEF@_W-J,HETBW=9#7.A%8,U`I
M*J*KLA.5H67:RE;:/['5X21.8@<K^1K=L)*C!0:G,BFPAO/:XU'\.%L<H8F*
M2,&AHG=KC=U85M2C_,!*[41$+>"5TEI:)J4R2M<B+6;N%JV[GDNMBRT6,NIB
MBZ6[1>M96TFMG[5HWF*V([!O,5_?_L,=YEL)XPYSM,#]&LSU`^NYM?9$Q?Z=
M@[C#'`6+_MP5;P7LD3.4RZ1-J$HJ$%3TYJT\R524U,JEEKX<\NRD*%1%=CA,
MIBO2Q4K*\I<K^J&KQ[8;Q/0Y>WLR^L1TQ3<MQAW@:('.:'?`>MJO^^;Q.D;-
M`9%`2WUP>G/KF1:K*.E=0K52%:4Z0;0R%26U<JI5J*@+6J6*DEJ5H65DO._:
MT7EX(?49[WL1<S,GD)G],\O"M:RH9;]`2S9[(K%(]JMR>74)54E5E'+*#^SL
M5U%2*Y=:E[-?571EORJ5LI64I=GO.[>"G[T!=%?8Z^(EA)[#_LP:J&L1I2>_
M0$LDQC!JR'0?RR@T/$3Y,^O1D<A._&SR[2>\5&I=;#&347J+WM*ZI?E5+192
MZV*+I8S26_1GUC.Z^J<6S>'&]IKV7'?5QM]G-:TQQI&^RA51&HHHBBE**$HI
MRBC**2HH*BFJ#&2:Q#:!NDF7G[U(7N(,1PNU(%R+*`U%%,44)12E%&44Y105
M%)44L:\7V`7QKG)G^-<(_$WOL3Z_U.OZ<&A'V^:=?6DPFV&R'##_#&+E^_@.
MHC^M("6!_$+"+IF'.&;'I&7S18AC9@=?ACA#=?"[$&>(#NY-0W8JYBK!5QLX
M"J(ED3\-8TR?M`23?)@Y2PJ4E,X2?!SRQ>D):][1QHJ9Z.*PL%\P6$Y]F4'?
M5;":A7CS12]B=1OBS0_E.,1!CUPW(_*688S5%*V#-5_(5G2T!,NUL'268*T#
M-=?-PLH%:JX2K$.@YBK!,5;(=F.N'OBHX[(2AS(H<7F&LP64N%S#KADE+M\*
M;XX25P]P7!>R+2;M&T[M<*6NON'P"26NON$,!26NON$H`"6NOF$WBQ)7#U;H
MP<I9LD8)VV337D<H8:>2KI(`):Y>XQ0)):Y>1^@U.^IPJ<U1TO=@,F0[/FAZ
MV[S4?VS.+_M3.SK4SYB&IOT[MS/_)(K_T35O_4G#4]/A4Z;^OZ_X=*W&QR!3
MML9\;II._H&F)\/'<(]_`P``__\#`%!+`P04``8`"````"$`V%4Q/H@;``">
ME@``&````'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;*R=6W-<-X['W[=JOX-*
M[V.I[ZTNVU-1G_MU:VMV]UF195L5VW))2CSS[1<\)!H$_DRKY<Q+%/\(XI`@
M2`+L<WG[]W]^_7+VQ]WCT_W#MW?GLS>7YV=WWVX?/MQ_^_3N_'_^4?QM>W[V
M]'SS[</-EX=O=^_._W7W=/[W]__Y'V]_/#S^]O3Y[N[YC#1\>WIW_OGY^?ON
MXN+I]O/=UYNG-P_?[[Y1R<>'QZ\WS_3/QT\73]\?[VX^3)6^?KF87UZN+[[>
MW'\[]QIVCZ?H>/CX\?[V+GNX_?WKW;=GK^3Q[LO-,[7_Z?/]]R?6]O7V%'5?
M;QY_^_W[WVX?OGXG%;_>?[E__M>D]/SLZ^VN_O3MX?'FUR_4[W_.EC>WK'OZ
M!ZC_>G_[^/#T\/'Y#:F[\`W%/E]=7%V0IO=O/]Q3#YS9SQ[O/KX[_V6V&Z]F
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MM!9T%O06#!:,$5#6I5D(UEW08I+>G=A[72W:AXYZ;Y"Y.EA\#R0#D@,I@)1`
M*B`UD`9("Z0#T@,9@(PQ4<:E=0J,.UN]<3OG<?NZBK3`T)\CRX,76B_%P$`R
M(#F0`D@)I`)2`VF`M$`Z(#V0`<@8$V5@,J0R\'&K.NG)JCRAKSU9TY_(S@NS
MR!Z$N%H&)`=2`"F!5$!J(`V0%D@'I`<R`!ECHJQ*09.RJM_B3G!;5U$;V)/8
M1X%D0'(@!9`22`6D!M(`:8%T0'H@`Y`Q)LJ:M,>#->>K-V3]5X8,3I&VKB=K
MNG3DODOCO@>A@_L"R8$40$H@%9`:2`.D!=(!Z8$,0,:8*(.[Q!DCM!/<UU74
M!O8D=E\@&9`<2`&D!%(!J8$T0%H@'9`>R`!DC(FR)B4E8,T5Q6K'EUI72YO2
MDVBS"B+:>5?:>3-;*P^U:/`CEU\?:JFFN^P(VG[2_CO5U.T/:"T1Y!Y1ABA'
M5"`J$56(:D0-HA91AZA'-"`:%=+6=0$[S+/-UJULQYW#I9[&.P**W(.%COL'
MU,NYGO:0S9]XB`N+H0^G1&@N\[5]\$AY"*`L5(RD<D0%HA)1A:A&U"!J$76(
M>D0#HE$A[2$N,+;6W=#AU8L.XB-JBG]YS[IVQP5D;R'[0&8O.(BMEW,][2#;
M/W$0%WK:+IRVA/B@5?4AQ+'Q$@(H<U$_]50Y"*`"I4I$%:(:48.H1=0AZA$-
MB$:%M(.X$#2V[@OKAA,WJ[)':]J^HOW@ZC"8TZG(WIW3.)-N#_Z4(<H1%8A*
M1!6B&E&#J$74(>H1#8A&A;25:88H*Y\<S[NY90WN$1T1\-3<!ZD(98AR1`6B
M$E&%J$;4(&H1=8AZ1`.B42%M71>'QC[LK/M3\?W,:3+N[9%V[^6E=>^#%(])
M%G1%'I\C*A"5B"I$-:(&48NH0]0C&A"-"ND!<*&K'8#3EF@?]-+ZQ':[GGD4
M^?(>488H1U0@*A%5B&I$#:(648>H1S0@&A72UG4!=VS=%Y;H$)_')O7(^/#,
M^O!!BL<BFP'*$16(2D05HAI1@ZA%U"'J$0V(1H64E><_G:E,-?6B$5#LPX@R
M1#FB`E&)J$)4(VH0M8@Z1#VB`=&HD+:NS52.^_`<TY.`C`_#[P6^8K3H9E*1
MW3I'5"`J$56(:D0-HA91AZA'-"`:%=)6_NE<:HZY5$#*A[U4A#*4RA$5B$I$
M%:(:48.H1=0AZA$-B$:%M'53N=1LRJ6>/]_?_G;]0&$'^5_"M1?T\Z+_T7&.
M>16CZ&>:@&@^L<]FC&A%EC![:0[*<Y'BB@6B$E&%J$;4(&H1=8AZ1`.BD9&_
MFT/]`NG2K]/WP+G/UN*P(J#(=_>,_'T:TX^WC,C1(RN;\]Q<I,3*_HH+V75+
MD8IUF>.U2J185\U(=#6,5+M6)@IM18IU=8Q$5\_HJ*Y!I%C7R&BREYX:K\LB
MW;T")LP.2`V/EUK$PQ/0XC`O<JXHJ&`D%4M&5#\:5SFTG"9G)5+<YYJ1Z&H8
M*5TK$TVU(L6Z.D:BJV>D=1D?&42*=8V,)EUZ+&RNF5B/J/9A0<($<XX))B-I
M>L9(#)\C*AA)Q9*1ZO-2C@?#6(1&^/NQW.2LN:+H:A@I72L3%;0BQ?;K&(FN
MGI'695;80:18U\AHTJ7'PF:F+XP%II]SC]2\"$B:GK%4/!9!2E#!4E*Q9*3Z
MO)23N#`605<\%M"()JEK9>S7BA3;KV,D[>H9J7:MS'P=1(IUC8P28W$D27W%
M_HT)ZQP35D;2HRR@N>SR.:("*Y8B%2]=YGRM$BDV18VZ&I&*=*W,]M:*%.OJ
M4%?/:'U8BP=$(Z/$>+C<,M[23SX3(QO"]N&1"]YD?5^9-64?*E*8P1W+&-'V
M'54T$R!G*>V.9@P*EA+U):.CZBN6HB5/&K$VNWO-4J*^8714?<M21UO?L92H
M[QD=53^PU-'6CRPUJ5>+)*UM/^D(4TV=>0?DEH'(E&9SWG/%*+X.:*$KFITD
M%RGVH`)UE2Q%"T/4"#.>E4BQKAIU-2)U1%<K4JRK0UT]2QWMXR!2K&M4NO3@
MV<3^Y%E,<9V=Q0'1U?C*>T09HAQ1@:A$5"&J$36(6D0=HA[1@&A42%N7UC-<
M(U^9<BZ<$C-+`I+-:!^DXI23D4HYUV9#ST6*!ZU`5"*J$-6(&D0MH@Y1CVA`
M-#+"E'-AT_WCL=LD;JSL<WWES@%%@4&HZ!HBB\72[,FY2(F5@RY)[4J1BG2M
MC:Y*I%A7S4AT-8Q4NR#E%"G6U3$273VCH[H&D6)=(R,,'RC3UE/CA>%QXF9X
M/%+#$U`\/`')MIA/EZ9[;P45C*1BR4CMNFN3VE4BQ7VN&8FNAI'2!2FG2+&N
MCI'HZAEI7:9=@TBQKI'1I$LO4Z1++5,OC(43-V/AD1J+@*3IV2(@,7R.J&`D
M%4M&5#^:8R:=J$2*^UPS$ET-(Z4+4DZ18ET=(]'5,]*ZS`H[B!3K&AE-NO18
MN+PY#JM?&`N?9L<G90N/U%@$)$W/6"H>BR`EJ&`IJ5@R4GV&]%^DN,\U(]'5
M,%*Z(.44*=;5,1)=/2.MR_C((%*L:V0TZ=)CX9+D5XR%$S?SPB,U%@%)TS,7
MM%+%:$'*$16,I&+)2/5Y;?I<B13WN68DNAI&2A?DEB+%NCI&HJMG)/')@&AD
M-%74AK>Y_@N3`)/Z!2;UC*2=&2/Q^!Q1P4@JEHR4L=8F7ZU$BHU5,Q)=#2,Q
M5HNH8R05>T92<4`T,IHJ:BL?R>!//U%98#8?D/)Z+T6A,ILB"U*46#+*$16L
M2RJ6(A7O!B:;KT2*U=>HJV$DIR`MHHZ1-*)G)!4'1",C-/[RI[/FJ:9>9@)Z
MX?B$I<3;,T84),G&NK+')RREO=U(%2PEZDM&1]57+$7;CS0"CD]82M0WC(ZJ
M;UGJ:.L[EA+U/:.CZ@>6.MKZD:4F]6H6+G\Z`Y]J&D?P2;DY/C%38\\5)4_/
M`G)+LHS!QAQYY"+%<ZI`725+'3\^$2G65:.N1J2B=EG?:$6*=76HJV>IHWT<
M1(IUC4J7'CR7B,<1PLG')TM7TPR>1_&R&:0BE"'*$16(2D05HAI1@ZA%U"'J
M$0V(1H6T=5^7PB]]0AW'P@'INTXV]CA1I'C(,T0YH@)1B:A"5"-J$+6(.D0]
MH@'1J)"V,JUO/^G#KJ;Q88\BA]TO`66(<D0%HA)1A:A&U"!J$76(>D0#HE$A
M;5W:=M"ZKSP"7#HEQM`!2?2T#U+Q$2`C=00(=YV(%/M_@:A$5"&J$36(6D0=
MHA[1@&ADA$>`2Y?0PNK\6MO[K%BM*@'%MO=(V=XC?3"XL;](3&VDW&]^B(*+
M@")=94`K=0"W,0<-E4CQ.-:(&D0MHBZ@J!%]0*9#YG1R$"ENQ*ATZ=GA,M^_
M/$(^?58C%%`\0AY%'<J6`:G9L3%':;E(<8<*1A)`E0&9$;*IN$BQKAIU-2(5
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MK]P3)R5Z-`-RP7S4&[-#[8-4?`='0*OE-`B+S6)I9E(N$MR_`O64+!6FHQF`
M2HI928U*&I&*>V$,WHH4Z^H"<CM=U'T[F%SQT%<82Y%@U6-`WF9J.KJ'R'$Z
MOG8L\7?\22\]*2H/^^T#HF>9N5T92ZF=!1;@($6=F%;)Y>+JTIBS0-WE2;HK
MUCV;=%^9(:]1;W.2WE;TQH-IXH*.U1^?OR==<>`K'JRT7AK?&?ERB2GMS@U@
M518W^,?#=YJKR1O;HQM)7>1B5NB`XF0.488H1U0@*A%5B&I$#:(648>H1S0@
M&A72$\X>2$R1CUCZI$<(:"D'0P<4A:M!*@Y7&:D)!_=SB!3/U`)1B:A"5"-J
M$+6(.D0]H@'1R"CAY136'//RTVSOE)B-*Z#8]AXIVWMD<A\S1W/:Q)SZ.)D+
M*-)5!N3<3/8*2.9$BL>Q1M0@:A%U`46-Z`,R'3)+\R!2W(A1Z=*SX]]QU+'"
MHPY&\0AYJ:A#69!R]RE&5C6+=BY2W*&"D6QM94!FA$Q<4HD4ZZI15R-2<;ML
M,B=2K*M#73TCW4>;S(D4ZQH9)::5.Z6`S>.4D'[ESS?BM#L@G<Q!2,]2DKID
MC&C^R.!A+.&O&%*7^>)R81/%@A6)[I+14=T52_GPT;:YYF+1VS`ZJK=E*7)8
MZ=G6N%(7I%X*'WW_W7,\HLM::6!=(9987-)[;O6CPB,W"C.\E3L2`7=X[0X7
M3E_D#K+K22\]U4\ETO0MI`>AHDS%+%1<SWUZL%I=FL[D(L'N7@041:LE2_FD
MT4R_2DI91XTZ&I&*.V%TM2+%NCK6]4*HZ'M_Z.IR;?:7@57+8>'(JA,SVQU]
M_.6A=$K,ANG1*LX./%)I79!22Y7UU9R4./7KX*OKU=;.O"*(1+K+@%9'=5>L
MVV<'6S-,->IM3M+;BM[8"\PBW`6IEV;T*58:^(H'*RVOS,P9@T@J220K'7.#
M$[,#I\7X@4<J.P"4N4%R(9%,Z1Q1@:A$5"&J$36(6D0=HA[1@&A42,4_Y,7:
MTL?O6IK$M4D#TC]7;NUAJ$CQ`I,ARA$5B$I$%:(:48.H1=0AZA$-B$:%M)63
MAQZG!"QK/.D(:!V%EH@R1#FB`E&)J$)4(VH0M8@Z1#VB`=&HD+:N/4MXP8?Q
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MUE4K77JZN+0#\H23%J.0KLGH7=,[%]VTT2<`-DO?LY1DTQFCH[EMSE(JF[XR
MIU8%2XGZDM%1]15+T;"*']N?7FN6PNS9!6X_:4J?",2'*9,R2)EA(PT5);[.
M0D5]+^>5/0D3*?:1(J`X;1:IR")7YOBB$BG652M=VM]<1@#^]LHC!MKM8'GV
M2+L>'#&$BE$ZF07DSLADU*],OIB+%/>Q0%VE2,6Z3')8B13KJI4N9:^-32M^
MYD>'28E>O`+21S)7-MG@BI%_!>1^8Q9[06H?I-S/5@<I^FZ6/HDJ4'UYDOHJ
MK=YL.;52KZV:3"/$"T]+BS>84@04[PF(,D0YH@)1B:A"5"-J$+6(.D0]H@'1
MJ)"VM(OK_^I\W_CD(%X?&47A6$!Q.,9(.2O\:"92/"$+1"6B"E'-",.QC0W[
MCX=CD[B9LSZP5\X54!2.A8KZMQW[\W@N4M+GH$LV]%*D9!K/[/%3)5*LJV:$
MX=C&!<W@$#[@.#T<F[08Z_AH7%DGH-@Z'KT0C@7U),4]*@**0KM2I&+KV'!,
MI%A7K73IZ>)"XC^QS@O^XH-I-4<\,GNB683W[FLZ+FB3>"EC1+8ZK-XS7.-#
M1?ISD)I?FNX7K$O4EXR.JJ]82JLWJ4#-4AB.;9)QOZSQ)R6"DQ+C9S[LUSLG
M1!I<,=XY?467ND;V,N%K'BJ2%+M+@;I*D8IUF2BO$BG652M=VO62F<!K[85)
MP2:5%&"D$:2DVUFHZ(Y<#_9*>*&OZ`ZU#E+S2Q.C%MP(45^>I+X*4D:]"0]K
MI5Y;-9D4B%5/C#0P0=AX1)$CC^T>488H1U0@*A%5B&I$#:(648>H1S0@&A72
MEG890+QTOK!>.G$SLSUR86/D2B9\WV\.4FSX#%&.J$!4(JH0U8@:1"VB#E&/
M:$`T*J2LO$WF(Z><%TPUM<$#BK=L1!FB'%&!J$14(:H1-8A:1!VB'M&`:%1(
M6S>5E_S4R_"WF)L$Y'+SR+UMRB=2!_=&E",J$)6(*D0UH@91BZA#U",:$(T*
MZ0%(IBLGN3?F*%N/E'L#RE`J1U0@*A%5B&I$#:(648>H1S0@&A72UG49QNE+
M]-8G)'%(&Y#V8?L`P%ZDQ(>]+JK(*$>I`E&)J$)4(VH0M8@Z1#VB`=&HD+:R
M2W%B*T<'WL?WQ*U/CI3!/5(^#"@+%2.I'%&!J$14(:H1-8A:1!VB'M&`:%1(
M6]=E/6!=">A.2BNV/G52A@XHBN>"5'R@P8AB$%G#9^;@*Q<I=O:"$9Y+;)-Y
MTDE+GD]H5"]"<D3+7-0^DQ/NITOJE),1^=:A(@;[+!7GA#/[HH*"I3`GW+ID
MX2\/GL\X5+=#]D)_#JV?STRNNI^N3A%0E!,&I'/"F<T)14K&,S0B,9XO9!RG
M.2@F'%N/U&G"?&92SCU+2:*5!?1"'A>D5*(UL_?`%4J]GI<N+#\RM*<E6EL?
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M:@%M"JD2N@[=994JH?'Q!ZBV;3-J`7U&*E%G3BWPD9:M,Z<6T&=[4G6H!;0?
M)DH65,?_5&"U+:D./2>;J#.C$OH8:*J$O,IO25;;;$4ETYO]H61-)=/[R:!D
M0R73-S2AA'R'/F66:`$U(.G5=/GDU>GBR6O3I9-7I@LGKSNC4?'QDFDK_<*T
M<[^C8%NSS7KG3M&QA$[-=^Y,'$NR[6KGHN94R89*4FW^9;;[)3U:U.2$IFOG
M+"E.SII:2WY9[GY)3OYL,Z=N)%614:Z31ME3R3Y9DE&)^S4PT?7-DDI2)BZH
MCOM!#.O0+X;4MI0V^K6,2I)UUJN=NZ4KH6U-`T;W+F$)W>^U<W<U80G=`+/+
M?9IO7*:D$G>S2JK.%=5)+0MT2P?52970LRD[]_0):J.G37;NF1(LH6=(=NX)
M$2SIJ<0]X($EV9KL1C?Y8<DUV>`Z:0.Z2V_G[D7#.G2S'O4T9>N,;.UN0\,Z
M!=5Q=Z-A2;9:4*M3HYVMR'?H84&L0P]`D@U2)?14(FE+E=#C?:0MU6IZ6(]L
MG2JA1^_H.JD2>I".KI,JH9=+[-S;(Q*MIA+W2@@LH5=`[-P+'K"$WMZP<Z]G
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M@DK<&VVQA%[]3Q9-^0&]B)Y*4M:AUZ)32<HZ]))N*DE9AUX9324IZ]`[C:DD
M91WZ<!S%+:F2;$&KF#\#,3Y*WU`A;:FUBKZ(0K9.E=#W3<C?4B798DXEJ7B'
M/I"W<U\W0HO2=_)V[BMXJ1*:/W14D2JA^4.?`TN5T/RA&SY2)31_DBV@#P'N
MW%><L`Y]#W#GOO:7*B&/3[:-OI5&):FVT9>[J"35-OI@%)6D6D#?HZ16I_SM
MFMIVG:Q#'US<[9,E&96XSV%A?PHJ<5_%PA+ZON+.?3TQ54)^G;0!?7N.2E(V
MH"^A44G*!O0!+BJ96G!Q<-*G]V^_WWRZZV\>/]U_>SK[<O>1,OW+-^Y6HL?[
M3^[7$O^/Y_#JE%\?GI\?OM)AP/G9Y[N;#W?T.;O+-R3\\>'AF?]!';GX\?#X
MVW2:\/[_!0```/__`P!02P,$%``&``@````A`%-%;\;\!```WA<``!@```!X
M;"]W;W)K<VAE971S+W-H965T."YX;6R<6-MNXS80?2_0?Q#TOI9(R5?87B0-
MTB[0`D71R[,BT[80231$.9>_[Y`B;?%F*WK)QA/.G#DSP^-9KK]_5&7P1AI6
MT'H3HDD<!J3.Z:ZH#YOPG[^?ORW"@+59O<M*6I--^$E8^'W[\T_K=]J\LB,A
M;0`1:K8)CVU[6D41RX^DRMB$GD@-?]G3ILI:^-@<(G9J2+833E49X3B>1556
MU&$78=4,B4'W^R(G3S0_5Z1NNR`-*;,6\F?'XL14M"H?$J[*FM?SZ5M.JQ.$
M>"G*HOT40<.@RE<_#C5MLI<2>'^@-,M5;/'!"E\5>4,9W;<3"!=UB=J<E]$R
M@DC;]:X`!KSL04/VF_`!K1[311AMUZ)`_Q;DG?5^#]B1OO_:%+O?BYI`M:%/
MO`,OE+[RHS]VW`3.D>7]+#KP9Q/LR#X[E^U?]/TW4AR.+;1["HPXL=7N\XFP
M'"H*829XRB/EM(0$X&=0%7PTH"+9QR;$`%SLVN,F3&:3Z3Q.$!P/7@AKGPL>
M,@SR,VMI]5]W"(FDNE@BM:>LS;;KAKX'T&\XS4X9GQZT@L`JIR[")4M?DI`=
M#_+`HVS">1@`/H/*OFU1O%Q';U"-7)YY[,[`S^N9RXD(LKFD!&GT4W*71R'S
MPQR9EXNG\M@9^C#8#9/H,)QY`CV]#<>=X%R?A$6T.Y.*LO=YI38@FD[FW@E0
M%+D?M`?^N5;.`I6'N@GLHT+X?C4Y33SC`W:'*?<3J)?*2DN_M`C%[N+.;-1!
M7+F?CBHM-C&8-I,8`HR[Q+B?#B$M,#G7`B/D)L;%V+HO`YK(_714:;&)+76(
MVP/)#^MQI45OD^<.(!CX472$HXZK3#8A!+F8*#A.!U1->!HP/!B8]&XE[F[Q
M4R;RH#D4C@:P5!8'/X>4H!EH\[T[ACJI@*M]N63*I--+/?3&2@H7$V-LE,E!
MCU_\WLS?'DC^C6:&EB9])*<>3F.E`]G:H4P.3B[UP(L!NHAL_5`FO6<S#[^Q
M"H)L"5$F![\OB0BR5429])[-W9SP6!D1COHU4R:;$W;(2!HO)]#WVR,I'`T4
MIXHL//3&J@B6DM&[W\KDH&>HR!U.MG1@:=);=EW#]"5KK'1@6SJ4R<')D`ZQ
M9,WC^\K(]Q-#191)NV78LW_@L2HB'(U9D<+BH.=0$3P=LM-A6T642>?G64/P
M6!41C@8_[R:"OZ0BXK01VK6,8,\RPK?O_O=,]W^1`5N"<-2!E<GN6>)0D4%[
MHW`T4%PJ@CV[2#)6182C`2R%Q4'O2RJ2V"JB3'`!K]LP]BP@R5@5$8X&)RDL
M#DX.%<%H?E]%$EM%E$F_99Y=)!FK(L+1H.=5D<2E(H/HV2(B8@&P3L^SBB1C
M140X&O2\(I(8(B*N]:!52W@:,%)0='Z>M20=*RC"40=6)GLZ4T-0;G]OB]-&
M:*DB^HWS["(IO_F]97RP2`I'`YC'`I.#DZ$B`H6G?H><+2>I-.D-\RPEZ5@Y
M$8X&.:^<I`XY21;)@-U?>!HP4F(T?HEG*TG'ZHEP-("]>I(Z]&30-YQP-%"D
MQ.CT/$L)/)YJLWEG6*1B])9C$0`22*YO9]UK:O=D69'F0'XA9<F"G)[Y2RF&
MM\:+]?**^X"YOVE/5P_=ZVYT^0N\KIZR`_DC:PY%S8*2["%F+#:.IGN?[3ZT
M]`19P1LK;>%=5?QZA'=T`N^-8I?=4]JJ#X`<75[FM_\#``#__P,`4$L#!!0`
M!@`(````(0#Q]GAI"P,``',)```8````>&PO=V]R:W-H965T<R]S:&5E=#<N
M>&ULG%;;;MLP#'T?L'\0]%[+CG-I@R1%NJ+;@`T8AEV>%5N.A=J6(2E-^_<C
M)<>-XW3Q]N(+39ZC0U&D%[?/94&>A#9254L:!2$EHDI4*JOMDO[\\7!U38FQ
MO$IYH2JQI"_"T-O5^W>+O=*/)A?"$D"HS)+FUM9SQDR2BY*;0-6B@B^9TB6W
M\*JWS-1:\-0%E04;A>&4E5Q6U"/,]1`,E64R$?<JV96BLAY$BX);6+_)96T.
M:&4R!*[D^G%77R6JK`%B(PMI7QPH)64R_[RME.:;`G0_1V.>'+#=2P^^E(E6
M1F4V`#CF%]K7?,-N&""M%JD$!9AVHD6VI.MH?A>-*5LM7()^2;$W1\_$Y&K_
M4<OTBZP$9!OV"7=@H]0CNGY.T03!K!?]X';@FR:IR/BNL-_5_I.0V]S"=D]`
M$0J;IR_WPB2048`)1A-$2E0!"X`K*266!F2$/[O[7J8VAZ<XB,;A%+S)1AC[
M(!&1DF1GK"I_-SX-DL<8-1AP;S#B:3"9A7%T&83Y]3AY]]SRU4*K/8&:`4I3
M<ZS`:`[`Y_6`$/1=H_.2SBB!M1K8A*=5%,8+]@2)2QJ?.^\#UU>?UH,!:<L,
M;,.9T1F9,;.XE#MO.*89G:>)_X4&G9<4KJ^+[PGT/J[6.GK&72)?(<'LS2(Y
M)!7C(/MP^PMIX^2+]#B+`#\\B^CLJ-HT-I;C/$;A^'PFIUVJP0(QKLO:6/IJ
MH+2.U2!%/`N#BSG$N"Y%8X$R.<KJY+PP;-)'9V"P,(SKLC:6OK";/D4<3@=4
M!P9V.1I+5]GTO+((&MU_27.!7=Z#J2\NPC-_FL`I]*:+_00#3U@:4U?>[`UY
MV`5.B2<#LAIAX`EQ8SHC[Z2%N*H<M'F1[Q5^,/F^=3!U]5V_H>^DIUSHSFTG
M:8\W=A74&;OAYOJ&'W%^!I1";\4'412&)&J'XVL$7;VUMJ-U/<+X4_MXOO;*
M6/L%1E[-M^(KUUM9&5*(##!#MR':#TW_8E4-JX+)IRQ,._>8P\^-@,[N3GNF
ME#V\`#-K?Y=6?P```/__`P!02P,$%``&``@````A`*>BQY3A!0``Q!<``!@`
M``!X;"]W;W)K<VAE971S+W-H965T-BYX;6R<6%UOHS@4?5]I_P/B/0$;2*!J
M.AJHNCO2CK1:[<<S)21!#2$"^O7O]]K78%_3YJ,O,XU]?'U\[O7!]NVWMWKO
MO)1M5S6'E<OFONN4AZ)95X?MROWG[X=9[#I=GQ_6^;XYE"OWO>S<;W>__G+[
MVK1/W:XL>P<B'+J5N^O[XXWG=<6NK/-NWAS+`_1LFK;.>_C9;KWNV);Y6@ZJ
M]Q[W_857Y]7!Q0@W[24QFLVF*LK[IGBNRT./0=IRG_?`O]M5QVZ(5A>7A*OS
M]NGY."N:^@@A'JM]U;_+H*Y3%S<_MH>FS1_WL.XW%N;%$%O^F(2OJZ)MNF;3
MSR&<AT2G:TZ\Q(-(=[?K"E8@9'?:<K-RO[.;+(A<[^Y6"O1O5;YVQM].MVM>
M?VNK]1_5H02U(4\B`X]-\R2@/]:B"09[D]$/,@-_MLZZW.3/^_ZOYO7WLMKN
M>DAW!"L2"[M9O]^770&*0I@YES2*9@\$X%^GKD1I@"+YF_S_M5KWNY4;+.;1
MT@\8P)W'LNL?*A'2=8KGKF_J_Q#$!*DQ"%=!`F"O^OFE03PD)-=WG_?YW6W;
MO#I0-#!E=\Q%";(;"#PL#&F,2_ULI<!.!/DNHLA8L(@.TO-RMXQNO1=0M%"0
M%"%+UQDAC"*R`2$2`>Q&BK!NFV(`&?Q8^X&1&$09<6N^]`.(Q6B*B/@((1Q!
M.I/C:6X"#!5@2+%<C&&EH"E"0IE_H7!F-)")PVLF%N"5"ZL:<["PTX206.9P
M%BP39@$R`F"AG\0C=4(,ZMI41!36^:R)098RRS$\*H,00QFC@1!84`*G4R+`
M5)FE7A=.C)!0*K,(0DHK,WNC6(\EE*#Z34U.4Q)@BU)")TT1@I1"J[PSLS/2
M622$Q/?)VOWGDR0&46*Q;Q%#B"(66\6=D5ZFE234$DKMM%8";%&RY$@1LI#I
M2Y:ASI#,;F9V!TO_$[T8^,[U@LE1M*QC[2-870ICU+790I1A'WCV^:S)450C
M;B4F51@4:<9Y8(F8*0`F=A9$6D7*4!BG45>GD\?09DU;B@.KH!0&F3&^L%PA
M4_U(C'%=CY27<-'+>:'GFKP"'5BE;?!E\<UC@=8#JXJ1;DV:LK(\_#*K9%,S
M#R:J(4;E,XIBRT`R%40!@G"IRY)2M-S\3$+1DHEPDU(;;%L(-^,6\TP<KF!'
MJT(SNBFMJSR>34W>MO%4888=D,23'6`:_2PPO(TRN\KJV=3K8VV+JM(0,Z1J
M$7+M4:K8"((%H5&.E)QE^V>RB78-E3R>&F)KZI0-EB[.J_*\8K;0R:\R=O:!
MLT]*"3&J5F+;.S(50_6SSU+&+6\_K8I$4SN-]?[&E"F,2AE+F&_[`T7P*(AT
MVHEJ_$N>+T=9)"T*J<(@R="/C/,<9I(`..-+O5<I16'CAKE>9F-<C+(H6BZ5
M*@Q2Y/["MX3."&`6FI\'2E'8L4'Q3(K1O,W"3VS_YX@Q/MMF"YW<LODSDT_M
M/;&\*.6(,2<?6J2K!EHGRN0J-Q<W5"M#B?Y,J$I'#&8H\)F5P4S%D$PIE:L<
MG$\=/-'5J*@,!CU:D1J%Y!B+F>$0E(QEVA=6\-2\$[V+%2G3FC_2Q^P7%$-M
M<I2B9=T74D1[-C_(B6WA?+!P63J,6TO(QO[)]=PR]`LI38T]T6M6JB$&$S=C
M/#'.`1*1<1/!?#\T;D%$-W$^-G?^923E*&I.B=Y32%)AD&3XP<V"`%@4?G;A
M";YD\7*41=&V>(51NW,13TX.!,!8%']V7PR^Y/%R%+W_))9#I`IC>)G90G-Y
ME8L'Z-!F[4.A6-<+!3)G'XQ='NQ'."5B.;HHJA"<\+2S!^C1$'\\3S'?MG8%
M,@D-UF[O/WCW_$II3UV=^;:MR]`K%U^#X*ERE`%W'^W6FJ)(^)B*CXUUV6[+
MK-SO.Z=HGL5#*8.+^-B*C[@I/.+*%T]O[(`WU&.^+7_F[;8Z=,Z^W,!0?[X$
M\BV^PN*/OCG*Q[['IH?74_GG#E[+2W@Y\^<`WC1-/_P0^HWO[W?_`P``__\#
M`%!+`P04``8`"````"$`76VU].4"``#V!P``&````'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;)1576_;(!1]G[3_@'B/O_(=Q:D:5]TJ;=(T[>.9V-A&M8T%
MI&G__2X0N\;INNPE,7`XG'ONY;*]>:XK]$2%9+R)<>@%&-$FY1EKBAC__'$_
M66$D%6DR4O&&QOB%2GRS^_AA>^+B49:4*@0,C8QQJ52[\7V9EK0FTN,M;6`E
MYZ(F"H:B\&4K*,G,IKKRHR!8^#5A#;8,&W$-!\]SEM([GAYKVBA+(FA%%.B7
M)6MEQU:GU]#51#P>VTG*ZQ8H#JQBZL608E2GFX>BX8(<*HC[.9R1M.,V@POZ
MFJ6"2YXK#^A\*_0RYK6_]H%IM\T81*!M1X+F,;X--\D*^[NM\><7HR<Y^$:R
MY*=/@F5?6$/!;$B33L"!\T<-?<CT%&SV+W;?FP1\$RBC.3E6ZCL_?::L*!5D
M>PX!Z;@VV<L=E2D8"C1>--=,*:]``/RBFNG*`$/(L_D_L4R5,9XNO/DRF(8`
M1P<JU3W3E!BE1ZEX_=N"PC.5)8G.)%-0?UZ/KB7QK2`3WQU19+<5_(2@9N!(
MV1)=@>$&B+O`K(P^U+]%"B%JDEO-8K@@"`G9>=HMUEO_"1Q-SY"]A2PQZB&A
MBT@ZA$X$J.LE0MQCB5/(X-O>=XKT)E=1-#IO_P9DI.@2,8]ZB*,1K/M_C7H3
M5,+`DF70TQMC]Q8R,W6@G4X&$XZ`F2O@?7,T.,8079^+Q7QTL(6L3"XGT^4Z
M'`$2!Q#.@O6J9W"$07T/G7E?F`:/'!EGS4(&C@PFG(,7[L&ZLO]=-GJ3Z\SR
M->,V)18R,\[`]>VC-JN)L_J:34<97(+K+='@D:*I>^;>0JRB21C-W.6D6Q[?
M*_TV#:[^^YG1X)&,T3E["QF4S`@`#5ISG`%0,JMQR=C^:_M3345!$UI5$J7\
MJ'MK");WL[;M[Z'MFR;I]PO0=EM2T*]$%*R1J*(Y;`V\)92)L(W;#A1O37\X
M<`4-UWR6\+Y2N&2!!^"<<]4-M'/]B[W[`P``__\#`%!+`P04``8`"````"$`
MW/$]!=`(```E*```&0```'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6RLFEMO
MJT80Q]\K]3M8?J_-Q3=0DBH&%I!:J:IZ>28V2="QC07DY)QOWUEV@9T9#L=I
M^Q+BW\X,_&>69;C<_?SE?)I]SJNZ*"_W<WMAS6?YY5`>B\O+_?S//\1/N_FL
M;K++,3N5E_Q^_C6OYS\__/C#W7M9?:I?\[R9081+?3]_;9JKOUS6A]?\G-6+
M\II?8.2YK,Y9`S^KEV5]K?+LV#J=3TO'LC;+<U9<YBJ"7]T2HWQ^+@YY6![>
MSOFE44&J_)0U</SU:W&MNVCGPRWASEGUZ>WZTZ$\7R'$4W$JFJ]MT/GL?/#3
METM994\GT/W%7F6'+G;[@X4_%X>JK,OG9@'AENI`N69OZ2TATL/=L0`%,NVS
M*G^^GS_:?NHZ\^7#79N@OXK\O3;^G]6OY7M<%<=?BDL.V88ZR0H\E>4G:9H>
M)0+G)?,6;05^JV;'_#E[.S6_E^])7KR\-E#N-2B2POSCUS"O#Y!1"+-PUC+2
MH3S!`<#?V;F04P,RDGUIM^_%L7F%_[;SV5->-Z*0H>:SPUO=E.>_]:`.H9P=
M[0Q;[>QN%NNMY=JPKUN#N#H(;'409S4$F=C[2CO"MG-T%LYN;:\W<O<3GC#:
MBH:M]K0WB]UZO=KLMM.>&^T)VP_N$[+:[A.VVG-UVR[A3&T=8?O!@_6T)VRU
MY[3*I9H;[50+LR9[N*O*]QF<OS`+ZFLF5P/;AV#='%,9[F?=MR8=S#89Y%%&
MN9^#?IA7-9PIGQ^<W>IN^1EF]T';[+F-C2V"SD).91DVI""B0%`04Y!0D!I@
M"4GH,P$S_7_(A(PB,]%IV'?`2`V1W5ET+B$%$06"@IB"A(+4`$@VG)NF[/'%
MI:NS-+Z?P]^).FL;KT]!P$C(2,2(8"1F)&$D-0G2"4N)J5--](5<$Z8E2S\X
M.6`SH5D9;5:#9D9"1B)&!",Q(PDCJ4F09A!G:IX6*HU;H=T\W"NR@8TA?4UF
M;V_4N86,1(P(1F)&$D92DR"AL&:;0F\NKO3#FA4Q*\E(R$C$B&`D9B1A)#4)
M$@A+*Q7HK!>0CP\NU#(.%JS(!O9L%'E#BMP;]45F)&)$,!(SDC"2F@3E0/:U
M[%)UPQDL_;!F1<PB,Q(R$C$B&(D921A)38($PO77%#A]NDICK$H14LDMJ61O
MU%>2D8@1P4C,2,)(:A(DU(9>V%1Z\_G:.F+5&IG%Y"CD*.)(<!1SE'"4(H2E
MRG;#F+731;55<P)7FZX\>XV0/F7EVKU5J*UV<)4W3N,=+GXT6'7A!4<Q1PE'
MJ4;J(+!DV6H8DHWJ-J_%X=.^A$,$"2.I<*%WU!VEZE=0)A1"F5`(94*A'30"
M1B8\FHG>:L@$0['-4,)1JM%8)F0W0C,!MU%P:+<G0G4T*!$:M;>/;;H"6R%G
M0*%&WEKUXY9-KMS18##D@(6)!ZNVK;=LTM<G@T$7)M5('0V>&[)7H1E9W["(
MRP:,K'<:>3"5ADI[%JYTH*T<USA95"QOTZ.HBS4@P1UC;I5PE")'K%XV,%3]
M1^>#:H)@)UVZ]_*A`.1FAZ[A'KN[TH[F%%'(@ZKW&;37;-705I"UWLKQ')QG
MH0]"G@R]E;TC5K&VFMYCTEGA/;IXC^GW]HA3+UNK;Z?^C_+ZK34)'CCTBY+J
MSU#N%2*3D)PC@:VLT"34CL.M8J2MO`$)[AASJX2C%#GB3,@&BV1"]9(C"[(I
M7C5F2+Q"9.*1=2:03YWDJ6M./(76<KW__."ZUF:[79.Y$FD_,.IFNN"AXL&J
M79]6*\]9[4C7DPQ&7:@4A<()D@T:29!]TQJE.CN4(87(]*#MM:VLT/30CKM>
M?*2MO`$)[AASJX2C%#EB];)KH^H_ND:IS@\E0B$R54B=`EL[FE-%H>D5(]*.
M'EXQR$HFNO#F&N5XI#>(NUB3JV+269E[="UR]4F_MT>4>KA>3J7^MC6J#8);
M9(W,QHFCD*.((\%1S%'"48H0EBW;66/&32]#CFI^S;FE$;KS<2UZ_1NLNC4@
MY"CB2'`4<Y1PE"*$)<O&TI!LM,C?4:\Z4J1>(51=AD*'H8@CP5',4<)1BA"6
M*EM*(O5?/;J`U9%V@!J1PI/K2#!8#857L<"Q0Q&W$AS%'"4<I0CA;,!R0;-Q
MT[7%D8[DM%8(%9ZA4#L:5A%'@J.8HX2C%"$L5;:-I/#P+@;H[3<_\F4/5:W1
M<(D(M!6L,%TU0XW07:!KD0XR&JPZ1\%1C,)CB;*'^Z\251^(SFB-!CV!HQ"2
MJ)!G?>O^COL(C;:J[W+8S5R,?+!6V;)1K;=T18YN_XP;%HU60Z,;=%:#YE`C
M;WB3$'$KP:UB9(5%R*[J7XE0[1BJDD);..7Z&Q[7HIV_HZQ@1>BF6*C1"CN2
MKCGBCF+<D323,7+$ZF4K1=5_](S4'9I93850:^=:M+5SM*-98(76,)&-#)*F
M+>*.0B/B2/LXY(@2X4XW6C<]H&ICX`59(SPC;-(2!MK*G!$:;<PG&:Y-&IB(
M.XIQ1W(!C)$C3@1IO=H^9)@1MW6<\."++M(:&1>=@*.0HX@CP5',4<)1BA"6
M+9LAXT28[KG@&P^F3Z'M\`0VT%8&"CF*.!(<Q1PE',EO3^1QJ3TJ?>I;$O6"
M_YQ7+WF0GT[U[%"^R>]$7/DDH\?J(Y:]`U^Q0*,*JQ,;<6"D_;Z%C;@PTJYH
M;&0%(^W:0$=<^;7,Z'Y<V`]H&3F"C0]OQ$;XUH>W1"-\Y\/+E1'N^?`N8H3;
MEB\?W8^,.#"B+K9$1VCO?'DGSGW@SMN7M]I\!+H17S86?`0^(7H<50[)&LV5
M+,E(G#T49*P>CRO_<3RU4*?1,JU]>,O*#S2T5R![S`,>BH+LL9'0WH#/6`'A
M&1;XC(V$]A9\QHH+#WK`9VP$7I'X>WCNR(\Z@)%@=`1>F$"TL12'M@,C8]'@
ME0=496P$GK7#48\5`!Z?0[1V9-G/)/A(ZYJ]Y+]FU4MQJ6>G_!E.3JM]"%ZI
MS[S4CT8_E'PJ&_A,"ZXU\'T.?(Z7PZ<QENRCG\NRZ7Z`^&7_@=_#/P```/__
M`P!02P,$%``&``@````A`*LJ4[S9!P``YR,``!D```!X;"]W;W)K<VAE971S
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MU_R<US^:H./1)76BX[4HD]<SY/W=G">IC-U\(.$O>5H657&H)Q#.X`.E.:^-
MM0&1GI_V.63`9!^5V6$S?C&=V%J,C>>G1J!_\NRC4OX?5:?B(RCS_6_Y-0.U
M89[8#+P6Q1LSC?8,@;-!O/UF!OXH1_OLD+R?ZS^+CS#+CZ<:IGL!&;'$G/T/
M-ZM24!3"3/@PTN(,`X"_HTL.I6&!(LGWYOB1[^L3_`?>Z7M5%Y=_.3#9`%J'
MF7"`HW`PEQ-S/ET.^,V%'QREW^P1/QA-,T`X2K^'KK<4?G`4?K.)M5J8BZ&!
MVL(1CO*"#PT4[JAFH'"4?@\-="W\X"C\K.ED;BWLE3D@J0G5TER2_?/(-0T^
M^4TMN4F=/#^5Q<<(;E`35H-;PFYWTV'!9!7Q.FCKZF=E!>7!HKRP,)LQ"`?U
M5L&]\.W96BZ>C&]0OZFPV5(;$UOLI`6K.A;6U8&G`U\'@0Y"'40ZB!5@@"RM
M-G"'_!_:L#!,&YG55@)%+$T(:2%=7!UX.O!U$.@@U$&D@U@!2`BXXY$0_4N,
MK`5FO1G#WSNU(&S6K2@[0EQ"/$)\0@)"0D(B0F*5H-1AT4*I\_MC8O]TH94J
M,$>XJ>!P1P9NM)QW,A#B$N(1XA,2$!(2$A$2JP3)`.DB&>Y7`+-N<I?UN^5D
M"0=%C:56]:V1=',)\0CQ"0D("0F)"(E5@G*'?03E_G`),$<L`R?J?!/B$N(1
MXA,2$!(2$A$2JP3E#"LYROG^?#-KG"@G2XBOS+>MS7=KU,XW(1XA/B$!(2$A
M$2&Q2E#NK$&F6^(#MSQSQ#)PHLXW(2XA'B$^(0$A(2$1(;%*4,[0@J"<[\\W
ML\:)<J+-]TJ;[]:HG6]"/$)\0@)"0D(B0F*5H-Q9VX.2?_@&;SRQ$`*I4TZ1
M2Y%'D4]10%%(4411C!!.G[4_:KW?GWN3=TNPL<E9W`J$<N96,_X-@O=RHLV"
M)D-9$]:X1CP12W'T!5HA1UOK'8/.2HXKI+&BSDH9A#W#@XB1(Q:+M4BJ6$JM
MU*<\?=L6D!QDVB/B#/IBT2WS1@MIR!'2D"-%"M?DR(9VI=/0GN+A>\)*<?0%
M6F%'"SL&G56G(1E$1*UB=$4L&.NL?B)8CT;PO:<5B?=D2"2.;&A3E/3G.(N=
MR:VL65NAKD2PQRN.VA<43UIUCKY`K-UK'<V%MK`%TE&ULFRMO0FE51<^D@@[
M:OMD+*T:1ZPN:]@^IRYO]9"Z'*W0IFT3=85C\W!"?$OCR(+=I17)LC61/+A4
MLVMTCKY$4&.M8X^ZO>&)NB1\),*O8.5OPUNVMN+$<A#\:8OZ_8\]3?FDNLQ3
MVQ@X&JI=;H5JEZ,YY-=EL2+W/''TF^'#%T]U/GO4[0VOK:ZAB*6,*Q)(&Y>V
MI,3($=<N:SX_5[O,4U.7([1\$N2:!'D4^10%%(44113%".'T6?^IIC^P&O)V
M%8I5+LU;L^U@U<+0]K)=9R4=78H\BGR*`HI"BB**8H2P#*PE5650-M0!17@S
MBQ3A2-GX=B9!+D4>13Y%`44A11%%,4(X?=:5JND/Y,R;6)2SZ&N[PMB9'"DR
MN`+9ZDIK+;6ET*..OD!#S1>_(EC)(@MIK*@_EE:P,7)$8EEW&O7'FZ\F"EX]
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M410CA-.'>QZE?W_;96_CM(93(+M[P+&CR*7(H\BG**`HI"BBB+UQ9D/EX^(Y
M\S?(_*W?)2N/V2X[GZM16KRSM\,S]EBBQ?S5]=9:R'?7^IFU`P_2H,IU;DX=
M]HRI[\P2SBQ[S]APIGDO1J*MX,RJS\>:P\B:VM-\X'7[2]-^:'P+K^&;2=*Y
M!8'ZKC!SX&T0S>-E#O&;U_EZ(!A1WX"VH&&O/>C1*P>HT2L&:-$G!3S+<MBS
M&#I4>'X%.?>=V9IK9PO]`O6!IM'9]9Z!KM#Q>L]`<^@$T*[1:-#R.$&O#_2%
M3MA[!MI#A[4W-!JTA#!7?6?@T:.S[<UT!V=VO6?@$:/#'I'1Z\"31LBGKUC@
M^1F<Z?.!AXQ.R,\8;6'`SRQNR3'[/2F/^;4:G;,#W&C3Y@U"R7^HP3_4Q0TV
M\_'HM:CA1Q?-OR?X04T&K[ZG$[B1#T51RP\P7*/]B<[S?P```/__`P!02P,$
M%``&``@````A`&4D=,XG!@``H1D``!D```!X;"]W;W)K<VAE971S+W-H965T
M,34N>&ULK%G;CJ-&$'V/E']`O*\QX+MLK\:&3E9*I"C*Y9G!;1N-<5O`[.S^
M?:HO0%<7L3R3O"SKTU7E<ZJ*KG;/^O.W\N)]Y55=B.O&#T=CW^/77!R*ZVGC
M__D'^[3PO;K)KH?L(JY\XW_GM?]Y^^,/ZS=1O=1GSAL/(ESKC7]NFMLJ".K\
MS,NL'HD;O\+*451EUL#'ZA34MXIG!^547H)H/)X%959<?1UA53T20QR/1<X3
MD;^6_-KH(!6_9`WPK\_%K6ZCE?DCX<JL>GF]?<I%>8,0S\6E:+ZKH+Y7YJLO
MIZNHLN<+Z/X63K*\C:T^D/!ED5>B%L=F!.$"391J7@;+`")MUX<"%,BT>Q4_
M;ORG<,6BJ1]LURI!?Q7\K;;^[]5G\?9351Q^*:X<L@UUDA5X%N)%FGXY2`B<
M`^+-5`5^J[P#/V:OE^9W\?8S+T[G!LH]!452V.KP/>%U#AF%,"--(Q<7(`#_
M>F4A6P,RDGU3S[?BT)PW?CP>S</Q,IY#E&=>-ZR0(7TO?ZT;4?ZMC4))J@L2
MF2#P-$&B>1_DCF-L'.'9?OML-)V/XQ#(WOO&B7&$IW%<WK6':$HF/%N&TX<8
MSHPC/!]B&.C\JG(E69-MUY5X\^`=@`S6MTR^4>$*@K5UTLGI*O=OA8-DRR!/
M,LK&G_L>U*2&;ONZC1?1.O@*'9(;FQVU";'%OK60-91A$Q=(78!90`"*.EE0
M\O]!EHPB9;6$=BW0ZW14[EN+UB5Q@=0%F`4@#=!]MH;A5Z>M@#2&E^1N!8S-
MLM.S)TA"D)0@S$808VA[F[%NII%\8^^3EW[0@/"XTS_::#;IV1,D(4A*$&8C
MB#W0M-G?IRR-%>6VT#N-S.!AB8B=%N^,6K>$("E!F(T@RO#&VI0?3KCTP^PU
M8F>7(`E!4H(P&T%487.PJ=[/KC3&_#3B9'?B9+<SZK)+D)0@S$8097D8(7OC
M`^TL_3![C=C9)4A"D)0@S$8051@S+M5H.H*^>>=&+N-@ZAJ905VMMIXZB>^,
MNL03)"4(LQ&D)H3SABLGA,$(>N[WC7+$_`UDYYY""852"C$$8<9R$'VD5T(]
MP6#O:U.W,]!\H@9I-`[=;!N#*.Y\DM;'+E,X7>`RI<9J`EN@5<P9MF(H/%8I
M1]6'5.H9AU1J:#%K53HT]J'Q40=-<Q[04`QOK,5_COFGQA&LVI0R%`M+DL/L
M0Y+T%$22--07SF&V#[4!*IR&%O!F6Y)(X3JK7I(="TN2$^Y#DO1H1)(TU%?)
M8;8'8[5CV%72D%.EI5NESJJ79,?"DN0$="7!D1R2=B[REYV`W,&+-+`YQ-!>
MYHPJ8SA[@X;Z@CDD]_(G"_B@@FEH"H^^8,NQJZZSZM79L;`Z.33_JSH]>%'M
M-#3IWX-]:*SL:K60+6A@Z]!F<]BS+=G."9ZA^%BCG+*NQH>V=#V>D3`SL?L]
M<Q\2**%02B&&(,Q8#EN+\4!SP:_!KKOT:$8TS;2V$QLOW1\,86?5=DI"H91"
M#$&8N1RL%O.'CX6AGLA(A!G2=JX)E!A':\BF%&((0HRC@8$_5^_W.\\O*A!^
MR0V$3S!+]V#>6W5EH%!*(88@+.JC9X*(G@D,9"5X3Z&$0BF%&((P8SE?G<:9
MQ>K<]=XZF.'=M\TNTI!3!_<(WUOU=>@<6RBE5@Q!6)6<E(ZJATZ3L.V[$\-`
MJ`[:RH(2:I52B"$(,Y:#T&'\H>-\9":J708-.65PCYC&$:S:G"<42BG$$(1%
MR?EGB;J_G\J+-F=:&VBN+_GD!=&>0@F%4@K)NT\97L?2-/5=IKX<*WEUXGM^
MN=1>+E[E/24X;-<=K"]1=U$,MZCJ%$Y6)K"BLDY6INW-J[L2SE=R'$'"R<H"
M5A:#*TM841<ZKD\TAN]1<YZLR+M?E42R$L%*-/0]0%K=%KL>LQ53+>+B(&50
M"0@9U`$R!E6$H`)^==&<)&&TDB?]H9485H:JDH036!FJ2A).865((5R4/PU]
MRPZ2.)Q#2.$`JQVTRA"GIPG$'_KB'720HAITN84+\EMVXK]FU:FXUMZ%'Z$Q
MX5H<>KG25^SZ0R-NZCC\+!JX&E?_/<.?0CB\,6-Y9CX*T;0?(']!]\>5[3\`
M``#__P,`4$L#!!0`!@`(````(0"*FN%P:`<``'\?```9````>&PO=V]R:W-H
M965T<R]S:&5E=#(R+GAM;*R96V^K1A"`WROU/UB\GW#U!13G*.8NM5)5G;;/
M!.,8Q386D.2<?]]9=H'=&>+8[7D)\<?,L#,[.SNP]U^_'P^SMZ)NRNJTULP[
M0YL5I[S:EJ?GM?;7M^C+2ILU;7;:9H?J5*RU'T6C?7WX]9?[]ZI^:?9%T<[`
MPJE9:_NV/7NZWN3[XI@U=]6Y.,&=754?LQ9^UL]Z<ZZ+;-LI'0^Z91@+_9B5
M)XU;\.IK;%2[79D7096_'HM3RXW4Q2%K8?S-OCPWO;5C?HVY8U:_O)Z_Y-7Q
M#":>RD/9_NB,:K-C[J7/IZK.G@[@]W?3R?+>=O>#F#^6>5TUU:Z]`W,Z'RCU
MV=5='2P]W&]+\("%?587N[7V:'JIY6CZPWT7H+_+XKV1_I\U^^H]KLOM;^6I
M@&C#/+$9>*JJ%R::;AD"99UH1]T,_%'/ML4N>SVT?U;O25$^[UN8[CEXQ!SS
MMC^"HLDAHF#FSIHS2WEU@`'`W]FQ9*D!$<F^KS4+'EQNV_U:LQ=W\Z5AFR`^
M>RJ:-BJ926V6OS9M=?R'"YG"%#=B"R-P%49,^/>"@B,4X-HKF'>K^=Q9K);P
MV`N:<+<;+UR%IGM1?B'DX7KCDY9"$ZY"TQH#<V&$L+*Z$<+UJA'"^#MYN`IY
M^])S=#Z!73X$69L]W-?5^PP6&4Q1<\[8DC4]L-4G`A_ID!H?90:D!#/RR*RL
M-?`9)KV!='Y[<$S[7G^#%,R%S(;*F*J$WTNP?&-F`PQ"#"(,8@P2#%()Z!"$
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M<^3Y<'_PG-B(!QE65L$&2L-DN-_;2&4;2AY`@29QF'=Y,#'UL)/W<\_T5.<Y
M<:&6CO/J&JIW/A>R[*$2!$)M,9"0D(AHQ40F(225M12?6<N*-[@;YYZ94-WG
M9`6!EMS'VYE0D]*!$U=>#>8<5P,A!(M9LHWVC$C8ENN*N4)"\36/2R8?A_;N
M])/'*0&'+N)"P+]59PCE9_T$LZ%&G!.4<&@I^%Q(3CBA-N['(2$1T8J)3$)(
M*FLI_IO0C>,`6'-6;2XOLDY/=5H@E&>HB/B]HI1H`LU9^7Y[L&UCL5S.47J$
MHU!?.2)J*AZENOKC.*[EK);J2D]&H=Y4JIA2`\0Z,+PDKRE#)F_=8%ONG[(1
M".7%0AV>+Z3DQ.@55X.MD**(*L94*J$H5115[UDCAKV_L2"9O)E3`L$12A4T
M3WZO**<*5_RD*`E%5ZU*J'1%O7DP*=4NM-W'O:V+93#II>0GV@;:8M+/GJB&
MGC6''X?^NM+$WE%1;1)([H0H"B@**8HHBBE**$H5I+K-^D+D-B](M[[E,4.H
M0G&TD'="V\`[(6ND01&D^H4;4!12%%$44Y10E"I(C0;K$J5H?%*4>4\)YOJ1
M;]AW$G!F.7;Y/D4!12%%$44Q10E%J8)4_UCW)_DG-?N?N,K;1A:Y8?$ZN&/=
MF%Q*R76"`BH54A11%%.44)0J2/6>]8'8^UNK*^\EE3D7:*R;OBDZSA$%`BEO
M.[:!>JEPE.I3*J(H5LRK+K)F[/^Z*!HZ.:T%&OWQ38[D%QJ!7..C-QJJ$PFT
MY,T(?8.)%1W55]9E85^O:A5X>Z;,(4?.V`OZII`:?0X$<L?/%R&5BJA4K$@I
M3D#\_IL3G:):;P5:RHO4-G`?+*3D?D<@1U5$K61(%:-I1=1AQ8JBZOU4MW?C
MBK1HXR>0TN_8!NYW>D5I@@6:0]$:RIQMH$XFI(K1M")N;A1%-1"LT<*Y?&L@
M>+,FI[7%D9H1)NJ3?"&E9`177$!LQT"8:.L.J6(D$%)$;Q>QHJ@&XF>T8>`)
M[D4$DK<FB@**0HHBBF**$HI2!:ENLR9(FO_+NS&<_A#_.)(;#R$EH8"BD**(
MHIBBA")V*C5V/]P_?LK$3Q6.1?U<^,7AT,SRZI6=(%DKV"H&S(^WH(?R6`L#
M&R"Z\V@NO$=X!KT#G0?H=!TDTME8-IR6=5^9R!VG/T=#=P+3]-@+'WT.O.!Y
M[(V.WH']W6-;-;T#QW6/U@3?P#'>E*6-!<.:D@='IOQX=+S'R7!M3-"`SI\.
M:6."Z[Q.8->7'GQUHQKQTH/O:I0'K@<?32B/70\^BU`>F`:$MJNXZ,GP+0%"
M.W5GXWCP.9G:\AW/G^*!X\'W;RH?S#WX+DQY"L&8XL'""Z=2*EYX2<?UP04X
M_CQGS\7O6?U<GIK9H=A!<AO=Q].:'Z#R'ZWXP/54M7#P";LW'*K!07<!YUD&
M^PBTJZJV_P$#U8>C\X=_`0``__\#`%!+`P04``8`"````"$`HXT]+_\&```0
M'P``&0```'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6RLF=MNHT@0AN]7VG=`
MW(\Q^("#XHR".6M76JWV<$TPME&,L8!,9MY^J^D&=W41VQ/M31Q_5!5=?Q?=
M9?KQZ_?RJ'W+ZZ:H3FO=G$QU+3]EU;8X[=?ZWW\%7U:ZUK3I:9L>JU.^UG_D
MC?[UZ==?'M^K^K4YY'FK0813L]8/;7MV#*/)#GF9-I/JG)_@RJZJR[2%K_7>
M:,YUGFX[I_)H6-/ITBC3XJ3S"$Y]3XQJMRNRW*NRMS(_M3Q(G1_3%L;?'(IS
MTT<KLWO"E6G]^G;^DE7E&4*\%,>B_=$%U;4R<^+]J:K3ER/D_=V<IUD?N_M"
MPI=%5E=-M6LG$,[@`Z4Y/Q@/!D1Z>MP6D`&37:OSW5I_-IW$,G7CZ;$3Z)\B
M?V^D_[7F4+V'=;']K3CEH#;,$YN!EZIZ9:;QEB%P-HAWT,W`'[6VS7?IV[']
MLWJ/\F)_:&&Z%Y`12\S9_O#R)@-%(<S$6K!(676$`<!?K2Q8:8`BZ??N\[W8
MMH>U/EM.%O9T9H*Y]I(W;5"PD+J6O35M5?[+C;J,AB"6"`*?(H@YGYCSZ?(G
M8LQ%#/@4,>S)W%K8JY\9R%($@<]^()/58C%?KNS[L[%%$/C\_$@>1!#X[$=B
MWJNKP>>HFW(O;=.GQ[IZU^`Y@EEHSBE[*DW'A%+I)YM/S3#]'\T^3#N+\LS"
MK'5(#R:V@9+]]C0WS4?C&Y19)FQ<:J-8;'H+5E,LK*<"7P6!"D(51"J(59!(
MP`!9!FV@]OX/;5@8IDV?E=N#BU@6EFK36_0NG@I\%00J"%40J2!602(!),1,
M$6)\)>AK@5G#,R_5@K5<X`1=8?,PB+(AQ"/$)R0@)"0D(B0F))$)2AW6CI$:
MF+!G_[H*S!$>*OB0'@EEGEUNM)Q?9"#$(\0G)"`D)"0B)"8DD0F2`=)%,ES/
MG5EWN??UZW*RA$5T4,-:KG!1;`:CWLTCQ"<D("0D)"(D)B21"<H=!HURYTOD
M'27`'+$,G,CS38A'B$](0$A(2$1(3$@B$Y0SK.0HY^OSS:QQHIS(B7(RX[M\
MM[AS8L.B(]7$`ZX)G[@%G*R0FZWL).%@U)=21`+%@XUT?WN&[Y_(;D@AUNW2
MC;.KBO909*]N!5G!SC*BW`PV2+YMLB!8.$YDX3B1A>/$AC7K(IP]Q0/WB5O`
MR0J[*2M2.!@-PI%`,;%)9!ND$O0J'ZDT(@ST=KTRS!$KPXD-2Y24]1QGO>%&
MUFQ84#U!X.F6W)3MR"=N@;B;[&8NE`4K'(V]Q$.*2.QXU,W&;HGLAB1E7=KG
M-.T\L:@"K6`AD.115>T=N]\-HC-CHUCK%LR\Y*@(Y%/'H$?R\TN5%59*>%7:
M/M9E7+%`*Y!/&I>RJB3($:O+FL$/GNOK%6OR-A)V_/[1<06Z4;/"2BY:@>:H
MV%?J(TX=@_Z.\GR.J,N'JH17UM"(AH_'QZ6L(0ERQ.JR#O-SZC)/I78YDM=*
MDR"/(I^B@**0HHBBF*($(9P^:S/E]&]4%.]*445QA!NIE;)I;<S!JB]%CR*?
MHH"BD**(HIBB!"$L`VLS91GN[JA8.ZU6`4?2_K@15A+R*/(I"B@**8HHBBE*
M$,+ILTY33O]&%?#&%.+UD^FRMS$@`ZI\CE#.'-UHL$0LR3$0Z$:+=;'JQQ71
M6/'%2EZ/E8)-D",6B[6HLEA2K=S?9YF\T44:<H0TY$B2PA..-WHM824Y!@+=
MZ+8N5A<-R2!B:I6@.V+!6,?Z@6`W"HWWND@DCFYM8-P*;6`"00E*V[#:=IG$
M,1"(_;X>'$<VL-'PI#T@X>/^CG)XRU9[K]ZJ:R.QNJS3_9RZO$=&ZG)TJ_D2
MCI<FQS,Y4KHCTGP1QT`XLAWJFKJCX8FZ)'PLPM]JOF1'K"YK>C^G+F^7D;H<
MW:I=;H5JER.E.R+-%W$,3'%'>(*OJ3L:GC1?)'PLPBOC(LV7[(C4M3[]PZ'S
MQ,V70/+R29%'D4]10%%(44113%&"$$Y?[>ROKX86;><%LB_O,#84>13Y%`44
MA11%%,44L<,@U@[P<?&<^>$.?]-?YO4^W^3'8Z-EU1L[N+$>X'?V@/FIDFO.
M'=:TP$:D7K&F<.#4+3_DRG`4I5R!,ZIG:RP6.'3R*?:N!;<8LY\Y\&Z6CNEY
M#O%'`T$6HTDL''C#1P.Y2P?>@HUP$T8$Z^38%1@3-+?T2FP[\&Z$\L1VX`T)
MY=#'.2[LY/3*!JYL1J_X<,4?O0)MFQ-"(T6C03,"5\;N`QV;$XU>@<;-88T'
MC0;-&N0_=L6U'7<LSXWM;,:X;SOPFHK>(;`=>($WPE<.O)^B/+*=J./&4%5P
M'GE.]_GO:;TO3HUVS'=0]M/N[5S-3S3YE[8ZP[H&IY)5"R>1W;\'.'G.X?!I
M.H$F85=5;?\%;FP,9]E/_P$``/__`P!02P,$%``&``@````A``2BD$K+$P``
MCV<``!D```!X;"]W;W)K<VAE971S+W-H965T,30N>&ULK)U=;]RXDH;O%]C_
M8/C^V*V6^L.-)`=QZ_L#6"S.[EX[=B<QQG8';F<R\^]/42R*K'HY[;9W;N+D
M8;%$OBR214E6/OSSC\>'L]]WSX?[_=/'\^1B=GZV>[K=W]T_??MX_C__*O^Q
M/C\[O-P\W=T\[)]V'\__W!W.__GI/__CPZ_]\V^'[[O=RQEY>#I\//_^\O)C
M<WEYN/V^>[PY7.Q_[)ZHY.O^^?'FA?[Y_.WR\.-Y=W,W5GI\N)S/9LO+QYO[
MIW/K8?-\BH_]UZ_WM[M\?_OS<??T8IT\[QYN7JC]A^_W/P[.V^/M*>X>;YY_
M^_GC'[?[QQ_DXLO]P_W+GZ/3\[/'VTWS[6G_?//E@?K]1Y+=W#K?XS_`_>/]
M[?/^L/_Z<D'N+FU#L<]7EU>7Y.G3A[M[ZH&1_>QY]_7C^>=D,ZS2\\M/'T:!
M_O=^]^L0_/WL\'W_JWJ^O^OOGW:D-HV3&8$O^_UOQK2Y,X@J7T+M<AR!_WH^
MN]M]O?GY\/+?^U_U[O[;]Q<:[@7UR'1L<_=GOCO<DJ+DYF*^,)YN]P_4`/KS
M[/'>A`8I<O/'^//7_=W+=_K;\OSLR^[P4MX;5^=GMS\/+_O'_^-"=F$KS[DR
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M!I4&M0:-!JT&G0:]!D,`+DG)24X:R;]#3N/&R.F$N';`ZSM7VCD+5R77H-"@
MU*#2H-:@T:#5H-.@UV`(@-".HD]H%U^T7<09ZX_G].>1B&.;JTG'+9`<2`&D
M!%(!J8$T0%H@'9`>R!`2(1BM]4(P.W<OS-IQ7#M3D28\_3@BGC5:9EX\(#F0
M`D@)I`)2`VF`M$`Z(#V0(21"/!))B'=<,6,]*N:FU[4E2_H1:)BI23D9N6HY
MD`)(":0"4@-I@+1`.B`]D"$D0C':\(5B)X>;J2C%LR2,+2`YD`)(":0"4@-I
M@+1`.B`]D"$D0BG:!T&I^>*"E'WCMFH<2>4L6=*E@[!;J+";C*:P`U(`*8%4
M0&H@#9`62`>D!S*$1(AISF:8H9RPRIF*4CQ+PK`#D@,I@)1`*B`UD`9("Z0#
MT@,90B*4HG17*'5\23/64AY+5&PM56Q-1E-L`2F`E$`J(#60!D@+I`/2`QE"
M(A0S>;^0[.0U;:PIY6,4AA>B'%&!J$14(:H1-8A:1!VB'M$@D-3-Y+]Z4B[3
M<5*^<8DS!R@5AXQ4(*Y4('JK*1(1%8A*1!6B&E&#J$74(>H1#0));4U^K+5-
M%B<L>.8<J:6T2,0DH)PK!E8%HA)1A:A&U"!J$76(>D2#0%(WDR=KW=ZUZYIS
ML-;1(A62:QV2DY4/24`%NR=?SJI$5"&J$36(6D0=HA[1()"4UF316MK30M+F
MWW34<'V]-L<.4C<(MBVB'%&!J$14(:H1-8A:1!VB'M$@D-3-Y-*A;L=W9'/C
M3<<=9^,RW[O2<3=9.95S]A4$68&H1%0AJA$UB%I$':(>T2"0U,]DV*%^IV_/
M-C>GH7&*7)L[N3KN`.5H52`J$56(:D0-HA91AZA'-`@D=3/)=*C;*W%G<V\A
M%J?C7K]M8E&:3)+FC%:TH_C3R'PFH[/`BB6CM:RH;FE5WLH-8HV^&D:J$<I7
MBQ4[[SYLO5K3>V_E&C$(7U)XDYN_07B;R@OAP^Q^O`FZ32P2PEND^JQNIQ98
ML62DA%=W:BMOY?I<HZ^&D6J$\M5BQ<Z[#X57BUKOK5PC!N%+"F]2_#<(;T\$
M0G@^)(01;Y$0WB)O5"1@5#)2(JM[0Y6W<OVKT5?#2(FL#OPM5NR\^T#D5,W-
MWENY1@S"EQ!YKD]+QY>5T5P>D1B%>S^C4&1&@<AH5#(2(L]7:MI7WLKUKT9?
M#2,ELCKYMEBQ<\C?8>X1#0Z-*Z=4-':.XL3JY?O][6_7>UI8R2BB=$J/6>S#
MESD>H1@)H:V5$-HB,G;J%%PQL"H=\OEJA:AVR/MJ&-$#WR`$Y^H<UV+%SB%_
MQ1[1X%!$5G/$.7TUF-L34;@:,!+Z6:M`F9RMTC!2P:I$JPI1[5"H'_OR[ENT
MZA@EU/Q`YE1M!GU@Y@9[$-YD8)ICRQL4M*<<H2`??'SCMW.+A()<D<X>KE4%
MFI6,DL"LBK`:JS81LQ;-.D9B.4E3M9STWLJU=A"^I(;O/C7-\=3$:"4'66VV
M6[:B-KGVY8PRLUS04]DLG5_I5;+`:J6['F7(4VJ7+%1R5#GGV>A\KK:E&OTV
MC*[F4PM;M.J<U7JRZA$-HJ*47A^\3CXXF-<LU!F,T3J4(DW5=KYU%<<75.S3
M:T99,JJ39(OE8J$VX`*KE0[1[#\FO6WH?#TZ7]!+32I8:^?'MZB9D%]EVHE-
M6G<.T<G,Q5$?88-C]J4<\1S<G*S"]>/T`;!G,K&46*1B7P7;=FZM1.Q;E,E)
MH_;U@BNNR-CKO59JEE$KG!#3%<UL2^87:W6U&IO9,!)S`CK3.:MP3EBK*X\&
MX5[."7TH/'U(\'QHWJ>A::+FA-K:MVQ%]Y%=&.6,*&R]V&FJUI7"5113`(>$
MVR6L<$BL%4^4C%XY4D-;NZOY9C83"B<*7\Z;=<Y,3!0V"]C@["(3Q9SD8*+0
M>V.DS^D)H#T.BCG#)T09^NJ,M37#0,,HYHQ%F6G`]"Y/!LL6NW]ESEBK9/;*
M"$V7'+>H]?IBH3:V&AO:,$IF?K-KT:QC%,R1'M$@*LII8\YW_^\!LH=$,4`6
MR1F4J:QM.^>*/N;R"=E--UO.5^M4Z55,1M/,*R<4CFQD2[=77%W9?"&]@`4,
MFM1,KL-P2#,US]K);&I4Y]#1`.G9:MI(9^F5BN3!.<(9ENI3JUGWZ.4^LWF=
M/L5&+_(PRTAN2YD:B2U;A5/,^9JM1HTSRC-7<R5S@?5*1FOJT#0U<0"=E<TZ
MTOG%2J4J-;IN&"4SFHJ3;QQ!K-DQDKNG7H1[MN(L-*$>Z]QZ$+[%%*0#0V0*
MGO)$;*RI1LV>>=6\4Q)M7<5@WDW(S@Q:=VC05(@7D]$4XJ5#YFGJ)&UDV&R[
M$GHP.*Z"LXLKM2O6SI-O5..0>2PV.4\SE1NUSLS7[!P**T*K>K;BF9<MDE3M
M\8/S$YEXY!I7SI.&S=14PV91>"!/`>6("D0EH@I1C:A!U"+J$/6(!H%DN)LS
M<;CC1&[^T.+E[OZD?(3V!^UK1O)I9:96F*VWFK(S1`6B$E&%J$;4(&H1=8AZ
M1(-`4C]S>@[U.SG1I1LY$'<6B;@#E'/%P*I`5"*J$-6(&D0MH@Y1CV@02.I&
M&Z+0[96X,^9JDEH4R+!-+:)5P@>91?)N:Z;6E4)4E.TTIYYP?%]IISTDA;E7
M:I%HIT6BG1:I=JI%N6!?MJ)LISD(A.T,XO`-B0<?)\+I;9%HOD6B^1;)NZ^9
MRIN*-*PHFV^R\K]H_BN*<]H?-MDBF2OIFR';U%J)7(E]F8>=?H-;J#RY$#5E
M-TRZ^KYN<*(;=L,BF3SH\^0VA0PY=\@\.@RZH9+%PIGA9IK%LMB37L$8:\IY
MRDB-ALZ!V"H<#>?+/(@+NJ'2C4+4%*-!B<0[1V.LJ;IA4Z9P'K!5@')$!:(2
M486H1M0@:A%UB'I$@T!2-YU+'9^!&290C&1.L-`Y@;>:EFM$!:(2486H1M0@
M:A%UB'I$@T!2/YU3!6OQ*U)B>D6G&+/S!4&V190C*A"5B"I$-:(&48NH0]0C
M&@22NL5RJ7>]5&=NPJIT@9$*294(;+V5#TG.P/SSP0*M2D05HAI1@ZA%U"'J
M$0T"26E-&O2NC<G<F]-26B1"$E#.%0.K`E&)J$)4(VH0M8@Z1#VB02"IFTG+
MM&[O"TF;X(698<;(/!D--CB5]&T#,Q^4OJIC1<2NC+`JPNH(:R*LC;`NPOH(
M&R23,IO$4,M\6L)A4THAJT5!X&TS0#FB`E&)J$)4(VH0M8@Z1#VB02"IFTE8
M0]U>V5XXOPV2S,PBM2RJQ'WKK5RTY8@*1"6B"E&-J$'4(NH0]8@&@:1^[\[7
M,\S7&8FXLU8!RM&J0%0BJA#5B!I$+:(.48]H$$CHMH@>$-[X(&ET(I-LA_RM
MPRTC>JUI"CU&:\J,_+*YU$^-O)6K6"*J$-6,[!5EM_6!XOAT6_!=UF"Z,0H"
M8LLH/$V[BK/P+FX*[[JZFMY_Z6K2>AAJH^X<5X&9$Z=VWL:;)[+;;SL/+/`\
MP$ATVUJ);ELD[X$L]>F;?0452T;R?9JE.N]6WLKW.6R$[+/.X5\9:DS<%YBX
M,PJ:GC/R0UB@4<E(]4\=H2MOY?MGVV`O*/NG<^U7^H<)]8+S8M_T+2/1/VOE
MC0HT*AFI_JF#?N6M?/^L]UC_CB2\I]\/6V#RRTB$LK42W;:(WAIT;2VX8F!5
M,A(+6;)2^5_EK9RO6OB2XQI+6$_*I!:8H#*2MVZ6^AC/5N&M&T9T:\8\7EHE
MZVP&R[.]7%"K=)<C[:9U'9X25>YRYJ$$O?4RN]!OF-7.8GQ6+]5Y=YZYP#R3
MD;P_!Z]JN8KA_F5]K2DY\/W$_8NOZ"N6SI=Y:_JO:U:!F8^8T)O41.>0)]^M
M6&`ZR4A%C#YELU4P]CDC<X*=>I8NU50HG'N*G<DJ@5=UHE;Z*7'EK\AQM%!9
M;\T6MIE2,Y/7A7GWJ-E;\Q^;'(9'EX5%*J1`/J[H(R/GBB;R)V'2I>I0P5;B
M^6U$/G9/>^/D*S(-K16]R\+RZ6&HW=7&9@KYEG]'^C@ZD>DC(QE]*[7R;-DJ
MC#Y&],-T)EUF5[I6@;5*1L??1JC8BB+;":4VMEJXED+IA%/%V;_V/TB!Z!O[
MP4/;)>:AC,)=#%&.J$!4(JH0U8@:1"VB#E&/:!!(:FARO'"N'L]TEC8E#&<E
M(WE&7JF\=.NMW**;(RH0E8@J1#6B!E&+J$/4(QH$DOKI3/CD_6&)23$C$7>0
M)^=H52`J$56(:D0-HA91AZA'-`@D=3.YZ1OBSJ:R(NXL$F)9%"21.16;&[0R
M>=8Y4>&M7'26B"I$-:*&423K-E\H$GT.8N7TK'OTHE9VFT_3E5WSMVPEI+!6
M(I^>K_4NR!7)RODJ$56(:D0-HY@4)K\-AU\MW2?]LI59<M3-=X?\YK]E%-XB
M871ED^3Y+%%[3N$-O`CV8H&;REN9O8O<J#-G[0V<FX91Y/;)TN2@(,DI[VB-
M-55$V(26[HVZ*V^=E9<F=R@\B$58Z9BO6CD45*TCK'$LDN:\.[->8F;-2.4V
MZA['EJU$;F-]'<]2"JXH\V_],F>)[BO7KC#SA&RQCKM70=D(]W(Q-=DFA,X;
M$^XE)[9^$;EF)!/NE3[ANHH^.G)&9OF?DN1TI3+UPENY("W15^6M0E_J[%-[
M*^>K$;Z$7JN_(\,>G<A9QTA&8:(S;+8*H]#YHF7!=Q+BI&`SD\T%LJH5O$3_
MU6G^ZZC_M6I_(_Q+7?^6A'R%"3FC<(-#E",J$)6(*D0UH@91BZA#U",:!)(:
MZH3<[(SO>J9J[A2K[9&1V81\`*UUKNZMW%S*$16(2D05HAI1@ZA%U"'J$0T"
M26EUKG[\K&->U]/Z642CYY39LE6`<D0%HA)1A:A&U"!J$76(>D3F"^"FC[;U
M5BS[16_[9>+'W?.WW7;W\'`XN]W_-%_KOC*_O#IA^RGQZ]6<OB4^_AHIE*3N
M*^.Z)%MOS*-'TA%*KJAD_#5^7;*D;Y;3XA>ILZ06T"$M5D(MH'TH4K(R7T"/
M>LO(&[W`%*F3D3=Z12=6DE')N'?J5F<+*AE_?1-*EE0ROCD#)2LJ&9,W79*0
M-_O[;%!"WNC=S$C;4NH/O>0>*Z'^T.O;L1+J#[V@'"G)2#=Z/2Y20@,7';=D
M1BT;TP-H,_FB7[.(^$JHS70K+E9";;:_?0[>J,WVB*A*Z&/WG^.^J$+L&G3Q
MJ+V1*V+_.=M\IJD4::R)BABG48R&!(UA=`@I'J+A0+,H-HGH%+HQQR]L4;Y<
M;LSY!DOH/+,Q1Q8LH8,"U8E=G\X!5"=60CD@U8F%`V5T5"=60H_R-N9!';:`
M'H)124Q)>DQ$);&>TC/;C7D6%/.VHCJQ5E^3;M=1W;948D[5Z(WN,5!_8FW+
MEPLJB=6AWX7<F%]^1&_7Z6)S3:^"8PF]P+_91DOH#?V->7T<Z^2+&?4T.O5(
MG>NH.O3,?;.-EA148I[4X77HT3I=)S:5Z/$SE<0F$WWH@32(C39]#8/F7ZR$
M/D=`=6):TV_*4TFL;?3KVE02BVOZI6$JB>E&'Y:B%L3Z<TUMNXZV;4LEYL,:
MJ`Y]G6231TL**C%?V<`Z]*V2C?FP!I;0]TDVYO,:6-)0B?G*!I;0UTHVYEL;
M6$(?+2$-8N-#7_BBZ\0TH$]XD;=8"7W):V.^TQ6Y3D(13R^KQTJNJ"2V'M!'
M?:AML>BE[])02:P%U]2"ZV@)?3:-QB=6A[Z+1J,0*Z'/HVW,Q\^PU?3]+BJ)
M]8<^.D4EL?[0EY)H3&/]H2_[4,G8@LMI[Z+_#N7'S;?=<//\[?[I</:P^TH)
M&#W1I?MXS_8_5+'_>.'G'%_V+_0?HHR//+[3?WRSH_^V869^>_WK?O_B_D$=
MN9S^*YU/_Q8```#__P,`4$L#!!0`!@`(````(0`1@<G)L`4``/X4```9````
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;*Q878^K-A!]K]3_@'B_(1`@!&UR
MM8'P(=U*577;/K/$2="&.`+VX_[[CC$FMH=-5[=]63:'F0-S/#,>_/#UO3X;
MKZ1I*WI9F_9L;AKD4M)]=3FNS3^_)U\"TVB[XK(OSO1"UN8/TII?-[_^\O!&
MF^?V1$AG`,.E79NGKKN&EM66)U(7[8Q>R07N'&A3%QW\;(Y6>VU(L>^=ZK/E
MS.>^51?5Q>0,8?,9#GHX5"6):?E2DTO'21IR+CIX__9475O!5I>?H:N+YOGE
M^J6D]14HGJISU?WH24VC+L/\>*%-\72&N-]MMR@%=_\#T==5V="6'KH9T%G\
M17',*VME`=/F85]!!$QVHR&'M?EHA[GMFM;FH1?HKXJ\M=+_1GNB;VE3[;]5
M%P)JPSJQ%7BB])F9YGL&@;.%O)-^!7YOC#TY%"_G[@_ZEI'J>.I@N3V(B`46
M[G_$I"U!4:"9.1YC*ND97@#^&G7%4@,4*=[7I@,/KO;=:6TN_)FWG"]L,#>>
M2-LE%:,TC?*E[6C]-S>R!RI.X@XD<!U([%G@>:X?+('DCB/<[9\.U\'1G]GN
MW&?/ON.V'-S@.K@Y,]?QED'_TG<<(>O[Y\%U<`QF3N#9W@=/M+A:O?AQT16;
MAX:^&9#1H$=[+5A]V.'*-(3J_-'C.GRT#*`_(WED+&L3H@"%6\B=UXT[7SU8
MK[#>Y6"SQ3:V:A$)"[:XC#;6@9T.)#J0ZD"F`[D$6"#"J`0DSO^@!&-A2H@8
MM@*X2>-H80L+X1+KP$X'$AU(=2#3@5P"E+`7..P%%.]TV8GU9DY08-)Z+Q9J
M5-O!9#4J$2$D1L@.(0E"4H1D",EE1`D7*ANO\HQ5]_V(F1_4"%QN*6[/M9BY
MD=]WR3Z#(X3$"-DA)$%(BI`,(;F,*#%#<'+,]P-EQGV@(AVW')&CXLB"]\Z^
M4CD20)*-\CBNK\JS&XT$=8*(TM%&)EJJ1-EH)(ARF4B)W5=CY_VM7^_N5)7/
M6\KWA`E-%M#'>'=C'*HD')$EX8@L"4<"1O.Z<>:VIP:Q&^^+(!+$D8XV`X>K
M<F3C?<&1RQR*$-"<Y21@0CC>#'2;"!UV+1$[<U-CY\@2LDU:ZD!]L8@;.8NQ
M^N/!#1XXNMF>YK8;W&0CQ]4VD@1QIY_ASJ:X/:V"<YE;D8^-F6B?_$3?8'ZJ
M?AP)8*%&(1Q/WPH'MWYDXGLA1Q;P@I*;MI7L1B.1#PDB2D<;F4CKWMEH)(AR
MF4A1!J:&GU*&^:G*<$3-+$]+^8@;R9G%D0!>4%)&K[;12`24(*)TM)&)M":6
MC4:"*)>)%&5LV$=_2IK>4=5F@+2TT1IC)!REO!D@+7'TPKM9B;`2S)7>K&2%
MM/K,;E:"*U>X5(W8.*87%@SNL)B?[L\V'^GXUTE?+=L!4G/)UZH]&JSD9!H@
M3VE!OE:>NYN5"#'!7.G-2I++UVHVNUD)KESA4N5B8]Q_E8N/@HI<'')O<VMD
M#U9R*G$HD'L0[N&#HP>+<JM'7VLP":9/!^@^?39-KW6)7*%7%62CX<<*?J=7
M*+Q_VQ5M/E\J$G)(G@D&*PF*,;3#4(*A%$,9AG(%4L-FTZ$4]OU=G\VY6G,>
MH.5MZ(LP%&-HAZ$$0RF&,@RQ`PCV7OPE>'S\0(%_T]:D.9*(G,^M4=(7=EC@
MN##)C#`_R8AM.V05#.6FW8&*#5D]XCMP^O'H3.!;=BHRA3LA?'%AGNTBA&\3
MC#^ZX2,$AV]LW1`&^PG<!B98[JD[X#+)E7LAS(?8(PY"F!PPG@8A#`(8CU?A
MKO^NT^5;A;`]3MC;<Q"\;R2Z!]QA^P7VV7KA=NI=(R^,IO#8"^'[`O/$?@B3
M-L83+X1Y&^.I%\+GQ03NAS!M`VZ-(<#IT[4XDM^*YEA=6N-,#I!P\WXF;/CY
M%?_1#2WEB79P[M1WEQ.<,Q(XX9BSC>Y`:2=^L`>,)Y>;?P```/__`P!02P,$
M%``&``@````A`.H;T1`!%0``"6H``!D```!X;"]W;W)K<VAE971S+W-H965T
M,3@N>&ULK%U;<QNYCG[?JOT/+K\?VRVI)5F5Y%2DOE^WML[N/CN.DKC&ME*6
M,YGY]P=L`DT"X$CMR;[$\<>/7Y,`+P#[XG?__./I\>+W_<OQX?#\_C*ZNKF\
MV#_?'SX_/']]?_D__\K^L;Z\.+[>/7^^>SP\[]]?_KD_7O[SPW_^Q[N?AY??
MCM_V^]<+4'@^OK_\]OKZ?7-]?;S_MG^Z.UX=ON^?H>3+X>7I[A5^??EZ??S^
MLK_[/%1Z>KR>W=PLKY_N'IXOK<+F98K&X<N7A_M]<KC_\;1_?K4B+_O'NU=H
M__';P_<CJ3W=3Y%[NGOY[<?W?]P?GKZ#Q*>'QX?7/P?1RXNG^TWY]?GP<O?I
M$?K]1[2XNR?MX1<E__1P_W(X'KZ\7H'<M6VH[O/M]>TU*'UX]_D!>F#,?O&R
M__+^\F.TZ9<WE]<?W@T&^M^'_<^C]_^+X[?#S_SEX7/S\+P':X.?C`<^'0Z_
M&6KYV4!0^5K5S@8/_-?+Q>?]E[L?CZ__??A9[!^^?GL%=\?0(].QS><_D_WQ
M'BP*,E>SV"C='QZA`?#OQ=.#&1I@D;L_AI\_'SZ_?GM_.5]>Q:N;>03TBT_[
MXVOV8"0O+^Y_'%\/3_]G21%*69$9BL!/)S);QU&\?(/*`E7@)ZK,KIS(B<M#
M0X<^P$^LN'9=.%%OA?7@YWC!Q2Q>K8>^GZ@(DV>X(/S$BK=7J^CF=KZ")IRH
M%X%[K;6-G]&25^LX7BS7YZJ.CH+_8-755;2X&2Q\ZIKDG,AY)W+FF>CA:$XM
MA_^,QIKDG8C\:OZ#5=<G'7MMQ^@PY).[U[L/[UX./R]@'8&N'[_?F54IVIA!
M3H/==G\<_G\U^F'8&Y6/1N;])7@=!O81INSO'Q8WLW?7O\,TNT?.5G,BSM@1
MP\PI(YM(()5`)H%<`H4$2@E4$J@ET$B@E4`G@=X#KL'6H\%AR/Q_&-S(&(.3
MJ;8$.`\(^^^(0542":02R"202Z"00"F!2@*U!!H)M!+H)-![`+,N3"5EW3FL
M#.&UFT:OJ06KM#=ZH[FPWA8YMZ/%=PI)%)(J)%-(KI!"(:5"*H74"FD4TBJD
M4TCO(\RXL-@HXT:PM8'=OCW<_[8]V%TM8.LY+`EVH3`:L-;`#V^EF/-U8(ND
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MR8:_YX#3,V&HR:V.T`JV?[=6QV*UV"%KY@R?4$7C=4J^HE@,])0J<I:P?48L
M)Y]/DB^0%4'#O%8LQ19=:OUJDGY-%4\VOR&6:WX[2;Y#UIGF]TR?#P63[ODK
MX?2A8!-%B+AHF&XC"ZUATW,>78K==H<L:!-53!":PWKM510;1>I85#'36CE!
M$0Q_3TQXM/!HI%82YEI6$71:K?9HI-80YM1:A$[WLW,LTNJ9%G>@R2B5`]^8
MW)CS(+&8$N1:OT/(3V80XMG,4FS,J6-1AS(-Y1HJ-%1JJ-)0K:%&0ZV&.@WU
M"`42&W,2QFQ_9O&T"2J;,1;R]ZQ!%))Z+[E!*#J3W7@T9V=[@;F;I;E'\R>(
MV(4*CT9J)6*>6N71/#65XW@T4FNT6NO13JAU'HW4>E+3B8XQVUO<9!-9YB8+
M,3=9B+D)*_H1WW!MV#`]+$/,JYHCQ(.^I4@O"L>B7I=:JW(LWX1B%:X=B[0:
MK=4ZEJ\EVM4Y%FGU3(LO6+`5OL4;ABXB#@LQ;UC(,VEB#H5-1<_R:0#+$/.J
MY@AQ;RQ$P%LX%O6ZU%J58_D6%%M;[5BDU6BMUK%\+;':=HY%6CW3XMXP":J_
M?9Q9PFP^"]XE[6UD(>8-"WDF39#%O8%BGH<RY'E5<X2$-T2`63@6M:S46I5C
MG;!@[5BDU6BMUK%\+3%*.L<BK9YI<6^8A/4-WK#Y+?.&A9@W+.29-(FPHF?Y
M-(!EB'E5<X2X-Y:BUX5C4:]+K54YEF]!L1'5CD5:C=9J"7+GW)V&>H("FX3)
M5M]@>IO<,M-;B)G>3X'QSA!69*;76!:IJCE"PO1J(MB*P")SE5JK(LB9J]90
M0Y"+15J"7,5.0SU!`3N;K-2WLY=P3$_^33@N=P4+,?-;R!N^"5;T#P`TE"'D
M5<P=RQNKZ@S`L9SQ52,JDG?9>ZVAAB#?^*CE*G;$<E!/D#8^Q+!_:?S3"_]0
MDV_#")U)_)'E)_Y4$39HEZ"IQ)\J,M92'`]DQ'*9<SY)OD#6F<RYU/K5)/V:
M*IYL?D,LU_QVDGR'K#/-[YD^VVIF?SOQ'VJ*H1!,_,4AS8XJNI0R08@GQ"N1
MJZ>.1;,JTUHY06;XNW$ECW(*CT9J)6&N915!I]5JCT9J#6%.K47H=#\[QR*M
MGFEQ!P83_W@X13TSEW6V/[.0OWAJ*-%0JJ%,0[F&"@V5&JHT5&NHT5"KH4Y#
M/8.X==^6VIOC0[$?(;1RR_=.0XF&4@UE&LHU5&BHU%"EH5I#C89:#74:ZAG$
M36K28[7SO_&D"L(F-+2;XXL;$3)NB>5FX`XA6!!I;B4(\<,K=2O>L:ABIJ%<
M0X6&2@U5&JHUU&BHU5"GH1XAVVWN#I,?_[([C(C8"Q!RAMZ9!_^`Q6R/+'-.
MX!;KE<B+4ZQI3KZ<]95:CK1;*/'$1&)<.!9IE1JJ-%1KJ$'(ZU*+D#BE6XFQ
MV7DT:D;/U+B73([\RU["1-L9<3M#R/>2A;PN)<CB,V0ECG]2QZ(.90AY6CE"
MPD<R<70LTBJU5N58OK]%)E0[%FDU6JM%2/11Q)F=8Y%6S[2XTTQZK9PV:6O&
MQ-SWE(5XF+U2L95EP>I+[4MF6)%-"AUF6];B9GCX,;I=+437,]3QI/-)T@55
M-,_V_/YA)EQ=4K%K<C5)MT;6F=BWT?KM)/T.6<XD<@[W3)J[WF3??\_U>`C@
MNQY3>9B8;EE;B^AX-\.*;BHG",7F\;7?/T3KY3H2M5)'H0&3::$<(8A;AT=C
MQ5I6N&(2*;5(Y5A^-^2!M&.15D-:$)QZ_1=[1(LLU]EX+MK9.0II]Z0]6(V[
MT"39RH5OC5-LIN[M6]L90F:Q][HC=JD=TKSIEB`4+P8OS%=S>1:=.@9U,-,Z
M.;%P0@H/%*Z81$HM4CF6WPMA\=JQ2*M!:,5'L_*FM9+KJW;FR"#IGC63.=,\
M0_O+SAQ$>)2#T,(]R+PCEC</$5K#&NL\KI9@9,5V"9XMYK<RH,VT=CY)NR#M
M:!@ZM\+EI=:M)NG63M?KV5I$!@W)GY[`DZ[8T15'*RT78NST=#D]I^$D+S`,
M5N8]&/O(T;\.W\'!^,ND!X('23$H[#&(]V3##EE>()0@Q`,.=<_<L6B49QK*
M-51HJ-10I:%:0XV&6@UU&NH1LMWF$]*<-/SJZCJWQQ7^ZDJ0FWT[A)CML>*9
MM(/$O`MD6BU'2(2T8D$O'(L\66JHTE"MH08AKTLM0N?2#H]&S>B9&O>2//X8
M3NG?N`?.]:$(0;Z7+,OK4H(L/D-4VN%8U*$,(4\K1TCX2,2BA6.15JFU*L?R
M%KV53#L<B[0:K=4B)/HH8N_.L4BK9UK<:<$#EBEI!SS0(=-XA'C:H6)/9/G!
M"E5D48[>\^P5,<:>S6_F,J7)M'8^2;N@BC;,D6TNJ=C+.R;IUE21]6PMAE)#
M6J?#'&(Q+6FE#EG.2O`N)G_JM*=&#;WAPP&T?WVE-2)BE[,0?\IO+5:]W1PK
MNIF>(+2<V3`VCF]$9U+'H.&>:9V<6#:[$=.O<*6D46J-RK&\J;P66K5CD59#
M6F="&MO[L:N+I8A5.I)VMVE[D@Z$+^9HYI<W32,B7&FAV(]B+<1F-%:$9=4S
MEARLZ=S2X`UGF^[':SGU,J1XXCE"T6GQ@L1M'"L=56KA:IIP[82]OJW%.MP@
MZTSN,NV2'5UR--3B5LR>'BG64'Q6F_.:$T.!`MG3MX#,C2@Y%BSDWP)"E@<E
M&DHUE&DHUU"AH5)#E89J#34::C74::AG$+>T/,HY8U)]?C.WD'\+2$.)AE(-
M91K*-51HJ-10I:%:0XV&6@UU&NH9Q$UJ4O<3@W=:XH7G*/Z=@\6-2#VW<V2Y
M_6>'D!<=)@CQ*$S=`G(LV@8R#>4:*C14(F0;P8P#NSPWSNGQ-M#Y<DX0G$Q3
M0W<CYM;XA#">!<G#@=2CD5Q&&!R?$983)N3$FE9X-*I:$@8'JH!Q<P13=AO-
M3G]0:($IN7>J2A"S$M)L.^R36LCC8^-6[..I8U&GLO$"SN2YHWG;C!0K'(O$
M2B[&+11,I:?$^PN=/R/$XWT9D^^0Y6W@"56$B.?$&1=59*Q;<6J8$<N%YODD
M^0)99VX)E$R?VS*8\$ZRI<YR%Q82$;(X@=\ARSLM2A`R>Y*SY:U8VE+'HE&2
M::W<L7PMD:T4CD5:)=/B1@HFF&\\%5CH7!,A/O941H$L-O:L5LQ'E8CB4ZP(
M+.ICIK5RQ_+M)0+!PK%(JV1:W%XF"_C5[6YA1,0Z;R$^OF[E+4&JZ';`!*$S
MY]'(BF%-'$<A?,J))YZ9EL\GR1=A>9$*EDR>6]7D&<JJOW26N\`,Q]\E$'+6
MVR'+CQ\0XGN$.LMU+!HTF89R#14:*A$*Q0\R,S@3/^@4`.YFF*'FQ?L[A.`\
MEYJ>("0.''7T@/K^&2JI.3OG?Z&F@@>M5I*:?LYU(4/WO_60\:`B9IZ-Z)F%
M+,0L9"$^*N1FGZ(\L,BT&4*>5NY8;C)&4JMP+-(JF1:?0,$H?-)>-X;>=)GM
MPD)B[1:+Q0Y9;.W&BFSM5H<*5-%GS>07FC)B.5/FU"Z_HGJ[N*"*/FMV(P9?
M22Q]Q@;W[`)KT1MWQ$&$CS.$^`JO=D2JZ-:H!*$E1"#>VBWBK-2QR(^9ULH=
MR]<2T4CA6*15,BTV],R>HM?NM]I+Q_2#+GQ6RL\)([4C(LL?A0B=.7Y*D;;D
M6Z((IC*MGT_3+\+Z(I`IF3ZW:S`5<':==BH4Z[0`(7_!TU"BH51#F89R#14:
M*C54::C64*.A5D.=AGH&<4O+1.'T+@M/I<CH#2'_5$A#B892#64:RC54:*C4
M4*6A6D.-AEH-=1KJ&<1-&DPKINQ'\)0(6M>M4/`91!ZI;I'%QK"MZ$&)9J4:
MRC24:ZC04*FA2D.UAAH-M1KJ--0SB!L<MKM?7X6-B-BU$'+[T<ZD9L#R8V:$
M6'0TBT3\GSH6;2L9T^(="J8$DT:0COQC"[&]9!:)<Y\=LMA>@A6AR^/>JT*.
ME"HREGSE)2-6(.0PD;!*?]Q2/^D,%>[X*.=9B(4<LTB$0CNJZ%R<(,1#CDB%
M'%8>6,Z?V(A!B_LS&+^_M8\V"O?RCVUL(>%:$='LD,5<BUHPCD_ZUM)8F!#)
M6W\9T^?]#D;FKM\3MW$=I<<6\M:[G882#:4:RC24:ZC04*FA2D.UAAH-M1KJ
M--0SB%D:[E+R671Z&Q_H?+%#R-_&-91H*-50IJ%<0X6&2@U5&JHUU&BHU5"G
M(?,!:[-RV&Y;D]H/4MNO\S[M7[[N=_O'Q^/%_>&'^=AT!-GLAW<CCI_"CA>;
MCR`%:X$H@=UZ8[:N4,DME`SO'<LZRQOZLK8H^3B#Z\#]J(#:?+4Q-_]")6LH
M"=7Y.+_=?(0X)E`GGD';AGOYH@7;>`XEH3IP?K$Q6;I6@RQN8W(T70(YV<9D
M7+HDB6.H,QQQBA;``@TEH9["!\D_!ML,'RH?#E6$TA8Z&>1#%T,]_`C&MZNH
M$$H6RXTYW-+=V()1MD&CP%'49A<L@1.I30J'05HM6:RA)&3B#.J8XQ9=!TZD
MH&TA-3B+@9)P'7`+W,L*J450$C(FW/L"]X=*X#8`M#ID4#C4![502;)80)W0
MM(&#;:@3*H$'<C;FD9M`JZ'$/$BC2^#!F8UY+$:7M%!BGFK1)7"7%=2"$Q=L
ML`W:`.Y;@K?#UH')$;1ULHB@)%0';EN"MT,E\#0NM#I<,@/KA(8[//<)-@B5
MP,.8H!8J@6<:02WD.7A"$:P3*H'G#>$ZH1)X>A"N$RJ!5S\VYMT.[05XEV-C
M7MC0)?""QJ8.EL"[%1OS\H2N`^\DP'5"/H6W#.`ZH1)X=0"N$RIIH:0+EB0S
M&*/PE+9N`;ST!VJA$G@3#]1")?!"&ZB%UAUX/0U:'2J!E\W@.J$2>'4,KA,J
M@8]1P0H:ZBF\\0XM"(TW>'\=6A`J@7?1H06A$GBO'%H0*H&76Z$D-.NW,[.*
MA\;H=@:M#J[7\*FNC?D>A?8"?+%K8S['%2J!%MC@6ZS^\!TC*`GY![ZI`R4A
MB\+W7:`DM"K#%TF@)#1&VPA&5;#5\#6/31$L@4^<;<I@"7SI;%,'>PI?W(*2
MD*WAZT]0$NHI?(D(2D(]A:_B0$FHI_#1%B@)]12^*`(E(?]LH=7;8,D.2G;!
MD@1*TF!)!B7FXRC:V_!5.;!H:!S`M\V@)&0=^,X6E(2L`]]\@I*0=>#[0U`2
ML@Y\'@=*0M;IXPU\"U6W&3X["?T,S1[XB"1HA4K@@Y!@Z5`)?-P11ENH)(E@
M5X"O".H6-/$&ONVJ\18F2,@N+4R/D%5:F!PAF[0P-4(6:6%BA*Y;QAOX:*UN
M3P7#.-2>"@9QJ#T5#.%0>RH8P*'V5#!\0]=-8`D)C9QMO-F&^+MXLPOA"6PB
M(3R+-_"U7]W?'`9FJ+\Y#,M0?W,8E*'^YC`D0_W-8?D9KGL]+HWPAWB^WWW=
MMW<O7Q^>CQ>/^R^0.]T,7_-XL7_*Q_[RBB\J?3J\PI_@@?0*_O0)_,FE/?S5
MD1OS%PV^'`ZO]`MT['K\(TX?_BT`````__\#`%!+`P04``8`"````"$`3U+U
MI9P"``#6!@``&0```'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6R45=MNVS`,
M?1^P?Q#T7LN7-&F,.$6ZHEN!%1B&79X56;:%6I8A*4W[]Z,DUW.6H,U>+(LF
MSR&/*'IU_2Q;],2U$:HK<!+%&/&.J5)T=8%__KB[N,+(6-J5M%4=+_`+-_AZ
M_?'#:J_THVDXMP@0.E/@QMH^)\2PADMJ(M7S#KY42DMJ8:MK8GK-:>F#9$O2
M.)X3246'`T*NS\%05248OU5L)WEG`XCF+;60OVE$;U[1)#L'3E+]N.LOF)(]
M0&Q%*^R+!\5(LOR^[I2FVQ;J?DYFE+UB^\T1O!1,*Z,J&P$<"8D>U[PD2P)(
MZU4IH`(G.]*\*O`FR6^N,%FOO#Z_!-^;R3LRC=I_UJ+\*CH.8L,QN0/8*O7H
M7.]+9X)@<A1]YP_@FT8EK^BNM=_5_@L7=6/AM"^A(%=77K[<<L-`4(")TDN'
MQ%0+"<`32>$Z`P2ASW[=B](V!4Z3:)'$RVP!*%MN[)UPD!BQG;%*_@Y.R0`5
M0-(!!-8!))M'EXLX2X#S'1`2$O+UW5)+URNM]@AZ!BA-3UT')CD`GRX(*G&^
M&^=<X`5&D*N!0WA:9\OYBCR!<FSPN0D^\!Q]DM&#`.G(#&SG,SMGQ^RD=:G<
M!,.4)CU-D_T/C7,N,#S'Y(\+##XSWR_3>F:'1*%%(G>^;XOJXD!]6-X@'9Q"
METY9`?Y\%9VSIQIE'"Q3';/EXK22\T.JLPMT<8>L@^6X&FBM:36>8@Y-_IZ&
M+NZ08K!`FTQ4O3I=F!O29]\!YWQ(-5BROQT1YDBX9Y+KFG_B;6L04SLW(U*X
M.:-U'%^;U,7_:Y_E&S_6R/@!QDI/:_Y`=2TZ@UI>`63L^TR'P10V5O60)LP%
M96&@^-<&_A\<+D_L!*V4LJ\;(";C'VG]!P``__\#`%!+`P04``8`"````"$`
MO3+NLE@%``!`&```&0```'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6R<6-F.
MJT80?8^4?T"\7T,W>)7M*T]&DUPID:(HRS.#VS8:H"U@MK]/]4*[-VS&+YYQ
M4=NIJCZ4>_W]HRJ#-]*T!:TW(9K$84#JG.Z+^K@)__G[Z=LB#-HNJ_=926NR
M"3])&W[?_OS3^ITV+^V)D"X`#W6["4]==UY%49N?2)6U$WHF-3PYT*;*.OC:
M'*/VW)!LSXVJ,L)Q/(NJK*A#X6'5C/%!#X<B)X\T?ZU(W0DG#2FS#O)O3\6Y
M[;U5^1AW5=:\O)Z_Y;0Z@XOGHBRZ3^XT#*I\]>-8TR9[+@'W!TJSO/?-OSCN
MJR)O:$L/W03<12)1%_,R6D;@:;O>%X"`E3UHR&$3[M#J(5V$T7;-"_1O0=Y;
M[?^@/='W7YMB_WM1$Z@V](EUX)G2%Z;Z8\]$8!PYUD^\`W\VP9X<LM>R^XN^
M_T:*XZF#=D\!$0.VVG\^DC:'BH*;"9XR3SDM(0'X#*J"C094)/O8A!@"%_ON
MM`F3V60ZCQ,$ZL$S:;NG@KD,@_RU[6CUGU!"/"GABZ?VF'79=MW0]P#Z#=KM
M.6/3@U;@N,])>%!9#B4)V3$G.^9E$\[#`.*W4-FW;;)<KJ,WJ$8N=1Z$#GPJ
M':0T(LA&I01IZ"GYR]-'9LHL,BL72^5!"/0PV!\F,<,PY`GT]'HX9@1Z.HC8
M!BIT4EYV'5?J!D33R7QP`GJ(S`[:`W]4Y=(X5J`$;*DD)E"/"N['5Y,I\U"J
MG%*BUQ.A@8K.S%!BED8`9'9F5"EQT<"(Z6A8"!RG(V(P0S.&E,"\J+(BE*BR
M&B/)*-@Y)2.B,CLSJI2XR):>$#,XW[<FDMF9(:3$!);Z@2&8>!W9]>GGVF:P
M7I0XXX[8@;^G:-R01]$[,U4`Q,#W6FXE$:,`+?`-3)(P^'F5KJ7('/I+`L9H
M(`^/C#K6W-`JIJ`.J"E[C^BGF)U^'1,_6WC!7A0W&(M;6F$D69@3,E,%-B,S
M!AA?3<D7>C6ER#,A]Q(&4HRA3\A<`9!M'&019-'(C0EQN8,[@**:$W))P*S@
MO>R!7/KH19X)\1!(&B\G4(0;\%P&05X*6:CZ&O#PERB$:YOCV(O<`<'W4@@W
MY%'T`;%?U+V66TS\)0KAVA8F+X5<$C`K>"^%8,D7VFGK11Y,'@I)YO'M-PR6
M=*%'\3$(ONPD)CR+04;O!8S<K'=;+_+`\Y`)GH[9K[!B$[7U]"*#(?'0OOHE
M-L$NF_0BSP&XESJPHH[+`4CC"P#!D+V6IYH6FURG$.Q22"\R&!(/+(YL[];?
M,:,GA!N:)Z\7N9@2'YO`JQJF[#H\;FA%8;Y`9`[(P/:86&PR'IYD$>WD<5\0
MV`//8I$;F%SJ2*0(ZG'9B/'`XIAXV&34VL,-K6)*-O%@\E`'1O,1+7.I(Y$B
MLV4#6UWB89-Q\%PRX;[\+;.8@PW&.'@NB2129,(;6.J2>WF%&UK=DU3CZ9Y%
M(GSN1RVMB4LHO<C$-[!RI?<2"C<T\?4B%U]J$<KU$\>U+=>21<P3-[!GI8P,
MM$5\-(MP0RLP\P4B#R:+17@4EOH-<"Z=I%)D-FQ@!4KOI1-N:($;I)/40R?)
M(AGQ*XI;6F%\?)(,[$#IO7S"#:W`DF(\S?/P"1KSADM=/NE%1ON2RP9AK'AP
M;6K,YHUA4<N)6KBX`X"IK4#B'E5<5E:D.9)?2%FV04Y?V1WI#&X9E53=W^XP
M^^5LR]/53DRZ_0`A>,*O6ITGL]4.?I=XG&&P@87-]V2QVHG[XTBY@_O;<W8D
M?V3-L:C;H"0'R#WF-T>-N`$67SIZ!O1PBTL[N+GE_Y[@II[`C2;?T`^4=OT7
M"!VIN__M_P```/__`P!02P,$%``&``@````A`#Z_;^I"!P``"AT``!D```!X
M;"]W;W)K<VAE971S+W-H965T,3DN>&ULI%G;<N(X$'W?JOT'RN\#^()Q7"%3
MX>(;WJJMK;T\.\8$5P!3MC.9^?MM698LJ34$=E]"..H^+1VU+BT>OWX_'4??
MBKHIJ_/",,=38U2<\VI7GE\7QE]_!E\\8]2TV7F7':MSL3!^%(WQ]>G77QX_
MJOJM.11%.P*&<[,P#FU[\2>3)C\4IZP95Y?B#"W[JCYE+7RM7R?-I2ZR7>=T
M.DZLZ=2=G++R;%`&O[Z%H]KOR[Q85_G[J3BWE*0NCED+_6\.Y:5A;*?\%KI3
M5K^]7[[DU>D"%"_EL6Q_=*3&Z)3[\>NYJK.7(XS[N^ED.>/NOB#Z4YG755/M
MVS'036A'\9@?)@\38'IZW)4P`B+[J"[V"^/9]%-S9DR>'CN!_BZ+CT;X?]0<
MJH^P+G=I>2Y`;9@G,@,O5?5&3.,=@<!Y@KR#;@9^KT>[8I^]']L_JH^H*%\/
M+4SW#$9$!N;O?JR+)@=%@69L==W(JR-T`/Z.3B5)#5`D^[XP+`A<[MK#PK#=
M\6P^M4TP'[T431N4A-(8Y>]-6YW^H48FZ10G<7H2^&0D8\>:S;V.Y(HCA.BB
MPV?OZ(U-9^J2V%?<W-X-/GLW\^X^SWL.^.PYK+$WFSFN-[\>'%9.UV?X[!W=
MVP;[T#O"YW_NM0D)TD4G__0L]GAN3A_L3[IMLIDF__2>WFV>D!LTYI`D-^L]
MH?G6I>\Z:[.GQ[KZ&,&>`+UH+AG984S?!&*2N#8,BDX[3^6?93)D'V%Y)C0+
M`R81W!M8?M^>G.G\<?(-EDS>VRRQC2E;K)@%26I"NU:!C0H$*A"J0*0"L0HD
M*K!5@50`)B`<5P\$0^J197^G>H2&J,?&O63`(*>E2,4LF,M:!38J$*A`J`*1
M"L0JD*C`5@52`9"DLC52.2"5?H=D>46\("&%O+),-:]ZFP<NWPHA:X1L$!(@
M)$1(A)`8(0E"M@A)1422"?9N*:.NRT.L8>7"A[#N/#E5EM3(=09]*&+3TZ-;
M:!3Q8/(XD64IRW/#C5C2!8@HY#8BD2OW*.)&C"A&1`FW&8A,QY&)MMR($:4B
MD20LI-H=PA+K3EA&O*2(J")%1!4IHJBHK-P--V+4`2(*N<TP>,M2\C[B1HPH
M1D0)MQ&)'A05N1$C2D4B244XZN]0D5C+*E)$5)$BHHH4452TY3YON!'K<X"(
M0FXC#EY9'1$W8D0Q(DJXC4!D3^4>;;D1(TI%(DE%."?O4)%8RRI21%21(J**
M%%%45-;/AANQ/@>(*.R187N-$!(CKX0B<GA;V5"VW(B%3T4B23)2**GW%',V
M)K>M]E#F;\L*-BXXIC7[I0WW$7I+(22RDA01E:2(J"1%/-BRA;UQ)L_^AANQ
MH02(*.P1EV_$$4)BY)501`YO*YO*EANQ\*E()"D)]]Z?*:D1#TH`IAYQE-6C
MR!SVW$$96UFI*VIDV7S4Z]Z-3!V[+9HS95UN>C?1R+*5_`UZ)EAH`Y.G:!/>
M$B[2AE,F.;XE7')+N*TVG'),II^$DV:5%")H6JW9&/2[/JN=HSRM/32'Q<AE
MM6SE^%DQQZXP[J_KI!-P79MW%0!4G<HBZ5V@G:5I@%G"P4H,K^1'-%@QKIAQ
MB;<84TV'9'`D98JZ)0VMC#9EM/0%0+S^DQH.B^Z2$O^.7:EC46:@+SA@$0LS
MH)S;J]Y17%H]Y(E+TG25HVHS6+%!!I@K'*R&3B"N:+!B7#'F2@:K*US;P8IQ
MI1*7G/&DTD!'`KR:W*4]+5?@!LTB+DD5#$DL9[^C2+CJK2`WF..ZASRR8T)B
MX>RGQ-#.7`+,$@XL@U*6C;(?<<6,"UIXSFBRGSMJLY^WLBZFC%:3_:2(^=\3
M0"LA:0(H)!\KCK)05R:UDI*?0A[L0H,"Z&#I'3U88MS*<I1#(^BMYM>/%L9U
M-6+$K,2(IJ=,:7Q3Q(1Q78VX959B1,M13N;TLXCR<B.5%9IM>@/[Y(2A-9DT
MQ102[UVDB(5E)T!K#&TP%&`HQ%"$H1A#"8:V&$HE2!8)-A])I$^4(>;*SD^A
M^5";K\B#$MF0!FB-H0V&`@R%&(HP%&,HP=`60^2)?>@J588^F=,WQU-1OQ:K
MXGAL1GGU3I[#;1<V2P[3MWK82/T-;#NP!2DML#GZD;8E@9:MM@5>_I]U7$OR
MBX`FQM+RX0T+QU[:/KS:8/S9\9]AV+AA:3H0H3M8E&$LS1G[-4)I2<'%TW"M
MS2E(TFW!B@?<ED`270M<=$`27<O:-(%--W@X\X%-UP(G.+#I6F+'AZH%CS]Q
M?'B?T>`S?ZO3*W%]J*$U]G,?"D4-[OE0]F`\<'RHO3`>.CX\/&GPF0]/*1K<
M]>%Q0(//?:B`-;CG0SV'\:7C+W7XRO%7.GSM^/#2AGG6,Q_>CC2XZ\-KB`:?
M^U#?:W#/AVH5\`E/)?@EZI*]%K]E]6MY;D;'8@]+<]H5US7]+8M^::L+[%;P
M>U35PF]0W;\'^,VQ@*?Z*;EW[:NJ95](`/XKYM._````__\#`%!+`P04``8`
M"````"$`KZ(T'#$!``!``@``$0`(`61O8U!R;W!S+V-O<F4N>&UL(*($`2B@
M``$`````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````G)%12\,P%(7?!?]#
MR7N;9,,AH<U`94\.!">*;S&YZX)-&I)HMW]OVG5UHD]"7L(Y]\NY)^5R;YKL
M$WS0K:T0+0C*P,I6:5M7Z&FSRJ]1%J*P2C2MA0H=(*`EO[PHI6.R]?#@6P<^
M:@A9(MG`I*O0+D;',`YR!T:$(CEL$K>M-R*FJZ^Q$_)=U(!GA"RP@2B4B`+W
MP-Q-1#0BE9R0[L,W`T!)#`T8L#%@6E#\[8W@3?AS8%#.G$;'@TL[C7'/V4H>
MQ<F]#WHR=EU7=/,A1LI/\<OZ_G%8-=>V[TH"XGT_C0AQG:K<:E`W![Y_\TT6
MPJ[$O[52R2$=DQY$!)6E]]@QW4EYGM_>;5:(SPB]RDE_-I0PLF!T_EKBDVN<
MYQ/0C`'^33P!^)#[YY_S+P```/__`P!02P,$%``&``@````A`*>?O/>5````
MJ0```!````!X;"]C86QC0VAA:6XN>&UL/(Y!"@(Q$`3O@G\8YNYF]2`J2184
M?($^(&1'$T@F2R:(_MYX\=)0-%2WGMXYP8NJQ,(&M\.(0.S+'/EI\'Z[;@X(
MTAS/+A4F@Q\2G.QZI;U+_A)<9.@&%H.AM>6DE/A`V<E0%N+>/$K-KG6L3R5+
M)3=+(&HYJ=TX[E7N`K3:0S5X/B+$_@$A_5)9K?XC]@L``/__`P!02P,$%``&
M``@````A`+=NK.G]`@``LPH``!``"`%D;V-0<F]P<R]A<'`N>&UL(*($`2B@
M``$`````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````G%9=3]LP%'V?M/^0
MY1W2`ILVE`9!`6W2!A4M\&A=G)O&PK$CV\GH?OUNFO4C8#+H6VS?>^[Q/<>Q
MXY.G0@8U&BNT&H7#_4$8H.(Z%6H^"F]GEWM?P\`Z4"E(K7`4+M"&)\G'#_'$
MZ!*-$V@#@E!V%.;.E<=19'F.!=A]6E:TDFE3@*.AF4<ZRP3'<\VK`I6+#@:#
M+Q$^.50IIGOE&C!L$8]KMRMHJGG#S][-%B413N+3LI2"@Z-=)K\$-]KJS`47
M3QQE'&TOQL1NBKPRPBV201QM#^,I!XEC`DXRD!;C:#,1?T=HFC8!86P2U^ZX
M1NZT":SX0VT["H,'L-C0&84U&`'*$:TFK!TLOV5IG4GNM7FT.:*S<40![>3R
M<SMV^UL<)8??EA'TU1O9@EU!@6EP`VJ.[ZDQ])=H2+:;I=K=-LR$DVBOLPD8
MY^L*N6W3EB6WMBDMS951&-F/72A'DK`?JC64T$LR_YJS;M-8*ZNE2,%ARLY`
M@N+(IB^:^99X-H'_EY@ZJM28V3*=L>N2/+'&;M1M^758=5/&NGAW"G1$6U>9
MY<@(K@2U\$).JZ(`LVB(6C%7@LXBN9`!Y[I2SIMR26YF-<@*FZQ,*.JG`,F$
M(J-6WI1KEZ-AG'@8S%%942.%TQB9U'[BIRT#RTI8P(/$I=Y$RU0DHK^C]V`,
MD??C7:%K:A$>,;$Y&#_&U&G^R.`WF)25Y!3O=JBAA7"MPHT-N28?TKFA/G3/
MSEJ&L982'K19_FS8#=:HJE<(]`K2GK;G!N]7Q)_3+XD_IU\3?\Y*%#9K5'RK
M-GW1SR7JB^U5BGG%W3HQ_AWU=_O`"]J?<[A#SM$..9^].?U.\.^GWPG^G+43
MSM&!D&^VPF[AS$_BA7GZT%\+?B<V\^O;[TV_][S_$=:WA]XJGPHCY>1LV.E5
MY^I^=EG_%.K1WI8S?4Y7W.K!TYV,I\W/-:5[>K6^F8B_TUO'R`9DG#<OC705
M\W*A>9[=M6_09'BT/S@<T,MK:RZ.-J_-Y"\```#__P,`4$L!`BT`%``&``@`
M```A`#[*`F7Z`0``7AD``!,``````````````````````%M#;VYT96YT7U1Y
M<&5S72YX;6Q02P$"+0`4``8`"````"$`M54P(_4```!,`@``"P``````````
M```````S!```7W)E;',O+G)E;'-02P$"+0`4``8`"````"$`C5\\HQ$"``!M
M&```&@````````````````!9!P``>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"+0`4``8`"````"$`F48[W[L#``"Z#```#P````````````````"J
M"@``>&PO=V]R:V)O;VLN>&UL4$L!`BT`%``&``@````A`(6&S?87!```\@T`
M`!@`````````````````D@X``'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+
M`0(M`!0`!@`(````(0"K#"+H\@(```P(```9`````````````````-\2``!X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L!`BT`%``&``@````A`$&AIYP<
M`P``<PH``!D`````````````````"!8``'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"+0`4``8`"````"$`T83I;!<#``#]"```&0``````````````
M``!;&0``>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+`0(M`!0`!@`(````
M(0!Q;"'[7P,``!L,```9`````````````````*D<``!X;"]W;W)K<VAE971S
M+W-H965T,S`N>&UL4$L!`BT`%``&``@````A`&_)FRH&!```60\``!D`````
M````````````/R```'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"+0`4
M``8`"````"$`B/^9>+H#``#.#```&0````````````````!\)```>&PO=V]R
M:W-H965T<R]S:&5E=#(X+GAM;%!+`0(M`!0`!@`(````(0`/(J$DD@0``#X1
M```9`````````````````&TH``!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M4$L!`BT`%``&``@````A`#MBS?J;`P``=0L``!@`````````````````-BT`
M`'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+`0(M`!0`!@`(````(0!3#1+.
M#0,``.$(```9``````````````````<Q``!X;"]W;W)K<VAE971S+W-H965T
M,S0N>&UL4$L!`BT`%``&``@````A``OE5Q#G"```R"P``!D`````````````
M````2S0``'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"+0`4``8`"```
M`"$`X\>QC"X#``"1"0``&0````````````````!I/0``>&PO=V]R:W-H965T
M<R]S:&5E=#,V+GAM;%!+`0(M`!0`!@`(````(0"F2#V)J`0``%X1```8````
M`````````````,Y```!X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"+0`4
M``8`"````"$`,A+/&Y("````!P``&`````````````````"L10``>&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L!`BT`%``&``@````A``E0>2*V/0``^\D`
M`!0`````````````````=$@``'AL+W-H87)E9%-T<FEN9W,N>&UL4$L!`BT`
M%``&``@````A`&X#A8S=#@``4)4```T`````````````````7(8``'AL+W-T
M>6QE<RYX;6Q02P$"+0`4``8`"````"$`^V*E;90&``"G&P``$P``````````
M``````!DE0``>&PO=&AE;64O=&AE;64Q+GAM;%!+`0(M`!0`!@`(````(0"O
MEF&X50(``(`%```9`````````````````"F<``!X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L!`BT`%``&``@````A`$&Z"#4[`P``W0D``!D`````````
M````````M9X``'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"+0`4``8`
M"````"$`*P86/DT#```?"@``&0`````````````````GH@``>&PO=V]R:W-H
M965T<R]S:&5E=#,W+GAM;%!+`0(M`!0`!@`(````(0`)W&EX`0,``&L(```9
M`````````````````*NE``!X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L!
M`BT`%``&``@````A``!3TC]U`P``=`L``!D`````````````````XZ@``'AL
M+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"+0`4``8`"````"$`TF(15:X/
M``"B2P``&0````````````````"/K```>&PO=V]R:W-H965T<R]S:&5E=#(S
M+GAM;%!+`0(M`!0`!@`(````(0`<UA%N*`0``)(-```9````````````````
M`'2\``!X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L!`BT`%``&``@````A
M`$Z2L9E_!@``TAD``!D`````````````````T\```'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"+0`4``8`"````"$``NQ#F=`(``!1)P``&0``````
M``````````")QP``>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+`0(M`!0`
M!@`(````(0#853$^B!L``)Z6```8`````````````````)#0``!X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"+0`4``8`"````"$`4T5OQOP$``#>%P``
M&`````````````````!.[```>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M`BT`%``&``@````A`/'V>&D+`P``<PD``!@`````````````````@/$``'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+`0(M`!0`!@`(````(0"GHL>4X04`
M`,07```8`````````````````,'T``!X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"+0`4``8`"````"$`76VU].4"``#V!P``&`````````````````#8
M^@``>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!`BT`%``&``@````A`-SQ
M/070"```)2@``!D`````````````````\_T``'AL+W=O<FMS:&5E=',O<VAE
M970Q,RYX;6Q02P$"+0`4``8`"````"$`JRI3O-D'``#G(P``&0``````````
M``````#Z!@$`>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+`0(M`!0`!@`(
M````(0!E)'3.)P8``*$9```9``````````````````H/`0!X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L!`BT`%``&``@````A`(J:X7!H!P``?Q\``!D`
M````````````````:!4!`'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"
M+0`4``8`"````"$`HXT]+_\&```0'P``&0`````````````````''0$`>&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+`0(M`!0`!@`(````(0`$HI!*RQ,`
M`(]G```9`````````````````#TD`0!X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L!`BT`%``&``@````A`!&!R<FP!0``_A0``!D`````````````````
M/S@!`'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"+0`4``8`"````"$`
MZAO1$`$5```):@``&0`````````````````F/@$`>&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+`0(M`!0`!@`(````(0!/4O6EG`(``-8&```9````````
M`````````%Y3`0!X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L!`BT`%``&
M``@````A`+TR[K)8!0``0!@``!D`````````````````,58!`'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"+0`4``8`"````"$`/K]OZD('```*'0``
M&0````````````````#`6P$`>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M`0(M`!0`!@`(````(0"OHC0<,0$``$`"```1`````````````````#EC`0!D
M;V-0<F]P<R]C;W)E+GAM;%!+`0(M`!0`!@`(````(0"GG[SWE0```*D````0
M`````````````````*%E`0!X;"]C86QC0VAA:6XN>&UL4$L!`BT`%``&``@`
M```A`+=NK.G]`@``LPH``!``````````````````9&8!`&1O8U!R;W!S+V%P
;<"YX;6Q02P4&`````#$`,0!`#0``EVH!````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EYIAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Net loss per share (Details) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" onclick="toggleNextSibling(this);">$ (37,915)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" onclick="toggleNextSibling(this);">$ (14,098)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Denominator for basic and diluted net loss per share (in shares)</a></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">33,067,752</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">24,492,487</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Net loss per share:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted (in dollars per share)</a></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (1.15)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.58)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EUGAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>The Company (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Aug. 04, 2014

</div>
          <div>state</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>The Company</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_MinimumAgeOfAmbulatoryPatient', window );">Minimum age of ambulatory patient</a></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_NumberOfStates', window );">Number of member states of the European Union</a></td>
        <td class="nump"><a title="ptct_NumberOfStates" onclick="toggleNextSibling(this);">31</a><span style="display:none;white-space:normal;text-align:left;">ptct_NumberOfStates</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">$ (460,466)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">$ (422,551)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_MinimumAgeOfAmbulatoryPatient">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the minimum age of ambulatory patient.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">ptct_MinimumAgeOfAmbulatoryPatient</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>ptct_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_NumberOfStates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the number of states of european union</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">ptct_NumberOfStates</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>ptct_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2FAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock award plan (Details 3) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based compensation expense recorded in the statement of operations</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense" onclick="toggleNextSibling(this);">$ 9,748,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense" onclick="toggleNextSibling(this);">$ 3,705,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
        <td class="nump"><a title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" onclick="toggleNextSibling(this);">70,600,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average remaining service period for recognition of unrecognized compensation cost</a></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based compensation expense recorded in the statement of operations</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember]" onclick="toggleNextSibling(this);">4,667,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_ResearchAndDevelopmentExpenseMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember]" onclick="toggleNextSibling(this);">1,944,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_ResearchAndDevelopmentExpenseMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based compensation expense recorded in the statement of operations</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember]" onclick="toggleNextSibling(this);">$ 5,081,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_SellingGeneralAndAdministrativeExpensesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember]" onclick="toggleNextSibling(this);">$ 1,761,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_SellingGeneralAndAdministrativeExpensesMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested share-based compensation awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair value of financial instruments and marketable securities<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair value of financial instruments and marketable securities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value of financial instruments and marketable securities</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:28pt;"><font style="display: inline;font-weight:bold;font-size:10pt;">3.</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;font-weight:bold;font-size:3pt;"></font><font style="display: inline;font-weight:bold;font-size:10pt;">Fair value of financial instruments and marketable securities</font></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company follows the fair value measurement rules, which provides guidance on the use of fair value in accounting and disclosure for assets and liabilities when such accounting and disclosure is called for by other accounting literature. These rules&nbsp;establish a fair value hierarchy for inputs to be used to measure fair value of financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 00.00pt; display: inline;">
			<p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">Level 1&#x2014;Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the balance sheet date.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 00.00pt; display: inline;">
			<p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">Level 2&#x2014;Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves,&nbsp;etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 00.00pt; display: inline;">
			<p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">Level 3&#x2014;Inputs are unobservable and reflect the Company&#x2019;s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">Cash equivalents are reflected in the accompanying financial statements at fair value. The carrying amount of grant and collaboration receivables, accounts payable and accrued expenses, and debt approximates fair value due to the short-term nature of those instruments.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">Fair value of certain marketable securities is based upon market prices using quoted prices in active markets for identical assets quoted on the last day of the period. In establishing the estimated fair value of the remaining investments, the Company used the fair value as determined by its investment advisors using observable inputs other than quoted prices.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">The Company reviews its investments on a periodic basis for other-than-temporary impairments. This review is subjective, as it requires management to evaluate whether an event or change in circumstances has occurred in that period that may have a significant adverse effect on the fair value of the investment.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">The following represents the fair value using the hierarchy described in Note 3 for the Company&#x2019;s financial assets and liabilities that are required to be measured at fair value on a recurring basis as of March&nbsp;31, 2015 and December&nbsp;31, 2014:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:55.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">March&nbsp;31,&nbsp;2015</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Quoted&nbsp;prices</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">in&nbsp;active</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">markets&nbsp;for</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">identical&nbsp;assets</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">(level&nbsp;1)</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Significant</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">other</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">observable</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">inputs</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">(level&nbsp;2)</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Significant</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">unobservable</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">inputs</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">(level&nbsp;3)</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Marketable securities </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>243,642&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>243,642&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Warrant liability </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>229&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>229&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:55.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">December&nbsp;31,&nbsp;2014</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Quoted&nbsp;</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">prices</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">in&nbsp;active</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">markets&nbsp;for</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">identical&nbsp;</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">assets</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">(level&nbsp;1)</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Significant</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">other</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">observable</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">inputs</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">(level&nbsp;2)</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Significant</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">unobservable</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">inputs</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">(level&nbsp;3)</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Marketable securities </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>265,493&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>265,493&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Warrant Liability </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>188&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>188&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">The following is a summary of marketable securities accounted for as available-for-sale securities at March&nbsp;31, 2015 and December&nbsp;31, 2014:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:55.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">March&nbsp;31,&nbsp;2015</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Amortized</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Gross&nbsp;Unrealized</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Fair</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Cost</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Gains</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Losses</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Value</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Commercial paper </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,748
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,774
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Corporate debt securities </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>186,810
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(320
				</td>
				<td valign="bottom" style="width:02.50%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>186,534
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Government obligations </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>37,346
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(33
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>37,334
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>243,904
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>91
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(353
				</td>
				<td valign="bottom" style="width:02.50%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">)</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>243,642
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:55.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">December&nbsp;31,&nbsp;2014</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Amortized</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Gross&nbsp;Unrealized</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Fair</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Cost</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Gains</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Losses</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Value</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Corporate debt securities </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>230,379
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>80
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(428
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">)</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>230,031
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Government obligations </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,501
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(46
				</td>
				<td valign="bottom" style="width:02.50%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,462
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>265,880
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>87
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(474
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">)</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>265,493
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">At March&nbsp;31, 2015 and December&nbsp;31, 2014, the Company held securities with an unrealized loss position that were not considered to be other-than-temporarily impaired as the Company has the ability to hold such investments until recovery of their fair value.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">Marketable securities on the balance sheet at March&nbsp;31, 2015 and December&nbsp;31, 2014 mature as follows:</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">March&nbsp;31,&nbsp;2015</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Less&nbsp;Than</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">12&nbsp;Months</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">More&nbsp;Than</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">12&nbsp;Months</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Commercial paper </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,774&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Corporate debt securities </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>138,306&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48,228&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Government obligations </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,312&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26,022&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Total Marketable securities </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>169,392&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>74,250&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">December&nbsp;31,&nbsp;2014</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Less&nbsp;Than</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">12&nbsp;Months</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">More&nbsp;Than</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">12&nbsp;Months</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Corporate debt securities </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>157,758&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>72,273&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Government obligations </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,003&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>29,459&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Total Marketable securities </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>163,761&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101,732&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;color:#000000;">Level 3 valuation</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">The warrant liability is classified in Other long-term liabilities on the Company&#x2019;s balance sheet. The warrant liability is marked-to-market each reporting period with the change in fair value recorded as a gain or loss within Other income (expense), net on the Company&#x2019;s statement of operations until the warrants are exercised, expire or other facts and circumstances lead the warrant liability to be reclassified as an equity instrument. The fair value of the warrant liability is determined at each reporting period by utilizing the Black-Scholes option pricing model.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">The table presented below is a summary of changes in the fair value of the Company&#x2019;s Level 3 valuation for warrant liability for the period ended March&nbsp;31, 2015:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:81.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Level&nbsp;3&nbsp;assets</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Beginning balance as of December&nbsp;31, 2014 </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>188&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.50%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Change in fair value of warrant liability </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>41&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Ending balance as of March&nbsp;31, 2015 </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>229&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">Fair value of the warrant liability is estimated using an option-pricing model, which includes variables such as the expected volatility based on guideline public companies, the stock fair value, and the estimated time to a liquidity event. The significant assumptions used in preparing the option pricing model for valuing the Company&#x2019;s warrants as of March&nbsp;31, 2015 include (i)&nbsp;volatility (68%&#x2014;70%), (ii)&nbsp;risk free interest rate (0.56%&#x2014;1.13%), (iii)&nbsp;strike price ($128-$2,520), (iv)&nbsp;fair value of common stock ($60.85), and (v)&nbsp;expected life (2.21&#x2014;4.48 years). The significant assumptions used in preparing the option pricing model for valuing the Company&#x2019;s warrants as of December&nbsp;31, 2014 include (i)&nbsp;volatility (68%-70%), (ii)&nbsp;risk free interest rate (0.89%&#x2014;1.65%), (iii)&nbsp;strike price ($128&#x2014;$2,520), (iv)&nbsp;fair value of common stock ($51.77), and (v)&nbsp;expected life (2.50&#x2014;4.70 years). See Note 6 for a description of the warrants issued in connection with the convertible notes.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13504-108611<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001104659-15-033863-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-15-033863-xbrl.zip
M4$L#!!0````(`$$PI4;%ZDQ:%ID``*49"P`1`!P`<'1C="TR,#$U,#,S,2YX
M;6Q55`D``QJ52%4:E4A5=7@+``$$)0X```0Y`0``[%WK4^M&LO^\6[7_@];9
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M6:Y'+(W61,ES@UE_+"F.K_M`5EC\?:;\F\)+RYU.YX2_C8I"13J+RB;K/3T1
M+\.B.ITJYU+M>&B_GL`+Y%6M-^2Z(B=K9AEX''N:ERH.#_K,/M9LDTNRH<1U
M,]=6FW)[6>VB1/@!@&5(R#CZ8$#</B\<O$C2#UJ2I`L4TKFKC:A)'NE`XD([
M]R9C^KGF,G-L(-W\V<BA@\\UI+X>DGG\[NHUZ414A,"P+8^^>](3U1")'`CP
M1@L>,_USK>N^W`]>E!=%?L%:7@*Z7JX)<_Z7&#[].HG^_(51ASC::')+7ZG1
M?6?N;/$;:^Q[+B^@W%&S3YUY5=Y1XOH.13NX=NB_?;"NR?SZ$B7=1ZKY8";6
M4%0L!`;\P#OF38)?\)OI^&0`U$I<D#2EKQ`]O9M_U+XT&@VYT6XTSN2+D_BS
MN"J7#K'IZ`$\$N`\I^]C@VG,$[1(.H-RPE\$/)RO)\+:EYGRLS*\.)G;ZK9D
M+5+#')J6Z&$5<1<G:2E>G*04=C&F#K/UA/JX@7I?$(_UA@*F<7$2/@MK2'QS
M<1+@>1&XY6:`;K5"=X7N`J%;K<O-K=&]U'7?,M)G!E#3,XCKIC#X&W$<:',*
MQ4\>1!+(#?_@?O#DV=H?J>]ZMFG:%G]>.J#.BB/&0DH>>2)RH4CCMF=D6FZ7
M6J&N0MTN7-T<U'7?B*,_0W2<0@OGZ7Z,,6\YT))B(];0#!]%U]!L9U0IJ%".
MNQ4H2(E4\6`0ZQLQA7YP-/ER]6\?*(+1;*=KZ;>V-7RFCGD#(V:@])5B>7C.
M.4\]Q%H/WZ\GQ57[@O(ZWUI>!^SWE7JCE8-7::W"[#+QEA!2VZ!E.VVAPO:J
MK>_,>7R_?F$;I%WZ8FX=H!9T9\]VAKYMD9]&'UY:)*W+6MY:!?TYWB6@*_+W
M#6`X?AH5I):>*H;=0OAL0_7++T&X">K?./:,WCP2:Y@N>\<L9OIF.3"15XR:
MI<U(9'%[*9GM%&R(M#7`%@7.10<;>:_`EA5L29D=`-BR#:,?J>LY3/.H7J(@
M:`%RYO)2].'TVC-2E:;V-C,5^>]H8,+]]]0@):O[/JPAZ#Z\^9Z'O=-AJQB.
MK`Q;1;$M(XD-D#C7Z+XO-&[D=RI$[BRVK?JTXL>3:RHXFAT2DP@]VQS;%FZ&
M2&];L1W*AE;/=QS<2_$S8=:M[;KE4/Q2%A-;0I;Q6`$B#8BNIOFF;^#FTV_4
M^]5R*#'8?ZA^8[V"/>'G!XF1K&P?`&QRW&M4=!#L8N=&`<>IE>;*,FY=[JDK
M/1Z*C]V=P@]EA6/?F^JJU8X=@;!,*Q]%!.&!K8),@U!%$.:\Y[ARA>5UA>IZ
M*(P"L%*AL/*%)?&%'X/"79SRJ7Q?J7Q?WK,!53A7<##MTH45<VJI<DVE=TV[
M.N)5^:9"H>F#?-..CJ,%N]\#B=T[CVPX\M8`TB7M>S=`B<-SMSQ2G9I\6\P#
MIR95P?*BSV_V5-4'>,YAH90_`+.K-143L::J#O@<QH[BR?V;V<BAM#*TDAA:
MK*S*U$IG:M?LM;*TDEA:K*O*T#(/1/9N:57L6!I#^QYBQUT-^/=O9U7P6")+
M^RZ"QX.UM2IZ+(^I?1?18ZX3C^K.@9F)LSSC8J5(K"F[F2V.-_3/''Y"2%)'
M8\1X(-#(-QOL1C-\G>J_,6_4(^ZH:^GX/SQ*\$H,J*,DAR!FF4X;XF9<%WV\
MMY,,V,VIGJW*$9P]1W`S_QZG3#F"BP'N*]=C)G33]X.H=/3')7,UPT;15&C/
MA/8L0JW@GRO\[\B_;`>[-X@W,>:%7DL<^7M"SIC':'IWP;TWH@X6C-^7`Y-K
M,AKK>R&GAZ_D\,X6^ETH>BFWWX.R#S5^WP`)AQK4[^;FCRJJKZ+Z+=']`7LE
MJ["^"NN_._Q7<7V1XOJB:+D*[$N@[753D0$Y.C-\3,<6,W?U+@+6:\<V,6N/
M[_&Z[@=7Q+'`H;D/U'D:$0=\X_P*#B"QV>X$4Z5)^T#P79ECPYY06KXK<CX"
M@`NE<X`@5),@5"L/6`@`?KP'7/N8^:&`K_*`Q?.`^P'A@F[XQM)LDT;[AFYM
MC7^5`M$3-0P0[L_4@I&Z`4%S5S>9Q<!X"4KWZGT,VBO+&&`)PXEDW5DX/L#N
M<@NP@%.G.)T#0KO$"1U[C$4#B1T01-;@\P"!L:`KJ[Q(L;U(H>*>RHL4QXM\
M##`6+317J=*C-82/3)6^^QT$5<KS`J<\_X"=`95A[]NP=[5>5%EV.2S[@U:0
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M3](=WV_4,'!*]-GQ7>^6F0R&21M&BIM9U(-CZ[[F=8<.+8&%Q4B:%6@`^<42
M+6N,N*%5S==L<2?.EJ^4%*[SWN,2P9*T$:7=<+XL*\0!G1E=FO&CQ+O(ER?U
M*/%)T#G3O97Y%7ZJ=A/=5?971!U&+G3O`<#N/$N16,M%:>J+TBBBTM2ZTMC-
MZL_>&?V@99._UNN_6LR3P(V@,.IU\=C'9R@E?)F0ALY>@9.X<2SWS3<IB-).
M#89,<4ST"W-MM2FWSW]]NKPX"1_&OFC^][S:2VK9)K,658Q>CIV[N`_:753S
M;!47)PD.1*%Y#,<6G&YN#'^F&UM<AS)3!Q_.NKA`L&X=S9DZ%LIS<24+>)DG
MNF0E@(QG?VS0:6C`\RN##T"GW^!T61=>Z/CRVB!#*8#:(QVLMK<!,5P0S$PE
M<=UB?X%WS5R-&+]3XEP)F&=JIA[ZPV4UQFU>VAI/;2F*!&DMX9F;J=%_!NTM
MK&U1@TA3]N;PO_,:C&J;;4[0LHE`DWYG88VS#6)8DZD=N5'_9[H%K"*N6,S1
M]N"Y0XP;2Z?O_Z"33"TD_?7"&F<:C%?S^*$,]][WL#O2F97&_W1/*J&I\3?"
M2B6=:LP$(_A<N_EV7?NB*&?J6;-]FJ)E26,SA`EL/U*(%3UXCRN3&7'T._J'
M535.MWO-#.KT0.=#V\DF_ZZF40.[`JI+O)9DXZEJI]M\I$.^X]CR</(P4Z,/
MSSWI^9>KQ^[#U:_/-[VG(^GF6^\XV7*Z<M$T=^5`K^-3O6=;KF^@0##MC8UH
MP>->X:[70&ISL)`(&*?`T$RBH0X]24=1.P!/Z,DS-YPCP;'85M$KRZ<=.0>"
M7PDS2-^@U[;S1(S$&2<<^MP!_,2O^U?JW%N4^[<P4<5V`I<;<EMI)CC8@I*/
M8&C[`?$JB;2;S;9R6`)9/+NS2AC-CMKJ%%T8ZYMK6VVV&J5A9_=8AXZW>790
M\M@"ZJ>-9OZ.L#?"9:T;*]X_&NX:O;?NB/,'];"-N/*E??K4RM)JWQZSDY6.
M7;$P%9:L9(';:PX\Q&N-MO5(7ZGE+P^?,HJZ(ZOM!*%S6MN&F(Q"@XAZ*UK<
M.!O7,Y#TU8`P/%.L^9/A?=+9ZT]#[Y,4_"VYWL2@GVLF<8;,JAMTX)TWQMZG
MX+>#]S[P!S7\ZB]__M.?\,-Q^C->8`"$U`?$9,;D_)F9@+=O]$UZM$UBB7<N
M(.-<DIMC+ZJ+5X8OP_ITYHX-,CF7F&4PBXI6?R+F^)/5=\>?L/@)ED\2<S+.
MB[3&,M)0RG5FX3Q:4D*1Q*0QT7$<%,BLJ81"6\4CI^"-\J_ZMJ$G2)(CR<N-
MXQ3S,S^V(%6%1_P3,-ZA=8[%MB4\Q?Q".C>21,HRI,`T%LLF?Y24%<!SI3TE
MW!M+^A]B^<29Q#2CHSV2H/^6\$@&L282L2S;MS08)N-3!LZ."6W8`XE(#R/B
M4DF6M&"OF#1V[*%#3"@H,<^5W#&SX*GINYIO$$<BGF./1SA43RKVC7DCZ?I8
M^L4>#(#-^BV1^*8WZ=;3@0!]]L6-I1U+_\7__F]>`HE[$HW=A8UU@\;B77/2
MVXAI(\D#6QA2!W@BTM_:QRT)A&W@:S/<WP96,^'3C@/'-D6;Q])S0BS@BEVF
M\SJ\$7,37R)(00]^GR\4L%<J]:E&?!`3TDC&N%*&?:2D00])'490DB@K)^B%
M'*K90Y0S$#2VH?1$>K-]0X=Z)!?8<`>,"K%@24>''\R3B#LEU+"Z@>WPECV\
MBTHR`0@C5Z(6?G:'(^%8^8I\)"$`CM=!;MK&`5F?:W(MZFW2]AE^R7\D.Z7P
MQY)^<EY'F.@[+^G8=D%Z,,CG86?7=:GG?K,M+8^I$/4L,?!:U=1V5&4(+5KR
MAD1%^SBA]",=XL$JVYE$FSH?!.;O^]`U<!6X:XT$RK=!<:F$(78ZY6I/R#BS
MX!)BQX&2!<4Q60[.1+G>_2#`]@.W[BJ^*T;WN"H822B2>U\-5(F^>RQ`%CK<
M*B+9."*YMZ2N/P1?$9.LBBXI'9.\06=GV7R)&[M?XO&W5SYT]Y186,QD+NYQ
M.9*@\[OJ'4E#G%*'PB8?HN)R"?&]$>CR/Z*SQ$[R&<JX$#=8).XS89#+YSA0
MSY<^1`$6]/!1-*-/W#">P0X>>N@)T&6YF&L"2HE<6BXGPC(O[RZ/,"PB9C_P
M'Q!DP!#9@JZ?#.'C`<8*$TH<`2^`(75$T+&(:F(8]IN;$HUG!Z63[$"K*0%=
M@:.Q3:9)7>!/R.BJ>Q0$1PR]OCEV&#($;..7S3/)%-N'^)*R&SZ/:@0_BM&*
MX0,V;.>-3(YB%=YHU$"&\-];1K61!_+Q*+.0.0R=%G`'KR"*^A<%TP*N(`[U
M(;@#(V,`/A']6/0-'H'04[3<49UI`#%7Z@[QB+A@\*X+6D5Y84,BW"+05[IN
MJ%ZL`YC^H]Z'>@<04?4)D*W1\-V4Z($`('#@.]CKHN?6><2&,K.2&N%R^.$=
M0-SY!(KM,X-Y7$TH9(-ZE!,S-&QH[@CK&3#'%/`0P;42!]<0M\)_09N6*7$X
M!1I#WS.@@!N4$[#=>Q:OD4@0(?2[G*(!#X\=OJ2&4,34;USLNJ`=7M+!`%K2
M)N)3,J!`*X3.1,3!PB20!MW'5-QHFJWCA'^)_D+4&@3&#:,`?"[.KD"<P+TG
M"`Y%&#R9H`:C/XG+W'2HK=OPB6ZCQ4LC`C;B^D@E6HX$^.&B`@W3=]QY0E%C
MG-@@U`>):!KVI=28H%U#+`YN._39+C$0S6#*U$26ASRU$`KC6.HB_K11VO6,
MA.L!@Q\S3TR``8>B8Q!2>X.QQ%211`G@DAF\QD#_P5`JT%D@=PSRB1:^X^@&
M_$8@XQ3'-45C$F)Q5(,F^\#LV$%#@"&,[T'PG&992!A[,!>!@+$B&A0_:8\R
M\[C7L7RD0J@:Z$AX%*Z'/J56/`8A:%)B<8USH<=1$]<-^L3`$;GAP57N2,!J
MA<C3>D\;SG1G*Q0G,`Q_./:$&%[8,]O<)J$/`,\#-DQM<$NNR!TE>`XMYPT&
M<%Q7F!.?`SL82X(]`53"^CESA&N,9RE`0A;R&@I5*#F(]]&MHT*@:_`">"&K
M'O2FDM@P)=FO0',`6G2+,6:X1[9<WZ0!NG0*XM2%#5D^]\M`$>K*=MRD97._
M9:)I\0(""`DU<BD>10/HA'?R`5QIY$*/@+VBS?T5*)0%XTQP#W1O(\;U@^M$
M1#X=M^/=`A0Z7WU1`'Y`IQ]7#7W:K>3(9Z&D4M+DQX"AKP6BHMCF080V\R4Z
M_X#M0^OWJ-DE52::_D;#$=X3=P<YSM^W&J>)H?]40TD2N/GAV7L>%ZW/[A0!
MRNR>'#EL/-5$HFV1F!5B!!U=)CA8D0\MUOG725PDT"#/S!'5R/?U=(/`ANI=
M'F/=6!KV(K2+R5_Q8#E!/8C<'0OV&^W][/Z4--6D-)NU+XUC/`6]?Z%]G/)$
MJ4(K:0;QS93O^1`![5(AXO>3&,(\VPD8\,_F3:X=3AJ9E3L.&VI#57=FE*MD
MGX?>12(C]\:"?H$7_!DG&=QKV_F&LB">C[U6(N=1E@XJ<T:H50+O*$IK:]/*
MSG*P23S.YX7!J`MUXA)(L%7OEHG`4P1Q?!H[\2B>_P_V[%7SI85?#S_+=3V\
M52V'BQI#\\'52;Z$R*?5A!&%8VRW6A[/9S)Z+6%+Q%NPBMKBY2]AO(3N>7:1
M5:P@N]'48S0Y>5YNG27\ZAO3O1%(M/%C9`^>6/FFAA'8X>=:H\9_NV.BA;^#
M[_LXL>34^;+VV*7GX1^?1,6@8XCK&S_.V'B:/<^)?HK?NO3*K1T;\#S;K*7I
M/3WEE0;T356X6/PHKOI(&+#<.#T^;?^XF4JVU$I:(X&&/#V;#!K-XU9.,DAX
M5XQ&J;.Y5-(,K\$C``9@9>$0<#F_LLIU'@#.L\?G\MC#I1PJ_7#9P7^D\"5'
MV<*WHG;^WK4-IDL_\"%-(RH@NIW9[_<JZK.,^%O2644]_ZQ7G(%IWY%.MNP;
MS_+N;*,*T857AE495N$,:VY(L5/;PG!E!Z8@Y];/[L,4Q&\G]7M)J`'0GQ]G
M](GVQ]#!=0(,=&SG7/JAU[NZNK[.*ADI_%=>*J9@;"35Y8VCZ0T#ZO!R,+Z.
M%DXZ'$G!<GNP#!6N0?)`FQCNDK6A+7UP;H+/-_3+[(M7&9DRZW_G>]"U'?#<
M]XO\;S'$G`=^_Y8_%.7F<;NHZEE3MEP^"0?,&_I4@V;>'#+^7!/_CV*TQ/!P
M8-C$2T^YA*N[RI%RVHI-H3+VRM@K8S]48^\<*7(S'V.7\PVI]F3L>866AQ9`
MQBD=@OW785*'>#-6H4?LQ1V?[]/\9?GHM"/GV=E7NMJAJU8[>;KJ<JBJ&NMG
M==4/CCV@_`@&,:0!I=4X/O\YU4(&<S!R.\LIF*O46TCU*FH5JU>Q>N;=$U5D
M7KIH3SF2E9RBO4I5NU65>B0WSZK`O`K,5QZQYD?CJF#\<#8X%#-0E(\ZK6H%
MIT)6_LAJ'G4ZN79U94=6QDXPQTVO.^WM#GE3[*$N&`.]DF[[.-[[R/UYU<+P
MUFK8JT=7CEI*KI.&E8U6-EK9:*XVVCF2FSFMTI9XAD'\Q`G-:0&%;PM\-"OO
M#"R[.=6[_,2PI<]6G\NM)\T.X)MG']B@Z3QI7C]'25-I!=>&Y$UR+A)5Y>!>
M@^6-;$A(AGRILM+9A`Z')^?JFG@!D<CZ=C]`V/)O0;0/#C69;[KQ30BYWAQ0
M5V5UFNP-2-HY6QD3Z]35L].=L`4H3^XZN*8Y.09%46;UL+BQ+0G+=,/`C/%G
MH<LW?7[4@GMFS`/AT!'>#/M*;RQ,VHMW.GRCWOW@F;QO)\%Z6VE/4YJE]=V1
M/IOB1&17Z869WMQ4UHU$TU!]?`5&C,OP,HPU[SNI*V>'(9EKVX'(S!)8TR:9
MQ1#<"%00,63P9FUEQIL5@O*]([MY.N.=RBB8+8&MMF?ZCBVD$.5I?2`,5-,3
M"4:W<\[MIMQN3JEJ?CN;$I/A:C!%#3/N9Z/%@($#RG1^8J.K(/MHCL$9=&BM
M-)UKD;!CLA.7<R&2(H3?8C,88261'=Z$"/%5(NMDT.B:^)8[JEIR,3R)O+`_
M\\2_!HZ8=)-9_!).3)T6M+ZNP<OM4[D(`LD8E'?:ZEGQR/YP.*NGI^V2BR%?
M.+<:9SG`V?*8S@P?VX\OAKMZ%ZF5KQW;Q"J";/GW@ROB6,`!YM'DC71%_N+-
MG7>2J0:X[C.\</$TP5,>].V7Y3B.VZ[AKY/Y%:0@%I[CSY2#L,'G890SI5$)
M?E/!@XOS'(8'WM;,M-G`VU;/U%;9P;Z\-YOB6.UTFF<-Y:!8+H5]JZ?-]IE2
M"?Y#[5LY53OM'?M4?J78UI.H37EJ9,>K7;.I#(LBG4ZKV5BSI7PFB)M*JRW/
M:7'^S.N*AC-P>M:9&6TL:7?A7<I;KIN=MM2.DJ9B85.YD)3(5OTOV\'4R.[]
M`"^$AFA7S.4LL*_M[NEN`I.*7`I&-[^`6VFIT_-V'\1C=''WUTGTYR\,!C$P
MIIO<XH@NW4FY'L-+6^X'4>GHCWAM>2J1>:*-.TJP`(ZCKAWZ;Q\G]](3?V'9
M1$F\_@)L"QSFVO>9[\TX,LHS*G/S_^V]:W/;2)(H^OENQ/X'7,],A'P"8I,`
M^&I/=X0LV7V\MVUY+;LGYI,#`HLBID&`@P(D:W[]S:PJO/@07P`)D+F]/2V2
M0#WR79E9F3YH!RX>,,X%?%O(7`L4[@$89-$`V5[83:<L=%QTG,Y8^"F(/JAF
M1O]PH\FUS=%3@O_!41YA/8"?C;U^_7FW=EUAL(_`[PQZW?G0;SWWN8>\[R]$
MMP^SQ=,4]T>3#B<A[:N`7B[@]EL8<)Z%-C&4]U:T>=L[P6$^B+_O:@ZYN2,)
MUT'[#$&VNYQN'(%M$7O:]$Q5O[W5T3@S>N<(SGU$T7P(^QP@MKLDFD^2/CZT
M,&&F)$6^D*ZS[W(.N;MCL<]\EO=9P&QW!K+V%]`'!M<6.<G=3;TU]=O<D=C'
MG`]6G`/(]G!8'(O`Y.4$)GI,[QTQ&6Q^_,G/6_YBCQ=+,?O#AH-@GRA+M[VQ
M&57%[K=R>`_;&QM%E:ZUCJ>MSF+F9/.@LZ>37*0(-AD">[G/-S?G=MD\KNJC
M':E/2*ZN?^NS?S([3'VN^VFC3L]<R"+8:SD'VUHN+S:YI++0)WE/XN[V^]U-
MV;MQL-F=[('D-S7#:@"5S95=IS<TAYM&(.JTL\U8H18!X>:!;2\)@AG/FVJ(
MIH%F=P'2Z9B=ZOCLK<U=4/WJFK_K/WP./-=YEO]+W>-7E@<Y:+?M=;W.!1*Q
M.?9G;.[BRX35BG=Q4@">@^?7"<.FBL%T9OO/V$)G[/JVC^H`WAH'X50`6+,%
MS%]J:0[/BH;ET21D3)O"5!.N,1_TR(NOB9[G$QC^GC%?FX5L9H?PROVS&.Q:
MKDO7GH"_@SC2['CD1KHVBT,>V[#3*!#/A;''>#:#[!CY@&X>6#Q/>JG?O;MN
M:=<LC&S7+^Y.K#^(_"!BVBC-&^&:CX]XWC,\+74B_)&#$$_N7/%LY?``PC,<
MP3-,K%M[D+>N8!CXA<U4'TLEA.!-&-R=P0;P75PG"D=X1MSHXMK%;U=7GU\#
MC!Z9!!((J!%>IQII`/)@ZD;X<!XB/'8F:T#2T@#QG,&,$0O=Z?(]<0"Y![@`
M^#);[`RF_E?L.P)H8FLY)(FY_O(#$#I\PR6B8%U+!Y;4M+1CK20(7"TB@^,$
M(8,]Y1&`DXK'0"E,L[<[[<O_KT6B8&=1\$%"-IBY/N(7,`13V`\"9[KX*?87
MT7HX*1&RL<<<)!_/T^S1OV)5\P6DP\0%B@?V4PP+CZH<H^)S/E`<YW;XC%PR
MDPI$L[4QV`L9>>(6LNW-`N[*AK3P>.Q%8H<!&,I*M(B.8V`=:V,O>))LM>+)
M)5O7X%<W&*T#@-A7E*[>%?)HY#KBZF8BW)))86?`L.S'C(D6:,FLSV`7J7E6
M\ET7!0J^`-RL!:(B>"(?U$(7?A_'8(')T3=BO8I*C6UFVBTU!_-V!)QT[MP'
MWQT#;/UH;C2P,LE(/+C@RE<*SD$HA9BFZ@4JF!EI=_)2K$VCM4B6^0][K-0J
M5F,L5%?<<=UF?N\KU[D3(.[BZ13E)@@;GG%(P8Q1/+(:8*2-MS7,EUI6:*M[
M#`Q5S^4"\NMQ(E3(B'$G=.^E"?4)+5TCT1W*U`JJ,N?FC;>E4USY?@SC?F&S
M(`0E["^Q[F!Z#T9)+<]<-C3JX7<_G(GM/XCQIZZH=:9=@-'_&D>;TZZ&TG@7
M*PS)UV1)TJF]/@"F4SN=VNG43J*`3NUT:C_\J9U8;S,SYQL7B&7J5B(GV.YE
MX4CM+(54@;US2DFJ-Q1F;O0LM1MJ7@WO([IH#&32$)EL:O_),OP(.6!S'D]G
MDMNCB0VB93P&+E3LB8<1U/Q3V;84EF'+8B3XJI>53Q>?,R,$'T0?$0@S(:U6
MO"-G&<%:$H&P;).Z>''5>D+VR/Q8K8"I0F[:*!:"-'M)&"U"'K2T*R>*A;R5
MPL<1!L/(A7V#;`B#*;P6\!R<2$B4*"0P<NY'09@0C8/Y:X#'61B,8J`[A4\"
M^<ZRX];7KN(',""R)5O21-7SIJ_V9.-9(7+'+AM)UL=?W\4AZ'_;SWD1=%2A
M[ZYU[2$$8QT>AEW]R01+V3'P2JC*TPLU^Q6>X9X=^G9F/(`E'B56R@W8^<SW
MP9B(N0.6?:B-GGD$<TZ>P2:)N3Q'^2".1$'(J2K*Q,4B_.G-QQM='%>F]W@L
M",`LFL$#TD)_$$;>HU3MDKR`#%DH+9Q5JP;+#*R@`FB$J,2G\]M11GP*H'<@
MX>`DXVA7L#\)HW=7B5WG2D]5Z(HCCQ1NQD";"B-&"K?TB)>.^$W8L#,O!MH(
MPB?[6<]0^,%AGI#7\._O+G,F$<`G8JZ/FW/YRMW!3SR^_Y<0Z0&\[4O1]^@"
M\<GSE<^>X"MU>$W7\I&!L08DQK6K![S9+C?X\0JPBO#"B5R`.6P=A#OG"7J%
MQ'7YGY?W,.[8C;1[VQ.'2O7;'.AA`;#`<1P*PPP/B<)P19B]X"N3*D2@*74'
MXF(>O`"FTX5*=-&^1_+X#`=UIIF:`PP#YJ<'Y"B/`$!-FB`GA3&4/:`"A#4*
MK'%U_57^C(L$$(*&3564I[2*KHYXTFA/:C)K;(S.2.=9OFJ/&:P5M)R=:!>F
MUJ"T%%JQK9Q\2?]"JO5L.+M.%/&)"JF@^83T1)<2@%!]\XP83/]$AY.D^H2D
M1P&JQ4`8Y>)8SF-<)7*.!O0C0`481@T*HR/&Q&(E;!`BCH.!'@9V/%X2@>-#
ME,IL;J,C`-X>L2EN6?H.$!B@;+DXVA=%ST2*'F!X4;<:\W]AAU(Q2*@]N7!>
M*CZ2>P*]$)X84>%?V4@*9PKND<O'MI/\)J@;Z#<E,K'B;*1D;0X0/U(U8/(>
M-@M6&#!"E!P:"EN6$$8-AI88GMX8,I2X7I-X>0`@,:Y"HAK6D9,HF7L$`(I=
MKM`<0[M$U.R5-E56M3>Q;A)!E#,#"X>V`M[GG>=%92L1I]P4,'/P;'NI.2</
M2Z`#0/(`#[,`Q!*7A73EGA/.>6+JL(?6DB!L9;"%XCY1Y@:!S=D"8Z*DO+3>
M5NPU`:I$LJH+)\Z#LYP/56X5S#26'O8>8<V*:%$L9C0C)+(/QBY3U#5B`,Z1
MY"$_%G(9S6S`51#R/&<+N25K).(#DA!R:!10S*S4G'2*@;B*E`L:`;5B(.05
M(-15!CX:P61GEFAG?F$.@!R]#G#`*3HO@7'\D1V."-S[N-T^VL^Y>%)J7;Y/
M3W!9`@%ZA07$N?8V@/]H%^^O[MZ^3E"S],%O,W$NO+BZ^_8:K*%6<:[+]E#7
MOLBC@E14U[#*T$9/FS@%7X/]&TQ!FX,&NONFJ7<DXS//G<(J(U3#P,1215Q*
M8\0?P8OA\R6?,0=#BLEY1$CH!U\H#NTA=J6G//9':+8H\21.WM*F`@`Z:)/(
MQ=B9O_SR'JN#:_8,1+`-0FHLM":(3:Q'#@!8,MV2':CCO;3:91P$I;9ZZ3\L
M'4;.IFRI1Y'>C*H0MPVF#JJKAR`8"4W(6?CH.DPXNN%IL`90XZ<B6(%72EQ<
MD.WQH+B:G`64<P78]Q@#$7%6S%=FNI*E.LIM83@!Q,#&D2&.Z#EWJ)]S5&HV
M6)8BW(,(=Q2&TZ459'8^)/RO>/2@?/@XG@B2"MU2_$%Y*5(@CM0\1?4.HCNX
M%\$8]"O&WA@A8.?@DT<6Z!PFW"EX*)%.2&5_%WT2&$D"'A848(^!&I;X.SM=
M<8CKM;1W=HAAF=G,<YW4R$?].T,RPL@*/`/\).MD@3DC\"U)5UDEB0C4F"NT
M?,C@"(8TCROUA"4HE;6\+0Q?7LJ-Y'S3RG.>=^'8HV`F259%.KWGHN'G<DV>
M%W"G3TB]+',W)6\+2VZ>Y(6MA%L%9"R/S_BC8E!0Q&)(I^XEY.<="3DY#Q(\
M%>`)LI!&,XOS^DT^WHU8S91#VJ^!9\];;WX+$'$@RD$:^/D?;G+Q31CG6RHN
MA+$J)`S0.4.BG\^KR*RQ:^&11+&"I%V8JY6]=/,FOQ\TE1]=-([AF)P)_IR1
MGWE8BQ/#4L'.Y6XV/T,!C)SR-&&"ZX2)K$[HR)&1.!0&\7WT\IX*Y]_\GAX"
M:9R+/>&!$,26NJF32%JP.>$_^"F&Y6D*COF`KO0"AZG9+2(WVK?674L&2/,F
ME&0[$9@28$H!LRPRK3P5!4`N2$@A"*24S`)-F\A%/8W5%5[G2J_G0T(J0BM&
M3*)?0H6EIZD\!22AK#0\!=L5TL@N:!D7!(\397Z+)-X-?XF&R`(LRQB`1%2I
M9K^T'+YD]A.!MXPLO,PNXJEY!G+,3V,QR"9),1&T'^3?>'E-RATX*J-ADB!(
M'<=!9DBGR9*'Y?C"YY;Z')W0%3X&,=V413]K%YW7&4"!OWEL8]LXD+8PMO(\
M@ARUPQ#M/N5(<<&F>Z-=&+E71W`L>&2A=$X)VS>4&TD-X[R[QA?KAB',W!"1
MB-JY4JR-W1_R_<2\Q]V]$=N[L'(O.;`W5O!2)1`=H5B74$V\41BM@WE)9&Q#
MT_C;S\*)Z"RE\D\L`GM5>L3PEB4%KG>7&)^_7N=ME3O0]O-^8L%&@O<YJD10
MCN+$,4[<R..U,201!A(G4SC#NBJ8"/822I.$B82]DI=?XKPDD[->/M0O28;;
MS*F1MWS1/,[;E*^7OWD=C(3](%90&.#J[KKX_AV8A<',=;1>NRL,[66J+F<R
M*XJ>"P,LD>+BE%M$42)XI76Z3*A*(W&96,5S?01R7!J%8E!UN@X`@HAQC`\A
MFL`LY$+:SO!,F'K,DX.]/&>\+$\QUB/$9V(2NWR)N$Q=L\7X0QIW@@V*?#"A
M+>X]]T$YTDD.E&8Y(+$G!`>DGI)9T9..[H'DRGOBFE`QKJ1,@XQM:4(LA$'\
M@-ZUD+G3^SA$&F+2-^)@UAG2WT-H3R7ZGV<8_<.(CNW*<P*<C_#(!$K?E_X,
M&9N,A/O#]3G0<9QX,Y37_G]L.%J$.<>G2D(K>CER+J24R8(POPGI)7QYU4H<
MBNVC#TQM7')?%HG",#Z?N+.9=/3=LXGMC1,IN,'NQ%IF]K-X:&*/TH`4`X8?
MZ9H[%KF+@?(3+0K.U"03<2"PR5K:V]2;I=R'8S?DD?9O@%TDPRR+0',SUUO>
M$3J74V#S=.-NNF]=^2P+_,W@C`J\S"?(_Y@D$.&96"0FY24&,7DU3(YZ/Y<,
M*+/#U$E!$/^]2*W2L'?F$TK>Y`21!4*1L1'3RC1.G<+26RBB?FGVUQ(EE@PG
M.;$P$Q)5CC748M(DMNQ`4R"BW+RPG.2\D&2EV\6-2#^IU&HJ"5C[TP^>_+P#
M6@4;I3:=VL^)$T$DP^<&5%R4\(_,3TO&P=G$R$3*99X*KD%,V/=!F&6J_(;I
M3XG91;#>2VR@"9>$#Y!Y'D*FO&^9HE9Y`XERFK^B)[(>?(;J;!J$60IIXBOX
M&;/(@/5BL+6%J1C/0$K`4@'C(H]BS!A_H\%^@<MQH&2>-UE:`KZ<>$ZS[`A,
M=5N:#O+!3X-@1>6F,F(83[P)J31+K9@<!%`:9/=O$M<J"BU<LOAC9>)$%L;S
M1U*D*"CFHG,I0(4+V'8F+@R0'*Y4Y!.MDD=R3Y:G(!/OO[P*DLN.3MQ@4M!(
MUY>N5``JP04"!4KF25Y*Y@_C":&D%]&V",7KV?%7.;"S6<&BFP2CO`8N!J>E
M6@0R8VGTSA9&5DYZ9J?$(E]D0$$S<W&KA>#((U,)5\F>TRQWP3$%1V!^DN3`
M*&<I;D[F:<)47&2WR>.^.GE@J#%_-!19<()7Y@91/@KF3_"YA)%DN%UFF:=1
MZR`.-4PX>)31V55#SODFB]/=%^)/,Y&)ERU3N1CG_9)SKZLCLAH)C_:X%)$5
M)<R:U!6;("(OL%=C%T1@(M+G/;7X=99+H&@_794,5-^SO%/8SJ,^MX$T/_`^
M;^#)U#GE7)83J0!2FMM<0+N"^VBU?R3+AN.)1WJ);RC*:[-'&V:,YW+XYJ"5
M"GH!+(PLY;:IST.H*!U<(3UDL_E$'0JWBPCH^:ZZHY&Q>YH`DN(Y2>&3CA5I
MBV<9#ZFC760)V%.FCITS3!F&G8$^RMO$:<0N\^[@*HJ+(`U2601&F@+*CY!&
M+]=D5:JLI154F9RE,T,B9(E\6<8MH0RG<C:_D!P_JJNQ2P]U+R>[\F5'^R3)
M/#E*/LE(-$\<AAC)EBG>ZI+A\BDR.5R#XCT[%>(IEO197JWT*KH&`8T9,6L+
MY)H;U/ZU.L6:IAM-6LXZS<W+-W>Z@V[W6.O<IK7.0J7T(\!S@PXFO8&Q/S@]
MT!*WXW\(<R&Z#;]@)/_=#_2(<O89M5'Z(U>_\LYF]9R7#EVHRJI^FNOFB%54
M/_@\"F,4"%_8B,FKD)^%X5`8X.5'WX-FG1L[3?!0BQ/=ZQ=J#P?^"UWMNWD\
M&*]^-;I&NU7`PBX@/1^L?,5;Z]6CI6,,""M;8.4I.&N<+%:3/CI*2'S5$"DD
MO>J(E%,27K=Q)!)Y5=)P`W1'-8(J#_X/G]YC@X)UT,^![B0!79'P68!TOTV@
MKD*D+`"Z!P>X`P*ZAJ+[)&5'#>%\HJ*CCI"NO^3`(C*RDAUZBY*P!CHQLRM=
M5%>\'J&'=7=KABTMAT\5VLIAE,(\Y<'Z5I;S`$GD,9L3;$L*H4E@:@&6OF$:
MG]GI)7X;LX4<#.O*[..@B(`T3^<]NP^+*<!XT0'O->4JM&!.KKCB_T,D/WK/
MVE_;+1/CSUY2)RO:JJ#HW%4&O'JOMI)<X%1;PHP(&=V2VYK;!F]I[V7F$M8;
MF,93M;LT(VA--=107#2546+^<[.),J<PGMQ1-`&2:?\M;2`0"2K`TC>J<<$O
MK]JOQ&>DFN2S>O\><U;#2Q%2G7'V<_+'&SFP-D"_U]\*/1&Z5EX/B05%8?I1
M?AYA#HG[X/_R*@IFKXJ+A2%[QM_>W-O.GP]`F?X(9P_"G[6_7%^_>_?^_1NU
M[**^^W]68D5+_A6,@R"]G$@9U6GW6KW^W][D.SQHEYV=>7A'-A8$N#K2JD;]
M*1JM!.)]$$7!=`Z.;;/5*1..2T&W$\7C'$5ZWGNOG9;9KLM>RZ")OY9/#QVS
MU7\11AMN4"PRU^%$&)]O7H&6>0KMV2^OY']3<9,31F,OL*-B1Y0D:Z"CMSN]
MC"CV(P6C5Q=2V)WLY>=P;S%Z@L*R5YVP;`9M)#L"P@:5[:-G?0WK=X66/B:#
M#ZU2V;L9B"J+B<_*%NJ3+50VX]=3YP\-DS0^:?P-1,*`-'[S-#Z8]&:7=#[I
M_`T8?$@ZOW2=+SUW0%\_=P#Y/EX.^LO-$/_1DA^%OV[EKW)T\;NH\Z;]I2W^
M+WU`AIV6O%]+<Z/3)P?#[G)J*2AJ:'$L`&0/[_KYVAD;.5N+`F:YB*A(PI`[
M-W7G'A$+QY3FEMX>DD=)?L2`WCQ\&A"FK%E>0M*HA](^2DA-^"9B],FE\>P.
M[ERCKO2NNRAWH&[]/\^U:UFL8R++>XB[O+$H+3:.O>(%6)'!DQ0E2YHR9?UA
MYFH'BJI:6$A97(2/@JPZ2G9Y6%R)QY?^P3P/QL;R;C&/M-_=J>C!>E'\_G6:
M"['REBZ6),%^QMHT\)@3>[+G#UJ4N+SD"GPD:A0D%_VSR@]B'+ZP4Y:56</2
MT*(@F*@9C=VO0JR1AF778&V7\(UL8\5=;#`@RS3=,[$%52LPPPC\9V[?\^!6
M[8RQ%<P2A,%>XYGLTP5`!:@^J,+Z?^T-6L,T?T2T-P+`>^QRY#Y@XZI\:9JT
MC*:\H:W`FFQ7H?:%)D%9!<1D6[(W<SK'DVB8F%8>SS>ANKQ_OBPTH<HU6/("
MD!AA4D(BU_M&?>.)0A:VP.2"(6!KOCU%+@T][_/;CI%I.COY:UOF2XI$O$@'
M\)#8?;(I!ZN&9:TEEP,WK3=9W*1J*<=^.%[,\>:YK'H:RP%D3;OB=%0YH9RT
M+Y1<(FFJ(+X6JM0D8BPK[''W\4I[C[(FUVXJ&?1%0;#P[@L,^Q2$WN@)2SPM
M%LM5;%Q<:/*(D'=/>?'NI3(O:5O'06G((OX%^:<%H9Y4PTGK:<61*HW%-6%]
MROHTRR?7L3Q+6BH*F`7;+=D/LO5KTE0@+=Q5K!F!E25YU@Q/3<J*X%4]30J@
M%?UK)<.D.L[WL&BF;"*#HD95_\_`MP)XP(9,%)D9,2SC+Z>8`$M/P/;96#PN
M69$4C]A:3.A?444H*:(3+*,,L<@,EK+\-[%^>:S/IC,OD!B8-U424I6/L*26
M5-9@B:563AY-CN8AFPE;2>%=L%,ZW*/\*JOB):LUJH;-41AXHFJ4+&0LJ`"7
M@ST_1!-475:@/V9=DNU2]Q?3_M4E@\]V>!N*:PDC41/B,POO)J*[2+!YW8SN
MPJ4$3*CL%!>[9L(R5KBR8D:E"Q2_\BO5.96-M@+=XOTD4<FC6,QC]5S[+&HE
MM*I=TP?9E&@O()G&8#@PA\8+ZY'3[+J6S6%CFM;`--N]?9>RZ<7(,F#SXGV@
M+595*I0V650))7U@%2OH>%E-G/53;U&E9\N99R&;@.$%QM@''\W83RRZ'7^U
M?[QX#<O*7\-:#XW+CM4>#.;7M6KF<I8X=U-L[1+-_G"^J-4^2PPBNM%&)FMN
M:?DX70YY*3(UY517Z#0&"3Y+\=A:K44S,/]ACY5:Q8A%(0*QX[K-_-Y7KG,O
MUW6.8T5_/#B_7V`KDM=)"TG9\Y(E';#GWHC8E*^&*%']-@>U]2A)>Y/GJN;C
MV0R['R9]"H5#;93T:T4?2F&,[!06^VF#L@<XI4FO`3XC_3#2/R?N?7$&IZ_-
M2T,2>E>>PW,591&R6,YY"FL1+JB-&%+4P\V0OQ%_[G##DBXS;GJ9$49>N,U8
M#`?ODB33[;:Z[2/'EX^>!&.4!H.<6G:$T[N6.7C&L7/PC@KJP2XI,\NMG-1D
M_):JN`7RO`^UG_8TIM)I?D/U^=/%[T)WOJYTJEN_TN$_IDJ_TFGN4H."Q`:)
MC=J)C?=!"`]4RVG7HIVX\USI)*I5W$+?9V(T8K0Z,-K7(+*]2CG@*CL@5:N7
M\?!5K<#('^PJG>G#<J=."2G@[0;+"_EYCSM:ZDQW/G>TWMJ>:`QD1]H-<T1Y
MO05/@U7%)2ZC7$"?W;V*I;]O?W&++ES`X!5<N"@)/1O"MI*;&!?FH%\EAS>!
MW!8=!20-:H0>D@8'E`;=-DD#D@8U1@])@\-)@[ZYEVW065.^J`GDMITT*.MH
MNNL!U*CI`71U0L5/*J1^S\;8+#UD#A9R%RTFT5G*JSN5-NOLN:US])ARHV-T
M"3WU1<]%Q[#VQ\_I">\FXK)3#S?P.3M]ZZISK\1]/9Y3J4DJXNK\-'(!GTZ,
MLEJ0+PBR0Y)V=O/5JB[=C4B62)9(EDB62+8:DEWG'6H&R9+'9U>/#SEVRI!U
M9U,RD)Q*1!KDT#J(0^M<Z8B<:4=WIC4@@W)5$THZU=4N1:).1SG*D3C-Q@07
M1L^@E*DJW`,D#T@>-%`>6/T2#B,D#T@>D#PX"7G0-WM5NLF;0&][)5'*CTWM
MDI&L60Y;9A7<%PO\%<L!WK`Q"T,V^H+U?V,F;[Q'^]:3[!:+$RZ?9,>%;%%=
MLF_NL`P`GN/*`L<E5I7LSI64S,^SXPJV+!K9,^>1LG(%:;'DVS%2$Y"2>.H+
M$W>TKP,><5&@]*W-V>BSJB9-%217<OH>2VN_M+3CEFD<4)E&52D'"]9J]I,=
MCC1X>TD9C^KHHZFDNU&@V)_WJ':%0]4L-!LJ]CIX&R`6@K%VXX)TBX*0:_9L
M%@:/3-;EP]<UB3#0C4".&'W^#$C3M:>)*_N:/+I8OC$IR/<0VJ*0O.A\(EX,
M9K+Y!B(<*^9+],]R8EOVHM"QW4H4N@Y6_A-/+7XCI+8LZRAS+\6WE_<H6=4,
MFFK[4FBOTS>'^M#L:UP4BA8M+$3Q9/E^2UL#.PFF%#*VW*4<N*N;AI4;>&')
MN%A+[P$@\_"0K9=")@I<^H&&#(W?8V<+.9;]:+N>J.N'L'4YCX7C/!8MI:*)
MRP7W4/G*W3GF`V+].5OO#LSB*RQC3Q$6(O$Y(1/4>/^L&7JWW=;QQ(5C^C&6
MBQ!\H1"<U=9/D(H<UQYJ[V0!5!S]]P!XZ2L+IZ4QX"*!JA]6<!5VUK+YI,!D
M1'6UHKI%F;V.;.Z98T^9QL9C&!-_3%O)H2VKR&?EFCY\OFWE`)[^]77=]"O(
M%2=STP<+8E)'WP2/["@6/=7F?EM!RR\J"-GZ9X$;YW2"Z/T5(DR72M]U^W2Y
MZLLWQ8$O.J]S^+:Z0B:LF'>-V%^!D4W%AOCQ!:U^8>16NE1J7<@&=J;>MMJZ
M926J[S56;0;EI3H@J8TO'6%^QSR^_Q=S1/.D(-<M0J%RS<8[P^%`>Z>:^^@I
MDXA]7@.-Q%Z$!"9W>RLEH=QJ.2"35:I%'SB8/NGW@^VWA&871/CD<H0(GI]'
MV)U,!X'J8W%>_!.P/&:B=2*\$K)9#&9(HD#R;;5DYT,7``GFDHMV0DH;,V`!
M^-\XQ,]1TM/+CT);-KO+1I6F%A@.,2#2S*%:;%/TU4HTF([CW#,T3'!M4CB,
MW1!['MJBL1VS09",X?0+;STS.\RU`EQL_K=&*A6(QPN>@*_QS4R#+J<=7;/^
MMC&=Y8EKV7[D%]EV1+5X7[7KTD9,(G<!,^O$->G*W77E>[QE]3\V$&:8TYA)
MHD@T"8/X8;(JD:389-65G7IL(++(%HV].KK5[>G=;KNH59`*DXZM:=>PI>KN
M%FDF0%89FKH)XSRA00_G]MB1;0:%<I.Z#K38Y0HU)A72_&N)_!-C3NU1D<%Q
M9Y^N[FZN_G?Q16Q\ITP^;$PV!7$4NK!ET5;55RU7@QC6!$B;`)GR/`GGFZDY
M.7<6D?'N9'REBN(_+QKE:'VA!@*#P>:JF#ZG6O7)^\>I56_5(`=Q#ZR4$R<^
MC5JX-;_U='+U;S_%Q:*8P7B!-,LL[*I4*)'_BCTVZ`+@R;'"/\3/;'19*0?8
MCRRT'ZHMG\Q^8%]I7NTDXA1+C$QZC)BWU#E"-K5='Y!3Z2PY?U.E\Z`3AH0$
M:?O:"8RK)-Y<*?F[P&6NSUVGTED>L9UP!5QV5NT2R+-PVL+V\!>`MZJ$>]+@
M/1$2.NY]<B*G$R,G(B$B(9)(C3U!7+C^"V97J8?H21!SVQ\MZ>Q*1OZ>%3VL
MDLNQU;ZBQVT^9XOZHE6NP&MY.=/4+=/0A_U**SB<$#*36]BUV&O-;T+7DN"-
M+G`C$7LYDNNH%5X/<S`X%41O?4`X3Z133=X]W-VU-WE_PSQ;-J+*NYL+_V/J
MZC31FQ"S:(*2H9D8FL<DT2X(RA+.3B=$GDING+25T$2D;6L`GC0":Q#-)\]F
M9:KFG4I[K=#0:_H)H?F>RPO#M/2!2=VZ*PD%D9.SR4Y.8-S!7C472<B=B;_K
MM!!-3DYR<IZ]D_-]6IB$W)R-<'->&#W=Z)70W*L)IEAUYBH9I75PB%K]5I<<
MHN?F3VLBTL@A2@[1LW&(8ID[<H>6XRFH8Z_MH]JOW2$U_*G."UM'<B-;>T6_
MGWJ@YZ@9Y8-!JVN22FF\2CEI>_>T:(S\WN3W/GN_]]Q]MH-WJ6X&]>RAE@[:
MR_"H/DR]9_3U@5F"%7-"1%&#!J1T[*A#F]&CGB[,5H^N`]1,5A_5:"R#3P>M
MH6@=4>]ZQ#4A.`JWUBC<VK':NCD<4NB'0C_+R?X/QE6/HG<_9DQTW,(^*=BG
MYQB'I*8?OINBDNOI&[9TTS3TOD&YR8TY<M4#SO4V`.J)GZ,>TXQ6O]*8\`DQ
M>:VU!1WMB$CI2MAVVJ"6$KECFKIA[I692^&S4PZ?J4O3HLD?A<_JI]&WJK%[
M5$FCM\V^;O3H%D#E1[F#UUT^$0U]GHQIMEO#`3%EK03U"9RO#`J=;:D$2!+7
M(71F=?6.V3_3R)G\B,;^/%B27VO<I_RH/>&_3I@VMMU0$\W6L#'\`U85Y=K4
M'C%X48O@@6@2,J9-X?4)UQB<Z48K#U1/-M>P"2.;S@(8B`4Q]YXUQB-W:HO(
MG1QQ!!_2R;288Y8C?B\[SXN<1\[CJ6RK3'WHD_?7]:'OF@MMZ#M&K\#):QP$
M2T4##&OUSKU=G-7JE02#VG8/LMK'OK]Q<MUTOJ+HS-`D9>@+=%IJOVR4U-E<
M<R*[TJE!'V0SH6*H@"$[K<&@N0RYM^-6">7SR?WYXO(_+\=HB;B((\SY"=&,
MJ$S6-STVL(?,/Z33X&#AVBUYNPR:[;2ZUM\T@;*__,#N4V^T3JO?_UMEXK#I
M-%N66#PUX9>F.SX&GAVYGAL]5R?XFD$JVXBWYDL26,%E;UB=X&@&SLEJVEEP
M`,%.R58JQ58Z88.EV^JVM4NMU^IT*@N$G*2E0B[H?5S0U\%T9OO/TNL+PLH/
M-)8(+@"C"])SQ+5Q$&JVYRD7=4O#-Z4C`AZS'UEH/S#E4A8.YJ)C.Y#>9/D`
MCAN'B=LYY^#69BQT@]$&;NZ_FD#(!CZO\8D=LE:SW=2UH8&8PSR(E>S8=/V&
MN].9YXY=P,F419-@E/UX\P;O`(T8*C@87[S*"EHO0WY+^P9X#>$9EZN!]"4O
MA&P6,LXP#H(_)J0%X^!'O&Z$E*,HQ?9'XFL,>X2V$\6V)T:1],F6&.XPCJ"8
ME"21G+(8R;W-9:3$UF"941"Z#@R9>]_V;>^9PPY@H!EC(:[2CH`58$@`E.O9
M(8(DR@'UR072ACWA8O`W,$AB'H7/.F!);0W`"YMX=CP&7P)Z=+&SL>O;ON/"
M`CPFP2#W%:;>F%#%<G`ZN2$-EI9NXEOKKJ7]%L"[_A0@JMTQ!Q@O<@')7T-F
M\SA\AE7Z6.P"\_2BY,=GEWG`\["OQ8"1$`0257/[74!\MBKBSVWX$W_[V8U`
MD3O+O7%`KT"8".J[*'#^U*Z>['"T:"YL*PGROI+<'%S,88LY-&2=1(KS^/Y?
MBJ8=%D:VZR.9B]>0M728R_%B448%?N+!%&C<1@G#6?CH.@SO$@+C"?8=N9(=
M+\*YB5]+FA=S7BY1+?//JX7JVM/$=2;:!-C[GC$_$U()D\<S%1`%I/[)HFS$
M'.]F$!F^X5)P\"2.FBD['9D.J=\7?/<HA-R\K"(6V#-2GH:G9=@6C!58"CS'
MX4T02B"_4?PIY"S%WSRI4'![T^`VC+P0W2X>$=9X`Y:>1GK6\=->]L!*.2>R
M\E+3CAG;3NO&66OJQIGJJA/%N3?W$ZP)^&:J.L.;L`LJ\1\<WZ5[,!<F":W3
M%EHOYY5VCWZ9]N0DU:=X>L_"#%'!>($VR\R$N1/V.I'_.IV]MM;K4E8@G;T'
M:?Y#N4XKI?\KZ30Z4-[9;W@>KG2&&SAK9YMY;[OA@;;V![H&R)K:SYI:#`@K
M4^I\`L+_8_NQ'3YG(*8J6;4UU4K*H]L01I7<2^IW!KK5KK2O]0E1T?'O5=<#
MS'6]YV<>^\9U/9D<[S]2,9;2C)%3,SE^4[&Z6I^":Z(!E!W1^)OT^3@NX7TG
M7P?1P,E>6*=SZJ:EGNE46L:IM)96XX79;>OM`77;K$0V4H'+#0]SM>0-.%%U
M2^B#4`\".+[:/#7E^#X(Q\RE,]4^OME#Q@Z/JV9UTRJA1T$3U$1UJI049J(P
MCZP6!R4X&ILAV^C,N"W1?_,?Y:F1F@$U)<P)Z]5&08QYX@UO$M*S]&&?`IUT
M0#V7`^J@2P?4.1TM/](M\/UN`(?,00TPDI?=+N55.0=^9#Z7-ZS41;>D0"F/
M[(B)VZ7BJB\+;7F1S^;JRA;5$*5K5OM@I6Z.E5JD;'?IFM61RXE^#(KE1-\=
MM^)G%;Z7,TI.)L%Y)H)SM[LN=.UK'_E441%BHDQ2Z7L3ID6:LS::LU(?]REK
MUL9(J[-IB%6U"Y=HAVCG^.JI=LJ(XK!8#8:A[T%4$!RQ1^8%,^&>K4R#-3V.
M0$&S<PB:67JOU\^(@LB>R/X<R+ZC#RVK'+(_R:CQSA;%J=D-=\R#WQYT[8'Y
M++0]83_8HZGKNSS"H.YC)>V>SO`@<R[)SUV]/>B4J7&)2DZ02CIZOU<2E=#!
M]I0/ME^#"+02G6++,.?KF4),9XGRJ]R<3([W4.];`SJ_$\,3PY\'PYMZO]TE
MSP7ENY>>[WXENC>MNJ063;"7$[:%LF>S,/@A.D-YS]I?^^U63X/5>:+/R%B+
MA$$:^Y@R_^##%'.)\DZ`;;*9)QI+10$\J6[(K4RMM\/0]A]$-GW6*RU67;,8
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MNJ^T$7,`<AY'A\6OE^U6=Y#M8LW$Y:VRFU]E=^TJ.ZU.MZ15IB#?9GV_*G66
M$D!.M<U?XE"?I1(N:)ISE=5YAT(.0BG$-*67%<R,-&]O(Z&_//<OTP+]UB)C
MYS_LL5*K:`X5S)L=UVWF][Y=E[=U@/C$(@U$%,_:::X&3/D4TE3BW<30$`)(
M8TK29/#5A)Z<SH0XO'^6;591I?F`"M=WL%/>!:+D-?Z:5X.7B1KT12L-5'KP
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M2:J88V+)L'1K:.C6H%^/"&]SY/(9'W`6[SS\7)F`;KH9L/-!YUQMO_-$NCIL
MG"O2R>`_78/_[8*!3]8\Q4D:$B<Y\V`G7A%O%EN6$C'Y/Q3WK`$:*.Y9.C]C
M88IF'?2KB8!N.\)V`F'.$I0?J=90&6#?8H3YI;RX['4U*G(DKYF]S.K>M:S$
MOF4IY@#U0;83CO!.IB:O8FKB!N;*0DUHC^-]#UV\F#0PQ@I"H<M\!VL&98YX
M?%A4=AH'(0,S?@1B"*LSS8(PTO"]M$:!JH\`HSD1E1[8G?*7E!X`V`9/7)NX
M/`I"U[&]#.KY>A"B.!5(<5$&*U<:0M>>)BYV-H%'$'NN[W@Q4HAJ16W?!S!2
M;G3XUXD]4=I`Q[)3Q:H4\,D-Y2`<BQ^X2"61>YFN256B8#;,>1*E*!I?^*#?
MION[IW9+TEQ7^*!'K:S+"7^DMR2O<E4.@O'*$@?45WIO%RE)L=.68NM<;U1Y
MH&31194'RJ5&TJ/[$2/UCZZ/AJ3^T8>V(AJ@+ZGO+]$+T<MQU5#ME,YBYHK2
M."><$CGGGKV+L-;YK2CD7^'E_::G1&TEB&K91\72>T9?'YAFMFE":_/1:NH=
MTP2TMLM!ZTFVR-E9#9R:L/^6M)X)X3^A*_JR<*$`Z%S2!,_)405-S]*'_9+$
M#-'&2=%&WQKH5K=7I@IJ!FW0>6/K=!!JWUL_A\?)-(L$%34T]$&;#CE$4^6=
ML`8#0S<&I:JWIM/4G.*3'YN:&)RL60[KEM7S<65KP;D.A"(3\7;\[H<SP;:?
M7^R(W?K7-I_LT2+1R+=(O#2Q1Z)A`0_F5K=RVKGE36=>\,R8ZE3YNVO?NYX;
MN8Q?QV&([4#SJ[SBWV_'WSO&J@:3"^L:FAVCN*YU\^V_O,VA9IJ];AFKNY,]
M2K,.G_D>H)\"=2R_$EU8A864_QV;@WX*HG\R6&FNQ>R.N^J^^K7?[@F!O+BM
MTM=Y('!\%FFY[X-0?87/=;;JX/G9_.<!P+%TG448O;?=\`_;B]G5Z%\QC[`/
M[.WX'Z(E<,3W:.VZ0-O=(F6_.&]92]Q2:%F=_9?(>3R5T8UW/UCHN)Q]#K%=
M\$M2Z[L:YGLZS-OGA-6?KSV;\ZL?+D^?4DOXR+`38OKM%Y2JA><^VC_<:3R5
MS[W8U+;]ZE>C:RS=^HK]-&'[KK_Y]CO&X*"[3XGR+'%?^>Z/BWK9@EST0%\K
M0`\L!7[];/US\+%CW*S;<K:'YNVX@/U?/QO_['T\RG:+ZN=@^.U^-,SCX/<P
M&UY`K_&QTZMDPW\$>(T+EXO'E3J0]DMBW9KK4]]N]=>*]67[;#)\7A+\B_#I
MK97\!X//$61%D\CG")+E:-3SQ>5_O@\9^X"ITW#DJPMO;4P\%D*GW>EU7X;/
MLGTV%SH;TXZ$3GLPK`5T:B9W%.ETS#,"SK:4T^V5!IP;ESM>P&-X+'47;^7'
M4G&-U"V=BW',W\%6GV4TIA!NJ+O#OJIZ!NMJ9V@J.*-@9J0W@#:*A*\K1FJV
M%L,-^0][K-0JQL4*<:X=U[U'R8]U@$!NP"A:S+`^P]CU;=]Q;0_&X%$83T4]
M""SD`9O^DZF*$LR)0^&'7PW#\HFIJ72^:=V.I)B*K-\A"V>,,^1,F8V2"A&B
MA;''>%*98Q8&C^X(UO80NR-`'N!1EN:(N41I-H;K:[;C!+$?88T-65LQ$8&B
MJCI(<:;P[671%IB(^1J/L0S(RM==CJ4_/#:2Y=F?M0!+O^1?@,&PGRL\W-)@
MP[`ZL8\,2R"M@;Y<#M/D5SUQX;70F3R+D5U_%L,2HT"[%UL<X9\*./FW"L2\
M?%^X#)?GQI^%;H"$_1\FP9_-A6,*5:!%S)GX[K]C>.2%V5T?OI=U=3SVR#S^
ML_8[_E?K:!<38$C8:C+;\VM=_6;H8H7R@ZE=`!D4GCN#2B@+O[]YM:XZ2CI`
MF/XUFANGH#IF2W[,H%`LSI1&JU4X?EF*F?I;B/GBT)JHQX(*8BGP4C"G*]I"
MWKS)X3>75C"/M154</<\!84P+XK>J#@\(O4O/][V%Y&Z!*M%R&P)]]U14(!Z
M'A\5079+J2[S3%0NCAQ&\;^"+A[&WGSS;1%<`S'R[SC`_\S0R\ZEH!;UD*3:
MY5+TH04BBBPI>0;?Y<5T-+&C0EVNB:J_I*QTE%4@CQF6YI(/WMN>T!A\PEBD
MC<!47F(6+</`3QFW;9V*DJ9-8D6T^13)057R:@E&2'J1]"+IM8WT,O+2ZX.T
MCJ2=![+'7Q!BJE3<DQM-0*(E!I`04UA/+KCG+'P4G(/B34@J%&QYN?:L:\P5
M,XS<D#F1]ZP)(S#YU$ILI\184[/.K07'YRX`T%YIY"[(7'W)&)D(7AQP3AK#
M>(GP3G>,%?3D)'JRWI7@VPY,VH7;8BT<5;H]-+"T\8SP[#)OI,%Y[1$^Y4SM
MR&F]EN9F8N0FTXU8".L3RP#C>08V/1C>83#%Z9P@#(/[`,<>"1L_6YK<*^H0
M&W_!)YDL`X@OREV"H>QS[4(]6AA,KN(UJ1]2/Z1^2/TL5S_F$O6#(BOV<X((
M95K(QAY6',T9P]FKPS<<!6CB,!9%2@/M">6?DDPS.P0A#[(/G5]/00P2%)TI
M(-%1-HO2JDN%L/!KI-;W"-<<S(0)SE-GPCVF-B8NFGN4U*X/8GTJ1:7]:(-*
M@6V0(*R9GV[)ND7:>+YN+M*B(KU<A5S'D02!=).YI'@$>D^Y5Z.<ZTC2D&.'
MH7C!GJ+[#+U9#QA/$=0MZKX*Q8DD`W80<P7I@[I7[C8.)/R<<@-\&<:P("S3
M['/Q&/KNV#T,-YN%P0]WBL9"WG\U@G^%!TO4#PZCRPBS7WSAO9-U?`-!TJF/
MN%:^J1.BL:)[WF%A9*>&Y9PS'EVP4KK$L\!/99FT)F..U+23ET&]I$269W.T
M\IY5->>D2+/VP==2_VTB(>$+05JC.<<L_A:R*>P$GW1%:K>@HF)9<>E?+;K!
M05B/&!(C@$^8H*ZP^9,1-'OTZ/(@3#:<TPMK[&TBX&H(.*\10_;HLB<^AS..
MI&4K0G(=T=I5DJ+`U27B"N3/=`82+WP65>+=4`H=Z<"7PR+Y\_C^7TR=KVR<
M!WX#^0P'(B!QWWZ0X1,0;$PZ]!F&-F2<`LCW$7_$4XZXHX/LX;BA$T^Q%CKR
M"[K3`L?!NR=*NH/DELN6?T]M]+D!/]EP-GSPW3&PD:1)%O*L#+H_3]2*)3*0
M$#%61XQ9??R0S8`R!`7.(40*#_PR"PZ-&'="]UZB_A-(#LU,S^-+;<QUX:?L
MR*V(=*2B6BJ>-"H:!I)+0A3WHD2^9!,DR?&+[1INP#[`Y(J%GZV?3XG*&E]G
MWZI!+8;2<%3$S_$KE]2BZGZGLZ;L?K=+9?>W(,<7\EL&R^7_DF+[Z8>*JEQ3
M86$2;*<NV#;H4TQ%^2L5;.)"-!%J-81*"K@T.OU?X7+),"A]+PN$>Q]J/R5_
ME[L`U\\FE\ZO`TZNW&S9"N#\>,B])YZ]'`C$R?2`:[@0Z9#9`CJO26J1U*JY
MU+K+G'D'9!7A_3SD?*FO_*#R&+WR1Q1`!@D@$D`D@);-FD^K.">18%8A$L[*
M#[18>]<JN11CG6OO+G<\+@G85Z9YFE[Q<E.6,H_;BJ@>8"Z?6O]:/F%VL*!&
M39&U(:0K*7AK6*;>LPPJH4S,3\S?5&3MW$ZN?.SE,Z3)O"`)0Q+FZ,@B\X*8
MGYC_3)F?S(OMG63U(/WC.\M.VR6F*L3EKC#7.A!3W[#+4>T+8WB^30JW113I
M`J((H@BBB),7YC5(^#Z!YFIT(ZH&=%0:CNHF`FN16$0WHHZ=6;3T=FCA4I15
MV3F_J62\Y?F>9-M9RC:Z%'5LV4:7HBHD5-+!E5V*6B#9ZE)?Z?[5(?>^>/_J
M@+/352^2Q22+UQ$M7?4ZW7L==-6+!!`)(+KJ15>]Z*H77?6J2?R-TC$I'?-,
M<K%[7=T:FI2+3<Q/S-]49)U;ME4]2)\D#$F8)D@8,B^(^8GYSY3YR;S8WDE6
M#](_OK/LM%UBR56OW^FJUWYAEV/:%YW!@*YZT<6>>F=^$D40132%(DY"F-<@
MC9VN>M6WQ1IV*--X/)UBY[Y@O*)QI>I:BGTB`VRGGK7!O80O+KD]]WA$#<_H
M>A]=@:E;YLB"(J3K?<?.)J.&9_O9""382+#M;N$?T4U]XG+M:AJ$$?P^(EI=
M1ZO=-;1J]$@'5TJKOX4!S]TY^^:'#!9*M%M;WUK=".B][2Y>#B)#C0PU$B#5
M&&JD_$J37=<!7[S'1&1:A_,$T6G>2+-=?_$B&A$JR=-ZT>GO<)984K"#")4(
MM5Z$^H?MQ8M7B>G40I=K]XDN7P?3*0L=U_:TF3UC(=VKW9>;*/>=<M^;??&E
M,]3[UH`XGCB>./X\.-[H$;<3MQ.W-PM9YY:]7@_2)PE#$J8)$N;8)XB^M;]7
MJAZD>'SOU*G[H,)9$-H1TT;L/CI(D;=FD,^N3OBCLOZ@IP\Z;4)1?5%D[269
M"3O58N?"-$K@GN:99Z]W$O9-PBR*QJY9@EG4#.;;TOAY*:'P7*-SOP6/+/2G
ML!8MN`<PV9$;^%3[MG2I<,2LA7H>X,R^;EKD%":"*BW"T"%B(F(JS40VJZ0F
MLIV)#C?6DF78\TT7;"5:^G6RY\_G:M&IQKY@O=HHB+%RRR&SB"G&53)2CFJY
M6J8^;)^=RY08E1BU68PZ+.&(23Q*/$H\6N7)O5O"T;UYI+3;`9WXF_B[6?R-
MQG+/,LXTQ"D_GD0!7"J&2J5HZG73=\%K3<50CWTE?6EAZ$(]5*L2N^>,+JR3
M;#M+V4;U4*D>:E-HE>JA'KO4%M5#I7JH5`^5##4RU.HJ0$CY526[J!YJ;<\3
M1*=Y(XWJH9(\;0"=4CU4(M1&$"K50RWAU$+U4(]?BZ+IV?_'R5:ALD8-RF(Y
MD;)&AMG6S?Z06)Y8GEC^/%A^4$(MEGJ0(7$[<3MQ^YKT=,NHM.YY\XCO=24G
M;)(4)"F:+2GP*-`V][IQ=I9W_\^TQ.FA"WDU@W8:Z%0_ILPQNWJW?7:77(DX
M-B*./M$%T<72(TT)9?R:9PKO=FXAFMI4$5F]<[WDN4\B:#.BJLU((6WZP>DX
MOI(=[I/7`]#GZ2TI%5U']9?TNOJ`@BG$]L3VY\3V@Q*.I?4@1.)XXGCB^$W\
M#?LU?J,0*DD+DA;G(BWP6&`-]RH)>))A5/GQ)"J)[;/0]C8+7<_:5Y'VT0Z=
M2:%>D6:T.UW-]D?:TG)&^+.E:]&$:=?!=&;[S]J$>:/\S8`G-YK``%J<%E[0
MO(!S;19P%^.\\+(=:4\L9,`LD>8$/G>!5>&Q*-#NF1;`X"`6)K9_&;$I7C\(
M`3":"[.Y^)3-B].KS_:]Z[G1,PXR"7!%L3,!6#PR'F&@F<-Z(M?30N9@\/E9
M"\;XFAMJ8Q@6F2IFK1WQ5]+-EC,B/:"[/YDLFY>C'$$;3+NW/=MWX)<)8Y%F
M[TJEVM2.8B`RH(]QX'G!$__YM/';^"*%_?;QXR"U=.XW]?K=0B"1BB,=^9KH
MHB@M%"CL5G(X.Z,;I"37SE*N44&18PNVWUF^Z-M7.#TL4.U]J/V4_%WNY!TC
MF_HC/#RABA$5L0R9`N69`D'(3IMCSLKR6+Q*H,R.9F19E>^YO@ZF4Q8ZKNUI
M,WO&0BI94:\@"]U3:U"(Y43NJ76&>K]O99Q!O$^\3[S?+&0MR(3C84^PV5]^
M8+2A"B?)2<9R=[9C3]U:/7BEM6:0SZZ.@Z.:&>9`-]N],NT,0E95R+(&NF$,
MRL'5"5_D(O_"D8L8--T.:*`'N*:'V(YNYOVG1%I$6J4EH.IMHR32HM/+^9Q>
MO@:1[6G+L_KH_-*,&PSD2*OA/86CVAF]H6X.2S4TB&6)98EE*RQ[9>E&MWWV
MO@SY\23N"U%2/R6_UBLO:>&P34G]1\[D6WH'JI#7;U46G6PJ%6]YKB?1=I:B
MC?+ZCRW;**__+%B&K`'*ZR?+@^+N]<R4:GH0ZS@.S9KEC9*C\QP2_+M]O=\M
M*9N+F+\6]$3,3\R_6?3#T(V^2=DKE+U2[TS.9M!.`T_VQQ0^/;W=+DGV$)6<
M+)480]WJ#L\^0$].CR8D6#;=^FE,'E<]`'V>9Y^3*1[=Z9EZO]<AUP<)`!(`
M9RD`VAV];]+MG;+S0AM2_OFPY;V71X57R8'?V2/S-%.461?>E8KW<\*`?_F8
M,&':DQV&-@SBN4E)?)=KCF=S[HY=-H+!M%LLL:]Y@?]P">0\31_-%6%7Y?6S
M"B?#-[Q8F;VEK9QMBN>4$0CG2_%7I#';F6@AFP5A!$)#F['0#4:R4P!.YDQL
M_X'ARK)B_*)2/TAA4?#?UAYL^#4(92L!?#'=ANL[P91I%^S'C/F<O=8U'V9\
M:1L\LB,FW7UC+8#%*(>?[!`09;N"B4.FL1]81HZSD0Y_SESX!M8ANA3`<AU\
MR!]ICALZ\11&!OAPS6/V*#]0#CRRR0%L+L,(;M#7V+]C`3Z?1V&,JY,`SD%$
MMBQ8#O(10TP"E8RP8OYR>-\_:S'LT/T/?H<CO?5`OE_>.9/`0\S/1'N&6>AB
MYK@V#4;,V[4E`C'J>D:5!_E9R#AJ%4`/\X(GQ*6M\7@*:Q1-*B1O<&2.:"DY
M+"7Q!8&KC8%H%RD'O\5!%(4P'QEN1;^%7=LGU)(6&G^O8M`YOI>X-!S5+;K2
MC$S*[K$]Z2>>22F$:$X.9G^"ZF81I3:6[N570NU<O?QO&:S;1^,KL;3!-`0U
M_T*3(W+^U\KW1VE/%7K^3$I[6NKW&Y1:O:X>%'E\)73:JN9ZF<L%5,WB$;'6
MACJ9Y35+<+%*"D">57++F9N][_S1HLV[JNDG&;RU,G@IV-THD_=D@MV&46H6
M93UHD@H@U3IH\WZS4!SCD3NU,:(3<]1KMJ]":Y>%T)JN/4U<T:/<\>(1[.'1
M#EU$&9>]RU5?<PQK.CC88^#9D9SDWN;P1>!K#[$+(\'JM1GPM.N`E8K!()=Q
MV:.=1X'S9\["UT6L4@R;+A+^RS`J:<,N_@WCX03L,8T_<N`==^PZN$V;\W@Z
M4\%2+F/)LY#-8.$JHK@LABB"3#A]\M#2B%46<GU1_2MH:1?NZ^S7'&@N>H._
M90-;;T!\OM;AZ?SCH<L!*"'#XT_$0@"%)NX37[1;W5[A[4ZK8ZKW\P/P*'3_
M9&*7\-9?.\;@\J^&WC7:XM''W)/%PQ5@9PK0D5BY^&NOW1IT7TN<7.3?2G'N
MN6.8P&@9G?RJK)8UT)Z9'?+71\71"V[)3=!TN25N!L,YW/2Z&^$F_](N:.IV
M6OW^1FA2I?=2-/7;*9KN8$>?`MA(3X#:UH#CG="5J"A*$PY"A,<2<T[@^S`'
M/I1E2P3^(PLC%Y6X#T/RC8+TB2*0(A#$W"^O.D*JO6!1YQ6'EO_P]Y]B?OE@
MV[.?42;^@8"[<;GC!3P&E'T%7?_6`^#]^M__I6E_7WCT]RS=Y".S\971K?\%
M$]J11M_:W.7?_.">L_`1Y>$'?Q9'\'/@._"6B&:G,R`PT+3XPL:_O+J)92;'
M]P[\@]+B^]?@N_G=E!]>_:JLBW0W.4MC/C:K/DN;J*#Z#ZH\*:Y=Q[@V1;)/
MSF5V2I%LBEV3$Z]B[P=%JT_">7>>T>K&..LH/GT&KCJ*3T<4D3YU\YHBTLV4
M,>=CS%(,NKEF[+G&H!MCR%+4^2Q,V1I%G7>(,U<=("DQZK$BKJ*&Q;NC_W"C
MR<)HO#A<<>YD><^_V:[_>\#Y!QG"&WWPW]DANGGX%L&6[VIQW]/%O7U.9[C&
MJZ]7/UR>/O4/:>-_%'ZC5UKLNW*2;_!'!\S;$7/<J>WQ7UY=FJ]^M3H@099`
MN.K]EP-VOF)>,58!Q%?\^^WX>\=00+4J!2J<TDN!ZHO;.PX$#T.5H!L.#<#?
MF,]"V[OR1U>CJ>N[/$*>?&3OY%7X%_G5RO.KM79W_:[5+FQOS=SE+70NBKN6
MCON]3G?WE0+7AX`O=L/D?S_X5XX#&CKBG^UG1!D.XSAAS$8Y@5XFI"]-JV\4
M-K#;FBK?UY:(N>QV!\,#[.N&C5D(RO4+)C'%I3+!I3GHK=G!W.QE+G9;>!O#
M0:?LU<X"[D:B[L:5"".6"MU.?^URY^<O><7;@KAC#DI?LGCT$R@$4`*@,JJ2
M,H:Y9N6KUU'1#K:F[^IV\!D3YMQ1PAY*4X`XJHCTS>XZ.MID197O:DL,&8:Y
M3@"5L2VPEYC[*#-G2Q5'1GO-ZG,SE[7(K260T5LG-5]8I<RP_"`J*"G8`[^H
MDDC^PR<6E0G13G^>'-;/7_**MP1OU[!*6O%GH/)28;ET73A+<?Y5PG?^;+E>
M1%G];M$L72E/7YYS"_G1$QRXY90@/.XP<W<2>",6\G>RK-9^>S=-HS-<M9*E
M$^Z]O"W`-!QVC95PVFYUUU)5[@DN`VAEU7K4##NL8`N(F,/V=@O(*FO?I86U
M2X&%T>M:PZ*A\L)<^RQJ"_!89L\RREM3@[.Q7[PA-/?@BX/FPY>Y):=;R#GT
M-;.7!43?9#&&O(=YVRC0/@/,`X3V2?ND?=(^:9^T3]HG[9/V2?ND?=9_GXL#
MG.@5T=V:4M(5T1K=MEO(8>^NR6$W>C)!EJZ(;IXINN:*Z&)V<_8!7305$.U9
M71%]27:IW1B=5F=.JU0BRK#![=@+GG[6)NX(=%L.(/-3UD:T50"B[8AF*Z`=
MNF'JGM<*MQ-]1T=%Q9+P=\9YAL&O$]M?H.K[4/MI8YMLS72=7(^NC_#SI(K;
M^,1$ZYGHD.;#T3%1M341A.S4>*A3E:ZN`P]M:<V<=TMF>4,YF$ZQ%9CM:3-[
MQD*Z!UBO>X!4SJ),4BR]T>JIE+,8ZOV^5<XU0.+V6I`3<7NMN;UDBTM*@4/B
M*U\5M#(SM1[D?<2:%;N%!1I@=8:S0-3`';%[>#--NZ,Z.+LY`8YJ/)@#W6SW
MRK0>"%F550X:Z(91:NVR9N"*/`/;RNC?T$7CRY;B]P`5U5"<_`.GX[^MZ6&T
MHYMY5RB1%I%66;6.>GK;*(FTZ(1RRB>4KT%D>UIV,XC.*$=VC>U0;XU<8.6[
MP'9`PU%MB=Y0-X>E&A/$I,2DQ*1E,FG?T@W59NJ<?1+R8U6E)MO;E)J<0_BY
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M5FH516%!M.VX;G/W[.9U@/@Z8=IU,)W9_O-JB)1/&DVEVDV,A,]?KS4`*R@\
M%D>NPW,IH1]\IZ5=1!G,M2#4X/G7VI/-84PGB=N/-/AL:S?,LY_LD&G)#R"-
M-/C_Q7XU6F<X'+1P+,W%-Q^\X!Y.T?=N,)O8X=1VQ%K@&T=-/`Z<F,,\,!JN
M!S;FH#/X6==&[)%YP4QXA6T?'5Q)K6_W/VH%8UBW[7G/FCV:NK[+L>7Z2-?X
M%+[4IH$'@A?,CR@'!"T"3##L"P]C:K`E&T?Y\ND*E^@%#\]:R,8LA&&T*,#-
MSP(>74:A[7,G=&<XK5B\'X6!UT+X:AZ+8%ZN925%KQ'VV<>;-P!2L;L4KIIO
M3QE.+U;AA('_/`50A"].I\W"P&&<,ZYK3Q/7F8@!<-R0/<2>'07ALP9`\R/8
MYL2.M,`!Q8-SBZQ_;01:2.P;L#J&)0-ZICB<_P!_(PA<U#LS%_8^#H.I=@-?
M11,P4QXF8I;"LI+%2!@D9#0!B"4H1.(!-`!XW8@+?*/!`W_))M:`-?@(,^?Q
M''-<(3X/P\]"%Q0H["EBSL1'[(`*+<X'3`#*$C"%('+]F.'?:D!<,V>YB<$B
MFR"=X?#!DR\`D>R/,R"6R'W$YSW/OD^(W`YATP]L*H#ZY,(`'K-1RFIS](R#
M`0FE2WU6%+ZPY'OFN;!`A2+^#$0[M<48`)&,.C<C!,#\+(1=XNJ`DF*?_9AY
M@2L8=P9/V4`D")$P?LA82ZPU!_7"^C*R';Y!40!TXHNEY=`Z<V<,Q0ZPW2B4
MZYC&7N3.BLPFV`MH%>2)%PN8A4BP,)`X!L`O@>](6.&*7'^,*`AB04+P)D".
MQ/_.XG\E3I&`D8)&L1/IVE<D,<\&)"=/=0SCC79A1[8'1JG_&DC,8<`8(VTJ
M+%HA0N)H$H2)&!;"`@7$NQB8E@$=8EL&EW/X44?-\NX:B4"[BA]B'A4O)@BA
M)X4+LR,9`1SCL1!H&IAW&D=RCIO8F3#?QV\X"'4;Q`9P#DPW>193^-.;CS=B
M%GMZG\C"&;PK6>.!:5WMF=DA%Z2&=)S(9+,#4A"O3P!P03)SG+^PF7?`=<$4
MR/D*EBCW\^X*>0;$Y2J0P$\\OO\7T+-0([X?`_>&[-$%7.,"`+#L"?7B<W&N
MCVSD.H!1KET],-^1>WOW\0K`Y'G!4R(<D:^`/7@"+Z$#7/[GY3V,.W8C#72N
M[3LL^:VX.,%L7!O'(3(K"I61BS]D6G@IW=CWKN=&SU+:3H'708WA8J2*UW&<
ML0LB48#^,V@"@*WF`'T*^1B%V*0#8*XP)148+%7H6ZZT[=7U5TW\C&L$"$[A
M`5S0V/4%`$%[1GF!@A:ODHUL/(:)'"E+N#UFL-014'%&GF()>J(&\>S4TNX8
M*RCN+P!%[;WMP"9X]KTEON?:%["#(FD:?,E4[A5*6CCV"WL$%.YGR5O:-:S$
M'2%-%6P!I/@$]B-0<"YN[,$.Q88$-7R\FH-\,H&2^P4(P!B94GZ!%DB6EB)+
M-<^.?9!%HYSD1+:Q<_8I@)R[J#RUWQ@P!+P$?R[>TA+R#ZD5E#9("L$#\*=@
M3_@D)P+K$,P2&75"0Y%S22/O4MLLB"-!S&*H<8RN!"GJ]+P,XK&#I#..O81[
M%;V`E>4D9F'(7)">(1?VCN:SAR!RI4.B!?OW4\M-STL)8?3=,P8F(;P:"SV?
MC`-[LT.TS\7D2+\/H3T5H)$6%T.[/@:K!O?W!"R!%D2`DA\,*;">.#S,?H!E
MKTOS#4TP>%D*3&4VJ#>R<0`BW!T)Z:<>%+;6D^MY4MPPE(VXA57R6_+4/9I1
M]Z`LB'?*X1VD%#^(--!M3!XON?O@NRBX85!EDZ">9(DICV<EI:_R"E7S8Z&R
M`<.AD,S<A9V`50`_2FI`62Q$K"1`T.T/+#/)\Q)TQ&8,O2JH+GWM3X;<.@*6
M&X'.YKHZE:)R01.7(>TBF<)ZE0&1/[_`K)D8P!,.%Y%CM3,UV@Q."7!:`3GA
M,ZE,@GM0`WY>FSGVS(W$$\@XXA`4`'.+$\O"E.J\I*909^49T'5FG@5*U:='
MDBMAZ"PYP*,HF>?OD3RF.O$TE@IP!)K%<<7D0CG]<$'O,]CP7ZU>NV5I@`P/
MYEX\'*(B!TA+"1=D_LX$UR"-@$A=/`JID]DLOO?`^`K&P+>`+I[`&';&H\#Y
M$]'PGMV',0!IB6R]!56^('5U,3U8)@(+<S,LF^!_X&15&,+4<:F/8LD>G`+E
M`3$]Z_I@8$:N1'WB3Q"#Z<7S):#KWO;_%-<C],)[XL*$A!;N6M=`<`*VD002
M:3UG6_%XAN:1Q/=#FE&GSJ:S"?"'CT"=X5[#!Z"#_RC@B]^EK0PT^!@(,PKC
M$S.>$KD\D4F/27+L&R7VZU)[,6%G)S6#-A*C%;GC%WWL<SYX%EW;?`*V&W`^
M&[U]_@;[^^!?2[\"@'Q#Y[R5=\Y;K^!([LH'O\$?'>,5(-8!$O?X+Z\NS5>_
M=MIMRX+_:>=6NOE*JMG"7'QAW18N.\;0,"O=PON$#ZY28ZARQ'0&'9!E&^QJ
MP\4=;*-;HL\$;CWT-C^`G./10?%Y:1F]_B;[W'!M!]OGEN@TVKWVP?>I'C\H
M/CNF90XVV>B&BSO81K<5KV;/,KI5;O2##^8.^QV/EJ4BR&H/%Q"4S;7K,K8&
M7W_860#?1LNX>K3!9@)C[&MP+>S!.[3@)H&'SNNW<,1W#@FO]:NI;BLEPWS[
MK3Q=.>)X#X0,5._#G\KD_AR`Z?XL_S?-KJ#LB:,Z`-;%^K\P1\;_7,YC=+&D
MN,5CNC^RPQ'Y6W;VMWS`L/SS_'D73VG*@H,#8<9-VIV".-?>!O`?[>+]U=W;
MUPEJEC[X;2:.ZA=7=]]>:Y^"5G&NR_90U[XH%XXXBZ(2"FTG":!>QW`2G@*G
MMS0805/O2.\<\]PIK#)2P6;T?0;^I?+SC>#%\/F2ST#8C$%B)7ZBD#G!@R^=
M'0\Q'#71E2-CR\ICJ?UV=?59>3C%<1T##V(Q-A[C`2@SCUW>VSP?-T4__8A%
M+,34`N'47)ANR0Y"]N_8#97',?6W)"_]AZ7#R-E4P.71]F(9K<%M*X?!0Q``
MM&$5G(6/KH,.8.'\?<X"^S*I0()7.EMP02"(@^)J<IXEC.-Z`4<OL7V/OF,<
MPQ>G8UVSIXAN(!=$@_0RH*@-T3T5/0MWFUJ^<$"`$:*-O>`)5A:Z(G0O$.XH
M#*=+*_C;\BZ_?\6CAZF*7L-X$XRU"Y]#\0>,=D4Y(*H$!2?@PHTCL)QWI(D(
MBS=&"-@Y^.21Y7*,&*F8/Z(Z#=*A$T5$X%GH(@+N&?"PH`"9-;'HR$>'&8S;
M:VGOI+=[-@-]E$8"T>,Y0S**(C:"9_Q(NO,!`A+?DG2%ZY*E(E!CKO#9A2P*
M`Z1Y7*DG,G5$3HYRQL&7EW(C@.1_`>!EODP:QA2LBFZZ43"3)/M9)@S,>_$Q
M74<$%7&G3TB]:E@10%1OXT@+)#^Q'UF25S%.98R(IN90Z*B,'QP>($+!_3V%
M_+)HNI+S(,%3`9X@"VFTD*$DJ2!-I,J4PUV*N'P`]+<`$8=!(!;Z^1]N4GDB
M:.Y;*BY$Q$I(&*!S='A'<P["JRR@?)VD[PC2+LS5*@1/<_M!!R.>?X#!`,BI
MX`^S&"V`W9:Y.\6)8:DS.`BYV?P,!3!RRM.$":Z+1"A*1AV0(X6C&-/9HY?W
M5`B2Y_?T(/;DR#VAWS3+LDLDK8S]X:<8EJ<I.&8*2J4,B3R\-(<*'OC6NFMI
M=HP2/F="2;:#=2@PI8`9!T&$#)C3!%RE,Q0`N2`AA2"04E+*1H#`:!.Y*&,2
M.2&;B%:IU^%E=YI^)R`O1I0*3:FPU,&>IP`$!4I7&4"52!?2R"YH&1<$#PBR
M-+D!HSVH?.$O<<%!@&49`QS58;WEH6?NR!0(]PX;?8'_#5T$CCADW4T`9EPY
M")Z_BD,8'9M6H+;Q!99[UO%O*.^!E5(N-IU:*49KS?5^TZ`"RUO0WPL>BT'F
ML$AD:(8W(4TKH-:S*I%(0NNTA=;+-TZ[5$JY;$GU*2Y:X,%X@3;++!HKK4DB
M_W4Z>VU)GJ6L0#I[#]+\A_B9C2JE_ZM'%MH/[`5-4.9LOV$&6*4SW,#!-]O,
M>]L-#[2U/]#_3=;4?M;48LTF94J=3\VF_[']8AZH2FBE@DWU,]5.H<)I9Z!;
M[391T7%J`%$9XS(%6L>D,L;+Z_^T^L;^1D@]:._XQLBIF1S"*F<C*E:\N1U1
MLCTNN?R0.,_'OPGO._DZB`:HMO#YGE/_$+%Y.I66<BJMI=5X87;;>GM@58G+
M)AQ47E<B&\W:T'C-#W.UY`TX476'=**B$]5R=G@?A&/FTIEJ']_LN;3SN#!U
MT^KM3Q!-4!/5J5)2F(G"/+):')3@:&R&;*,SX[9$_TUE=&MVM*IN#QTHZQ7F
M/)D>"&;/TH=]"G32`?5<#JB#+AU0YW2T_$AM/AX*U[1VN&A5O*J5EFUY]V.&
M]])*K<)BF)91+.^T,-T^J]FR,(C5[7;-G59368T:HV,L7]"J$C';+FGKVBF#
M=K^SXY)^%U73WXL:L!]=WYW&T\_VL[@S>!.SPC*O^/?;\3:H:P][RU?U\J0[
MK?1:E6W89\&==F>G!:NY=UHW5DE[9/\4=<;W6GM_IZ7GIM]U^4$<EK#\MMG=
M<?W)_#NN_^LD9"7`?[Z>X0[S[[J!IZ"$Y5L[DD\R^XN+_P*/*VG]B46ER;XN
MEB)LO[3NXL1S:\1KXU>.$\9L]+LK;^%C_;.5@J1C;*Y#AW-UN5Z>;,^%;<%F
MPVYWOW5A[8^030"B(#>D=DEK<XV#D-OYYF57:7D1@/[M^*O]XS-62@G\JP@,
MG_LXDA6]/ML+&]N_1NK"+JM;>7W`M*7ET#&64,.QX?0^".'4XDL2=)Z_9E6=
MKOR1JJ`O/AT+:I<=P]H(;)7L9#,@HL7W%M'%OC#'LSD7A2U$,<=DCE():2-X
M;+"H8^SNNYKN>UK%X]V_8SB!X<2!CYKNZH?+TZ>NLJ+F,-DW/V387@RK:>*I
M#E__S79]7.)'4=RD-"X\#?#-,<66L-J8]TH%UG%9YB#K;1(3U!$@!R3K%[:?
M,^$^I<U7]C1EC7Y_<6E+)]IC05M4JS:&2RAET_7`CT'1-Z*.!Z7ZB+I+(+9R
MYM)6N7V5Z"5GE`V7F9P!OP97CBBVM:QW<:E>R:[9+;+(1DLH>]7;"OEAISTH
M?=6?L4%1&#U_QO8<8$JB8)*=7<H\0@UZ+R]\Y2HJ6?V6@!\,S')6'[*9[8X4
M#\!S\L`LBHN6XBDP!X.B.-M@QC*6N#DH>YTYK^@.*PP<QD;\?1A,/W`>8ZW`
MVW&NCG?973CFD;]N_M7+O8/3+NSP(Q:[!>5_.ZY<SG6,_NK5;[2<*G>S;?2F
MW9USA)6Y&T3=K2@RR]_]P`9:7/2&JZ[/R=K9%Q:[7,;,.T&WEAK#3G=A92NG
MVFM1V[B0YU7=QFOZ(OK%(M[1N"U%KEJ6592K2^?8;1E;4%"G/]A^%3.EK&['
MOP?^PU<63F^PM5>)4L;LSZUJ^93S"^,,D\@`E3=9-[D*[.=.=S`8SBWPA:G+
M6N6V;7/Z0W,>N5NL$@OULM$[.\0ZX3QWGKY1C?+V(O]+RS"ZW<[<\M;-6<(:
MMSA_6+VVU>OMN4116A[EL;A47:HJ[K?GUC8WUSY+V;I%4W]>FFVRF"]9WP'J
M=[(FV>>@M=G7]SN1+1-R"*QX#R<%WA?ZR:8-(7C:E^)IPGS5QH*+^N"),Q,;
M)\B_1=UF47`=!!-V9$@0Y`HVQ];!V$YBZ<-R?-&2/.W([H!MRT+7%M--6?2S
M=M%YG0$4S"8XI:#73V-8B%WU9<>.JF&(#2_$<5DT.>9OM`LC]^J(>?!:*%NG
MBJ8?H=Q(VA%$5#L7S9=#;&(+/\,09FX(T7`V=&4]]['[0[Z?]#7!W;T1V[NP
M<B]A=6KFY#N*)Q`=Q2R!*@_P]6?L&A'#O-3.81N:QM]^Q@Z_KK.4RM%^3_K(
MX\F*$W1WEAB?OU[GFS3<:3[+FDUC!%RQD>!]<<."!YYHM3)6/\,?N6[O22^$
M")@@2GHP^].;CS>B)0\+01X$\XW(\071J"$OOT2C&"8[NK_8S<@5[9>#4'X2
MG8LVZ^:4;_F!?4'RS31>+W_S.ABEX;7B`%=WU\7W[^+[2/03[K6[HL/(,E67
MJY.A*)H7H;!$BHOV/D44)8)7MN58)E1E=XQE8A4;&D4>4]TPQ*"JK5``$$2,
M8Q=Q1).'Z9PH;6>V:'"LFO(D'8U4`^\7Y:EL\0SB,^D%XO(EXE)VYUCHC:Z-
MXU`T(($-`IU-!;Z#>\]]D.%.DK+E60Y([`G!8;/OA,R`PG+<CGV1DHR9I"<3
M/&WG&KUC+R]7=.I*FI;;,+`[O8]#I"'9@1[XEW'1%?LAM*<2_<\S[-\-/Z(+
M5LB5^V?1*R9IWJW9<30)T)^&H[L^!SJ.DS9.;B#ZW:^J>5EL[Y3KG94R61#F
M-R';H[V\:B4.Q?:Q^9?:N.2^M,^]]@2TS"?N;"8[G-VSB>V-$RFXP>Y41W+A
MQ1#MYY6%@^X6-M(U%\PGSU--[9<)SM0D>V+2)FMI;],V7JIOVM@->:3]&V"'
MW6M@<8M`<[.>8_D.<`BX'(786:]S-]VWKIJU%?B;<?2'NGR"_(\MUR-L!B3Z
MS><E!C%Y-4R.>A^`C6V/IT+J8P<D=5(0Q'\ONM1K5VC9H^1-3A`X#**,"\9&
M3"O3..V&)]NDP;BI(N?+E%@RG.3$PDQ(5#G64(L1"\LM$]XO$%%N7EA.<EX0
M^I4S9)+\1F2#.*G50C9&BM/^](,G/]]Y;VP[8+VH7E-3^SGIGL1C9Y(?4'%1
MPC_`R.B14^/@;&)D(N4R3P77V#7H/I`.'D$:PE^4F%T$Z[W$!IIP2=]$9)Z'
MD*FV8YFBEFTL6:*<>&(@)B('WL;KO,#+TR!,#?_45_`SWO8%UHO!UA:F8CP#
M*0%+!8P+E_:8,?Y&@_T"E^-`R3QOL&F=\$=K^'+2,BX,GFU/Q/F`'L8BK[\H
M<5K:!S_M_EE4;@_,Q]00>%=Y$U)IEEHQ.0B@-)!O"'M%]91#H85+%G^D*Q0R
M*_.9Y_J7P@]"I"@HYMJ2I@`5O>]L9^+"`,GA2K5\1:OD<>.^;$3I:Q5DTO:0
M"W-*-BQ\4&$RX0:3@D:ZOG2E`E`)+A`H4+)H'"H.2ZD_C">$,D+#=LL>Q'IV
M_%6=^[)9P:*;!*.\!BYVY95J$<B,I6U+;6%DY:1G=DHL\D4&%#0S%[=:Z`KY
MR.19-MVS:E>H.*;@",Q/DAP8Y2S%S0DW))CE/D=7OCKNJY,']EC-'PU!_"A>
MF1M$^2B8/[%5VT`$@NPS#,N+O2AMUQO$H6;+BZK"&;%BR#G?9'&Z^T+C33@\
M1_EE*A?CO%]R[G5U1%8CX=$>EP*$J<R:U!6;("(OL%=C%T1@(M+G/;7X==9$
M6=%^NBK9H?>>Y9W"=A[UN0W@LD0SW/N\@8<<D!"HLI=4YTQ!'0MH5W`?K?:/
MI/(>3Q/2([W$-Q3EM=FC#3/&O"B>YZ"5"GH!+&RIF=NF/@^AHG1PA?0(G`3Y
M@NS0[2(ZF?JN;-N9:_*>=KY.\<R9YXF6R\*Q(FWQK-5SZF@7[9'M*5/'SAF`
M%G<&^BAO$Z>M2C/O#JZBN`C2()5%8*0IH/P(:=O6E<:!;.*MVK6OH,KD+)T9
M$B%+Y,LR;@EE'UG.YA>2XT=<!Q+ZLD/=BJ6RY$K\DJ.]<.&Z_,_D*/DD6_#R
MQ&&(+7Q!ZRDIL'**3`X?L_?LVHAS,4`M`A3JG7570K<,VP^-3C&[96ZNW1>R
M9="^;PV,+1;B@"2*/78[5F8._VP_H_ZZ\D>+%S2I#>^+5-[\-KR]XQ=FVP,K
MI=3[.;N6?M:QRW*>7$N_Q:)W"V1:9D^ZA<'W'1`E-C$6,5;M&.N&.:S8-[9J
MWD+;KP)6./=VC[TS*XGZ;CKS@F>&SHDI'LULZ>6^9SX;NYCV(<]BTB]EH]T-
M]CP522VEN&4=V\117<V?.P9U\5M:P58W>]V,%8C9B=F)V4^5V8>ZV3'*8?:3
MK.2[LVEY:@;D=>`GH5`9%?.CT'9$0G#BH:_UB;V^Y_-CLG^GH_>&G3*5/>&J
M0E%M#<L4U<U`%9WUMQ75G\-@S#B7V6(BYXS.\67[5&MIS,');5"2,4?HK25Z
M38ML=;+5URF`)),"T_]$S)\L\\99>Z;>,4NR]@A5U:+*TCO&@`QS,LS7R651
M,)",\1-*<*BGH=C1AUV*X!!EE4]9ACX<EJKJFDY96RK!$I->*]5VIYP4>ZH!
MXQU:Z%)@N/S`\`YH.*I$-_6N6:K3D'B4>)1XM%0>'>H=HZ0H;8,]#/(C=55^
MR%]`W.?^W`LW\9+RPR\UY&GZ9;SV2QB?>_#%0?.&=F[)Z19RW*:9O<QTW_7V
MS)S$W6>`>8#0/FF?M$_:)^V3]DG[I'W2/FF?M,_Z[W-Q@.7'T,97".EVC^]D
M/*%@2#,*&1C'CL:>7"&#K'7U`GF66;T`^T'SGR[06\3XZTJGNO4K'3[KT5CI
M-%D#2!(;)#9J)S94N_=*62#I)5_I)*HIP4*',6(T8K0Z,-K7(+*]2CD@%^2I
M5B]C!*E:@9$/3U4ZTX>(3:M0S&=>C4F=Z<XG$?RM[8D2U':D+:THA@UV+$H4
MKU?N#A5D*9,4.VTJR+(LU^?"'/2KY/`FD-NBHX"D08W00]+@@-*@VR9I0-*@
MQN@A:7`X:=`W][(-UEVY:@*Y;2<-RCJ:[GH`-6IZ`)4WD9V\XP1[@`53]M,%
M-G9^K=VS<2!;<'HVYVF;ZPIK"37K[+FM<_28<J-C=`D]]47/1<>P]L?/Z0GO
M)N*R4P\W\#D[?>NJ<Z^FLBA3IE*Q!9]H*[E,&V.H@5S`)Q2CK!;D"X+LD*0M
M\/:7'QBUJ"[=C4B62)9(EDB62+8:DCW+@CSD\4D]/N38*4/6[>FEWD[8D5.)
M2*.&I$$.+:(C<J:=A#.M`1F4B\V.,7VR2[ZS^J5(U.DH1SD2IUFB]L+H&90R
M585[@.0!R8,&R@.K7\)AA.0!R0.2!R<A#_IFKTHW>1/H;:\D2OF1RK`^K"S#
MNGWQU)656/W(';E>',&[66F(=S\<+QZQT?LPF.+P<21R,V_'[^S0![G'/[/P
M;F*'32[.6C$=-+X.4K]]?/_6'EBI6WRI%G46S#7N8*,G;5&JL["YYEM7!8%G
M^`K&V=^+3L5*3.@SNO9/4NRTI5C=`UDG)[K06"-J+(\:28_N1XP6:<C::$AJ
M#G=H*Z(!^G*K&]!'S9:M.K9-]$+T0KE$*W*)E,8YGURBNP@]I+>SBN^WUR-<
M=2!!5,O0CZ7WC+X^,,ULTX36YJ/5U#NF"6AMEX-6N@=3UX-'&<+^F__(>,1&
M6@C_"5T'_^1"`="YI`F>DZ,*FIZE#_LEB1FBC9.BC;XUT*UNKTP5U`S:H//&
MMBI(U':G<T:]'!X[M`2OIS4,*FIHZ(,V'7*(ILH[80T&AFX,2E5O3:>I.<4G
M/U):Y,.*M,B2,AE79DH^VJZ'T'\?A'>VEYOC"W,"WW$]5PQ-3>N;W^QR'B"T
M3]HG[9/V2?ND?=(^:9^T3]HG[;/^^UP<8/GIM/&7M:P:./3W\!F4Y9VV!LW-
MY5VXK-7IK+FMA369#,HR+S/+?,FMK/1#1=<A*`.=A-?I":^UA0<[K>'@E/*)
MCR^[KJ9!&,$WB]VVZY1G5`OJ[&YP#YHT:ZG4^5L8\-Q5Z&]^R&!I1*UER%+C
M^"9$%23SWG9#,KC(X"*#JS*#BU3:'O+I.N`1::^2M!=5;BC3V+)=GQ-I5D.:
M)#/WH$RL3,>(-(DTZT>:?]A>S.B\L=]Y8_'VA55R,F[M;U]<!],I"QW7]K29
M/6-A-1<Q\/#2]`3G3?FG_#K06WF*ZP'F,DBS*66@2T+/AK"MIK704.];@_TM
MFGH0'_$X\7@]T7-,'C?VJO-._%T+`B+^KC5_4U-EDB(D14B*--=*P)/`?AVB
M3O(Z\\Z>I-/S%X6S(+0CIHW8/;R9WBNNSG'4#(+9-<9]5&8?]/1!IUV/2$8=
M423C%L=$D55"MS["3E78N3"-$KBG"2;8ZYW$>Y-PB<*P:Y9@^C2#W;8T<%Y*
MS3N?:-EOP2,+_2G,K@7W`!B[PB+)IQ0S:U#B7SV/969?-RURX#8Q]:2>!&5T
MB)B(F$HS@\TJJ8GL8Z*\%_1B&39[TT59B=9\G6SV4[Z(<ZIQJAW*O%(\JOQX
MU`YH.*H]:IGZL'UVSDYB36+-NK/FL(2C(G$E<25Q9;EG[FX)A^XF$,]N1VOB
M8>+ANO,P&KT]RSC3D*/\6%6+B`+)S]/[NBJAF@*HHAK32O-CYWE@WU%S)%4@
MD:T3=Q>8LZ15'F>15!*6]DG[I'W2/FF?M$_:)^V3]GE&^UP<(#TP42N`LL^O
M:U#3I)AR+:I!42N`PY>#NF$.F]ZS<'4W`*L2+^H9%8LB^74F\HNZ`5`W@/I2
M)W4#H&X`S:%6Z@9`!A<97&1P-?Q2X,G))^H&4*+VHFX`91I;U`V@.M(DF;D'
M95(W`"+-FI(F=0,HX;Q!W0".4=VMZ3=OCY-O3L5`RR1%*@:Z(C_=;.MF?[B_
M;5,/ZB,F)R:O)WJ.R>2#$BH8UH/PB+^)O^N)GF/R]X5E5-K9IPGD]KJ2LS%)
M`Y(&39,&:-*WS;TJ.IQEQ:RS*?!_Z!*WS:"6!L:LCREES*[>;9]=V9@&14".
M21Q]H@NBBZ4'E1(*7#?!W-WM-$)4M*GJL7KG6E)EGY3*9D0YZYJ,V?3CT'%\
M'CO4:ZH'H,_%ZU$J@H[J]^AU]0&%.HC1B=%/F]$')1POZT%ZQ./$X_5%T'$]
M!?NU**:0)DD$D@BG)!'0O+>&>Q7$/LFPIOQ858W=PC+W\<2D2RU4MYHE:Y;#
MPIR_O.J(85X(1^;WJ.4__/VGF%\^V/;LYSMGPD:QQV['5X^VZR%TW@?AG>VQ
MNS3A_0MS`M]Q/5?$/[_B,U^!9M]Z@?/GK__]7YKV]\71WMFA#Q3"/[/P;F*'
M[*W-7>?*']VX7ARQ47$0#<9'+OC"QK^\NHE#,<_W#OQCM#O=[U^#[^9W4WYX
M]:MBA'1/.::8K\>E/DOV+=#JOMANOX3MN0=?'+3!A=GF`4+[I'W2/FF?M$_:
M)^V3]DG[I'W2/NN_S\4!EA]!&U]@N=<[?C;+'HZ!<OR:)U9@8VT)R&'+H'I9
MVSEOUQ38^#H)&<M0-H4G)KF2D`R$X"C[^-$.G<D+%'T?:C]M++36K`SK/%?!
M,8;17(Z9<X*2X"3!N5GFK$7UW,J6G.C`)LK<FS*-5I]4>MF$645/A+/2G(NW
M(I7:;$8R>;L\LLI.E9_B*0OM**BB_O-II:<=5R_7Z*[]0C;$X7!`]+:QMB5Z
M.P"]H?)L.KV5I40;KRKG-2.+-"_@%143:-Z]X!V2,7>W^'=(]:.,2Z$)CHR%
M#4%83:*UV=>'G>[^C-D$\CE81C4Q\8&9N".OZ)XK$W<LO3W<LP8<VF5-()_M
MF)C<'7N[.VZ8'TQ=GQP>U3H\7I`Y=`(ECT?Y'@\B.')YD,MC7W,DIQVU,?Q[
MCU>"--L?:2-Y*4CS$Z?(C(4:QVM#Y![935L>T\8V3;W=Z^O][EZ5ITX;2U+%
M'!-+AJ5;0T.W]JT145:$MSER^8P/.)\6!/3/=-`I^Z!SKK;?>2)='3;.%>ED
M\)^NP?]VP<`G:Y[B)`V)DYQYL+/3*B/4V31">OU_*.Y9`S10W+-T?FZWNB5$
M/9M&2(L1T&U'V$X@S%F"\F-3*T[ML;3V-DO;#.Q;C#"_E!>7?92+VV9I][8_
M^%HT8?!OR)@FKV)JX@:F-G?QTNSH&MX_$O8XWO?0Q8O7P13.J<\:^S%CH<M\
M!]ZT,T<\/@R/A6P<A`S,^!&(H4@+V2P((PW?$Y:]^\B4N]Z%T9RHM0EY%7=<
M04&SK4J0K:QC-IUYP3-C=RQ\=!V6#,1&"#CF<U&J[,J#(<1?MV,LEO;@PW9&
M,*\;P',\X@VN=%:QE&E^40&+[L:>V@W$=44%3.6LI!N(FUMFVQ45^!@4BPJ\
M.[6B`N4UUFG`U4@2G&<B.-=&.[I45*!LR4E%!:JC3%+I^Q%F%44%2'/NICG/
MKA5=\^*"Q]6C6V4HGWA:`M$.T<ZQU5/ME-&2Q)624]9JG]+RA7&&O@>9U<(>
MF1?,IK"6ZC);FIX<M56,O!9[K6L$VY09*;7L.63IO5X_(PHB>R+[<R#[CCZT
MK'+(_B1;;NUL49R:W7#'//CM0=<>F,]"VQ/V@SV:NK[+(XP"/])5M^:Y[(XI
M>KIZ>]`I4^,2E9P@E73T?J\D*J&#[2D?;+\&$6@E.L668<[7LR4MG272LT0]
M$71,/3'4^]:`SN_$\,3PY\'PIMYO=\ES<:)7-Y(URV&KR*TO-RU^5?;]>]L-
M_["]F%UQSB)^Y8]^=^U[UQ-MR3\RF\<A&]WZ7[!5>0@TABG^G'J+-[\G8?VO
M\-`^:9^T3]HG[9/V2?ND?=(^:9^TS_4#+#^Q-OX:L%6#\-@>?H2R8CU88Z6I
M5S,60LN=SIK8<K?;ZAIT:6@KI^^:2T.+52NR#Q7==*,+122\3D]XK<V+Z;2&
MI?=U/'/A)9(H*B'-\[J+:QP[9>OD*/-_XR#*%]"8A:[#^`*IEEDWP_6SZ6P'
M,UPKG0ZP\2>+<B5#QDN:,)6Z/SR/N0XP?+9-$:6J=-8+#R\=95-V7I.\(7E3
M.WES!\MPQ\`=0)95LD.`Q>FJG>&>L_!1)`)4*RUG\8%%AT&B@T3'^8J.V#]=
MUC:K8.VS\I,L7@FP2LYSJ_V5@(_"HA:N=XX)5B+IJIHK`E;E+5`.ISL.FS%<
ML]:2AZ3/*O*%VR7G"Y>(G@UA6U&S.%/O609=$"!V)W9O#GIV+I)4!KX$*_WE
M!U8!K"9<0U+D1,B4I`@9#<3NQ.[$[G5`SRD;#2=Y57%G5]:I.:S^88>A#:]X
MZH[@<W7.JF80RJY)04>U&HPA537:-.Y$\IYH@&B`:.`D!'8-DI#K62VBP&1;
M<MC\0"].VN"+1K1/VB?MD_9)^Z1]TCYIG[1/VB?MLWG[7!P@/5]1P8"RC[MK
M4$-W;K?TUE#!@,-?%[AA#IO>LW!US0!J0KK&>T7RB^07U0R@F@&-)DVZB%<V
M9<[7#%@@TC)OL%%!@OWWMUB0H-+YJ-H!24J2E#@653NH_Y5HJG9`HN.,10=5
M.R`/#U4[H&H'=).);C(UX2;3AK"M)J.UU]6MH4D7%XG=B=V;@Y[3O\10#_(F
M*4)2I)[H(:.!V)W8_6S8G8P&JG:PN2OKU!Q62;6#WZG:P7[I3,>T&CJ#`54[
MH)ON=8M&$@T0#=27!DY"8-<@?;J>U0X*RUS'82^E>*=++5P<FB5KEL/"G+^\
MZHAA7K"?\GO4\A_^_E/,+Q]L>_;SG3-AH]ACM^/WMAO^87LQNQ()<E?^*#'1
M7,8_,IO'(1O=^E\PRA@"\M_:W.5?$9Q?@5C?>H'SYZ___5^:]O<E0\<1O/S1
M]=UI//T"AJ?M?;:?I_`'?Q^$MS,6VA&,^#M,PN:&!"[SD1F^L/$OKVYB?##P
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M[>Z9KJN29^\F=LC>PO.CZV`Z8SX7*;!W$;QR.\,_^156!76C9\J<;7[$_5PR
M"VB?M$_:)^V3]DG[I'W2/FF?M,]3VN<I9LY20Z73;JA$1=0/6T3]4USL`!>,
M%TBSU"8)TEM4"?E3/P%BA7UH\Q_B9S:ZK)0#[$<6V@_5-A)@/UCHN+S:243;
M*6)DTF/$O*7.$;*I[?J`G$IGP<!,:#M1O*2#8IGS`%E,24B0MJ^=P+AZ>`C9
M@QU5W=(G"EV?NTZELSQBR:0*N.RL&OF09X$\"T>LU7S2X"5]3>1$Y$02J3[@
M/1$2(HETO!/$1;XK>K6'Z$D0<]L?\==DY.]GY%.WSC>W<<0C(";8DV9'V@US
M6#$$9'9T#6ML4P?/4A1X+:^%F;IE&OJP;^RO0L\"F4FKI5KLM0PI4&&_HUH2
MO-$%;B1B+T=R';63Q&$.!J>"Z*T/".>)=.KW=<K]OG[#;E]L1%V^-A?^Q]35
M'=WJ]O1NMP1]?4*(428H&9J)H7E,$NV"H"SA['1"Y%F')F/-\1G7UP`\:036
M()I/GLW*5,T[E?9:H:'7]!-"\SV7%X9IZ0.S4E].$^RJ:D)!Y.1LLI,3&'?0
M(]\7.3G/#-'DY"0GY]D[.=\'X9BYY.9LC)OSPNCI1J^[OQAO@BE6G;E*1FD=
M'*)6O]4EA^BY^=.:B#1RB))#]&P<HC,W)'=H29X":BTP9[]VAQ9Y82OSPM:1
MW,C63AW`=43/43/*!X-6UR2?9.-5RDG;NZ=%8^3W)K_WV?N]Y^ZS?;1#9[)P
MF:V25O.GZA0_W^XZ/:.O#\P2K)@3(HKEYQ%J?%6'8\?9L*9IMGIT':!FLOJH
M1F,9?#IH#;5G9H?UKD=<$X*C<&N-PJT=JZV;PR&%?BCTLYSL_V`<4X&"4'OW
M8\8<_#L*M$?X]BB'I*8?OINBDNOI&[9TTS3TOD&YR8TY<M4#SO4V`.J)GZ,>
MTXQ6O]*8\`DQ>:VU!1WMB$CI2MAVVJ"6$KECFKIA[I692^&S4PZ?J4O3HLD?
MA<_JI]&WJK%[5$FCM\V^;O3H%D#E1[F#UUT^$0U]GHQIMEO#`3%EK03U"9RO
M#`J=;:D$2!+7(71F=?6.V3_3R)G\B,;^/%B27Y<M?:=EKJ,XB9CE#132I1;Z
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M-CMZ-A-*^@H8LM,:-+C+X][N7264SR=#Z(O+_[P<`SO!0X`CS`P"VX)5X>F5
MLK[I$80]9/XA70L'"^INR=MET&RGU;7^I@F4_>4']JAZHW5:_?[?*A.'3:?9
MLL3BJ0F_-"GR,?#@0.7!B:XZP=<,4ME&O#5?DL`*+GO#Z@1',W!.5M/.@@,(
M=DJV4BFVT@D;+-U6MZU=:KU6IU-9N.0D+15R5&_HJ-[=L;S2:8VC3`(/#AG\
MW;]C,(T^!1'[AQUB%RU^&WY!RN#DGUZ)_3V6UMYF:<L$SM<)T\:!YP5/6`_!
MY9JM`?IA)<]:,-8B^!4C&[;_G!VBAF^X%N2**#PI3&LVQW=69(3]7#$D*(BP
M1GD.6[UC1R&/'D3HM+K&L4\C5>>J=%KM`041R@PB*%56J<>>HX*NQMH[!9+?
MO')5IV4:1/YEDG_2)JM2^I^%KK,X0QGD/SP!\G]QCT:GU;&(Y,LE^9DK#R;5
MD.317:+'O!<C#='S<0'"`6H:^/`&'GXKT_!-]^?L8=S6(UIZS!S5GFYTVQFL
MB9HVVZO1ZBW:BO6@)LK]_KD]:/6(V9=U;1RTVJ5Q^_!<N'VYF4SD9+0[_=*(
MB2Y^[^II)3.V-$=5302.,E:/R=M]O6V6:A>>$'J4]4>&5F)HG99-<T*4JBR7
MQM\!QMBQ9OLCS6@;[5H[UIIC99`;C=QH.[O1:GD>Z91KL9P%0A-/5BWV6F\K
MIYY$;^A=HTU>G=V].O7$*A@\Y%HYT9S=T\K:O&$.F]ZS<"%QT]HU<;.DX'3Y
MF#N%5,ZC%Y39`RNE'?9.O1Y$1UFPE-BSN1UYRJF<6)>O^22_31/2+I5#*97\
M&YW*>1KD3ZF<IY7*V>#LXC)\T.?5):MZ'_3P7"YS+S=N*1VGQ%1.J3#/@IJ0
M<^J:W$6^=RSCV^W5%#VGDO9P1MQ.J9P'2.4\@0A2608NF;''\LW61.`H8_5$
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M'T4J[CQ\\N#Y\.D]H,VT>NN`4\G&#PSQ.&3\'T+`L='5(POM!_8;,LZ-';'W
MMAMBZ6)V8&1T\]@P7OT*)LG`."`R-H+)H?`D9N8OLX7YO8O`-R4FU-\[("+]
M];-G^Y_LJ7QE%CG1=_'4!Q_S9]Q'AK_C)!LR4]_LFH9U"`P6H=5P'.5*B%>+
M'ZO7,4\7.Y\"_Q&HG8T^Q0B-`GJN^/?;\?>.D:CS2G1)OS.PUJO:"K9:'PA7
MK*Q[UK!_%@#>3E570=U+E'/_(,IY<Q@T`BN56TS=\T3*'V(YM3E&P-EO<!#+
MI[COXT"[`0>)[O#PR-B%-^[7+^M^?EGI>+DV,TF/K*\LG';*`_]JT_0+KK+P
M[$?[ASN-IPI%OW[N_;/SL=.^F<-#)1L^<<"Z?@&PW7_V/AX)JKMPT4OS_)&V
M@OR"?7!K0+=SHL7*BQ;KU:_M5F]8BHV_.53.!0T%*E^/AO[IH`';0K\/&?N@
MFD(WAA?:G7Z_(B0L@\EYH&`[/H#)R[`[#XP">:R^'5^-1BZ^8GOB.7X51Y,@
M=/_#5ECT70E\X5WK*N!G[K5%=YFTX*[\T>^!_X!*;<YUUAYN:.`;79$27P*D
MUV^]9!B_"-GDD-I=!\F7'(\Y.@<2P05<>S;G*F97H&Z9MK255\T<#LTRI,PJ
M>%0#[D?;]3"6^SX(Q4&@?*BOA5R9U+IB5T>#W>;,CTR^2@#`]T>C:\/:)%Y<
M"8IV.2W<)K:1J'Z`$X!:"%V?NX[0&YT]?%\+ZG%M6-OJ=LS^(O@JV5A)-+XX
MS]Y>]+5P6R"Z3MOL&[TR_+BKME,9M.:\*TD9CL]8*:-*&'87G7V84%8)"%_:
M8V5\/#?I%S:UP03U'ZX!IJ'M1+'M5>W\>/7KY\$_C8\=HPQOT>X[+)MVDZH9
M:T+&Y8!P'>MWAV6<$U;OK5S@Y5(TZ@`\D)F],@(MJW=7+OB*$?C?PH#S8X*O
M8W5[W6X9QL[J_54)P`,&/+;31P9HHTXY65.[;;Q<J-]FQ36+1MA!C<N.U88S
M9SG&^;J-50:__9-@MF=STS*-82E9`JOV<WAP52<4K9[1'YAE)&0='%I;VN+E
MD=RB,6YT6Q4QZI;&^%$@6^4IQVSU:@'8/<X`JR===08PJC[E=-H?#:O$8\X.
M6RR7>&4.Q)4_2F/'`7Z5.WY=/3R$[`&LAF/J=-,T3*-4G;[SQ@\-_V/H-@!W
MWRCC9L66NSPT;&LDKXU6O\03_GY;+U>,;[V6H_FPRI;NY>U\2\;@FSDMV:J3
MXFI&..#I6/H>C-9@&T%4ZLY+A_J"VZVV<#<'@U9WF]--R9LO&?1+7':U!;W5
M;W6W.867O/>2(?^B1ZH^0.]V6NTR@;[YMI?`>XN3>.K*>_O\NVO?BWPW$>8N
M`$3=LRX_+C[OS@0P+N24;;O+12S7;).])?<VEFURX<K[BRA=>P@RA@.K-Q<V
M7YABAR5L?AW=Z)OB%+;7"O#>_XW+'2_@()+2&__;7)O_556M2"L/Y"I8S#<:
M4I]E&=-"18FZUV2HJKU6OO15#D(IQ#15?T/!S$@;"6Q4^V9Y,X*L&$ZOM5A1
M(O]ACY5:Q:HGA2HF.Z[;S.]]Y3IW`D12^V(U.,JGBZ:2["95EJX\;_O6;T\L
M!!6$FL$=NVR$K>`\I6%<EG2&^VB'SF2A+5Q75/];W35.NV>.'7.&*Y)B%XYV
M,(4?^)=B(6`LP!"1.W*]&(6=-@N#1Y>C]=`B.MB9#LKO#+@"_[NV!:P)DAK?
M!+#;%=VQSKL)H%$:#&K;$JICR.*@U!)J\PJ$I]P$\#1(?ILF@$3^Y9)_HYL`
M=EKM4V\"V#%;%K5]+9GD*VT"6%8WYD8V`52&*%4O+U?#-[U`[![&+35R*K$)
MX!E1$TABLZ[41%7;L6I[OZ[H.96&.=(\K@<9'L5,)G(JLPE@J6UIZE&I?F<#
ME\S88SFJZB)PI+%Z3-XNL0G@R:%'67]D:"6&UFG9-"=$J<IRH2:`!W.L-<?*
M(#<:N=%V=J/5\CQ26A/`,T)HXLFJQ5[K;>74D^C+;0)XAEZ=>F*UQ":`)^A:
MD1^;V@3PM+(V5V?F[IJX65)PNGS,42HGI7(>.XN"4CDIE?-,29Y2.2F5\\A^
MW?I*?$KE+)_D*963?-#D@ZZ=XX92.2F5DU(YS\OW7D?TG%;:0SW(D%(Y*96S
M!L14EH%+9NRQ'%5U$3B4REEG]%`J)Z5R-H-2*9634CG)C49N-$KE)(12*N>>
M5DX]B9Y2.??TZM03JY3*>;JIG,F:Y;`PYR^O.F*8%XR3_!ZU_(>7JCVOJ.:\
MI`CT!\YC-KJ)0R`%615=MKS.%6M/NS,<MUNH:0W,^1+76ZV^N/MOG-V.W_$(
MYHC8-HT\J<YU^6G'ZZHR`[(P>9@EZ*IX`R<%VR4IW;.0S6Q)XPC6L>O;ON/:
M'HRCRO)S&`)Y8AR$4ZQ/_^1&$^VWJZO/6LA`P@"+:;`R6W9=T*(`/OW),OR(
M([L-S#F5/*A%$SO2[/&8.9%(&X<%!&&$I9VGH)LBD1H.S[-(OEJH]@R?1ZDL
MPP>15X'A<>95[\A91K"6)%%]V29U\>*J]83LD?FQ6@'[@?TFX,-(")O<2_AI
M)F1/2[L2O8'@!QY[$0J5V,/%P[Y#;1P&4W@MX#DX;511NB*M412`1>&85$&_
M\D=?D#/S'?&V[H"1_OE_719BT>;GWP&R7D$?).NX':=/IW]DBFRNB41NCH_,
MQ@<0J^^10IGO/!<F2)_-/<F_,"<.$9V;-KP;#`IM%EX"TY$!FC[SP9_!5.(!
M\VS@]V*SDM.A1\,8-@2>M23'/<!7[!PDVR3>CH7QF7OIK<U=!T:[P5X":\QG
M*V]D+K2=R2^]#2NWK*%A#7(]?79;4>6[FC.=7]Z5:;9[_7Z^R]8^N_I_+R_?
M!T'DPU%(NP.[`U9U>0D__?VG'_>A!W_\_U!+`P04````"`!!,*5&(8X='3$*
M``"[C0``%0`<`'!T8W0M,C`Q-3`S,S%?8V%L+GAM;%54"0`#&I5(51J52%5U
M>`L``00E#@``!#D!``#M75MSZR@2?M^J_0]:S\ON@^-+[,PD=;)3.;E,I2HY
M=B69W=FG4UC",7LD\`!RXOWUVV#9EF-=D.Q$V,Y++A(T?/TUT$"#OOSZ&OC.
M!'-!&#VOM8Z:-0=3EWF$/I_70E%'PB6D]NL___J7+W^KUYU+CI'$GC.8.O>8
M<^+[SB7C8\:1!`%.O1XE_./KPYWC,3<,,)6.&^5Z(7*TR/>5$^\9.T[WJ-4^
M.H:2E[F_(@&I09X6TSYJ+=[,RV?TS.DV.HUVL]5U6F?=YEFWX_3O%^GN`<&0
MY"7T"?UQIGX,H$#G59`SX8YP@.Z8J_&<UT92CL\:C9>7EZ/7`?>/&'\&4<WC
MQB)7:@KU7WV>K*X>U5OM.@!]%5[-`;53H<LV*&2>7+TE&>D)%1)1=YE^3?[+
ML4[=.CT];>BWBZ2")"4$L:W&'_=WCUHO]44!H#W'^<*9CQ_PT-&2SN1TC,]K
M@@1C7]5`/QMQ/#ROC:4KZXJ!YO$,_T^/$FA4MG')J&`^\12K7Y&OA#^.,):B
MYBCIOS_<KE0+)`T(.W)9T%"O&R9R-$`C+3?>!=;BH>@->V,\:RJ;X$L3:!/0
M2Q:,.1YA*L@$WS&Q+;P)<JV"C<3HQF<O6X.[E/>!,*^(<'TF0HXO7)>%4),^
MFJ*!CR^H!T]XB+WKUS%P@,45EHCXAG#+R*T$-EA90*3F`*H&Y$@8#V%<)*4!
MFT@L#-5%OAOZNOG?P;L(GBIY\TXSICW\*C'UL+=X2J0J`8:&)@S:SD(<_!V7
MZ$0BG<(=L48'^'SFKE3$5^,RXZL\1N*TJ"$2`RT//)=GA,9JV.\TL"_%_(EB
MO%-OMJ*!^*?H\?<+(6*X?33`OO9_5EXV*JO89<@Y:#BS?E&:[R?'W9.3XTZG
MW6V?GG9__N6D$ZMYS&0N^"H(Q-VY?/ASS8I6N8I2-$08!%I:G8`1S/,/.0O6
MU1<5QHI4G'$/<W!,:TXHH#YLK,I"?LUYP>1Y)/6;*FA1';-JR/#K^L^03)"O
MF[:\1)Q/H6G_"_DA3J'+**^M-&:1M4YP>:BV$G^/^`_HL&'0>L1NR(F$'CR[
M=6;DV`^2BP*,J&W;1FV?XS$B<Q<$S+8G1YB;=,`&.?>#ZK)`(\J/;:/\`;L8
M>B4P7?$-RVR2$]/N!ZWFT"(B.UE$CCEAT`M,=1.OIB$SF!;+:1_\3PE&JH:>
ML?)0`5QJ"T[/8BO'R0VT(([M=\;K$ROUY/L5'C-!]/0GUFE\8]1-;'5&>7:!
MF?)`;.TT[P@:$%\/\X#G43+WQXCY4%>AK$U.4YI8?K:*P>37VSY[,^4BWD?D
M`;+5]8[5.WND7D]H-7&&@[0A*EO92UWR,Z:U@`2K^2[FFVV*VE9[N,)##+7V
M'O`$TQ!G4Y^<>(]8+@#0UNFS=FQB"DAU[?(S6$VL(:,%T=G*JK%[MY[0:A:-
MO25#7+;RIS:>&-4@,M>DWR2SCSM#'A+6H$V@V3I*7G@>F56ECXAW2R_1F$A5
MKV0/*3GU'I%9!*&M31+\MS!0&L>SQ8"5F(9;ZK)`1S9\P[(W?$*OZ=YP$2G[
M9`-;0&[KVLJ#"@:@V+M&G!+Z+&)8P44D+DE?G<[+N$<64!*LR>)U%%K1>!-;
ML?V`B]0HKICF4R,OVMF1%TO9#ALZI6+$*K!]:+#+UIMBYBMI%,G==@NX;9VV
M3TY:[7:GHJG/3,/T.;?^"2GM:Y?Y2DZ8[A@",W&T*M]`>D0^%M%4/'W/Z$TJ
M^W@TY21ATF,`;?LN<\K.$52@SYD7NE)7*VFCZ$T2^Z@P4>B;/2,33._<FE((
MN60^*#\*^H]`);&2E&XOJ#$&9NL4)*KS#2CB-XYH:N3C6KI=IZ\8,%MG"8N.
M?1XNG>=MS-/91U_Y,<H,7&X+K%?6!`4&1:GPR"LP1I_I,(T(2VISS,AC,;>9
M#"4USJ(P;5V^^PU34(&O-NV\@%`BI%+(!&?3G)-K?X@N`]36(?662LRQB&9.
M$8)OC+*Y;M(G$B99[2.]S"RQ-%(3UBN?-NK5R#B:%9A9NZ"IF?:#]A(835RO
M!,(_>.$NZ3BBR?K=<9'UNY5"G(*''JO9<GR['I^SEY&9HXJ67&HITJYV:L!"
MO(GFH['5QTK;`[J8(.*KD*DAXP+%#Z=<>/\-A8RBHK5&^HQK<J3D9!#JLRQ/
MK(_R@E?>K]2=MZ<J]&.K:YBFBQO&H6)T%NSE3I\XH@*Y&C+U]'\1Q^]HK^]2
MA[VUWH_3UH[X/['["4S\GDXAOP>$.T5O/ZC&65!5[7,V(0#ZZ_1W@55HBC[D
M'X*WN[Z]N^Y*F$NHR!]*JN!BWG\!;6`R"WO=&+6A4/OZF!)V\,8#V[8Z;'79
M]L"]?@>V]LDIO\(P=+I$HTV-Z5\F.5!^<U5@JT=[@PC7P;1+1Z<W_#?B67N)
MF7D.U`"*Z\36+4EU*`EK@@+EZ?Y/JZ$W5#<@Z>-+X!_W.0Y(&(A;.L$SK*D7
M[I02=J`VM$5EY09(5K59^CB"F9*^%E)-RF!&EC6P)"<^4.LHH(R(_:YM70NX
M0!P#@BL\^WU+HVM(YH?F$J\C2=UK*R/L0(UGB\J*C.O$NJYE'6/L-A1C(XKE
M^;050YU$)O'S#IA$=']'F>YE/>NG@113360GO^R`G9@<UC>V'!-AG[:TJ;(B
MZSJUW^N91U%$Q\C+F%2ZB$]#*J>B^0)<TW[[>7/'1($1;"7?IZ44T,O</*Q;
MH$W1V6R%8,L[.H9"=\:P-MS1V40=MBX(P["KEY6>V(7[9T@X3KV(,,5TS`7L
MC)ELPO.Z,6VHH-R-HJJ<Z#5<2=<)FQI-4MY/>RFH&VN/S(#"7(P]H4YMJ6-?
M8/3W2"HHT]ZPB-D4E7.H)K05/=FZ8Y6BPAM"$76W[`$9"MT9.]O0`]I$';::
MTP,>1SUN;WC'Z/,3YL$5'J3?UY*<?&=,8!,.UPVED#KL]65B'>:M$*'Z_(T^
M)#*_@,Q@0$K,=Z!644XO.W%6;&5L55!ZNIKB^A5SEXAE[&R6[Y*4[]-4"NBE
M9)3UQYK*]7"(7=D;7K^Z(T2?\0.2N$>52E-L)#W#SAB'J8-1$&K)SU=L-ZJ^
MU&?P8ERD1-=WFMUFRZD[2_'PS[P$9SPKPD'4<]"L$`='I3A_C\KYA]V!]A]Z
MA7A%;3T8^VR*\0/6M]D9`\O-9U_++\'F2LLOA?C#+JV*L*CC+:&O9^2SSSYR
MY$JU93"[X2*9U.("]H;=+4&W=9D\0@:CW1`+H>MT@PTZK8Q,>T/]!G!M71-X
MHXE"8],>TVL*T_R^U@K.\Q9U/;(S[1W-)>":QQ^_ES]N])5F$T_\=-T3C\G6
M3K@;E[XK'O@BI.).A4"(FU`"N'M"21`&\PVGJ]30$N/<E=ZIEUVYG$9>2(A]
MC;X@OXG7\96'OA-W`QOB5.M;$_P?\%1S+V<T%G2(]I('?R<6>\VQLI!OQV;F
M@@[49C+A[\2JKS'6)RAU.QW-4M)A6DT._IWX]K$YV!>V':.)Y!RHR62A-YG0
M&.XV?&G,2(I\?WCR?U!+`P04````"`!!,*5&>X/UD:T7``#JNP$`%0`<`'!T
M8W0M,C`Q-3`S,S%?9&5F+GAM;%54"0`#&I5(51J52%5U>`L``00E#@``!#D!
M``#M75MSVSBR?M^J\Q]XO"\S#[9LR?8DJ62W%,?.NLJWDCV9W:<IBH1D;BA"
M"X"VM;]^`8JB2`D$+R+()JV71)9PZ<N';J#1`#[__6WF&B^(4`=[7PY.CHX/
M#.19V':\Z9<#GQZ:U'*<@[__[?_^\OG_#P^-"X),AFQCO#!N$2&.ZQH7F,PQ
M,1EOP#@\#`O^\^OHQK"QY<^0QPPKK/7JL.>HWE?BV%-D&&=')_VC`>]Y7?NK
M27EIWE[03/_H)/IEU3_V/AEGO=->__CDS#CY=';\Z>S4>+B-RMUR#B9.5D'7
M\7Y^$O^,>8?&&W4^4>L9S<P;;`7\?#EX9FS^J==[?7T]>AL3]PB3*6_J>-"+
M:J66$'\=KHH=BJ\.3_J'G-$W:A\87.P>#?K.T<FJN/C59E&%>.&SWO+'>%%'
MT;3C469ZUKKI+5)>!T'IDX\?/_:"7Z.BU)$5Y,V>]/YY>_,8B/`PZH`+VC`^
M$^RB$9H804N?V&*.OAQ09S9W!07!=\\$3;X<S)G%#H6RC@=+4?WUFT,M%U.?
MH"O3(3],UT?WDRO'XXT[IGO-NR$!RNC0LV]-\A,Q<^RB1V3YQ&$.HM_X%XY+
M#PQ!PN^CZP3MO+NQ@X\L/.N)GWN5=1:(*I=J>T`$U*]50OTVBFA0JX@&;131
M::TB.FU(1/?L&9$+/)L3](P\ZKR@:^XT9^@&4T'QT.*.SW>%IY*49&A6UBA5
MUV\C8OO#),3D2BW)_5;U1IBX0TR(^P&1QV>3H++6,[691IAZ9-CZ.7PUB?W@
MFEY)_:0T`H>APDI*:P4.2X5=4EHKC;#$#=3,82M#?X$]QM<=?/U1?MJ6I\6&
M6'5=<QPNE$;H!7D^*LVCHJG"S`7TF\1:,1E^C),3M>!XK&<[LUY8IF>Z;E("
M*=VN5B=B&706""96,RG/"JCBGX7+P]ZAC6>FXY4D,:V9ZND-FC^<H=D8D;+$
MRMJHG-)GWB"Q_#$ZC(13DEY%2SKQ@":F[[+=`9%L1THQ+^-XCABB-[Q,6%+0
M4],"-$89>F/(LY$=?>LP0<;I\>#XQ#@TUGWR/T2WQHOHU\`38[+JV7#671NF
M9QNSJ'.#1KT;OX3]_UK`$`7B$BK&5H)J5T1AL'Q`!$U-3#H.VO/IX=0TYR+(
M<]I#+J.K;X0Q/CT\/@G#+G\-O_XSDNV04A3(\L8QQXX;,'&+3"$+^Y[;5LX8
MX0Z$%[C#'EG]^=6D#GT2O*^(X_88N4'`K.KV>TV*Y^LB)%;H_8J@__C<E2Z&
M;P[-8EQ5,V)I/42&),D<'[JK'L)17-(X86(C\N7@9-7:A."9%CV%U.."LO`I
MYPS/A0Q,MV%MRZC\EG!]:=I6U=2D[6WOG%/5V9B6*E'%8M>5^.?YX.S\?'!Z
MVC_K?_QX]MN'\],Z]+IRLDTI5LHV4%W3R$;=)J:`.92]7567:I-SU)QJS09T
MEEJW&82DQ*^+Z.,_'$2XL)X7-WQ1Y^9SL\K*#7C:?K.>5BD.2&J/XW.;Z,(6
M6]$&/`><`_"98SJ=W_>HY;9X:)V:A^JN+RES9B83Z_@5Y=&']=);Z;:+-0'5
M?6>.@+CJB[$,0,T1==?>W&<TP'4_WV1,5@."$LL@5SI\90P"5=F@L,H&C:@L
M99ZE0V4#B"K;81YYXWC+W7"-T;M8'YI@$>R@Z`]O;0E+BI;=9_4;V%K&WC]9
MV&/HC5VZ@0/Y<D#15'Q8_\[QC.PO!XSX#<5*AR^FXPH6KC!Y-..A^!1TJ2I`
ML"#:0:,2P)PXF']>!)`&8&Y6*2><R9$S?6;TGAM%9GHB/S9%O^HJM6IXT)"&
MU2+(UO'G7G+S#,"&6C18,G?4^GIVU(P^\#TUD?=K^RZ7;OH`5^V9%:C?A"6X
M-?^-R1/OA=Y/OJ$QXW"Y_(_/8;RF3A&PRUT;SMY887W&+4!N?@'8^!RT*@,U
M!>H#"<45Q')!Q0**P]6F6M#QMSK4#37X)O(!N>7C_O;!Y";P#K-KSW)][KK_
M<-CSA4F?19H@_T^PQ9VT\,;*",`N#4*(Z10>$G$X[,(\"#`LCZHAP?B:WPQ]
M*^M`6+'MJ%(E?P"T%AQE**`Q17D(JZ^=M*7@#8"F\DP9LX)O!=MH+KA6BMFX
M+@M,L+L7'!O.,&'.?Y%]@2E+@4+NVA",\,YPR,TMM!B9@O#U>;3O!%/ZNT>0
MZ0I.OG/!?D433-"3^59<_7G;A6#O=0(CKQRZ`!EQ6DX'9#;:K14RIX`@LR&'
M]D`&^C[+6>U*;FF,/3*@F3'V@:88^P!XC/W:>T$T.-WX#^R*W11E1#VU=!/C
M=TV,6/LH0N6R@G"BXAD:B(]/&2,`#&F2K`ON":;<5/PW.$RJ7%?GJ0@DP)T.
MMG0%R1GJML)`AZVK4N(^--V2T'1^H.]CTM!CTF5UN0]&UQJ<**<FV%'H[2E:
M5LQ96:.Y"',.1N2><&-JVKWHL<#>K<G"OX2==[Q[#_T+F21:@18."^1K%)9Q
MS06,75FN+A2T?4&.^"8W@?<OB&2HN8+V8-EEI88KX+:5D:(H;IH9*3K5%"DZ
M!1XIBL2K3NT-<GE_]_"8(O(BF`V.??"?,9>*ZP3S@%P7G5363<-GL5=\+"Y<
MDZHR.C/JP(E8Z4)"R@%LF3``3`HKE,(FC_E.\>KK%TC,+=<@DH)&GVCVP-/7
M;RRL-C@^!A8[A`=&J;@`X#,\JZ,,8FR4@1`KK&U82<XU`8IU/#*3!>OW@/+[
MR?)VU_19BZ(\P+MB-,Y8%((`H-8X44HK+RL(9#Z0"<U$X%?"1[OU`-H][J@;
MJ+Y,;`5A+R`T<Z-LHQP$GY:.MLW]K@WB`8A^9'I3559'[/<&'$W606B-CB;&
M.!0U*<=&H@005[(%KBT!0QL)>44,VDOD%3M4=W#+A3?S9TI=;)2!X`8D`$H<
MR4Q2#$'.YENVG)-E(.RB9<DY23$`.5?HKK)VQ/5T!>`F)`VBTQ1&:OGF?862
MN#!=2QQ9X!]'V'6O,!'/U^A';EJ_$(Q7"P&=)DYH)TUD5U>*U(@M]FB2/YJ4
M1A145&6C:.H+PC2F-@.0=6%L!?+L"D13N!2G!<7QKU7B[+5W:1)/9)U4#-L2
M_7?,V.J'<@D9@X7WD%)_%I`2)`0A]HQM[.+I@LM-=GG=<$P9,:VT`^45M`LA
M.:QVWU]>7&U`UN7;'%D,V3^P&)=BK(Q,EN=EIZP&0'GA78=2%C#2A-`&!(P<
M^O.*(#Y`&"*(LH+ZEU<'Y;AT:U\N@C;H_O)-'!ZBZ($X5K%!GZ@'RB_H'^L)
MWJ&I.7A06:7/>`$(]SUH45R<26@:4CF0)T1F)9SOLAJ$BQUJ=[E+UIM*Y*_P
M3?J8EE)3^D^WGRP-VC6L>,.&$]!@_,(+T5^#A'YS38B!934$+6UYP%0MU4C^
MJM3]8DTTFMRVO!]/$(B]X'!(C@0W>1TX:?EE-"A-8),S"L#(;Q"FS)]**0LD
M_R`7$!./%\G9Z8)20&<L5*,HJ/D,,9-QA]CZYJ[U8<%5D$^Y%5^\&0B!#"5P
M$Z=="[,'0+5\1HB<J7?A$R+>-\VEQXPZ$.(/N966P0L`#>7TUUF)%<6;:2YI
MHBS+*:,QQS2GK<D..;GD]NA^HKB]LF@K$(9XC2!9,PXMGJ&B>GFGY@A9(KO;
MF3C6<L,Y`PL[M0@A&%D%+G820ILPL@,8&M)Z2B13M]:+J%=/N&OUMEFQJ-7Y
M=M1JU5!;0D[AZ920['L2O.RF"C"I*C1XF"M)CR*4I"@/)XR4K17)42X92P`L
MI)2Z/,?NY#6`!(\R89>I($#AHTI5!#J45)7:H`:36GKN/P<`]R?V]7FAE$5@
M,2^T/WM?VX9%F\_>[P]S-R5Z<6_@^BZ^$;+1,N/@`?%%EZTP5GDJPCG^7<QJ
MY>$-O.Z4!BU?52`F+C]&\RL1D/73K$;04V]]JH4Z&5?3_O2*E1XP=VT(?K$(
ML/.K-\8D?'7RKM071!2H#V$+2)-*XVR"5^J5\[*+3N/5(>S>Z%%IG$L`&I7.
M_[:V)O+$LVX@;-?G8R<S;-7RK7@I3_<^H\STQ$7J1=2:J`;!TE:DX@1?T/9)
MI10G3IQ$/]+P5WI21*O9;4&PP!6I.IO9IC92[Q`3.[K<,P0G5<)-T`CX&1NJ
MOQWW-S=4>8.&2/<WYH@85+2YOJZ_#WQS-?88J,<<VW%]QGWE^MV#R[?EJ>TK
MCA&Q->ZS(-WA?K(ZQ+T2HVI#MNI.&LFTVHWRKPMY`XJ8EM8>X6PDZT%@(LM+
MIR`!."XY>7?F#"G#-=G5@$3<:AAZV7")RZ6[.@<=G@.&`Z@QO<O9W,4+A(+-
MG?N`%&6`0%$>0MPN+](3IVO260*@H!&BC,^*&;*S-QE3RD)8$Y913`H[`)2R
MHW')BMY4UWR#QS(J%E$B-:/B66!;HT@[<C^<8=]+NX6JHK;AVIYJH%B1F)H*
M;RQ3;L3E;@^NZ17+%O^PG2T>-&>8HCUCSAML2];XVJ`L)W^<#%OHC4\YS25D
MB;B&.7AW\>MB7>;!7(CO`@'FBVGLW'X3=D9@0[AJ1?PA601BP*`BS<8'?Y)I
M`/.2%4'*9=UF(2`+=QG(9,(&M*XN(6[0:^9B*JA^29OR\/+R?+:XA0A[4W&-
MT+5G\;')/:X@B#N/C])54<&Z$):O<D!%;RCG9T:'&@+GOM'CR2!=].KR$":&
M&>)6,Z`/Z4*1:4KFWQ?50P6-0MAJS#4V=N)2AT931JI*7YE5(!RAS=!&)@\`
MO'<GS[AHG>_NC\3HG@3OC\0T/@=K\Y&8Y?#EO:@R!9)EX!QTT6JZ-K@&H*OR
M3*YY\>Q<2U`]70$QF5+,;UTQ7#GW>P3MVA7H4$@CJ(*:))`W.0!H4H#.<9*<
M'N\3"+3%:NI2(MRD`]B/5Z?$";1.ZO:O5K^S5ZOW;R77).?]6\DP9O!I)O$F
M(X.LBH:;RQVK3BSRK+&=75%;$\9*"_;.%V,FE!P=^NP9$W%=>=7P2^\'@GW1
MA,OJA07MM&1I%I>[>NNSVC2X=O7IV?26ZRSZ/3@H>!T>W:X:CH6[A[!1"@RE
MA678&?!NC,\7TW&%^[C")&!9L^W<[@["OC$P<&;*K'-@'-JVLV2@+E^NZA'"
M2WA`(:D26W6H3,OUJGI.LOS[T1__&UGL"<?N=@BJ;:YCFB*B5CR>UX''IB39
M/H@./<\WW6O/(HA769:J!9;RCFN%XF_MA:)<>FV'WU`<$1*Y<^84A<DHZ=<#
M02"H5KA^Z`I<LZ3:F>EGN-:+,3?"KLOGV>+'JF>>&9W5"M6/K9AT9DBLPS"4
M^GF-_4#8C]([BC4!LGK/#@.+R?#7=X)IY9LZJIY:'5>O'8]2$8)#9'#*A5(?
MV=]\PH6RI#9<LZV3E.CJVKU4!URBH59'P(OCJ82$P,%E1VEQ\4R0PWS.L:Y]
M&%5/K8YJUV[`I"+L&B(OW^8.6;ZTJ1F1TIY:'=2N'9%2$78-D3\096+M;W-N
MD4@N?<+BJ]`KB"TGK>N0_-VW.@!>.W;SR[5K@*X+N4U#M.K`>`/FM?-8C`GS
M#R0N#.=#\@41<XH2]XH+04_J"CCF)J3>>-!Q2Z.1N<7Y3K'=+*`[%]4L:$8:
M`'T+D9Z:5"V-K>E`>Y44="QNJA/Q58J]<ZA?\=<H\`L2T;$8;Y/8+RCYSL%?
M$H]L8@`4)J-C4><FAT!AV7=N$$A"H,UX@8)D="S0W:P?*"C[U@V"G4.I#:Q_
M=R6J8]'T!I?%NVJB:\.EV7$!<P#HC]4W.`#>+=+7YZ#63TW0X9@R8EJ5GZ',
MUV>]T<YZ+TG0*SF0X!QGLSLN;!M&2"B3?W^!O8!YWW3%C<A]%63KIJ0+8?M<
M]F$+XG5+NFO`+SP?2Y--VJ/8D`CL0JR_]F%2I0*Z-GK@#!/XXT%3_+_V\=`=
MX)>1^I7ID!^FZZ,AI?XL5(%GWR+VC&WLXNE"UY2^2,_USH?:<<M4$?EU&JXC
MA_Z\(@A=>PQQ6\%&)JL\OI*_WU9/W8M;`VU0EDNWTT!>3<A^8)<WXW(VZX)R
M6L^MGF`#`G.:?$'"N<Q<2L6TEFERC@Y;/1NN`+R:Q`KW!I=P0G_MV;X5%%PF
ML%UA<B>>!#*9STE8Q$]_5GI?2YGN6YVN4@ZC]0L9I)7=@7EE7F;PXS?N72+M
MU')K00XJ6IV5TM!DHJRL6V"D&7$\ZE@!P>EW#NGNK-[E6BTW`^L66=?,:6S?
M*,FU_L,[F_TU&3RH9UAK.I*S*<BN831[TV8XG1(TY5Z@%@SO0$^3,87V87P'
M08,<`]5LU"19K6$/;JO#)H,+#:%8DR2S8?JYMQ8RG_'\7'Z9_"XD.B'EU]?7
M(RZKL8./+#SK!0)>;RHNGW`61(K'Y[XA9CHNC>S%4H7HC2'/7M_#Q1PFVC\]
M_G#<-PZ-=6/\CZ`]PQ0-&G/>(O_JE[!5H_\K;V'F>C1!6X2"_O'QH"<Z$/([
M:&)H5OT:W.9(K*[]_?/-:2_]I6T&[9]OSL?DFI?]\\WO^?GFMCW,VO#KNG`?
M9JTNK+)_Q2\[CV7_BE]IP68^Q76'O9=@(:CQ<O:21+0Z14!/9E9)28)<K^OE
M7\\5=<7[;X6_UF(]:@9\YZZZVS^$6:.Y;@'2._MH9B;GRTAU8T#?[+[5V5\M
M`/JFO-\/T,-[<1K$NH2"5B>2M0#N$I&_'\1'XL_,/`*Q/BU&9:L=1=,+V&*B
MWH\8_=F9E9+V3M;%9<P:M('VGD97<NX);X@5IN^=K,KACK/"&GL_@RUV#2B\
MD5:,N%9/];HPS(JI"U1F6*3.S,RP069F6)07-FA-7MCE;.[B!4*/B+PX%DJ!
MB!O0PC_=3T;(PE-/O*R]M*D7F#*:+T>LTKZ:,,;7'D<5$J?1@N%R$Q*JR!Y3
MUH"82Z8!#W$3I)0'`'>;0I\R72RC#I"\KQS8S:$H0.E<E:OJS_/!V?GYX/2T
M?S8X/CG[[</Y:1W:0Q/3=UF=ZI,R"D"C(T01%]#ST+._H1?DXKF@71R0\"C*
M2M?+K@DAZ)$+M!M9>-F<`=#=(W)YF]/OR./3/I=3.[1G7,CBZ"QS7E!(,%5J
ML6`;$!;7A?59D$<`FJUF1I"5>EEY+\WE86H2F#PIL]+Y6EL3-$/^D"UG/QQ4
M:0<\<E:&8&YJ@%9><4`+E.42311*":(`]`DSTXW_+L1SA]F_$%L+;A>#5:X_
M".&L&I"F48+O!IQ+65]A$GXERJ4=FZV;"`BI*VV&<8I8FXJ><G)G#@O"OWS:
M*J[.Y?-8Y%D.HF'8,V<D]>/QR68D-=:V87JV8<5;C\*JK0FJ7F"7CSV\G-+'
M#\APP7$D6"D_/_%/U+2"B'J^B&IU'35A%<51M/M)C"Y%(#6E+,00:M7:CQN;
M%#$`<'';C)IRWI0A@,*M`(FN*J&<F%X79?"]JA9T-%:7NJ%&9M-,V@/!MF^Q
MX92@X&\E`(HV`B%>6Q+Z<0@491N$NGUQ._?<)&PA#HDK_+*\:`-N.2W[J1:W
M+)<"`$V.T-PGUC.?$4<XVZ15N6%6H#X03ZS";G)C)3=G[TF/H-UNY;JMWM^F
M7*OZ!W)=L5/T1'S*;IR9.'$B=9:9I2%XQ<)HC*XO57$&+6@W$BY`X?IBOS?@
M[]+2$&OQ=S'6H2A*G1\0+P'$46W!:TO`@&:$M^:;,_-G2B%OE`%AJ+:1$9?R
M!L4`Y%S!H,W:::^VB^:VV76(2K['7ITEK7^#/64^$LLEXDR,T-1W1=W%K>,B
MRK"'PO3O^['K3(,="NF;&J6:@;"1K@L\Y:72W+9.Q"KV1IQRST>%]G-.CF7[
M.;%&C;#5MNSCA.3&=MUN^=K$F;M<+JXCCC6(VYECF%'MU91M;+\?L^-^S&Y:
MW.^Y[/=<0$X$2T78(4W)-4;4*U<?1=;1%+]PO^LL-<<_;"J,?_7G#9J:[J7'
M/>)"8C*E)>!$R'<WE%(&:U?"LG-I%'3[YX9-F`(T*X$FZ84LS400M0\D9%Q0
MPE(>=`2"1Y@O*[G=>[P=7F'?LX,9<GHD6%F\27.>AI%H$:2D7(=DH]65Q`3+
M"L")V>YN@67\:96QU##(BS1L:M.QL2VX2JQM9:(#:5>+B[,VTWK!BSB6Z<;"
M+Q$I\A50_FJ-/^"6`I](Z+FX`+"N*6SKLL+9NS387/!Z=S$D][O+.1`PX>C-
MR"CEK"!.N/354$5A"*'E:E2;Q6FI</'GWE*887"5?_,_4$L#!!0````(`$$P
MI4:$(P7;-TL``*!#!0`5`!P`<'1C="TR,#$U,#,S,5]L86(N>&UL550)``,:
ME4A5&I5(575X"P`!!"4.```$.0$``.U]:W/D-I;E]XW8_X#U;.R4(U*N5WNF
M[>F>B2RIY%&LJJ20Y.[I<&QT4"0RDV,FF4TR527_^L6+))@)DB`($I<I?^BV
M2@+NXQ#WX'WQI__XNHW0$TZS,(G__,W;[]Y\@W#L)T$8K__\S3X[\S(_#+_Y
MCW__G__C3__K[`R=I]C+<8`>G]$GG*9A%*'S)-TEJ9<3`>CL3!3\KP]WURA(
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MWUTU^OY#39:HQ#S3@O<U]X>W!UKYFOPD7*""6X0PO0))"0;\-<=Q@`..%)6=
M^+4"$6UC25H':I?[^1EMJF_>\X;R3_0W?[\0@;2,@X]Q'N;/5_$J2;>LC2X?
MLSSU_+P0Q,SGDG3K]82).D.5+-.Z1U[J%T:0'SM@$R5>^PEI3KO\+!*?C%5?
MI<FVGPO<C*1'I;]'CP9-I/"]YGB*LV2?^F6CUVHQLK]]OUEI.ZE)>1K'9S_?
M]W#FWPLER(L#Q-4@2<^?N'F]FJ[0RC2NO.R1J24=R-KS=I1]__`:1WE6_(8V
M\C^<O7DK^/"?Q*__?I^3^*66/7B/%8L(?!H+`6W`[4[1UJHN`;!I=AAJV@Y+
M<>@7)O#_`6AYA/KQ%?DQZX)`+CB7%GCDG+(5EJ7FT!*/C;70&JE0Q*0>-4DK
MGN5DQ(VO';DW-,@R['^W3IY>!SCD\45^.`PK\JN_\X[E#J]#VFW%^6=O>TCI
M+<6`AE278S2@FLH`#*=.4TU;FQA55%(1%3MMTSLGC3WUHBLR$/_Z?_%SH^O'
MY<`WO@;7ZJWOH!#HYM=DZ\#V)\0B)A<1P5.UP&*(_4#$*IP^^#/@]J9RI&AF
M\M^`MBZEB8/G353:U"WI%J=A0B:%P07IQUL\/2PW@[:E=.VPD=4*`6]M:EL'
M-SLNELS8`T0%3]4"ET1Y0`VXC+RUPNO#OP-N<4I7BI96^R/0%J:VT;1EE=(0
M%3=5>SK?IRGU(,Q\+_H;]M)F4FLI"KB5=3E8-+BF<D#;7J>YILU0"$9<,J*B
M)R<Y,0SEEMSA79+F8;RFD^;]X5*01G'`C5/'T8-YA+(LT$:J9?+0685HKZ5X
MQ.5/VU8OPPBGYR1$UDG:/+D]+`6^92K=JC?(6A'0[5!MZ<#FQX2B0NK$!)EL
MMTE\GR?^K_<;CP!VL\_IIC`],=`<C>V5P#=)':</*+.E!N@&JV7X4/ID.A!3
MLD!<#9+T3#VSK@8TE^0WJMZ^N23@MMOAWN'\^J`8T%;:9>W@.;8\!F6BW;1&
M/M77:X_ULK-ID0H7U6U2*CB+5JFRUU:[%$M`5EJFA=WRF]5E&'NQ'Q*ODRQL
M.9'4LRK05FP"@'*/O:4>P#9N9+[Q:D`29TD4!NRDYP<OHB<.R2@!X]QABU]F
M&='?T;:/"@%OQ6JGY/9:+P&X9388:KPPRL2A7PJ!CHZ!C.*5ZR`2JR=:L71<
M=A8AU>#B<60=%`0?8$WV#FN1BW)%#4;`V?:R\,YCTG]T%X#G7K99Q@']S\=_
M[,,G+R)F9<O\W$O39S+S_HL7[9N.W>K6!1Z@O2"0`U:K(N``[F>_<5,GXMFQ
M<O:#I&B!O!P5NA!3-DJ([XJM][8PGQ@+G_Z`92PP^6VR0MS8$7$@`_8T!XW$
M(UZ'<4S;Q+AX=%*_8R3<=0J?O/17G-/S]_?8WZ=D,H>+'K`!JO8:P#L`#7=E
MVF\I#ICL=:PV;<*5;%0)+X=P;H)W(G^S4KB[<+U-\<X+@X]?=SC.,&&LFWR#
MT]K`M0$DO9K`P[>'^W(8:U0#',Y]K#=MYD('$DI8)\74H(-)FIL(GQ("S)5D
M#(.$8>#7IG#NHO\.^Y@,&0@999]QWA[O366!1WBKBW),*PL"CN)V>TT;K21U
M@8A<QW$Z@9,Q'GR'S=(:ILXJ$OR`Z^P\Y])-VNT-)NGVDMR+M!<D![OT0-6!
MZ<MNTX1,^//G6^(-2WA`9L,[NKM(B*-Q%-!:!7B@Z3A<'[0VEP<<AEIFFX_1
MN/`%8N)Y"HM"`>L`78U/1W3Z,OR*`Q&OQOU?4W89O*,[^%E]2/V9M&9E'Z=;
M!V@H]G*YRBC34<%Q,!:9MECV%I/O96%\MB.&TW5,1.0COUCG?Z*+IG1EU]LF
M>_;7U(NS%29:`Y0GI'"8!FCGI71-!:V2M%AB>4:[?4J,KDW"XM)@$0NDOD=^
M3C&;LODY%_J(48KS?1K3!&`I\G:[*&1_^>*E04:T/?/D-RL2U"B),7JFA_U(
MR4?\G!!EU`,:S!X[VN\_^Q%>H'"%HB1>X_2[4?A%Q:?3?+I"P=&$'U5*IJ54
M!W[S]N5Z0,1];!T)PF56M1/'TPC``Y<#`^T>LYEROF!IHN`Z'JY#[S&,V'H[
MH0%V7V"31`'A#3JZRI\[CA#UJ`X\IOH"(4>=;EW`<=G;!=-F+RDJ)Q9D*#+R
MJ:0GG#XF[;,+9PADDJI_9OO5^>`;9U8(0>\486N%^02]QGG"YM+S"&S;9^XD
MT7".%X[H;^%B5*EP>-!PZ?MLOG?K/=-%>\)9Y#?I'@?'"#0-9'I)`![*!G#4
M!L[ZU0$'NXD7QD-PH0L)9:PO$^J0BAH<'3=V`<E.@L03D!0[WHXF+=!AF(XX
M+S!?'+O#3SC>XW:.;"P,G`[;G9293UT2,,EU&&R^6"763(5<Q[PUMI<IEPMI
MHJ$]HH,??GJ#CEF-+4;H**8;)71UCR,X5S\((,T9W(4<6^677&W<@=2J`#P$
MNYV50[&Y-."0U##:M/7R7:I:@+K:JYK,6[KY>$;,V,*(5LG5;M:"'X\*=QKZ
M0L`1I[+20N_GO-.SU-N!B!LIOU;K9=OC8L`CJ,FQVA7:@S*`8ZG15/.L)G+2
M,R9S@:ZR;(_'N>^HL:DTEH\9]_%_O_GNS9NW]'`//P;T'5KN\TV2AK^1&=[;
M=]\OWKQY0_^',I8![M]0R-#@YS&J;'#H_?O%'_[X?O'^S;^(DO0F\2?2-#?H
M_=L%HB?:C$6_6_SQAS\NWO_P3A)]@7V\?21=KI#^!X?+Z$'`<NMXT:T7!E?Q
MN;<+"94U+:,UE@;.'1UNUI;"U44!,TF7Q<8+F:5<1`6C,$9"M*.U[/']I)>S
MSHB?OMK/2;>W]MM]1#-4L=$Y(;Y=BC<XSL(G?!7[R19?)QF]`'.S>O"^-B][
M]Y0"/8[-8#G8ZNHC`G+<&WHR8&.CT">.<=8T(JX2O:)*OV4'Y>FY7*+971J.
MJ2$JDLF13IZ>\15)..B/[A-Q.,:BEH9C9$1TMD6=A8ZX[EL+G8@H<WGE-_?"
M&`<?O91^H$RR]@*O0C]LOO^K41%XEZ+O?/UF<%<MP!U'#^-M-/B`RW1U6QB"
MKU,FSCT\N=D`C+(@\%AM=JZ>`O>P%.!8;#'6M#W>UT[4BA/&RSQ/P\<]SS*3
M)V1&YVZ[<02?^0(LV+/$RB/5W>O23=6`AZFNXWTN$0`.86W3[5X:<+YK,HZS
M1ULI`&\)2.O:A$=O4I:U/&!+W+<X9>^-=*^(M]0$'M\]W&_8G&FJ!CC*^UAO
M9POGEM\9YHKXA@Y]G8&_9^,HA>5T((@]GG)S![T*8Q0D4>2E&5T[X/LIWX(@
M`?["4+5#U(V>HL9\@K[)W89@/RP^CR!OM-I.<(M'J2KYS@-Z+(=%('O5_BG?
M"044N7R77!>BLO3<(K;N9FNT\J)SBM0#BVU&Z:C'*/J'J%U/17B*\PO@0K/Y
M]4?-*G,+TH:7'W7*SRE<;;[ZJ([9EO<>'07N"#Z+Z)6/'+D.8;Y]5C[DU7%_
MOKDT\,#M<%..V8:B@,.URV+S5BN]O%:*S^B6\`W/AT4*.-P\\2*<B2MGGW%7
MTVTN#;SI=KA9VTM1%P7<=+LL-D]`)^Y%TG,MKM,\C.RD66*'AO2/Q+[;-`GV
M?LZL/O"HH0C0"&ISJ,SE>/!WZ*D;F\RUE*F1YV6D#"_NW"+LL<2)%%&TXYI1
M1E6C8)_2$0RMEN)=DK+TB/R<T,1)$6V#0DE#"$1,HH.$AV/X5'R_`?>I&VCC
MG"[U/B9\3"!X2>550SG(!-+F6LDBJD+0J:35YDGXQ*\L>*(DDF%VC8-N(0:D
M>)3L>&96\N\H].GI.\(PWCK%8B`*AX%&P;(FM$CU,(YC[5PT@7?.4SP(MRY)
MN_PI]>+&O*NJ<D#IJ].U^AG)@T*`9PW-M@X<2G-:XC)=G8"T[1H3XSZ^#B9!
M>E,E^+'5X%;+K!QP7#59:F,6[NCPHF6/^'DG$4PNLZ,4^>C%`VA9Q^I76WG@
M$=;I:BTU2E-AP%'7;;-QJI#RU8)"M/.UL"F<+=+V.4QX>B?F,LLXN*AF,L+G
MQJZ_O0[P.-5RN3[B;*D`.%[U[#;O,Z59L"2_"&%7P]+)?)9F_N[B]R<<$S:)
M:.K18!O&(>4HNDC1'L'=M8#'L*;;<A1W5`$<Q[J6&T^\N'R>:[BFP6TLC^WW
M/8[(/]8+M)8`\&JJ``V<=<<I\(.WT;76`3+@`&VVU=Z`V,VTU+YG?&*:'(V!
M`41:=4._"XU:R;E$V[%[RGBKBLTAXA36#H^Y6LH1QX%GT4$JA"\<)P!.15W%
M9`"`LYP[*/CE<Q*7U-"\^*I9%7A@]@&@?NZONQ[@T.UEOFE3+Y24H2ST?,LR
M[I:JQEOPU4AC."T0(=/B.$VV[%W-[286[*H$/,3UG#Y*F=U8`W!8:QH^+)FT
M+/\HM!TFT![;[U=BE/RM"&/CM[3MQ#(AILZQ\F$9X)&J=$D.S%H!P'&HMG/(
M8;S::'C2C"]=L6??5U7&M&D&_-/X,AU'_!6'ZTV.@R49"7EK_'E/4Q/?K(ZN
M+'7L!QN(`<XTIL#(9-17!F"^,G;%-#0*A4AH1%PE/?HI;L]+6A?H(HSVM+3K
M_6AG.)UY`B>1:5RZ%'BT;SW5U&ER,"YPG&S#F)(E3$J5G/[@9:%/]S]YRS6`
ML%78C.FU&R1=DFV6-%.JU7!H(L)EZOFA`FX`/+X=$2R):-"*_.^Q1",0'5$L
MAG95MB*6PXBS\SB3X(&,/")<'X[@:<%B.J8NTL(6V:OT*+F[%G#NU71;)MF.
M*H#95-=RTZ9=R*^2LX'AQK%=5T=U=Y:VJ<AN;/\_'U/\F:(G@):ZKLR\<+/B
M2QD$$D4*_*[\![VE`&=%0UCJN:=[B0#,FJ:>C)`:I/[,R+73U3*=YR)NZ;W1
M))878!\2OOS:=:G"FG3@H689QJ.-N>&B`8>F;0^';7EI/@*T0,*DAHV)L=?M
M-$8+L'`]?B'&X>V3)FB63UX841#(%)CF\+C'_C[EV<&#_]YG.>5P#>AZ?A![
M6F=*DY9AUZ%/2RIG2*NV/1^1;DM3SXBM9]185%F+*G/[$+/#TQJ`/\;/<8J]
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M>'"PWH)DP+%GV<$AF\HL'`M#T.,S>D5M06'\+:INOU;V+%!ED91)W_E96""(
M,C17E-QJMVIIZM?2`'>T5TU0LH?D#M,8#R-<NV;PD&C"V$&"(ZD"3HEC`BP3
MY!AZ`-/EJ.Z:AKID%)V*E&:AXPM2Y,\]:1;`'N4<0$]+T,LCL.2W]&>?XKWG
M$"M9V.$6YP7-,^Z'JN3F#46`TY[*(9FNY+\#IAFEF>:GMBMA;H9$D[DS7>1<
M>F'*W@"N>.!F]5<O;4MZWE4'>&QIN2P'6VL%P-&G9[?Q:CF1+EZVKN33Y8A"
M@YL8'=?I\PVIAVD/2!^VYCL#Q.4O7#Z*0N\QC)R^;[_T_12S+9(MW2KYC=EX
ML[H(,Y\^OI$MX^`VQ=MPO\VNXB<LNOZF$8NI,.`4,`RDVKS!2!)@TACHD/$P
MM%"+7LF*OZ715>IFNZ&%]@62]-OEFA\X3#%>T]76UB&]([0D;12AG=!!C[*$
MS:A,N,4A;FQ@=NX<QUG;T+RQ,'`6:7>RMJ&A+`F8!3H,-DX&2\6>T9\#)`MV
M]!+C^$[ZDN`B"Z?3YWU33.RZP/R_TLK"N;<+<R_J?O%77P#PZ.T/QL&[P)JU
M`4>Y@1/F*?*X"O2J4$;3;$DK=4*A\VV/"3'ADXGL8#TMR[`8Z12S";=K:\>`
MD!'-S@N#"[S":8H#D86-#'78<:\E<T`;74UALR.3/B"U$XN.I%F13"^'+!..
MT%UD_&9QQL]H<KVN)A*.4"K@*!*$,SP2?H>)G8+,!2%!XI\[[./PB9Y8TZ>9
M>IW9L8G"Y7;2D"K,BAM4=ENF`$D%G&BWZ7>+@R[#]@+ODBS,308)RJJS"^)F
M`-IC^;C>K$*ZQ7S+D2TT@>O*1T!`B)0[;'@=]=+GJZ"WWC-E(_K&D.^G>P)?
M-;/1!E%3V.Q8H0]([3RA(VE6S-'+(<M<4NA&0CE_N(NK1Y)^**L4DV!5@K*3
M0/$$*.X?&5*LW8C$\6(R8\([K2)FQS;=@'2L<C;6GQ6S:+AA>Z6S>%NAF%<#
MY)`14>'N1TF\/B.&;>6U34A\4:RVB$?">XSP#NO-CAD:7.^:FM0JS8H#FFRW
M/BGA:I#0`R78;;M?^IFJ_9S+7;0&``<+!4X(=D"S=^<,,)58<LS]'3-GC["X
MAJ_S+@,X\N*GQT:Z2-M?^#S)S!!$#5+K*7E^Y&;JX$@D5YHSWXNT4R-Z>)$V
M+"&$0'NWWK.X&+?T_[$/4TS@(ACDS[?$W7P9!Q_);W?;YG1EO00`IZ_^8,@4
MI5\;,`T9.&%\!D*HHA<=A3)4:%L@IF_!%CI+E:YVEJ8$A9B_\>B)D&2%5N%7
MPKNN]Y>.O/]4)FVL,DGJ(M=0=V[$T`9!*R>H*LZ)#EKMM\D$E2)TWY@9U!D!
MC`.#'/O`,J,2QO,Q#K)+$A?W'MOG^N3EU*SGFU4?0C"0`YT<3*&I$45?(9!)
MP]@7\^.47",?85.=;.!0:*7Q-`&?Z$Y,IL>'(?)_O.WNWU"*`[S=%1?8@+',
ML"G;*/-`^/QC!S1[BRV`F<F28^X75T"M($\)'UM!W@D#7I=KR;`651IPN@QC
M+_9'6DON+WR>M&8(H@:]]90\/YHS=7`DNBO-F>]:\M2('JXEKTH((=#>'=Z)
M>?+-ZCJ)UP\XW5[@QR8B:RD.G)JZ')7)IJDL8/KH--G\@DPAF,X]KLM#:52X
MJZ6=T9PM%[78(P:%JX'"54>K.'GB_WK#9H+9QZ\X]<.L\?%FG7K`8U;;]<95
M&54EP%&L;[NE51>J`PDEJ-0"8(EE`N>QD$MY+=DIIVANHOPJR_9DB(!O5N?)
M=IO$#`P-T)KJS2C*6UUOBG)EI9E$>;OM=AIZH4.\,4RT\,!WE=MW?/_I+&97
MPV"W?XQ"GR"PPBE]*7VN"PVCS'7@<X0=T.PM*`!F%TN.N5]``+5>.B5\M?52
M"A^L)8./A$/]_&;U\:O/DC+=D>G:34Q!:X"TM0)PXNEV5B:5YM*`"4/#:-/6
MS$73<4<A'%'I='I-Y;N99TSB+R[\3:F_OLA>1OSV%7X['WP,'VF<U+!BX!CB
M-`8,+D8'\,<!HZ$2BDN'KU\%\HU(-A:@YV+8#_@?^_#)BQSG*][O=A%[4<^+
MBK?[KN)5DF[Y.[0=KS-JUP;.'3UAJ*4XUJL*F#/Z>F!\"$K24[W=B"15SK<9
MG4`1A)D?)=D^98LZC!O"2J?++`$$+YSEMU[8M"]Q4`1XE*L<JE_SK_X..%Z5
M9II?WN?"$)7FZHJ^17\8K[#4GB2"2!QQT0X?,!<L0K.+D!^KHUIQH%B&N"BI
MH*/GM2`6>+#:`J[V7OI`F8!)P9IK@P*/6K!`P@;I/"4=]*I6"U%EB/.^WSF"
M#8,"=E8C3N*SPY$!2G'$7L7.$_G\)8':UAKC+O=S2FS?OWDO:(W^YN\\?_M5
M_'-,YC91^!L.?O+"F#[C>!-K7$4QE0&4L`9!0MG)2(!C*@H2?\]:JN)YFV'^
M##C;1!QA!W[\\K&R?(/1OK0`K8D)Z%7$7E(E\:.\?$&KQ8+`NJ/JNU&X2D7T
M;E"MWGVK5**?&(S7!8P`;O:X!J=G&W,W'+U)UUXL'M`Z3^(LB<*`3VW9@UU9
M$=(W*]'G>=$]^0WKE;H.QMN2#93G1X%0'IU:$0QXB&K7/].@?2!=`GWVRHL=
M/E;YF5XWQ#>K[AT:54'@`=+L7&V_Y:@4X*;;8JSQ/@$32<?V\C6+!_PU1Q](
MR_O5U44+^YZ"B#B1P9F,WFX)[_C22_(-0+16`!Z!W<X>/.7:4!IP1&H8;3X/
MWY)1&[NTGH7K.%R%/GWCV"LUHIU0Z:XY?_"R,+M9R=TFZ47O*W./\:'4PIBE
M`=&!(H&'A`W`Y*`9(@]P6%EQRS3PF'(:=K)Z-O66#$"5!:@P`4"_Z12X.3!6
M^3Y]M7+:U05W5`'..#H.RXS25AXP8VB9;=JPJ7#T1*7S=&QB6HC"F"C8\^M]
ME!^`K;*H,.GJ?KOJS+"UMW:@K15FUM[M,3EK\$R\M#4&H7^;P.WYQ3F=U:9X
M@^,L?,)7L9]L\6><WZP>O*]=^_=:-8''?`_W:[OPW=4`QW\?ZX<]&N/+FNB9
M4J*JV%D0[T_MMWN^!9RH:N1X"RPXDAQW]8,:U688%BK'NV)"KC.S@%":;KS-
M5FO55R(.^/8CU02@=QP=@Y-@!/%$7U:\T>=%73/`]AK`>4##W8-4Q4W%`4>_
MCM6FC1[XJXN'+T\>/3M9O%DO_:H:/9_SM^:ZND/K2H`'S3B@*K8[+&D`')HC
M.3HXFH4]"]6KLOS!`=[;2;^6)L,+)"P#T.U#11@F7[)T()LD"@BL],&&_)F.
MD;JNF'55`LYG>D[7+I2UU@#,-YJ&F[;NOWIIZKF]+*ETL`KHKKZ\3_U9-NL6
M*+I;N*+R[!I[FP_&FWN2IG]&7!>?]\J7)\;N"S5204T'B7LJ^.BE,4T]=8O3
M^XW7>5VKI3CP0.]RM)8QI:$LX##N-'E(&@"Z,(-V9"2;4=&.$J2,Z:!8>A(+
M45Z>I^'CGF_/Y`E=>Z+IZ3*)%BHT?H03NUW==EOYF45O:[?<6'A&\6NOCRDD
M(R(:,=D`)ISCN=O-5],%:#5D8)DDZ;R5':BZX_<=SY,LSYC[U/2@R//<T04/
M%@H\U.V`)O/!,(F`2<.28X,&],C[XJ4!VA$9,PBT#S(07?WE<*FG$FKML!G%
MFEKD*01;AV>FT29-DGG*Y-(")$Q`S(8%[^3/6,RC\O$`]WV^:P#AT!7-*AWF
MG(SC@&=O6^/8[Y4XI:<,X%1D!,G!P1-]`8!IQLR/`4=2"FT\H9^L#WB`:!S`
MZB?D%$*DZW!6#PES#Q*K![=J45)3..GJM<X!+I?(#.:/IDP]241D):D8,#SA
M>*_15_:L"C3^30"HTO'HU0,8ZT;FF[=C20\2BJ9KOTU=6=^Z,V[!RHZK5T7P
MF:3Z^F$A@Q3-&T5^"$G?)&5GW>$T]T*Z`,NW-^2VGW+#ILX'-14VRD`'TH<#
M0,)Y(H"#V\7/_/\UK_QW5P9*D&8@**[Q=]0$V,T;.C#X:GZE:,&OWS^C7\1_
MG0_BI\9B)UWV=\<`/V?X9O4QR\.MEQ_EVFPL!#RBU4[)D5LO`3A"&PPU;7T_
M\T<N2X'PPG`<AW$AT.+T@N;XC4EA?E*;KJ3?K$2/WMZ!]J\---X,82@G&?I5
MH4\S##RQLR5UF*7E662N+\T1*T09>XO*S3QC0G`D56@9\\TY=+,J1MKHB.4<
M3#8<P2&W@UV:!'L_+]J#RU?(OD@#KC2)R8\^S]G99RIB(`8HI0X%IOXH63\9
M@(=!QJZ8GVC[4LL55E,);]0T.3YWV"?"HV<49AF](";U0UE.J,9+C]Z#F8Y5
M!)L2&Y-U'-(^6X]&=.H!YPUMUV6BZ*P$F!GT;3=OZGSL(*F`1P#3P9!6*AQ>
MIO,W.-A'9*I8II9:9AEF^Z_2==E/V*,#Y>`FOJ,)G^A[[VS]Y8'>,NB\<&=9
M!W#F&`72VL4]FPH`,](X?AH?P!/6T&%_E1]N@;A);%8@7Y4OK$)L>T+8A?BB
MY2_,-/=<!Q?@*O><5\$;2?#F&R]']#9(2A]P3?GS2X\8;0O8R9]74CJ[&'F4
M<,5G>*3F0R#=Y9,71A3&RR2]]^1G46@'1!`@/M,.HB?/&HN=#;4.`T[-IF8R
M9T&@`UVS$=*E"6>K)#W+O-H[1:AN!D"&=(5@E5-:_4Z6F"]B_M*F1WYQC#.$
M))VJIY^Z"*VK#G"VTG)9IJ+6"H!Y1L]NTQ!0/FP&AB'&]5TF4'7\)_QYO4>/
M:/#)7S88.WQGMQQ':@P??XZ3QPRG3]2CJWBWSP^(5#=3MUU5P#EE3("5><$M
MZ@',8*.Z.SP+^4)W:KE`LG6(F0=U;`42<VF\Q=\OS8H'3%>UY.AY]9K6/V?H
M&C\1Q-ZS/W.0Z6#L"\^/4\Y;';Z[)8UCJ^2T+">>(F<NS>G;=\)I*!4XVUJ"
MK6&Z:2(2,(?:\LS*9%-*P<S36+:EKX;"B,X1K,A/F;?Z*-,U94&))H$GOJ[!
M6\L8*K(FUY*&]F?`_B+G1'^&@#5R7T]Y<R$^4[<LL5XMMR^+445Z7YB$YQ(Y
MRE-)S"X=56<!P6;P+5%3YWHL\C+>I'?A>M.=*6:(O-DPF"%4:OKJ*6P6W&7J
MDXWP:TRNND"%`8A,J+@)`-EK<NRJ@5I](IKL<W9JC"X(?'&>GK4"Z#!C'IW4
M^X3D+\)H3T:+/<=:?:7-AJ2,8%)35"]1LR`H,X]LT--Q$LH%6V[SV<!`Z`=(
M2^X0H^.IO7@YF/SSL00K$&#%1XDNV9*9(EDM!/I:QGG(+">SV&J;Y^-7/]H'
M.+@DT7Q>.7R,>X]9I#U%LR$]V^`VS#@M:9D%55IWULKL5#)*WLDMS$*T@:#S
M.G,H\_]"XUF0<&_"C%Y8\KT(E:@7],IPI`?GGKR(3WJK<2,$OJT2*<JI%MDH
M^V9'?\R6/G&(C+-[CAP'")X-GPX%KV'*:RAU%GPYV#DKDV`I\:ELQH)/CY&P
MA#[8Q6T!R(3N@*QFQ&SPB!*F#GE"'2Q6$^EAES2;JPS.7XK]XV66[;?\=\8,
M-TC)#-EN.*A=S&>N868L:,%1VXPH3$+,IB-*+`U#DF6@^1$(Q)X$US[CURB*
M'!\'1U[6?!UVZP6X.'48T%+%GQQ>?D_B)V(T#N[(_Y,A+_F)0<K0[C=4-!0%
MG"Z'`%2["&\@!S#U#7+'^$)\H1156@6=<;WPQG=.<))&=&&\2M*M6!.(#[8\
MT@I%-O*#,-+[N-U%R3/&]SA]"GVL'A4O(V8+6Q(0UXU_(_T"3L.$/R?08T/$
MNC[@A#8ZU`V;*G:5`:;&\7VVLC$C;$/"N)8Y=&4AK5C9B+B1_/41,(P[#_@S
M"6U??M)%G)%A*0Y2NK0KSE!G.1DPLF$\/6*XPSQ]*X@MGLM]OD_QIS`.M_OM
M'4U1%A6/N%PFZ0VW-5Y?8^)M[[0'@V3/AHHM0-B0YL!<\"PHUH9_5M(:,#N0
M,`1Q2ZI'F.@&;6D,XM8`9$PH:*XXFEN!9D3UT1.%S!*+Z3.%I\LUW8G:/M+S
MUTGZ?$N<)(H.T-*J`)1P])TM\V*VEH:>"E//>$MI]HM6ZJWYLE"IC[18IG#B
M5)?C.O^I[FVE``D-#K)93NKQ\?>U2$B?]]M'G-)3D8I4V.H2D"E'[4[),?4_
M0R>5!FLML4C,I/--."J?98S>IV2D[\5H'RLRG8W+(I:]_5RZQP4Z8(G1/-IB
M]E/UW>CW_%A\NY]5W\Y!6@'-]%2DP.<D3FM7B-E(KV'P:%,^4"H;#4IEUH"A
MP@%/V^S[.#P_0)$20"35K9("T".WLG8Q73N:HSD(Y0_/DM&7-(T;COWGY=>P
MZ?$,O9IS";]N]Y6!U5QM#B&C8;WQ`+<2C$K)Z!<J&T)K5_E]D6R]\'"4UJ_F
M7%I[M_O*UMY<;0ZM7<-ZN]0O-WRNR'5JETD@6/3$P&WX9V7O_(D-N7M`J*@Z
M0P)H`J"+`0[KS8P"&LVW//R31G^_<$V`2,`Z")6SCG/Z2F.<\L?_#'%*@F7S
MS/)#Z0UMVRO/)=RU0&@8X+;4G$/(ZSE@H]<KQ8,<YF;',/0>\+;)F$LH](&D
MLPML$C"'P.CEA^U.4?J]%#;@!LF3`-,-P'3,43Q0*3U!4/Y0/=#7.E+N*0(X
M;Y@`(M-&G_J`6</(#=/8*)31!PZE.)%^E%]8=SJHGA27AR3W(@"C"I;Q-6.#
MJ'=ZDV9E#>"1K^&N<GQP7!QP7.M8;:&+X])Y7MYW4.;!([A\'Z[C<!7Z-,TP
MS[@I97\..0BO(I:=^-VWL"+Y?>](?C_G2'[?+Y+?SS*2#ZVV',GO`4:R+9?E
M2-['C5'\'D(4#]CYO@YC?$73`(^XNR[KF`M3V(34]HF,4L$<V,BJGS96Z7J]
M#WAT7N,#?S"0FH:8;:ZI#P:^7<\#-C\#".81P.8'Q1H^06L%X#S7[:Q,6LVE
M`3.0AM'#Z<1-\(_HVB?5HU;N@K)(V4OHB^?LO:D2HS6`TU$%>&#J."R'9EMY
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MUSFCI0)H6M"QV[P-"^F\KY4[6,=A/8W7`?4:PE(S>]>W1_BVE0<>NIVNRF';
M6!APR';;;-IP^>/5L$)U/&]_2IYP&O,$D8]1N(:3'K)Y0?&ZXT1+7QG`8]D(
MDKX+S=<S.'%BYL<$"\[7KL^*3(N,<@>Y>,*9OBJ6I,@COS@&#<(HH!FAY39)
M<YK&ER;P[;TQ?U@;.*OTA$'OL$BM*F`FZ>N!::24TEBR:Y!MWO?W6YJ8$`<_
MI4F6_1RGV(NHR3]Y8?P!D]#%#][7_CAJRYUOG/2#3C."](3.,[9Z^F8<=84%
MK">Z/^BM)2L0,P-5=B!J".*6(&(*M,-?4R&HQ`5FG]V(R#7YUQC\=2CW!/E+
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M/:74%`J<"^R`IK=(HR,1,*-8<FSP\HQJ,WC!3XY41BS09_I0W\,7'#UA]"F)
M\PWY'=S[Q9-`R-*<(267+=`USC+TL/%B]/:=`,SB4UFZGM\\X;2#FFS(`\I*
MUJ`J'^T:(@SZ$U]6?!NPQ[SGS_LJ#EP<G+T\2,ZQ99;1)"@KPAC\/3%*5JLP
M\TE\/A,[T2J)HN0++43_3!=NLUJ!B5\I=`MUN3!_J5B8/R!^1$U`Q`9$C7#&
M^.Y1:R7[3VRG8C#9VQFXECZW9]IAJ75^EC*&L>1D]!7PV">U&$UHO7UF3PW0
M;F1L8)5YMRSI`#P`'LU5&]FWNE-N,;L62+:,)QU$==O<[X%(3PP4;CV?1U[6
M=G^_J\Y<0K7-Y89W)(XKS"&(6NTVC8A2)&(RG6^=6*2,0[STWI@84>]<(FIL
MZ$?J#=5*YQ#9H_MN(=NNLKN\.>HN-7K+#\_HB'5@/+<QA^_PJ(_>Y,GQ6O>V
M#\L`9T.E2XI\=^`WI]5V#LWOYG;#>12?7-XFI&^KTZ4[%M#T#??$_[5E[-Y6
M'GA<=;I:NQ'85!APO'7;;'Q5G;%]LD),I/.ANNQ?Z]A:61!X,VUVKI9(XJ@4
MX(;98NRP%GE3MDBGP[C1_$NZ_)LVT502,VLZ\T<=EH,><4VN'69[JA6"'&^-
MM@[),D0F4*(Q.L^U-(IS&17I+L#NB/%MA\CEOP,/J"-7Y$`J_P@X@(YM-&U;
M3)+S`1.SHI6VZR7FT+Z:J5KZ,_0V9NO%<=[*G/+R"/XX'_1\"N-PN]^V1LYA
M&>"QHW2IECU7+@`X?M1V&I\:YM(<Q]`H/KE,:/VU.WP.RD`/'Y5+]>337^<1
M/DH[S0_=?X40/F/X=!([TM>Z3QS:504\F,<$>*2MYNL9W&<:U5UH!["N7=^E
M@HNV>-]PA;[`>9K)(EKG7N33/!WDQ[LDBBZ3E/@9C/^5&O6^'+9MAWXDZE4K
M?1D\W.$[+%)>(,E<]`LU&`F+Y\_1(WV)\PU=<LE0R._)KL#SMX"/;G?3*WA'
MJ&5UV+(ZR.5!IK8+M6/IF@M/CP&QDIMM*IH#'X_BKPT.E@Q#7^B#*\=<FQV0
M+2'D(X:NC@F.=YUKA],P"3[&K5G68"+^D3UX6N0B&!&=^]Q+\_GA\P&OPSAN
M@0A^=].`#TT22M/L%:\#7<4?O91ZVKDN,X'^$^V6C#^%C:ZJM_(3[+[,,7#4
MI;7U:`N>`/D5M?S;ZG4R\JO">L<S#/`?A\\T*&+P)QG++-MO=ZS'6\;!)YQO
MDB")DO4SF7:1OV'VE+DTIUL^9GGJ^4U/(]B0.Q>6'@J=DGU-A<Z!50?[9N&*
MCV0#>_%4LH)E6N9VL#_)RS6_%+:X7EYQAF&E&.TSTA_D"<)9'F[IZVX:ZRGT
M;M4^)S_^5J01^1!Y_J]G]_Z&`)"AA(D^VZ6A3PMLDP!'L.CQX]<=]G,<_"6A
M:U/4ISOB>X_OU2A@AH37#D87LZEKSXS".IRPRU4+5*A#E3Y$%<+AHY$`D?Q]
M15^40F3F[Y.QW[>PZ.$NS'Z]3#$9@A+P"#/V)(>&ZC.DAC8@NHA!57=FM-#J
M@FU2H,H0U88*=<`X810TJ-"S%?4Z++QFC\Q"IH>/7^D3UAF^)0.<?H.&>KT9
M$H+2]>XA@E1I9A2@MMW^@(!K04P-G)"WZ_U]GH:_8D3G!23`PQB1V4[DI1D-
M<Y1MO!0[#/1[JK\MHFL%@(?NL3.UV^+E7P$'H\)(XW9'1;D,+8N^U(^JL:#)
MP,52VXSB`:=;@XF(J`8\[G0=UYU4TSJ`8U3;]-$FT%0+I.[2HN^ECU&X<KBG
M+#WPQEZM/T^VNQ1O<)R%3V0JX"=;3+=>VO*C]A0!/,9-`*FE\>]1'W#L&[EA
MO&`MO9'(M*&:.L3U%?N<SM.,EJEM/OYC3S.<$5N3F#[)HY.JJ*$.\*C0<EF9
MLDA5`7"[U[/;F/294%1)=7X9_\#-U@1&366!M]U6%^4VJRP(N*VVVVNKC3I.
M9^3822<CL<\XKY["K9ZG*L[!M%YA-A`#/'Y-@6D8E6G)`!SUQJ[8&)T1C?(K
MS=*#;NPD&GO/VNVUZ\GAD>"@DK/7K_C;U=_2M,#2,QK5(QX@.*9M5'_=<4';
M0,Q\.*87,`8SO^L97)HV=F6B&>"UZWO.DP/$0?%KH(0<%'H`SI/P2U1%J1'N
M>*<-HP]XE:3X#OLTR62X"GU^J8.0]\WJP?O:\`&&203.1A;@DHEI@#C`'&7#
MJV'1V$)1"_3(3$!'-BS8&"I9(6*'&^YR#YR*QEZ_BABW"]S20Q-@DM<`ECH-
M.C+EG9D3S)1,`IDOIB,&ATNDVUV4/&/"BFQ\)9W8/]^G*9E0-JU<:=0#'OG:
MKM>64;LJ`8YY?=N-5QZ%AK.4JY#OKBR0T.)HJ74RYUF@DR@7-QP?<8Q784[\
MIW.9`A@RITGW7F3U-6DJ$@?G9#RQC_(P7B]C^@]V[08'=SC#)#@VZK`V$@`T
MOLW!J!Z([E,;_(O01LX8'XK&I)/+V/8?O5WE>VGZ3&]2\7-?'GMI@?Y!)!Q`
MV0:3(4!`STV3OR2/4;CF8V+:0U*;`E(\3?;K#?FO)TK22-IYSVSID=Z6\TO?
MV)_\TCN4"O>F?AIZ4LR%-G1>AZ%2B`J-;CC8`23GG2W"Z4(U1>(V35:8S`*3
MV(LN<=>`J[,24#;NY_3!DG-+#<#C+$W#AT:[+!]1!8Y'6".[77-WA1WO-"5[
MTL/=\BZH,W#5A>$';(N3!X&J*`D[0-L,'A"83"P2<MW'XZA>B@&8X[5+P3K:
M"Q>=E8"'I9[31RN5C34`AZFFX<-6Y8K>%,Y*Q11N.W]14KS'>I/>A>M-WG8"
MO[4"\&#M=E;QTJ2B-.`@U3#:>`Y7O,Q8/$A,9OI,O/M3\DJO6T[(MY6?8QMN
M.AG?6'AN+=CN8[['#1C&N[YUGW4>^&VH,<<VW/GDKZKXW-JQ[4>`BY9\4[9D
M".\!C^BS,GJ=GZ>_P(_Y59SE*5OZO\,!YM<X;UDVXI:.2*LB\&C6=UX.ZNY:
M@&.[A_&FS9VJ0)4.FIJUT+)`7(_S;JL=AM;^2[/JK)M^<X^F4V^VS=\2WQ\$
M@-3^R^;OM*]S`8*:!8!W?P]?DM9;9/JU9\T&1S#H$T)9=;:<<.S!>+1`=#F^
M%S85%B0<_Q5LU!-5[2^O]ZD_[\@_AJ)'[%>5YQO]"A]&C'^J#38#6,2#!.</
M[$S-NS?OW@!;P;KNN-O960EXV.LYW;F4=3V#6YJ:AH^PN'/M^O[ER*X+N0[/
MSR@=O-GG6>ZQ![OZX%*O-L?X53C>&<%2G;G%L,ITZU&\0)(:0%%LT_G"9YY(
M$U@TU[+OEG_,Q%^SMWU`TY`UQ[C7A:B3#+H$S8TAM/T9@3;JV:RE,EE9R-&[
M8VZ@*O&`F?FZ>"N-3'-8HF+ZMIJ_C(.+,-KG..AX)4R_-G!^Z0E#[4*C7E7`
M'-+7`^-0$'KHM!\Q30OV:*'/9L-"F_,7NJ9"@U[<IG>7*QIPQP+$ENK6]O+)
M"R-Z/.PA.4^VVR2^SQ/_UTT2!00ZCD8[*YA+`\X2`V&26<-0%&`6&>K1D#BJ
M)X`JE=.W[;AZ).LO6,<UTSA#;+_%*:62V1".'0!/CF`L$,OI$(H[(ID%>U@;
MKX"=J[![&1=AYA,K]VGG"\?FTH"3R$"8>LQMFD0!)I6A'HTZ]UF([):2`<X'
M*:X`.YX>_>CP30=_@X-]A&]6RS@/`^IZ^(2KG+T?O_*WYR])(-)<6'N>3.1F
M=8A>VSTMZTJ`\]0XH-:>F;"J`3"KC>2H:>P6YM#57]D@*<LU*DQ"M%$@R2A:
MZ9@MW=]8&XCLAV>U@):K!N-J!,X.$\!=2\$PGCK`O#&%U\9I$AJ(P_45"K7+
MG[TM;KT^H5%MEA%Y['AW6%5U9A<;"M-M-W"JPO%-"5>^+]J=GSZK*UM&N6$'
M05M/1K>5!Q[6G:ZJLK<>%08<R-TV#TY8RD0C+MOQ.>;QO.5.)CO'"=?O<):G
M(<U$R`QJ#<NFLL!#LM5%.1R5!0&'8KN]YAE3"ZDB$-U&X.A.9E0LM`&P]J3A
MNNOY*'OB@8>Y;2`MSF>O9W#!P;J+M@?RO9>XKEU?G``#*:3#40-!66YIML=Q
M`"]EGS;3U2&T2'-<\.ERW(%_C@EN@;@]L^0V2U`^)+D7B1LG"-?P\[W(IX_T
M$?40=CJ+W5Z:<;YZCF-)S\>OV1OHV8?GJLRM]TQ_M_SBI8'>)N=P^<!)SSJ4
MZJW-@<(!DY]]'VUL:#(]9_3W`9*M0;(YZ/&Y5E"8A)A-[O<R;PD.=*6U9?/Q
MH`CP6%,Y)(>+_'?`+5YIIG&^?U)/K*<[WC(KW&K=(#LJ-),FU[SY52\Q@V9G
M:7-':GA.=[$F=VO`VV,?_[$/\^=E'%PG\?H!I]LKT@!C.E:E:HDE/R@7NOO6
M!1I31A"4CXWI5H3^SEAO/RP\,1;&JR3=\@',#J<Y:=;TR:<\86^,49V(F\7.
MJ5+#SJAEJ#0-4=LF?AQL,J"$ZTOA.E*XSB!RL^$P+1:JMJ`"Q"(ILOV3`W_>
MOF\FPH[RD,E/Q]62\-H*0R<Y+=LG(+:W[\5FH5,F&Q4-E7_,<8=T-:K#C5_5
M^D"-DF$3YY+?]R4N&T(ALYLUT`[&?`,D0N=)>PXZ&26J1@8BZ2$,YG6/;V5!
MZP"3_1$BE;M'T$[#L]@Y-(S!VZB_NPID8M=TN*3MCO+025G7_&G&KTW-?6(F
M'1N4YIFW6_X;V^_6;^SP.`S;5B-:VFZN'90!2F&M+M6.F<@%`"_DJ^TT/O;!
M-BNI..<[2.8;P!4D<:"U#S62*N`A,";`M7,+(^@!')"CNFN\+L1.FW[H.,'P
M09Q@$`7K)Q@D:J#3$R@[?B#A+C81^-$/YU?;=*^TS?`JF]85MCE=71OK$A>(
MFVKCWE`#/%9IXJ#KCILQ5@1##V%KX/4:=71*A4P2]IP;-*+H.!/9<23RVO7=
M%P@P2OR%=HI9OA4DGG#ZF(#'XNA2)Y/O\-ZQ,2:?][1S$X>8L^4^WR1I^!L.
M;&/?HN=42;\+6BM]0).24^P2.GUUUD,L$+>M/(*?H<J\F?48HZ%<021N&'F-
M$,V`./G$N7J4+V/))A\V7LQG#=E/[*V.*_%&G^VOU%_]J=*LX8>PPKX]=9\B
M*9M"X)"KQ9J79+-(;9L3J\7R0[9`W'`4%B^!SHS'I_XP3-Q(O=V8LX*I<3KJ
M!LE/Z4'^%+16@SF#?O%@^%"D?K],4H;CR*,5A;I3[?<T@1YCEG&HZQ3[-5V7
M0<TYRB<A5DG*^Z^9=5ICHWX\!ZE!%F;9WB,A.V/>709!2*MXT51+.JT:3YU]
MN^&V2L#-ZDZ9@S6\!D'#E9TGLPHT(O05;EZ%FY6EH:8;>[:7Q/B_[_>/_XW]
M_"&1GG_F^P&J@YDNC`!*PFX_2G5A<6H+H!\D=P>(A:/I]`!Z?#C*R[AJ>D`]
MJ90CCVE'>TKJY$]%CBLLT8^0,/7-R]E]`7X:3[,?1:I-]I8=E.(W]]5GE#QH
MV'R=X)#]_#[3T?RG-3(@][W+.-Y[T57LIYA4X:4F^48-BE]4']L&_GC]JDKK
MB^M+6T$8J_\D[/"(Z3"=<+''#(B>$2%W6G@5IEF.`N^9EL>>OR&_R4A7BIZQ
ME]+=$Z7$JH>=>]<ZR@<9MSOE)J/"9E'V%#K043Z&@"LLX&IJTZJ`X+\HXV$^
M/>J2)I>EE_J\-<UQR8Y#5P,$!Q^STZ`7W`/K?:RI>N9V:UYXCZT)CJ6>?%?J
MDGE*&NC_WK,#^7#3]O@>RWPN-0UQ]:9RZ/1&`R-_0.U1@A1]&B,&](I\*Z\(
MY&]GN#,ICM%(6-\E4729I/2/MO<MNI0!'21,`[*5K<A63:>X"ZGGL,,-R/+$
MHKPH^@LU$@DKYW9K:5S(JX[2^7N!%A%2+H&.J>?E4.GQ`N=H2EX&@=I<);//
MG8LQ%\1V[!3QQSB8B#@M02UW+5[.!JDX#HKQ*G<*O2)C7C[*/1JG6L3N/O?2
M?/;H/>)U&+.L:=H8SJ=;JA^9_RE-,NMI`UHUG7C7U`*OS<Y)H>:$NZ<V;R%T
M4(?7D>AOB(WS'-F/`;:X@`2$05EJV2S;X^!BGQ*:YYZ*`QY5<IGLXU><^F'6
M?#S;1!!T_C,&YRA74B\ID-G+W!D(Y%18-=IUR1\XA#%>>R3&6ZEI>B1+24"X
M9R`Y7R;I"H?YGG@QUO7U5DW0V6L\>&V.WA1J(//?B-Y"($C)/@`4"1!L(?-4
M./3CUUV8LCIC<ZA:TXES:`N\-CE4H>:$.;3-6P@<*MDW?PX=`VPF\U08]"\X
MR^D1CH!XA6EJC(>$_DJ,M>F5[5%WO'JH/W&N[?LA;!*PKNX39N7>$$"@:FXT
M>]JH,)L>-:2_+A<+J.FC;K6-OHHYV:<1<"8IPA*:3^2W1IMQ\^D$IF+[%TCK
MD_#W2R)JV(Q\,J1K'V9)XHG3J70.X:\X7&]H[_6$4V^-BR7LVS3T,3ULMYKJ
M?*Z^(2=.R.8?9Z03:9I6G#"E#P`#`N?7SK05#B#A0;EGAY@/Z)?E8Y:GGI_/
M_[#P5-^JT'/F"4AQ`>F.JCKY?L+ME_R]1SCX#`ZZ@=^Y?[:$?Q*GFT?],MIG
MG@/2IWAI1G_%YPBG<OQY:GC;#D5W@PRH?VU\RE%Y_G&,/M:J!7/O9^U_#CO/
MQO96/^?^=@04QNQS,_.#V2YZWA&?GYW^^\A'N4^*]\MSLBZIOZ\1I\[^1A_%
M:@?0RX)3[@/,@`#1#2B.P)]J3S#M5ZJ?KC^I[D!QD-9%A]#?C%/O$@P_C-5.
MH:<-I]PMF$(!HF-0'OT_U:YAZB]5OS9P4IV#XH2PF]E"7S-.O7,P_#"69PR]
M;#CESL$4"A"=@_).PZEV#E-_*?D^Q*RZAL'GCAWLV@\V:N[=QB0?;=K+%:?:
MI4P##(03`?H7,>;9Y<#^DJ;W-DZILW+;*_W>_9A]AI$N@;S0#F6./<?I=PY3
M?17M^R6G1/O5P[$78>9'24:7!(LCYB-]T"Z=)T[Q6I#;)/96A2=,YWI^0R!Q
MZ45JR=39W_48]P,<7>M(\=8+V;%4$L5,!WWI@WBY=<S/C]T0/C9`V'S*]Z[P
M]KQR]H'X^J[M8TYNR1RXW,WG.6+X:<V`SON.T(#0&[1?#RE]0)(3Z$'!<A-V
M$C/[6OIW&N;;<_1>4VN"^^U(']ZJ@2?>S]C_F#:['WO6G7"O-`)($#JK`3L7
MI]:3`?K"!CL:\^WIX'1IO_===C^/S4[J]][(%AH0NIV7U;.X^%HZVR$SW/>X
M],+T+UZTQ\LLVV_%.F4<?,+Y)@F2*%D_C[7[T4OS'/J$:>"WLA.BKQ8ZYT_D
MO4..I]8B9BZ2[&4S#,GB^6Z.3/@UJ!H.OU?I.A'2O@NS7R]3C*]B\JG(Q.;.
MRZV?3NJA]R41=AOTH]&U2NE+(>M6W\%1]0)1>Q$U&!46(VKR"1#U*%^""CU;
M4;C"`JZ4R$6O/-+MT:&V3TR:XR$C%8+%XMA?DHB(B<+\>2KF;M3\DKB['?[1
MV%NM]J7P=X?W`!F\7,NO3#X5"A_I8Y2(/56(@2)PD_6G-OQ&64C743@'NAX5
M;"O+XIW:H)/SN$Y#YN09+F2/#WRU^VQXX'.7^SDET._?O!?T27\S^!#L51SL
M?5:09^:[3-+/27R?>_F>F/`L/W5\`+H#]4"IU=6'H$0[M6['M!LD_I[:R1QT
MW""'3ZSQCF"`::('NFD5EJK1FF<#724IBI/X+"O4HXSJ1PDWX+M16%;5L\T.
MVJN^6,YP^4(GHRK[XP690)0]W$B7*?I;`93,'7\6FS>K>IH`?43M``D(9TDT
M,D.S(HBZ((W.9[86XNA+E5@6U[18=X$"BN6*8OG$9CKV+M:.-H[/TS#.0I_!
M0M\GNE2^O3:Z,J"T/@W(%D?D#9H`DO1$#@_B8O1!CXM%N1H7%U2,2AO%\L<O
MU$PD[)SXG`=PT)?K=8K7E$3#$K0G5:\TGW&V="NKCMM(/6&;/J`D.QG4(SU2
M5E<&D&JG\QG"R+=VT_2`?$_BX3'+V/=]:LSUEM\`$+LO,Y4]T"1D/<2>$R?S
MP9]JVFR5#<:<<&<P'!,(G87^3<]J;#I%GP(@.^58GV]@8DK7W8_)1O'QC:<Z
MIA-<W3Q6.(<.9%2P1[J(>:`->A<PKM,0.+Y&XW#(&R;P?1-&NJ9CDR[PXS_V
M8?Y\%6=YRHX%9#?$M_1AX\4"W\])_,1ZJ>85<6=&S(&V)_\H5@;[1A9`I_?I
M@7!(^=QP)%F.F.F$N[RXZA!*\\F/^^TC^3NA-R8V<[HZ/],/=XCA2?<(W%EW
M'Z[4_WL_4/\4$W<!7/G+9O\##&9(_#/<#YC\\WSP2$6_8S;`3K8<3P8LXGF?
M>VE^DH@V9.ELP_44NE2^#EB<V9K\HQZI?[$=JOI#3-.?UG6_R.ZT`0+XO:E8
MR"^/F-HE_Q_X-XG9%H2CKM3RIQ&`G3BOE\\B.Z-VE04OEMT;/\<T!'^D_D5R
M?#,*\&F^>N;\A)G>_@>JOPY_PGQ?SHXZKUV`V$WI:>6+[3<&?=:)%^/ZF/@B
M^Y]A2,'OHZ2%/;UK;O/-M`GT6YO=+GQ9_1_@IO![3]?G`T+KWG[OT\!?S!ZK
M(SOI':SQOZS6YE;W%>X3V^>:'/>V+;"3>)FZYU(SO*%$?_M>['C"\%.ZV'#[
M?61A$R/XPXO#+;L3S0H#[@MS?:?8;XEE;OH(.KQ.JZ=Q+[;',OF(DVX?:EGV
M(OLJ(X#@=U226R^UCYKTR]9W*T%-N?P-#O81OEE]W.ZBY!GC>YP^A3YN0#YB
MMI"?;E9WV$_6<?@;`9[U\^=)EF</]&I;T\<<21?TCF5,B&O]Q!B*(-/^J/X:
ML[BPBJZU%'8A81AJHO@%JJRC%2O[Q%0",0O1+\S&HTVUZ?CB*O:3+:;Y@1G]
M7@N;EU_#PU3D>C6`QZZ&NW($MA0''$<Z5IOG?*:R42D<%=+1+U0^O)9\D=#7
M<?LA5=:99VNNNZS1GGF%^;7H`[M':--<@Z-##]"\GBZ6[W"&21QLEG%P@9]P
ME.RHA33W3ISA3[CE3JE>3>!QW<-].;HUJ@&.\3[6FS\&P74@H@1)6I!0@W[A
MBAP%_*00T"1>0:7%7;#;&>Q?AS&^(DS6-&RUKP4XB8P$JTPXEE4`)J>Q/#7.
M.V1](DIM0\PX1^0'#6(945]>O<6BKTB)_C3@^X/T$$96CJ0(SLD.IZRXP_P>
M`BP<J+$4_4K#Y]"N#)P&^X$@LYM>3<"DU=,!XS3TA9I&$BJ&5VZ(92(8NO@"
M^`"K/,W&MENRAR3W(OGOE%T_)_G?<%[Q[A`F-]0'G&U&A[KW\,M$&6!.&]_G
M"89DI7U\FS=;U-F2FD?*Y.@9Y]*`#?"PS`G@/\=I-9BM,:Y/U)T@W?)A[F62
MBE_1<DVYD"<WXJ42<^M'F82ME1:\1`IO!P(LKR^*F3A]/54R_<3X?IRO<_2T
M8(KIW@6]&Y&)[[6KT$TKU722O@?:@]SPQ8-X?8V)D]E=M0C\&><-WZVK#G!^
MUG)9IM/6"H#93\]NX]>)"NF(BU^@.VE[@S`4AM.L+_?TM-XG$JS;_5:<]<LN
M]KBX:JX'H(:4>35]75A:@J%+Q'S"0]L3>P'#52*ALSB0FR&BE?PQS'PO0G_#
M7HH^>:1@F#^##ZCS?9J2'X<A7@DYC7`Z`,4@FH2$^0?3H2,3Q=)G_#5'#U]P
M]$1*)'&^.=HJF6;$.S%*]%EJ\)1Q%3]\22C+-6VGF\@Y#>(XAL:`.RHA\Z</
MA2^C,\B"4@C=>"6J66\,FSLL0D3B^E_F0!]$*[9#(+*DDZ&0(WC,2*04<Q(T
M<NS-A$1"E<^#2NS!1*+\7V=`)I<$;2M<(@LZ%2HY`L>(24HIIT`DQ\Y,QR-4
M]RQHQ!Y()+S_.`<6"9_LC$AD02?#(H?@F+%((>4D6.3(F0E9A.B>!XM8`XF$
M]P_@66087"?#%P-(8O[,,.TZZ3CQ3S?L+<3_8"C8R0&TXNYOA?L1U8EV0@V$
M7!KG-,/'8T(A><)2MI)L&0>?250U_/F!_)1Y/KL&H)=(PZ(BX$PS'KCJ%!JV
MM`#FKQ&=M9$\HV:4G`,I8W<1B5UG?E,1))OF/FN&!7RO.^XK6E8!G`W&`%3F
M`9OR`3/`*&Z:QK[%>+]V?3D1%+`\`QR)*CI`P[$?FCTBOLO]G!+<]V_>"WJC
MO_F[=/.<.'>'U_N(UGW^%$8XRY,8B_'?S6,4KOD5QP/0!H@!2E-#@:%49"K#
M,=T$B<\2[C%C+'UH"TD,=L071B7TYJV4QH!12UH:0>84PHJLG%"@+YO0WX@$
M]CE-K[CUGM$C&:-P"W&`\H261OLXH(&&T]P+8Q9P],S9GLQ8O'6*.0%\-PHA
MJ4C>&=H7&O#V1]=E=IDG'.^Q=`[]TS[*PUV$+W`4TG/D9'0IDWS;W,U8&%"J
MLP-2/2V-B23`HZR!#IF3'E,K7Q%9H$+S65"IKH^UG$^6'HB"FY5D4TMRP::R
MP(.EU44Y%I0%`3?U=GN-5_V(5+HB(`_XBRF!US@)<)Q?\'C4[ZD'^JWYR?I+
M`=[T#6&I)=KH)P)PN)AZ8IQZ0R;Z)8^@Y@!RFMO,*33=Y.(\Y6'3"D,KFW16
M`DX>>D[K+.2!IP9-PZTOMCD.^^G<3N)J5CXTC#/L?[=.GEX'..013'XX#%SR
MJ[]?X[47?6337,6@5ET":$BVN$/C3_%G@,'69J5I$V/R$!=H:1"JV[RX4F4&
M:\6?`3<LE2-%JY+_!K1)*4TTSB<A6I*3U-)3>S-@'^(N\3>8C!3O/RTODWT<
M,(I7CH8TB@.-#5U'R_V#EK+0]PET3+>P'Q#&JR3=\O'`CJ_<TY-6>8*8`6PJ
M0$Q`E0T3K^"/B@-SD4X$[]$G)#OI:!@XD<?'']4B$95;*XHAGK(`9+)1.E/2
M2^VOT`E%;:SY<P@5;SP^(YHP=)VD(<[H0J6TB^CYFQ`_X6!BUK#K;"EMP("V
M*UJ4P]:&(K.(F./AJ^KOLXD:2P/`BW"UPC0Q0G/(!'@5QCB@8>5LW]RVVU($
M.1G(.W)J`#&<DR*A[T72:8)2GWK/I$<UR`32P_&25#3J0">:/BZ,.NXOS^\(
M@VK'A>B>.JF=\!3^1&K(V(L?8BEJRMU_BET-`:8`M-!1>QRGTN)R%C&I^W(3
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M07N?WE<&<!HP@J26W:*/`,"$8.:'<4X*K@T)=>RX1%UA\5Z&ZT&"$UP6:"V`
MH:<JO)I&>,?C;],DV/OYLMA7-#HNWR@$.(&8@:)SG%XM`3"%&#IB_[B]4(A*
MC4`/X(\$S.4^#BBY6CN*/X0R]C&!9^>E^?-G;ZLZOM51%'SX-SM8#_+C<J!#
MN<5<\X"MA"(JU?E]TCN\(ZAMB'5E#!YZKCQ"95(?>$/N#45]?TZS,N`FW]^'
M`2<FA":IAU($AY-#3=/#H>_Y@-VUOY*!M9]L\4.ZS_+K<!OF.&@^\-1:&F@@
M:[I9;K`U%X6^PZ9A^:B'F1XV&!4V(&8$$E9,O.DV(A!J_UR>/9K"V9S*EGW[
MT^O*CFOR$_EE\2M1F_SF_P-02P,$%`````@`03"E1MG76J?N+```UI(#`!4`
M'`!P=&-T+3(P,34P,S,Q7W!R92YX;6Q55`D``QJ52%4:E4A5=7@+``$$)0X`
M``0Y`0``[5U9<^.VEGZ?JOD/G)Z7Y*&[O7<[E<R4VDO&-;;EDIUD[E.*)B&)
M-Q2IR\5MY=</P$6D1&(C`1*$6+?JQFUCX?G.=PZV@X.?__M]Y1IO(`@=W_OE
MP_&GHP\&\"S?=KS%+Q_B\*,96H[SX;__Z]__[>?_^/C1N`J`&0';>-T8#R`(
M'-<UKOQ@[0=F!!LP/G[,"O[?M]F]8?M6O`)>9%A9K>].M-S6^Q8X]@(8QOFG
MXY-/I[#GHO8W,X2E87M),R>?CK=_R?OWO9^,\\]GGT^.CL^-XY_.CWXZ/S.>
M'K;E'J`$<X=6T'6\OWY"__<*.S3>0^>GT%J"E7GO6XD\OWQ81M'ZI\^?OW__
M_NG]-7`_^<$"-G5T^GE;"UL"_>MC7NPC^M7'XY./4-#WT/Y@0-B],.F;H9.\
M./JK0RCO>&%D>E91OM+^]].D]/'EY>7GY*_;HJ%35Q`V>_SY_Q[NGQ-</FX[
M@.@9QL^![X(9F!M)2S]%FS7XY4/HK-8N^H+D=\L`S'_YL(ZLZ"/2P-%I*O]_
M7F?4R/\[\>P;+W*BS9TW]X-5@OX'`[7_V^QNY\-@6Z^._\GR5Y_1GS^SM90(
MR83TY[:B/4>0H>A+KGPO]%W'1H3]9KH(M^<E`%'()AA+.TJ)]60&\,]+$#F6
MZ8J2<:_1O@7>_C*<SJ=KD+J]-@K%-:B2H%?^:AV`)?!"YPW<^Z$H>6O:54IL
M,US>NOYW8>(6[74HYK436JX?Q@%`<)O>AE&<NGJ]?/9SO%J9P68Z?W86'AS4
M+1,Z><OR8^CEO<431-IR`+=0K*WV(O*MZ02_FVX,IO-;QX/.T#'=.SCT!LD(
M%\(A[L$,_@*1^>J"9V#%@1,U@*!I+[U`,H5C0+#C,.[@-'65N`WXI5!U\2IV
MD<G5E(0FR(V.@`Y[`2HC,1PX-TAQZ:<&,;!OWM?PZ_AIPM!@+X+^808!-%IN
M>8IZO7SV(X@0A9Y`\+R$<QO>KZ]4[\<G1[[UU^2[&=A/<*[&[7OW:O<U&JZ<
M*/=T<,Q&?A\N?1LX4F)3/0GGNN9KMBJ?@3?@Q=Q,JV]#X2F`W*G`(*<$+^B?
M'4T,\KZ&.3UHAI2P;M6<*C0#A;G97J<-S63;KZW"%**9))A&%)A.-).GO@W5
MIA;-9&-HL,\=A88;"H,:2:_A+QRWHZ%TV]GP`#KI%*&3(4)TVBE$IT.$Z*Q3
MB,Z&.FEMZ)3$]:OFM+4A+.SM]CIQ;2A=I;H*4]>&LN!:44@D[G$0VXP",_*&
M:L(THHY`W$K"M:*.2-R3"UPKJJV<&G*0I45EMF@;RTAHBELX.-:'$*ZDL7OX
MQTPBU*>(0)P29.`]`IX-[.UOG0CU<71T='ED?#3RALH_FIYMI*T:S>)[$AFA
ME*YO[7R+BT*^_("F/_2;/TD23E[AI-.THKPAJ!C@IBTQUOO,]8F9Q(FT(;`^
M+?RWSS9P4+S;&?H!??[9QZ/C+/#L/^&O_DP[GX&%@_KTHD=S!?:^%U?LSXO3
M\XN+T[.SD_/3HY/S+U\OSDI?7*;.)-C]>C.P\C[@CQ4V[:HK*_%YG43_?+26
MCKMER3SP5UR`9E_A<TKE!S8(?OEP_,&(0_BM_AJUBF*0NE+0%90L0,L8&[S_
M+]A@-;173A<5L8B5Z>BD!QWE@KW`9FM44_[S\#5"E293Q&F/BH`S9\>'(MG7
M<.5*T,A..7U40Q<KT]%9#SJ:P"^TT5?>NN:B1C<[?Q^^3NCB9+HX[T$75W&`
M!+Z%TT?3_0<P`[S)X(H.7T-<DF7*NNAO)I!^[0RL_0"M7U!4:1SB)P2UQ8>O
M-&[I,L5]Z4UQMXX+@BO(JX4?X"=P.Z5T41-=J$P[7_LS*W^U\KUD`R39<PNG
M<83NMZ#+3WCC(E3217?<,F:JO.QQ^E>X\EOXFSKGB"DY?*7Q"):O:H]Z5U4Z
M86535JFL;NJBB98K#+</\?/G_0V[=MMX3-?.6#;QCH_0)MZV.?ASN44C:]+@
MOLK6F*9S,WQ-VHO#CPO37*=<!6X4YK_9)VWVZS^W0I1.EY_\T"%L^/%5;6Y[
MS86:A"$$GO+YNX64L;TFBD'FQR$6=OL/BCD'<`IJWZ=08<5(9(A`$(*D9)]:
MSN;,3,K>*ZN<SAETAU,XBVB:Z!U=-D0'7O`_-_^*G3?338[`HBLS"#9P&I<$
MRV!XP%1745ZPJ+A*C^82:T*7NNBH#$H,20@UM*(&KYS8(XEA$>(I`&O3R4.?
MH&TDH6`[0&*(P5!3*X(TE1=[9#(LHLR`!:##1%'HCR`B4Z.VK%9D8)<0>QK3
M7/UKN)*$#FJ3M-K[9)-EDJF5[IE-OGKJPZES/S+=7L<&?PV":(,"QI*=#SAE
M6J-5&*0\=E#`5U&4!-S#`*>$O4\4<-%-8(U6T.'N2/;H>U:M73/5&;:*FXNH
MR1B?RDITZ,/6,(,LHL;KGGWWO6.^.FZRBH%,3HYXEKX+10N1PXHVE"TBUNK*
MT:'I3F$K@06Y^#<0O/J].H`2"FQ;B?@*RC&CE8:)A#F@[4;LW:DJ'+AAA+T%
ME2G4<.G04GA-6'2=?6QVAX%,F/K"^G&#0\[>EQ2R1AOF448_]?-Y@-8KC9ZG
MI\G2JB0R=ME)KZ`R%41,-#@EU\\WT)V"[A2@B:J)4RB%(Q*/K?>*Z:Y])GD%
M;5OL+D&+@X;CGI8;MNVD@CR9CGWG79EK)TKR@]<N+>I+Z\X/'K%%G4S4GD;U
M11)B'I-MQI-'$$WG+^8[?EW*TXKVI!(`!_8^S8#)-D/W[3U@WYB!YWB+L(03
M7,`YEH,_$Z=5U)U2#1'`7NX9,(NJ6&+#BO<+ZLX21HFQEXJ:3WE[9P4-R89G
M-;HSII'\V)M,;9=,W=_3V'\ZIZ1`PJ6-<_9+&\8/.UW\.%[BZ'-I#'4Q#9(O
MM9/E8.F)`,IJ&5=3.0?1]!"WJ:R:'*M4KG-.XF@)A[2_"P>`)\=^#1U)P22C
M)ANH%;'OPC!F)T):6E\2$.33))B+X]8[2Q5]J<!XZ5UD!'>'4T7LPX,LT\03
M\MW>HFW#GQN-GC7LP3#2W:OMMU/FA)C2B"GG)\>0(,>7)^='YR<G/<7B/YLN
M"+.8@4=`DP936CGCYD&]9@^!0\K>YWZ8\&SXW4^!;\=6E$A3%XV]5T0Y)?*H
MH5`BLV@2-%=L`9T(4B/F=:V*+NO*Z:109ODTF7YG(MY"_'[-GR&L/Q;8*Z>)
MTOGDTV3*O0<5VQBLF<)9I-/DCD4VX?46^<,1E,D7MKQR%&@W_>*34QN''P((
M,$HO<0W9[_K)I<`,`:SS)]11CA1\:JT;"GBE[7UN+H8:OP(/(N>B:'][Y7A)
M0O+(>0-D<E!J:4>/)O)JXCLJT+$.(-J1@$U"3>)=M\(6\50TQ1<EE5.]H#D#
M14)-5'_G09\#PBB5-B/[H^_Y.0SXY0-+5<W(T5AD*5'1O=V7*4N\`P7IS@RV
MDF8<:2"LA&#H/K@!R4\=0';*:*9YNFRB`I%['C3^`,YB&0%[`OV1N0"/\>H5
M!--YY123L@W!VXQF=!$BOH2@9-4858+BFQDZ%EJV.VX<86-(FC6F'+N$\(./
M=ISH"-H6Z7]6D]\$R(/SV'A&J:4<H=JYJR;2"@J.KR-(YS$K.Q>/RC,<2NC*
M*4_HRDXG1M:+PB$LI=BGE%W)FZ>5&UKLX<XLK>2$/?]R>7%V].5+;R$OPY_P
MBD"^Q41XZ!OJ+#<2G]"K45"A410XKW&2V/G%3^\QT([IQ+1^(*23B98V>=5P
M($W>3,=%<,S](#3+J<<G]C_C,,KRBM)`Y"2RH%Z5([A,*K(37R:ZFOOO6S^`
MJR0OS7]D;5X"TPNA0A!"GIW\RTWY)-$XI'S#:"H]8RUE)"FB1;_V=L5C'U)*
ME@M"#>4X*F>^PHN`M`/'[E?29KB\=?WOK"OH,ZX5-&S<R%L?QLIYBP?[,KE2
M)2?=E[/+T_/3X\L^U\3HXYX"_\V!RORV^2T$]IVW/5:?0+?ZEF87]#WXBQC^
MKKBP0T%`3.,J.Q@VQ=8NN64AH\E<;_B;-1)U?,![.,6<+GSQ9\#R/<MQP8[X
M+SXC[K3W#B5T==@L[0Q1;7:`K@'\8LM)T,;0M%Q$.7IUIO$JV:BX:.(1;TTG
M2'*5%%A/YW^8`>GZ&+'.2*(V0&D26XX>&`")CE=HS^3O1-_3^;43ID\1P$7U
M4P!63KP*[[PWD*D'-Y(V:FSDH10$V^Y,7*8$]<`"K>?[O#:9Q36`9'L'>"%I
ME*PO/%*L$4+24IMTGM$C`%#@:Y#^MX1BE@R9GN2#L8&1:,)0TR3\NHK"4_I2
M</Z@2^V+P<Q$9&E,.5*V9`8+U1KCTG:UH,RP6<6D]"HQ,[]*=0Z11C3QVZX"
M%&9+]M)I$Z=4K7J(W&%$09MY>A4!EO?LF$G%TM@ATJPQ+OK.[K.[?MD[6$W(
MAF_B$"G&B8:V,_>]-Q@YQL.=>H=((18()#P(,[Q8"RDQ%LHQKNM#<]'8:9)G
M`H-,NK4L*2R(LW'EJ"LO+$@$,IH<2\');+9G.;'^%3L!@%A!`*+-DVMZ$9SC
MHK=;D@1A&/*Q-Z`<P22RHTK%ECAILUM6P>'!#/X"2>1X<4.#E6MU=4>:-8-(
MFQTV"+0%@!VB7+<H"RJTK0<S0J)OIG,>MO&V<^#,$P*7)AF(VR$O99YWV.R4
M@)TFV9,QR&1ON<A9FG`VKAQUY2U-1""CB0^=@74VF9G.[WUO\0*"U35XQ5$-
M5UPY\DC4?)5F7*CHL\@HST70"U/31)3PYAT$EA-B4QI1ZQTVF9K!(V&GI+CQ
M^Z5_@J$G[-`KK4F.I/Q),P:"U=8;"<8/CZ#Q#G>I7*V;I(S`2YF/'38Y)6"G
MR1+B9CX'%IP+W[Q;2]-;@!D<_J<>`@M#0WP%Y2@F8*K/*:TFX2(8<VGOK`;A
MF>2M$'F=2^OHD)Z="\(`91R!_T%')&^FBU8S$XA-$&P@"LEM,@R#F.KJR)WF
M@@N*#8'4='R4]B2(#HP[QP=+GF-A^;A3]MQXO=Z&B]=K-T'2=',D[[RY'ZQ2
M=5*2U;#5UM'WM!%=4,;DON<^^4,I3Z:#VVHJ%U&/!2U46!>D2!%5D\0!.5(H
M@!?^6)PM>7;-(A%=-7;],`YHZ:';-JL>N\0,4<(QR6AXJ=H3Y%?)JO'.^\T+
M@.DZ?P/[5]/QT(W2J<<0S]"H#>5((T7C!;'$@23U.?2M$D1G+2P`0Y?536_#
MEIWP^`C^S_AH%-7A/UZ6P,A:^:!T$L)IL#"]+/=#D5,Q37OZ5`)R.L\H9KI%
MMD5:]G(Q;?>R<X/"=L!T3M^@J114SFT(5?'.[@R;[-*F-O(<P'.\6IG!9CI_
M=A:>,W<L%)^:WGV#/O8)(FB5!AF*>SBINH>L?92M-"QZ,,QM%\:ZZ$-A[U'%
MA);_CE"A#SM'3]B$TWG9#*!5$+7^`A7]S<6?;[9I4CG?05=PV2$(%WV`KF.;
MW:OD3N\\B%F<^E,4$HJ?KU)<R6G5E:#^C#?4(?(F\[Q+PRGZ-$S/-E;;7HVP
MW*W"WF4+92$PS;^0J_2:2J_T13070JRCG(]@45-M_CMFZ0;H!DBO&J37YN-5
M[*(8L9J2<.[%ZA'.JAXA:="P=MX1<Y+.C1]@H?#'Q!^8Q1<8?EV-[",4]@^$
M_/FT_226FJH\H^!'@.8P:-64\QD<JJ.]F$"5<X#>`YMG(\LMQ>H=SJO>(6_:
M6*=MY\X`M6Z`HGF%[3Y#)<QA,5W:M(!8HZ=4J#L*KF11R;.'E7Y5VI]*<V/0
MO(+83I3S(0PTV$MW*AN-`7J:_:3.%(=R474HI184]AE)Z.S2=Z&"0G2B'VW0
MP$%];H5<J9<S^=IO*C1"<PK,]96S=S85[AS#MY)5XMO6\NP9SJ+0$B-_HIG1
MK+]4S1HV9*#5@K&&2X,P:TMA`]]_G)IBVOCB*KP^3C-B;'GEC):F%M+[XMH-
MMHD_FGPW`QMEO&"TS:\UQP>H'<-$#1GKM"6%+;.T*3(OIP&?@63WX<H/HS#1
M-_I`.\_>0+'?MHWV\O`*ZS=_*W\SS1>T;%4YCR&&+CNOMDA`:(#>!]TA<Z+\
M%"*-H5\`C^,D\[+JBDJ-)CL)UEZS"OLE`A[L@6E\;?2TI4C_1(8-1HY&E/,I
MC52]M_'85OY!>@P7\L`/,F^YDXB4["J.C^I<1:DUHVA.BHO`Q1'62$2W=KZJ
M8@(>R;WA[)6KKC)FVD0U1<1B&VD':)1LL4E<,4HG1_!_S6.4C!_RWGY4>\37
M)5QI[[,VZ?\S!B91*BOC%%J%(#414I,K&+^%<)ES$T;."BYN<&&KNX4&KG,&
M87I/58L9YE$,OP<+I\=/:"4ZG6=C&-FH.6L/5,,BI-0D%=@C^%["+/`]^*.5
MQFCS#`*\S0R4.$+%U20;168SZ&$^.)U#,K!1AEIOX!QI)I^TAT=4"TU^V7G$
MC;B..#V"_Q,:H&S\D':O^,)"BTCE9VL)[-A%[-B^4)T\)0:)48J)>0`F^EA[
MBAZLBX,`6EDRZ4X418T^$-F'<GZ'-Q):/AJ:K&D*H"9OIN,BN6_]`*78+OQ4
M_N"LDVB<DXW-FM6(@`(!Z'VM)89SM6,AA5#$.H-G"[]TFJR]MD`Q..7?//\U
M!$'RCNN=MXZC/?MAO?HCL*O!$Z\S4*2M]!2^:,0UOS^KSN\%7C<:R&Q?PWM'
MI8D`D3!;:O'.KYJTJIS?:GAK208,`SRXI%YJXO)$YU5/Q'2U:2`^1H,[3CNT
MISX;S>]0.)M4SIMPWE\2+OL`74A^UXC+4UQ4/47>SD"<@3Z7E[8<KO^Z7"_3
M8.8LEO38Y\;M*><,&EQN$BK[`)W!WE4G+I_PI>H3JA>>!N(=!GWSJ6#Q_G>A
MU;P%Q[9KQXWA?)ES?L#5FG+>@.?6E$B9]3LN\"+'1N+#]56Q:7GS;KDQ=`OH
MC1VT!(OS!'B\]_#$=Z0)%:7"(>V`H:N;?UQ#U=?J4+5__V\@`]5X$;`Z==M>
M.RM_>_EAN2RA[X9S_&O:\([!G2K@?\1?!Y0$DG9C9^5*9.*_RNB@,YF4"V$8
MK]+?->9I\TX.E+."`=/DV/[13]*B`WL&_S]P+/A3`DZ"&Y\W;=+4`7!1&"R:
M1`>4%F"KM>MO`)SQ!F^.!>J'EXF;?$LR[\UB3O^&P"?/_23:X%CDBNWO`+C;
M+78##"<@7'3F6K5<5E<MQ%0!`UG"'$C.@%)@:HQR_#\XGK.*5S/$+3>WLUL_
MR#+_>XM[8(;<9W@MVE;.5;7.,"`/E@%N[1=/I]!]S=GX_@K&TGIY?P5ST3&C
M\V2!-@=7KR@&Q@\V3[!_V%G=W49B!>7,7_@;*PTQD/KRTHD@+CS&JU<0H'/+
MFAO*-24.1-L,0DM8H[=0KZAKB9'I>,#.SP!*,7+78.Y8#LZ]T2OJ3YR66!!6
MX!56J'8O\1J)[+*M1\Z$OYQB_)#UK_B"18N;B;RWXV"!1]\+JI?E:!*W;5\Y
MA]/XIH44)+"SDUY)]6V3"89,_C8`_XKANFTS>7=PR5,8:JI+!"F*)1")$R,U
M*5(GPK6_@D,NC2+XFNI2A%-E!.5S2J_)$6J=^.'6LAX`FN9S\&:_JKK$X50W
M&W&8Q->-.=\VVQ__QP$!U,5R<P_>@,LV+!$JJ\N>[D<F7IBPRV]EO$Q5(NYA
M"MN&NLSAUR2CZ^&"0A,?E"?2*R4EJ5E%$$<QGB;4955C(E3)U1H03;BU%3JY
MF1\F-GK"-B&JUE"..:VU3/!*C.)KS)-3;IZ<'C9/2.)K$NPG8NYX[WB[+^Y*
MV!S<]J$<%WN;?4M#4Y.H0GQ"+@Q/\16T)!V9!%7B<<*CR4":7P*&"*:W@*=P
M=(A,SX8P8GA$JC(RJ0E``[ROUNI(]H3Y3+;RZ(28,UGC9#R552,I)^G4E;F^
MNEY'8)K-@9R:/IC_](,7V$LXG5^#UPAZ@C3E1"$)88N:L;9R"F^GP"HAVN`P
M-#H0-Z"9ZRM'B38J;$0(_7>>40P]"-!X_V2N0?#H1W=>FC#@#R=:7IGA$H76
MP_\@:.`D`<T&B)M"S1L<(MVX=J0%0R,U[OBX+SH&:_2L'$!X%S!3&$>H<P"D
MXI5>DWW())DG!TVPY;6G")_DFNSEL4P?:=O07&TH1R/1$^CV:&CB>?#B3U9^
M$*'KRNBB,O>>\4[M0=))W`8Q'0M!TQ]7D2LY!"B*>R6_!GX8_N8%P'01-K_"
M,>`;F/LH$>,[/]W8VCUT(K9`2>K5L;/A\!2E#)7!TYUV1YXV1JGME.\RY:D'
M%JC["E,O5&/J\$]SN^46;Z*5H=QC/&4^-!/]PF)^:'8Z'IK)%^(NR9V%=/(_
MOHM.C(E'9)C2RKD`W@,Q'KD(<^N>I\F%%&B#A'#L52VHG`9Y-$+2)U%`I8ZN
M=K_Y"LX6%I!.Z=U\XN8=O:+"VB7JAZ989EG'`RGM#Z0:,F,\B1I/HN2R:3R"
MTNP(2A@W#O+LJ3JQHYTT$6HHS(UVTU8V275,OX7?:4&6\F!&V;_08.QX4P_\
M`YC!=KW'O7O%TN@`6"9N/ZLQ(%(G.J>"4OVQRCU]`P&%6ZW;TXA6<K"0ZMZ.
M%=]_+?"E[;^>2=I_/1OW7SL40L!3\BP9Y01UHYSO:IQ83B8@2NTOEK*3Y#)O
MKEPS)-V/(-91EP,R=4J@$C-(:O*B/6K[`+#E^I'5K[K\9":*5+_%@9HF^^?9
M35GB/M1.&74IU*GZJS2DHZ0)9;;IKA.,LK>M"2,FMKS.5.**E.8"2*D,=^4O
M)@YMU8+*:9]/#37G&FPB:N(%T)E@]A`G]3QUIYQR>F?46_VQ*%TT3?0],[T%
M*8!F^W?E]-N35R<#@CVZZDVW1"LNE5!.OV2@,8K1WV"SEXF(:MTIHZ9BN8Z/
MZ?+HHESSG:[<<AD=E$N51Y,X$8$#%BV00$97RE&M[TU0V=A*>\-VL+2_,ET+
M76Z"/\Y\U[WU`_0"NWP;J.]79X/@C;+H!VQ-1OVZO.<H'*4"5+B+5+B+ZW:3
MDQ0?)*4OG2V!@XX$LY".MB!36"</K#]'9A`-T"`PJ*$KVNCZ:Q[=?N?ECS4*
M-A+N_D?#$6PX8C2@VX)#HW'E>+2/CN$6%(V?CBPWGJV"04S",%XE@B2QB2!:
M^K;O^HL-U$)=/FO68+NF[>H\#C1>2@@%4S>77@+GYGT-K`C8O_O(FR!KGID1
MRX.[Y`;4Y:108K`1D`,BW1:E)11F3OC7;0"@E<.O`V'$R;.ZZB/+F@"DM3=#
M5Y)#\!0X%I\3*]4;6<6%C"87+I^74`\DWA0%#I8@%`AT.W.H&<)?0+!J,#E"
MU0Z6-8V`R;AT/J#'=Y)[ZE?^"K:T!%[HO,&A&!8#:.\(`EC*KE=3$JUQLAME
MC#?:SHZ.]V^T)>T:5KEAPTF^P?@!%@I_3.ZSF<6'&'Y=#?0MV_MMBM]NJ\'[
M$433^8OY3EEW,]7LY6HWD2A;2I'NL?$TH9Q?XE#ISEWMMC(K==UH&WB<IFU'
MPOA><AV6(:B^KHYR:FZMKYKY"3<`2NE\[ZN)L?.U9973,;]"JDIEEU23S9.2
M84"_5R3A+?(.Y"=2Q%`_WF:4(P^[XHF#07/A->$3G,4#9^%=Q?"+/6O#1!YB
M':V8PB^I)OMGC.,O+5J4MQGER"-A'B($D\.B63[#;\>RO)6ADHSWN%,$+%H%
M?Y%02!\PF`$+W>USYHZ5!C50F->BQ4-AH6B(-/%\+=S=Z.,$8"'A8*K_M(^*
MC*8]1](I.YP>"SL%JP]YDW=Z`67W8R\*G\P-FNFF!Q9!#&QT5..%@/-TXKQZ
M.I'W8*S3+O+#"-2)`;)>AG+ND,$4YCB9+BW.CUBCE^W&U=KU-P`.S@GC2P=\
MZ6(8)PBUGG(C$X.R=G8<&PG8^VX1+I=K:F%7<-85NY'C+5!>?M]+I`?V#"H#
M`KFL5SE_`T/5O2!)-9FZ9D`\!?X<P&D[$N$6T/P"N=)0B=%".DTBH_9F!E02
MU!360/FL4FD2!)7,?S/.,\\,R)6&3H(&TDF+8NK5`Q1K`V9F<+0P=)JT%37C
MS$5;SOB1Z7:T=LS27'(N$2^J2\2\H:&L`I,\;TO?A1H+TT/(1S\"E(4@K5*/
M.1LS_*?!S%DL(U*$&;Z"<O;+IJ2:K(VLPBD51%3[[82@,6QYY?3(J15&M0XC
M-*SVTUF2J];5&(9F^;.L,LO:^U;-F*>[F>*JJA\S;-."@97/L-W:KX^YLI70
MXY@K>\R5/>;*QND;/>Y6O&HV`S9(K\(])>>\!$=.KZ@J(YI[](8R*Y5`FRP#
MT=FS5%5.Z0UUQJM\_4<&LOPOWWWB>,%8>V#TX1I7VD!P&!R"79%S^S/7/V`>
M44#0)!2`#,*M\]:&2$7UP^41!0--@@AJIX3WE+M%Y$K*44;.!C597DW"#6HE
MG\91&)D>>F*;AR"E:L.@"%G#C#2A2:W)Q*96]ITD5=L_AME?PV,>]M#:.B!*
M-8)"VK1'7OC"(XA06#\<CI,$5WQ1#%^J40RP/0.EVS'6(#!"U.10XAGRQ-8Y
M%)1(!GSQ7N+9][X&Y9>U)IY][;AQ!&Q.63"UE3-_FLIV`MM;R*C)^`%MLY25
MZPW:))J?O?BEO>@L5"0%ATR:AJTI3R(>8E1I)A*5PZ2=&+HI1S.1Q&A-NZ[H
MUON=T3\`FJY!*WX#@;D`CS'::YC.$T,/2\L&BJ_C;48Y]HEU<D+@$#19AI_P
MZO<;BD1`HP3&'N0-F(9O3#F^"6$('_$XT=%D<*48=G)OHUB@T>[I-FQ-.?J)
M=7<B4=%D2YL"23-Z#8U&7(KGIE6W7JOK':83YBVF$XXM)N-DW&22&(9K+8$=
MNV`ZGWB18R.:.F_@&;UIE-SLNGE/'XF[A4:$TH?$*6VF\WTQ2)=KQ':BO$LA
M;5EU`(52%SU:2OEM4]\`(;Y08H_*,:\#-E4IW#7``^#SH[D"Q`A(6C7EF-6U
MDEEI1H%,EQ5@EK$GV>2;)D(0HY*PY0?"*XI6:^;97`)KPHH9@/,*!Z7NH5^S
MJ"VK*QO8A=4DB+&E=Z;%J8EJ7CF^#7&^Q!0O=^"$GJQ0BA(Y;$[;5H[*4EDE
MG,0$$`>X_97>!$4OE#^YIL<77_6U&E^5-&>8J#UC#1L<2G15Z:FX.=(^\,+T
M!?<TS^25'T9AHGWT@?:3N4'AXK3CBG:-(H:=GYR=7'P]^W)Q\>7R].M%W_MJ
M^3XP^O9"G`F*/5PDUXO#;YNB3"900BZV+;66[2OGV"00@+0-)P,^I78LD(M"
M,VK"EEFYB')\D*NJ*C6H8"BI7>+NTVXAY31,11RO))6W@C#YB].47>@%6M];
MH/=B[SP+`@3G54@HV/%E[<*>JZZR*F9:UK<7557=)S.]/4&.3_'Z)I770,?<
MXDE8[1;AC,="#1PQ%,=>^'M>)K1N5`.ZR,&@]^@=#(TP?H]$$DH5#2C01$)-
MKI3JFS"MZQG^F%]-#;6/^=7&_&IC?C7<B4CBU6`OI%"G<AGE]-RU6Z>CH50^
MM>:@%()Z-M/^CXRNE*,;7?TU,X&N@-'$*;'&(ZD?A]29YNNFGV/,TH!CEGID
MSL'%.<T0IH0)T/;OZK&DX\D/&0GL%DAO2B4[@J*$<HHE`XU1C/Y^_L'QG%6\
M(JIUIXR:BB5\6U6U='ET4:[Y3E=NN8P.RJ7*H\D82QV?<,/3/26*N'W#RM&H
M\YUJ.1!J\HQC8W1V4U=,XFCI!\[?V"ONPOM1C]=R>":0T%Q0:C+L-@8K/2@O
M4C2'25:#EZ7II=L.X:])XLN[+&.S:-IS=C]:0R\(:Y.K291/R3.LW?I!`I_D
MT6"_N]$,.D&T]W`?14@_L6TG%;VK61"^QY'Z78':>RP4+C!6]+PP_?=S_/I/
M8$4O?CD]':JVOV;MYR,.C_<*X=S[(K@K4YAX7FRZ=YX5`%@E+=4)_>LZ'BG?
M,;89S2\.C.83=/48Q0B;"Y#%FN&?7^G_@T:S4`3SS%R^'.KR(-L_*,$T\UT7
MKJC0'T6O#(B='9Y)](!G1O>O(]USQ&KG1]+ZT8?D_-R32GSZC*CMZ<`ZV5I]
MCLP@&C#S=S>*?PW\4/AQ+KZGD?TBV<\*L"YQ"\E%SS",@7T=!Q#Q5.YL+Z"(
ML0WS9]^PTQ?NAD;>5N*9V^/7=F/^,J6E!Q8H3<R`73)$?PZ<"&6?EW5"B^]I
MI+9(E\P*<-MM>6VX?_.^=H*DCFSNU_0T<E\D]UD!;KL/7\O](JO'EV$:@DHK
MTN/1"F3C*VB7/EV3WGA#'@)^!R%ZSLFSH0,!Z*[3BX]^E4T>47R'5(-@[7X<
M+$2:22O4QSW[\O)*NH6,IB!YWL3!^7'C?JNIO7<D\\V&I\"Q`-+BO*LS+,8/
MT<=J>CS?:H-U9D*7HPFQH-FOW>AC+&(YW)MQC2=K^!M^M><Q,FQ+W!>,]B7,
MOB0K19?3N[8PYDCU:F!<'S':6&<VUEXOAW)-B(9DS0E6'X;&^1FCJ75F:B(T
MT_NM)$6,K>;(K)]1C>LS1F/K<%QKKQD)]YZ*T]9S12U/TST0?4YF==D$&<]R
M^8[U>C"W=A\UCG;JG`DW'?O&D^(^[6\T-,4,38!%'?HY=)&&HWB^E/;2K=0^
M];&>KD^7^6'-C[V.=#""5SIRK]P.;@90EG/X^RO?2W",31<]XW5",HUNOT0?
M@VG,8XPM*:`'G1(ZMH"3>T:,0_E8DMV)^\#1'"68HV3UZ'0TW0)E=<QQM#LU
M[$ZP@6E_*(U3Z:WI!+^;;@PF81BO,OUZ]@.(EK[MN_YB(VO)Q=ZS/@;4V<*K
M);CYY%"+V:$H_&9.^-=M`,"=!\6"8_S,C(3OY['VJX])M&2J9)MAQEZGY90H
M\/(I\>^^"YMQG6C3E<G4]SP:33=&PX'^H:]O2/!)6<90.QR-1/R:I1GHO2]-
M1*>9S99N=YX=6TG!-&[_U@\>T1OD9A3#3]B4TQOML;_K[D=;$)QC5I`*",&M
M>=3<R<#F3RPW69(_7L.A=*O-3O(*4K]B-)..$A`VTX1V6?FW7B0*'"]TK$1T
M?$YEN9WI0W[6S:D>\,Q7UUJL$\3$.^T"*#^,>K<_95C?`QFEQD8SP"ST2KCN
MP="3Q2)(TMAU8B^-OV>TIV[#G'G4<.A[5-43UUW0.CAJW^MPM!9)1^DL.$O;
MEOKY<UES<#;Z5_KK_=]F$%24!Y7QZOB?+'^5]E`$)R0;"HG(3Z[I78/(=-QP
M&RB9,@.\1\"SBXSFD1.A]L^.OAZ=&!^-HC'XCZ0]PT0-&FO8(OS5#UFKQLF/
ML(65ZX4$`%`'2!L?>G`#A2#3>9DO,^"B9*]7?AB%%;K0XJ[;-8IH=G[RY<O%
MR<7Q\=GY\9?SLYY<I*BWZ'$>4>I;]WTN.B40H,;1284/.ZWN@XGIM\)>)N\.
M[O60G3+*,4*NLJKDH*.AE(*;@U((ZB7#V:.Y`M<^BGD3GKP`WY5R=*.KO\$R
M0Q0PF@2'S.`:*G#0>BJ9`#T`0D;<VK+*L:8S!E3)QPZ0)NQIOR\M>M.&O.%]
M2(.G)`@%[9R\@>#5'R9W;_X5.]'FSH.V'B?:FD9+$+PL32];?#_ZWENR6X4_
MO^KG(]2S">6#KL7A?.@NGQU).6GY>?O7QUC$<;@7PQK?*&T+Y6[$2>>&M=O]
M:%?]VA6#-B2<CA51?'WM`TL#-#V9[,VZ=KL?K:M?ZV+0AI077`O[NM#-OK+4
MN3V:6.4+1BOKU\K8%#(^%ZO!FFNHN5N':5A,^A`4?#[H8$5V)*D!_DKL$O)\
MY0XKSH8\^BFXC=A:$3J%-O8,M<+FJ(\-=F@::AHTR8K'G4V>Y;9Z!LWY?:-5
M*V[5(O0Y[JXV6.JC='3JF3?/QXVVK;AMMU9F[\D]5+=E76?>^N]1#<J0V^I2
MT#M[]?M;'=^(.F6^$75*O1&UO0]U.MZ'XF^TW\M/-ZNUZV\`>`;!FV,!C/&Y
MR;?`GZ;S&;#\A>?\#45)>)S(QW812F!?RDV:Q%"K_@:4;-R4NBQSYT$7!E!^
MJ,39WV="$>Y&$6HH1Y/NE%HE%"].0Z`%\3(4L8YRU.!5#[.""?)J$GL\@\J"
M0"\GGGT-WH#KKY'\*"&$%P+:U25:S:$0A:#FVAM)C>36A##/P(5M+GX%'EP`
MN!"$B;UR/`<-QI'S!C(<0B)UN-K0DD3M$=#D3%+,6'Y/N?LFN!?E*-GGW*@+
M;#4A>X8"L.M!RJP>E\>`J;)RU.R"'E52M@!+DW&:"??MMEZRQQ6^^)'IEO^.
ML'_THW^`J-!*&Q?;I+^1T3W@JXG#E09:JLA;/\A^A<KA$KQU^Q&CN:@"^@`S
MP$'A5TZ4[J]Z-GH9#BY2@&<Y(,P.*AC//BZ/CO?//DIM&Z9G&U:Y]>U!B.+'
M("2`ML)23CTXV^C#;T[7`"U$O<4]@$"'LV*#XQ'@Q"+64<XK-5)DV<'PBTN8
M6/;\',.>++<QBMAX<#QG%:_R\Y;KF,9KSE:TIT0C``@3KV&0Y"H.$-#M.)(U
MHAQ%1&BX,6](H$A8M/8>`,D(RYWW\MW_!S`#W.8?=SLC[3APT3'TEAT9V"L0
MP[UM2R/[N)"1L,H:#O]N_3@00K]M0R/[>(`1%-8X4/(Y;V)\W[:AD7P\P$AX
ML&PHY&O'N)%F5#0R;EVTY1;:456%6\4A^97O0N;X::Q%.4DL7/<_^IZ%^?,+
M_"F$^*.`>+:P75$=*<?8UGLE'6%$F!WVO)V"DF)/YR6!"&&ZM665XT1'*JUR
MB1T>=;=@JRB9]<`0`^LX6U&.0NR:K`GY$""[)K$?./M["GP[MJ+)`JZHT;^)
M7.)K1#DJB:!#E60"0-&&8[$'OP$J(MJ@5QT(PU==4>7XTMOHQ8R.ND=#,[".
M`VL)5QE;`]B7BGC;A+F^<JQA5EY5[^V$[MV+8%XK_P.X+@J/?PGB,+IW5BBC
M9.TP0RFMG*;;J:M0?Q.Y>U>V(#>!7"5AG-C^73GE]S8XD"%1=W6;?#?Y^EA1
M0CEUDU'':$E_^WTPW]'>(5&M.V745"S7A)\NCR;*%>#8[BFWL$1VH1RU>EP_
M2$95K4-.S+RS=!47RCT#B]A%=3</C@O"R/=`=N(Q?76=1<*+?98V;48Y)DHG
MQ-YD5A1F@ARINT^Q;2HIF7'S6TQ1WI(WX,6`*V#^^*@N8+[4J)&U*C]0'F-@
M=2+28][YJO:S=Y%\3^DVQT/L1L[:A0IT'93E"KKBLA613OZ:-::,!VFBZ-TM
M#6'B*Y5!1;^S.H&:DG(>-Q[!C4=P6BZG&AVY*4J5;H_8AL*9$%B?%O[;9QLX
M*5W@#_LL@;_Z\QXL3/?&@S/`3<UP4E-".?U+&418!<>>ALG77/IEM2=:^W]6
M1F>LL.XJ@BI*[Y:'6:W,?&L)H$]Z?IC<^K%G)Q#CSZ$(Q972(%4?>TMS7KE4
M5>=V*Z'&4U8+**,RJ8Z246[L&9%8Q=1ZP[HBRBB'$3\<X`-TBE>PB&.9;FG#
M;BM._:*&M9JB2F5WE$UE[%W5/6V"T8YZFC>H#)4ZV2H1C).$HQJQPT1^[P0*
M#*!X^\G$R(6'3PVN<Q4^'*1YHMI3DY\_IVK+3AC@;_X?4$L#!!0````(`$$P
MI4:8C%XZ]PH``-]N```1`!P`<'1C="TR,#$U,#,S,2YX<V155`D``QJ52%4:
ME4A5=7@+``$$)0X```0Y`0``[5S=4^,X$G^_JOL?='F:?0@A!&87:MBM`,,4
M53"A@+V=>]I2;"71C2UY)1G(_?77DC\2?\EV/@:NSB^06-VM;OU:+;6L]*??
M7GT//1,A*6?GO>'!80\1YG"7LOEY+Y1]+!U*>[_]^O>_??I'OX\N!<&*N&BZ
M1'=$".IYZ)*+@`NL0`#J]V/";Q</M\CE3N@3II`3<[U0M4CY+@1UYP2ADX/A
MT<$(>EYQ7V`)U"#/B#DZ&*8M2?^<G:&3P?'@Z'!X@H9G)X=G)\?H_BZENP,+
M9K2.\%6Z9])9$!\CK)2@TU"1:R[\*S+#H:=@`-A?(?:,)!@7CVAK,@1KS0J+
M.5%?L4]D@!URWELH%9P-!B\O+P>!<J:4'SC<-XH<CD;#'H*19_(,=,B0OHP.
MN)@#V>%P\.WN]M&HEQ!3]DRD2NE?I\([D,0YF//G0=2FY8_ZA\/^J@>/LN^9
M+@Q;W,EHH)NG,.`).>.,A7XY@ZO$0"T#,@"B/E`109V4KYXIRR#(K%*MCP-H
M30BE"D2YS;I%6SS,6JQIW-PPQ8)/!E'C.BFUC`YE4F'FI*/SZEF(O]W"6*XH
M\^,>0SL\/3T=F-:5#]!Z'^CG50&G4DV]S"6T?`2A01,?9P<0)K[@'I$ISPS+
MJ=$I:2EGFF,<E/+HAG(6[1GE_9B6$B9&YCH&5.)P.M`:#F*R'DQTA,Q4QXQQ
M90*5>98\#0+*9CQ^!`\U,F=:Q!,H@/2'WQ]NJ@;:=/4(4DULN.1,<H^ZNN,+
M[&FT'A>$*-E#%!1N0)>JD2CBDAEEU"@-[G`(41*E8N#SNB04BT*1K$^#O("\
M[!#"[(3]:CX'@D@0:89'NW','9/8.!WL.:&W`>-*LVJ^^&D"Q\Y12A_*R6P2
MD&@=L\%5P6#'[<B.VTHFXC.TDMHAV!+!2^[#*"P(D_29W'+9%,@BGQW/41L\
M,\*1EM[AVA97+!?7'G]IC&=*;\?QN!6.(!09J1U^6?RNJ'0\+D-!QH[#0QBO
M>[S$4X^,F0M/1$C<SZ\!3``BKXC"U(MQW(#/AN?QX<GA$#!<B84OB6041*(1
M9B["D7!$8NGH0RS_IP[:*F@AC/E4F=D`\,`\49`C0JY(*T%MP&&'\[0(YYI,
M@Z2S+K6#L1+&.!5/_@,>GV'@U/(&MK["-P;$\#6AM$=5P$W#EF3_:Q\U8I$T
MM":N`ZMM.G&/!30OB*)@4]/<(LM4EVB<-$\TT(>,Z&[RV6)H@-FR+%)&SVVH
M#`&50CQ\6A`4<W?#7C7LCZ'O8[&<S![IG-$9."G$M6A?`&O'/;BU7CWRH#3D
MLD-V5(0LEJNWE'(E6>])8M$HB&5WB%8A>HVI^"?V0C*975,&L8AB[X9))<)D
MNW&'Q7?8#,".[Y$XH0`EBPAO*,6.^*B(N.X'/>N.-.BSI"M$5WV9I=%/>T,R
M[:YS@BHGF,"*(S+9]0T#,I/`1QE$Z&N+0),B)2QL!7_87J#=-8Z+KF$$P2YV
M_8B`FD[1!R"2/R7Y2M(SXF4<NO/.43;.2ENGHS5`;YJ'=A!60?@'%@)6R0)2
MZ7,[(!^+@"2<W9A7C?E7HG3DNR?B<0$;_/S0YYOM"/Q<1``$(!WC4``!36H9
M'1:56UC%G>_C%RS<>TB]"EO5;*L=B5]*MJ2:'V$M``4@H<-A@U.P%L=?-0BU
M/??JX*J&R_/P-+Z>\D">"0L+<:R4Q@K0\+`,H#4I*!;3`;-=2KY=:MXH13^"
M%/UH\Q0=?4AZZ8Z]=IRM/^FO.\K98UDV1QA!YC[::>:./D3==IZQOQ2^W$EV
M)=;N+\=%?]EA.M]YS_9Y?;EW-&6SHW]21+_AN^8.UX;)?CE\N58[2A^+*"7\
M'1!M3P#*\2@GLL/R<Q&6XFE`!U#+8X%R?$II[/#\4H0G?T30@;/-64$Y4O4,
M=MA.B[#5W)?I,&SVQK[BA7W-_:7N??V/S!<K;J%M)\P.\*[?]787V/;L'$<[
M]8ZC6O<HG"SMQCW04><@^W&0T4X=9%3K(+L^<4H<9-0YR'X<Y'BG#G)<ZR#'
M>W*0X\Y!]G<J6;$5V9E<N]/L]YI1MT=I?H!5X0?Y9CN<EKLK'1:MS[`J(*F@
MLB/3Z$Y+A]&F&!4VZU5D=2@5=N$6E+JM=>/CQHJI5$YDQZC!G:1N'FV(3V$:
M55#5(52\)9%'J-_-HHU1*B2>%51U*#4XN.]RQ,TNCE7^S+6:U(I6XVMD_U>A
M3__1]8@>R`R9*CEG6#B:UEY+9Q`(#JNY3G('B8A>+&!A2@WI>CG]I##.GS`V
M!Z^^EY`4.LA6]C'>D1_.6,M$A*Y7<]Z3U`\\Z'GP-F8!<&W-RF']'JT"KVIK
M5=81WZ-1,,_;&@4LQ&MLSZ=!OKY1_"1;!\E400)6+A1BI>7+:NI_1274;KEC
M9-9S?HT8^[I64W]XU!]^/``5$KU;J%,L]M1(%T^(#-=&BEBK:%5H4<JC/_17
MS!L.1;'(6CM4=@C)>M&T)DH8%OTMK7"FU1AI-=H,1WF5MX8*)`RZYY-,GY7]
M6<N;V1R@E'%`/"63)P5W,(7/FI0)7!NHN%PAPE.I!-:EXF;8D_'M=QV)_KPB
M`9?4'%&;\\&QE$3)KYPYH="_Y^\9JV&K4T]']:Y%QR\E]`5[&4*G5(7:^"^"
MA\%YSQ3:.],GB#T4A:OHB<\9[&W$4I]OZMT`&&N>3Z,2`^<]ETRI2IY"?*7<
M?3+\D;>HED:7_R(@,K2B;8_&.8*XY=:YH8BK<EC-BU1:06JIVC&.F5)8F]%N
M;CV(H&R>MWT#(_,8QM<U=4F*T-/76>+;,IJ:N`^P2X,%>W&9]>*V3&^">C.?
MSH%N,KP;D`PH/A.=+>HBH'?$GQ*16%]#LXFQ4:'0,Y?[F+(=H)RSZO-?(?@D
M@'3+V?R)"#^G_>%IUL(6]._0V@<.$1R4?[P;7_.0N49$UD`[R3NTZ8YZ1"J8
M#.-7*A,K\@^;Z>VJ,Y?Z^C44-XKN*=!4&7!E1JA@0OKXQPY^HG=1SWN\-"^`
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M[6=YN?RT.?D[3%%KE'\BK^K"`\@:&KM.O\6:JQ(Q>P#7HTQ7?[P"W3T>:.)T
MURFS&X]FI&^\I]Y^E7=#QQ!^,5>U8(W_RIFNJ!DJ+I;1?(U(=[>Q:-.E9=^?
M#\/;[/I;;N]+<AM&_=`?ZR`W]J?Z1178<@_BU\YVZH@LMB:JO@]KT]"O*Z^F
MCE%X:K&',D7F1+P/<RX7VG5OV.\,EBQ/KV%?8&+J.UP35EZ@,8X0[?G>*(U-
M3J>W!IZH>\%A_JI'[*TA7WC\/Y:N%PS]@WB>OG?\)$*I;JD/FKC9Y<%*46I^
M1=BOL3Z_E.UU)JRM=9!5/Y!Y'*/R)S.3J4?G.+,L;,:Z7S])DYM]N<GX&5-C
M`"QBVO77?SDQ57>PI$7?)L\0&!GY%\$B_2%&>N*_G8RW&<%=!90;!GM(<!.P
MS[SHD&HRB_>5IF+1LK`%;<5AFX<EN\P?M0A%%QRBMZ_P];]02P$"'@,4````
M"`!!,*5&Q>I,6A:9``"E&0L`$0`8```````!````I($`````<'1C="TR,#$U
M,#,S,2YX;6Q55`4``QJ52%5U>`L``00E#@``!#D!``!02P$"'@,4````"`!!
M,*5&(8X='3$*``"[C0``%0`8```````!````I(%AF0``<'1C="TR,#$U,#,S
M,5]C86PN>&UL550%``,:E4A5=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`
M03"E1GN#]9&M%P``ZKL!`!4`&````````0```*2!X:,``'!T8W0M,C`Q-3`S
M,S%?9&5F+GAM;%54!0`#&I5(575X"P`!!"4.```$.0$``%!+`0(>`Q0````(
M`$$PI4:$(P7;-TL``*!#!0`5`!@```````$```"D@=V[``!P=&-T+3(P,34P
M,S,Q7VQA8BYX;6Q55`4``QJ52%5U>`L``00E#@``!#D!``!02P$"'@,4````
M"`!!,*5&V==:I^XL``#6D@,`%0`8```````!````I(%C!P$`<'1C="TR,#$U
M,#,S,5]P<F4N>&UL550%``,:E4A5=7@+``$$)0X```0Y`0``4$L!`AX#%```
M``@`03"E1IB,7CKW"@``WVX``!$`&````````0```*2!H#0!`'!T8W0M,C`Q
M-3`S,S$N>'-D550%``,:E4A5=7@+``$$)0X```0Y`0``4$L%!@`````&``8`
*&@(``.(_`0``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>20
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%\W,F8T-#@U85]D9#4V7S0U.35?.#,P-5\P
M,&%C,#!A9F0X868-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-S)F
M-#0X-6%?9&0U-E\T-3DU7S@S,#5?,#!A8S`P869D.&%F+U=O<FMB;V]K+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P@>&UL;G,Z=CTS1")U<FXZ<V-H96UA<RUM:6-R;W-O9G0M
M8V]M.G9M;"(@>&UL;G,Z;STS1")U<FXZ<V-H96UA<RUM:6-R;W-O9G0M8V]M
M.F]F9FEC93IO9F9I8V4B('AM;&YS.G@],T0B=7)N.G-C:&5M87,M;6EC<F]S
M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7U-T871E;65N='-?;V9?3W!E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7U-T871E;65N='-?;V9?0V]M/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A
M=&5D7U-T871E;65N='-?;V9?0V%S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^5&AE7T-O;7!A;GD\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#<N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y3=6UM87)Y7V]F7W-I9VYI9FEC86YT7V%C
M8V]U;G0\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,#@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y&
M86ER7W9A;'5E7V]F7V9I;F%N8VEA;%]I;G-T<G4\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#DN
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y/=&AE<E]C;VUP<F5H96YS:79E7VEN
M8V]M95]L;W,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,3`N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y!8V-O=6YT<U]P87EA8FQE7V%N9%]A8V-R=65D7V4\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,3$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y787)R86YT<SPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970Q,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYE=%]L;W-S7W!E<E]S:&%R
M93PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970Q,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K
M7V%W87)D7W!L86X\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,30N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y#;VUM:71M96YT<U]A;F1?8V]N=&EN9V5N8VEE<SPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970Q-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;&QA8F]R871I;VY?4F5V
M96YU93PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970Q-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U
M;6UA<GE?;V9?<VEG;FEF:6-A;G1?86-C;W5N=#$\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3<N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y&86ER7W9A;'5E7V]F7V9I;F%N8VEA
M;%]I;G-T<G4Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#$X+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^3W1H97)?8V]M<')E:&5N<VEV95]I;F-O;65?;&]S,3PO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970Q.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D%C8V]U;G1S7W!A>6%B;&5?
M86YD7V%C8W)U961?93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C`N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y787)R86YT<U]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C$N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y.971?;&]S<U]P97)?<VAA<F5?5&%B;&5S/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#(R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VM?87=A
M<F1?<&QA;E]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C,N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y#;VUM:71M96YT<U]A;F1?8V]N=&EN9V5N8VEE<U\\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,C0N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y4:&5?0V]M<&%N>3$\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,C4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y&86ER7W9A
M;'5E7V]F7V9I;F%N8VEA;%]I;G-T<G4R/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(V+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^1F%I<E]V86QU95]O9E]F:6YA;F-I86Q?:6YS
M=')U,SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970R-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D9A
M:7)?=F%L=65?;V9?9FEN86YC:6%L7VEN<W1R=30\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C@N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y&86ER7W9A;'5E7V]F7V9I;F%N8VEA
M;%]I;G-T<G4U/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#(Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^3W1H97)?8V]M<')E:&5N<VEV95]I;F-O;65?;&]S,CPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970S,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D%C8V]U;G1S7W!A>6%B;&5?
M86YD7V%C8W)U961?93(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S$N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y787)R86YT<U]$971A:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,R+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^3F5T7VQO<W-?<&5R7W-H87)E7T1E=&%I;',\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,S,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y.971?;&]S
M<U]P97)?<VAA<F5?1&5T86EL<U\R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,T+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^4W1O8VM?87=A<F1?<&QA;E]$971A:6QS/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#,U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VM?87=A<F1?
M<&QA;E]$971A:6QS7S(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S8N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y3=&]C:U]A=V%R9%]P;&%N7T1E=&%I;'-?,SPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970S-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;6UI=&UE;G1S7V%N9%]C
M;VYT:6YG96YC:65S7S$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S@N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y#;VQL86)O<F%T:6]N7U)E=F5N=65?1&5T86EL<SPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970S.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@(#PO
M>#I%>&-E;%=O<FMS:&5E=',^#0H@(#QX.E-T>6QE<VAE970@2%)E9CTS1")7
M;W)K<VAE971S+W)E<&]R="YC<W,B+SX-"B`@/'@Z06-T:79E4VAE970^,#PO
M>#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T<G5C='5R93Y&86QS93PO
M>#I0<F]T96-T4W1R=6-T=7)E/@T*("`\>#I0<F]T96-T5VEN9&]W<SY&86QS
M93PO>#I0<F]T96-T5VEN9&]W<SX-"B`\+W@Z17AC96Q7;W)K8F]O:SX-"CPO
M>&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H
M:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC<F]S;V9T($5X8V5L
M(%A0(&]R(&YE=V5R+CPO<#X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S<R9C0T.#5A7V1D-39?-#4Y-5\X,S`U7S`P86,P,&%F
M9#AA9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\W,F8T-#@U85]D
M9#4V7S0U.35?.#,P-5\P,&%C,#!A9F0X868O5V]R:W-H965T<R]3:&5E=#`Q
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%4$-!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$
M;V-U;65N="!A;F0@16YT:71Y($EN9F]R;6%T:6]N/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^07!R+B`S,"P@,C`Q-3QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$;V-U;65N="!A;F0@
M16YT:71Y($EN9F]R;6%T:6]N/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!296=I<W1R86YT($YA;64\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/E!40R!42$5205!%551)0U,L($E.
M0RX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5N=&ET>2!#96YT<F%L($EN9&5X($ME>3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^,#`P,3`W,#`X,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@5'EP93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,3`M43QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@4&5R
M:6]D($5N9"!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y-
M87(@,S$L#0H)"3(P,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%M96YD;65N="!&;&%G/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#YF86QS93QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0W5R<F5N="!&:7-C86P@665A<B!%
M;F0@1&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^+2TQ,BTS
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^16YT:71Y($-U<G)E;G0@4F5P;W)T:6YG(%-T871U<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^665S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@1FEL97(@0V%T96=O
M<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/D%C8V5L97)A=&5D
M($9I;&5R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%;G1I='D@0V]M;6]N(%-T;V-K+"!3:&%R97,@3W5T<W1A;F1I
M;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,S+#@T."PR-S8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D1O8W5M96YT($9I<V-A;"!996%R($9O8W5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XR,#$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@4&5R:6]D($9O
M8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y1,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-S)F-#0X-6%?9&0U
M-E\T-3DU7S@S,#5?,#!A8S`P869D.&%F#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S<R9C0T.#5A7V1D-39?-#4Y-5\X,S`U7S`P86,P,&%F9#AA
M9B]7;W)K<VAE971S+U-H965T,#(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$525T%%/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,3X\<W1R;VYG/D-O;G-O;&ED871E9"!"86QA;F-E(%-H965T
M<R`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S
M<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^0W5R<F5N="!A<W-E=',Z/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@
M97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,S8L.#(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`T.2PW-#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DUA<FME=&%B;&4@<V5C=7)I=&EE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C0S+#8T,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V-2PT.3,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A
M:60@97AP96YS97,@86YD(&]T:&5R(&-U<G)E;G0@87-S971S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#$Q-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L.#@U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-E:79A8FQE
M<RP@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#$W.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L
M-#0U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&]T86P@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(X.2PW-C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS,C,L-3<Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&:7AE9"!A<W-E=',L(&YE
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PT,#@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#$U.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&5P;W-I=',@86YD(&]T:&5R(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S4Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-#@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@87-S971S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR.3DL-3(P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S,S+#(Q.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#
M=7)R96YT(&QI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R=65D
M(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,RPU
M,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR.2PQ,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D1E9F5R<F5D(')E=F5N=64\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,W,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,L,S4T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8W5R<F5N="!L:6%B:6QI
M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,L.3`U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S(L
M-#<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y/=&AE<B!L;VYG+71E<FT@;&EA8FEL:71I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(L,CDU/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPR-S<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!L:6%B:6QI
M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8L,C`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S0L
M-S4R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VUM;VX@<W1O8VLL("0P+C`P,2!P87(@=F%L=64N($%U=&AO<FEZ
M960@,3(U+#`P,"PP,#`@<VAA<F5S.R!I<W-U960@86YD(&]U='-T86YD:6YG
M(#,S+#0X,RPS,#8@<VAA<F5S(&%T($UA<F-H(#,Q+"`R,#$U+B!!=71H;W)I
M>F5D(#$R-2PP,#`L,#`P('-H87)E<SL@:7-S=65D(&%N9"!O=71S=&%N9&EN
M9R`S,BPX.3@L,SDR('-H87)E<R!A="!$96-E;6)E<B`S,2P@,C`Q-#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!P
M86ED+6EN(&-A<&ET86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C<S-"PT.#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW,C$L-S(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!8V-U;75L871E9"!O=&AE<B!C;VUP<F5H96YS
M:79E(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<S-BD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W
M,S<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!8V-U;75L871E9"!D969I8VET/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@T-C`L-#8V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#0R,BPU-3$I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@<W1O8VMH;VQD
M97)S)R!E<75I='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W
M,RPS,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR.3@L-#8W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5&]T86P@;&EA8FEL:71I97,@86YD('-T;V-K:&]L
M9&5R<R<@97%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#(Y.2PU,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#,S,RPR,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S<R9C0T.#5A7V1D-39?-#4Y-5\X,S`U7S`P86,P,&%F
M9#AA9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\W,F8T-#@U85]D
M9#4V7S0U.35?.#,P-5\P,&%C,#!A9F0X868O5V]R:W-H965T<R]3:&5E=#`S
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%-D9!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#
M;VYS;VQI9&%T960@0F%L86YC92!3:&5E=',@*%!A<F5N=&AE=&EC86PI("A5
M4T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D-O;G-O;&ED871E9"!"86QA;F-E(%-H965T
M<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM;VX@<W1O8VLL('!A<B!V86QU92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]M;6]N('-T;V-K+"!A=71H;W)I>F5D('-H87)E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3(U+#`P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C4L,#`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]M;6]N('-T;V-K+"!I<W-U960@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS,RPT.#,L,S`V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S(L.#DX+#,Y,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T
M;V-K+"!O=71S=&%N9&EN9R!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,S+#0X,RPS,#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS,BPX.3@L,SDR/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W,F8T-#@U85]D9#4V7S0U.35?
M.#,P-5\P,&%C,#!A9F0X868-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO-S)F-#0X-6%?9&0U-E\T-3DU7S@S,#5?,#!A8S`P869D.&%F+U=O<FMS
M:&5E=',O4VAE970P-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15I-044^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^0V]N<V]L:61A=&5D(%-T871E;65N=',@;V8@3W!E<F%T
M:6]N<R`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@97AC97!T(%-H87)E(&1A
M=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E=F5N=65S.CPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@<')O
M9'5C="!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#4L,#8Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VQL86)O<F%T:6]N(')E=F5N=64\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/CDL,30W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F%N="!R979E;G5E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`W-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@<F5V
M96YU97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L-#@R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PR
M,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^3W!E<F%T:6YG(&5X<&5N<V5S.CPO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@9&5V
M96QO<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W+#DS
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$U+#@X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4V5L;&EN9RP@9V5N97)A;"!A;F0@861M:6YI<W1R871I=F4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#8Q-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L-30P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5&]T86P@;W!E<F%T:6YG(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT-2PU-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR,RPT,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S(&9R;VT@;W!E<F%T:6]N
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S@L,#<Q*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$T+#(Q
M,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DEN=&5R97-T(&EN8V]M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-3(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y/=&AE<B`H97AP96YS92D@:6YC;VUE+"!N970\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,V."D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U-RD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@S-RPY,34I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q
M-"PP.3@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E=E:6=H=&5D+6%V97)A9V4@<VAA<F5S(&]U='-T
M86YD:6YG.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y"87-I8R!A;F0@9&EL=71E9"`H:6X@<VAA<F5S*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S,L,#8W+#<U,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(T+#0Y,BPT.#<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE
M="!L;W-S('!E<B!S:&%R92`M(&)A<VEC(&%N9"!D:6QU=&5D("AI;B!D;VQL
M87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H,2XQ-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B0@*#`N-3@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\W,F8T-#@U85]D9#4V7S0U.35?.#,P-5\P,&%C,#!A9F0X
M868-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-S)F-#0X-6%?9&0U
M-E\T-3DU7S@S,#5?,#!A8S`P869D.&%F+U=O<FMS:&5E=',O4VAE970P-2YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P149(04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]N
M<V]L:61A=&5D(%-T871E;65N=',@;V8@0V]M<')E:&5N<VEV92!,;W-S("A5
M4T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I
M9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P
M,34\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@
M,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY#;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!#;VUP<F5H96YS:79E
M($QO<W,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H
M,S<L.3$U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)"`H,30L,#DX*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/=&AE<B!C;VUP<F5H96YS:79E
M(&QO<W,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E5N<F5A;&EZ960@9V%I;B!O;B!M87)K971A8FQE('-E8W5R:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&;W)E:6=N
M(&-U<G)E;F-Y('1R86YS;&%T:6]N(&QO<W,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$R-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUP<F5H96YS:79E(&QO<W,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,S<L.3$T*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,30L,#@X*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-S)F-#0X
M-6%?9&0U-E\T-3DU7S@S,#5?,#!A8S`P869D.&%F#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S<R9C0T.#5A7V1D-39?-#4Y-5\X,S`U7S`P86,P
M,&%F9#AA9B]7;W)K<VAE971S+U-H965T,#8N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4U34%'
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;G-O;&ED871E9"!3=&%T96UE
M;G1S(&]F($-A<V@@1FQO=W,@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N
M;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A<V@@9FQO=W,@9G)O;2!O<&5R
M871I;F<@86-T:79I=&EE<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XD("@S-RPY,34I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XD("@Q-"PP.3@I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%D:G5S=&UE
M;G1S('1O(')E8V]N8VEL92!N970@;&]S<R!T;R!N970@8V%S:"!U<V5D(&EN
M(&]P97)A=&EN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$97!R96-I871I;VX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8S-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4X.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VAA;F=E(&EN('9A;'5A=&EO
M;B!O9B!W87)R86YT(&QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06UO<G1I>F%T:6]N(&]F('!R96UI=6US(&]N(&EN
M=F5S=&UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT.#8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#<T.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-S`U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-H
M86YG97,@:6X@;W!E<F%T:6YG(&%S<V5T<R!A;F0@;&EA8FEL:71I97,Z/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A
M:60@97AP96YS97,@86YD(&]T:&5R(&-U<G)E;G0@87-S971S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#(S,2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-3@I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-E:79A8FQE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR-C<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E
M<&]S:71S(&%N9"!O=&AE<B!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R=65D
M(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U+#4X
M.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@S+#0W,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D]T:&5R(&QO;F<M=&5R;2!L:6%B:6QI=&EE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C,I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C,I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R979E
M;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#DX,2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S.#8I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3F5T(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@86-T:79I=&EE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S8L-#(U*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$S+#0S."D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0V%S:"!F;&]W<R!F<F]M(&EN=F5S=&EN9R!A8W1I=FET:65S/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!U<F-H
M87-E<R!O9B!F:7AE9"!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#@X,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Q.#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S97,@;V8@;6%R:V5T86)L92!S96-U
M<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q.2PQ,#@I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,C4L,S4T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4V%L92`F86UP.R!R961E;7!T:6]N(&]F(&UA<FME=&%B;&4@
M<V5C=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`L
M-3DX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C$L,C<S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F5T(&-A<V@@<')O=FED960O('5S960@:6X@:6YV97-T
M:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(P+#8P-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#0L,C8W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H(&9L;W=S(&9R;VT@9FEN86YC
M:6YG(&%C=&EV:71I97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4&%Y;65N=',@;VX@;&]N9RUT97)M(&1E8G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,W*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!E
M>&5R8VES92!O9B!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS+#`Q.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F5T('!R;V-E961S(&9R;VT@<'5B;&EC(&]F9F5R:6YG
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$X+#$X,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE
M="!C87-H('!R;W9I9&5D(&)Y(&9I;F%N8VEN9R!A8W1I=FET:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#`Q.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q."PQ-#8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5F9F5C
M="!O9B!E>&-H86YG92!R871E(&-H86YG97,@;VX@8V%S:#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,3(T*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!I;F-R96%S92\H9&5C
M<F5A<V4I(&EN(&-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$R+#DR,RD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L-#0Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N
M9"!C87-H(&5Q=6EV86QE;G1S+"!B96=I;FYI;F<@;V8@<&5R:6]D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT.2PW-#@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PT,30\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@
M86YD(&-A<V@@97%U:79A;&5N=',L(&5N9"!O9B!P97)I;V0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,V+#@R-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q-2PX-34\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4W5P<&QE;65N=&%L(&1I<V-L;W-U<F4@;V8@8V%S:"!I;F9O<FUA=&EO;CPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H
M('!A:60@9F]R(&EN=&5R97-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E-U<'!L96UE;G1A;"!D:7-C;&]S=7)E<R!O9B!N
M;VXM8V%S:"!I;F9O<FUA=&EO;B!R96QA=&5D('1O(&EN=F5S=&EN9R!A;F0@
M9FEN86YC:6YG(&%C=&EV:71I97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0VAA;F=E(&EN('5N<F5A;&EZ960@9V%I;B`H
M;&]S<RD@;VX@;6%R:V5T86)L92!S96-U<FET:65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7S<R9C0T.#5A7V1D-39?-#4Y-5\X,S`U
M7S`P86,P,&%F9#AA9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\W
M,F8T-#@U85]D9#4V7S0U.35?.#,P-5\P,&%C,#!A9F0X868O5V]R:W-H965T
M<R]3:&5E=#`W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^5&AE($-O;7!A;GD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY4:&4@0V]M<&%N>3PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4:&4@0V]M<&%N>3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX@/&1I=B!S='EL93TS
M1&UA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"@D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
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M/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)
M"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O
M;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG
M/E!40R!4:&5R87!E=71I8W,L)FYB<W`[26YC+B`H=&AE($-O;7!A;GD@;W(@
M4%1#*2!W87,@:6YC;W)P;W)A=&5D(&%S(&$@1&5L87=A<F4@8V]R<&]R871I
M;VX@;VX@36%R8V@F;F)S<#LS,2P@,3DY."X@4%1#(&ES(&$@9VQO8F%L(&)I
M;W!H87)M86-E=71I8V%L(&-O;7!A;GD@9F]C=7-E9"!O;B!T:&4@9&ES8V]V
M97)Y+"!D979E;&]P;65N="!A;F0@8V]M;65R8VEA;&EZ871I;VX@;V8@;W)A
M;&QY(&%D;6EN:7-T97)E9"P@<VUA;&P@;6]L96-U;&4@=&AE<F%P975T:6-S
M('1A<F=E=&EN9R!A;B!A<F5A(&]F(%).02!B:6]L;V=Y(')E9F5R<F5D('1O
M(&%S('!O<W0M=')A;G-C<FEP=&EO;F%L(&-O;G1R;VPN(%1H92!L971T97)S
M("8C>#(P,4,[4%1#)B-X,C`Q1#L@:6X@=&AE(&-O<G!O<F%T92!N86UE(&%R
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M,T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY4:&4@0V]M<&%N>28C
M>#(P,3D[<R!L96%D('!R;V1U8W0L(%1R86YS;&%R;F$F(W@R,3(R.R`H871A
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M=7)I;F<@,C`Q-2X@4V5E("8C>#(P,4,[4FES:R!&86-T;W)S)B-X,C`Q-#M2
M:7-K<R!296QA=&5D('1O(%)E9W5L871O<GD@07!P<F]V86P@;V8@;W5R(%!R
M;V1U8W0@0V%N9&ED871E<R8C>#(P,40[(&9O<B!F=7)T:&5R(&1E=&%I;"!R
M96=A<F1I;F<@=&AE($5-028C>#(P,3D[<R!A<'!R;W9A;"!P<F]C97-S+"!I
M;F-L=61I;F<@82!D97-C<FEP=&EO;B!O9B!T:&4@<FES:RUB96YE9FET(&)A
M;&%N8V4N/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P
M="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S
M<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-
M"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z
M,3!P=#LG/E1H92!#;VUP86YY(&QA=6YC:&5D(%1R86YS;&%R;F$@;VX@82!C
M;VUM97)C:6%L(&)A<VES(&EN($=E<FUA;GD@:6X@1&5C96UB97(F;F)S<#LR
M,#$T(&%N9"!E>'!E8W1S('1O(&5X<&%N9"!I=',@;&%U;F-H(&%C=&EV:71I
M97,@86-R;W-S('1H92!%14$@=&AR;W5G:&]U="`R,#$U(&%N9"!F=71U<F4@
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M=&EO;B!D97-C<FEB960@86)O=F4N/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
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M,C`Q-2P@=&AE($-O;7!A;GD@:&%D(&%N(&%C8W5M=6QA=&5D(&1E9FEC:70@
M;V8@87!P<F]X:6UA=&5L>2`D-#8P+C0@;6EL;&EO;BX@5&AE($-O;7!A;GD@
M:&%S(&9I;F%N8V5D(&ET<R!O<&5R871I;VYS('1O(&1A=&4@<')I;6%R:6QY
M('1H<F]U9V@@<'5B;&EC(&]F9F5R:6YG<R!O9B!C;VUM;VX@<W1O8VL@:6X@
M1F5B<G5A<GDF;F)S<#LR,#$T(&%N9"!/8W1O8F5R)FYB<W`[,C`Q-"P@:71S
M(&EN:71I86P@<'5B;&EC(&]F9F5R:6YG(&]F(&-O;6UO;B!S=&]C:R!I;B!*
M=6YE)FYB<W`[,C`Q,RP@<')I=F%T92!P;&%C96UE;G1S(&]F(&ET<R!C;VYV
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M97,N/"]F;VYT/@T*"0D\+W`^#0H)"3QP/CQF;VYT('-I>F4],T0Q/B`\+V9O
M;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7S<R9C0T.#5A7V1D-39?-#4Y-5\X,S`U7S`P
M86,P,&%F9#AA9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\W,F8T
M-#@U85]D9#4V7S0U.35?.#,P-5\P,&%C,#!A9F0X868O5V]R:W-H965T<R]3
M:&5E=#`X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^4W5M;6%R>2!O9B!S:6=N:69I8V%N="!A8V-O=6YT:6YG('!O;&EC:65S
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P
M,34\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4W5M;6%R>2!O9B!S:6=N:69I8V%N="!A8V-O=6YT:6YG('!O;&EC:65S
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U
M;6UA<GD@;V8@<VEG;FEF:6-A;G0@86-C;W5N=&EN9R!P;VQI8VEE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX@/&1I=B!S='EL93TS
M1&UA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"@D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
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M,T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)
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M(&YO=&5S('1O('1H92!#;VUP86YY)B-X,C`Q.3MS(&%U9&ET960@9FEN86YC
M:6%L('-T871E;65N=',@87,@;V8@1&5C96UB97(F;F)S<#LS,2P@,C`Q-"!I
M;F-L=61E9"!I;B!T:&4@0V]M<&%N>28C>#(P,3D[<R!!;FYU86P@4F5P;W)T
M(&]N($9O<FTF;F)S<#LQ,"U+(&9I;&5D('=I=&@@=&AE(%-E8W5R:71I97,@
M86YD($5X8VAA;F=E($-O;6UI<W-I;VX@*%-%0RD@;VX@36%R8V@F;F)S<#LR
M+"`R,#$U("@R,#$T($9O<FTF;F)S<#LQ,"U+*2X\+V9O;G0^#0H)"3PO<#X-
M"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.C$P<'0[
M)SY"87-I<R!O9B!0<F5S96YT871I;VX\+V9O;G0^#0H)"3PO<#X-"@D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$P<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^5&AE(&%C8V]M<&%N>6EN9R!F:6YA
M;F-I86P@:6YF;W)M871I;VX@87,@;V8@36%R8V@F;F)S<#LS,2P@,C`Q-2!A
M;F0@9F]R('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@F;F)S<#LS,2P@
M,C`Q-2!A;F0@,C`Q-"!H87,@8F5E;B!P<F5P87)E9"!B>2!T:&4@0V]M<&%N
M>2P@=VET:&]U="!A=61I="P@<'5R<W5A;G0@=&\@=&AE(')U;&5S)FYB<W`[
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M92!#;VUP86YY)B-X,C`Q.3MS(&%U9&ET960@9FEN86YC:6%L('-T871E;65N
M=',@87,@;V8@1&5C96UB97(F;F)S<#LS,2P@,C`Q-"!A;F0@;F]T97,@=&AE
M<F5T;R!I;F-L=61E9"!I;B!T:&4@,C`Q-"!&;W)M)FYB<W`[,3`M2RX\+V9O
M;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF
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M;F-I86P@:6YF;W)M871I;VX@87,@;V8@36%R8V@F;F)S<#LS,2P@,C`Q-2!A
M;F0@9F]R('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@F;F)S<#LS,2P@
M,C`Q-2!A;F0@,C`Q-"!R969L96-T<R!A;&P@861J=7-T;65N=',L('=H:6-H
M(&%R92!N;W)M86P@<F5C=7)R:6YG(&%D:G5S=&UE;G1S+"!N96-E<W-A<GD@
M=&\@<')E<V5N="!A(&9A:7(@<W1A=&5M96YT(&]F(&9I;F%N8VEA;"!P;W-I
M=&EO;BP@<F5S=6QT<R!O9B!O<&5R871I;VYS(&%N9"!C87-H(&9L;W=S+B!4
M:&4@<F5S=6QT<R!O9B!O<&5R871I;VYS(&9O<B!T:&4@=&AR964@;6]N=&@@
M<&5R:6]D(&5N9&5D($UA<F-H)FYB<W`[,S$L(#(P,34@87)E(&YO="!N96-E
M<W-A<FEL>2!I;F1I8V%T:79E(&]F('1H92!R97-U;'1S('1O(&)E(&5X<&5C
M=&5D(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B9N8G-P.S,Q+"`R,#$U
M(&]R(&9O<B!A;GD@;W1H97(@:6YT97)I;2!P97)I;V0@;W(@9F]R(&%N>2!O
M=&AE<B!F=71U<F4@>65A<BX\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$P<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.C$P<'0[)SY5<V4@;V8@97-T
M:6UA=&5S/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P
M="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S
M<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-
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M/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)
M"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O
M;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD
M.V9O;G0M<VEZ93HQ,'!T.R<^26YV96YT;W)I97,@86YD(&-O<W0@;V8@<')O
M9'5C="!R979E;G5E/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
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M92!#;VUP86YY)B-X,C`Q.3MS(&%B:6QI='D@=&\@8V]M<&QE=&4@:71S(&=L
M;V)A;"P@8V]N9FER;6%T;W)Y(%!H87-E(#,@8VQI;FEC86P@=')I86P@:6X@
M;FT@1$U$+"!W:&EC:"!I="!R969E<G,@=&\@87,@04-4($1-1"P@86YD('-U
M8FUI="!T:&4@9FEN86P@<F5P;W)T+"!I;F-L=61I;F<@861D:71I;VYA;"!E
M9F9I8V%C>2!A;F0@<V%F971Y(&1A=&$@9G)O;2!T:&4@=')I86P@9'5R:6YG
M(#(P,34N)FYB<W`[)FYB<W`[5&AE(&QA=6YC:"!I;B!T:&5S92!C;W5N=')I
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M(%1H92!#;VUP86YY)B-X,C`Q.3MS(&-O<W0@;V8@<')O9'5C="!S86QE<R!I
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M<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE
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M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*
M"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ
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M;VYT<F%C=',@=VET:"!#=7-T;VUE<G,N($%352`R,#$T+3`Y('=I;&P@96QI
M;6EN871E('1R86YS86-T:6]N+2!A;F0@:6YD=7-T<GDM<W!E8VEF:6,@<F5V
M96YU92!R96-O9VYI=&EO;B!G=6ED86YC92!U;F1E<B!C=7)R96YT($=!05`@
M86YD(')E<&QA8V4@:70@=VET:"!A('!R:6YC:7!L92UB87-E9"!A<'!R;V%C
M:"!F;W(@9&5T97)M:6YI;F<@<F5V96YU92!R96-O9VYI=&EO;BX@05-5(#(P
M,30M,#D@=VEL;"!R97%U:7)E('1H870@8V]M<&%N:65S(')E8V]G;FEZ92!R
M979E;G5E(&)A<V5D(&]N('1H92!V86QU92!O9B!T<F%N<V9E<G)E9"!G;V]D
M<R!O<B!S97)V:6-E<R!A<R!T:&5Y(&]C8W5R(&EN('1H92!C;VYT<F%C="X@
M5&AE($%352!A;'-O('=I;&P@<F5Q=6ER92!A9&1I=&EO;F%L(&1I<V-L;W-U
M<F4@86)O=70@=&AE(&YA='5R92P@86UO=6YT+"!T:6UI;F<@86YD('5N8V5R
M=&%I;G1Y(&]F(')E=F5N=64@86YD(&-A<V@@9FQO=W,@87)I<VEN9R!F<F]M
M(&-U<W1O;65R(&-O;G1R86-T<RP@:6YC;'5D:6YG('-I9VYI9FEC86YT(&IU
M9&=M96YT<R!A;F0@8VAA;F=E<R!I;B!J=61G;65N=',@86YD(&%S<V5T<R!R
M96-O9VYI>F5D(&9R;VT@8V]S=',@:6YC=7)R960@=&\@;V)T86EN(&]R(&9U
M;&9I;&P@82!C;VYT<F%C="X@05-5(#(P,30M,#D@:7,@969F96-T:79E(&9O
M<B!A;FYU86P@<F5P;W)T:6YG('!E<FEO9',@8F5G:6YN:6YG(&%F=&5R($1E
M8V5M8F5R)FYB<W`[,34L(#(P,38N($5A<FQY(&%P<&QI8V%T:6]N(&ES(&YO
M="!P97)M:71T960N($5N=&ET:65S(&-A;B!T<F%N<VET:6]N('1O('1H92!S
M=&%N9&%R9"!E:71H97(@<F5T<F]S<&5C=&EV96QY(&]R(&%S(&$@8W5M=6QA
M=&EV92UE9F9E8W0@861J=7-T;65N="!A<R!O9B!T:&4@9&%T92!O9B!A9&]P
M=&EO;BX@4')E<V5N=&QY+"!T:&4@0V]M<&%N>2!I<R!A<W-E<W-I;F<@=VAA
M="!E9F9E8W0@=&AE(&%D;W!T:6]N(&]F($%352`R,#$T+3`Y('=I;&P@:&%V
M92!O;B!I=',@9FEN86YC:6%L('-T871E;65N=',@86YD(&%C8V]M<&%N>6EN
M9R!N;W1E<RX\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N
M8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G
M/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ
M93HQ,'!T.R<^26X@075G=7-T)FYB<W`[,C`Q-"P@=&AE($9!4T(@:7-S=65D
M($%352`R,#$T+3$U+"`F(W@R,#%#.U!R97-E;G1A=&EO;B!O9B!&:6YA;F-I
M86P@4W1A=&5M96YT<R8C>#(P,30[1V]I;F<@0V]N8V5R;B8C>#(P,30[1&ES
M8VQO<W5R97,@;V8@56YC97)T86EN=&EE<R!A8F]U="!A;B!E;G1I='DF(W@R
M,#$Y.W,@06)I;&ET>2!T;R!#;VYT:6YU92!A<R!A($=O:6YG($-O;F-E<FXN
M)B-X,C`Q1#L@05-5(#(P,30M,34@<')O=FED97,@;F5W(&=U:61A;F-E(')E
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M(&%F=&5R($1E8V5M8F5R)FYB<W`[,34L(#(P,38L(&%N9"!F;W(@86YN=6%L
M('!E<FEO9',@86YD(&EN=&5R:6T@<&5R:6]D<R!T:&5R96%F=&5R+B!4:&4@
M<F5Q=6ER96UE;G1S(&]F($%352`R,#$T+3$U(&%R92!N;W0@97AP96-T960@
M=&\@:&%V92!A('-I9VYI9FEC86YT(&EM<&%C="!O;B!T:&4@0V]N9&5N<V5D
M($-O;G-O;&ED871E9"!&:6YA;F-I86P@4W1A=&5M96YT<RX\+V9O;G0^#0H)
M"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P
M/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE
M.C$P<'0[)SY2979E;G5E(%)E8V]G;FET:6]N/"]F;VYT/@T*"0D\+W`^#0H)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/E1H92!#;VUP86YY(')E8V]G
M;FEZ97,@<F5V96YU92!W:&5N(&%M;W5N=',@87)E(')E86QI>F5D(&]R(')E
M86QI>F%B;&4@86YD(&5A<FYE9"X@4F5V96YU92!I<R!C;VYS:61E<F5D(')E
M86QI>F%B;&4@86YD(&5A<FYE9"!W:&5N('1H92!F;VQL;W=I;F<@8W)I=&5R
M:6$@87)E(&UE=#H@*#$I)FYB<W`[<&5R<W5A<VEV92!E=FED96YC92!O9B!A
M;B!A<G)A;F=E;65N="!E>&ES=',[("@R*29N8G-P.V1E;&EV97)Y(&AA<R!O
M8V-U<G)E9"!O<B!S97)V:6-E<R!H879E(&)E96X@<F5N9&5R960[("@S*29N
M8G-P.W1H92!P<FEC92!I<R!F:7AE9"!O<B!D971E<FUI;F%B;&4[(&%N9"`H
M-"DF;F)S<#MC;VQL96-T:6]N(&]F('1H92!A;6]U;G1S(&1U92!A<F4@<F5A
M<V]N86)L>2!A<W-U<F5D+CPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS
M1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3!P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M9F]N="US='EL93II=&%L:6,[9F]N="US:7IE.C$P<'0[)SY.970@4')O9'5C
M="!386QE<SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R
M<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB
M<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
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M>#(P,4,[05-#)B-X,C`Q1#LI(%-U8G1O<&EC(#8P-2TQ-2P@4F5V96YU92!2
M96-O9VYI=&EO;B8C>#(P,30[4')O9'5C=',N(%1H92!#;VUP86YY(')E8V]G
M;FEZ97,@<F5V96YU92!F<F]M('!R;V1U8W0@<V%L97,@=VAE;B!T:&5R92!I
M<R!P97)S=6%S:79E(&5V:61E;F-E('1H870@86X@87)R86YG96UE;G0@97AI
M<W1S+"!T:71L92!T;R!P<F]D=6-T(&%N9"!A<W-O8VEA=&5D(')I<VL@;V8@
M;&]S<R!H87,@<&%S<V5D('1O('1H92!C=7-T;VUE<BP@=&AE('!R:6-E(&ES
M(&9I>&5D(&]R(&1E=&5R;6EN86)L92P@8V]L;&5C=&%B:6QI='D@:7,@<F5A
M<V]N86)L>2!A<W-U<F5D(&%N9"!T:&4@0V]M<&%N>2!H87,@;F\@9G5R=&AE
M<B!P97)F;W)M86YC92!O8FQI9V%T:6]N<RX\+V9O;G0^#0H)"3PO<#X-"@D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I
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M='5T:6]N+B!0<FEO<B!T;R!*86YU87)Y)FYB<W`[,2P@,C`Q-2P@=&AE($-O
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M;F<@:6X@=&AE(&9I<G-T('%U87)T97(@;V8@,C`Q-2P@=&AE($-O;7!A;GD@
M:7,@<F5C;V=N:7II;F<@<F5V96YU92!F;W(@5')A;G-L87)N82!A<R!P<F]D
M=6-T(&ES('-H:7!P960L(&%S('1H92!#;VUP86YY(&AA<R!E<W1A8FQI<VAE
M9"!A('!A='1E<FX@;V8@8V]L;&5C=&%B:6QI='DN/"]F;VYT/@T*"0D\+W`^
M#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I
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M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.V9O;G0M<W1Y;&4Z:71A;&EC.V9O;G0M<VEZ93HQ,'!T.R<^
M0V]L;&%B;W)A=&EO;B!A;F0@1W)A;G0@4F5V96YU93PO9F]N=#X-"@D)/"]P
M/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY4:&4@=&5R;7,@;V8@
M=&AE<V4@86=R965M96YT<R!T>7!I8V%L;'D@:6YC;'5D92!P87EM96YT<R!T
M;R!T:&4@0V]M<&%N>2!O9B!O;F4@;W(@;6]R92!O9B!T:&4@9F]L;&]W:6YG
M.B!N;VYR969U;F1A8FQE+"!U<&9R;VYT(&QI8V5N<V4@9F5E<SL@;6EL97-T
M;VYE('!A>6UE;G1S.R!R97-E87)C:"!F=6YD:6YG(&%N9"!R;WEA;'1I97,@
M;VX@9G5T=7)E('!R;V1U8W0@<V%L97,N($EN(&%D9&ET:6]N+"!T:&4@0V]M
M<&%N>2!G96YE<F%T97,@<V5R=FEC92!R979E;G5E('1H<F]U9V@@86=R965M
M96YT<R!T:&%T(&=E;F5R86QL>2!P<F]V:61E(&9O<B!F965S(&9O<B!R97-E
M87)C:"!A;F0@9&5V96QO<&UE;G0@<V5R=FEC97,@86YD(&UA>2!I;F-L=61E
M(&%D9&ET:6]N86P@<&%Y;65N=',@=7!O;B!A8VAI979E;65N="!O9B!S<&5C
M:69I960@979E;G1S+CPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I
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M;W5R(&%C=&EV:71I97,@=&\@86-H:65V92!T:&4@;6EL97-T;VYE.R`H,BDF
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M"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$
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M"@D)/'`^/&9O;G0@<VEZ93TS1#$^(#PO9F]N=#X\+W`^#0H)/"]D:78^(#PO
M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M-S)F-#0X-6%?9&0U-E\T-3DU7S@S,#5?,#!A8S`P869D.&%F#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S<R9C0T.#5A7V1D-39?-#4Y-5\X,S`U
M7S`P86,P,&%F9#AA9B]7;W)K<VAE971S+U-H965T,#DN:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY&86ER('9A;'5E(&]F(&9I
M;F%N8VEA;"!I;G-T<G5M96YT<R!A;F0@;6%R:V5T86)L92!S96-U<FET:65S
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P
M,34\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^1F%I<B!V86QU92!O9B!F:6YA;F-I86P@:6YS=')U;65N=',@86YD(&UA
M<FME=&%B;&4@<V5C=7)I=&EE<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F(&9I;F%N8VEA;"!I;G-T
M<G5M96YT<R!A;F0@;6%R:V5T86)L92!S96-U<FET:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/B`\9&EV('-T>6QE/3-$;6%R9VEN
M+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I
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M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT
M/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY4
M:&4@0V]M<&%N>2!F;VQL;W=S('1H92!F86ER('9A;'5E(&UE87-U<F5M96YT
M(')U;&5S+"!W:&EC:"!P<F]V:61E<R!G=6ED86YC92!O;B!T:&4@=7-E(&]F
M(&9A:7(@=F%L=64@:6X@86-C;W5N=&EN9R!A;F0@9&ES8VQO<W5R92!F;W(@
M87-S971S(&%N9"!L:6%B:6QI=&EE<R!W:&5N('-U8V@@86-C;W5N=&EN9R!A
M;F0@9&ES8VQO<W5R92!I<R!C86QL960@9F]R(&)Y(&]T:&5R(&%C8V]U;G1I
M;F<@;&ET97)A='5R92X@5&AE<V4@<G5L97,F;F)S<#ME<W1A8FQI<V@@82!F
M86ER('9A;'5E(&AI97)A<F-H>2!F;W(@:6YP=71S('1O(&)E('5S960@=&\@
M;65A<W5R92!F86ER('9A;'5E(&]F(&9I;F%N8VEA;"!A<W-E=',@86YD(&QI
M86)I;&ET:65S+B!4:&ES(&AI97)A<F-H>2!P<FEO<FET:7IE<R!T:&4@:6YP
M=71S('1O('9A;'5A=&EO;B!T96-H;FEQ=65S('5S960@=&\@;65A<W5R92!F
M86ER('9A;'5E(&EN=&\@=&AR964@;&5V96QS.B!,979E;"`Q("AH:6=H97-T
M('!R:6]R:71Y*2P@3&5V96P@,BP@86YD($QE=F5L(#,@*&QO=V5S="!P<FEO
M<FET>2DN/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P
M="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S
M<#L\+V9O;G0^#0H)"3PO<#X-"@D)/&1I=B!S='EL93TS1'=I9'1H.C$P,"4^
M/'1A8FQE('-T>6QE/3-$=VED=&@Z,3`P)3L@8V5L;'!A9&1I;F<],T0P(&-E
M;&QS<&%C:6YG/3-$,#X\='(^/'1D('-T>6QE/3-$=VED=&@Z,3AP=#L^/'`@
M<W1Y;&4],T1W:61T:#HQ.'!T.V9O;G0M<VEZ93HP<'0[/CPO<#X\+W1D/CQT
M9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T('-T>6QE/3-$)W=I9'1H.B`P
M,"XP,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SX-"@D)"3QP('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0[;6%R
M9VEN.C!P=#LG/@T*"0D)"3QF;VYT('-T>6QE/3-$)VUA<F=I;CH@,'!T.R!F
M;VYT+7-I>F4Z(#$P<'0[)SX@)B-X0C<[/"]F;VYT/@T*"0D)/"]P/@T*"0D\
M+W1D/CQT9"!S='EL93TS1'=I9'1H.C$X<'0[/CQP('-T>6QE/3-$=VED=&@Z
M,3AP=#MW:61T:#HQ.'!T.V9O;G0M<VEZ93HP<'0[/CPO<#X\+W1D/CQT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$=&]P/@T*"0D)/'`@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P=#MM87)G
M:6XZ,'!T.R<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#LG/DQE=F5L(#$F(W@R,#$T
M.U5N861J=7-T960@<75O=&5D('!R:6-E<R!I;B!A8W1I=F4@;6%R:V5T<R!F
M;W(@:61E;G1I8V%L(&%S<V5T<R!O<B!L:6%B:6QI=&EE<R!T:&%T('1H92!#
M;VUP86YY(&AA<R!T:&4@86)I;&ET>2!T;R!A8V-E<W,@870@=&AE(&)A;&%N
M8V4@<VAE970@9&%T92X\+V9O;G0^/"]P/CPO=&0^/"]T<CX\+W1A8FQE/CPO
M9&EV/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,S9P=#MT
M97AT+6EN9&5N=#H@+3$X<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[8V]L;W(Z(S`P,#`P,#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P
M/@T*"0D\9&EV('-T>6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@<W1Y;&4],T1W
M:61T:#HQ,#`E.R!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P/CQT
M<CX\=&0@<W1Y;&4],T1W:61T:#HQ.'!T.SX\<"!S='EL93TS1'=I9'1H.C$X
M<'0[9F]N="US:7IE.C!P=#L^/"]P/CPO=&0^/'1D('9A;&EG;CTS1'1O<"!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G=VED=&@Z(#`P+C`P<'0[(&1I<W!L87DZ
M(&EN;&EN93LG/@T*"0D)/'`@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P=#MM87)G:6XZ,'!T.R<^#0H)"0D)
M/&9O;G0@<W1Y;&4],T0G;6%R9VEN.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#LG
M/B`F(WA"-SL\+V9O;G0^#0H)"0D\+W`^#0H)"3PO=&0^/'1D('-T>6QE/3-$
M=VED=&@Z,3AP=#L^/'`@<W1Y;&4],T1W:61T:#HQ.'!T.W=I9'1H.C$X<'0[
M9F]N="US:7IE.C!P=#L^/"]P/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1T;W`^#0H)"0D\<"!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,'!T.VUA<F=I;CHP<'0[)SX-"@D)"3QF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#MC
M;VQO<CHC,#`P,#`P.R<^3&5V96P@,B8C>#(P,30[26YP=71S(&]T:&5R('1H
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M=&AE(&%S<V5T(&]R(&QI86)I;&ET>2`H:2YE+BP@:6YT97)E<W0@<F%T97,L
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M87)G:6XZ,'!T(#!P="`P<'0@,S9P=#MT97AT+6EN9&5N=#H@+3$X<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)
M"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[8V]L;W(Z(S`P,#`P
M,#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\9&EV('-T>6QE/3-$=VED
M=&@Z,3`P)3X\=&%B;&4@<W1Y;&4],T1W:61T:#HQ,#`E.R!C96QL<&%D9&EN
M9STS1#`@8V5L;'-P86-I;F<],T0P/CQT<CX\=&0@<W1Y;&4],T1W:61T:#HQ
M.'!T.SX\<"!S='EL93TS1'=I9'1H.C$X<'0[9F]N="US:7IE.C!P=#L^/"]P
M/CPO=&0^/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G
M=VED=&@Z(#`P+C`P<'0[(&1I<W!L87DZ(&EN;&EN93LG/@T*"0D)/'`@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@
M,3!P=#MM87)G:6XZ,'!T.R<^#0H)"0D)/&9O;G0@<W1Y;&4],T0G;6%R9VEN
M.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B`F(WA"-SL\+V9O;G0^#0H)"0D\
M+W`^#0H)"3PO=&0^/'1D('-T>6QE/3-$=VED=&@Z,3AP=#L^/'`@<W1Y;&4]
M,T1W:61T:#HQ.'!T.W=I9'1H.C$X<'0[9F]N="US:7IE.C!P=#L^/"]P/CPO
M=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`^#0H)"0D\<"!S='EL
M93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,'!T.VUA<F=I;CHP<'0[)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.R<^3&5V96P@
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M;&4N/"]F;VYT/CPO<#X\+W1D/CPO='(^/"]T86)L93X\+V1I=CX-"@D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#,V<'0[=&5X="UI;F1E;G0Z
M("TQ.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V-O
M;&]R.B,P,#`P,#`[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.R<^0V%S:"!E
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M#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MC;VQO<CHC,#`P,#`P.R<^)FYB
M<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^
M#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE
M.C$P<'0[8V]L;W(Z(S`P,#`P,#LG/D9A:7(@=F%L=64@;V8@8V5R=&%I;B!M
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M=&AE<B!T:&%N('%U;W1E9"!P<FEC97,N/"]F;VYT/@T*"0D\+W`^#0H)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[8V]L;W(Z(S`P,#`P,#LG/B9N8G-P.SPO9F]N=#X-"@D)
M/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P
M,#`P,#`[)SY4:&4@0V]M<&%N>2!R979I97=S(&ET<R!I;G9E<W1M96YT<R!O
M;B!A('!E<FEO9&EC(&)A<VES(&9O<B!O=&AE<BUT:&%N+71E;7!O<F%R>2!I
M;7!A:7)M96YT<RX@5&AI<R!R979I97<@:7,@<W5B:F5C=&EV92P@87,@:70@
M<F5Q=6ER97,@;6%N86=E;65N="!T;R!E=F%L=6%T92!W:&5T:&5R(&%N(&5V
M96YT(&]R(&-H86YG92!I;B!C:7)C=6US=&%N8V5S(&AA<R!O8V-U<G)E9"!I
M;B!T:&%T('!E<FEO9"!T:&%T(&UA>2!H879E(&$@<VEG;FEF:6-A;G0@861V
M97)S92!E9F9E8W0@;VX@=&AE(&9A:7(@=F%L=64@;V8@=&AE(&EN=F5S=&UE
M;G0N/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^
M#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[8V]L;W(Z(S`P
M,#`P,#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$P<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[)SY4:&4@9F]L;&]W:6YG
M(')E<')E<V5N=',@=&AE(&9A:7(@=F%L=64@=7-I;F<@=&AE(&AI97)A<F-H
M>2!D97-C<FEB960@:6X@3F]T92`S(&9O<B!T:&4@0V]M<&%N>28C>#(P,3D[
M<R!F:6YA;F-I86P@87-S971S(&%N9"!L:6%B:6QI=&EE<R!T:&%T(&%R92!R
M97%U:7)E9"!T;R!B92!M96%S=7)E9"!A="!F86ER('9A;'5E(&]N(&$@<F5C
M=7)R:6YG(&)A<VES(&%S(&]F($UA<F-H)FYB<W`[,S$L(#(P,34@86YD($1E
M8V5M8F5R)FYB<W`[,S$L(#(P,30Z/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[8V]L;W(Z(S`P,#`P,#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P
M/@T*"0D\9&EV('-T>6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I
M;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P
M<V4Z8V]L;&%P<V4[=VED=&@Z(#$P,"XP,"4[;6%R9VEN+6QE9G0Z,'!T.R<^
M#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I
M9'1H.C0Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"3QF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MC;VQO<CHC,#`P,#`P.R<^)FYB<W`[
M/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X
M="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@8V]L<W!A;CTS1#$Q('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HU-2XU,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB
M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P
M="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$
M.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)
M"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z
M8F]L9#MF;VYT+7-I>F4Z.'!T.V-O;&]R.B,P,#`P,#`[)SY-87)C:"9N8G-P
M.S,Q+"9N8G-P.S(P,34\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C`P)3MP861D:6YG
M.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO
M<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-#$N,#`E.W!A9&1I;F<Z,'!T
M.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V-O;&]R.B,P,#`P,#`[)SXF;F)S<#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P
M)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)
M"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)O<F1E<BUT
M;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$
M.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E
M<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*"0D)
M"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[
M=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93H@.'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[8V]L
M;W(Z(S`P,#`P,#LG/E1O=&%L/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)
M"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[<&%D
M9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M
M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S
M<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P
M="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@
M.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H
M=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA
M;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@.'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[8V]L;W(Z(S`P
M,#`P,#LG/E%U;W1E9"9N8G-P.W!R:6-E<SPO9F]N=#X\8G(@+SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT
M+7-I>F4Z.'!T.V-O;&]R.B,P,#`P,#`[)SYI;B9N8G-P.V%C=&EV93PO9F]N
M=#X\8G(@+SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW
M96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.V-O;&]R.B,P,#`P,#`[)SYM87)K
M971S)FYB<W`[9F]R/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[8V]L
M;W(Z(S`P,#`P,#LG/FED96YT:6-A;"9N8G-P.V%S<V5T<SPO9F]N=#X\8G(@
M+SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z
M8F]L9#MF;VYT+7-I>F4Z.'!T.V-O;&]R.B,P,#`P,#`[)SXH;&5V96PF;F)S
M<#LQ*3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#HQ,BXP,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y
M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M
M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y
M1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)
M"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG
M:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.V-O;&]R.B,P,#`P,#`[)SY3:6=N:69I
M8V%N=#PO9F]N=#X\8G(@+SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.V-O;&]R.B,P,#`P
M,#`[)SYO=&AE<CPO9F]N=#X\8G(@+SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.V-O;&]R
M.B,P,#`P,#`[)SYO8G-E<G9A8FQE/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ
M93HX<'0[8V]L;W(Z(S`P,#`P,#LG/FEN<'5T<SPO9F]N=#X\8G(@+SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF
M;VYT+7-I>F4Z.'!T.V-O;&]R.B,P,#`P,#`[)SXH;&5V96PF;F)S<#LR*3PO
M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M
M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HQ,BXP,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D
M97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S
M;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[
M<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L
M9#MF;VYT+7-I>F4Z.'!T.V-O;&]R.B,P,#`P,#`[)SY3:6=N:69I8V%N=#PO
M9F]N=#X\8G(@+SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N
M="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.V-O;&]R.B,P,#`P,#`[)SYU
M;F]B<V5R=F%B;&4\+V9O;G0^/&)R("\^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#MC;VQO
M<CHC,#`P,#`P.R<^:6YP=71S/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX
M<'0[8V]L;W(Z(S`P,#`P,#LG/BAL979E;"9N8G-P.S,I/"]F;VYT/CPO<#X-
M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W
M:61T:#HP,2XP,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC96YT
M97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P
M="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)
M"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#HT
M,2XP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG
M/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)
M"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P
M=#MC;VQO<CHC,#`P,#`P.R<^36%R:V5T86)L92!S96-U<FET:65S(#PO9F]N
M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M,#$N,S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL
M969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG
M<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)
M"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ
M,'!T.V-O;&]R.B,P,#`P,#`[)SXD/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`N-S`E
M.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P
M="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$
M.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M
M8V]L;W(Z("-#0T5%1D8[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W
M<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/C(T,RPV-#(F;F)S
M<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS
M,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z
M,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$
M.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N
M9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[
M8V]L;W(Z(S`P,#`P,#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F]R
M9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO
M;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB
M;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO
M<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIR:6=H
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T
M)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.R<^)B-X,C`Q-#L\+V9O;G0^/"]P
M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D
M:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M
M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C,P
M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ
M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y
M1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD
M+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#MC
M;VQO<CHC,#`P,#`P.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P+C<P)3MB;W)D
M97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N
M92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O
M<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R
M.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\
M9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-#,L-C0R)FYB<W`[#0H)
M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z
M,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)
M"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,S`E.V)O
M<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N
M;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[
M8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L
M;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.V-O;&]R
M.B,P,#`P,#`[)SXD/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`N-S`E.V)O<F1E<BUT
M;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$
M.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R
M+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ<FEG:'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)
M"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE
M.C$P<'0[8V]L;W(Z(S`P,#`P,#LG/B8C>#(P,30[/"]F;VYT/CPO<#X-"@D)
M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,#$N,#`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP
M<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\
M+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@<W1Y;&4],T1W
M:61T:#HT,2XP,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E
M>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.R<^5V%R
M<F%N="!L:6%B:6QI='D@/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[<&%D9&EN
M9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I
M9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C$R+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^
M/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,C(Y)FYB<W`[#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*
M"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1'=I9'1H.C$R+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT
M+6%L:6=N.G)I9VAT.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[)SXF(W@R,#$T
M.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X]
M,T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$R+C`P)3MP861D
M:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.G)I9VAT.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.V-O;&]R
M.B,P,#`P,#`[)SXF(W@R,#$T.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A
M9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
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M9'1H.C`Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO
M<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)/"]T86)L93X\+V1I=CX-"@D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93MC;VQO<CHC,#`P,#`P.R<^)FYB<W`[/"]F;VYT/@T*
M"0D\+W`^#0H)"3QD:78@<W1Y;&4],T1W:61T:#HQ,#`E/CQT86)L92!C96QL
M<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V)O<F1E<BUC
M;VQL87!S93IC;VQL87!S93MW:61T:#H@,3`P+C`P)3MM87)G:6XM;&5F=#HP
M<'0[)SX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$=VED=&@Z-#$N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V-O;&]R.B,P,#`P,#`[)SXF
M;F)S<#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,3$@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C4U+C4P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y
M1#D@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T
M;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C
M1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G
M:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC96YT97([
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@.'!T)SX-
M"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E
M:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[8V]L;W(Z(S`P,#`P,#LG/D1E8V5M
M8F5R)FYB<W`[,S$L)FYB<W`[,C`Q-#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,#`E
M.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)
M)FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)
M"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HT,2XP,"4[<&%D
M9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M
M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@,3)P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[8V]L;W(Z(S`P,#`P,#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)
M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED
M=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G
M/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P
M86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[
M8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P
M,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T
M.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE
M.CAP=#MC;VQO<CHC,#`P,#`P.R<^5&]T86P\+V9O;G0^/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R
M+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)
M"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$
M,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)O<F1E
M<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R
M9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#MC
M;VQO<CHC,#`P,#`P.R<^475O=&5D)FYB<W`[/"]F;VYT/CQB<B`O/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O
M;G0M<VEZ93HX<'0[8V]L;W(Z(S`P,#`P,#LG/G!R:6-E<SPO9F]N=#X\8G(@
M+SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z
M8F]L9#MF;VYT+7-I>F4Z.'!T.V-O;&]R.B,P,#`P,#`[)SYI;B9N8G-P.V%C
M=&EV93PO9F]N=#X\8G(@+SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.V-O;&]R.B,P,#`P
M,#`[)SYM87)K971S)FYB<W`[9F]R/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ
M93HX<'0[8V]L;W(Z(S`P,#`P,#LG/FED96YT:6-A;"9N8G-P.SPO9F]N=#X\
M8G(@+SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG
M:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.V-O;&]R.B,P,#`P,#`[)SYA<W-E=',\
M+V9O;G0^/&)R("\^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O
M;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#MC;VQO<CHC,#`P,#`P.R<^
M*&QE=F5L)FYB<W`[,2D\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG
M.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO
M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z,7!T(&YO
M;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R
M9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P
M="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N
M.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#MC;VQO<CHC,#`P,#`P
M.R<^4VEG;FEF:6-A;G0\+V9O;G0^/&)R("\^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#MC
M;VQO<CHC,#`P,#`P.R<^;W1H97(\+V9O;G0^/&)R("\^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE
M.CAP=#MC;VQO<CHC,#`P,#`P.R<^;V)S97)V86)L93PO9F]N=#X\8G(@+SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L
M9#MF;VYT+7-I>F4Z.'!T.V-O;&]R.B,P,#`P,#`[)SYI;G!U=',\+V9O;G0^
M/&)R("\^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I
M9VAT.F)O;&0[9F]N="US:7IE.CAP=#MC;VQO<CHC,#`P,#`P.R<^*&QE=F5L
M)FYB<W`[,BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)
M"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y
M1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O
M='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE
M("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E
M<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`X<'0G
M/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M
M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#MC;VQO<CHC,#`P,#`P.R<^4VEG
M;FEF:6-A;G0\+V9O;G0^/&)R("\^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#MC;VQO<CHC
M,#`P,#`P.R<^=6YO8G-E<G9A8FQE/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ
M93HX<'0[8V]L;W(Z(S`P,#`P,#LG/FEN<'5T<SPO9F]N=#X\8G(@+SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF
M;VYT+7-I>F4Z.'!T.V-O;&]R.B,P,#`P,#`[)SXH;&5V96PF;F)S<#LS*3PO
M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M
M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@<W1Y;&4]
M,T0G=VED=&@Z-#$N,#`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@
M,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P
M="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N
M="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#LG/DUA<FME=&%B;&4@<V5C=7)I
M=&EE<R`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO
M<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P
M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M
M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$
M.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF
M;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.R<^)#PO9F]N=#X\+W`^#0H)
M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C$P+C<P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D
M97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N
M;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB
M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO
M=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR
M-C4L-#DS)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C
M0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-
M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,#$N,S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O
M<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@
M.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G
M/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M
M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[)SXD/"]F;VYT/CPO<#X-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M,3`N-S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL
M969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG
M<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M
M86QI9VXZ<FEG:'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#LG/B8C>#(P,30[
M/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HP,2XS,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R
M9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@
M;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[
M8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)
M"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^
M#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US
M:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ
M,"XW,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE
M9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R
M;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`]
M,T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,C8U+#0Y
M,R9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&
M1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T
M.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M
M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE
M("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K
M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)
M"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z
M,3!P=#MC;VQO<CHC,#`P,#`P.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P+C<P
M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ
M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y
M1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD
M+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N
M.G)I9VAT.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[)SXF(W@R,#$T.SPO9F]N
M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\
M+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P
M('-T>6QE/3-$=VED=&@Z-#$N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P
M,#`P,#LG/E=A<G)A;G0@3&EA8FEL:71Y(#PO9F]N=#X\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N
M-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)
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M93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N
M8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ,BXP,"4[<&%D9&EN9SHP<'0[
M/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P
M-BXV-R4[=&5X="UA;&EG;CIR:6=H=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P
M.R<^)B-X,C`Q-#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P
M=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ
M,BXP,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ
M,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIR:6=H=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)
M"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z
M,3!P=#MC;VQO<CHC,#`P,#`P.R<^)B-X,C`Q-#L\+V9O;G0^/"]P/@T*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H
M.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-
M"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.SMF;VYT+69A;6EL>3I4:6UE<R!.
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M"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"3PO=&%B;&4^
M/"]D:78^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[8V]L;W(Z(S`P,#`P,#LG/B9N8G-P
M.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*
M"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ
M,'!T.V-O;&]R.B,P,#`P,#`[)SY4:&4@9F]L;&]W:6YG(&ES(&$@<W5M;6%R
M>2!O9B!M87)K971A8FQE('-E8W5R:71I97,@86-C;W5N=&5D(&9O<B!A<R!A
M=F%I;&%B;&4M9F]R+7-A;&4@<V5C=7)I=&EE<R!A="!-87)C:"9N8G-P.S,Q
M+"`R,#$U(&%N9"!$96-E;6)E<B9N8G-P.S,Q+"`R,#$T.CPO9F]N=#X-"@D)
M/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.V-O;&]R.B,P,#`P,#`[)SXF;F)S<#L\
M+V9O;G0^#0H)"3PO<#X-"@D)/&1I=B!S='EL93TS1'=I9'1H.C$P,"4^/'1A
M8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G
M8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.W=I9'1H.B`Q,#`N,#`E.VUA<F=I
M;BUL969T.C!P=#LG/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T1W:61T:#HT,2XP,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)
M"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[8V]L;W(Z(S`P
M,#`P,#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z
M,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P
M/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0Q,2!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z-34N-3`E.V)O<F1E<BUT;W`Z,7!T(&YO
M;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R
M9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P
M="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N
M.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#MC;VQO<CHC,#`P,#`P
M.R<^36%R8V@F;F)S<#LS,2PF;F)S<#LR,#$U/"]F;VYT/CPO<#X-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP
M,2XP,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ
M,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC96YT97([9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)
M"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C0Q+C`P
M)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93MC;VQO<CHC,#`P,#`P.R<^)FYB<W`[/"]F;VYT/CPO
M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T1W:61T:#HP,BXU,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS
M1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC
M96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@
M,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R
M+C`P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F
M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$
M.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG
M.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I
M9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@.'!T)SX-"@D)"0D)"3QF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M
M<VEZ93HX<'0[8V]L;W(Z(S`P,#`P,#LG/D%M;W)T:7IE9#PO9F]N=#X\+W`^
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N
M=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R
M<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O
M;'-P86X],T0U('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HR-BXU
M,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ
M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P
M,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP
M<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I
M>F4Z.'!T.V-O;&]R.B,P,#`P,#`[)SY'<F]S<R9N8G-P.U5N<F5A;&EZ960\
M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT
M+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*
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M+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[8V]L;W(Z(S`P,#`P,#LG/D9A
M:7(\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1'=I9'1H.C`Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT
M97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D
M/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$=VED=&@Z-#$N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)
M"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V-O;&]R.B,P,#`P
M,#`[)SXF;F)S<#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P
M=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-
M"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R
M+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N
M;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E
M;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`X
M<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O
M;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#MC;VQO<CHC,#`P,#`P.R<^
M0V]S=#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#HQ,BXP,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P
M,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O
M;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$
M.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`X<'0G/@T*
M"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I
M9VAT.F)O;&0[9F]N="US:7IE.CAP=#MC;VQO<CHC,#`P,#`P.R<^1V%I;G,\
M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT
M+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R
M9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@
M<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@
M.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O
M;&0[9F]N="US:7IE.CAP=#MC;VQO<CHC,#`P,#`P.R<^3&]S<V5S/"]F;VYT
M/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T1W:61T:#HP,BXU,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG
M;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C$R+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL
M969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED
M(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D
M:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M
M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@.'!T)SX-"@D)"0D)"3QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O
M;G0M<VEZ93HX<'0[8V]L;W(Z(S`P,#`P,#LG/E9A;'5E/"]F;VYT/CPO<#X-
M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W
M:61T:#HP,2XP,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC96YT
M97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P
M="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)
M"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#HT
M,2XP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG
M/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)
M"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P
M=#MC;VQO<CHC,#`P,#`P.R<^0V]M;65R8VEA;"!P87!E<B`\+V9O;G0^/"]P
M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D
M:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M
M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C,P
M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ
M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y
M1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD
M+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#MC
M;VQO<CHC,#`P,#`P.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P+C<P)3MB;W)D
M97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N
M92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O
M<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R
M.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\
M9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ.2PW-#@-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N
M-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R
M<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS,"4[8F]R9&5R+71O
M<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y
M1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M
M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#
M145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ
M,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P
M,#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F]R9&5R+71O<#HQ<'0@
M<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[
M8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z
M,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E
M>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS
M1&9L;V%T.FQE9G0^/"]D:78^,C8-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M
M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB
M<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#HP,2XS,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P
M,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O
M='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P
M=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT
M.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#LG/B0\+V9O;G0^/"]P
M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HQ,"XW,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[
M8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ
M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$
M.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*
M"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV
M-R4[=&5X="UA;&EG;CIR:6=H=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.R<^
M)B-X,C`Q-#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC
M;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS
M1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S
M<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P
M,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T
M=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C
M1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T
M.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.R<^)#PO9F]N=#X\+W`^
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C$P+C<P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB
M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P
M="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y
M(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG
M(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I
M=CXQ.2PW-S0-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=VED=&@Z,#$N,#`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%
M1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)
M"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T
M;W`@<W1Y;&4],T1W:61T:#HT,2XP,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC
M,#`P,#`P.R<^0V]R<&]R871E(&1E8G0@<V5C=7)I=&EE<R`\+V9O;G0^/"]P
M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P
M.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H
M=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\
M+V1I=CXQ.#8L.#$P#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X]
M,T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT
M+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F
M;&]A=#IL969T/CPO9&EV/C0T#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R
M<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O
M;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP
M,"4[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y
M;&4],T1F;&]A=#IL969T/CPO9&EV/B@S,C`-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[/@T*"0D)
M"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^
M#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US
M:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO
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M+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HT,2XP,"4[8F%C:V=R;W5N
M9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P
M.R<^1V]V97)N;65N="!O8FQI9V%T:6]N<R`\+V9O;G0^/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP
M,BXU,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG
M/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P
M-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@
M,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R
M+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL969T
M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P
M,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O
M=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS
M1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS-RPS-#8-
M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN
M9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HQ,BXP,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D
M97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S
M;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[
M8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N
M;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^
M,C$-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HQ,BXP,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB
M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P
M="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$
M.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[
M)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D
M:78^*#,S#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.R<^*3PO9F]N=#X\+W`^
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE
M("-$.40Y1#D@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E
M<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@
M;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA
M;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO
M870Z;&5F=#X\+V1I=CXS-RPS,S0-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,#`E.V)A8VMG<F]U;F0M
M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB
M<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HT,2XP,"4[<&%D9&EN
M9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@
M,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
M"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MC;VQO<CHC
M,#`P,#`P.R<^)FYB<W`[/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[<&%D9&EN
M9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I
M9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C,P)3MB
M;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@
M;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P
M,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T
M.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.R<^)#PO9F]N=#X\+W`^
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C$P+C<P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB
M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P
M="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y
M1#D@.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T
M>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-#,L.3`T#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A
M9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS
M,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z
M,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE(",P
M,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG
M.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I
M9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#LG/B0\+V9O;G0^
M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#HQ,"XW,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P
M,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O
M;3HR<'0@9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C
M1#E$.40Y(#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I
M=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^.3$-"@D)"0D\+W1D/@T*"0D)
M"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[<&%D
M9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M
M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C,P
M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ
M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P
M,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z
M,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.R<^)#PO9F]N=#X\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C$P+C<P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P
M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M
M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$
M.40Y1#D@.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV
M('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,S4S#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P
M<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O
M;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[)SXI/"]F;VYT/CPO<#X-"@D)
M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,#$N,S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E
M<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,G!T(&1O
M=6)L92`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[
M<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[)SXD
M/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z,3`N-S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED
M(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E
M<BUB;W1T;VTZ,G!T(&1O=6)L92`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
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M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^
M#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"3PO=&%B;&4^/"]D:78^#0H)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[8V]L;W(Z(S`P,#`P,#LG/B9N8G-P.SPO9F]N=#X-"@D)
M/"]P/@T*"0D\9&EV('-T>6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A
M9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D97(M8V]L
M;&%P<V4Z8V]L;&%P<V4[=VED=&@Z(#$P,"XP,"4[;6%R9VEN+6QE9G0Z,'!T
M.R<^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1'=I9'1H.C0Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"3QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MC;VQO<CHC,#`P,#`P.R<^)FYB
M<W`[/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[<&%D9&EN9SHP<'0[/@T*"0D)
M"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[
M=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#$Q('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#HU-2XU,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y
M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M
M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y
M1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)
M"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG
M:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.V-O;&]R.B,P,#`P,#`[)SY$96-E;6)E
M<B9N8G-P.S,Q+"9N8G-P.S(P,30\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C`P)3MP
M861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N
M8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-#$N,#`E.W!A9&1I
M;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V-O;&]R.B,P,#`P,#`[)SXF;F)S<#L\+V9O;G0^/"]P/@T*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H
M.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
M"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N
M/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)O
M<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N
M;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[
M8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP
M=#MC;VQO<CHC,#`P,#`P.R<^06UO<G1I>F5D/"]F;VYT/CPO<#X-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP
M,BXU,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ
M,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC96YT97([9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)
M"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS
M1#4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C(V+C4P)3MB;W)D
M97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL969T.C%P="!N;VYE
M("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O
M<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*
M"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV
M-R4[=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93H@.'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[
M8V]L;W(Z(S`P,#`P,#LG/D=R;W-S)FYB<W`[56YR96%L:7IE9#PO9F]N=#X\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ
M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$R
M+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)
M"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT
M.F)O;&0[9F]N="US:7IE.CAP=#MC;VQO<CHC,#`P,#`P.R<^1F%I<CPO9F]N
M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI
M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\
M+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T1W:61T:#HT,2XP,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS
M1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0D\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[8V]L;W(Z(S`P,#`P,#LG/B9N
M8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#HQ,BXP,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y
M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M
M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y
M1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)
M"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG
M:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.V-O;&]R.B,P,#`P,#`[)SY#;W-T/"]F
M;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T1W:61T:#HP,BXU,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA
M;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D
M97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S
M;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[
M<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L
M9#MF;VYT+7-I>F4Z.'!T.V-O;&]R.B,P,#`P,#`[)SY'86EN<SPO9F]N=#X\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ
M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ
M,BXP,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F
M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C
M,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN
M9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT
M+7-I>F4Z.'!T.V-O;&]R.B,P,#`P,#`[)SY,;W-S97,\+V9O;G0^/"]P/@T*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I
M9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E
M<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T
M)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS
M<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E
M.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P
M,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T
M.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE
M.CAP=#MC;VQO<CHC,#`P,#`P.R<^5F%L=64\+V9O;G0^/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q
M+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)
M"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-
M"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.C0Q+C`P)3MB
M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I
M9VAT.C$P-BXV-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.V-O;&]R
M.B,P,#`P,#`[)SY#;W)P;W)A=&4@9&5B="!S96-U<FET:65S(#PO9F]N=#X\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A
M9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N
M,S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T
M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y
M1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U
M;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T
M.V-O;&]R.B,P,#`P,#`[)SXD/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)
M"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`N-S`E.V)O
M<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N
M;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[
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M,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[
M)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS,"4[8F]R9&5R
M+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D
M97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@
M(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G
M:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P
M,#`P,#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F]R9&5R+71O<#HQ
M<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$
M.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG
M:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&
M1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL
M93TS1&9L;V%T.FQE9G0^/"]D:78^.#`-"@D)"0D\+W1D/@T*"0D)"3QT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U
M;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)
M)FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HP,2XS,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@
M(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R
M+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO
M;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG
M.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I
M9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#LG/B0\+V9O;G0^
M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#HQ,"XW,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P
M,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O
M;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y
M1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG
M:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^
M/"]D:78^*#0R.`T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#
M145&1CLG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I
M9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#LG/BD\+V9O;G0^
M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#HP,2XS,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P
M,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O
M;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y
M1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG
M/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P
M-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@
M,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#LG/B0\+V9O;G0^/"]P/@T*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HQ,"XW,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R
M9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@
M;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[
M8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N
M;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^
M,C,P+#`S,0T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#HP,2XP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&
M1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T
M.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)
M/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O
M<"!S='EL93TS1'=I9'1H.C0Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT
M.C$P-BXV-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P
M,#`P,#`[)SY';W9E<FYM96YT(&]B;&EG871I;VYS(#PO9F]N=#X\+W`^#0H)
M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED
M=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P
M/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[8F]R9&5R+71O<#HQ<'0@;F]N
M92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D
M97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W
M<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/C,U+#4P,0T*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H
M.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-
M"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R
M+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N
M;VYE("-$.40Y1#D@.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A
M<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXW#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E
M.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#HQ,BXP,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y
M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M
M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y
M1#E$.2`[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@
M<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/B@T-@T*"0D)"3PO=&0^#0H)"0D)
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3L^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T
M)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.R<^*3PO9F]N=#X\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y
M1#D@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T
M;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C
M1#E$.40Y(#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I
M=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,S4L-#8R#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,#`E
M.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO
M=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z-#$N,#`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN
M9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3)P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[8V]L;W(Z(S`P,#`P,#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T
M.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,S`E.V)O<F1E
M<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE
M("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,G!T(&1O=6)L92`C,#`P,#`P(#MB
M;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO
M<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[8V]L;W(Z
M(S`P,#`P,#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F]R9&5R+71O
M<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y
M1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@.V)O<F1E
M<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C
M0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV
M('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-C4L.#@P#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P
M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T
M)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,S`E.V)O<F1E<BUT;W`Z
M,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y
M1#D@.V)O<F1E<BUB;W1T;VTZ,G!T(&1O=6)L92`C,#`P,#`P(#MB;W)D97(M
M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#
M145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ
M,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P
M,#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F]R9&5R+71O<#HQ<'0@
M<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[
M8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUR:6=H
M=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
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M;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C
M,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M
M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N
M;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN
M9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[)SXD/"]F;VYT
M/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,3`N-S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P
M,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T
M;VTZ,G!T(&1O=6)L92`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ
M<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE
M9G0^/"]D:78^*#0W-`T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO<CH@
M(T-#145&1CLG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M
M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#LG/BD\+V9O
M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#HP,2XS,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P
M,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O
M='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N
M92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z
M,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.R<^)#PO9F]N=#X\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C$P+C<P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P
M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M
M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$
M.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I
M9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T
M/CPO9&EV/C(V-2PT.3,-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,#`E.V)A8VMG<F]U;F0M8V]L;W(Z
M("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P
M/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D\+W1A8FQE/CPO9&EV/@T*"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.V-O;&]R.B,P,#`P,#`[)SXF;F)S<#L\+V9O;G0^#0H)
M"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC
M,#`P,#`P.R<^070@36%R8V@F;F)S<#LS,2P@,C`Q-2!A;F0@1&5C96UB97(F
M;F)S<#LS,2P@,C`Q-"P@=&AE($-O;7!A;GD@:&5L9"!S96-U<FET:65S('=I
M=&@@86X@=6YR96%L:7IE9"!L;W-S('!O<VET:6]N('1H870@=V5R92!N;W0@
M8V]N<VED97)E9"!T;R!B92!O=&AE<BUT:&%N+71E;7!O<F%R:6QY(&EM<&%I
M<F5D(&%S('1H92!#;VUP86YY(&AA<R!T:&4@86)I;&ET>2!T;R!H;VQD('-U
M8V@@:6YV97-T;65N=',@=6YT:6P@<F5C;W9E<GD@;V8@=&AE:7(@9F%I<B!V
M86QU92X\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93MC;VQO<CHC,#`P,#`P.R<^)FYB<W`[/"]F;VYT/@T*"0D\
M+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P
M,#`P,#LG/DUA<FME=&%B;&4@<V5C=7)I=&EE<R!O;B!T:&4@8F%L86YC92!S
M:&5E="!A="!-87)C:"9N8G-P.S,Q+"`R,#$U(&%N9"!$96-E;6)E<B9N8G-P
M.S,Q+"`R,#$T(&UA='5R92!A<R!F;VQL;W=S.CPO9F]N=#X-"@D)/"]P/@T*
M"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.W1E>'0M86QI9VXZ8V5N=&5R.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V-O;&]R.B,P,#`P
M,#`[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/&1I=B!S='EL93TS1'=I
M9'1H.C$P,"4^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS
M1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.W=I9'1H.B`Q
M,#`N,#`E.VUA<F=I;BUL969T.C!P=#LG/@T*"0D)/'1R/@T*"0D)"3QT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HW,"XP,"4[<&%D9&EN9SHP
M<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT
M.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3)P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[8V]L;W(Z(S`P,#`P,#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N
M-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)
M"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0U
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HR-BXU,"4[8F]R9&5R
M+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D
M97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.V-O
M;&]R.B,P,#`P,#`[)SY-87)C:"9N8G-P.S,Q+"9N8G-P.S(P,34\+V9O;G0^
M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1'=I9'1H.C`Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N
M.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T
M<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M=VED=&@Z-S`N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V-O;&]R.B,P,#`P,#`[)SXF;F)S
M<#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT
M97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@
M.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ
M,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$
M.40Y(#MP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ
M,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC96YT97([9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@.'!T)SX-"@D)
M"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H
M=#IB;VQD.V9O;G0M<VEZ93HX<'0[8V]L;W(Z(S`P,#`P,#LG/DQE<W,F;F)S
M<#M4:&%N/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[8V]L;W(Z(S`P
M,#`P,#LG/C$R)FYB<W`[36]N=&AS/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[
M<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI
M;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF
M;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P
M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y
M1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR
M:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*"0D)"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X
M="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@.'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[8V]L;W(Z
M(S`P,#`P,#LG/DUO<F4F;F)S<#M4:&%N/"]F;VYT/CQB<B`O/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M
M<VEZ93HX<'0[8V]L;W(Z(S`P,#`P,#LG/C$R)FYB<W`[36]N=&AS/"]F;VYT
M/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T1W:61T:#HP,2XP,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG
M;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO
M='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1"=W
M:61T:#HW,"XP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG
M.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@
M,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-
M"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I
M>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.R<^0V]M;65R8VEA;"!P87!E<B`\+V9O
M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&
M1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T
M.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M
M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE
M("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K
M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)
M"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z
M,3!P=#MC;VQO<CHC,#`P,#`P.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P+C<P
M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ
M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y
M1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD
M+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO
M=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ.2PW-S0F;F)S
M<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS
M,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z
M,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$
M.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N
M9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[
M8V]L;W(Z(S`P,#`P,#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F]R
M9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO
M;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB
M;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO
M<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIR:6=H
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T
M)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.R<^)B-X,C`Q-#L\+V9O;G0^/"]P
M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HP,2XP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D
M:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M
M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-
M"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL
M93TS1'=I9'1H.C<P+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV
M-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[
M)SY#;W)P;W)A=&4@9&5B="!S96-U<FET:65S(#PO9F]N=#X\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*
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M"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS
M1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P)3L[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M
M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L
M;V%T.FQE9G0^/"]D:78^-#@L,C(X)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I
M;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@<W1Y;&4]
M,T0G=VED=&@Z-S`N,#`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@
M,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P
M="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N
M="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#LG/D=O=F5R;FUE;G0@;V)L:6=A
M=&EO;G,@/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L
M;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[
M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[8F]R9&5R+71O<#HQ<'0@
M;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB
M;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z
M,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E
M>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS
M1&9L;V%T.FQE9G0^/"]D:78^,3$L,S$R)FYB<W`[#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB
M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
M"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N
M/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)O
M<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO
M;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[
M8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L
M;W(Z("-#0T5%1D8[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P
M/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/C(V+#`R,B9N8G-P.PT*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HP,2XP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG
M.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I
M9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS
M1'=I9'1H.C<P+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[
M=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[)SY4
M;W1A;"!-87)K971A8FQE('-E8W5R:71I97,@/"]F;VYT/CPO<#X-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP
M,BXU,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ
M,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)
M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D
M97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D
M;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@
M.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.R<^
M)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.C$P+C<P)3MB;W)D97(M=&]P.C%P="!S;VQI
M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D
M97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P
M="!N;VYE("-$.40Y1#D@.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO
M=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ-CDL,SDR)FYB
M<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB
M<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#HP,2XS,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P
M,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O
M='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N
M92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[8V]L;W(Z
M(S`P,#`P,#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F]R9&5R+71O
M<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y
M1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@.V)O<F1E
M<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#L[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N
M;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^
M-S0L,C4P)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D\+W1A
M8FQE/CPO9&EV/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V-O;&]R.B,P,#`P,#`[)SXF
M;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/&1I=B!S='EL93TS1'=I9'1H.C$P
M,"4^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y
M;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.W=I9'1H.B`Q,#`N,#`E
M.VUA<F=I;BUL969T.C!P=#LG/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HW,"XP,"4[<&%D9&EN9SHP<'0[/@T*
M"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV
M-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P
M="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[8V]L
M;W(Z(S`P,#`P,#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A
M9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB
M<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0U('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HR-BXU,"4[8F]R9&5R+71O<#HQ
M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y
M(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG
M:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M
M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.V-O;&]R.B,P
M,#`P,#`[)SY$96-E;6)E<B9N8G-P.S,Q+"9N8G-P.S(P,30\+V9O;G0^/"]P
M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1'=I9'1H.C`Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E
M;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-
M"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED
M=&@Z-S`N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.V-O;&]R.B,P,#`P,#`[)SXF;F)S<#L\
M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT
M+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O
M<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T
M('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y
M(#MP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T
M.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC96YT97([9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@.'!T)SX-"@D)"0D)
M"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB
M;VQD.V9O;G0M<VEZ93HX<'0[8V]L;W(Z(S`P,#`P,#LG/DQE<W,F;F)S<#M4
M:&%N/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[8V]L;W(Z(S`P,#`P
M,#LG/C$R)FYB<W`[36]N=&AS/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)
M"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[<&%D
M9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M
M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S
M<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P
M="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@
M.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H
M=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA
M;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@.'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[8V]L;W(Z(S`P
M,#`P,#LG/DUO<F4F;F)S<#M4:&%N/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ
M93HX<'0[8V]L;W(Z(S`P,#`P,#LG/C$R)FYB<W`[36]N=&AS/"]F;VYT/CPO
M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T1W:61T:#HP,2XP,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS
M1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC
M96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@
M,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^
M#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T
M:#HW,"XP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P
M=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P
M=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)
M"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z
M,3!P=#MC;VQO<CHC,#`P,#`P.R<^0V]R<&]R871E(&1E8G0@<V5C=7)I=&EE
M<R`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO<CH@
M(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G
M:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB
M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P
M="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y
M(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T
M)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.R<^)#PO9F]N=#X\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C$P+C<P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M
M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE
M("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K
M9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A
M<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ-3<L
M-S4X)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%
M149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)
M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,#$N,S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E
M<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO
M;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A
M8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*
M"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ
M93HQ,'!T.V-O;&]R.B,P,#`P,#`[)SXD/"]F;VYT/CPO<#X-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`N
M-S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T
M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y
M1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U
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M.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T
M9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S
M='EL93TS1'=I9'1H.C<P+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P
M-BXV-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P
M,#`[)SY';W9E<FYM96YT(&]B;&EG871I;VYS(#PO9F]N=#X\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*
M"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M
M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO
M;F4@(T0Y1#E$.2`[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P
M/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/C8L,#`S)FYB<W`[#0H)
M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED
M=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P
M/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[8F]R9&5R+71O<#HQ<'0@;F]N
M92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D
M97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W
M<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/C(Y+#0U.29N8G-P
M.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1'=I9'1H.C`Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P
M.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@
M=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.C<P+C`P)3MB86-K9W)O=6YD
M+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV
M-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[
M)SY4;W1A;"!-87)K971A8FQE('-E8W5R:71I97,@/"]F;VYT/CPO<#X-"@D)
M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP
M<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS,"4[8F]R
M9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO
M;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@
M.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#MC;VQO
M<CHC,#`P,#`P.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P+C<P)3MB;W)D97(M
M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R
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M=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP
M<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS,"4[8F]R
M9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO
M;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@
M.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#MC;VQO
M<CHC,#`P,#`P.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P+C<P)3MB;W)D97(M
M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R
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M=&@Z,#$N,#`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP
M<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\
M+W1R/@T*"0D\+W1A8FQE/CPO9&EV/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ
M,'!T.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.V-O;&]R.B,P,#`P,#`[)SXF;F)S<#L\+V9O;G0^#0H)
M"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M
M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[)SY,979E;"`S('9A;'5A=&EO;CPO
M9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V-O;&]R.B,P,#`P,#`[
M)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.R<^5&AE('=A<G)A;G0@;&EA8FEL
M:71Y(&ES(&-L87-S:69I960@:6X@3W1H97(@;&]N9RUT97)M(&QI86)I;&ET
M:65S(&]N('1H92!#;VUP86YY)B-X,C`Q.3MS(&)A;&%N8V4@<VAE970N(%1H
M92!W87)R86YT(&QI86)I;&ET>2!I<R!M87)K960M=&\M;6%R:V5T(&5A8V@@
M<F5P;W)T:6YG('!E<FEO9"!W:71H('1H92!C:&%N9V4@:6X@9F%I<B!V86QU
M92!R96-O<F1E9"!A<R!A(&=A:6X@;W(@;&]S<R!W:71H:6X@3W1H97(@:6YC
M;VUE("AE>'!E;G-E*2P@;F5T(&]N('1H92!#;VUP86YY)B-X,C`Q.3MS('-T
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M9&ES<&QA>3H@:6YL:6YE.V-O;&]R.B,P,#`P,#`[)SXF;F)S<#L\+V9O;G0^
M#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#MC;VQO
M<CHC,#`P,#`P.R<^5&AE('1A8FQE('!R97-E;G1E9"!B96QO=R!I<R!A('-U
M;6UA<GD@;V8@8VAA;F=E<R!I;B!T:&4@9F%I<B!V86QU92!O9B!T:&4@0V]M
M<&%N>28C>#(P,3D[<R!,979E;"`S('9A;'5A=&EO;B!F;W(@=V%R<F%N="!L
M:6%B:6QI='D@9F]R('1H92!P97)I;V0@96YD960@36%R8V@F;F)S<#LS,2P@
M,C`Q-3H\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T
M)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MC;VQO<CHC
M,#`P,#`P.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QD:78@<W1Y;&4]
M,T1W:61T:#HQ,#`E/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I
M;F<],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93MW:61T
M:#H@,3`P+C`P)3MM87)G:6XM;&5F=#HP<'0[)SX-"@D)"3QT<CX-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z.#$N-3`E.W!A9&1I
M;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V-O;&]R.B,P,#`P,#`[)SXF;F)S<#L\+V9O;G0^/"]P/@T*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H
M.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
M"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N
M/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,34N,#`E.V)O
M<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO
M;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[
M8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP
M=#MC;VQO<CHC,#`P,#`P.R<^3&5V96PF;F)S<#LS)FYB<W`[87-S971S/"]F
M;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T1W:61T:#HP,2XP,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA
M;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS
M1"=W:61T:#HX,2XU,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D
M:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P
M<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T
M)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.R<^0F5G:6YN:6YG(&)A;&%N8V4@
M87,@;V8@1&5C96UB97(F;F)S<#LS,2P@,C`Q-"`\+V9O;G0^/"]P/@T*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P
M=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT
M.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D
M97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N
M92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O
M<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R
M.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC
M,#`P,#`P.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$S+C<P)3MB;W)D97(M=&]P
M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$
M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR
M:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%
M149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T
M>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ.#@F;F)S<#L-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,#`E
M.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G
M/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)
M/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@<W1Y;&4],T1W:61T:#HX,2XU
M,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T
M(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT
M.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.R<^0VAA;F=E(&EN(&9A
M:7(@=F%L=64@;V8@=V%R<F%N="!L:6%B:6QI='D@/"]F;VYT/CPO<#X-"@D)
M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T
M:#HP,BXU,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G
M:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.C$U+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE
M("-$.40Y1#D@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E
M<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@
M;F]N92`C1#E$.40Y(#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R
M87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^-#$F;F)S<#L-"@D)
M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T
M:#HP,2XP,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G
M:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^
M#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG
M;CTS1'1O<"!S='EL93TS1"=W:61T:#HX,2XU,"4[8F%C:V=R;W5N9"UC;VQO
M<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E
M>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.R<^16YD
M:6YG(&)A;&%N8V4@87,@;V8@36%R8V@F;F)S<#LS,2P@,C`Q-2`\+V9O;G0^
M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP
M861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI
M;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q
M+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F
M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@
M(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG
M<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)
M"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ
M,'!T.V-O;&]R.B,P,#`P,#`[)SXD/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3,N-S`E
M.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P
M="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,G!T(&1O=6)L92`C,#`P
M,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N
M9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N
M;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,C(Y)FYB<W`[
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*
M"0D)/"]T<CX-"@D)/"]T86)L93X\+V1I=CX-"@D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MC
M;VQO<CHC,#`P,#`P.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#LG/D9A:7(@
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M:6YG('1H92!#;VUP86YY)B-X,C`Q.3MS('=A<G)A;G1S(&%S(&]F($UA<F-H
M)FYB<W`[,S$L(#(P,34@:6YC;'5D92`H:2DF;F)S<#MV;VQA=&EL:71Y("@V
M."4F(W@R,#$T.S<P)2DL("AI:2DF;F)S<#MR:7-K(&9R964@:6YT97)E<W0@
M<F%T92`H,"XU-B4F(W@R,#$T.S$N,3,E*2P@*&EI:2DF;F)S<#MS=')I:V4@
M<')I8V4@*"0Q,C@M)#(L-3(P*2P@*&EV*29N8G-P.V9A:7(@=F%L=64@;V8@
M8V]M;6]N('-T;V-K("@D-C`N.#4I+"!A;F0@*'8I)FYB<W`[97AP96-T960@
M;&EF92`H,BXR,28C>#(P,30[-"XT."!Y96%R<RDN(%1H92!S:6=N:69I8V%N
M="!A<W-U;7!T:6]N<R!U<V5D(&EN('!R97!A<FEN9R!T:&4@;W!T:6]N('!R
M:6-I;F<@;6]D96P@9F]R('9A;'5I;F<@=&AE($-O;7!A;GDF(W@R,#$Y.W,@
M=V%R<F%N=',@87,@;V8@1&5C96UB97(F;F)S<#LS,2P@,C`Q-"!I;F-L=61E
M("AI*29N8G-P.W9O;&%T:6QI='D@*#8X)2TW,"4I+"`H:6DI)FYB<W`[<FES
M:R!F<F5E(&EN=&5R97-T(')A=&4@*#`N.#DE)B-X,C`Q-#LQ+C8U)2DL("AI
M:6DI)FYB<W`[<W1R:6ME('!R:6-E("@D,3(X)B-X,C`Q-#LD,BPU,C`I+"`H
M:78I)FYB<W`[9F%I<B!V86QU92!O9B!C;VUM;VX@<W1O8VL@*"0U,2XW-RDL
M(&%N9"`H=BDF;F)S<#ME>'!E8W1E9"!L:69E("@R+C4P)B-X,C`Q-#LT+C<P
M('EE87)S*2X@4V5E($YO=&4@-B!F;W(@82!D97-C<FEP=&EO;B!O9B!T:&4@
M=V%R<F%N=',@:7-S=65D(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@8V]N=F5R
M=&EB;&4@;F]T97,N/"]F;VYT/@T*"0D\+W`^#0H)"3QP/CQF;VYT('-I>F4]
M,T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S<R9C0T.#5A7V1D-39?-#4Y
M-5\X,S`U7S`P86,P,&%F9#AA9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\W,F8T-#@U85]D9#4V7S0U.35?.#,P-5\P,&%C,#!A9F0X868O5V]R
M:W-H965T<R]3:&5E=#$P+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^3W1H97(@8V]M<')E:&5N<VEV92!I;F-O;64@*&QO<W,I
M(&%N9"!A8V-U;75L871E9"!O=&AE<B!C;VUP<F5H96YS:79E(&ET96US/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M3W1H97(@8V]M<')E:&5N<VEV92!I;F-O;64@*&QO<W,I(&%N9"!A8V-U;75L
M871E9"!O=&AE<B!C;VUP<F5H96YS:79E(&ET96US/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&-O;7!R96AE;G-I
M=F4@:6YC;VUE("AL;W-S*2!A;F0@86-C=6UU;&%T960@;W1H97(@8V]M<')E
M:&5N<VEV92!I=&5M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/&1I=CX@/&1I=B!S='EL93TS1&UA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG
M:'0Z,'!T.SX-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X-"@D)
M/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^
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M<B!C;VUP<F5H96YS:79E(&EN8V]M92`H;&]S<RD@86YD(&%C8W5M=6QA=&5D
M(&]T:&5R(&-O;7!R96AE;G-I=F4@:71E;7,\+V9O;G0^/"]F;VYT/@T*"0D\
M+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-
M"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/D]T:&5R(&-O;7!R
M96AE;G-I=F4@:6YC;VUE("AL;W-S*2!I;F-L=61E<R!C:&%N9V5S(&EN(&5Q
M=6ET>2!T:&%T(&%R92!E>&-L=61E9"!F<F]M(&YE="!I;F-O;64@*&QO<W,I
M+"!S=6-H(&%S('5N<F5A;&EZ960@9V%I;G,@86YD(&QO<W-E<R!O;B!M87)K
M971A8FQE('-E8W5R:71I97,N/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7-I>F4Z,3!P=#LG/E1H92!F;VQL;W=I;F<@=&%B;&5S('-U;6UA
M<FEZ92!O=&AE<B!C;VUP<F5H96YS:79E(&EN8V]M92`H;&]S<RD@86YD('1H
M92!C:&%N9V5S(&EN(&%C8W5M=6QA=&5D(&]T:&5R(&-O;7!R96AE;G-I=F4@
M:71E;7,@9F]R('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@F;F)S<#LS
M,2P@,C`Q-3H\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N
M8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\9&EV('-T>6QE/3-$=VED=&@Z,3`P
M)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL
M93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[=VED=&@Z(#$P,"XP,"4[
M;6%R9VEN+6QE9G0Z,'!T.R<^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1'=I9'1H.C4U+C4P)3MP861D:6YG.C!P=#L^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T
M)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N
M8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#HQ,BXP,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y
M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M
M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y
M1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
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M.F)O;&0[9F]N="US:7IE.CAP=#LG/D]N/"]F;VYT/CQB<B`O/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M
M<VEZ93HX<'0[)SY-87)K971A8FQE/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ
M93HX<'0[)SY396-U<FET:65S/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)
M"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[<&%D
M9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M
M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S
M<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P
M="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@
M.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H
M=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA
M;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@.'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[)SY&;W)E:6=N
M/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF
M;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[)SY#=7)R96YC>3PO9F]N
M=#X\8G(@+SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW
M96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^5')A;G-L871I;VX\+V9O;G0^
M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N
M.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M,3(N,#`E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE
M9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@
M(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N
M="US:7IE.CAP=#LG/E1O=&%L/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$
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M;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-
M"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL
M93TS1"=W:61T:#HU-2XU,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP
M861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P
M="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M
M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF
M;VYT+7-I>F4Z,3!P=#LG/D)A;&%N8V4@870@1&5C96UB97(F;F)S<#LS,2P@
M,C`Q-"`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO
M<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P
M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M
M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$
M.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF
M;VYT+7-I>F4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F]R
M9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO
M;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB
M;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO
M<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^
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M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,S`E.V)O<F1E<BUT;W`Z,7!T('-O
M;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O
M<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P
M="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C$P+C<P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M
M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE
M("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K
M9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A
M<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,S4P
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T
M)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7-I>F4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS,"4[8F]R9&5R
M+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D
M97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@
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M;&4],T0G=VED=&@Z,3`N-S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P
M,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T
M;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$
M.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I
M9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T
M/CPO9&EV/B@W,S<-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z,#$N,#`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^*3PO9F]N=#X\+W`^#0H)"0D)/"]T
M9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S
M='EL93TS1'=I9'1H.C4U+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`R,'!T.VQI;F4M:&5I9VAT.C$P
M-BXV-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^3W1H97(@8V]M
M<')E:&5N<VEV92!I;F-O;64O*&QO<W,I(&)E9F]R92!R96-L87-S:69I8V%T
M:6]N<R`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T
M)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS
M<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E
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M93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C$R+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I
M=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^*#$R-`T*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3L^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
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M;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-
M"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL
M93TS1"=W:61T:#HU-2XU,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP
M861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P
M="`P<'0@,C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M
M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF
M;VYT+7-I>F4Z,3!P=#LG/D%M;W5N=',@<F5C;&%S<VEF:65D(&9R;VT@;W1H
M97(@8V]M<')E:&5N<VEV92!I=&5M<R`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXU
M,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*
M"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV
M-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P
M="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L
M<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P
M)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL969T.C%P
M="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P
M,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD
M+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N
M.G)I9VAT.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M<VEZ93HQ,'!T.R<^)B-X,C`Q-#L\+V9O;G0^/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP
M,BXU,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG
M/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P
M-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@
M,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R
M+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL969T
M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P
M,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O
M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L
M:6=N.G)I9VAT.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)B-X,C`Q-#L\+V9O;G0^/"]P/@T*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P
M=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT
M.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C$R+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL
M969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED
M(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K
M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT
M+6%L:6=N.G)I9VAT.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)B-X,C`Q-#L\+V9O;G0^/"]P/@T*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HP,2XP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG
M.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I
M9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS
M1'=I9'1H.C4U+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0@,'!T(#!P="`R,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[
M=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^3W1H97(@8V]M<')E:&5N
M<VEV92!I;F-O;64O*&QO<W,I(#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A
M9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HQ,BXP,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[
M8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ
M<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y
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M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D
M97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S
M;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[
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M<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E
M.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P
M="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P
M,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#L[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ
M<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE
M9G0^/"]D:78^,0T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1'=I9'1H.C`Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)
M"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-
M"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.C4U+C4P)3MB
M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I
M9VAT.C$P-BXV-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^0F%L
M86YC92!A="!-87)C:"9N8G-P.S,Q+"`R,#$U(#PO9F]N=#X\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T
M.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,S`E.V)O<F1E
M<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE
M("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O
M<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R
M.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B0\+V9O
M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#HQ,"XW,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P
M,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O
M='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE
M("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N
M.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL
M969T/CPO9&EV/B@R-C(-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z
M("-#0T5%1D8[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^*3PO9F]N=#X\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M
M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI
M9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C
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M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`N-S`E.V)O<F1E<BUT;W`Z
M,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y
M1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR
M:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%
M149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T
M>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH-#<T#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K
M9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/BD\+V9O
M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#HP,2XS,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P
M,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O
M='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE
M("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP
M<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P+C<P
M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ
M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P
M,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N
M9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N
M;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^*#<S-@T*"0D)
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M/"]T86)L93X\+V1I=CX-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)
M"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N
M=#X-"@D)/"]P/@T*"0D\<#X\9F]N="!S:7IE/3-$,3X@/"]F;VYT/CPO<#X-
M"@D\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\W,F8T-#@U85]D9#4V7S0U.35?.#,P-5\P,&%C,#!A9F0X
M868-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-S)F-#0X-6%?9&0U
M-E\T-3DU7S@S,#5?,#!A8S`P869D.&%F+U=O<FMS:&5E=',O4VAE970Q,2YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D%C8V]U
M;G1S('!A>6%B;&4@86YD(&%C8W)U960@97AP96YS97,\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT<R!P
M87EA8FQE(&%N9"!A8V-R=65D(&5X<&5N<V5S/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4@86YD
M(&%C8W)U960@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQD:78^(#QD:78@<W1Y;&4],T1M87)G:6XM;&5F=#HP<'0[;6%R9VEN
M+7)I9VAT.C!P=#L^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^
M#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT
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M;G0^/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^
M#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\
M+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)
M"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P
M=#LG/D%C8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U960@97AP96YS97,@870@
M36%R8V@F;F)S<#LS,2P@,C`Q-2!A;F0@1&5C96UB97(F;F)S<#LS,2P@,C`Q
M-"!C;VYS:7-T(&]F('1H92!F;VQL;W=I;F<Z/"]F;VYT/@T*"0D\+W`^#0H)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/&1I
M=B!S='EL93TS1'=I9'1H.C$P,"4^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C
M96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA
M<'-E.W=I9'1H.B`Q,#`N,#`E.VUA<F=I;BUL969T.C!P=#LG/@T*"0D)/'1R
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M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P
M)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)
M"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,30N,#`E.V)O<F1E<BUT
M;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y
M1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R
M+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT
M97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/DUA
M<F-H)FYB<W`[,S$L/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[)SX\
M+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I
M9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P,34\+V9O;G0^/"]P/@T*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H
M.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
M"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N
M/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,30N,#`E.V)O
M<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO
M;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[
M8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP
M=#LG/D1E8V5M8F5R)FYB<W`[,S$L/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ
M93HX<'0[)SXR,#$T/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,2XP,"4[<&%D9&EN9SHP
M<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT
M.C$P-BXV-R4[=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^
M#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG
M;CTS1'1O<"!S='EL93TS1"=W:61T:#HV-BXP,"4[8F%C:V=R;W5N9"UC;VQO
M<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E
M>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/D5M<&QO>65E(&-O;7!E;G-A
M=&EO;BP@8F5N969I=',L(&%N9"!R96QA=&5D(&%C8W)U86QS(#PO9F]N=#X\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A
M9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N
M,S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T
M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y
M1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U
M;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T
M.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C<P)3MB;W)D97(M=&]P.C%P="!S
M;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB
M;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ
M<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF
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M"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S
M;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB
M;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ
M<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A
M9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#HQ,BXW,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R
M+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N
M92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C
M:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R
M87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^.2PS
M,3(F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=VED=&@Z,#$N,#`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%
M1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)
M"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T
M;W`@<W1Y;&4],T1W:61T:#HV-BXP,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T
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M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.C$T+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N
M;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^
M,3$L-CDQ)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X]
M,T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-"XP,"4[.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT
M+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F
M;&]A=#IL969T/CPO9&EV/CDL,S0Y)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I
M;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@<W1Y;&4]
M,T0G=VED=&@Z-C8N,#`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@
M,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P
M="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N
M="US:7IE.C$P<'0[)SY0<F]F97-S:6]N86P@9F5E<R`\+V9O;G0^/"]P/@T*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG
M.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I
M9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C$T+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG
M;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z
M;&5F=#X\+V1I=CXS+#,X,B9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R;W5N
M9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF
M;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$T+C`P)3MB86-K9W)O=6YD
M+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
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M;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-
M"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL
M93TS1'=I9'1H.C8V+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV
M-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^06-C;W5N=',@<&%Y
M86)L92`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T
M)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS
M<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,30N,#`E
M.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE
M/3-$9FQO870Z;&5F=#X\+V1I=CXS+#$S.29N8G-P.PT*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP
M861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,30N,#`E.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO
M=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT+#$R."9N8G-P
M.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1'=I9'1H.C`Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P
M.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@
M=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.C8V+C`P)3MB86-K9W)O=6YD
M+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV
M-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^3W1H97(@/"]F;VYT
M/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[
M<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#HQ-"XP,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y
M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M
M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y
M1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG
M:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^
M/"]D:78^,2PY-34F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L
M;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[
M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-"XP,"4[8F]R9&5R+71O<#HQ<'0@
M;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB
M;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z
M,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E
M>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS
M1&9L;V%T.FQE9G0^/"]D:78^,BPY.3@F;F)S<#L-"@D)"0D\+W1D/@T*"0D)
M"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,#`E.V)A
M8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R
M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HV-BXP
M,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T
M(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT
M.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T
M.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS,"4[8F]R9&5R
M+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@.V)O
M<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*
M"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV
M-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P
M="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N
M="US:7IE.C$P<'0[)SXD/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N-S`E.V)O<F1E
M<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE
M("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,G!T(&1O=6)L92`C,#`P,#`P(#MB
M;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT
M.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO
M9&EV/C(S+#4S,B9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T
M)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,S`E.V)O<F1E<BUT;W`Z
M,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y
M1#D@.V)O<F1E<BUB;W1T;VTZ,G!T(&1O=6)L92`C,#`P,#`P(#MB;W)D97(M
M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*
M"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ
M93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C<P)3MB;W)D97(M=&]P
M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$
M.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R
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M"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"3PO=&%B
M;&4^/"]D:78^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)
M"3PO<#X-"@D)/'`^/&9O;G0@<VEZ93TS1#$^(#PO9F]N=#X\+W`^#0H)/"]D
M:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?-S)F-#0X-6%?9&0U-E\T-3DU7S@S,#5?,#!A8S`P869D.&%F#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S<R9C0T.#5A7V1D-39?-#4Y
M-5\X,S`U7S`P86,P,&%F9#AA9B]7;W)K<VAE971S+U-H965T,3(N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY787)R86YT<SQB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E=A<G)A;G1S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\9&EV/B`\9&EV('-T>6QE/3-$;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR
M:6=H=#HP<'0[/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*
M"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ
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M)SY787)R86YT<SPO9F]N=#X\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$P<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M<VEZ93HQ,'!T.R<^06QL(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS
M(&]U='-T86YD:6YG('=A<G)A;G1S('=E<F4@8VQA<W-I9FEE9"!A<R!L:6%B
M:6QI=&EE<R!A<R!O9B!-87)C:"9N8G-P.S,Q+"`R,#$U(&%N9"!$96-E;6)E
M<B9N8G-P.S,Q+"`R,#$T(&)E8V%U<V4@=&AE>2!C;VYT86EN960@;F]N+7-T
M86YD87)D(&%N=&ED:6QU=&EO;B!P<F]V:7-I;VYS+CPO9F]N=#X-"@D)/"]P
M/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY4:&4@9F]L;&]W:6YG
M(&ES(&$@<W5M;6%R>2!O9B!T:&4@0V]M<&%N>28C>#(P,3D[<R!O=71S=&%N
M9&EN9R!W87)R86YT<R!A<R!O9B!-87)C:"9N8G-P.S,Q+"`R,#$U.CPO9F]N
M=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*
M"0D\+W`^#0H)"3QD:78@<W1Y;&4],T1W:61T:#HQ,#`E/CQT86)L92!C96QL
M<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V)O<F1E<BUC
M;VQL87!S93IC;VQL87!S93MW:61T:#H@,3`P+C`P)3MM87)G:6XM;&5F=#HP
M<'0[)SX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$=VED=&@Z-34N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/CPO
M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T1W:61T:#HP,BXU,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS
M1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC
M96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@
M,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M
M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL969T.C%P="!N;VYE("-$
M.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E
M<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*"0D)
M"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[
M=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93H@.'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[)SY7
M87)R86YT/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[)SYS:&%R97,\
M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT
M+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R
M9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@
M<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@
M.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O
M;&0[9F]N="US:7IE.CAP=#LG/D5X97)C:7-E/"]F;VYT/CQB<B`O/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O
M;G0M<VEZ93HX<'0[)SYP<FEC93PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,#@E.W!A
M9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB
M<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#HQ,RXT,B4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$
M.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T
M=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@
M(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^
M#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW
M96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^17AP:7)A=&EO;CPO9F]N=#X\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$=VED=&@Z,#$N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ
M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R
M/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@<W1Y;&4],T0G=VED
M=&@Z-34N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP
M<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)
M"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE
M.C$P<'0[)SY#;VUM;VX@<W1O8VL@/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N-3`E
M.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G
M/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[8F]R9&5R+71O<#HQ
M<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$
M.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG
M:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&
M1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL
M93TS1&9L;V%T.FQE9G0^/"]D:78^-BPR-3`F;F)S<#L-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N-3`E
M.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G
M/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS,"4[8F]R9&5R+71O<#HQ
M<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$
M.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG
M:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&
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M=VED=&@Z,3`N-S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O
M<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@
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M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C$S+C0R)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB
M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P
M="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y
M(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG
M(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I
M=CXR,#$W)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C
M0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-
M"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N
M/3-$=&]P('-T>6QE/3-$=VED=&@Z-34N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ
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M93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P)3L[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M
M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L
M;V%T.FQE9G0^/"]D:78^-RPP,S`F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[<&%D9&EN
M9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I
M9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,S`E.W!A
M9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C$P+C<P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I
M=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,3(X+C`P)FYB<W`[#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,#$N,#@E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I
M9'1H.C$S+C0R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.G)I9VAT
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G
M/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M
M<VEZ93HQ,'!T.R<^,C`Q.2!A;F0@,C`R,#PO9F]N=#X\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N
M,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)
M"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T
M;W`@<W1Y;&4],T0G=VED=&@Z-34N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN
M9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[9F]N="US:7IE.C$P<'0[)SY#;VUM;VX@<W1O8VL@/"]F;VYT/CPO
M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP
M,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[
M)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D
M:78^,3,P)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C
M0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-
M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,#$N,S`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN
M9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P
M+C<P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H
M=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\
M+V1I=CXR+#4R,"XP,"9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XP."4[8F%C:V=R;W5N9"UC
M;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS
M1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S
M<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C$S+C0R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE
M/3-$9FQO870Z;&5F=#X\+V1I=CXR,#$Y)FYB<W`[#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C`P)3MB
M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
M"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)/"]T
M86)L93X\+V1I=CX-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X-
M"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^5&AE
M(&9O;&QO=VEN9R!I<R!A('-U;6UA<GD@;V8@=&AE($-O;7!A;GDF(W@R,#$Y
M.W,@;W5T<W1A;F1I;F<@=V%R<F%N=',@87,@;V8@1&5C96UB97(F;F)S<#LS
M,2P@,C`Q-#H\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\9&EV
M('-T>6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E
M;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P
M<V4[=VED=&@Z(#$P,"XP,"4[;6%R9VEN+6QE9G0Z,'!T.R<^#0H)"0D\='(^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C4U+C4P
M)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E
M.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)
M)FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M
M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO
M;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G
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M#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A
M;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P)3MB
M;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL969T.C%P="!N
M;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@
M.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P=#LG
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M1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C`X)3MP861D:6YG.C!P=#L^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M,3,N-#(E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE
M9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@
M(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N
M="US:7IE.CAP=#LG/D5X<&ER871I;VX\+V9O;G0^/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C`P
M)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)
M"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)
M"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.C4U+C4P)3MB86-K
M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT
M.C$P-BXV-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^0V]M;6]N
M('-T;V-K(#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P
M.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P
M,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T
M;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$
M.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I
M9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T
M/CPO9&EV/C8L,C4P)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P
M.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,#$N,S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P
M,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T
M;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$
M.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[
M)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P+C<P)3MB
M;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@
M;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@
M.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A
M<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ,C@N,#`F;F)S<#L-
M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,#$N,#@E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN
M9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,RXT,B4[
M8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y
M(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC
M;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R
M87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,C`Q-R9N8G-P.PT*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HP,2XP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG
M.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I
M9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS
M1'=I9'1H.C4U+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[
M=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^0V]M;6]N('-T;V-K(#PO
M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)
M"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@
M;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV
M/C<L,#,P)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C,P)3MP861D:6YG.C!P=#L^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T
M)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7-I>F4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L
M:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A
M=#IL969T/CPO9&EV/C$R."XP,"9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C`X)3MP861D:6YG
M.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)
M"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ,RXT,B4[<&%D
M9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M
M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIR:6=H=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/C(P
M,3D@86YD(#(P,C`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C`P)3MP861D:6YG.C!P
M=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T
M<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I
M9'1H.C4U+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z
M,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q
M,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*
M"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ
M93HQ,'!T.R<^0V]M;6]N('-T;V-K(#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P
M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T
M)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)A8VMG<F]U;F0M
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M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C,P)3MB
M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-
M"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I
M>F4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F%C:V=R;W5N
M9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N
M;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,BPU,C`N,#`F
M;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,#$N,#@E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[
M<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ
M,RXT,B4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG
M:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^
M/"]D:78^,C`Q.29N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XP,"4[8F%C:V=R;W5N9"UC;VQO
M<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\
M+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"3PO=&%B;&4^/"]D:78^#0H)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`^
M/&9O;G0@<VEZ93TS1#$^(#PO9F]N=#X\+W`^#0H)/"]D:78^(#PO9&EV/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-S)F-#0X
M-6%?9&0U-E\T-3DU7S@S,#5?,#!A8S`P869D.&%F#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S<R9C0T.#5A7V1D-39?-#4Y-5\X,S`U7S`P86,P
M,&%F9#AA9B]7;W)K<VAE971S+U-H965T,3,N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.970@;&]S<R!P97(@<VAA<F4\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.
M970@;&]S<R!P97(@<VAA<F4\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T(&QO<W,@<&5R('-H87)E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/B`\9&EV('-T>6QE/3-$;6%R9VEN
M+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I
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M/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)
M"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O
M;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF
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M;F5T(&EN8V]M92`H;&]S<RD@8GD@=&AE('=E:6=H=&5D+6%V97)A9V4@;G5M
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M.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@
M,3!P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N
M="US:7IE.C$P<'0[)SY4:&4@9F]L;&]W:6YG('1A8FQE<R!S970@9F]R=&@@
M=&AE(&-O;7!U=&%T:6]N(&]F(&)A<VEC(&%N9"!D:6QU=&5D(&YE="!L;W-S
M('!E<B!S:&%R93H\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG
M/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\9&EV('-T>6QE/3-$=VED=&@Z
M,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S
M='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[=VED=&@Z(#$P,"XP
M,"4[;6%R9VEN+6QE9G0Z,'!T.R<^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C8V+C`P)3MP861D:6YG.C!P=#L^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,G!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG
M/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)
M"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0U('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#HR.2XR."4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$
M.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T
M=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@
M(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^
M#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW
M96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^5&AR964F;F)S<#MM;VYT:',F
M;F)S<#ME;F1E9"9N8G-P.TUA<F-H)FYB<W`[/"]F;VYT/CQB<B`O/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O
M;G0M<VEZ93HX<'0[)SXS,2P\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C(R)3MP861D
M:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P
M.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-C8N,#`E.W!A9&1I;F<Z
M,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R<^)FYB<W`[/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[<&%D9&EN9SHP
M<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT
M.C$P-BXV-R4[=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.C$T+C`P)3MB;W)D97(M=&]P.C%P="!S;VQI
M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D
M97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ
M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^,C`Q-3PO9F]N=#X\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ
M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ
M,BXW."4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F
M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C
M,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN
M9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT
M+7-I>F4Z.'!T.R<^,C`Q-#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N,C(E.W!A9&1I
M;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[
M/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V
M86QI9VX],T1T;W`@<W1Y;&4],T0G=VED=&@Z-C8N,#`E.V)A8VMG<F]U;F0M
M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z,3!P
M=#LG/DYU;65R871O<CPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O
M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)
M"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,30N,#`E.V)O<F1E<BUT
M;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$
M.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R
M+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ<FEG:'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)
M"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R
M.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO
M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N-S@E.V)O<F1E<BUT;W`Z,7!T('-O
M;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O
M<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P
M="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ<FEG:'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S
M<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C`R+C(R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\
M+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P
M('-T>6QE/3-$=VED=&@Z-C8N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY.970@;&]S
M<R`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
M"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,S`E.V)O<F1E<BUT;W`Z,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[
M8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUR:6=H
M=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)
M"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P
M<'0[)SXD/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N-S`E.V)O<F1E<BUT;W`Z,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[
M8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUR:6=H
M=#HQ<'0@;F]N92`C1#E$.40Y(#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`]
M,T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^*#,W+#DQ
M-0T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1'=I9'1H.C`R+C4P)3L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HP,2XS,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D
M97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D
M;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@
M.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HQ,2XT."4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D
M97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D
M;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@
M.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE
M/3-$9FQO870Z;&5F=#X\+V1I=CXH,30L,#DX#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N,C(E.SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G
M/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M
M<VEZ93HQ,'!T.R<^*3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^
M#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T
M:#HV-BXP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P
M=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P
M=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)
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M;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C$T+C`P)3MB;W)D97(M=&]P.C)P="!D;W5B;&4@(S`P,#`P,"`[
M8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ
M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$
M.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*
M"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV
M-R4[=&5X="UA;&EG;CIR:6=H=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[
M)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ
M,BXW."4[8F]R9&5R+71O<#HR<'0@9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUL
M969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG
M<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M
M86QI9VXZ<FEG:'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C(R)3MB
M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
M"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT
M<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z-C8N,#`E
M.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P
M<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@
M+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@
M,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M9F]N="US:7IE.C$P<'0[)SY$96YO;6EN871O<B!F;W(@8F%S:6,@86YD(&1I
M;'5T960@;F5T(&QO<W,@<&5R('-H87)E(#PO9F]N=#X\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N
M-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)
M"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#HQ-"XP,"4[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P
M/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/C,S+#`V
M-RPW-3(-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T1W:61T:#HP,BXU,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF
M;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C<X)3L[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ
M<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE
M9G0^/"]D:78^,C0L-#DR+#0X-PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C(R)3MP861D:6YG.C!P=#L^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-
M"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H
M.C8V+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T
M.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T
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M<W1Y;&4],T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%
M1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)
M"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#HQ-"XP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&
M1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T
M.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIR:6=H=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)
M"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*
M"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HQ,BXW."4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#
M145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ
M,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIR:6=H=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)
M"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N,C(E.V)A8VMG<F]U;F0M8V]L;W(Z
M("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P
M/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI
M9VX],T1T;W`@<W1Y;&4],T1W:61T:#HV-BXP,"4[<&%D9&EN9SHP<'0[/@T*
M"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG
M/D)A<VEC(&%N9"!D:6QU=&5D(#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A
M9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS
M,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ
M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P
M,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z
M,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXW
M,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ
M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P
M,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG
M;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z
M;&5F=#X\+V1I=CXH,2XQ-0T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T
M)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7-I>F4Z,3!P=#LG/BDJ/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,S`E.V)O<F1E
M<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@.V)O
M<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*
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M<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@.V)O
M<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#L[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[
M)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D
M:78^*#`N-3@-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@
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M<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^
M#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE
M.C$P<'0[)SXJ/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMT97AT+6EN9&5N=#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.W!A9&1I;F<Z,'!T(#,V<'0@,'!T(#!P=#LG/CPO9F]N=#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C-P=#LG/CPO9F]N
M=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P
M<'0[)SY);B!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H)FYB<W`[,S$L
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M:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA
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M<FEO9"X\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T
M)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P
M.SPO9F]N=#X-"@D)/"]P/@T*"0D\9&EV('-T>6QE/3-$=VED=&@Z,3`P)3X\
M=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS
M1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[=VED=&@Z(#$P,"XP,"4[;6%R
M9VEN+6QE9G0Z,'!T.R<^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1'=I9'1H.C<P+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
M"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P
M.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E
M>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D(&-O;'-P86X],T0S('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HR-BXU,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB
M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P
M="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$
M.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)
M"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z
M8F]L9#MF;VYT+7-I>F4Z.'!T.R<^07,F;F)S<#MO9B9N8G-P.TUA<F-H)FYB
M<W`[,S$L/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,2XP,"4[<&%D9&EN9SHP<'0[/@T*
M"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV
M-R4[=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)
M/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1'=I9'1H.C<P+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
M"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P
M.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E
M>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP
M,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z
M,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P
M,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z
M,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US
M:7IE.CAP=#LG/C(P,34\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG
M.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO
M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[
M8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ
M<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y
M1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)
M"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT
M.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P,30\+V9O;G0^/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q
M+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)
M"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-S`N,#`E
M.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P
M<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@
M+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@
M,3)P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M)SXF;F)S<#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)O<F1E<BUT
M;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$
M.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R
M+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT
M97AT+6%L:6=N.G)I9VAT.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P
M)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M,3(N,#`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL
M969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.G)I9VAT.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[
M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1'=I9'1H.C`Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N
M8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\
M=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.C<P+C`P)3MB86-K9W)O
M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P
M-BXV-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^4W1O8VL@3W!T
M:6]N<R`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO
M<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C$R+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X
M="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$
M9FQO870Z;&5F=#X\+V1I=CXT+#8R-RPX,S,F;F)S<#L-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N-3`E
M.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G
M/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[8F%C:V=R;W5N9"UC
M;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R
M87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,RPQ,S,L.#,P)FYB
M<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A
M9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D
M/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T
M>6QE/3-$=VED=&@Z-S`N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY5;G9E<W1E9"!R
M97-T<FEC=&5D('-T;V-K(#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I
M;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[
M8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@
M;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P
M(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I
M9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T
M/CPO9&EV/C,V-"PY-S`F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[<&%D9&EN9SHP<'0[
M/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P
M-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@
M,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M
M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL969T.C%P="!N;VYE("-$
M.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E
M<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#L[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N
M;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^
M-S0X+#0U-B9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1'=I9'1H.C`Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
M"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT
M<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.C<P+C`P
M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M
M:&5I9VAT.C$P-BXV-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^
M5&]T86P@/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L
M;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[
M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#HQ,BXP,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P
M,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O
M;3HR<'0@9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C
M1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR
M:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F
M=#X\+V1I=CXT+#DY,BPX,#,F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U
M;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)
M)FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@
M(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R
M+6)O='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@
M;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA
M;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO
M870Z;&5F=#X\+V1I=CXS+#@X,BPR.#8F;F)S<#L-"@D)"0D\+W1D/@T*"0D)
M"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,#`E.V)A
M8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D\+W1A
M8FQE/CPO9&EV/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*
M"0D\+W`^#0H)"3QP/CQF;VYT('-I>F4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO
M9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7S<R9C0T.#5A7V1D-39?-#4Y-5\X,S`U7S`P86,P,&%F9#AA9@T*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\W,F8T-#@U85]D9#4V7S0U
M.35?.#,P-5\P,&%C,#!A9F0X868O5V]R:W-H965T<R]3:&5E=#$T+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VL@87=A
M<F0@<&QA;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N
M(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E-T;V-K(&%W87)D('!L86X\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@87=A<F0@<&QA;CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX@/&1I=B!S='EL93TS
M1&UA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"@D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
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M9F]N=#X\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T
M)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P
M.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*
M"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ
M,'!T.R<^3VX@36%R8V@F;F)S<#LU+"`R,#$S+"!T:&4@0V]M<&%N>28C>#(P
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M;BX\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
M"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO
M9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T
M.R<^26X@36%Y)FYB<W`[,C`Q,RP@=&AE($-O;7!A;GDF(W@R,#$Y.W,@0F]A
M<F0@;V8@1&ER96-T;W)S(&%N9"!S=&]C:VAO;&1E<G,@:6YC<F5A<V5D(&)Y
M(#(L-3`P+#`P,"!T:&4@;G5M8F5R(&]F('-H87)E<R!A=71H;W)I>F5D('5N
M9&5R('1H92`R,#`Y($5Q=6ET>2!A;F0@3&]N9R!497)M($EN8V5N=&EV92!0
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M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*
M"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY);B!-
M87DF;F)S<#LR,#$S+"!T:&4@0V]M<&%N>28C>#(P,3D[<R!";V%R9"!O9B!$
M:7)E8W1O<G,@86YD('-T;V-K:&]L9&5R<R!A<'!R;W9E9"!T:&4@,C`Q,R!,
M;VYG(%1E<FT@26YC96YT:79E(%!L86XL('=H:6-H(&)E8V%M92!E9F9E8W1I
M=F4@=7!O;B!T:&4@8VQO<VEN9R!O9B!T:&4@0V]M<&%N>28C>#(P,3D[<R!)
M4$\N)FYB<W`[)FYB<W`[5&AE(#(P,3,@3&]N9R!497)M($EN8V5N=&EV92!0
M;&%N('!R;W9I9&5S(&9O<B!T:&4@9W)A;G0@;V8@:6YC96YT:79E('-T;V-K
M(&]P=&EO;G,L(&YO;G-T871U=&]R>2!S=&]C:R!O<'1I;VYS+"!R97-T<FEC
M=&5D('-T;V-K(&%W87)D<R!A;F0@;W1H97(@<W1O8VLM8F%S960@87=A<F1S
M+B!4:&4@;G5M8F5R(&]F('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@<F5S97)V
M960@9F]R(&ES<W5A;F-E('5N9&5R('1H92`R,#$S($QO;F<@5&5R;2!);F-E
M;G1I=F4@4&QA;B!I<R!T:&4@<W5M(&]F("@Q*29N8G-P.S(T-2PP,#`@<VAA
M<F5S(&]F(&-O;6UO;B!S=&]C:R!A=F%I;&%B;&4@9F]R(&ES<W5A;F-E('5N
M9&5R('1H92!#;VUP86YY)B-X,C`Q.3MS(#(P,#D@17%U:71Y(&%N9"!,;VYG
M(%1E<FT@26YC96YT:79E(%!L86X@86YD(#(P,3,@4W1O8VL@26YC96YT:79E
M(%!L86XL("@R*29N8G-P.W1H92!N=6UB97(@;V8@<VAA<F5S("AU<"!T;R`S
M+#`T,"PT-#0@<VAA<F5S*2!E<75A;"!T;R!T:&4@<W5M(&]F('1H92!N=6UB
M97(@;V8@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!S=6)J96-T('1O(&]U='-T
M86YD:6YG(&%W87)D<R!U;F1E<B!T:&4@0V]M<&%N>28C>#(P,3D[<R`Q.3DX
M($5M<&QO>65E+"!$:7)E8W1O<B!A;F0@0V]N<W5L=&%N="!3=&]C:R!/<'1I
M;VX@4&QA;BP@,C`P.2!%<75I='D@86YD($QO;F<@5&5R;2!);F-E;G1I=F4@
M4&QA;B!A;F0@,C`Q,R!3=&]C:R!);F-E;G1I=F4@4&QA;B!T:&%T(&5X<&ER
M92P@=&5R;6EN871E(&]R(&%R92!O=&AE<G=I<V4@<W5R<F5N9&5R960L(&-A
M;F-E;&QE9"P@9F]R9F5I=&5D(&]R(')E<'5R8VAA<V5D(&)Y('1H92!#;VUP
M86YY(&%T('1H96ER(&]R:6=I;F%L(&ES<W5A;F-E('!R:6-E('!U<G-U86YT
M('1O(&$@8V]N=')A8W1U86P@<F5P=7)C:&%S92!R:6=H="!P;'5S("@S*29N
M8G-P.V%N(&%N;G5A;"!I;F-R96%S92P@=&\@8F4@861D960@;VX@=&AE(&9I
M<G-T(&1A>2!O9B!E86-H(&9I<V-A;"!Y96%R('5N=&EL('1H92!E>'!I<F%T
M:6]N(&]F('1H92`R,#$S($QO;F<@5&5R;2!);F-E;G1I=F4@4&QA;BP@97%U
M86P@=&\@=&AE(&QO=V5S="!O9B`R+#4P,"PP,#`@<VAA<F5S(&]F(&-O;6UO
M;B!S=&]C:RP@-"4@;V8@=&AE(&YU;6)E<B!O9B!S:&%R97,@;V8@8V]M;6]N
M('-T;V-K(&]U='-T86YD:6YG(&]N('1H92!F:7)S="!D87D@;V8@=&AE(&9I
M<V-A;"!Y96%R(&%N9"!A;B!A;6]U;G0@9&5T97)M:6YE9"!B>2!T:&4@0V]M
M<&%N>28C>#(P,3D[<R!";V%R9"!O9B!$:7)E8W1O<G,N/"]F;VYT/@T*"0D\
M+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-
M"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/D9R;VT@2F%N=6%R
M>29N8G-P.S$L(#(P,34@=&AR;W5G:"!-87)C:"9N8G-P.S,Q+"`R,#$U+"!T
M:&4@0V]M<&%N>2!I<W-U960@82!T;W1A;"!O9B`Q+#0U-BPU-3`@<W1O8VL@
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M=&EO;BX\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T
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M)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QD:78@<W1Y;&4],T1W:61T:#HQ
M,#`E/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T
M>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93MW:61T:#H@,3`P+C`P
M)3MM87)G:6XM;&5F=#HP<'0[)SX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-#$N,#`E.W!A9&1I;F<Z,'!T.SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R
M<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^
M)FYB<W`[/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[<&%D9&EN9SHP<'0[/@T*
M"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV
M-R4[=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C$R+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL
M969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED
M(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D
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M;VYT+7-I>F4Z.'!T.R<^;W!T:6]N<SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E
M.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)
M)FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[8F]R9&5R+71O
M<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$
M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M
M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E
M>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^5V5I
M9VAT960M/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[)SYA=F5R86=E
M/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF
M;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[)SYE>&5R8VES93PO9F]N
M=#X\8G(@+SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW
M96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^<')I8V4\+V9O;G0^/"]P/@T*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I
M9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E
M<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T
M)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z
M,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$
M.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I
M9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT
M+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
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M/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E
M:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[)SYC;VYT<F%C='5A;#PO9F]N=#X\
M8G(@+SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG
M:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^=&5R;3PO9F]N=#X\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X]
M,T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[8F]R
M9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N
M92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB
M;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T
M.R<^06=G<F5G871E/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I<W!L
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M;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-
M"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1'=I9'1H.C0Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)
M"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N
M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI
M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[8F]R
M9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO
M;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB
M;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H
M.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
M"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N
M/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)O
M<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N
M;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[
M8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)
M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T
M:#HP,BXU,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G
M:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC96YT97([
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^
M#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P
M="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y
M(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H
M=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA
M;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A
M9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB
M<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[8F]R9&5R+71O<#HQ
M<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$
M.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG
M:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M
M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^*&EN)FYB
M<W`[/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
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M;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-
M"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL
M93TS1"=W:61T:#HT,2XP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP
M861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P
M="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M
M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF
M;VYT+7-I>F4Z,3!P=#LG/D]U='-T86YD:6YG(&%T($1E8V5M8F5R)FYB<W`[
M,S$L(#(P,30@/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M
M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB
M<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#HQ,BXP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&
M1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL
M93TS1&9L;V%T.FQE9G0^/"]D:78^,RPT,S(L.3<R#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB
M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
M"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,S`E.V)A8VMG<F]U;F0M8V]L
M;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)#PO
M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.C$P+C<P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%
M149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T
M>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-2XP,`T*"0D)"3PO=&0^#0H)"0D)
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXU,"4[8F%C
M:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)
M"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P)3MB86-K9W)O=6YD+6-O;&]R
M.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.G)I9VAT
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G
M/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC
M;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS
M1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S
M<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P)3MB86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.G)I
M9VAT.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R
M<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XP,"4[8F%C:V=R;W5N
M9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF
M;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)
M/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1'=I9'1H.C0Q+C`P)3MP861D:6YG
M.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q
M,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*
M"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ
M93HQ,'!T.R<^1W)A;G1E9"`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D
M:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E
M.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE
M/3-$9FQO870Z;&5F=#X\+V1I=CXQ+#0U-BPU-3`-"@D)"0D\+W1D/@T*"0D)
M"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[<&%D
M9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M
M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,S`E
M.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)
M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C$P+C<P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^
M/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^-3$N,#(-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU
M,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T
M.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,3(N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ<FEG:'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)
M"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G
M/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P
M86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$R+C`P)3MP
M861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.G)I9VAT.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB
M<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1'=I9'1H.C`Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)
M"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)
M"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.C0Q+C`P)3MB86-K
M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT
M.C$P-BXV-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^17AE<F-I
M<V5D(#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R
M.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO
M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,3(N,#`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT
M+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F
M;&]A=#IL969T/CPO9&EV/B@R,S0L.#,P#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O
M=6YD+6-O;&]R.B`C0T-%149&.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE
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M=&@Z,3`N-S`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N
M.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL
M969T/CPO9&EV/C$R+C@V#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R
M.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO
M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,3(N,#`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ<FEG:'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S
M<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,3(N,#`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[
M<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ<FEG:'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF
M;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%
M149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)
M"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$
M=&]P('-T>6QE/3-$=VED=&@Z-#$N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM
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M="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P)3L[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ
M<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE
M9G0^/"]D:78^*#(V+#(V-0T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3L^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG
M/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1'=I9'1H.C`Q+C,P)3MP861D:6YG.C!P=#L^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-
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M8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G
M/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$R+C`P)3MP861D:6YG.C!P=#L^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MT97AT+6%L:6=N.G)I9VAT.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H
M.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-
M"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T1W:61T:#HQ,BXP,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X
M="UA;&EG;CIR:6=H=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,2XP,"4[
M<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI
M;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T
M9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S
M='EL93TS1"=W:61T:#HT,2XP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&
M1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T
M(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT
M.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7-I>F4Z,3!P=#LG/D5X<&ER960@/"]F;VYT/CPO<#X-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[
M)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[8F]R9&5R
M+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D
M97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@
M(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I
M=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^*#4Y-`T*"0D)"3PO=&0^#0H)
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M;VT@<W1Y;&4],T0G=VED=&@Z,#$N,S`E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R
M+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N
M;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN
M9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P
M+C<P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL969T
M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P
M,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O
M=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS
M1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS.#@N-3,-
M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN
M9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[
M8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@
M;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P
M(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC
M;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS
M1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIR
M:6=H=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U
M;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)
M)FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[8F%C:V=R;W5N
M9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG
M;CIR:6=H=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,#`E.V)A8VMG
M<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)
M"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*
M"0D)"3QT9"!V86QI9VX],T1T;W`@<W1Y;&4],T1W:61T:#HT,2XP,"4[<&%D
M9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P
M<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T
M)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7-I>F4Z,3!P=#LG/D]U='-T86YD:6YG(&%T($UA<F-H)FYB<W`[,S$L(#(P
M,34@/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[<&%D9&EN9SHP<'0[/@T*"0D)
M"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^
M#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P
M="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y
M(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG
M:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P
M/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/C0L-C(W
M+#@S,PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N
M8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=VED=&@Z,#$N,S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P
M,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB
M;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N
M92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SXD/"]F
M;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=VED=&@Z,3`N-S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P
M,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB
M;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N
M92`C1#E$.40Y(#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^
M/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,S,N-C`-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU
M,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T
M.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C$R+C`P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M
M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI
M9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ<FEG:'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SXX
M+CD@>65A<G,\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,2XS,"4[<&%D9&EN9SHP
M<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT
M.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[9F]N="US:7IE.C$P<'0[)SXD/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`N-S`E
M.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE
M/3-$9FQO870Z;&5F=#X\+V1I=CXQ-#`L,SDY#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I
M;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@<W1Y;&4]
M,T0G=VED=&@Z-#$N,#`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@
M,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P
M="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N
M="US:7IE.C$P<'0[)SY697-T960@;W(@17AP96-T960@=&\@=F5S="!A="!-
M87)C:"9N8G-P.S,Q+"`R,#$U(#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB
M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
M"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z,7!T
M('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@
M.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H
M=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE
M/3-$9FQO870Z;&5F=#X\+V1I=CXT+#,S,BPW,C8-"@D)"0D\+W1D/@T*"0D)
M"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N-3`E.V)A
M8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS,"4[8F]R9&5R+71O<#HQ<'0@
M<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[
M8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT
M.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[
M<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)
M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C$P+C<P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D
M97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S
M;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[
M8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N
M;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^
M,S(N-S0-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[
M<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ
M,BXP,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE
M9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@
M(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG
M<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@
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M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C,P)3MB
M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-
M"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I
M>F4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F%C:V=R;W5N
M9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N
M;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,3,S+#(S,@T*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HP,2XP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG
M.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I
M9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS
M1'=I9'1H.C0Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[
M=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^17AE<F-I<V%B;&4@870@
M36%R8V@F;F)S<#LS,2P@,C`Q-2`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP
M861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N
M,#`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T
M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y
M1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG
M;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z
M;&5F=#X\+V1I=CXQ+#`S-RPR-C(-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[<&%D9&EN9SHP<'0[
M/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P
M-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@
M,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M
M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E
M<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*"0D)
M"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^
M#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US
M:7IE.C$P<'0[)SXD/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`N-S`E.V)O<F1E<BUT
M;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$
M.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R
M+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO
M=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS
M,"XY.`T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N
M8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P
M,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB
M;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE
M("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.G)I9VAT
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M.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N
M,S`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C$P+C<P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R
M87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^-#4L,3,W#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,#$N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*
M"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D\+W1A8FQE/CPO9&EV/@T*"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@,3!P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[9F]N="US:7IE.C$P<'0[)SY4:&4@9F%I<B!V86QU92!O9B!G<F%N
M=',@;6%D92!I;B!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H)FYB<W`[
M,S$L(#(P,34@=V%S(&-O;G1E;7!O<F%N96]U<VQY(&5S=&EM871E9"!O;B!T
M:&4@9&%T92!O9B!G<F%N="!U<VEN9R!T:&4@9F]L;&]W:6YG(&%S<W5M<'1I
M;VYS.CPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G
M/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[
M/"]F;VYT/@T*"0D\+W`^#0H)"3QD:78@<W1Y;&4],T1W:61T:#HQ,#`E/CQT
M86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$
M)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93MW:61T:#H@-3,N,#`E.VUA<F=I
M;BUL969T.C$R-G!T.R<^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1'=I9'1H.C4S+C0V)3MP861D:6YG.C!P=#L^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
M"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P
M.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z,#0N-C8E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E
M>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HT,"XP
M,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ
M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P
M,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP
M<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
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M;&0[9F]N="US:7IE.CAP=#LG/F5N9&5D)FYB<W`[36%R8V@F;F)S<#L\+V9O
M;G0^/&)R("\^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M
M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C,Q+"9N8G-P.S(P,34\+V9O
M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1'=I9'1H.C`Q+C@X)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L
M:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)
M/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$
M)W=I9'1H.C4S+C0V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P
M="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UI;F1E;G0Z("TQ,'!T
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M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HT,"XP
M,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z
M,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$
M.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N
M9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG
M;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[9F]N="US:7IE.C$P<'0[)SXQ+C4T)2`F(W@R,#$T.R`Q+C<W)3PO9F]N
M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C`Q+C@X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\
M+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P
M('-T>6QE/3-$=VED=&@Z-3,N-#8E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY%>'!E8W1E
M9"!V;VQA=&EL:71Y(#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#0N-C8E.W!A9&1I;F<Z
M,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C0P+C`P)3MP861D
M:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/C8W
M)2TV.24\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C@X)3MP861D:6YG.C!P=#L^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T
M)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)
M"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.C4S
M+C0V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI
M;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T
M.R<^17AP96-T960@=&5R;2`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP-"XV-B4[8F%C
M:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)
M"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C0P+C`P)3MB86-K9W)O=6YD+6-O;&]R
M.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E
M<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T
M)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7-I>F4Z,3!P=#LG/C4N-3`@+2`V+C$Q('EE87)S/"]F;VYT/CPO<#X-"@D)
M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,#$N.#@E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP
M<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\
M+W1R/@T*"0D\+W1A8FQE/CPO9&EV/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R
M<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB
M<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
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M=&AE('1H<F5E(&UO;G1H('!E<FEO9"!E;F1E9"!-87)C:"9N8G-P.S,Q+"`R
M,#$U('=A<R`D,S$N.#(@<&5R('-H87)E+CPO9F]N=#X-"@D)/"]P/@T*"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY4:&4@0V]M<&%N>2!U<V5S('1H
M92`F(W@R,#%#.W-I;7!L:69I960@;65T:&]D)B-X,C`Q1#L@=&\@9&5T97)M
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M"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F
M;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF
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M"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T
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M86YY)B-X,C`Q.3MS(')E<W1R:6-T960@<W1O8VLZ/"]F;VYT/@T*"0D\+W`^
M#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)
M/&1I=B!S='EL93TS1'=I9'1H.C$P,"4^/'1A8FQE(&-E;&QP861D:6YG/3-$
M,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O
M;&QA<'-E.W=I9'1H.B`Q,#`N,#`E.VUA<F=I;BUL969T.C!P=#LG/@T*"0D)
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M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R
M+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)
M"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$
M-"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,S(N-3`E.V)O<F1E
M<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R
M9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG
M/E)E<W1R:6-T960F;F)S<#M3=&]C:SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,#`E
M.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)
M)FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)
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M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D
M:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P
M.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,34N,#`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P
M,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T
M;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C
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M="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L
M<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$U+C`P
M)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL969T.C%P
M="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P
M,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P
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M;F)S<#M&86ER)FYB<W`[/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[
M)SY686QU93PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;F<Z,'!T.SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)
M"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T
M;W`@<W1Y;&4],T0G=VED=&@Z-C0N,#`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN
M9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[9F]N="US:7IE.C$P<'0[)SY*86YU87)Y)FYB<W`[,2P@,C`Q-2`\
M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#
M145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ
M,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)
M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C$U+C`P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D
M97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N
M;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB
M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO
M=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXW
M,3@L-#`P#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M,#$N,S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL
M969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG
M<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)
M"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ
M,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$S+C<P)3MB;W)D97(M=&]P.C%P
M="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y
M(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H
M=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE
M/3-$9FQO870Z;&5F=#X\+V1I=CXQ,"XW,@T*"0D)"3PO=&0^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XP,"4[8F%C:V=R
M;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)
M"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)
M"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1'=I9'1H.C8T+C`P)3MP861D
M:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P
M="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UI;F1E;G0Z("TQ,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G
M/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M
M<VEZ93HQ,'!T.R<^1W)A;G1E9"`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP
M861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ-2XP
M,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T
M.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIR:6=H=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)
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M93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,34N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ<FEG:'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)
M"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE
M.C$P<'0[)SXF(W@R,#$T.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I
M;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@<W1Y;&4]
M,T0G=VED=&@Z-C0N,#`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@
M,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P
M="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N
M="US:7IE.C$P<'0[)SY697-T960@/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N-3`E
M.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G
M/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-2XP,"4[8F%C:V=R;W5N9"UC
M;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R
M87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^*#,U,"PP.#0-"@D)
M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[)SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*
M"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ
M93HQ,'!T.R<^*3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD
M+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG
M/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#HQ,RXW,"4[8F%C:V=R;W5N9"UC;VQO<CH@
M(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I
M=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,3`N-3D-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,#`E
M.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G
M/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)
M/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@<W1Y;&4],T1W:61T:#HV-"XP
M,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T
M(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT
M.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7-I>F4Z,3!P=#LG/D9O<F9E:71E9"`\+V9O;G0^/"]P/@T*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H
M.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-
M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,34N,#`E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R
M9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@
M<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@
M.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE
M/3-$9FQO870Z;&5F=#X\+V1I=CXH,RPS-#8-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[/@T*"0D)
M"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^
M#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US
M:7IE.C$P<'0[)SXI/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,2XS,"4[<&%D9&EN9SHP
M<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT
M.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[9F]N="US:7IE.C$P<'0[)SXD/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3,N-S`E
M.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE
M/3-$9FQO870Z;&5F=#X\+V1I=CXQ,"XX,@T*"0D)"3PO=&0^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C`P)3MP861D:6YG
M.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)
M/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$
M)W=I9'1H.C8T+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P
M="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UI;F1E;G0Z("TQ,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G
M/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M
M<VEZ93HQ,'!T.R<^56YV97-T960@870@36%R8V@F;F)S<#LS,2P@,C`Q-2`\
M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#
M145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ
M,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)
M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C$U+C`P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D
M97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D
M;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@
M.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@
M;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV
M/C,V-"PY-S`-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%
M1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)
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M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3,N-S`E
M.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@
M;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV
M/C$P+C@U#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\
M+W1D/@T*"0D)/"]T<CX-"@D)/"]T86)L93X\+V1I=CX-"@D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
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M9B!O<&5R871I;VYS(&%S(&9O;&QO=W,Z/"]F;VYT/@T*"0D\+W`^#0H)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/&1I=B!S
M='EL93TS1'=I9'1H.C$P,"4^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL
M<W!A8VEN9STS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E
M.W=I9'1H.B`Q,#`N,#`E.VUA<F=I;BUL969T.C!P=#LG/@T*"0D)/'1R/@T*
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M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP
M861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N
M8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$-2!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,S(N-3`E.V)O<F1E<BUT;W`Z
M,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$
M.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I
M9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT
M+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/E1H<F5E
M)FYB<W`[36]N=&AS)FYB<W`[16YD960F;F)S<#M-87)C:"9N8G-P.SPO9F]N
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M#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\
M='(^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C8T
M+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N
M-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)
M"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-2XP,"4[8F]R9&5R
M+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R
M9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG
M/C(P,34\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,34N,#`E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$
M.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O
M;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$
M.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`X<'0G/@T*
M"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I
M9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P,30\+V9O;G0^/"]P/@T*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H
M.C`Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
M"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT
M<CX-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-C0N
M,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N
M=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3)P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[)SXF;F)S<#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P
M=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M,34N,#`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL
M969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.G)I9VAT.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[
M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N
M8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,34N,#`E.V)O<F1E<BUT;W`Z
M,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y
M1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I
M9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT
M+6%L:6=N.G)I9VAT.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C`P)3MP
M861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D
M/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T
M>6QE/3-$)W=I9'1H.C8T+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@
M,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UI;F1E;G0Z
M("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M<VEZ93HQ,'!T.R<^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT(#PO
M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%
M149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)
M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,#$N,S`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP
M<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$S+C<P
M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG
M(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I
M=CXT+#8V-R9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO<CH@
M(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G
M:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ
M,RXW,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG
M:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^
M/"]D:78^,2PY-#0F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,#`E.V)A8VMG<F]U;F0M8V]L
M;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[
M/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V
M86QI9VX],T1T;W`@<W1Y;&4],T1W:61T:#HV-"XP,"4[<&%D9&EN9SHP<'0[
M/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)
M"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P
M=#LG/E-E;&QI;F<L(&=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E(#PO9F]N
M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)
M)FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-2XP,"4[8F]R9&5R+71O
M<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$
M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M
M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W
M<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/C4L
M,#@Q)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)
M"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-2XP,"4[8F]R9&5R
M+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D
M97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@
M;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV
M/C$L-S8Q)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R
M/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@<W1Y;&4],T0G=VED=&@Z-C0N,#`E
M.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY4
M;W1A;"`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO
M<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P
M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M
M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$
M.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[
M)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$S+C<P)3MB
M;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@
M;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P
M,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M
M8V]L;W(Z("-#0T5%1D8[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W
M<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/CDL-S0X)FYB<W`[
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,S`E
M.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P
M="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,G!T(&1O=6)L92`C,#`P
M,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N
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M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3,N-S`E.V)O<F1E<BUT;W`Z,7!T('-O
M;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O
M<F1E<BUB;W1T;VTZ,G!T(&1O=6)L92`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z
M,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E
M>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS
M1&9L;V%T.FQE9G0^/"]D:78^,RPW,#4F;F)S<#L-"@D)"0D\+W1D/@T*"0D)
M"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,#`E.V)A
M8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D\+W1A
M8FQE/CPO9&EV/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*
M"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY!<R!O
M9B!-87)C:"9N8G-P.S,Q+"`R,#$U('1H97)E('=A<R!A<'!R;WAI;6%T96QY
M("0W,"XV(&UI;&QI;VX@;V8@=&]T86P@=6YR96-O9VYI>F5D(&-O;7!E;G-A
M=&EO;B!C;W-T(')E;&%T960@=&\@=6YV97-T960@<VAA<F4M8F%S960@8V]M
M<&5N<V%T:6]N(&%R<F%N9V5M96YT<R!G<F%N=&5D('5N9&5R('1H92`R,#`Y
M($5Q=6ET>2!A;F0@3&]N9R!497)M($EN8V5N=&EV92!0;&%N+"`R,#$S($QO
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M=FEC92!P97)I;V0@;V8@87!P<F]X:6UA=&5L>2`S+C`@>65A<G,N/"]F;VYT
M/@T*"0D\+W`^#0H)"3QP/CQF;VYT('-I>F4],T0Q/B`\+V9O;G0^/"]P/@T*
M"3PO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7S<R9C0T.#5A7V1D-39?-#4Y-5\X,S`U7S`P86,P,&%F9#AA
M9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\W,F8T-#@U85]D9#4V
M7S0U.35?.#,P-5\P,&%C,#!A9F0X868O5V]R:W-H965T<R]3:&5E=#$U+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]M;6ET
M;65N=',@86YD(&-O;G1I;F=E;F-I97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@8V]N
M=&EN9V5N8VEE<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VUM:71M96YT<R!A;F0@8V]N=&EN9V5N8VEE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX@/&1I=B!S='EL93TS1&UA
M<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"@D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
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M>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@,3!P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z,3!P=#LG/D]P97)A
M=&EN9R!L96%S97,\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG
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M871E;'D@)#`N,R!M:6QL:6]N(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D
M($UA<F-H)FYB<W`[,S$L(#(P,34N(%1H92!#;VUP86YY(&%L<V\@;&5A<V5S
M(&-E<G1A:6X@;V9F:6-E(&5Q=6EP;65N="!U;F1E<B!O<&5R871I;F<@;&5A
M<V5S+B!&=71U<F4@;6EN:6UU;2!L96%S92!P87EM96YT<R!A<R!O9B!-87)C
M:"9N8G-P.S,Q+"`R,#$U(&%R92!A<R!F;VQL;W=S.CPO9F]N=#X-"@D)/"]P
M/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)
M"3QD:78@<W1Y;&4],T1W:61T:#HQ,#`E/CQT86)L92!C96QL<&%D9&EN9STS
M1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC
M;VQL87!S93MW:61T:#H@.#`N,#`E.VUA<F=I;BUL969T.C4T<'0[)SX-"@D)
M"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.C@P
M+C8R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI
M;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T
M.R<^,C`Q-2`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,RXQ,B4[8F%C:V=R;W5N9"UC
M;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS
M1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S
M<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HQ,RXW,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI
M9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T
M.FQE9G0^/"]D:78^,2PP,38F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,C8E.V)A8VMG<F]U
M;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)
M)FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)
M"3QT9"!V86QI9VX],T1T;W`@<W1Y;&4],T1W:61T:#HX,"XV,B4[<&%D9&EN
M9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@
M,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-
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M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C$U+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^
M/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^.30V)FYB<W`[#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,#$N,C8E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*
M"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX]
M,T1T;W`@<W1Y;&4],T0G=VED=&@Z.#`N-C(E.V)A8VMG<F]U;F0M8V]L;W(Z
M("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT
M+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SXR,#$W(#PO9F]N=#X\+W`^#0H)
M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C`S+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z
M,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)
M"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,34N,#`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[.V9O;G0M9F%M
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M<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D
M('9A;&EG;CTS1'1O<"!S='EL93TS1'=I9'1H.C@P+C8R)3MP861D:6YG.C!P
M=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T
M.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)
M"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ
M,'!T.R<^,C`Q."`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C$R)3MP861D:6YG.C!P
M=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M,34N,#`E.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV
M('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+#`S-29N8G-P.PT*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q
M+C(V)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)
M"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$
M=&]P('-T>6QE/3-$)W=I9'1H.C@P+C8R)3MB86-K9W)O=6YD+6-O;&]R.B`C
M0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UI
M;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^,C`Q.2`\+V9O;G0^/"]P/@T*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#HP,RXQ,B4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P
M=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT
M.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C$U+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL
M969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED
M(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K
M9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A
M<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ-S8F
M;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,#$N,C8E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[
M<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO
M=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T1W:61T:#HX,"XV,B4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"3QF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)
M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED
M=&@Z,#,N,3(E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P
M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HP,2XS,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[
M8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ
M<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y
M1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B0\+V9O;G0^/"]P
M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HQ,RXW,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[
M8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ
M<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y
M1#D@.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T
M>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT+#`Y-B9N8G-P.PT*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C(V
M)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\
M+W1D/@T*"0D)/"]T<CX-"@D)/"]T86)L93X\+V1I=CX-"@D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$P<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.C$P<'0[)SY/=&AE<B!C;VYT
M:6YG96YC:65S/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@
M,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF
M;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T
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M('5P('1O(&%N(&%G9W)E9V%T92!O9B`D-C@N.2!M:6QL:6]N(&%N9"!S:6YG
M;&4M9&EG:70@<F]Y86QT:65S(&]N('-A;&5S(&]F(&%N>2!R97-E87)C:"!P
M<F]G<F%M('!R;V1U8W0N(%1H92!#;VUP86YY)B-X,C`Q.3MS(&]B;&EG871I
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M=6YT<GDN/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P
M="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S
M<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-
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M<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE
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M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W,F8T-#@U85]D9#4V7S0U.35?
M.#,P-5\P,&%C,#!A9F0X868-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO-S)F-#0X-6%?9&0U-E\T-3DU7S@S,#5?,#!A8S`P869D.&%F+U=O<FMS
M:&5E=',O4VAE970Q-BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/D-O;&QA8F]R871I;VX@4F5V96YU93QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;&QA8F]R871I
M;VX@4F5V96YU93PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VQL86)O<F%T:6]N(%)E=F5N=64\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQD:78^(#QD:78@<W1Y;&4],T1M87)G:6XM;&5F
M=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@
M,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF
M;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T
M)SX-"@D)"3QF;VYT('-T>6QE/3-$)W1E>'0M:6YD96YT.C!P=#MM87)G:6XM
M;&5F=#HP<'0[('!A9&1I;F<M<FEG:'0Z,C-P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HQ
M,'!T.R<^,3`N/"]F;VYT/CPO9F]N=#X\9F]N="!S='EL93TS1"=T97AT+6EN
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M/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)
M"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O
M;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG
M/DEN($IA;G5A<GDF;F)S<#LR,#$T+"!T:&4@0V]M<&%N>2!A;FYO=6YC960@
M=&AE(&EN:71I871I;VX@;V8@82!0:&%S92`Q(&-L:6YI8V%L('!R;V=R86T@
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M964@;6]N=&AS(&5N9&5D($UA<F-H)FYB<W`[,S$L(#(P,30N/"]F;VYT/@T*
M"0D\+W`^#0H)"3QP/CQF;VYT('-I>F4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO
M9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7S<R9C0T.#5A7V1D-39?-#4Y-5\X,S`U7S`P86,P,&%F9#AA9@T*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\W,F8T-#@U85]D9#4V7S0U
M.35?.#,P-5\P,&%C,#!A9F0X868O5V]R:W-H965T<R]3:&5E=#$W+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%2D-!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6UM87)Y
M(&]F('-I9VYI9FEC86YT(&%C8V]U;G1I;F<@<&]L:6-I97,@*%!O;&EC:65S
M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R
M,#$U/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E-U;6UA<GD@;V8@<VEG;FEF:6-A;G0@86-C;W5N=&EN9R!P;VQI8VEE
M<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"
M87-I<R!O9B!P<F5S96YT871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQD:78^(#QD:78@<W1Y;&4],T1M87)G:6XM;&5F=#HP<'0[;6%R
M9VEN+7)I9VAT.C!P=#L^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)
M"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O
M;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD
M.V9O;G0M<VEZ93HQ,'!T.R<^0F%S:7,@;V8@4')E<V5N=&%T:6]N/"]F;VYT
M/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)
M"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/E1H92!A
M8V-O;7!A;GEI;F<@9FEN86YC:6%L(&EN9F]R;6%T:6]N(&%S(&]F($UA<F-H
M)FYB<W`[,S$L(#(P,34@86YD(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D
M($UA<F-H)FYB<W`[,S$L(#(P,34@86YD(#(P,30@:&%S(&)E96X@<')E<&%R
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M8V]U;G1I;F<@<')I;F-I<&QE<R!I;B!T:&4@56YI=&5D(%-T871E<R`H1T%!
M4"D@:&%V92!B965N(&-O;F1E;G-E9"!O<B!O;6ET=&5D('!U<G-U86YT('1O
M('-U8V@@<G5L97,F;F)S<#MA;F0@<F5G=6QA=&EO;G,N(%1H97-E(&EN=&5R
M:6T@9FEN86YC:6%L('-T871E;65N=',@<VAO=6QD(&)E(')E860@:6X@8V]N
M:G5N8W1I;VX@=VET:"!T:&4@0V]M<&%N>28C>#(P,3D[<R!A=61I=&5D(&9I
M;F%N8VEA;"!S=&%T96UE;G1S(&%S(&]F($1E8V5M8F5R)FYB<W`[,S$L(#(P
M,30@86YD(&YO=&5S('1H97)E=&\@:6YC;'5D960@:6X@=&AE(#(P,30@1F]R
M;29N8G-P.S$P+4LN/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7-I>F4Z,3!P=#LG/DEN('1H92!O<&EN:6]N(&]F(&UA;F%G96UE;G0L('1H
M92!U;F%U9&ET960@9FEN86YC:6%L(&EN9F]R;6%T:6]N(&%S(&]F($UA<F-H
M)FYB<W`[,S$L(#(P,34@86YD(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D
M($UA<F-H)FYB<W`[,S$L(#(P,34@86YD(#(P,30@<F5F;&5C=',@86QL(&%D
M:G5S=&UE;G1S+"!W:&EC:"!A<F4@;F]R;6%L(')E8W5R<FEN9R!A9&IU<W1M
M96YT<RP@;F5C97-S87)Y('1O('!R97-E;G0@82!F86ER('-T871E;65N="!O
M9B!F:6YA;F-I86P@<&]S:71I;VXL(')E<W5L=',@;V8@;W!E<F%T:6]N<R!A
M;F0@8V%S:"!F;&]W<RX@5&AE(')E<W5L=',@;V8@;W!E<F%T:6]N<R!F;W(@
M=&AE('1H<F5E(&UO;G1H('!E<FEO9"!E;F1E9"!-87)C:"9N8G-P.S,Q+"`R
M,#$U(&%R92!N;W0@;F5C97-S87)I;'D@:6YD:6-A=&EV92!O9B!T:&4@<F5S
M=6QT<R!T;R!B92!E>'!E8W1E9"!F;W(@=&AE('EE87(@96YD960@1&5C96UB
M97(F;F)S<#LS,2P@,C`Q-2!O<B!F;W(@86YY(&]T:&5R(&EN=&5R:6T@<&5R
M:6]D(&]R(&9O<B!A;GD@;W1H97(@9G5T=7)E('EE87(N/"]F;VYT/@T*"0D\
M+W`^#0H)"3QP/CQF;VYT('-I>F4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV
M/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E5S92!O9B!E<W1I;6%T97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQD:78^(#QD:78@<W1Y;&4],T1M87)G:6XM;&5F=#HP
M<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P
M="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S
M<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-
M"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H
M=#IB;VQD.V9O;G0M<VEZ93HQ,'!T.R<^57-E(&]F(&5S=&EM871E<SPO9F]N
M=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*
M"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY4:&4@
M<')E<&%R871I;VX@;V8@9FEN86YC:6%L('-T871E;65N=',@:6X@8V]N9F]R
M;6ET>2!W:71H($=!05`@<F5Q=6ER97,@;6%N86=E;65N="!T;R!M86ME(&5S
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M=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y);G9E;G1O<FEE<R!A;F0@8V]S="!O9B!P<F]D=6-T(')E
M=F5N=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^(#QD
M:78@<W1Y;&4],T1M87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^
M#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HQ,'!T
M.R<^26YV96YT;W)I97,@86YD(&-O<W0@;V8@<')O9'5C="!R979E;G5E/"]F
M;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^
M#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/D]N
M($%U9W5S="9N8G-P.S0L(#(P,30L('1H92!#;VUP86YY('=A<R!N;W1I9FEE
M9"!T:&%T('1H92!%=7)O<&5A;B!#;VUM:7-S:6]N+"!O<B!%0RP@9W)A;G1E
M9"!M87)K971I;F<@875T:&]R:7IA=&EO;B!F;W(@5')A;G-L87)N82!F;W(@
M=&AE('1R96%T;65N="!O9B!$=6-H96YN92!M=7-C=6QA<B!D>7-T<F]P:'D@
M8V%U<V5D(&)Y(&YO;G-E;G-E(&UU=&%T:6]N<RP@;W(@;FU$340L(&EN(&%M
M8G5L871O<GD@<&%T:65N=',@86=E9"!F:79E('EE87)S(&%N9"!O;&1E<BX@
M5&AE(&UA<FME=&EN9R!A=71H;W)I>F%T:6]N(&%L;&]W<R!T:&4@0V]M<&%N
M>2!T;R!M87)K970@5')A;G-L87)N82!I;B!T:&4@175R;W!E86X@16-O;F]M
M:6,@07)E82P@;W(@145!+"!W:&EC:"!I<R!C;VUP<FES960@;V8@=&AE(#(X
M(&UE;6)E<B!S=&%T97,@;V8@=&AE($5U<F]P96%N(%5N:6]N('!L=7,@3F]R
M=V%Y+"9N8G-P.TEC96QA;F0@86YD($QI96-H=&5N<W1E:6XN(%1H:7,@;6%R
M:V5T:6YG(&%U=&AO<FEZ871I;VX@:7,@<W5B:F5C="!T;R!A;FYU86P@<F5V
M:65W(&%N9"!R96YE=V%L(&)Y('1H92!%=7)O<&5A;B!-961I8VEN97,@06=E
M;F-Y+"!O<B!%34$@9F]L;&]W:6YG(&ET<R!R96%S<V5S<VUE;G0@;V8@=&AE
M(')I<VLM8F5N969I="!B86QA;F-E(&]F('1H92!A=71H;W)I>F%T:6]N(&%N
M9"!I<R!F=7)T:&5R(&-O;F1I=&EO;F5D(&]N('1H92!#;VUP86YY)B-X,C`Q
M.3MS(&%B:6QI='D@=&\@8V]M<&QE=&4@:71S(&=L;V)A;"P@8V]N9FER;6%T
M;W)Y(%!H87-E(#,@8VQI;FEC86P@=')I86P@:6X@;FT@1$U$+"!W:&EC:"!I
M="!R969E<G,@=&\@87,@04-4($1-1"P@86YD('-U8FUI="!T:&4@9FEN86P@
M<F5P;W)T+"!I;F-L=61I;F<@861D:71I;VYA;"!E9F9I8V%C>2!A;F0@<V%F
M971Y(&1A=&$@9G)O;2!T:&4@=')I86P@9'5R:6YG(#(P,34N)FYB<W`[)FYB
M<W`[5&AE(&QA=6YC:"!I;B!T:&5S92!C;W5N=')I97,@:7,@;VX@82!C;W5N
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M,C`Q.3MS(&-O<W0@;V8@<')O9'5C="!S86QE<R!I;F-L=61E<R!R;WEA;'1I
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M(&5X<&ER871I;VX@9&%T92X\+V9O;G0^#0H)"3PO<#X-"@D)/'`^/&9O;G0@
M<VEZ93TS1#$^(#PO9F]N=#X\+W`^#0H)/"]D:78^(#PO9&EV/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C96YT
M;'D@:7-S=65D(&%C8V]U;G1I;F<@<W1A;F1A<F0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQD:78^(#QD:78@<W1Y;&4],T1M87)G:6XM;&5F
M=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@
M,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF
M;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T
M)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E
M:6=H=#IB;VQD.V9O;G0M<VEZ93HQ,'!T.R<^4F5C96YT;'D@:7-S=65D(&%C
M8V]U;G1I;F<@<W1A;F1A<F0\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$P<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M<VEZ93HQ,'!T.R<^26X@36%Y)FYB<W`[,C`Q-"P@=&AE($9I;F%N
M8VEA;"!!8V-O=6YT:6YG(%-T86YD87)D<R!";V%R9"`H1D%30BD@:7-S=65D
M($%C8V]U;G1I;F<@4W1A;F1A<F1S(%5P9&%T92`H05-5*2!.;RXF;F)S<#LR
M,#$T+3`Y+"!2979E;G5E(&9R;VT@0V]N=')A8W1S('=I=&@@0W5S=&]M97)S
M+B!!4U4@,C`Q-"TP.2!W:6QL(&5L:6UI;F%T92!T<F%N<V%C=&EO;BT@86YD
M(&EN9'5S=')Y+7-P96-I9FEC(')E=F5N=64@<F5C;V=N:71I;VX@9W5I9&%N
M8V4@=6YD97(@8W5R<F5N="!'04%0(&%N9"!R97!L86-E(&ET('=I=&@@82!P
M<FEN8VEP;&4M8F%S960@87!P<F]A8V@@9F]R(&1E=&5R;6EN:6YG(')E=F5N
M=64@<F5C;V=N:71I;VXN($%352`R,#$T+3`Y('=I;&P@<F5Q=6ER92!T:&%T
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M8W5R<F5D('1O(&]B=&%I;B!O<B!F=6QF:6QL(&$@8V]N=')A8W0N($%352`R
M,#$T+3`Y(&ES(&5F9F5C=&EV92!F;W(@86YN=6%L(')E<&]R=&EN9R!P97)I
M;V1S(&)E9VEN;FEN9R!A9G1E<B!$96-E;6)E<B9N8G-P.S$U+"`R,#$V+B!%
M87)L>2!A<'!L:6-A=&EO;B!I<R!N;W0@<&5R;6ET=&5D+B!%;G1I=&EE<R!C
M86X@=')A;G-I=&EO;B!T;R!T:&4@<W1A;F1A<F0@96ET:&5R(')E=')O<W!E
M8W1I=F5L>2!O<B!A<R!A(&-U;75L871I=F4M969F96-T(&%D:G5S=&UE;G0@
M87,@;V8@=&AE(&1A=&4@;V8@861O<'1I;VXN(%!R97-E;G1L>2P@=&AE($-O
M;7!A;GD@:7,@87-S97-S:6YG('=H870@969F96-T('1H92!A9&]P=&EO;B!O
M9B!!4U4@,C`Q-"TP.2!W:6QL(&AA=F4@;VX@:71S(&9I;F%N8VEA;"!S=&%T
M96UE;G1S(&%N9"!A8V-O;7!A;GEI;F<@;F]T97,N/"]F;VYT/@T*"0D\+W`^
M#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/DEN($%U9W5S="9N8G-P
M.S(P,30L('1H92!&05-"(&ES<W5E9"!!4U4@,C`Q-"TQ-2P@)B-X,C`Q0SM0
M<F5S96YT871I;VX@;V8@1FEN86YC:6%L(%-T871E;65N=',F(W@R,#$T.T=O
M:6YG($-O;F-E<FXF(W@R,#$T.T1I<V-L;W-U<F5S(&]F(%5N8V5R=&%I;G1I
M97,@86)O=70@86X@96YT:71Y)B-X,C`Q.3MS($%B:6QI='D@=&\@0V]N=&EN
M=64@87,@82!';VEN9R!#;VYC97)N+B8C>#(P,40[($%352`R,#$T+3$U('!R
M;W9I9&5S(&YE=R!G=6ED86YC92!R96QA=&5D('1O(&UA;F%G96UE;G0F(W@R
M,#$Y.W,@<F5S<&]N<VEB:6QI='D@=&\@979A;'5A=&4@=VAE=&AE<B!T:&5R
M92!I<R!S=6)S=&%N=&EA;"!D;W5B="!A8F]U="!A;B!E;G1I='DF(W@R,#$Y
M.W,@86)I;&ET>2!T;R!C;VYT:6YU92!A<R!A(&=O:6YG(&-O;F-E<FX@8GD@
M:6YC;W)P;W)A=&EN9R!A;F0@97AP86YD:6YG('5P;VX@8V5R=&%I;B!P<FEN
M8VEP;&5S('1H870@87)E(&-U<G)E;G1L>2!I;B!5+E,N(&%U9&ET:6YG('-T
M86YD87)D<R!A;F0@=&\@<')O=FED92!R96QA=&5D(&9O;W1N;W1E(&1I<V-L
M;W-U<F5S+B!4:&ES(&YE=R!G=6ED86YC92!I<R!E9F9E8W1I=F4@9F]R('1H
M92!A;FYU86P@<&5R:6]D(&5N9&EN9R!A9G1E<B!$96-E;6)E<B9N8G-P.S$U
M+"`R,#$V+"!A;F0@9F]R(&%N;G5A;"!P97)I;V1S(&%N9"!I;G1E<FEM('!E
M<FEO9',@=&AE<F5A9G1E<BX@5&AE(')E<75I<F5M96YT<R!O9B!!4U4@,C`Q
M-"TQ-2!A<F4@;F]T(&5X<&5C=&5D('1O(&AA=F4@82!S:6=N:69I8V%N="!I
M;7!A8W0@;VX@=&AE($-O;F1E;G-E9"!#;VYS;VQI9&%T960@1FEN86YC:6%L
M(%-T871E;65N=',N/"]F;VYT/@T*"0D\+W`^#0H)"3QP/CQF;VYT('-I>F4]
M,T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5N=64@<F5C
M;V=N:71I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^
M(#QD:78@<W1Y;&4],T1M87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P
M=#L^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-
M"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HQ
M,'!T.R<^4F5V96YU92!296-O9VYI=&EO;CPO9F]N=#X-"@D)/"]P/@T*"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T
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M87)R86YG96UE;G0@97AI<W1S.R`H,BDF;F)S<#MD96QI=F5R>2!H87,@;V-C
M=7)R960@;W(@<V5R=FEC97,@:&%V92!B965N(')E;F1E<F5D.R`H,RDF;F)S
M<#MT:&4@<')I8V4@:7,@9FEX960@;W(@9&5T97)M:6YA8FQE.R!A;F0@*#0I
M)FYB<W`[8V]L;&5C=&EO;B!O9B!T:&4@86UO=6YT<R!D=64@87)E(')E87-O
M;F%B;'D@87-S=7)E9"X\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G
M:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$P<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O
M;G0M<W1Y;&4Z:71A;&EC.V9O;G0M<VEZ93HQ,'!T.R<^3F5T(%!R;V1U8W0@
M4V%L97,\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T
M)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P
M.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*
M"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ
M,'!T.R<^4%1#)B-X,C`Q.3M3(&YE="!P<F]D=6-T('-A;&5S(&AA=F4@8V]N
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M,#%#.T%30R8C>#(P,40[*2!3=6)T;W!I8R`V,#4M,34L(%)E=F5N=64@4F5C
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M<&5R9F]R;6%N8V4@;V)L:6=A=&EO;G,N/"]F;VYT/@T*"0D\+W`^#0H)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
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M9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP
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M=&AO<V4@8VAA;F=E<R!A<F4@:VYO=VXN/"]F;VYT/@T*"0D\+W`^#0H)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7-T>6QE.FET86QI8SMF;VYT+7-I>F4Z,3!P=#LG/D-O
M;&QA8F]R871I;VX@86YD($=R86YT(%)E=F5N=64\+V9O;G0^#0H)"3PO<#X-
M"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$
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M:65D(&5V96YT<RX\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG
M/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P
M<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M
M<VEZ93HQ,'!T.R<^5&AE($-O;7!A;GD@979A;'5A=&5S(&%L;"!C;VYT:6YG
M96YT(&-O;G-I9&5R871I;VX@96%R;F5D+"!S=6-H(&%S(&$@;6EL97-T;VYE
M('!A>6UE;G0L('5S:6YG('1H92!C<FET97)I82!A<R!P<F]V:61E9"!B>2!T
M:&4@1FEN86YC:6%L($%C8V]U;G1I;F<@4W1A;F1A<F1S($)O87)D("A&05-"
M*2P@9W5I9&%N8V4@;VX@=&AE(&UI;&5S=&]N92!M971H;V0@;V8@<F5V96YU
M92!R96-O9VYI=&EO;BX@070@=&AE(&EN8V5P=&EO;B!O9B!A(&-O;&QA8F]R
M871I;VX@87)R86YG96UE;G0L('1H92!#;VUP86YY(&5V86QU871E<R!I9B!A
M(&UI;&5S=&]N92!P87EM96YT(&ES('-U8G-T86YT:79E+B!4:&4@8W)I=&5R
M:6$@<F5Q=6ER97,@=&AA="`H,2DF;F)S<#MT:&4@0V]M<&%N>2!D971E<FUI
M;F5S(&EF('1H92!M:6QE<W1O;F4@:7,@8V]M;65N<W5R871E('=I=&@@96ET
M:&5R(&ET<R!P97)F;W)M86YC92!T;R!A8VAI979E('1H92!M:6QE<W1O;F4@
M;W(@=&AE(&5N:&%N8V5M96YT(&]F('9A;'5E(')E<W5L=&EN9R!F<F]M(&]U
M<B!A8W1I=FET:65S('1O(&%C:&EE=F4@=&AE(&UI;&5S=&]N93L@*#(I)FYB
M<W`[=&AE(&UI;&5S=&]N92!B92!R96QA=&5D('1O('!A<W0@<&5R9F]R;6%N
M8V4[(&%N9"`H,RDF;F)S<#MT:&4@;6EL97-T;VYE(&)E(')E87-O;F%B;&4@
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M;V-I871E9"!U;FET(&]F(&%C8V]U;G1I;F<N/"]F;VYT/@T*"0D\+W`^#0H)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L
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M86YD(&1E=F5L;W!M96YT(&%C=&EV:71I97,N/"]F;VYT/@T*"0D\+W`^#0H)
M"3QP/CQF;VYT('-I>F4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S<R
M9C0T.#5A7V1D-39?-#4Y-5\X,S`U7S`P86,P,&%F9#AA9@T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\W,F8T-#@U85]D9#4V7S0U.35?.#,P-5\P
M,&%C,#!A9F0X868O5V]R:W-H965T<R]3:&5E=#$X+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M,4%!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY&86ER('9A;'5E(&]F(&9I
M;F%N8VEA;"!I;G-T<G5M96YT<R!A;F0@;6%R:V5T86)L92!S96-U<FET:65S
M("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^1F%I<B!V86QU92!O9B!F:6YA;F-I86P@:6YS=')U;65N
M=',@86YD(&UA<FME=&%B;&4@<V5C=7)I=&EE<SPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!F:6YA;F-I
M86P@87-S971S(&%N9"!L:6%B:6QI=&EE<R!T:&%T(&%R92!R97%U:7)E9"!T
M;R!B92!M96%S=7)E9"!A="!F86ER('9A;'5E(&]N(&$@<F5C=7)R:6YG(&)A
M<VES/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/B`\9&EV
M('-T>6QE/3-$;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*
M"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMT
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M=#MM87)G:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^
M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I
M>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T
M.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F
M;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z
M,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
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M96YT.C!P=#MM87)G:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@
M,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF
M;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I
M;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T
M.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S
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M="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T
M.VUA<F=I;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\
M+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ
M93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMT97AT+6EN9&5N=#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.W!A9&1I;F<Z,'!T(#,V<'0@,'!T(#!P=#LG/CPO9F]N=#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SX\+V9O
M;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ
M,'!T.SMF;VYT+7-I>F4Z(#$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.W1E>'0M:6YD96YT.C!P=#MM87)G:6XM;&5F=#HP<'0[<&%D9&EN9SHP
M<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ
M93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E
M;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P
M<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O
M;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M
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M9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SX\
M+V9O;G0^#0H)"3PO<#X-"@D)/&1I=B!S='EL93TS1'=I9'1H.C$P,"4^/'1A
M8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G
M8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.W=I9'1H.B`Q,#`N,#`E.VUA<F=I
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M;2!S='EL93TS1'=I9'1H.C`R+C0X)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT
M+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!C;VQS<&%N/3-$,3$@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C4U+C4R)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O
M<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T
M('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y
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M;2!S='EL93TS1'=I9'1H.C`Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT
M+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*
M"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$=VED=&@Z-#$N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT
M/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T1W:61T:#HP,BXT."4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG
M;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C$Q+CDX)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M
M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI
M9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF
M;VYT+7-I>F4Z.'!T.R<^5&]T86P\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP
M861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N
M8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z
M,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$
M.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I
M9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT
M+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
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M+7-I>F4Z.'!T.R<^*&QE=F5L)FYB<W`[,2D\+V9O;G0^/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R
M+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)
M"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$
M,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)O<F1E
M<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R
M9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG
M/E-I9VYI9FEC86YT/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I<W!L
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M/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E
M:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[)SXH;&5V96PF;F)S<#LR*3PO9F]N
M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI
M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)
M/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#HQ,BXP,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M
M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI
M9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
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M+7-I>F4Z.'!T.R<^:6YP=71S/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX
M<'0[)SXH;&5V96PF;F)S<#LS*3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,#`E.W!A
M9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB
M<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT
M9"!V86QI9VX],T1T;W`@<W1Y;&4],T0G=VED=&@Z-#$N,#`E.V)A8VMG<F]U
M;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V
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M;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)
M)FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HP,2XS,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@
M(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R
M+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO
M;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG
M.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I
M9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[9F]N="US:7IE.C$P<'0[)SXD/"]F;VYT/CPO<#X-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`N
M-S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T
M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y
M1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U
M;F0M8V]L;W(Z("-#0T5%1D8[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$
M;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/C(T,RPV-#(F
M;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[
M<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP
M,2XS,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE
M9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R
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M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`N-S`E.V)O<F1E<BUT;W`Z,7!T
M('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@
M.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT
M.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[
M<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ<FEG:'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[
M)SXF(W@R,#$T.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD
M+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N
M8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=VED=&@Z,#$N,S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P
M,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB
M;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE
M("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP
M<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P+C<P
M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ
M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y
M1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD
M+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO
M=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-#,L-C0R)FYB
M<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A
M9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N
M,S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T
M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y
M1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U
M;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T
M.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P+C<P)3MB;W)D97(M=&]P.C%P="!S
M;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB
M;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ
M<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A
M9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.G)I9VAT.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^
M)B-X,C`Q-#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XP,"4[8F%C:V=R;W5N9"UC
M;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS
M1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S
M<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D
M('9A;&EG;CTS1'1O<"!S='EL93TS1'=I9'1H.C0Q+C`P)3MP861D:6YG.C!P
M=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T
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M;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C$Q+CDX)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`]
M,T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,C(Y)FYB
M<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB
M<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$R+C`P)3MP861D:6YG.C!P=#L^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MT97AT+6%L:6=N.G)I9VAT.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)B-X,C`Q-#L\+V9O
M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)
M"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ,BXP,"4[<&%D9&EN9SHP
M<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT
M.C$P-BXV-R4[=&5X="UA;&EG;CIR:6=H=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE
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M"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS
M1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P)3L[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M
M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L
M;V%T.FQE9G0^/"]D:78^,C(Y)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;F<Z
M,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\
M+W1R/@T*"0D\+W1A8FQE/CPO9&EV/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P
M<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M
M<VEZ93HQ,'!T.SMF;VYT+7-I>F4Z(#$P<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.W1E>'0M:6YD96YT.C!P=#MM87)G:6XM;&5F=#HP<'0[<&%D
M9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O
M;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X
M="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T
M(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T
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M<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N
M=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P
M<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP861D:6YG.C!P
M="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE
M.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMT97AT+6EN9&5N
M=#HP<'0[;6%R9VEN+6QE9G0Z,'!T.W!A9&1I;F<Z,'!T(#,V<'0@,'!T(#!P
M=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N
M="US:7IE.C$P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.SMF;VYT+7-I>F4Z(#$P<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.W1E>'0M:6YD96YT.C!P=#MM87)G:6XM
M;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG
M/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US
M:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP861D
M:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#L[9F]N
M="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMT97AT
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M87)G:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F
M;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z
M,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P
M=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P
M=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
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M.C!P=#MM87)G:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T
M.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL
M969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^
M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I
M>F4Z,3!P=#LG/CPO9F]N=#X-"@D)/"]P/@T*"0D\9&EV('-T>6QE/3-$=VED
M=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$
M,"!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[=VED=&@Z(#$P
M,"XP,"4[;6%R9VEN+6QE9G0Z,'!T.R<^#0H)"0D\='(^#0H)"0D)/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C0Q+C`P)3MP861D:6YG.C!P
M=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-#@E.W!A9&1I;F<Z,'!T
M.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*
M"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0Q,2!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z-34N-3(E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R
M+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N
M;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E
M;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`X
M<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O
M;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/D1E8V5M8F5R)FYB<W`[
M,S$L)FYB<W`[,C`Q-#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;F<Z
M,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P
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M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C0X)3MP861D:6YG.C!P=#L^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)
M"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=VED=&@Z,3$N.3@E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P
M,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB
M;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N
M92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC96YT
M97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@.'!T
M)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[)SY4;W1A;#PO9F]N=#X\+W`^
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N
M=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R
M<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O
M;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP
M,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ
M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P
M,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP
M<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I
M>F4Z.'!T.R<^475O=&5D)FYB<W`[/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ
M93HX<'0[)SYP<FEC97,\+V9O;G0^/&)R("\^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG
M/FEN)FYB<W`[86-T:79E/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[
M)SYM87)K971S)FYB<W`[9F]R/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$
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M*&QE=F5L)FYB<W`[,2D\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG
M.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO
M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z,7!T(&YO
M;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R
M9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P
M="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N
M.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/E-I9VYI9FEC86YT
M/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF
M;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[)SYO=&AE<CPO9F]N=#X\
M8G(@+SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG
M:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^;V)S97)V86)L93PO9F]N=#X\8G(@
M+SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z
M8F]L9#MF;VYT+7-I>F4Z.'!T.R<^:6YP=71S/"]F;VYT/CQB<B`O/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O
M;G0M<VEZ93HX<'0[)SXH;&5V96PF;F)S<#LR*3PO9F]N=#X\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X]
M,T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[8F]R
M9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N
M92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB
M;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
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M:6YP=71S/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[)SXH;&5V96PF
M;F)S<#LS*3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;F<Z,'!T.SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)
M"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T
M;W`@<W1Y;&4],T0G=VED=&@Z-#$N,#`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN
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M0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HP,2XS,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R
M9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@
M;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[
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M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`N-S`E.V)O<F1E<BUT
M;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$
M.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R
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M,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[
M)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS,"4[8F]R9&5R
M+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D
M97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@
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M;&4],T0G=VED=&@Z,3`N-S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P
M,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T
M;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$
M.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[
M)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.W1E>'0M86QI9VXZ<FEG:'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SXF(W@R,#$T.SPO
M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%
M149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)
M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,#$N,S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E
M<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO
M;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A
M8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*
M"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ
M93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P+C<P)3MB;W)D97(M=&]P
M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$
M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR
M:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%
M149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T
M>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-C4L-#DS)FYB<W`[#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R
M+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,S`E.V)O<F1E<BUT
M;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$
M.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R
M+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C$P+C<P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P
M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M
M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$
M.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MT97AT+6%L:6=N.G)I9VAT.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)B-X,C`Q-#L\+V9O
M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#HP,2XP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&
M1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T
M.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)
M/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O
M<"!S='EL93TS1'=I9'1H.C0Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT
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M93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C$Q+CDX)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I
M=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,3@X)FYB<W`[#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N
M-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)
M"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1'=I9'1H.C$R+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L
M:6=N.G)I9VAT.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)B-X,C`Q-#L\+V9O;G0^/"]P/@T*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H
M.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-
M"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T1W:61T:#HQ,BXP,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X
M="UA;&EG;CIR:6=H=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
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M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P)3L[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[
M)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D
M:78^,3@X)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D\+W1A
M8FQE/CPO9&EV/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*
M"0D\+W`^#0H)"3QP/CQF;VYT('-I>F4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO
M9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-U;6UA<GD@;V8@;6%R:V5T86)L92!S96-U<FET:65S
M(&%C8V]U;G1E9"!F;W(@87,@879A:6QA8FQE+69O<BUS86QE('-E8W5R:71I
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^(#QD:78@
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M="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T
M.VUA<F=I;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\
M+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ
M93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY
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M<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ
M93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E
M;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P
M<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O
M;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M
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M9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O
M;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X
M="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T
M(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T
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M<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N
M=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P
M<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP861D:6YG.C!P
M="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE
M.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMT97AT+6EN9&5N
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M;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG
M/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US
M:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP861D
M:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO
M9F]N=#X-"@D)/"]P/@T*"0D\9&EV('-T>6QE/3-$=VED=&@Z,3`P)3X\=&%B
M;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B
M;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[=VED=&@Z(#$P,"XP,"4[;6%R9VEN
M+6QE9G0Z,'!T.R<^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1'=I9'1H.C0Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)
M"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO
M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$=VED=&@Z,#(N-#@E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M
M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D(&-O;'-P86X],T0Q,2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z-34N-3(E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R
M9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@
M<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@
M.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O
M;&0[9F]N="US:7IE.CAP=#LG/DUA<F-H)FYB<W`[,S$L)FYB<W`[,C`Q-3PO
M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M
M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
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M93TS1'=I9'1H.C`R+C0X)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N
M.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M,3$N.3@E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL
M969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N
M="US:7IE.CAP=#LG/D%M;W)T:7IE9#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E
M.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)
M)FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0U('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HR-BXU,B4[8F]R9&5R+71O
M<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$
M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M
M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E
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M<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,3(N,#`E.W!A9&1I;F<Z,'!T.SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T
M.R<^1F%I<CPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;F<Z,'!T.SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)
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M='1O;2!S='EL93TS1'=I9'1H.C`R+C0X)3MP861D:6YG.C!P=#L^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT
M97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,3$N.3@E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[
M8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ
M<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y
M1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)
M"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT
M.F)O;&0[9F]N="US:7IE.CAP=#LG/D-O<W0\+V9O;G0^/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R
M+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)
M"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$
M,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)O<F1E
M<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE
M("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O
M<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*
M"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV
M-R4[=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93H@.'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[
M)SY'86EN<SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)
M"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#HQ,BXP,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$
M.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T
M=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@
M(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
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M="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L
M<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P
M)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL969T.C%P
M="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P
M,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P
M=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT
M.C$P-BXV-R4[=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93H@.'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ
M93HX<'0[)SY686QU93PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;F<Z
M,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P
M/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI
M9VX],T1T;W`@<W1Y;&4],T0G=VED=&@Z-#$N,#`E.V)A8VMG<F]U;F0M8V]L
M;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT
M97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY#;VUM97)C:6%L('!A<&5R
M(#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.C`R+C0X)3MB86-K9W)O=6YD+6-O;&]R.B`C
M0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-
M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,#$N,S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O
M<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@
M.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G
M/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M
M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P+C<P)3MB;W)D97(M
M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E
M<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C
M0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV
M('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ.2PW-#@-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N-3`E
M.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G
M/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS,"4[8F]R9&5R+71O<#HQ
M<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$
M.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG
M:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&
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M=VED=&@Z,3`N-S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O
M<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@
M.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@
M;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV
M/C(V#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A
M9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N
M,S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T
M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y
M1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U
M;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T
M.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P+C<P)3MB;W)D97(M=&]P.C%P="!S
M;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB
M;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ
M<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A
M9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.G)I9VAT.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^
M)B-X,C`Q-#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC
M;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS
M1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S
M<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P
M,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T
M=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C
M1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T
M.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7-I>F4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[
M8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y
M(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC
M;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R
M87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,3DL-S<T#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T
M.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T
M<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED
M=&@Z-#$N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT
M+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY#;W)P;W)A=&4@9&5B="!S96-U
M<FET:65S(#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-#@E.W!A9&1I;F<Z,'!T.SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R
M<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O
M;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,2XY
M."4[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y
M;&4],T1F;&]A=#IL969T/CPO9&EV/C$X-BPX,3`-"@D)"0D\+W1D/@T*"0D)
M"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[<&%D
M9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M
M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C$R+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R
M87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^-#0-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU
M,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T
M.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C$R+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`]
M,T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^*#,R,`T*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I
M9'1H.C`R+C4P)3L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L
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M<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HT,2XP,"4[8F%C:V=R
M;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/D=O=F5R;FUE
M;G0@;V)L:6=A=&EO;G,@/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N-#@E.V)A8VMG
M<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)
M"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,2XY."4[8F]R9&5R
M+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D
M97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@
M(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I
M=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,S<L,S0V#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P
M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T
M)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS
M<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E
M.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P
M,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M
M8V]L;W(Z("-#0T5%1D8[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W
M<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/C(Q#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R
M+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C
M;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N
M,#`E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z
M,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P
M,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U
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M<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E
M.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P
M,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M
M8V]L;W(Z("-#0T5%1D8[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W
M<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/C,W+#,S-`T*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#HP,2XP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P
M=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT
M.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO
M='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1'=I9'1H.C0Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[
M=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXT."4[
M<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI
M;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q
M+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F
M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@
M(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ
M,"XW,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE
M9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE
M(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#L[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M
M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L
M;V%T.FQE9G0^/"]D:78^,C0S+#DP-`T*"0D)"3PO=&0^#0H)"0D)/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P
M=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,S`E.V)O<F1E
M<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE
M("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,G!T(&1O=6)L92`C,#`P,#`P(#MB
M;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P
M<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O
M;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P+C<P)3MB;W)D
M97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N
M92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[
M8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H
M=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\
M+V1I=CXY,0T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)
M"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z,#$N,S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED
M(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E
M<BUB;W1T;VTZ,G!T(&1O=6)L92`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^
M)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.C$P+C<P)3MB;W)D97(M=&]P.C%P="!S;VQI
M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D
M97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P
M="!N;VYE("-$.40Y1#D@.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO
M=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,S4S#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,#(N-3`E.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^*3PO9F]N=#X\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q
M+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F
M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@
M(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ
M,"XW,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE
M9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE
M(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#L[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M
M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L
M;V%T.FQE9G0^/"]D:78^,C0S+#8T,@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C`P)3MP861D:6YG.C!P
M=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T
M<CX-"@D)/"]T86)L93X\+V1I=CX-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T
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M=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P
M=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
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M.C!P=#MM87)G:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T
M.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL
M969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^
M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I
M>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
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M:6YD96YT.C!P=#MM87)G:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P
M<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA
M<F=I;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O
M;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ
M,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF
M;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I
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M,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@
M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z
M,'!T.VUA<F=I;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[
M)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M
M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M
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M9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SX\+V9O
M;G0^#0H)"3PO<#X-"@D)/&1I=B!S='EL93TS1'=I9'1H.C$P,"4^/'1A8FQE
M(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G8F]R
M9&5R+6-O;&QA<'-E.F-O;&QA<'-E.W=I9'1H.B`Q,#`N,#`E.VUA<F=I;BUL
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M='EL93TS1'=I9'1H.C`R+C0X)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L
M:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)
M"3QT9"!C;VQS<&%N/3-$,3$@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C4U+C4R)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E
M<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O
M;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP
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M;2!S='EL93TS1'=I9'1H.C`Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT
M+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*
M"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$=VED=&@Z-#$N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT
M/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T1W:61T:#HP,BXT."4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG
M;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C$Q+CDX)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M
M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE
M("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D
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M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P
M)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)
M"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$-2!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,C8N-3(E.V)O<F1E<BUT
M;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y
M1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R
M+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT
M97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/D=R
M;W-S)FYB<W`[56YR96%L:7IE9#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A
M9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB
M<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$R+C`P)3MP861D:6YG.C!P=#L^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP
M=#LG/D9A:7(\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C`P)3MP861D:6YG.C!P=#L^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)
M"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$=VED=&@Z-#$N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G
M/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB
M<W`[/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXT."4[<&%D9&EN9SHP<'0[/@T*"0D)
M"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[
M=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C$Q+CDX)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@
M.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ
M,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$
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M"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS
M1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D
M97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N
M92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB
M;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T
M.R<^1V%I;G,\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)
M"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y
M1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O
M='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE
M("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E
M<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`X<'0G
M/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M
M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/DQO<W-E<SPO9F]N=#X\+W`^
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N
M=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R
M<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O
M;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP
M,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ
M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P
M,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP
M<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I
M>F4Z.'!T.R<^5F%L=64\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C`P)3MP861D:6YG
M.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO
M<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L
M:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.C0Q+C`P)3MB86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[
M=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^0V]R<&]R871E(&1E8G0@
M<V5C=7)I=&EE<R`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXT."4[8F%C:V=R;W5N
M9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF
M;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C
M,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M
M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N
M92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z
M,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW
M,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z
M,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$
M.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N
M9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N
M;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,C,P+#,W.0T*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG
M.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I
M9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C,P)3MB
M;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@
M;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@
M.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B0\
M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@
M(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R
M+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO
M;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI
M9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T
M.FQE9G0^/"]D:78^.#`-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z
M("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P
M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HP,2XS,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[
M8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ
M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$
M.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*
M"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV
M-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P
M="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N
M="US:7IE.C$P<'0[)SXD/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`N-S`E.V)O<F1E
M<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE
M("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R
M9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z
M("-#0T5%1D8[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD
M:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/B@T,C@-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N-3`E
M.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[)SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^
M*3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI
M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D
M97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@
M;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ
M,"XW,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE
M9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R
M;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`]
M,T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,C,P+#`S
M,0T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HP,2XP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D
M:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M
M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-
M"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL
M93TS1'=I9'1H.C0Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV
M-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^1V]V97)N;65N="!O
M8FQI9V%T:6]N<R`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C0X)3MP861D:6YG.C!P
M=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M,3$N.3@E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE
M9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@
M(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.SMF;VYT
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M,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R
M+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL969T
M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P
M,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#L[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI
M9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T
M.FQE9G0^/"]D:78^-PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
M"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N
M/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)O
M<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO
M;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[
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M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[
M8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT
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M+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HT,2XP,"4[8F%C:V=R;W5N
M9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R
M+C0X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,S`E.V)O<F1E<BUT
M;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$
M.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,G!T(&1O=6)L92`C,#`P,#`P(#MB;W)D
M97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@
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M;&4],T0G=VED=&@Z,3`N-S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P
M,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T
M;VTZ,G!T(&1O=6)L92`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ
M<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE
M9G0^/"]D:78^,C8U+#@X,`T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO
M<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P
M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M
M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$
M.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[
M)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P+C<P)3MB
M;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@
M;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P
M,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M
M8V]L;W(Z("-#0T5%1D8[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W
M<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/C@W#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R
M+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,S`E.V)O<F1E<BUT
M;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$
M.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,G!T(&1O=6)L92`C,#`P,#`P(#MB;W)D
M97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@
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M;&4],T0G=VED=&@Z,3`N-S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P
M,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T
M;VTZ,G!T(&1O=6)L92`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ
M<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE
M9G0^/"]D:78^*#0W-`T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O
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M,#$N,S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL
M969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,G!T(&1O=6)L
M92`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C
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M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`N-S`E.V)O<F1E<BUT;W`Z
M,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y
M1#D@.V)O<F1E<BUB;W1T;VTZ,G!T(&1O=6)L92`C,#`P,#`P(#MB;W)D97(M
M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#
M145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S
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M#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"3PO
M=&%B;&4^/"]D:78^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^
M#0H)"3PO<#X-"@D)/'`^/&9O;G0@<VEZ93TS1#$^(#PO9F]N=#X\+W`^#0H)
M/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@;6%R:V5T86)L92!S96-U<FET
M:65S(&]N('1H92!B86QA;F-E('-H965T/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\9&EV/B`\9&EV('-T>6QE/3-$;6%R9VEN+6QE9G0Z,'!T
M.VUA<F=I;BUR:6=H=#HP<'0[/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G
M/@T*"0D)/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M
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M9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M
M<VEZ93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI
M;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P
M="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O
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M<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[
M.V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP861D:6YG.C!P="`S
M-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q
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M=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO
M9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE
M.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP861D:6YG
M.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US
M:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMT97AT+6EN
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M:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P
M=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N
M="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP
M861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#L[
M9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMT
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M=#MM87)G:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^
M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I
M>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[9F]N="US:7IE.C$P<'0[)SX\+V9O;G0^#0H)"3PO<#X-"@D)/&1I=B!S
M='EL93TS1'=I9'1H.C$P,"4^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL
M<W!A8VEN9STS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E
M.W=I9'1H.B`Q,#`N,#`E.VUA<F=I;BUL969T.C!P=#LG/@T*"0D)/'1R/@T*
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M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP
M861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N
M8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$-2!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,C8N-3`E.V)O<F1E<BUT;W`Z
M,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$
M.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I
M9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT
M+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/DUA<F-H
M)FYB<W`[,S$L)FYB<W`[,C`Q-3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,#`E.W!A
M9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB
M<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#<P+C`P)3L@<&%D
M9&EN9SH@,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M;W9E<F9L;W<Z(&AI9&1E;CMF;VYT+7-I>F4Z,'!T.R<^#0H)"0D)"0D\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^/"]P
M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#H@,#(N-3`E.R!P861D:6YG.B`P<'0[)SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI
M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMO=F5R9FQO
M=SH@:&ED9&5N.V9O;G0M<VEZ93HP<'0[)SX-"@D)"0D)"29N8G-P.SPO<#X-
M"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z(#$R+C`P)3L@8F]R9&5R+71O<#H@,7!T('-O
M;&ED(",P,#`P,#`[(&)O<F1E<BUL969T.B`Q<'0@;F]N92`C1#E$.40Y.R!B
M;W)D97(M8F]T=&]M.B`Q<'0@<V]L:60@(S`P,#`P,#L@8F]R9&5R+7)I9VAT
M.B`Q<'0@;F]N92`C1#E$.40Y.R!P861D:6YG.B`P<'0[)SX-"@D)"0D)/'`@
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M<W`[36]N=&AS/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#`R+C4P)3L@<&%D9&EN9SH@
M,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[;W9E<F9L;W<Z(&AI9&1E;CMF;VYT+7-I>F4Z,'!T.R<^
M#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A
M;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q,BXP,"4[
M(&)O<F1E<BUT;W`Z(#%P="!N;VYE("-$.40Y1#D[(&)O<F1E<BUL969T.B`Q
M<'0@;F]N92`C1#E$.40Y.R!B;W)D97(M8F]T=&]M.B`Q<'0@<V]L:60@(S`P
M,#`P,#L@8F]R9&5R+7)I9VAT.B`Q<'0@;F]N92`C1#E$.40Y.R!P861D:6YG
M.B`P<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
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M="US:7IE.CAP=#LG/C$R)FYB<W`[36]N=&AS/"]F;VYT/CPO<#X-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M(#`Q+C`P)3L@<&%D9&EN9SH@,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E
M<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[;W9E<F9L;W<Z(&AI9&1E
M;CMF;VYT+7-I>F4Z,'!T.R<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T
M9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S
M='EL93TS1"=W:61T:#HW,"XP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&
M1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T
M(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT
M.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7-I>F4Z,3!P=#LG/D-O;6UE<F-I86P@<&%P97(@/"]F;VYT/CPO
M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS
M,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z
M,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$
M.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N
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M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`N-S`E.V)O<F1E<BUT;W`Z,7!T('-O
M;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O
M<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P
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M"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S
M;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB
M;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ
M<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A
M9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#HQ,"XW,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R
M+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N
M92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C
M:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X
M="UA;&EG;CIR:6=H=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B8C>#(P,30[/"]F;VYT/CPO<#X-
M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,#$N,#`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN
M9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@<W1Y;&4]
M,T1W:61T:#HW,"XP,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS
M1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I
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M93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C$R+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I
M=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,3,X+#,P-B9N8G-P.PT*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H
M.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-
M"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.SMF;VYT+69A;6EL>3I4:6UE<R!.
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M"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^
M#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#HW,"XP,"4[
M8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)
M"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/D=O
M=F5R;FUE;G0@;V)L:6=A=&EO;G,@/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N-3`E
M.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G
M/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P
M86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[
M8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@
M;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P
M(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC
M;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R
M87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,3$L,S$R)FYB<W`[
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R
M9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@
M<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@
M.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@
M;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV
M/C(V+#`R,B9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#HP,2XP,"4[8F%C:V=R;W5N9"UC;VQO<CH@
M(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G
M:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^
M#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG
M;CTS1'1O<"!S='EL93TS1'=I9'1H.C<P+C`P)3MP861D:6YG.C!P=#L^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M
M:&5I9VAT.C$P-BXV-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^
M5&]T86P@36%R:V5T86)L92!S96-U<FET:65S(#PO9F]N=#X\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HP,2XS,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R
M9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@
M9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y
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M=VED=&@Z,3`N-S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O
M<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,G!T
M(&1O=6)L92`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$
M.2`[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
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M;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M
M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B
M;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A
M9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#HQ,"XW,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R
M+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U
M8FQE(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#L[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E
M>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS
M1&9L;V%T.FQE9G0^/"]D:78^-S0L,C4P)FYB<W`[#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,#`E.W!A
M9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
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M<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N
M=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P
M<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP861D:6YG.C!P
M="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE
M.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMT97AT+6EN9&5N
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M;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG
M/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US
M:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP861D
M:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#L[9F]N
M="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMT97AT
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M87)G:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F
M;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z
M,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P
M=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P
M=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
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M.C!P=#MM87)G:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T
M.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL
M969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^
M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I
M>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
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M:6YD96YT.C!P=#MM87)G:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P
M<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA
M<F=I;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O
M;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ
M,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF
M;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X-"@D)/"]P/@T*"0D\9&EV('-T>6QE
M/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C
M:6YG/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[=VED
M=&@Z(#$P,"XP,"4[;6%R9VEN+6QE9G0Z,'!T.R<^#0H)"0D\='(^#0H)"0D)
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C<P+C`P)3MP861D
M:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I
M;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[
M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0U('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HR-BXU,"4[8F]R9&5R+71O<#HQ<'0@
M;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB
M;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z
M,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y
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M<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C<P+C`P)3MP861D:6YG
M.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,G!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z
M,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P
M/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[8F]R9&5R+71O<#HQ<'0@<V]L
M:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R
M9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P
M="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N
M.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/DQE<W,F;F)S<#M4
M:&%N/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[)SXQ,B9N8G-P.TUO
M;G1H<SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#HQ,BXP,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y
M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M
M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y
M1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
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M9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C$R)FYB<W`[36]N=&AS/"]F;VYT
M/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T1W:61T:#HP,2XP,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG
M;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO
M='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1"=W
M:61T:#HW,"XP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG
M.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@
M,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-
M"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I
M>F4Z,3!P=#LG/D-O<G!O<F%T92!D96)T('-E8W5R:71I97,@/"]F;VYT/CPO
M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS
M,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z
M,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$
M.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N
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M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`N-S`E.V)O<F1E<BUT;W`Z,7!T('-O
M;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O
M<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P
M="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT
M+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F
M;&]A=#IL969T/CPO9&EV/C$U-RPW-3@F;F)S<#L-"@D)"0D\+W1D/@T*"0D)
M"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N-3`E.V)A
M8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS,"4[8F]R9&5R+71O<#HQ<'0@
M<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[
M8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z
M,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP
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M=&@Z,3`N-S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E
M<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO
M;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A
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M(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)
M"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS
M1'1O<"!S='EL93TS1'=I9'1H.C<P+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I
M9VAT.C$P-BXV-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^1V]V
M97)N;65N="!O8FQI9V%T:6]N<R`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP
M861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[
M8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ
M<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y
M1#D@.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T
M>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXV+#`P,R9N8G-P.PT*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P
M)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$
M.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O
M;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$
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M(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)
M"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS
M1'1O<"!S='EL93TS1"=W:61T:#HW,"XP,"4[8F%C:V=R;W5N9"UC;VQO<CH@
M(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G
M:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M
M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/E1O=&%L($UA<FME=&%B;&4@<V5C
M=7)I=&EE<R`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC
M;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS
M1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S
M<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P
M,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T
M=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE
M("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP
M<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P+C<P
M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ
M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P
M,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U
M;F0M8V]L;W(Z("-#0T5%1D8[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$
M;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/C$V,RPW-C$F
M;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[
M<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP
M,2XS,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE
M9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE
M(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K
M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)
M"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z
M,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F]R9&5R+71O<#HQ
M<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$
M.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUR
M:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%
M149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T
M>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ,#$L-S,R)FYB<W`[#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q
M+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-
M"@D)/"]T86)L93X\+V1I=CX-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
M"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO
M9F]N=#X-"@D)/"]P/@T*"0D\<#X\9F]N="!S:7IE/3-$,3X@/"]F;VYT/CPO
M<#X-"@D\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y(&]F(&-H86YG97,@:6X@=&AE
M(&9A:7(@=F%L=64@;V8@=&AE($-O;7!A;GDG<R!,979E;"`S('9A;'5A=&EO
M;B!F;W(@=V%R<F%N="!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQD:78^(#QD:78@<W1Y;&4],T1M87)G:6XM;&5F=#HP<'0[
M;6%R9VEN+7)I9VAT.C!P=#L^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^
M#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\
M+V9O;G0^#0H)"3PO<#X-"@D)/&1I=B!S='EL93TS1'=I9'1H.C$P,"4^/'1A
M8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G
M8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.W=I9'1H.B`Q,#`N,#`E.VUA<F=I
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M;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT
M+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,34N,#`E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R
M9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@
M<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@
M.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O
M;&0[9F]N="US:7IE.CAP=#LG/DQE=F5L)FYB<W`[,R9N8G-P.V%S<V5T<SPO
M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M
M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@<W1Y;&4]
M,T0G=VED=&@Z.#$N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@
M,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P
M="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N
M="US:7IE.C$P<'0[)SY"96=I;FYI;F<@8F%L86YC92!A<R!O9B!$96-E;6)E
M<B9N8G-P.S,Q+"`R,#$T(#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K
M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)
M"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,S`E.V)O<F1E<BUT;W`Z,7!T('-O
M;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O
M<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P
M="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C$S+C<P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M
M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE
M("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K
M9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A
M<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ.#@F
M;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,#$N,#`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[
M<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO
M=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@
M<W1Y;&4],T1W:61T:#HX,2XU,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/D-H86YG92!I
M;B!F86ER('9A;'5E(&]F('=A<G)A;G0@;&EA8FEL:71Y(#PO9F]N=#X\+W`^
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[
M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-2XP,"4[8F]R9&5R+71O<#HQ<'0@
M;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB
M;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z
M,7!T(&YO;F4@(T0Y1#E$.2`[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$
M;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/C0Q)FYB<W`[
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M=VED=&@Z,#$N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[
M/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V
M86QI9VX],T1T;W`@<W1Y;&4],T0G=VED=&@Z.#$N-3`E.V)A8VMG<F]U;F0M
M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY%;F1I;F<@8F%L86YC
M92!A<R!O9B!-87)C:"9N8G-P.S,Q+"`R,#$U(#PO9F]N=#X\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T
M.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,S`E.V)O<F1E
M<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE
M("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,G!T(&1O=6)L92`C,#`P,#`P(#MB
M;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO
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M<W1Y;&4],T0G=VED=&@Z,3,N-S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P
M,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB
M;W1T;VTZ,G!T(&1O=6)L92`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO
M;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI
M9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T
M.FQE9G0^/"]D:78^,C(Y)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD
M+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N
M8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)/"]T86)L93X\+V1I
M=CX-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*
M"0D\<#X\9F]N="!S:7IE/3-$,3X@/"]F;VYT/CPO<#X-"@D\+V1I=CX@/"]D
M:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W
M,F8T-#@U85]D9#4V7S0U.35?.#,P-5\P,&%C,#!A9F0X868-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-S)F-#0X-6%?9&0U-E\T-3DU7S@S,#5?
M,#!A8S`P869D.&%F+U=O<FMS:&5E=',O4VAE970Q.2YH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D]T:&5R(&-O;7!R96AE;G-I
M=F4@:6YC;VUE("AL;W-S*2!A;F0@86-C=6UU;&%T960@;W1H97(@8V]M<')E
M:&5N<VEV92!I=&5M<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]T:&5R(&-O;7!R96AE;G-I=F4@
M:6YC;VUE("AL;W-S*2!A;F0@86-C=6UU;&%T960@;W1H97(@8V]M<')E:&5N
M<VEV92!I=&5M<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3=6UM87)Y(&]F(&]T:&5R(&-O;7!R96AE;G-I=F4@:6YC;VUE
M("AL;W-S*2!A;F0@=&AE(&-H86YG97,@:6X@86-C=6UU;&%T960@;W1H97(@
M8V]M<')E:&5N<VEV92!I=&5M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/&1I=CX@/&1I=B!S='EL93TS1&UA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.SX-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)
M"3QF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P
M=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P
M=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
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M.C!P=#MM87)G:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T
M.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL
M969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^
M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I
M>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
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M:6YD96YT.C!P=#MM87)G:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P
M<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA
M<F=I;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O
M;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ
M,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF
M;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I
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M,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@
M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z
M,'!T.VUA<F=I;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[
M)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M
M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M
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M9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M
M<VEZ93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI
M;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P
M="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMT97AT+6EN9&5N=#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.W!A9&1I;F<Z,'!T(#,V<'0@,'!T(#!P=#LG/CPO9F]N
M=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P
M<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O
M;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/@T*"0D\+W`^#0H)"3QD:78@<W1Y;&4]
M,T1W:61T:#HQ,#`E/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I
M;F<],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93MW:61T
M:#H@,3`P+C`P)3MM87)G:6XM;&5F=#HP<'0[)SX-"@D)"3QT<CX-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-34N-3`E.W!A9&1I
M;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R<^)FYB<W`[/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[<&%D9&EN
M9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I
M9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!N
M;VYE("-$.40Y1#D@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O
M<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ
M<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG
M;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@.'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[)SY5;G)E86QI>F5D
M/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF
M;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[)SY'86EN<R\H3&]S<V5S
M*3PO9F]N=#X\8G(@+SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^3VX\+V9O;G0^/&)R
M("\^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT
M.F)O;&0[9F]N="US:7IE.CAP=#LG/DUA<FME=&%B;&4\+V9O;G0^/&)R("\^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O
M;&0[9F]N="US:7IE.CAP=#LG/E-E8W5R:71I97,\+V9O;G0^/"]P/@T*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H
M.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
M"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N
M/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)O
M<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO
M;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[
M8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP
M=#LG/D9O<F5I9VX\+V9O;G0^/&)R("\^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/D-U
M<G)E;F-Y/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[)SY4<F%N<VQA
M=&EO;CPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#HQ,BXP,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y
M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M
M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y
M1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
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M9F]N="US:7IE.CAP=#LG/D%C8W5M=6QA=&5D/"]F;VYT/CQB<B`O/CQF;VYT
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M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C`P)3MP861D:6YG.C!P
M=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-
M"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N
M/3-$=&]P('-T>6QE/3-$)W=I9'1H.C4U+C4P)3MB86-K9W)O=6YD+6-O;&]R
M.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X
M="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^0F%L86YC92!A="!$96-E;6)E
M<B9N8G-P.S,Q+"`R,#$T(#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K
M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)
M"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,S`E.V)O<F1E<BUT;W`Z,7!T('-O
M;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O
M<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P
M="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C$P+C<P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M
M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE
M("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K
M9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A
M<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,S@W
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T
M)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7-I>F4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS,"4[8F]R9&5R
M+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D
M97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@
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M;&4],T0G=VED=&@Z,3`N-S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P
M,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T
M;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$
M.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I
M9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T
M/CPO9&EV/B@S-3`-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^*3PO9F]N=#X\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q
M+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F
M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$
M.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O
M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)
M"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P
M=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F]R9&5R+71O<#HQ<'0@
M<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[
M8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z
M,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E
M>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS
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M:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z-34N-3`E.W!A9&1I;F<Z,'!T.SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#(P<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[
M)SY/=&AE<B!C;VUP<F5H96YS:79E(&EN8V]M92\H;&]S<RD@8F5F;W)E(')E
M8VQA<W-I9FEC871I;VYS(#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I
M;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HQ,BXP,"4[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P
M/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/C$R-0T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P
M)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,3(N,#`E.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS
M1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,3(T#0H)
M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED
M=&@Z,#(N-3`E.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^*3PO9F]N=#X\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C$R+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`]
M,T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,0T*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H
M.C`Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-
M"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N
M/3-$=&]P('-T>6QE/3-$)W=I9'1H.C4U+C4P)3MB86-K9W)O=6YD+6-O;&]R
M.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0@,'!T(#!P="`R,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X
M="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^06UO=6YT<R!R96-L87-S:69I
M960@9G)O;2!O=&AE<B!C;VUP<F5H96YS:79E(&ET96US(#PO9F]N=#X\+W`^
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R
M9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@
M<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@
M.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.W1E>'0M86QI9VXZ<FEG:'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SXF(W@R,#$T.SPO9F]N=#X\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A
M9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[
M8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ
M<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y
M1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.W1E>'0M86QI9VXZ<FEG:'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SXF(W@R,#$T.SPO9F]N
M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$
M.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O
M;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$
M.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[
M)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.W1E>'0M86QI9VXZ<FEG:'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SXF(W@R,#$T.SPO
M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%
M149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)
M"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$
M=&]P('-T>6QE/3-$=VED=&@Z-34N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#(P<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM
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M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!S;VQI
M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D
M97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W
M<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/C$R-0T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R
M+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)
M"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P
M,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB
M;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N
M92`C1#E$.40Y(#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^
M/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^*#$R-`T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P
M)3L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7-I>F4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HQ,BXP,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R
M9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@
M<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@
M.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE
M/3-$9FQO870Z;&5F=#X\+V1I=CXQ#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;F<Z,'!T
M.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R
M/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@<W1Y;&4],T0G=VED
M=&@Z-34N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP
M<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)
M"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE
M.C$P<'0[)SY"86QA;F-E(&%T($UA<F-H)FYB<W`[,S$L(#(P,34@/"]F;VYT
M/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[
M<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP
M,2XS,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE
M9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@
M(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG
M<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)
M"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ
M,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P+C<P)3MB;W)D97(M=&]P.C%P
M="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y
M(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG
M:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&
M1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL
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M;&4],T0G=VED=&@Z,#$N,S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P
M,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T
M;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C
M1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T
M.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7-I>F4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[
M8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P
M,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M
M8V]L;W(Z("-#0T5%1D8[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W
M<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/B@T-S0-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[)SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)
M"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ
M,'!T.R<^*3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P
M="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y
M(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG
M:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&
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M=VED=&@Z,3`N-S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O
M<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T
M('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y
M(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG
M(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I
M=CXH-S,V#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7-I>F4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)
M"0D\+W1R/@T*"0D\+W1A8FQE/CPO9&EV/@T*"0D\<"!S='EL93TS1"=M87)G
M:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^
M)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP/CQF;VYT('-I>F4],T0Q/B`\
M+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7S<R9C0T.#5A7V1D-39?-#4Y-5\X,S`U
M7S`P86,P,&%F9#AA9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\W
M,F8T-#@U85]D9#4V7S0U.35?.#,P-5\P,&%C,#!A9F0X868O5V]R:W-H965T
M<R]3:&5E=#(P+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^06-C;W5N=',@<&%Y86)L92!A;F0@86-C<G5E9"!E>'!E;G-E<R`H
M5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N
M(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D%C8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U960@97AP96YS
M97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4V-H961U;&4@;V8@8V]M<&]N96YT<R!O9B!A8V-O=6YT<R!P87EA8FQE(&%N
M9"!A8V-R=65D(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\9&EV/B`\9&EV('-T>6QE/3-$;6%R9VEN+6QE9G0Z,'!T.VUA<F=I
M;BUR:6=H=#HP<'0[/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT
M/@T*"0D\+W`^#0H)"3QD:78@<W1Y;&4],T1W:61T:#HQ,#`E/CQT86)L92!C
M96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V)O<F1E
M<BUC;VQL87!S93IC;VQL87!S93MW:61T:#H@,3`P+C`P)3MM87)G:6XM;&5F
M=#HP<'0[)SX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$=VED=&@Z-C8N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT
M/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T1W:61T:#HP,BXU,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG
M;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C$T+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL
M969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED
M(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D
M:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M
M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@.'!T)SX-"@D)"0D)"3QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O
M;G0M<VEZ93HX<'0[)SY-87)C:"9N8G-P.S,Q+#PO9F]N=#X\8G(@+SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF
M;VYT+7-I>F4Z.'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[)SXR,#$U
M/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X
M="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C$T+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O
M<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T
M('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y
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M:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^,C`Q-#PO9F]N=#X\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,#$N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R
M/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@<W1Y;&4],T0G=VED=&@Z-C8N,#`E
M.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY%
M;7!L;WEE92!C;VUP96YS871I;VXL(&)E;F5F:71S+"!A;F0@<F5L871E9"!A
M8V-R=6%L<R`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC
M;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS
M1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S
M<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P
M,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T
M=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C
M1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T
M.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7-I>F4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXW,"4[
M8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y
M(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC
M;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R
M87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,RPS-C4F;F)S<#L-
M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN
M9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS,"4[
M8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y
M(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC
M;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS
M1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SXD
M/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z,3(N-S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED
M(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E
M<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N
M;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L
M:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A
M=#IL969T/CPO9&EV/CDL,S$R)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O
M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)
M"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)
M"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z-C8N,#`E.W!A9&1I
M;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T
M(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^
M#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US
M:7IE.C$P<'0[)SY#;VYS=6QT:6YG(&%N9"!C;VYT<F%C=&5D(')E<V5A<F-H
M(#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X]
M,T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-"XP,"4[.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT
M+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F
M;&]A=#IL969T/CPO9&EV/C$Q+#8Y,29N8G-P.PT*"0D)"3PO=&0^#0H)"0D)
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D
M:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,30N,#`E.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A
M<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXY+#,T.29N8G-P.PT*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I
M9'1H.C`Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO
M<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L
M:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.C8V+C`P)3MB86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[
M=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^4')O9F5S<VEO;F%L(&9E
M97,@/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z
M("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P
M/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#HQ-"XP,"4[8F%C:V=R;W5N9"UC;VQO<CH@
M(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I
M=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,RPS.#(F;F)S<#L-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[
M)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ
M-"XP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG
M:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^
M/"]D:78^,RPS,S0F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,#`E.V)A8VMG<F]U;F0M8V]L
M;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[
M/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V
M86QI9VX],T1T;W`@<W1Y;&4],T1W:61T:#HV-BXP,"4[<&%D9&EN9SHP<'0[
M/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)
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M.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C$T+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N
M;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,RPQ,SDF;F)S
M<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T1W:61T:#HP,BXU,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS
M1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S
M<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$T+C`P)3L[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG
M:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^
M/"]D:78^-"PQ,C@F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,2XP,"4[<&%D9&EN9SHP<'0[/@T*
M"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV
M-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P
M="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)
M"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#HV
M-BXP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG
M/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)
M"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P
M=#LG/D]T:&5R(#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD
M+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N
M8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,30N,#`E.V)O<F1E<BUT;W`Z
M,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$
M.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I
M9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%
M1D8[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y
M;&4],T1F;&]A=#IL969T/CPO9&EV/C$L.34U)FYB<W`[#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P
M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T
M)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS
M<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,30N,#`E
M.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P
M,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M
M8V]L;W(Z("-#0T5%1D8[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W
M<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/C(L.3DX)FYB<W`[
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*
M"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$=VED=&@Z-C8N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0D\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R
M+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)
M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,#$N,S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E
M<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,G!T(&1O
M=6)L92`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[
M<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)
M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C$R+C<P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D
M97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D
M;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@
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M.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q
M+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F
M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@
M(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ
M,BXW,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE
M9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE
M(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#L[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M
M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L
M;V%T.FQE9G0^/"]D:78^,CDL,3(Q)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I
M;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D\+W1R/@T*"0D\+W1A8FQE/CPO9&EV/@T*"0D\<"!S='EL93TS1"=M87)G
M:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^
M)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP/CQF;VYT('-I>F4],T0Q/B`\
M+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7S<R9C0T.#5A7V1D-39?-#4Y-5\X,S`U
M7S`P86,P,&%F9#AA9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\W
M,F8T-#@U85]D9#4V7S0U.35?.#,P-5\P,&%C,#!A9F0X868O5V]R:W-H965T
M<R]3:&5E=#(Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^5V%R<F%N=',@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY787)R86YT<SPO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y(&]F('1H
M92!#;VUP86YY)W,@;W5T<W1A;F1I;F<@=V%R<F%N=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQD:78^(#QD:78@<W1Y;&4],T1M87)G:6XM
M;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7-I>F4Z,3!P=#LG/E1H92!F;VQL;W=I;F<@:7,@82!S=6UM87)Y(&]F('1H
M92!#;VUP86YY)B-X,C`Q.3MS(&]U='-T86YD:6YG('=A<G)A;G1S(&%S(&]F
M($UA<F-H)FYB<W`[,S$L(#(P,34Z/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/&1I=B!S='EL
M93TS1'=I9'1H.C$P,"4^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A
M8VEN9STS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.W=I
M9'1H.B`Q,#`N,#`E.VUA<F=I;BUL969T.C!P=#LG/@T*"0D)/'1R/@T*"0D)
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M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C4R)3MP861D
M:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P
M.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,3$N,#@E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$
M.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O
M;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$
M.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`X<'0G/@T*
M"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I
M9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/E=A<G)A;G0\+V9O;G0^/&)R("\^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O
M;&0[9F]N="US:7IE.CAP=#LG/G-H87)E<SPO9F]N=#X\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N
M-3(E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)
M"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,2XS,B4[8F]R9&5R
M+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D
M97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
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M;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C(Q+C$T
M)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL969T.C%P
M="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P
M,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P
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M<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D
M('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#HT.2XV,"4[8F%C:V=R;W5N
M9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/D-O;6UO;B!S=&]C
M:R`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#HP,2XU,B4[8F%C:V=R;W5N9"UC;VQO<CH@
M(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G
M:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C$Q+C`X)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB
M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P
M="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y
M(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE
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M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C`R+C8R)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB
M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P
M="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y
M(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T
M)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7-I>F4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP."XV."4[8F]R9&5R
M+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D
M97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@
M(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I
M=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,3(X+C`P)FYB<W`[#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C`Q+CDR)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T
M.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,C$N,30E.V)O<F1E
M<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE
M("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R
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M,#$N.3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[
M)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R
M/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@<W1Y;&4],T1W:61T
M:#HT.2XV,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G
M:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M
M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/D-O;6UO;B!S=&]C:R`\+V9O;G0^
M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1'=I9'1H.C`Q+C4R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N
M8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=VED=&@Z,3$N,#@E.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A
M<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXW+#`S
M,"9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1'=I9'1H.C`Q+C4R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)
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M=#X\+V1I=CXQ,C@N,#`F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,2XY,B4[<&%D9&EN9SHP<'0[
M/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P
M-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@
M,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,C$N,30E.W!A9&1I;F<Z
M,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.W1E>'0M86QI9VXZ<FEG:'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SXR,#$Y(&%N
M9"`R,#(P/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,2XY,"4[<&%D9&EN9SHP<'0[/@T*
M"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV
M-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P
M="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)
M"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#HT
M.2XV,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG
M/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)
M"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P
M=#LG/D-O;6UO;B!S=&]C:R`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XU,B4[8F%C
M:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)
M"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$Q+C`X)3MB86-K9W)O=6YD+6-O;&]R
M.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\
M9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ,S`F;F)S<#L-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M,#$N-3(E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[
M)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
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M/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/C(L-3(P+C`P)FYB<W`[
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C`Q+CDR)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*
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M;VT@<W1Y;&4],T0G=VED=&@Z,#$N.3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*
M"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D\+W1A8FQE/CPO9&EV/@T*"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@,3!P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[9F]N="US:7IE.C$P<'0[)SY4:&4@9F]L;&]W:6YG(&ES(&$@<W5M
M;6%R>2!O9B!T:&4@0V]M<&%N>28C>#(P,3D[<R!O=71S=&%N9&EN9R!W87)R
M86YT<R!A<R!O9B!$96-E;6)E<B9N8G-P.S,Q+"`R,#$T.CPO9F]N=#X-"@D)
M/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.W1E>'0M86QI9VXZ8V5N
M=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R
M<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB
M<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QD:78@<W1Y;&4],T1W:61T:#HQ,#`E
M/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE
M/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93MW:61T:#H@,3`P+C`P)3MM
M87)G:6XM;&5F=#HP<'0[)SX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$=VED=&@Z-#DN,#`E.W!A9&1I;F<Z,'!T.SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G
M/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB
M<W`[/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T1W:61T:#HP,2XY-B4[<&%D9&EN9SHP<'0[/@T*"0D)
M"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[
M=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$Q
M+C4R)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL969T
M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P
M,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG
M.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I
M9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@.'!T)SX-"@D)"0D)"3QF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M
M<VEZ93HX<'0[)SY787)R86YT/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX
M<'0[)SYS:&%R97,\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`P+CDX)3MP861D:6YG.C!P
M=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-
M"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z,3(N-3`E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R
M+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N
M;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E
M;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`X
M<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O
M;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/D5X97)C:7-E/"]F;VYT
M/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E
M:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[)SYP<FEC93PO9F]N=#X\+W`^#0H)
M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED
M=&@Z,#`N.3@E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G
M/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HR,2XQ-"4[8F]R9&5R+71O<#HQ
M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y
M(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG
M:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M
M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^17AP:7)A
M=&EO;CPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N.3(E.W!A9&1I;F<Z,'!T.SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO
M=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@
M<W1Y;&4],T0G=VED=&@Z-#DN,#`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%
M1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N
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M9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,2XU,B4[
M8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y
M(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC
M;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R
M87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^-BPR-3`F;F)S<#L-
M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,#`N.3@E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN
M9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XY-"4[
M8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y
M(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC
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M;VT@<W1Y;&4],T0G=VED=&@Z,3`N-38E.V)O<F1E<BUT;W`Z,7!T('-O;&ED
M(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E
M<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N
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M"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.C(Q+C$T)3MB;W)D97(M=&]P.C%P="!S;VQI
M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D
M97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@
M;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA
M;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO
M870Z;&5F=#X\+V1I=CXR,#$W)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+CDR)3MB86-K9W)O
M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)
M"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)
M"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z-#DN,#`E.W!A9&1I
M;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T
M(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[
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M;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C$Q+C4R)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I
M=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^-RPP,S`F;F)S<#L-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP
M,"XY."4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ
M,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)
M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED
M=&@Z,#$N.30E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N
M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C$P+C4V)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`]
M,T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,3(X+C`P
M)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$=VED=&@Z,#`N.3@E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)
M)FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1'=I9'1H.C(Q+C$T)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT
M+6%L:6=N.G)I9VAT.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^,C`Q.2!A;F0@,C`R,#PO9F]N=#X\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$=VED=&@Z,#$N.3(E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB
M<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT
M9"!V86QI9VX],T1T;W`@<W1Y;&4],T0G=VED=&@Z-#DN,#`E.V)A8VMG<F]U
M;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V
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M("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P
M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HQ,2XU,B4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M
M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L
M;V%T.FQE9G0^/"]D:78^,3,P)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`P+CDX)3MB86-K9W)O
M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)
M"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z,#$N.30E.V)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C$P+C4V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF
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M#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C(Q+C$T)3MB86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A
M<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR,#$Y)FYB<W`[#0H)
M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C`Q+CDR)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z
M,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)
M/"]T<CX-"@D)/"]T86)L93X\+V1I=CX-"@D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N
M8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<#X\9F]N="!S:7IE/3-$,3X@/"]F
M;VYT/CPO<#X-"@D\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\W,F8T-#@U85]D9#4V7S0U.35?.#,P-5\P
M,&%C,#!A9F0X868-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-S)F
M-#0X-6%?9&0U-E\T-3DU7S@S,#5?,#!A8S`P869D.&%F+U=O<FMS:&5E=',O
M4VAE970R,BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P13)&/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/DYE="!L;W-S('!E<B!S:&%R92`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYE="!L;W-S('!E
M<B!S:&%R93PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y38VAE9'5L92!O9B!C;VUP=71A=&EO;B!O9B!B87-I8R!A;F0@9&EL
M=71E9"!N970@;&]S<R!P97(@<VAA<F4@9F]R(&-O;6UO;B!S=&]C:VAO;&1E
M<G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^(#QD:78@
M<W1Y;&4],T1M87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.W1E
M>'0M:6YD96YT.C!P=#MM87)G:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P
M="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T
M.VUA<F=I;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\
M+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ
M93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY
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M<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ
M93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E
M;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P
M<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O
M;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M
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M9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O
M;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X
M="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T
M(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMT97AT+6EN9&5N=#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.W!A9&1I;F<Z,'!T(#,V<'0@,'!T(#!P=#LG/CPO
M9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE
M.C$P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M<VEZ93HQ,'!T.SMF;VYT+7-I>F4Z(#$P<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.W1E>'0M:6YD96YT.C!P=#MM87)G:6XM;&5F=#HP
M<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N
M=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P
M<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP861D:6YG.C!P
M="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE
M.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMT97AT+6EN9&5N
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M;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG
M/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US
M:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP861D
M:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO
M9F]N=#X-"@D)/"]P/@T*"0D\9&EV('-T>6QE/3-$=VED=&@Z,3`P)3X\=&%B
M;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B
M;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[=VED=&@Z(#$P,"XP,"4[;6%R9VEN
M+6QE9G0Z,'!T.R<^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1'=I9'1H.C8V+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)
M"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO
M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M
M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D(&-O;'-P86X],T0U('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HR.2XR."4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D
M97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S
M;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[
M<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L
M9#MF;VYT+7-I>F4Z.'!T.R<^5&AR964F;F)S<#MM;VYT:',F;F)S<#ME;F1E
M9"9N8G-P.TUA<F-H)FYB<W`[/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX
M<'0[)SXS,2P\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C(R)3MP861D:6YG.C!P=#L^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)
M"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$=VED=&@Z-C8N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G
M/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB
M<W`[/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[<&%D9&EN9SHP<'0[/@T*"0D)
M"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[
M=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C$T+C`P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P
M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M
M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y
M1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)
M"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG
M:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^,C`Q-3PO9F]N=#X\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X]
M,T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXW."4[8F]R
M9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N
M92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB
M;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T
M.R<^,C`Q-#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N,C(E.W!A9&1I;F<Z,'!T.SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)
M"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T
M;W`@<W1Y;&4],T0G=VED=&@Z-C8N,#`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN
M9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z,3!P=#LG/DYU;65R
M871O<CPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R
M.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO
M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,30N,#`E.V)O<F1E<BUT;W`Z,7!T('-O
M;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O
M<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P
M="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ<FEG:'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S
M<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,3(N-S@E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P
M,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T
M;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$
M.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[
M)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.W1E>'0M86QI9VXZ<FEG:'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)
M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C`R+C(R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z
M,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)
M/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$
M=VED=&@Z-C8N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT
M97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY.970@;&]S<R`\+V9O;G0^
M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N
M8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=VED=&@Z,#$N,S`E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y
M1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O
M='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N
M92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SXD/"]F
M;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=VED=&@Z,3(N-S`E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y
M1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O
M='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N
M92`C1#E$.40Y(#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^
M/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^*#,W+#DQ-0T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R
M+C4P)3L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93MF;VYT+7-I>F4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS
M,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ
M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P
M,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z
M,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,2XT
M."4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ
M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P
M,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG
M;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z
M;&5F=#X\+V1I=CXH,30L,#DX#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N,C(E.SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T
M.R<^*3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^
M#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#HV-BXP,"4[
M8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)
M"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT
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M,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$T
M+C`P)3MB;W)D97(M=&]P.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+6QE
M9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R
M;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA
M;&EG;CIR:6=H=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)
M"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N-3`E.V)A
M8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X]
M,T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXW."4[8F]R
M9&5R+71O<#HR<'0@9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N
M;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[
M8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L
M;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ<FEG
M:'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P
M="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C(R)3MB86-K9W)O=6YD
M+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N
M8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\
M=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z-C8N,#`E.W!A9&1I;F<Z
M,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)
M"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE
M.C$P<'0[)SY$96YO;6EN871O<B!F;W(@8F%S:6,@86YD(&1I;'5T960@;F5T
M(&QO<W,@<&5R('-H87)E(#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I
M;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HQ-"XP,"4[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P
M/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/C,S+#`V-RPW-3(-"@D)
M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T
M:#HP,BXU,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G
M:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.C$R+C<X)3L[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N
M;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^
M,C0L-#DR+#0X-PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1'=I9'1H.C`R+C(R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)
M"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-
M"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.C8V+C`P)3MB
M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I
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M=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN
M9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HQ-"XP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG
M.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I
M9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIR:6=H=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO
M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HQ,BXW."4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D
M:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M
M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIR:6=H=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P
M.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,#(N,C(E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[
M<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO
M=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@
M<W1Y;&4],T1W:61T:#HV-BXP,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/D)A<VEC(&%N
M9"!D:6QU=&5D(#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T
M.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS,"4[8F]R9&5R
M+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R
M9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T
M)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7-I>F4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXW,"4[8F]R9&5R
M+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R
M9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG
M(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I
M=CXH,2XQ-0T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)
M"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P
M=#LG/BDJ/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,S`E.V)O<F1E<BUT;W`Z,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[
M8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUR:6=H
M=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)
M"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P
M<'0[)SXD/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3$N-#@E.V)O<F1E<BUT;W`Z,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[
M8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUR:6=H
M=#HQ<'0@;F]N92`C1#E$.40Y(#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`]
M,T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^*#`N-3@-
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M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT
M/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SXJ
M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I
M>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMT97AT+6EN9&5N=#HP<'0[;6%R9VEN+6QE9G0Z,'!T.W!A9&1I
M;F<Z,'!T(#,V<'0@,'!T(#!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C-P=#LG/CPO9F]N=#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY);B!T
M:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H)FYB<W`[,S$L(#(P,34@86YD
M(#(P,30L('1H92!#;VUP86YY(&5X<&5R:65N8V5D(&$@;F5T(&QO<W,@86YD
M('1H97)E9F]R92!D:60@;F]T(')E<&]R="!A;GD@9&EL=71I=F4@<VAA<F4@
M:6UP86-T+CPO9F]N=#X-"@D)/"]P/@T*"0D\<#X\9F]N="!S:7IE/3-$,3X@
M/"]F;VYT/CPO<#X-"@D\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!H:7-T
M;W)I8V%L(&1I;'5T:79E(&-O;6UO;B!S:&%R92!E<75I=F%L96YT<R!O=71S
M=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX@
M/&1I=B!S='EL93TS1&UA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T
M.SX-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*
M"0D\9&EV('-T>6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<]
M,T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z
M8V]L;&%P<V4[=VED=&@Z(#$P,"XP,"4[;6%R9VEN+6QE9G0Z,'!T.R<^#0H)
M"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H
M.C<P+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"3QF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X]
M,T0S('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HR-BXU,"4[8F]R
M9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N
M92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB
M;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T
M.R<^07,F;F)S<#MO9B9N8G-P.TUA<F-H)FYB<W`[,S$L/"]F;VYT/CPO<#X-
M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W
M:61T:#HP,2XP,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC96YT
M97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P
M="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)
M"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H
M.C<P+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"3QF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[8F]R9&5R+71O<#HQ<'0@
M<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[
M8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT
M.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L
M:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P,34\+V9O
M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L
M:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)
M"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)O
M<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO
M;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[
M8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP
M=#LG/C(P,30\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C`P)3MP861D:6YG.C!P=#L^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)
M"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$=VED=&@Z-S`N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0D\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^/"]P
M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P
M.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P
M,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T
M;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$
M.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.G)I9VAT.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T
M)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z
M,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y
M1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I
M9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT
M+6%L:6=N.G)I9VAT.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C`P)3MP
M861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D
M/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T
M>6QE/3-$)W=I9'1H.C<P+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@
M,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UI;F1E;G0Z
M("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M<VEZ93HQ,'!T.R<^4W1O8VL@3W!T:6]N<R`\+V9O;G0^/"]P/@T*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG
M.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I
M9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P)3MB
M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO
M=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT
M+#8R-RPX,S,F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z
M("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P
M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HQ,BXP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M
M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L
M;V%T.FQE9G0^/"]D:78^,RPQ,S,L.#,P)FYB<W`[#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C`P)3MB
M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
M"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT
M<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z-S`N,#`E
M.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P
M<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@
M+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@
M,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M9F]N="US:7IE.C$P<'0[)SY5;G9E<W1E9"!R97-T<FEC=&5D('-T;V-K(#PO
M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)
M"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[8F]R9&5R+71O<#HQ<'0@;F]N
M92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D
M97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W
M<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/C,V-"PY-S`F;F)S
M<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T1W:61T:#HP,BXU,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS
M1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S
M<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y
M1#D@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T
M;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C
M1#E$.40Y(#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I
M=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^-S0X+#0U-B9N8G-P.PT*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H
M.C`Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-
M"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N
M/3-$=&]P('-T>6QE/3-$)W=I9'1H.C<P+C`P)3MB86-K9W)O=6YD+6-O;&]R
M.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X
M="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^5&]T86P@/"]F;VYT/CPO<#X-
M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN
M9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[
M8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE(",P,#`P
M,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD
M+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO
M=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT+#DY,BPX,#,F
M;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[
M<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ
M,BXP,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE
M9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE
M(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K
M9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A
M<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS+#@X
M,BPR.#8F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z,#$N,#`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*
M"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D\+W1A8FQE/CPO9&EV/@T*"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP/CQF;VYT
M('-I>F4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S<R9C0T.#5A7V1D
M-39?-#4Y-5\X,S`U7S`P86,P,&%F9#AA9@T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\W,F8T-#@U85]D9#4V7S0U.35?.#,P-5\P,&%C,#!A9F0X
M868O5V]R:W-H965T<R]3:&5E=#(S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,4%!0SX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:R!A=V%R9"!P;&%N("A486)L97,I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P
M,34\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4W1O8VL@87=A<F0@<&QA;CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y(&]F('-T;V-K(&]P=&EO;B!A8W1I
M=FET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX@/&1I
M=B!S='EL93TS1&UA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-
M"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP861D:6YG.C!P="`S
M-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q
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M=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO
M9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE
M.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP861D:6YG
M.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US
M:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMT97AT+6EN
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M:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P
M=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N
M="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP
M861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#L[
M9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMT
M97AT+6EN9&5N=#HP<'0[;6%R9VEN+6QE9G0Z,'!T.W!A9&1I;F<Z,'!T(#,V
M<'0@,'!T(#!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[9F]N="US:7IE.C$P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.SMF;VYT+7-I>F4Z(#$P
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.W1E>'0M:6YD96YT.C!P
M=#MM87)G:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^
M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I
M>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T
M.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F
M;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z
M,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
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M96YT.C!P=#MM87)G:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@
M,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF
M;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I
M;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T
M.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMT97AT+6EN9&5N=#HP<'0[;6%R9VEN+6QE9G0Z,'!T.W!A
M9&1I;F<Z,'!T(#,V<'0@,'!T(#!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SX\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^
M/"]F;VYT/@T*"0D\+W`^#0H)"3QD:78@<W1Y;&4],T1W:61T:#HQ,#`E/CQT
M86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$
M)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93MW:61T:#H@,3`P+C`P)3MM87)G
M:6XM;&5F=#HP<'0[)SX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z-#$N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[
M/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T1W:61T:#HP,BXT."4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X
M="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P
M)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL969T.C%P
M="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P
M,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P
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M>F4Z.'!T.R<^;W!T:6]N<SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I
M;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[
M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[8F]R9&5R+71O<#HQ<'0@
M;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB
M;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z
M,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI
M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^5V5I9VAT960M
M/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF
M;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[)SYA=F5R86=E/"]F;VYT
M/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E
M:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[)SYE>&5R8VES93PO9F]N=#X\8G(@
M+SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z
M8F]L9#MF;VYT+7-I>F4Z.'!T.R<^<')I8V4\+V9O;G0^/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R
M+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)
M"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z,7!T(&YO
M;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R
M9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P
M="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N
M.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/E=E:6=H=&5D+3PO
M9F]N=#X\8G(@+SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N
M="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^879E<F%G93PO9F]N=#X\
M8G(@+SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG
M:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^<F5M86EN:6YG/"]F;VYT/CQB<B`O
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB
M;VQD.V9O;G0M<VEZ93HX<'0[)SYC;VYT<F%C='5A;#PO9F]N=#X\8G(@+SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L
M9#MF;VYT+7-I>F4Z.'!T.R<^=&5R;3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E
M.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)
M)FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[8F]R9&5R+71O
M<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$
M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M
M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E
M>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^06=G
M<F5G871E/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
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M93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO
M='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1'=I9'1H.C0Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"3QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X\+W`^
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M=VED=&@Z,#(N-#@E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N
M=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R
M<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[8F]R9&5R+71O
M<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y
M1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M
M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E
M>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P
M)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)
M"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)O<F1E<BUT
M;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$
M.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R
M+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT
M97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU
M,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T
M.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC96YT97([9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)
M"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!S;VQI
M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D
M97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@
M;F]N92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS
M1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC
M96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@
M,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z
M,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P
M/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[8F]R9&5R+71O<#HQ<'0@<V]L
M:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R
M9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ
M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^*&EN)FYB<W`[/"]F
M;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
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M93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO
M='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1"=W
M:61T:#HT,2XP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG
M.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@
M,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-
M"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I
M>F4Z,3!P=#LG/D]U='-T86YD:6YG(&%T($1E8V5M8F5R)FYB<W`[,S$L(#(P
M,30@/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N-#@E.V)A8VMG<F]U;F0M8V]L;W(Z
M("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P
M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HQ,BXP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M
M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L
M;V%T.FQE9G0^/"]D:78^,RPT,S(L.3<R#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O
M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)
M"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z,#$N,S`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C$P+C<P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X
M="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$
M9FQO870Z;&5F=#X\+V1I=CXR-2XP,`T*"0D)"3PO=&0^#0H)"0D)/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R;W5N
M9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF
M;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.C$R+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%
M149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.G)I9VAT.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)
M"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO<CH@
M(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G
M:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C
M0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.G)I9VAT.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XP,"4[8F%C:V=R;W5N9"UC;VQO
M<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\
M+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A
M;&EG;CTS1'1O<"!S='EL93TS1'=I9'1H.C0Q+C`P)3MP861D:6YG.C!P=#L^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI
M;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T
M.R<^1W)A;G1E9"`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C0X)3MP861D:6YG.C!P
M=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA
M;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO
M870Z;&5F=#X\+V1I=CXQ+#0U-BPU-3`-"@D)"0D\+W1D/@T*"0D)"3QT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[<&%D9&EN9SHP
M<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT
M.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,S`E.W!A9&1I
M;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P
M+C<P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S
M='EL93TS1&9L;V%T.FQE9G0^/"]D:78^-3$N,#(-"@D)"0D\+W1D/@T*"0D)
M"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[<&%D
M9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M
M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,3(N,#`E
M.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ<FEG:'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF
M;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)
M"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$R+C`P)3MP861D:6YG
M.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MT97AT+6%L:6=N.G)I9VAT.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P
M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1'=I9'1H.C`Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P
M.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@
M=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.C0Q+C`P)3MB86-K9W)O=6YD
M+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV
M-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^17AE<F-I<V5D(#PO
M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.C`R+C0X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%
M149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)
M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,3(N,#`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N
M.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL
M969T/CPO9&EV/B@R,S0L.#,P#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I
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M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`N
M-S`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT
M.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO
M9&EV/C$R+C@V#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%
M149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)
M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,3(N,#`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP
M<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.W1E>'0M86QI9VXZ<FEG:'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,3(N,#`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN
M9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ<FEG:'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A
M9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D
M/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T
M>6QE/3-$=VED=&@Z-#$N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V
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M"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P)3L[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[
M)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D
M:78^*#(V+#(V-0T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1'=I9'1H.C`R+C4P)3L^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/BD\+V9O
M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1'=I9'1H.C`Q+C,P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)
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M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)
M"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1'=I9'1H.C$R+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT
M97AT+6%L:6=N.G)I9VAT.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P
M)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T1W:61T:#HQ,BXP,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG
M;CIR:6=H=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,2XP,"4[<&%D9&EN
M9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I
M9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS
M1"=W:61T:#HT,2XP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D
M:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P
M<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T
M)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7-I>F4Z,3!P=#LG/D5X<&ER960@/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N-#@E
M.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G
M/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[8F]R9&5R+71O<#HQ
M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y
M(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG
M:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&
M1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL
M93TS1&9L;V%T.FQE9G0^/"]D:78^*#4Y-`T*"0D)"3PO=&0^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R
M;W5N9"UC;VQO<CH@(T-#145&1CLG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G
M:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SXI/"]F;VYT
M/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,#$N,S`E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$
M.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O
M;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$
M.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[
M)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P+C<P)3MB
M;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL969T.C%P="!N
M;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@
M.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A
M<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS.#@N-3,-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[
M)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[8F]R9&5R
M+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D
M97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@
M(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G
M:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIR:6=H=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
M"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L
M;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[
M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[8F%C:V=R;W5N9"UC;VQO
M<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIR:6=H
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T
M)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,#`E.V)A8VMG<F]U;F0M
M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB
M<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT
M9"!V86QI9VX],T1T;W`@<W1Y;&4],T1W:61T:#HT,2XP,"4[<&%D9&EN9SHP
M<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P
M=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)
M"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z
M,3!P=#LG/D]U='-T86YD:6YG(&%T($UA<F-H)FYB<W`[,S$L(#(P,34@/"]F
M;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T1W:61T:#HP,BXT."4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)
M"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!S;VQI
M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D
M97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W
M<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/C0L-C(W+#@S,PT*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I
M9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO
M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,#$N,S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@
M.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ
M,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$
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M,T0G=VED=&@Z,3`N-S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@
M.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ
M,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$
M.40Y(#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S
M='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,S,N-C`-"@D)"0D\+W1D/@T*"0D)
M"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[<&%D
M9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M
M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C`P
M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ
M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P
M,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP
M<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.W1E>'0M86QI9VXZ<FEG:'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SXX+CD@>65A
M<G,\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
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M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`N-S`E.SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA
M;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO
M870Z;&5F=#X\+V1I=CXQ-#`L,SDY#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;F<Z,'!T
M.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R
M/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@<W1Y;&4],T0G=VED
M=&@Z-#$N,#`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP
M<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)
M"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE
M.C$P<'0[)SY697-T960@;W(@17AP96-T960@=&\@=F5S="!A="!-87)C:"9N
M8G-P.S,Q+"`R,#$U(#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C0X)3MB86-K9W)O
M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)
M"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED
M(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E
M<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@
M;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA
M;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO
M870Z;&5F=#X\+V1I=CXT+#,S,BPW,C8-"@D)"0D\+W1D/@T*"0D)"3QT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U
M;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)
M)FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HP,2XS,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@
M(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R
M+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N
M;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN
M9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P
M+C<P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F
M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C
M,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R
M;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`]
M,T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,S(N-S0-
M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN
M9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[
M8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P
M,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M
M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4]
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M,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C,P)3MB86-K9W)O
M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)
M"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P
M=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F%C:V=R;W5N9"UC;VQO
M<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^
M/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,3,S+#(S,@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP
M,2XP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG
M/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P
M-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@
M,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^
M#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1'=I9'1H
M.C0Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UI
M;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^17AE<F-I<V%B;&4@870@36%R8V@F
M;F)S<#LS,2P@,C`Q-2`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C0X)3MP861D:6YG
M.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)
M"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3(N,#`E.V)O
M<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N
M;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[
M8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H
M=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\
M+V1I=CXQ+#`S-RPR-C(-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[<&%D9&EN9SHP<'0[/@T*"0D)
M"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^
M#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P
M="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y
M(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H
M=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)
M"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P
M<'0[)SXD/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`N-S`E.V)O<F1E<BUT;W`Z,7!T
M('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@
M.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT
M.C%P="!N;VYE("-$.40Y1#D@.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS
M1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS,"XY.`T*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I
M9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO
M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,3(N,#`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@
M.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ
M,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y
M1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.G)I9VAT.V9O;G0M
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M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,S`E.W!A
M9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C$P+C<P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I
M=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^-#4L,3,W#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,#`E
M.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO
M=&0^#0H)"0D\+W1R/@T*"0D\+W1A8FQE/CPO9&EV/@T*"0D\<"!S='EL93TS
M1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP/CQF;VYT('-I>F4]
M,T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F
M(&%S<W5M<'1I;VYS('5S960@=&\@97-T:6UA=&4@9F%I<B!V86QU92!O9B!G
M<F%N=',@;6%D92!O;B!T:&4@9&%T92!O9B!G<F%N=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX@/&1I=B!S='EL93TS1&UA<F=I;BUL
M969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"@D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG
M/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\9&EV('-T>6QE/3-$=VED=&@Z
M,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S
M='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[=VED=&@Z(#$P,"XP
M,"4[;6%R9VEN+6QE9G0Z,'!T.R<^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C4S+C0X)3MP861D:6YG.C!P=#L^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,G!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG
M/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#0N-C8E.W!A9&1I;F<Z,'!T.SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#HT,"XP,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M
M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI
M9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
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M9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/F5N9&5D)FYB<W`[36%R8V@F;F)S
M<#L\+V9O;G0^/&)R("\^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C,Q+"9N8G-P.S(P
M,34\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1'=I9'1H.C`Q+C@X)3MP861D:6YG.C!P=#L^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT
M97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D
M/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T
M>6QE/3-$)W=I9'1H.C4S+C0X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@
M,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UI;F1E;G0Z
M("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M<VEZ93HQ,'!T.R<^4FES:RUF<F5E(&EN=&5R97-T(')A=&4@/"]F
M;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=VED=&@Z,#0N-C8E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%
M1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#HT,"XP,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R
M+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N
M92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C
M:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X
M="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SXQ+C4T)2`F(W@R,#$T.R`Q+C<W
M)3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C@X)3MB86-K9W)O=6YD+6-O;&]R.B`C
M0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-
M"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N
M/3-$=&]P('-T>6QE/3-$=VED=&@Z-3,N-#@E.W!A9&1I;F<Z,'!T.SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY%
M>'!E8W1E9"!V;VQA=&EL:71Y(#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#0N-C8E.W!A
M9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C0P+C`P
M)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)
M"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P
M=#LG/C8W)2TV.24\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C@X)3MP861D:6YG.C!P
M=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T
M<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I
M9'1H.C4S+C0X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z
M,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q
M,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*
M"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ
M93HQ,'!T.R<^17AP96-T960@=&5R;2`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP-"XV
M-B4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*
M"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV
M-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P
M="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C0P+C`P)3MB86-K9W)O=6YD
M+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N
M.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7-I>F4Z,3!P=#LG/C4N-3`@+2`V+C$Q('EE87)S/"]F;VYT/CPO
M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,#$N.#@E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
M#0H)"0D\+W1R/@T*"0D\+W1A8FQE/CPO9&EV/@T*"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP/CQF;VYT('-I>F4],T0Q
M/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA<GD@;V8@:6YF
M;W)M871I;VX@;VX@=&AE($-O;7!A;GDG<R!R97-T<FEC=&5D('-T;V-K/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/B`\9&EV('-T>6QE
M/3-$;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QD:78@<W1Y
M;&4],T1W:61T:#HQ,#`E/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P
M86-I;F<],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93MW
M:61T:#H@,3`P+C`P)3MM87)G:6XM;&5F=#HP<'0[)SX-"@D)"3QT<CX-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-C0N,#`E.W!A
M9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)
M"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[<&%D
M9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M
M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S
M<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C,R+C4P)3MB;W)D97(M=&]P.C%P
M="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@
M.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H
M=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA
M;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@.'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[)SY297-T<FEC
M=&5D)FYB<W`[4W1O8VL\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C`P)3MP861D:6YG
M.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO
M<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-C0N,#`E.W!A9&1I;F<Z,'!T
M.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R<^)FYB<W`[/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[<&%D9&EN9SHP<'0[
M/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P
M-BXV-R4[=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)
M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C$U+C`P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D
M97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S
M;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[
M<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L
M9#MF;VYT+7-I>F4Z.'!T.R<^3G5M8F5R)FYB<W`[;V8\+V9O;G0^/&)R("\^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O
M;&0[9F]N="US:7IE.CAP=#LG/E-H87)E<SPO9F]N=#X\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N
M-3`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)
M"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-2XP,"4[8F]R9&5R
M+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D
M97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
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M/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF
M;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[)SY$871E)FYB<W`[1F%I
M<B9N8G-P.SPO9F]N=#X\8G(@+SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^5F%L=64\
M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1'=I9'1H.C`Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT
M+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*
M"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE
M/3-$)W=I9'1H.C8T+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A
M9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T
M(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UI;F1E;G0Z("TQ
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P
M<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O
M;G0M<VEZ93HQ,'!T.R<^2F%N=6%R>29N8G-P.S$L(#(P,34@/"]F;VYT/CPO
M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-2XP
M,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z
M,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$
M.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N
M9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N
M;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^-S$X+#0P,`T*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG
M.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I
M9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C,P)3MB
M;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@
M;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@
M.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B0\
M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HQ,RXW,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@
M(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R
M+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO
M;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI
M9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T
M.FQE9G0^/"]D:78^,3`N-S(-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,#`E.V)A8VMG<F]U;F0M8V]L
M;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[
M/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V
M86QI9VX],T1T;W`@<W1Y;&4],T1W:61T:#HV-"XP,"4[<&%D9&EN9SHP<'0[
M/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)
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M93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,34N,#`E.W!A9&1I
M;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ<FEG:'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SXF(W@R
M,#$T.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F<Z,'!T.SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G
M/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P
M86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$U+C`P)3MP
M861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.G)I9VAT.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^
M)B-X,C`Q-#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C`P)3MP861D:6YG.C!P=#L^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-
M"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H
M.C8T+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T
M.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T
M.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)
M"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ
M,'!T.R<^5F5S=&5D(#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O
M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)
M"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z,34N,#`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@
M<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/B@S-3`L,#@T#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P
M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF
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M;&4],T0G=VED=&@Z,3,N-S`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT
M97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4]
M,T1F;&]A=#IL969T/CPO9&EV/C$P+C4Y#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O
M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)
M"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)
M"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z-C0N,#`E.W!A9&1I
M;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T
M(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[
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M.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$U
M+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL969T
M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P
M,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#L[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI
M9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T
M.FQE9G0^/"]D:78^*#,L,S0V#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T
M.R<^*3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,S`E.W!A9&1I;F<Z,'!T.SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G
M/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M
M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$S+C<P)3L[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI
M9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T
M.FQE9G0^/"]D:78^,3`N.#(-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,2XP,"4[<&%D9&EN9SHP<'0[/@T*
M"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV
M-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P
M="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)
M"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#HV
M-"XP,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG
M/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)
M"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P
M=#LG/E5N=F5S=&5D(&%T($UA<F-H)FYB<W`[,S$L(#(P,34@/"]F;VYT/CPO
M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-2XP
M,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z
M,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE(",P
M,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O
M=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS
M1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS-C0L.3<P
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,S`E
M.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G
M/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M
M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$S+C<P)3MB86-K9W)O
M=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
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M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"3PO='(^#0H)"3PO=&%B;&4^/"]D:78^#0H)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@
M,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF
M;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`^/&9O;G0@<VEZ93TS1#$^(#PO
M9F]N=#X\+W`^#0H)/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@<VAA<F4M
M8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4@<F5C;W)D960@:6X@=&AE('-T
M871E;65N="!O9B!O<&5R871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\9&EV/B`\9&EV('-T>6QE/3-$;6%R9VEN+6QE9G0Z,'!T.VUA
M<F=I;BUR:6=H=#HP<'0[/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F
M;VYT/@T*"0D\+W`^#0H)"3QD:78@<W1Y;&4],T1W:61T:#HQ,#`E/CQT86)L
M92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V)O
M<F1E<BUC;VQL87!S93IC;VQL87!S93MW:61T:#H@,3`P+C`P)3MM87)G:6XM
M;&5F=#HP<'0[)SX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$=VED=&@Z-C0N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)
M"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F
M;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T1W:61T:#HP,BXU,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA
M;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@8V]L<W!A;CTS1#4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C,R+C4P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E
M<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O
M;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP
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M)FYB<W`[36%R8V@F;F)S<#L\+V9O;G0^/&)R("\^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP
M=#LG/C,Q+#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;F<Z,'!T.SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)
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M='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT
M97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,34N,#`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@
M.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ
M,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$
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M"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS
M1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$U+C`P)3MB;W)D
M97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL969T.C%P="!N;VYE
M("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O
M<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*
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M;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)
M/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1'=I9'1H.C8T+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I
M9VAT.C$P-BXV-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/CPO<#X-
M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W
M:61T:#HP,BXU,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$U+C`P)3MB;W)D97(M=&]P.C%P="!S
M;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB
M;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ
M<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG
M;CIR:6=H=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,BXU,"4[<&%D9&EN
M9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I
M9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C$U+C`P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D
M97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N
M;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP
M861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI
M;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIR:6=H=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N
M8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T1W:61T:#HP,2XP,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)
M"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)
M"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#HV-"XP,"4[8F%C
M:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/E)E<V5A
M<F-H(&%N9"!D979E;&]P;65N="`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXU,"4[
M8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)
M"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^
M#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B0\
M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HQ,RXW,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#
M145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S
M='EL93TS1&9L;V%T.FQE9G0^/"]D:78^-"PV-C<F;F)S<#L-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N
M-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R
M<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A
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M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3,N-S`E.V)A8VMG<F]U;F0M8V]L;W(Z
M("-#0T5%1D8[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD
M:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/C$L.30T)FYB<W`[#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T
M.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T
M<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED
M=&@Z-C0N,#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT
M+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY396QL:6YG+"!G96YE<F%L(&%N
M9"!A9&UI;FES=')A=&EV92`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D
M:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,34N,#`E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R
M9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@
M<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@
M.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE
M/3-$9FQO870Z;&5F=#X\+V1I=CXU+#`X,29N8G-P.PT*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP
M861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,34N,#`E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[
M8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ
M<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y
M1#D@.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T
M>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+#<V,29N8G-P.PT*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C`P
M)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\
M+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P
M('-T>6QE/3-$)W=I9'1H.C8T+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%
M149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UI;F1E
M;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.V9O;G0M<VEZ93HQ,'!T.R<^5&]T86P@/"]F;VYT/CPO<#X-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M,#(N-3`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[
M)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS,"4[8F]R9&5R
M+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@.V)O
M<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R
M.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B0\+V9O
M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#HQ,RXW,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P
M,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O
M='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N
M92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A
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M;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C
M,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M
M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N
M;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN
M9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$S
M+C<P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F
M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@
M(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG
M<F]U;F0M8V]L;W(Z("-#0T5%1D8[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P
M/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/C,L-S`U
M)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\
M+W1D/@T*"0D)/"]T<CX-"@D)/"]T86)L93X\+V1I=CX-"@D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<#X\9F]N="!S:7IE
M/3-$,3X@/"]F;VYT/CPO<#X-"@D\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W,F8T-#@U85]D9#4V7S0U
M.35?.#,P-5\P,&%C,#!A9F0X868-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO-S)F-#0X-6%?9&0U-E\T-3DU7S@S,#5?,#!A8S`P869D.&%F+U=O
M<FMS:&5E=',O4VAE970R-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/D-O;6UI=&UE;G1S(&%N9"!C;VYT:6YG96YC:65S("A4
M86)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@
M,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^0V]M;6ET;65N=',@86YD(&-O;G1I;F=E;F-I97,\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@
M;V8@9G5T=7)E(&UI;FEM=6T@;&5A<V4@<&%Y;65N=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQD:78^(#QD:78@<W1Y;&4],T1M87)G:6XM
M;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3!P="<^#0H)"0D\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.W1E>'0M:6YD96YT.C!P=#MM
M87)G:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F
M;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z
M,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P
M=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P
M=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
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M.C!P=#MM87)G:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T
M.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL
M969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^
M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I
M>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
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M:6YD96YT.C!P=#MM87)G:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P
M<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA
M<F=I;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O
M;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ
M,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF
M;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I
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M,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@
M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z
M,'!T.VUA<F=I;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[
M)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M
M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M
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M9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M
M<VEZ93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI
M;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P
M="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X-"@D)/"]P/@T*
M"0D\9&EV('-T>6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<]
M,T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z
M8V]L;&%P<V4[=VED=&@Z(#$P,"XP,"4[;6%R9VEN+6QE9G0Z,'!T.R<^#0H)
M"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#HX
M,"XV,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG
M/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)
M"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P
M=#LG/C(P,34@/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#,N,3(E.V)A8VMG<F]U;F0M
M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB
M<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S
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M=#IL969T/CPO9&EV/C$L,#$V)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C(V)3MB86-K9W)O
M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)
M"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)
M"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z.#`N-C`E.W!A9&1I
M;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T
M(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^
M#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US
M:7IE.C$P<'0[)SXR,#$V(#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I
M;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HQ-2XP,B4[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P
M/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/CDT-B9N8G-P.PT*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H
M.C`Q+C(V)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-
M"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N
M/3-$=&]P('-T>6QE/3-$)W=I9'1H.C@P+C8P)3MB86-K9W)O=6YD+6-O;&]R
M.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X
M="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^,C`Q-R`\+V9O;G0^/"]P/@T*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HP,RXQ,B4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG
M.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I
M9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C$U+C`R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG
M;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z
M;&5F=#X\+V1I=CXY,C,F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,C8E.V)A8VMG<F]U;F0M
M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB
M<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT
M9"!V86QI9VX],T1T;W`@<W1Y;&4],T1W:61T:#HX,"XV,"4[<&%D9&EN9SHP
M<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P
M=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)
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M93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C$U+C`R)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I
M=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,2PP,S4F;F)S<#L-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP
M,2XR-B4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ
M,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)
M"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS
M1'1O<"!S='EL93TS1"=W:61T:#HX,"XV,"4[8F%C:V=R;W5N9"UC;VQO<CH@
M(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G
M:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M
M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/C(P,3D@/"]F;VYT/CPO<#X-"@D)
M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,#,N,3(E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP
M<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)
M/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#HQ-2XP,B4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M
M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI
M9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C
M:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R
M87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,3<V
M)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C`Q+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\
M+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z.#`N-C`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0D\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^/"]P/@T*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I
M9'1H.C`S+C$R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO
M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,#$N,S0E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@
M.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ
M,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$
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M,T0G=VED=&@Z,3,N-C@E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@
M.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ
M,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$
M.40Y(#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S
M='EL93TS1&9L;V%T.FQE9G0^/"]D:78^-"PP.38F;F)S<#L-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,2XR
M-B4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T
M.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)
M/"]T9#X-"@D)"3PO='(^#0H)"3PO=&%B;&4^/"]D:78^#0H)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`^/&9O;G0@<VEZ
M93TS1#$^(#PO9F]N=#X\+W`^#0H)/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-S)F-#0X-6%?9&0U-E\T
M-3DU7S@S,#5?,#!A8S`P869D.&%F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+S<R9C0T.#5A7V1D-39?-#4Y-5\X,S`U7S`P86,P,&%F9#AA9B]7
M;W)K<VAE971S+U-H965T,C4N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$551T%#/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/E1H92!#;VUP86YY("A54T0@)"D\8G(^26X@5&AO
M=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D%U9RX@,#0L(#(P,30\8G(^<W1A=&4\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E1H92!#
M;VUP86YY/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DUI;FEM=6T@86=E(&]F(&%M8G5L871O<GD@<&%T:65N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-2!Y96%R<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(&UE
M;6)E<B!S=&%T97,@;V8@=&AE($5U<F]P96%N(%5N:6]N/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C=6UU;&%T960@9&5F:6-I=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@T-C`L-#8V*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-#(R
M+#4U,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7S<R9C0T.#5A7V1D-39?-#4Y-5\X,S`U7S`P86,P,&%F9#AA9@T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\W,F8T-#@U85]D9#4V7S0U.35?.#,P
M-5\P,&%C,#!A9F0X868O5V]R:W-H965T<R]3:&5E=#(V+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%5TY!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY&86ER('9A;'5E(&]F
M(&9I;F%N8VEA;"!I;G-T<G5M96YT<R!A;F0@;6%R:V5T86)L92!S96-U<FET
M:65S("A$971A:6QS*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S
M(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1FEN86YC:6%L(&%S<V5T
M<R!A;F0@;&EA8FEL:71I97,@;65A<W5R960@870@9F%I<B!V86QU92!O;B!R
M96-U<G)I;F<@8F%S:7,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^36%R:V5T86)L92!S96-U<FET:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#(T,RPV-#(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(V-2PT.3,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E8W5R
M<FEN9R!B87-I<R!\(%1O=&%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^1FEN86YC:6%L(&%S<V5T<R!A;F0@;&EA8FEL:71I
M97,@;65A<W5R960@870@9F%I<B!V86QU92!O;B!R96-U<G)I;F<@8F%S:7,\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%R
M:V5T86)L92!S96-U<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR-#,L-C0R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C8U+#0Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N="!L:6%B:6QI='D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C=7)R:6YG(&)A
M<VES('P@4VEG;FEF:6-A;G0@;W1H97(@;V)S97)V86)L92!I;G!U=',@*&QE
M=F5L(#(I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^1FEN86YC:6%L(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@;65A<W5R960@
M870@9F%I<B!V86QU92!O;B!R96-U<G)I;F<@8F%S:7,\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%R:V5T86)L92!S96-U
M<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-#,L-C0R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C8U+#0Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4F5C=7)R:6YG(&)A<VES('P@4VEG;FEF:6-A;G0@=6YO8G-E
M<G9A8FQE(&EN<'5T<R`H;&5V96P@,RD\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY&:6YA;F-I86P@87-S971S(&%N9"!L:6%B
M:6QI=&EE<R!M96%S=7)E9"!A="!F86ER('9A;'5E(&]N(')E8W5R<FEN9R!B
M87-I<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y787)R86YT(&QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`R,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$X.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?-S)F-#0X-6%?9&0U-E\T-3DU7S@S,#5?,#!A8S`P869D
M.&%F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S<R9C0T.#5A7V1D
M-39?-#4Y-5\X,S`U7S`P86,P,&%F9#AA9B]7;W)K<VAE971S+U-H965T,C<N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5!04%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D9A
M:7(@=F%L=64@;V8@9FEN86YC:6%L(&EN<W1R=6UE;G1S(&%N9"!M87)K971A
M8FQE('-E8W5R:71I97,@*$1E=&%I;',@,BD@*%531"`D*3QB<CY);B!4:&]U
M<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DUA
M<FME=&%B;&4@<V5C=7)I=&EE<R!A8V-O=6YT960@9F]R(&%S(&%V86EL86)L
M92UF;W(M<V%L92!S96-U<FET:65S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T:7IE9"!#;W-T/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#(T,RPY,#0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(V-2PX.#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R;W-S
M(%5N<F5A;&EZ960@1V%I;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/CDQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D=R;W-S(%5N<F5A;&EZ960@3&]S<V5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@S-3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#<T*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!686QU93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C0S+#8T,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V-2PT.3,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;6UE<F-I86P@<&%P97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY-87)K971A8FQE('-E8W5R:71I97,@86-C;W5N=&5D(&9O
M<B!A<R!A=F%I;&%B;&4M9F]R+7-A;&4@<V5C=7)I=&EE<SPO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ960@0V]S
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL-S0X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F]S
M<R!5;G)E86QI>F5D($=A:6YS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1F%I<B!686QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3DL-S<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;W)P;W)A=&4@9&5B="!S96-U<FET:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^36%R:V5T86)L
M92!S96-U<FET:65S(&%C8V]U;G1E9"!F;W(@87,@879A:6QA8FQE+69O<BUS
M86QE('-E8W5R:71I97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06UO<G1I>F5D($-O<W0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$X-BPX,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR,S`L,S<Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F]S<R!5;G)E86QI>F5D
M($=A:6YS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'
M<F]S<R!5;G)E86QI>F5D($QO<W-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,S(P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#0R."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@5F%L=64\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$X-BPU,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,S`L,#,Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y';W9E<FYM96YT(&]B
M;&EG871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^36%R:V5T86)L92!S96-U<FET:65S(&%C8V]U;G1E9"!F;W(@87,@
M879A:6QA8FQE+69O<BUS86QE('-E8W5R:71I97,\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F5D($-O<W0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,W+#,T-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,U+#4P,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)O
M<W,@56YR96%L:7IE9"!'86EN<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y'<F]S<R!5;G)E86QI>F5D($QO<W-E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,S,I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#8I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,W+#,S-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S4L-#8R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W,F8T-#@U
M85]D9#4V7S0U.35?.#,P-5\P,&%C,#!A9F0X868-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO-S)F-#0X-6%?9&0U-E\T-3DU7S@S,#5?,#!A8S`P
M869D.&%F+U=O<FMS:&5E=',O4VAE970R."YH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P1411044^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0Q/CQS=')O;F<^1F%I<B!V86QU92!O9B!F:6YA;F-I
M86P@:6YS=')U;65N=',@86YD(&UA<FME=&%B;&4@<V5C=7)I=&EE<R`H1&5T
M86EL<R`S*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R
M=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^36%R:V5T86)L92!S96-U<FET:65S
M(&]N('1H92!B86QA;F-E('-H965T/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L($UA<FME=&%B;&4@<V5C=7)I=&EE
M<RP@3&5S<R!4:&%N(#$R($UO;G1H<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q-CDL,SDR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Q-C,L-S8Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!-87)K971A8FQE
M('-E8W5R:71I97,L($UO<F4@5&AA;B`Q,B!-;VYT:',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C<T+#(U,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,2PW,S(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UE<F-I86P@
M<&%P97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY-87)K971A8FQE('-E8W5R:71I97,@;VX@=&AE(&)A;&%N8V4@<VAE970\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T
M86P@36%R:V5T86)L92!S96-U<FET:65S+"!,97-S(%1H86X@,3(@36]N=&AS
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.2PW-S0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O<G!O
M<F%T92!D96)T('-E8W5R:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY-87)K971A8FQE('-E8W5R:71I97,@;VX@=&AE
M(&)A;&%N8V4@<VAE970\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5&]T86P@36%R:V5T86)L92!S96-U<FET:65S+"!,97-S
M(%1H86X@,3(@36]N=&AS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,S@L,S`V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,34W+#<U.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5&]T86P@36%R:V5T86)L92!S96-U<FET:65S
M+"!-;W)E(%1H86X@,3(@36]N=&AS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT."PR,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW,BPR-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=O=F5R;FUE;G0@;V)L:6=A=&EO;G,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY-87)K
M971A8FQE('-E8W5R:71I97,@;VX@=&AE(&)A;&%N8V4@<VAE970\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@36%R
M:V5T86)L92!S96-U<FET:65S+"!,97-S(%1H86X@,3(@36]N=&AS/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PS,3(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#`P,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@
M36%R:V5T86)L92!S96-U<FET:65S+"!-;W)E(%1H86X@,3(@36]N=&AS/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(V+#`R,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,CDL-#4Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W,F8T
M-#@U85]D9#4V7S0U.35?.#,P-5\P,&%C,#!A9F0X868-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO-S)F-#0X-6%?9&0U-E\T-3DU7S@S,#5?,#!A
M8S`P869D.&%F+U=O<FMS:&5E=',O4VAE970R.2YH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P134V
M044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1F%I<B!V86QU92!O9B!F:6YA
M;F-I86P@:6YS=')U;65N=',@86YD(&UA<FME=&%B;&4@<V5C=7)I=&EE<R`H
M1&5T86EL<R`T*2`H5V%R<F%N=',L(%531"`D*3QB<CY);B!4:&]U<V%N9',L
M(&5X8V5P="!097(@4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES92!S<&5C
M:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^0VAA;F=E<R!I;B!T:&4@9F%I<B!V86QU92!O
M9B!W87)R86YT(&QI86)I;&ET>3PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y"96=I;FYI;F<@8F%L86YC93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q.#@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H86YG92!I;B!F86ER('9A
M;'5E(&]F('=A<G)A;G0@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^16YD:6YG(&)A;&%N8V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,C(Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6YI;75M/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^07-S=6UP=&EO;B!U<V5D('1O
M(&5S=&EM871E('1H92!F86ER('9A;'5E(&]F('=A<G)A;G0@;&EA8FEL:71Y
M(&)Y('5T:6QI>FEN9R!T:&4@0FQA8VLM4V-H;VQE<R!O<'1I;VXM<')I8VEN
M9R!M;V1E;#PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y6;VQA=&EL:71Y("AA<R!A('!E<F-E;G0I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV."XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV."XP,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)I<VLM9G)E92!I;G1E
M<F5S="!R871E("AA<R!A('!E<F-E;G0I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP+C4V)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`N.#DE/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=')I:V4@<')I8V4@*&EN(&1O;&QA
M<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$R.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^17AP96-T960@;&EF93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^,B!Y96%R<R`R(&UO;G1H<R`Q-B!D87ES/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,B!Y96%R<R`V
M(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^36%X:6UU;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D%S<W5M<'1I;VX@=7-E9"!T;R!E<W1I;6%T92!T:&4@
M9F%I<B!V86QU92!O9B!W87)R86YT(&QI86)I;&ET>2!B>2!U=&EL:7II;F<@
M=&AE($)L86-K+5-C:&]L97,@;W!T:6]N+7!R:6-I;F<@;6]D96P\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F]L871I;&ET
M>2`H87,@82!P97)C96YT*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-S`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-S`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y2:7-K+69R964@:6YT97)E<W0@<F%T92`H87,@
M82!P97)C96YT*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2XQ
M,R4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+C8U)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4W1R:6ME('!R:6-E("AI;B!D;VQL87)S('!E<B!S:&%R92D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPU,C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L-3(P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%>'!E8W1E9"!L:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XT('EE87)S(#4@;6]N=&AS(#(S(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XT('EE87)S(#@@;6]N=&AS(#$R
M(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D%S<W5M<'1I;VX@=7-E9"!T;R!E<W1I;6%T92!T
M:&4@9F%I<B!V86QU92!O9B!W87)R86YT(&QI86)I;&ET>2!B>2!U=&EL:7II
M;F<@=&AE($)L86-K+5-C:&]L97,@;W!T:6]N+7!R:6-I;F<@;6]D96P\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!V
M86QU92!O9B!S:&%R97,@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V,"XX-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-3$N-S<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S<R9C0T.#5A7V1D
M-39?-#4Y-5\X,S`U7S`P86,P,&%F9#AA9@T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\W,F8T-#@U85]D9#4V7S0U.35?.#,P-5\P,&%C,#!A9F0X
M868O5V]R:W-H965T<R]3:&5E=#,P+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%5$E!13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY/=&AE<B!C;VUP<F5H96YS:79E(&EN8V]M
M92`H;&]S<RD@86YD(&%C8W5M=6QA=&5D(&]T:&5R(&-O;7!R96AE;G-I=F4@
M:71E;7,@*$1E=&%I;',I("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE
M<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^3W1H97(@8V]M<')E:&5N<VEV92!I;F-O
M;64@86YD(&%C8W5M=6QA=&5D(&]T:&5R(&-O;7!R96AE;G-I=F4@:71E;7,\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L
M86YC92!A="!T:&4@8F5G:6YN:6YG(&]F('1H92!P97)I;V0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-S,W*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@8V]M<')E:&5N
M<VEV92!I;F-O;64O*&QO<W,I(&)E9F]R92!R96-L87-S:69I8V%T:6]N<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@8V]M<')E
M:&5N<VEV92!I;F-O;64O*&QO<W,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y"86QA;F-E(&%T('1H92!E;F0@;V8@=&AE('!E<FEO9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-S,V*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YR96%L:7IE
M9"!'86EN<R\H3&]S<V5S*2!/;B!-87)K971A8FQE(%-E8W5R:71I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/=&AE<B!C
M;VUP<F5H96YS:79E(&EN8V]M92!A;F0@86-C=6UU;&%T960@;W1H97(@8V]M
M<')E:&5N<VEV92!I=&5M<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y"86QA;F-E(&%T('1H92!B96=I;FYI;F<@;V8@=&AE
M('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S@W*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3W1H97(@8V]M<')E:&5N<VEV92!I;F-O;64O*&QO<W,I(&)E9F]R92!R96-L
M87-S:69I8V%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y/=&AE<B!C;VUP<F5H96YS:79E(&EN8V]M92\H;&]S<RD\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92!A="!T:&4@
M96YD(&]F('1H92!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#(V,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D9O<F5I9VX@0W5R<F5N8WD@5')A;G-L871I;VX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/=&AE<B!C;VUP
M<F5H96YS:79E(&EN8V]M92!A;F0@86-C=6UU;&%T960@;W1H97(@8V]M<')E
M:&5N<VEV92!I=&5M<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y"86QA;F-E(&%T('1H92!B96=I;FYI;F<@;V8@=&AE('!E
M<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S4P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H
M97(@8V]M<')E:&5N<VEV92!I;F-O;64O*&QO<W,I(&)E9F]R92!R96-L87-S
M:69I8V%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3(T
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3W1H97(@8V]M<')E:&5N<VEV92!I;F-O;64O*&QO<W,I/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,C0I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E(&%T('1H92!E
M;F0@;V8@=&AE('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@T-S0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\W,F8T-#@U85]D9#4V7S0U.35?.#,P-5\P,&%C,#!A9F0X868-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-S)F-#0X-6%?9&0U-E\T-3DU
M7S@S,#5?,#!A8S`P869D.&%F+U=O<FMS:&5E=',O4VAE970S,2YH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P139)04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^06-C;W5N=',@
M<&%Y86)L92!A;F0@86-C<G5E9"!E>'!E;G-E<R`H1&5T86EL<RD@*%531"`D
M*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S
M,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D%C8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U960@97AP96YS
M97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M16UP;&]Y964@8V]M<&5N<V%T:6]N+"!B96YE9FET<RP@86YD(')E;&%T960@
M86-C<G5A;',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPS
M-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#DL,S$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VYS=6QT:6YG(&%N9"!C;VYT<F%C=&5D(')E<V5A<F-H
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PV.3$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#,T.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')O9F5S<VEO;F%L(&9E97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L,S@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,RPS,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,L,3,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PQ,C@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#DU-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L.3DX/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@
M<&%Y86)L92!A;F0@86-C<G5E9"!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`R,RPU,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(Y+#$R,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-S)F-#0X-6%?9&0U-E\T-3DU
M7S@S,#5?,#!A8S`P869D.&%F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S<R9C0T.#5A7V1D-39?-#4Y-5\X,S`U7S`P86,P,&%F9#AA9B]7;W)K
M<VAE971S+U-H965T,S(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5#54%%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,3X\<W1R;VYG/E=A<G)A;G1S("A$971A:6QS*2`H5V%R<F%N=',L($-O
M;6UO;B!S=&]C:RP@55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q-SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E=A<G)A;G1S/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@<VAA<F5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#(U,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L,C4P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M>&5R8VES92!P<FEC92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3(X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$Y(&%N9"`R
M,#(P/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M5V%R<F%N=',\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5V%R<F%N="!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<L,#,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-RPP,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E('!R:6-E("AI;B!D;VQL87)S
M('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,3(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/C(P,3D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY787)R86YT<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y787)R86YT('-H87)E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3,P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!P<FEC92`H:6X@
M9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#(L-3(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`R+#4R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?-S)F-#0X-6%?9&0U-E\T-3DU7S@S,#5?,#!A8S`P
M869D.&%F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S<R9C0T.#5A
M7V1D-39?-#4Y-5\X,S`U7S`P86,P,&%F9#AA9B]7;W)K<VAE971S+U-H965T
M,S,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5924%#/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/DYE="!L;W-S('!E<B!S:&%R92`H1&5T86EL<RD@*%531"`D*3QB<CY);B!4
M:&]U<V%N9',L(&5X8V5P="!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E
M('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@
M,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R
M+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY.=6UE<F%T;W(\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^)"`H,S<L.3$U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,30L,#DX*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$96YO
M;6EN871O<CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$96YO;6EN871O<B!F;W(@8F%S:6,@86YD(&1I;'5T960@;F5T(&QO
M<W,@<&5R('-H87)E("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS,RPP-C<L-S4R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C0L-#DR+#0X-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.970@
M;&]S<R!P97(@<VAA<F4Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D)A<VEC(&%N9"!D:6QU=&5D("AI;B!D;VQL87)S('!E
M<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,2XQ
M-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B0@*#`N-3@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\W,F8T-#@U85]D9#4V7S0U.35?.#,P-5\P,&%C,#!A9F0X868-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-S)F-#0X-6%?9&0U-E\T-3DU
M7S@S,#5?,#!A8S`P869D.&%F+U=O<FMS:&5E=',O4VAE970S-"YH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P13)"044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3F5T(&QO<W,@
M<&5R('-H87)E("A$971A:6QS(#(I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.970@;&]S<R!P97(@<VAA<F4\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T
M86P@<VAA<F5S(&5X8VQU9&5D(&9R;VT@8V%L8W5L871I;VX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0L.3DR+#@P,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L.#@R+#(X-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O
M8VL@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/DYE="!L;W-S('!E<B!S:&%R93PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!S:&%R97,@97AC;'5D960@
M9G)O;2!C86QC=6QA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-"PV,C<L.#,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,RPQ,S,L.#,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D('-T;V-K/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3F5T(&QO<W,@
M<&5R('-H87)E/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E1O=&%L('-H87)E<R!E>&-L=61E9"!F<F]M(&-A;&-U;&%T:6]N
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-C0L.3<P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S0X+#0U
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-S)F
M-#0X-6%?9&0U-E\T-3DU7S@S,#5?,#!A8S`P869D.&%F#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+S<R9C0T.#5A7V1D-39?-#4Y-5\X,S`U7S`P
M86,P,&%F9#AA9B]7;W)K<VAE971S+U-H965T,S4N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5'
M6D-)/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K(&%W87)D('!L86X@
M*$1E=&%I;',I("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!E>&-E<'0@4VAA
M<F4@9&%T82P@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R
M+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-
M87D@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M36%R+B`P-2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4W1O8VL@;W!T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^3G5M8F5R(&]F(&]P=&EO;G,\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W5T<W1A;F1I;F<@870@
M=&AE(&)E9VEN;FEN9R!O9B!T:&4@<&5R:6]D("AI;B!S:&%R97,I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#0S,BPY-S(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R86YT960@
M*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M-#4V+#4U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^17AE<F-I<V5D("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@R,S0L.#,P*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F]R9F5I=&5D("AI;B!S:&%R
M97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-BPR-C4I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M>'!I<F5D("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@U.30I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y/=71S=&%N9&EN9R!A="!T:&4@96YD(&]F('1H92!P97)I
M;V0@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0L-C(W+#@S,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5F5S=&5D(&]R(&5X<&5C=&5D('1O('9E<W0@870@=&AE
M(&5N9"!O9B!T:&4@<&5R:6]D("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT+#,S,BPW,C8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-A8FQE(&%T('1H
M92!E;F0@;V8@=&AE('!E<FEO9"`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PP,S<L,C8R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E=E:6=H=&5D
M+6%V97)A9V4@97AE<F-I<V4@<')I8V4\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3W5T<W1A;F1I;F<@870@=&AE(&)E9VEN
M;FEN9R!O9B!T:&4@<&5R:6]D("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R86YT960@*&EN
M(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`U,2XP,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^17AE<F-I<V5D("AI;B!D;VQL87)S('!E<B!S:&%R
M92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3(N.#8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9O
M<F9E:71E9"`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#0W+C4R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!I<F5D("AI;B!D;VQL87)S
M('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,S@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y/=71S=&%N9&EN9R!A="!T:&4@96YD(&]F('1H92!P97)I;V0@*&EN
M(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`S,RXV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y697-T960@;W(@97AP96-T960@=&\@=F5S="!A="!T
M:&4@96YD(&]F('1H92!P97)I;V0@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S,BXW-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I
M<V%B;&4@870@=&AE(&5N9"!O9B!T:&4@<&5R:6]D("AI;B!D;VQL87)S('!E
M<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S`N
M.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^5V5I9VAT960M879E<F%G92!R96UA:6YI;F<@8V]N=')A
M8W1U86P@=&5R;3PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y/=71S=&%N9&EN9R!A="!T:&4@8F5G:6YN:6YG(&]F('1H92!P
M97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C@@>65A<G,@
M,3`@;6]N=&AS(#(T(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E9E<W1E9"!O<B!E>'!E8W1E9"!T;R!V97-T
M(&%T('1H92!E;F0@;V8@=&AE('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^."!Y96%R<R`Q,"!M;VYT:',@,C0@9&%Y<SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I
M<V%B;&4@870@=&AE(&5N9"!O9B!T:&4@<&5R:6]D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XX('EE87)S(#(@;6]N=&AS(#$R(&1A>7,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^5F%L=6%T:6]N(&%S<W5M<'1I;VYS/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN9'5C96UE;G0@9W)A;G1S(&9O
M<B!N;VXM<W1A='5T;W)Y('-T;V-K(&]P=&EO;G,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/CDS+#,U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@879E<F%G92!G<F%N
M="!D871E(&9A:7(@=F%L=64@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S,2XX,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!
M9V=R96=A=&4@:6YT<FEN<VEC('9A;'5E/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]U='-T86YD:6YG(&%T('1H92!E;F0@
M;V8@=&AE('!E<FEO9"`H:6X@9&]L;&%R<RD\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,30P+#,Y.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F5S=&5D(&]R(&5X<&5C=&5D('1O
M('9E<W0@870@=&AE(&5N9"!O9B!T:&4@<&5R:6]D("AI;B!D;VQL87)S*3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,S+#(S,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I
M<V%B;&4@870@=&AE(&5N9"!O9B!T:&4@<&5R:6]D("AI;B!D;VQL87)S*3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T-2PQ,S<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K
M(&]P=&EO;B!\($UI;FEM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY686QU871I;VX@87-S=6UP=&EO;G,\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4FES:RUF<F5E(&EN
M=&5R97-T(')A=&4@*&%S(&$@<&5R8V5N="D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$N-30E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!V;VQA=&EL:71Y("AA<R!A
M('!E<F-E;G0I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-RXP
M,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5X<&5C=&5D('1E<FT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/C4@>65A<G,@-B!M;VYT:',\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&]P=&EO;B!\($UA>&EM=6T\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY686QU
M871I;VX@87-S=6UP=&EO;G,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4FES:RUF<F5E(&EN=&5R97-T(')A=&4@*&%S(&$@
M<&5R8V5N="D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N-S<E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%>'!E8W1E9"!V;VQA=&EL:71Y("AA<R!A('!E<F-E;G0I/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV.2XP,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D('1E<FT\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C8@>65A<G,@,2!M;VYT
M:"`Q,"!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#XR,#`Y($5Q=6ET>2!A;F0@3&]N9R!497)M($EN8V5N=&EV
M92!0;&%N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4W1O8VL@;W!T:6]N('!L86X\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(&%D9&ET:6]N86P@<VAA<F5S
M(&%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L
M-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^,C`Q,R!3=&]C:R!);F-E;G1I=F4@4&QA;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K(&]P=&EO;B!P
M;&%N/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYU;6)E<B!O9B!S:&%R97,@879A:6QA8FQE(&9O<B!I<W-U86YC93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q,R!3=&]C:R!);F-E
M;G1I=F4@4&QA;B!\(%-T;V-K(&]P=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K(&]P=&EO;B!P;&%N/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O
M9B!S:&%R97,@;V8@<F5S=')I8W1E9"!S=&]C:R!G<F%N=&5D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#8Q,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q,R!3=&]C:R!);F-E
M;G1I=F4@4&QA;B!\(%)E<W1R:6-T960@<W1O8VL\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:R!O<'1I;VX@<&QA;CPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB
M97(@;V8@<VAA<F5S(&]F(')E<W1R:6-T960@<W1O8VL@9W)A;G1E9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S,U+#,R-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q,R!3=&]C
M:R!);F-E;G1I=F4@4&QA;B!\($-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K(&]P=&EO;B!P;&%N
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU
M;6)E<B!O9B!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-S,Y+#DS-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^,C`P.2!%<75I='D@86YD($QO;F<@5&5R
M;2!);F-E;G1I=F4@4&QA;B!A;F0@,C`Q,R!3=&]C:R!);F-E;G1I=F4@4&QA
M;B!\($-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E-T;V-K(&]P=&EO;B!P;&%N/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!S:&%R97,@
M879A:6QA8FQE(&9O<B!I<W-U86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C0U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^,C`P.2!%<75I='D@86YD($QO;F<@5&5R;2!)
M;F-E;G1I=F4@4&QA;B!A;F0@,C`Q,R!3=&]C:R!);F-E;G1I=F4@4&QA;B!\
M($-O;6UO;B!S=&]C:R!\($UA>&EM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:R!O<'1I;VX@<&QA;CPO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@
M<VAA<F5S('-U8FIE8W0@=&\@;W5T<W1A;F1I;F<@87=A<F1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#`T,"PT-#0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,3,@3&]N9R!4
M97)M($EN8V5N=&EV92!0;&%N('P@36EN:6UU;3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K(&]P=&EO;B!P;&%N/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%N;G5A
M;"!I;F-R96%S92!I;B!T:&4@;G5M8F5R(&]F('-H87)E<R!O;B!T:&4@9FER
M<W0@9&%Y(&]F('1H92!F:7-C86P@>65A<CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,BPU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;FYU86P@:6YC<F5A<V4@:6X@=&AE
M(&YU;6)E<B!O9B!S:&%R97,@;W5T<W1A;F1I;F<@;VX@=&AE(&9I<G-T(&1A
M>2!O9B!T:&4@9FES8V%L('EE87(@*&%S(&$@<&5R8V5N="D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0N,#`E/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W,F8T-#@U85]D9#4V7S0U.35?.#,P
M-5\P,&%C,#!A9F0X868-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M-S)F-#0X-6%?9&0U-E\T-3DU7S@S,#5?,#!A8S`P869D.&%F+U=O<FMS:&5E
M=',O4VAE970S-BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q
M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA
M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14M004,^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^4W1O8VL@87=A<F0@<&QA;B`M("A$971A:6QS(#(I("A297-T
M<FEC=&5D('-T;V-K+"!54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4F5S=')I8W1E9"!S=&]C:SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYU;6)E<B!O9B!3:&%R97,\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L
M86YC92!A="!T:&4@8F5G:6YN:6YG(&]F('1H92!P97)I;V0@*&EN('-H87)E
M<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<Q."PT,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9E
M<W1E9"`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,S4P+#`X-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D9O<F9E:71E9"`H:6X@<VAA<F5S*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,RPS-#8I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E(&%T('1H92!E
M;F0@;V8@=&AE('!E<FEO9"`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S8T+#DW,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY796EG:'1E9"!!=F5R
M86=E($=R86YT($1A=&4@1F%I<B!686QU93PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E(&%T('1H92!B96=I;FYI
M;F<@;V8@=&AE('!E<FEO9"`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P+C<R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y697-T960\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`N-3D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9O<F9E:71E
M9"`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$P+C@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E(&%T('1H92!E;F0@;V8@=&AE
M('!E<FEO9"`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$P+C@U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\W,F8T-#@U85]D9#4V7S0U.35?.#,P-5\P
M,&%C,#!A9F0X868-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-S)F
M-#0X-6%?9&0U-E\T-3DU7S@S,#5?,#!A8S`P869D.&%F+U=O<FMS:&5E=',O
M4VAE970S-RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P13)&044^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^4W1O8VL@87=A<F0@<&QA;B`H1&5T86EL<R`S*2`H55-$("0I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q
M-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY3:&%R92UB87-E9"!C;VUP96YS871I;VX@97AP96YS92!R96-O<F1E9"!I
M;B!T:&4@<W1A=&5M96YT(&]F(&]P97)A=&EO;G,\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@8V]M<&5N
M<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@.2PW-#@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`S+#<P-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N<F5C;V=N:7IE9"!C;VUP96YS
M871I;VX@8V]S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S`L
M-C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5V5I9VAT960@879E<F%G92!R96UA:6YI;F<@<V5R=FEC92!P
M97)I;V0@9F]R(')E8V]G;FET:6]N(&]F('5N<F5C;V=N:7IE9"!C;VUP96YS
M871I;VX@8V]S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,R!Y
M96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@8V]M<&5N
M<V%T:6]N(&5X<&5N<V4@<F5C;W)D960@:6X@=&AE('-T871E;65N="!O9B!O
M<&5R871I;VYS/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#8V-RPP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#DT-"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-E;&QI;F<L(&=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@
M8V]M<&5N<V%T:6]N(&5X<&5N<V4@<F5C;W)D960@:6X@=&AE('-T871E;65N
M="!O9B!O<&5R871I;VYS/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4L,#@Q+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,2PW-C$L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\W,F8T-#@U85]D9#4V7S0U.35?.#,P-5\P,&%C,#!A9F0X868-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-S)F-#0X-6%?9&0U-E\T-3DU
M7S@S,#5?,#!A8S`P869D.&%F+U=O<FMS:&5E=',O4VAE970S."YH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P155004,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]M;6ET;65N
M=',@86YD(&-O;G1I;F=E;F-I97,@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM
M:71M96YT<R!A;F0@8V]N=&EN9V5N8VEE<SPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<&5R871I;F<@3&5A<V5S+"!296YT
M($5X<&5N<V4L($YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`S,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D]P97)A=&EN9R!,96%S97,L($9U='5R92!-
M:6YI;75M(%!A>6UE;G1S($1U92P@1FES8V%L(%EE87(@36%T=7)I='D\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q-3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP,38L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$V
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-#8L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$W
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,C,L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$X
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`S-2PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P
M,3D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W-BPP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M;W1A;"!F=71U<F4@;6EN:6UU;2!L96%S92!P87EM96YT<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-"PP.38L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&=6YD:6YG(&%G<F5E
M;65N="!\(%=E;&QC;VUE('1R=7-T('P@36%X:6UU;3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]T:&5R(&-O;G1I;F=E;F-I
M97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&5V96QO<&UE;G0@86YD(')E9W5L871O<GD@;6EL97-T;VYE('!A>6UE;G1S
M('=H:6-H('1H92!E;G1I='D@;6%Y(&)E(&]B;&EG871E9"!T;R!P87D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-C@L.3`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-S)F-#0X-6%?
M9&0U-E\T-3DU7S@S,#5?,#!A8S`P869D.&%F#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S<R9C0T.#5A7V1D-39?-#4Y-5\X,S`U7S`P86,P,&%F
M9#AA9B]7;W)K<VAE971S+U-H965T,SDN:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5)0T%#/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;&QA8F]R871I;VX@4F5V96YU92`H
M1&5T86EL<RD@*$-O;&QA8F]R871I;VX@86=R965M96YT+"!2;V-H92!A;F0@
M4TU!($9O=6YD871I;VXL($-L:6YI8V%L(&1E=F5L;W!M96YT(&UI;&5S=&]N
M97,L(%531"`D*3QB<CY);B!-:6QL:6]N<RP@=6YL97-S(&]T:&5R=VES92!S
M<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*86XN(#(R
M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VQL86)O<F%T:6]N(&%G<F5E;65N="!\(%)O8VAE(&%N9"!334$@1F]U;F1A
M=&EO;B!\($-L:6YI8V%L(&1E=F5L;W!M96YT(&UI;&5S=&]N97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VQL86)O<F%T
M:6]N(%)E=F5N=64\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^36EL97-T;VYE('!A>6UE;G0@<F5C96EV960@9G)O;2!2;V-H
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W+C4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S<R9C0T.#5A7V1D
M-39?-#4Y-5\X,S`U7S`P86,P,&%F9#AA9@T*0V]N=&5N="U,;V-A=&EO;CH@
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M1")3:&5E=#`R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P,RYH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#0N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#`U+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970P-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#<N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`X+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970P.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,3`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Q
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,BYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,3,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#$T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q
M-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,38N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$W+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970Q."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,3DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(P+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970R,2YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,C(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#(S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-"YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C4N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#(V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970R-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C@N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(Y+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970S,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,S$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,R+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S,RYH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,S0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#,U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S-BYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S<N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#,X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970S.2YH=&UL(B\^#0H\+WAM;#X-"BTM+2TM+3U?3F5X=%!A<G1?-S)F
E-#0X-6%?9&0U-E\T-3DU7S@S,#5?,#!A8S`P869D.&%F+2T-"@``
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E56AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair value of financial instruments and marketable securities (Details 4) (Warrants, USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in the fair value of warrant liability</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
        <td class="nump"><a title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" onclick="toggleNextSibling(this);">$ 188</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value of warrant liability</a></td>
        <td class="nump"><a title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" onclick="toggleNextSibling(this);">41</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
        <td class="nump"><a title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" onclick="toggleNextSibling(this);">$ 229</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract', window );"><strong>Assumption used to estimate the fair value of warrant liability by utilizing the Black-Scholes option-pricing model</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsExpectedVolatilityRate[us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">68.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsExpectedVolatilityRate[us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">68.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsRiskFreeInterestRate[us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">0.56%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsRiskFreeInterestRate[us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">0.89%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Strike price (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsExercisePrice[us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">$ 128</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsExercisePrice<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsExercisePrice[us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">$ 128</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsExercisePrice<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life</a></td>
        <td class="text">2 years 2 months 16 days<span></span></td>
        <td class="text">2 years 6 months<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract', window );"><strong>Assumption used to estimate the fair value of warrant liability by utilizing the Black-Scholes option-pricing model</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsExpectedVolatilityRate[us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">70.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsExpectedVolatilityRate[us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">70.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsRiskFreeInterestRate[us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">1.13%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsRiskFreeInterestRate[us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">1.65%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Strike price (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsExercisePrice[us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">$ 2,520</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsExercisePrice<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsExercisePrice[us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">$ 2,520</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsExercisePrice<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life</a></td>
        <td class="text">4 years 5 months 23 days<span></span></td>
        <td class="text">4 years 8 months 12 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Common stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract', window );"><strong>Assumption used to estimate the fair value of warrant liability by utilizing the Black-Scholes option-pricing model</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of shares (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_SharePrice[us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember;us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 60.85</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharePrice<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_SharePrice[us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember;us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 51.77</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharePrice<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Agreed upon price for the exchange of the underlying asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Risk-free interest rate assumption used in valuing an instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price of a single share of a number of saleable stocks of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EDQAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Fair value of financial instruments and marketable securities (Details 3) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsLineItems', window );"><strong>Marketable securities on the balance sheet</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Total Marketable securities, Less Than 12 Months</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" onclick="toggleNextSibling(this);">$ 169,392</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" onclick="toggleNextSibling(this);">$ 163,761</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue', window );">Total Marketable securities, More Than 12 Months</a></td>
        <td class="nump"><a title="ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" onclick="toggleNextSibling(this);">74,250</a><span style="display:none;white-space:normal;text-align:left;">ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue</span><span></span></td>
        <td class="nump"><a title="ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" onclick="toggleNextSibling(this);">101,732</a><span style="display:none;white-space:normal;text-align:left;">ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsLineItems', window );"><strong>Marketable securities on the balance sheet</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Total Marketable securities, Less Than 12 Months</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue[us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember]" onclick="toggleNextSibling(this);">19,774</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsLineItems', window );"><strong>Marketable securities on the balance sheet</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Total Marketable securities, Less Than 12 Months</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue[us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">138,306</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue[us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">157,758</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue', window );">Total Marketable securities, More Than 12 Months</a></td>
        <td class="nump"><a title="ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue[us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">48,228</a><span style="display:none;white-space:normal;text-align:left;">ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue[us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">72,273</a><span style="display:none;white-space:normal;text-align:left;">ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherDebtSecuritiesMember', window );">Government obligations</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsLineItems', window );"><strong>Marketable securities on the balance sheet</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Total Marketable securities, Less Than 12 Months</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue[us-gaap_InvestmentTypeAxis=us-gaap_OtherDebtSecuritiesMember]" onclick="toggleNextSibling(this);">11,312</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_OtherDebtSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue[us-gaap_InvestmentTypeAxis=us-gaap_OtherDebtSecuritiesMember]" onclick="toggleNextSibling(this);">6,003</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_OtherDebtSecuritiesMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue', window );">Total Marketable securities, More Than 12 Months</a></td>
        <td class="nump"><a title="ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue[us-gaap_InvestmentTypeAxis=us-gaap_OtherDebtSecuritiesMember]" onclick="toggleNextSibling(this);">$ 26,022</a><span style="display:none;white-space:normal;text-align:left;">ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_OtherDebtSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue[us-gaap_InvestmentTypeAxis=us-gaap_OtherDebtSecuritiesMember]" onclick="toggleNextSibling(this);">$ 29,459</a><span style="display:none;white-space:normal;text-align:left;">ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_OtherDebtSecuritiesMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of available-for-sale debt securities at fair value maturing after the next fiscal year following the latest fiscal year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>ptct_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 320<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentHoldingsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentHoldingsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherDebtSecuritiesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_OtherDebtSecuritiesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ETIAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Other comprehensive income (loss) and accumulated other comprehensive items (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Other comprehensive income and accumulated other comprehensive items</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance at the beginning of the period</a></td>
        <td class="num"><a title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" onclick="toggleNextSibling(this);">$ (737)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income/(loss) before reclassifications</a></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss)</a></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeLossNetOfTax" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance at the end of the period</a></td>
        <td class="num"><a title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" onclick="toggleNextSibling(this);">(736)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gains/(Losses) On Marketable Securities</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Other comprehensive income and accumulated other comprehensive items</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance at the beginning of the period</a></td>
        <td class="num"><a title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember]" onclick="toggleNextSibling(this);">(387)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income/(loss) before reclassifications</a></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember]" onclick="toggleNextSibling(this);">125</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss)</a></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeLossNetOfTax[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember]" onclick="toggleNextSibling(this);">125</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeLossNetOfTax<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance at the end of the period</a></td>
        <td class="num"><a title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember]" onclick="toggleNextSibling(this);">(262)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ForeignCurrencyGainLossMember', window );">Foreign Currency Translation</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Other comprehensive income and accumulated other comprehensive items</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance at the beginning of the period</a></td>
        <td class="num"><a title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax[us-gaap_StatementEquityComponentsAxis=us-gaap_ForeignCurrencyGainLossMember]" onclick="toggleNextSibling(this);">(350)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_ForeignCurrencyGainLossMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income/(loss) before reclassifications</a></td>
        <td class="num"><a title="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax[us-gaap_StatementEquityComponentsAxis=us-gaap_ForeignCurrencyGainLossMember]" onclick="toggleNextSibling(this);">(124)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_ForeignCurrencyGainLossMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss)</a></td>
        <td class="num"><a title="us-gaap_OtherComprehensiveIncomeLossNetOfTax[us-gaap_StatementEquityComponentsAxis=us-gaap_ForeignCurrencyGainLossMember]" onclick="toggleNextSibling(this);">(124)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeLossNetOfTax<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_ForeignCurrencyGainLossMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance at the end of the period</a></td>
        <td class="num"><a title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax[us-gaap_StatementEquityComponentsAxis=us-gaap_ForeignCurrencyGainLossMember]" onclick="toggleNextSibling(this);">$ (474)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_ForeignCurrencyGainLossMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669619-108580<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ForeignCurrencyGainLossMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_ForeignCurrencyGainLossMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6IAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Accounts payable and accrued expenses (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accounts payable and accrued expenses</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation, benefits, and related accruals</a></td>
        <td class="nump"><a title="us-gaap_EmployeeRelatedLiabilitiesCurrent" onclick="toggleNextSibling(this);">$ 3,365</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeRelatedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_EmployeeRelatedLiabilitiesCurrent" onclick="toggleNextSibling(this);">$ 9,312</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeRelatedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AccruedConsultingAndContractedResearchCurrent', window );">Consulting and contracted research</a></td>
        <td class="nump"><a title="ptct_AccruedConsultingAndContractedResearchCurrent" onclick="toggleNextSibling(this);">11,691</a><span style="display:none;white-space:normal;text-align:left;">ptct_AccruedConsultingAndContractedResearchCurrent</span><span></span></td>
        <td class="nump"><a title="ptct_AccruedConsultingAndContractedResearchCurrent" onclick="toggleNextSibling(this);">9,349</a><span style="display:none;white-space:normal;text-align:left;">ptct_AccruedConsultingAndContractedResearchCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
        <td class="nump"><a title="us-gaap_AccruedProfessionalFeesCurrent" onclick="toggleNextSibling(this);">3,382</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedProfessionalFeesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccruedProfessionalFeesCurrent" onclick="toggleNextSibling(this);">3,334</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedProfessionalFeesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableCurrent" onclick="toggleNextSibling(this);">3,139</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableCurrent" onclick="toggleNextSibling(this);">4,128</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
        <td class="nump"><a title="us-gaap_OtherAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">1,955</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">2,998</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">$ 23,532</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">$ 29,121</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_AccruedConsultingAndContractedResearchCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for consulting and contracted research.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">ptct_AccruedConsultingAndContractedResearchCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>ptct_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of significant accounting policies<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:28pt;"><font style="display: inline;font-weight:bold;font-size:10pt;">2.</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;font-weight:bold;font-size:3pt;"></font><font style="display: inline;font-weight:bold;font-size:10pt;">Summary of significant accounting policies</font></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company&#x2019;s complete listing of significant accounting policies are described in Note 2 of the notes to the Company&#x2019;s audited financial statements as of December&nbsp;31, 2014 included in the Company&#x2019;s Annual Report on Form&nbsp;10-K filed with the Securities and Exchange Commission (SEC) on March&nbsp;2, 2015 (2014 Form&nbsp;10-K).</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Basis of Presentation</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The accompanying financial information as of March&nbsp;31, 2015 and for the three months ended March&nbsp;31, 2015 and 2014 has been prepared by the Company, without audit, pursuant to the rules&nbsp;and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP) have been condensed or omitted pursuant to such rules&nbsp;and regulations. These interim financial statements should be read in conjunction with the Company&#x2019;s audited financial statements as of December&nbsp;31, 2014 and notes thereto included in the 2014 Form&nbsp;10-K.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In the opinion of management, the unaudited financial information as of March&nbsp;31, 2015 and for the three months ended March&nbsp;31, 2015 and 2014 reflects all adjustments, which are normal recurring adjustments, necessary to present a fair statement of financial position, results of operations and cash flows. The results of operations for the three month period ended March&nbsp;31, 2015 are not necessarily indicative of the results to be expected for the year ended December&nbsp;31, 2015 or for any other interim period or for any other future year.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Use of estimates</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Inventories and cost of product revenue</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">On August&nbsp;4, 2014, the Company was notified that the European Commission, or EC, granted marketing authorization for Translarna for the treatment of Duchenne muscular dystrophy caused by nonsense mutations, or nmDMD, in ambulatory patients aged five years and older. The marketing authorization allows the Company to market Translarna in the European Economic Area, or EEA, which is comprised of the 28 member states of the European Union plus Norway,&nbsp;Iceland and Liechtenstein. This marketing authorization is subject to annual review and renewal by the European Medicines Agency, or EMA following its reassessment of the risk-benefit balance of the authorization and is further conditioned on the Company&#x2019;s ability to complete its global, confirmatory Phase 3 clinical trial in nm DMD, which it refers to as ACT DMD, and submit the final report, including additional efficacy and safety data from the trial during 2015.&nbsp;&nbsp;The launch in these countries is on a country by country basis. The Company does do not have sufficient history or experience from which to accurately forecast product sales or demand generation. As such, the Company has not capitalized inventory and will not capitalize inventory until the completion of ACT DMD and satisfaction of the EMA conditions or until the Company can reasonably predict future product sales. The costs incurred related to the manufacturing of Translarna have been recorded as research and development expense in the statements of operations. The Company&#x2019;s cost of product sales includes royalties and other miscellaneous selling costs, which were not material and therefore included as a component of research and development costs in the current year presentation. The time period over which this inventory is consumed will depend on a number of factors, including the amount of future Translarna sales, and the ability to utilize inventory prior to its expiration date.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Recently issued accounting standard</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In May&nbsp;2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No.&nbsp;2014-09, Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for annual reporting periods beginning after December&nbsp;15, 2016. Early application is not permitted. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. Presently, the Company is assessing what effect the adoption of ASU 2014-09 will have on its financial statements and accompanying notes.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In August&nbsp;2014, the FASB issued ASU 2014-15, &#x201C;Presentation of Financial Statements&#x2014;Going Concern&#x2014;Disclosures of Uncertainties about an entity&#x2019;s Ability to Continue as a Going Concern.&#x201D; ASU 2014-15 provides new guidance related to management&#x2019;s responsibility to evaluate whether there is substantial doubt about an entity&#x2019;s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards and to provide related footnote disclosures. This new guidance is effective for the annual period ending after December&nbsp;15, 2016, and for annual periods and interim periods thereafter. The requirements of ASU 2014-15 are not expected to have a significant impact on the Condensed Consolidated Financial Statements.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Revenue Recognition</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company recognizes revenue when amounts are realized or realizable and earned. Revenue is considered realizable and earned when the following criteria are met: (1)&nbsp;persuasive evidence of an arrangement exists; (2)&nbsp;delivery has occurred or services have been rendered; (3)&nbsp;the price is fixed or determinable; and (4)&nbsp;collection of the amounts due are reasonably assured.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;font-size:10pt;">Net Product Sales</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">PTC&#x2019;S net product sales have consisted solely of sales of Translarna for the treatment of nmDMD in territories outside of the U.S. The Company applies the revenue recognition guidance in accordance with Financial Accounting Standards Board (&#x201C;FASB&#x201D;) Accounting Standards Codification (&#x201C;ASC&#x201D;) Subtopic 605-15, Revenue Recognition&#x2014;Products. The Company recognizes revenue from product sales when there is persuasive evidence that an arrangement exists, title to product and associated risk of loss has passed to the customer, the price is fixed or determinable, collectability is reasonably assured and the Company has no further performance obligations.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company records revenue on sales where Translarna is available either on a commercial basis or through a reimbursed early access program and typically paid for by a government authority or institution. Prior to January&nbsp;1, 2015, the Company recognized revenue for commercial and reimbursed early access program sales on a cash basis once the product was shipped on behalf of the government authority or institution and payment had been received, if all other revenue recognition criteria were met. Beginning in the first quarter of 2015, the Company is recognizing revenue for Translarna as product is shipped, as the Company has established a pattern of collectability.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company records revenue net of estimated discounts and rebates. Allowances are recorded as a reduction of revenue at the time revenues from product sales are recognized. Allowances for government rebates and discounts are established at the time of delivery. These allowances are adjusted to reflect known changes in factors that may impact such allowances in the quarter those changes are known.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;font-size:10pt;">Collaboration and Grant Revenue</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The terms of these agreements typically include payments to the Company of one or more of the following: nonrefundable, upfront license fees; milestone payments; research funding and royalties on future product sales. In addition, the Company generates service revenue through agreements that generally provide for fees for research and development services and may include additional payments upon achievement of specified events.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company evaluates all contingent consideration earned, such as a milestone payment, using the criteria as provided by the Financial Accounting Standards Board (FASB), guidance on the milestone method of revenue recognition. At the inception of a collaboration arrangement, the Company evaluates if a milestone payment is substantive. The criteria requires that (1)&nbsp;the Company determines if the milestone is commensurate with either its performance to achieve the milestone or the enhancement of value resulting from our activities to achieve the milestone; (2)&nbsp;the milestone be related to past performance; and (3)&nbsp;the milestone be reasonable relative to all deliverable and payment terms of the collaboration arrangement. If these criteria are met then the contingent milestones can be considered a substantive milestone and will be recognized as revenue in the period that the milestone is achieved. The Company recognizes royalties as earned in accordance with the terms of various research and collaboration agreements. If not substantive, the contingent consideration is allocated to the existing units of accounting based on relative selling price and recognized following the same basis previously established for the associated unit of accounting.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company has the risks and rewards as the principal in the research and development activities.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ECUAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Warrants (Details) (Warrants, Common stock, USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">2017</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant shares</a></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightOutstanding[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember;us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember;us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">6,250</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightOutstanding<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_DebtInstrumentRedemptionPeriodAxis<br>= us-gaap_DebtInstrumentRedemptionPeriodTwoMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightOutstanding[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember;us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember;us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">6,250</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightOutstanding<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_DebtInstrumentRedemptionPeriodAxis<br>= us-gaap_DebtInstrumentRedemptionPeriodTwoMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember;us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember;us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 128.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_DebtInstrumentRedemptionPeriodAxis<br>= us-gaap_DebtInstrumentRedemptionPeriodTwoMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember;us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember;us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 128.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_DebtInstrumentRedemptionPeriodAxis<br>= us-gaap_DebtInstrumentRedemptionPeriodTwoMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">2019 and 2020</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant shares</a></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightOutstanding[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember;us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember;us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">7,030</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightOutstanding<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_DebtInstrumentRedemptionPeriodAxis<br>= us-gaap_DebtInstrumentRedemptionPeriodThreeMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightOutstanding[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember;us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember;us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">7,030</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightOutstanding<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_DebtInstrumentRedemptionPeriodAxis<br>= us-gaap_DebtInstrumentRedemptionPeriodThreeMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember;us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember;us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 128.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_DebtInstrumentRedemptionPeriodAxis<br>= us-gaap_DebtInstrumentRedemptionPeriodThreeMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember;us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember;us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 128.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_DebtInstrumentRedemptionPeriodAxis<br>= us-gaap_DebtInstrumentRedemptionPeriodThreeMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">2019</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant shares</a></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightOutstanding[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember;us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember;us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">130</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightOutstanding<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_DebtInstrumentRedemptionPeriodAxis<br>= us-gaap_DebtInstrumentRedemptionPeriodFiveMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightOutstanding[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember;us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember;us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">130</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightOutstanding<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_DebtInstrumentRedemptionPeriodAxis<br>= us-gaap_DebtInstrumentRedemptionPeriodFiveMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember;us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember;us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 2,520.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_DebtInstrumentRedemptionPeriodAxis<br>= us-gaap_DebtInstrumentRedemptionPeriodFiveMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember;us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember;us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 2,520.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_DebtInstrumentRedemptionPeriodAxis<br>= us-gaap_DebtInstrumentRedemptionPeriodFiveMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ERWAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 36,825</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 49,748</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
        <td class="nump"><a title="us-gaap_MarketableSecuritiesCurrent" onclick="toggleNextSibling(this);">243,642</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MarketableSecuritiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_MarketableSecuritiesCurrent" onclick="toggleNextSibling(this);">265,493</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MarketableSecuritiesCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" onclick="toggleNextSibling(this);">6,116</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" onclick="toggleNextSibling(this);">3,885</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables, net</a></td>
        <td class="nump"><a title="us-gaap_ReceivablesNetCurrent" onclick="toggleNextSibling(this);">3,178</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ReceivablesNetCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_ReceivablesNetCurrent" onclick="toggleNextSibling(this);">4,445</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ReceivablesNetCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">289,761</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">323,571</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">9,408</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">9,159</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DepositsAndOtherAssetsNoncurrent', window );">Deposits and other assets</a></td>
        <td class="nump"><a title="ptct_DepositsAndOtherAssetsNoncurrent" onclick="toggleNextSibling(this);">351</a><span style="display:none;white-space:normal;text-align:left;">ptct_DepositsAndOtherAssetsNoncurrent</span><span></span></td>
        <td class="nump"><a title="ptct_DepositsAndOtherAssetsNoncurrent" onclick="toggleNextSibling(this);">489</a><span style="display:none;white-space:normal;text-align:left;">ptct_DepositsAndOtherAssetsNoncurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">299,520</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">333,219</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">23,532</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">29,121</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent" onclick="toggleNextSibling(this);">373</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent" onclick="toggleNextSibling(this);">3,354</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">23,905</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">32,475</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
        <td class="nump"><a title="us-gaap_OtherLiabilitiesNoncurrent" onclick="toggleNextSibling(this);">2,295</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherLiabilitiesNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherLiabilitiesNoncurrent" onclick="toggleNextSibling(this);">2,277</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherLiabilitiesNoncurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump"><a title="us-gaap_Liabilities" onclick="toggleNextSibling(this);">26,200</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Liabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_Liabilities" onclick="toggleNextSibling(this);">34,752</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Liabilities</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value. Authorized 125,000,000 shares; issued and outstanding 33,483,306 shares at March 31, 2015. Authorized 125,000,000 shares; issued and outstanding 32,898,392 shares at December 31, 2014</a></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">33</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">33</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapital" onclick="toggleNextSibling(this);">734,489</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapital</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapital" onclick="toggleNextSibling(this);">721,722</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapital</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
        <td class="num"><a title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" onclick="toggleNextSibling(this);">(736)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</span><span></span></td>
        <td class="num"><a title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" onclick="toggleNextSibling(this);">(737)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(460,466)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(422,551)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">273,320</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">298,467</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 299,520</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 333,219</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_DepositsAndOtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the carrying value of amounts transferred to third parties for security purposes and other noncurrent assets that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">ptct_DepositsAndOtherAssetsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>ptct_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Assets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Liabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 2<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (f)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 24<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3,4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E5MAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (37,915)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (14,098)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">634</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">588</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in valuation of warrant liability</a></td>
        <td class="nump"><a title="us-gaap_FairValueAdjustmentOfWarrants" onclick="toggleNextSibling(this);">41</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAdjustmentOfWarrants</span><span></span></td>
        <td class="nump"><a title="us-gaap_FairValueAdjustmentOfWarrants" onclick="toggleNextSibling(this);">55</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAdjustmentOfWarrants</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums on investments</a></td>
        <td class="nump"><a title="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" onclick="toggleNextSibling(this);">486</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" onclick="toggleNextSibling(this);">414</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">9,748</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">3,705</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" onclick="toggleNextSibling(this);">(2,231)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" onclick="toggleNextSibling(this);">(358)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInReceivables" onclick="toggleNextSibling(this);">1,267</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInReceivables</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInReceivables" onclick="toggleNextSibling(this);">120</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInReceivables</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositOtherAssets', window );">Deposits and other assets</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInDepositOtherAssets" onclick="toggleNextSibling(this);">138</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDepositOtherAssets</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInDepositOtherAssets" onclick="toggleNextSibling(this);">17</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDepositOtherAssets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" onclick="toggleNextSibling(this);">(5,589)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" onclick="toggleNextSibling(this);">(3,472)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" onclick="toggleNextSibling(this);">(23)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" onclick="toggleNextSibling(this);">(23)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInDeferredRevenue" onclick="toggleNextSibling(this);">(2,981)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDeferredRevenue</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInDeferredRevenue" onclick="toggleNextSibling(this);">(386)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDeferredRevenue</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(36,425)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(13,438)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of fixed assets</a></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(883)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(186)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquireMarketableSecurities" onclick="toggleNextSibling(this);">(19,108)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquireMarketableSecurities</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquireMarketableSecurities" onclick="toggleNextSibling(this);">(25,354)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquireMarketableSecurities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sale &amp; redemption of marketable securities</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" onclick="toggleNextSibling(this);">40,598</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" onclick="toggleNextSibling(this);">21,273</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash provided/ used in investing activities</a></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">20,607</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(4,267)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payments on long-term debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_RepaymentsOfLongTermDebt" onclick="toggleNextSibling(this);">(37)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfLongTermDebt</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockOptionsExercised" onclick="toggleNextSibling(this);">3,019</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockOptionsExercised</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from public offerings</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">118,183</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">3,019</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">118,146</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCash', window );">Effect of exchange rate changes on cash</a></td>
        <td class="num"><a title="us-gaap_EffectOfExchangeRateOnCash" onclick="toggleNextSibling(this);">(124)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectOfExchangeRateOnCash</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInContinuingOperations', window );">Net increase/(decrease) in cash and cash equivalents</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInContinuingOperations" onclick="toggleNextSibling(this);">(12,923)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInContinuingOperations</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInContinuingOperations" onclick="toggleNextSibling(this);">100,441</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInContinuingOperations</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">49,748</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">15,414</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">36,825</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">115,855</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash information</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestPaid" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash information related to investing and financing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ChangeInUnrealizedGainLossOnMarketableSecurities', window );">Change in unrealized gain (loss) on marketable securities</a></td>
        <td class="nump"><a title="ptct_ChangeInUnrealizedGainLossOnMarketableSecurities" onclick="toggleNextSibling(this);">$ 125</a><span style="display:none;white-space:normal;text-align:left;">ptct_ChangeInUnrealizedGainLossOnMarketableSecurities</span><span></span></td>
        <td class="nump"><a title="ptct_ChangeInUnrealizedGainLossOnMarketableSecurities" onclick="toggleNextSibling(this);">$ 10</a><span style="display:none;white-space:normal;text-align:left;">ptct_ChangeInUnrealizedGainLossOnMarketableSecurities</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ChangeInUnrealizedGainLossOnMarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents change in the unrealized gain (loss) on marketable securities in noncash investing and financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">ptct_ChangeInUnrealizedGainLossOnMarketableSecurities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>ptct_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Depreciation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of effect of exchange rate changes on cash balances held in foreign currencies. Excludes cash equivalents.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCash</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 480<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositOtherAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other noncurrent operating liabilities not separately disclosed in the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestPaid</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) in cash associated with the entity's continuing operating, investing, and financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash outflow for purchase of trading, available-for-sale securities and held-to-maturity securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EGZCI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock award plan (Details) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>May 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 05, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Stock option</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning of the period (in shares)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">3,432,972</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">1,456,550</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">(234,830)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">(26,265)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">(594)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the period (in shares)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">4,627,833</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested or expected to vest at the end of the period (in shares)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">4,332,726</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at the end of the period (in shares)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">1,037,262</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-average exercise price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning of the period (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">$ 25.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">$ 51.02</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">$ 12.86</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">$ 47.52</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">$ 389</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end of the period (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">$ 33.60</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested or expected to vest at the end of the period (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">$ 32.74</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at the end of the period (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">$ 30.98</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-average remaining contractual term</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at the beginning of the period</a></td>
        <td class="text">8 years 10 months 24 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested or expected to vest at the end of the period</a></td>
        <td class="text">8 years 10 months 24 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at the end of the period</a></td>
        <td class="text">8 years 2 months 12 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Valuation assumptions</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions', window );">Inducement grants for non-statutory stock options</a></td>
        <td class="nump"><a title="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">93,350</a><span style="display:none;white-space:normal;text-align:left;">ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">$ 31.82</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward', window );"><strong>Aggregate intrinsic value</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at the end of the period (in dollars)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">$ 140,399</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested or expected to vest at the end of the period (in dollars)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">133,232</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at the end of the period (in dollars)</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">$ 45,137</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Stock option | Minimum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Valuation assumptions</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">1.54%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">67.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
        <td class="text">5 years 6 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Stock option | Maximum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Valuation assumptions</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">1.77%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">69.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
        <td class="text">6 years 1 month 10 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptct_EquityAndLongTermIncentivePlan2009Member', window );">2009 Equity and Long Term Incentive Plan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized[us-gaap_PlanNameAxis=ptct_EquityAndLongTermIncentivePlan2009Member]" onclick="toggleNextSibling(this);">2,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized<br>/ us-gaap_PlanNameAxis<br>= ptct_EquityAndLongTermIncentivePlan2009Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptct_StockIncentivePlan2013Member', window );">2013 Stock Incentive Plan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant[us-gaap_PlanNameAxis=ptct_StockIncentivePlan2013Member]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant<br>/ us-gaap_PlanNameAxis<br>= ptct_StockIncentivePlan2013Member</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptct_StockIncentivePlan2013Member', window );">2013 Stock Incentive Plan | Stock option</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares of restricted stock granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember;us-gaap_PlanNameAxis=ptct_StockIncentivePlan2013Member]" onclick="toggleNextSibling(this);">4,613</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember<br>/ us-gaap_PlanNameAxis<br>= ptct_StockIncentivePlan2013Member</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptct_StockIncentivePlan2013Member', window );">2013 Stock Incentive Plan | Restricted stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares of restricted stock granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember;us-gaap_PlanNameAxis=ptct_StockIncentivePlan2013Member]" onclick="toggleNextSibling(this);">735,324</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember<br>/ us-gaap_PlanNameAxis<br>= ptct_StockIncentivePlan2013Member</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptct_StockIncentivePlan2013Member', window );">2013 Stock Incentive Plan | Common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized[us-gaap_PlanNameAxis=ptct_StockIncentivePlan2013Member;us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">739,937</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized<br>/ us-gaap_PlanNameAxis<br>= ptct_StockIncentivePlan2013Member<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member', window );">2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan | Common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant[us-gaap_PlanNameAxis=ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member;us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">245,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant<br>/ us-gaap_PlanNameAxis<br>= ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member', window );">2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan | Common stock | Maximum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards', window );">Number of shares subject to outstanding awards</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards[us-gaap_PlanNameAxis=ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member;us-gaap_RangeAxis=us-gaap_MaximumMember;us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">3,040,444</a><span style="display:none;white-space:normal;text-align:left;">ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards<br>/ us-gaap_PlanNameAxis<br>= ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptct_LongTermIncentivePlan2013Member', window );">2013 Long Term Incentive Plan | Minimum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber', window );">Annual increase in the number of shares on the first day of the fiscal year</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber[us-gaap_PlanNameAxis=ptct_LongTermIncentivePlan2013Member;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">2,500,000</a><span style="display:none;white-space:normal;text-align:left;">ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber<br>/ us-gaap_PlanNameAxis<br>= ptct_LongTermIncentivePlan2013Member<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding', window );">Annual increase in the number of shares outstanding on the first day of the fiscal year (as a percent)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding[us-gaap_PlanNameAxis=ptct_LongTermIncentivePlan2013Member;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">4.00%</a><span style="display:none;white-space:normal;text-align:left;">ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding<br>/ us-gaap_PlanNameAxis<br>= ptct_LongTermIncentivePlan2013Member<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the percentage of shares outstanding to be added annually on the first day of each fiscal year in the number of shares authorized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>ptct_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the number of shares to be added annually on the first day of each fiscal year in the number of shares authorized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>ptct_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the number of shares subject to outstanding awards used to calculate authorized shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>ptct_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the inducement grants for non-statutory stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>ptct_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>ptct_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of fully vested and expected to vest options that are exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of exercisable share options (fully vested and expected to vest) that may be converted as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the weighted-average exercise price (at which grantees can acquire the shares reserved for issuance) for exercisable stock options that are fully vested or expected to vest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for fully vested and expected to vest options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptct_EquityAndLongTermIncentivePlan2009Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptct_EquityAndLongTermIncentivePlan2009Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptct_LongTermIncentivePlan2013Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptct_LongTermIncentivePlan2013Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptct_StockIncentivePlan2013Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptct_StockIncentivePlan2013Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Net loss per share (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of basic and diluted net loss per share for common stockholders</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;"></font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:66.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:29.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">31,</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:66.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;font-size:10pt;">Numerator</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.78%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:66.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Net loss </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(37,915
				</td>
				<td valign="bottom" style="width:02.50%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,098
				</td>
				<td valign="bottom" style="width:02.22%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:66.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;font-size:10pt;">Denominator</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.78%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:66.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Denominator for basic and diluted net loss per share </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>33,067,752
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.78%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,492,487
				</td>
				<td valign="bottom" style="width:02.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:66.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;font-size:10pt;">Net loss per share:</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.78%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:66.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Basic and diluted </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1.15
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)*</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.58
				</td>
				<td valign="bottom" style="width:02.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font><font style="display: inline;font-size:10pt;">*</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">*</font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:3pt;"></font><font style="display: inline;font-size:10pt;">In the three months ended March&nbsp;31, 2015 and 2014, the Company experienced a net loss and therefore did not report any dilutive share impact.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of historical dilutive common share equivalents outstanding</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">As&nbsp;of&nbsp;March&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Stock Options </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,627,833&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,133,830&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Unvested restricted stock </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>364,970&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>748,456&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Total </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,992,803&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,882,286&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EKPAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock award plan - (Details 2) (Restricted stock, USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Restricted stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at the beginning of the period (in shares)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">718,400</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">(350,084)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">(3,346)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at the end of the period (in shares)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">364,970</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at the beginning of the period (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">$ 10.72</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">$ 10.59</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">$ 10.82</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at the end of the period (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">$ 10.85</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and contingencies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum lease payments</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;"></font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:80.60%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">2015 </font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.68%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,016&nbsp;
				</td>
				<td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.60%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">2016 </font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.02%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>946&nbsp;
				</td>
				<td valign="bottom" style="width:01.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.60%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">2017 </font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.02%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>923&nbsp;
				</td>
				<td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.60%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">2018 </font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.02%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,035&nbsp;
				</td>
				<td valign="bottom" style="width:01.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.60%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">2019 </font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>176&nbsp;
				</td>
				<td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.60%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,096&nbsp;
				</td>
				<td valign="bottom" style="width:01.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>The Company<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>The Company</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">The Company</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:28pt;"><font style="display: inline;font-weight:bold;font-size:10pt;">1.</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;font-weight:bold;font-size:3pt;"></font><font style="display: inline;font-weight:bold;font-size:10pt;">The Company</font></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">PTC Therapeutics,&nbsp;Inc. (the Company or PTC) was incorporated as a Delaware corporation on March&nbsp;31, 1998. PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics targeting an area of RNA biology referred to as post-transcriptional control. The letters &#x201C;PTC&#x201D; in the corporate name are an acronym for post-transcriptional control processes, which are the regulatory events that occur in cells during and after a messenger RNA is copied from DNA through the transcription process. The Company has discovered all of its compounds currently under development using its proprietary technologies. The Company plans to continue to develop these compounds both on its own and through selective collaboration arrangements with leading pharmaceutical and biotechnology companies. The Company believes that systematically targeting post-transcriptional control processes represents an unexploited approach to drug discovery and development. The Company&#x2019;s internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company&#x2019;s lead product, Translarna&#x2122; (ataluren) received marketing authorization from the European Commission, or EC, in August&nbsp;2014 for the treatment of nonsense mutation Duchenne muscular dystrophy, or nmDMD, in ambulatory patients age 5 years and over in the 31 member states of the European Economic Area, or EEA. This marketing authorization is subject to annual review and renewal by the European Medicines Agency, or EMA following its reassessment of the risk-benefit balance of the authorization and is further conditioned on the Company&#x2019;s ability to complete its global, confirmatory Phase 3 clinical trial in nmDMD, which it refers to as ACT DMD, and submit the final report, including additional efficacy and safety data from the trial, during 2015. See &#x201C;Risk Factors&#x2014;Risks Related to Regulatory Approval of our Product Candidates&#x201D; for further detail regarding the EMA&#x2019;s approval process, including a description of the risk-benefit balance.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company launched Translarna on a commercial basis in Germany in December&nbsp;2014 and expects to expand its launch activities across the EEA throughout 2015 and future years, subject to successful completion of pricing and reimbursement negotiations. Concurrently, the Company has been pursuing reimbursed early access programs in selected countries where those mechanisms exist, both within Europe and in those countries outside of Europe that will reference the marketing authorization described above.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company has not generated significant product revenue to date and is subject to a number of risks similar to those of other early stage companies, including dependence on key individuals, the difficulties inherent in the development of commercially usable products, the potential need to obtain additional capital necessary to fund the development of its products, and competition from other companies. As of March&nbsp;31, 2015, the Company had an accumulated deficit of approximately $460.4 million. The Company has financed its operations to date primarily through public offerings of common stock in February&nbsp;2014 and October&nbsp;2014, its initial public offering of common stock in June&nbsp;2013, private placements of its convertible preferred stock, collaborations, bank debt, convertible debt financings, grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease area addressed by the Company&#x2019;s product candidates.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6FAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Consolidated Balance Sheets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">125,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">125,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">33,483,306</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">32,898,392</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">33,483,306</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">32,898,392</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EJCAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of significant accounting policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Basis of Presentation</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The accompanying financial information as of March&nbsp;31, 2015 and for the three months ended March&nbsp;31, 2015 and 2014 has been prepared by the Company, without audit, pursuant to the rules&nbsp;and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP) have been condensed or omitted pursuant to such rules&nbsp;and regulations. These interim financial statements should be read in conjunction with the Company&#x2019;s audited financial statements as of December&nbsp;31, 2014 and notes thereto included in the 2014 Form&nbsp;10-K.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In the opinion of management, the unaudited financial information as of March&nbsp;31, 2015 and for the three months ended March&nbsp;31, 2015 and 2014 reflects all adjustments, which are normal recurring adjustments, necessary to present a fair statement of financial position, results of operations and cash flows. The results of operations for the three month period ended March&nbsp;31, 2015 are not necessarily indicative of the results to be expected for the year ended December&nbsp;31, 2015 or for any other interim period or for any other future year.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Use of estimates</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_InventoriesAndCostOfRevenuePolicyTextBlock', window );">Inventories and cost of product revenue</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Inventories and cost of product revenue</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">On August&nbsp;4, 2014, the Company was notified that the European Commission, or EC, granted marketing authorization for Translarna for the treatment of Duchenne muscular dystrophy caused by nonsense mutations, or nmDMD, in ambulatory patients aged five years and older. The marketing authorization allows the Company to market Translarna in the European Economic Area, or EEA, which is comprised of the 28 member states of the European Union plus Norway,&nbsp;Iceland and Liechtenstein. This marketing authorization is subject to annual review and renewal by the European Medicines Agency, or EMA following its reassessment of the risk-benefit balance of the authorization and is further conditioned on the Company&#x2019;s ability to complete its global, confirmatory Phase 3 clinical trial in nm DMD, which it refers to as ACT DMD, and submit the final report, including additional efficacy and safety data from the trial during 2015.&nbsp;&nbsp;The launch in these countries is on a country by country basis. The Company does do not have sufficient history or experience from which to accurately forecast product sales or demand generation. As such, the Company has not capitalized inventory and will not capitalize inventory until the completion of ACT DMD and satisfaction of the EMA conditions or until the Company can reasonably predict future product sales. The costs incurred related to the manufacturing of Translarna have been recorded as research and development expense in the statements of operations. The Company&#x2019;s cost of product sales includes royalties and other miscellaneous selling costs, which were not material and therefore included as a component of research and development costs in the current year presentation. The time period over which this inventory is consumed will depend on a number of factors, including the amount of future Translarna sales, and the ability to utilize inventory prior to its expiration date.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting standard</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Recently issued accounting standard</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In May&nbsp;2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No.&nbsp;2014-09, Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for annual reporting periods beginning after December&nbsp;15, 2016. Early application is not permitted. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. Presently, the Company is assessing what effect the adoption of ASU 2014-09 will have on its financial statements and accompanying notes.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In August&nbsp;2014, the FASB issued ASU 2014-15, &#x201C;Presentation of Financial Statements&#x2014;Going Concern&#x2014;Disclosures of Uncertainties about an entity&#x2019;s Ability to Continue as a Going Concern.&#x201D; ASU 2014-15 provides new guidance related to management&#x2019;s responsibility to evaluate whether there is substantial doubt about an entity&#x2019;s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards and to provide related footnote disclosures. This new guidance is effective for the annual period ending after December&nbsp;15, 2016, and for annual periods and interim periods thereafter. The requirements of ASU 2014-15 are not expected to have a significant impact on the Condensed Consolidated Financial Statements.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Revenue Recognition</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company recognizes revenue when amounts are realized or realizable and earned. Revenue is considered realizable and earned when the following criteria are met: (1)&nbsp;persuasive evidence of an arrangement exists; (2)&nbsp;delivery has occurred or services have been rendered; (3)&nbsp;the price is fixed or determinable; and (4)&nbsp;collection of the amounts due are reasonably assured.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;font-size:10pt;">Net Product Sales</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">PTC&#x2019;S net product sales have consisted solely of sales of Translarna for the treatment of nmDMD in territories outside of the U.S. The Company applies the revenue recognition guidance in accordance with Financial Accounting Standards Board (&#x201C;FASB&#x201D;) Accounting Standards Codification (&#x201C;ASC&#x201D;) Subtopic 605-15, Revenue Recognition&#x2014;Products. The Company recognizes revenue from product sales when there is persuasive evidence that an arrangement exists, title to product and associated risk of loss has passed to the customer, the price is fixed or determinable, collectability is reasonably assured and the Company has no further performance obligations.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company records revenue on sales where Translarna is available either on a commercial basis or through a reimbursed early access program and typically paid for by a government authority or institution. Prior to January&nbsp;1, 2015, the Company recognized revenue for commercial and reimbursed early access program sales on a cash basis once the product was shipped on behalf of the government authority or institution and payment had been received, if all other revenue recognition criteria were met. Beginning in the first quarter of 2015, the Company is recognizing revenue for Translarna as product is shipped, as the Company has established a pattern of collectability.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company records revenue net of estimated discounts and rebates. Allowances are recorded as a reduction of revenue at the time revenues from product sales are recognized. Allowances for government rebates and discounts are established at the time of delivery. These allowances are adjusted to reflect known changes in factors that may impact such allowances in the quarter those changes are known.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;font-size:10pt;">Collaboration and Grant Revenue</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The terms of these agreements typically include payments to the Company of one or more of the following: nonrefundable, upfront license fees; milestone payments; research funding and royalties on future product sales. In addition, the Company generates service revenue through agreements that generally provide for fees for research and development services and may include additional payments upon achievement of specified events.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company evaluates all contingent consideration earned, such as a milestone payment, using the criteria as provided by the Financial Accounting Standards Board (FASB), guidance on the milestone method of revenue recognition. At the inception of a collaboration arrangement, the Company evaluates if a milestone payment is substantive. The criteria requires that (1)&nbsp;the Company determines if the milestone is commensurate with either its performance to achieve the milestone or the enhancement of value resulting from our activities to achieve the milestone; (2)&nbsp;the milestone be related to past performance; and (3)&nbsp;the milestone be reasonable relative to all deliverable and payment terms of the collaboration arrangement. If these criteria are met then the contingent milestones can be considered a substantive milestone and will be recognized as revenue in the period that the milestone is achieved. The Company recognizes royalties as earned in accordance with the terms of various research and collaboration agreements. If not substantive, the contingent consideration is allocated to the existing units of accounting based on relative selling price and recognized following the same basis previously established for the associated unit of accounting.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company has the risks and rewards as the principal in the research and development activities.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_InventoriesAndCostOfRevenuePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for inventories and cost of revenue.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">ptct_InventoriesAndCostOfRevenuePolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>ptct_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EPCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">PTC THERAPEUTICS, INC.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001070081<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Mar. 31,  2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="dei_EntityCommonStockSharesOutstanding" onclick="toggleNextSibling(this);">33,848,276</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityCommonStockSharesOutstanding</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_AmendmentFlag</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentType</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityFilerCategory</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityRegistrantName</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">ptct_DocumentAndEntityInformationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>ptct_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E1AAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair value of financial instruments and marketable securities (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair value of financial instruments and marketable securities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of financial assets and liabilities that are required to be measured at fair value on a recurring basis</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;"></font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:55.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">March&nbsp;31,&nbsp;2015</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Quoted&nbsp;prices</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">in&nbsp;active</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">markets&nbsp;for</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">identical&nbsp;assets</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">(level&nbsp;1)</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Significant</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">other</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">observable</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">inputs</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">(level&nbsp;2)</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Significant</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">unobservable</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">inputs</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">(level&nbsp;3)</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Marketable securities </font></p>
				</td>
				<td valign="bottom" style="width:02.48%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>243,642&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>243,642&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Warrant liability </font></p>
				</td>
				<td valign="bottom" style="width:02.48%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.98%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>229&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>229&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;"></font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:55.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;2014</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Quoted&nbsp;</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">prices</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">in&nbsp;active</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">markets&nbsp;for</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">identical&nbsp;</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">assets</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">(level&nbsp;1)</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Significant</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">other</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">observable</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">inputs</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">(level&nbsp;2)</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Significant</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">unobservable</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">inputs</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">(level&nbsp;3)</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Marketable securities </font></p>
				</td>
				<td valign="bottom" style="width:02.48%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>265,493&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>265,493&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Warrant Liability </font></p>
				</td>
				<td valign="bottom" style="width:02.48%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.98%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>188&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>188&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of marketable securities accounted for as available-for-sale securities</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;"></font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:55.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">March&nbsp;31,&nbsp;2015</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Amortized</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Gross&nbsp;Unrealized</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Fair</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Cost</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Gains</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Losses</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Value</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Commercial paper </font></p>
				</td>
				<td valign="bottom" style="width:02.48%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,748
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,774
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Corporate debt securities </font></p>
				</td>
				<td valign="bottom" style="width:02.48%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.98%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>186,810
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(320
				</td>
				<td valign="bottom" style="width:02.50%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>186,534
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Government obligations </font></p>
				</td>
				<td valign="bottom" style="width:02.48%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>37,346
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(33
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>37,334
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>243,904
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>91
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(353
				</td>
				<td valign="bottom" style="width:02.50%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>243,642
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:34pt;"></font><font style="text-indent:0pt;margin-left:0pt; padding-right:34pt;text-align:left"><font style="display: inline;font-size:10pt;"></font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;font-size:10pt;"></font></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;"></font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:55.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;2014</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Amortized</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Gross&nbsp;Unrealized</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Fair</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Cost</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Gains</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Losses</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Value</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Corporate debt securities </font></p>
				</td>
				<td valign="bottom" style="width:02.48%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>230,379
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>80
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(428
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>230,031
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Government obligations </font></p>
				</td>
				<td valign="bottom" style="width:02.48%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,501
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(46
				</td>
				<td valign="bottom" style="width:02.50%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,462
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>265,880
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>87
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(474
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>265,493
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of marketable securities on the balance sheet</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;"></font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">March&nbsp;31,&nbsp;2015</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.00%;height:21.10pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;height:21.10pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:21.10pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Less&nbsp;Than</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">12&nbsp;Months</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;height:21.10pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:21.10pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">More&nbsp;Than</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">12&nbsp;Months</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;height:21.10pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Commercial paper </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,774&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Corporate debt securities </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>138,306&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48,228&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Government obligations </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,312&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26,022&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Total Marketable securities </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>169,392&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>74,250&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;"></font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;2014</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Less&nbsp;Than</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">12&nbsp;Months</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">More&nbsp;Than</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">12&nbsp;Months</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Corporate debt securities </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>157,758&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>72,273&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Government obligations </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,003&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>29,459&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Total Marketable securities </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>163,761&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101,732&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of changes in the fair value of the Company's Level 3 valuation for warrant liability</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:81.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Level&nbsp;3&nbsp;assets</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Beginning balance as of December&nbsp;31, 2014 </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>188&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.50%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Change in fair value of warrant liability </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>41&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Ending balance as of March&nbsp;31, 2015 </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>229&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19279-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26610-111562<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.2,12)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EZMAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Operations (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNetAbstract', window );"><strong>Revenues:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_NetProductSales', window );">Net product revenue</a></td>
        <td class="nump"><a title="ptct_NetProductSales" onclick="toggleNextSibling(this);">$ 5,069</a><span style="display:none;white-space:normal;text-align:left;">ptct_NetProductSales</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_CollaborationRevenue', window );">Collaboration revenue</a></td>
        <td class="nump"><a title="ptct_CollaborationRevenue" onclick="toggleNextSibling(this);">338</a><span style="display:none;white-space:normal;text-align:left;">ptct_CollaborationRevenue</span><span></span></td>
        <td class="nump"><a title="ptct_CollaborationRevenue" onclick="toggleNextSibling(this);">9,147</a><span style="display:none;white-space:normal;text-align:left;">ptct_CollaborationRevenue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Grant revenue</a></td>
        <td class="nump"><a title="us-gaap_RevenueFromGrants" onclick="toggleNextSibling(this);">2,075</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants</span><span></span></td>
        <td class="nump"><a title="us-gaap_RevenueFromGrants" onclick="toggleNextSibling(this);">70</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total revenues</a></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">7,482</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">9,217</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">27,938</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">15,889</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">17,615</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">7,540</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump"><a title="us-gaap_OperatingExpenses" onclick="toggleNextSibling(this);">45,553</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingExpenses</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingExpenses" onclick="toggleNextSibling(this);">23,429</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingExpenses</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(38,071)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(14,212)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
        <td class="nump"><a title="us-gaap_InterestIncomeExpenseNonoperatingNet" onclick="toggleNextSibling(this);">524</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestIncomeExpenseNonoperatingNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestIncomeExpenseNonoperatingNet" onclick="toggleNextSibling(this);">171</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestIncomeExpenseNonoperatingNet</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
        <td class="num"><a title="us-gaap_OtherNonoperatingIncomeExpense" onclick="toggleNextSibling(this);">(368)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingIncomeExpense</span><span></span></td>
        <td class="num"><a title="us-gaap_OtherNonoperatingIncomeExpense" onclick="toggleNextSibling(this);">(57)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingIncomeExpense</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (37,915)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (14,098)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares outstanding:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted (in shares)</a></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">33,067,752</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">24,492,487</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share - basic and diluted (in dollars per share)</a></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (1.15)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.58)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_CollaborationRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the amount of revenue earned from collaborative research and development and licensing agreements during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">ptct_CollaborationRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>ptct_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_NetProductSales">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the amount of revenue earned from product sales during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">ptct_NetProductSales</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>ptct_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of nonoperating interest income (expense).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 9<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueFromGrants</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNetAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SalesRevenueNetAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Warrants<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Warrants</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Warrants</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:28pt;"><font style="display: inline;font-weight:bold;font-size:10pt;">6.</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;font-weight:bold;font-size:3pt;"></font><font style="display: inline;font-weight:bold;font-size:10pt;">Warrants</font></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">All of the Company&#x2019;s outstanding warrants were classified as liabilities as of March&nbsp;31, 2015 and December&nbsp;31, 2014 because they contained non-standard antidilution provisions.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The following is a summary of the Company&#x2019;s outstanding warrants as of March&nbsp;31, 2015:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:55.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Warrant</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">shares</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Exercise</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">price</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Expiration</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:55.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Common stock </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,250&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>128.00&nbsp;
				</td>
				<td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:55.50%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Common stock </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,030&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>128.00&nbsp;
				</td>
				<td valign="bottom" style="width:01.08%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.42%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">2019 and 2020</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:55.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Common stock </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>130&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,520.00&nbsp;
				</td>
				<td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.42%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The following is a summary of the Company&#x2019;s outstanding warrants as of December&nbsp;31, 2014:</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:55.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Warrant</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">shares</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Exercise</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">price</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Expiration</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:55.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Common stock </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,250&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>128.00&nbsp;
				</td>
				<td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:55.50%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Common stock </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,030&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>128.00&nbsp;
				</td>
				<td valign="bottom" style="width:01.08%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.42%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">2019 and 2020</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:55.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Common stock </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>130&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,520.00&nbsp;
				</td>
				<td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.42%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accounts payable and accrued expenses<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accounts payable and accrued expenses</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accounts payable and accrued expenses</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:28pt;"><font style="display: inline;font-weight:bold;font-size:10pt;">5.</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;font-weight:bold;font-size:3pt;"></font><font style="display: inline;font-weight:bold;font-size:10pt;">Accounts payable and accrued expenses</font></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Accounts payable and accrued expenses at March&nbsp;31, 2015 and December&nbsp;31, 2014 consist of the following:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:66.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">March&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;"></font><font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:66.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Employee compensation, benefits, and related accruals </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,365&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,312&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:66.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Consulting and contracted research </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,691&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,349&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:66.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Professional fees </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,382&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,334&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:66.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Accounts payable </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,139&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,128&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:66.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Other </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,955&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,998&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,532&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>29,121&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E1AAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock award plan (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock award plan</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;"></font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Number&nbsp;of</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">options</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Weighted-</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">average</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">exercise</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">price</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Weighted-</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">average</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">remaining</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">contractual</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">term</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Aggregate</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">intrinsic</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">value</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">(in&nbsp;</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">thousands)</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Outstanding at December&nbsp;31, 2014 </font></p>
				</td>
				<td valign="bottom" style="width:02.48%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,432,972
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25.00
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Granted </font></p>
				</td>
				<td valign="bottom" style="width:02.48%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,456,550
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51.02
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Exercised </font></p>
				</td>
				<td valign="bottom" style="width:02.48%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(234,830
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12.86
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Forfeited </font></p>
				</td>
				<td valign="bottom" style="width:02.48%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(26,265
				</td>
				<td valign="bottom" style="width:02.50%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>47.52
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Expired </font></p>
				</td>
				<td valign="bottom" style="width:02.48%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(594
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>388.53
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Outstanding at March&nbsp;31, 2015 </font></p>
				</td>
				<td valign="bottom" style="width:02.48%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,627,833
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>33.60
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">8.9 years</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>140,399
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Vested or Expected to vest at March&nbsp;31, 2015 </font></p>
				</td>
				<td valign="bottom" style="width:02.48%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,332,726
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32.74
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">8.9 years</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>133,232
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Exercisable at March&nbsp;31, 2015 </font></p>
				</td>
				<td valign="bottom" style="width:02.48%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,037,262
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30.98
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">8.2 years</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>45,137
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used to estimate fair value of grants made on the date of grant</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:53.48%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.66%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:40.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Three&nbsp;months&nbsp;</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">ended&nbsp;March&nbsp;</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">31,&nbsp;2015</font></p>
				</td>
				<td valign="bottom" style="width:01.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:53.48%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Risk-free interest rate </font></p>
				</td>
				<td valign="bottom" style="width:04.66%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:40.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">1.54% &#x2014; 1.77%</font></p>
				</td>
				<td valign="bottom" style="width:01.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:53.48%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Expected volatility </font></p>
				</td>
				<td valign="bottom" style="width:04.66%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:40.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">67%-69%</font></p>
				</td>
				<td valign="bottom" style="width:01.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:53.48%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Expected term </font></p>
				</td>
				<td valign="bottom" style="width:04.66%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:40.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">5.50 - 6.11 years</font></p>
				</td>
				<td valign="bottom" style="width:01.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Summary of information on the Company's restricted stock</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:64.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="4" valign="bottom" style="width:32.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Restricted&nbsp;Stock</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Number&nbsp;of</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Shares</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Weighted</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Average&nbsp;</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Grant</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Date&nbsp;Fair&nbsp;</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Value</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">January&nbsp;1, 2015 </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>718,400
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10.72
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:64.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Granted </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Vested </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(350,084
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10.59
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:64.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Forfeited </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,346
				</td>
				<td valign="bottom" style="width:02.50%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10.82
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Unvested at March&nbsp;31, 2015 </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>364,970
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10.85
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of share-based compensation expense recorded in the statement of operations</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:64.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:32.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">31,</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Research and development </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,667&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,944&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:64.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Selling, general and administrative </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,081&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,761&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Total </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,748&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,705&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Other comprehensive income (loss) and accumulated other comprehensive items (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive income (loss) and accumulated other comprehensive items</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of other comprehensive income (loss) and the changes in accumulated other comprehensive items</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;"></font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:55.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Unrealized</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Gains/(Losses)</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">On</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Marketable</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Securities</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Foreign</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Currency</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Translation</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Total</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Accumulated</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Other</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Comprehensive</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Items</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:55.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Balance at December&nbsp;31, 2014 </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(387
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(350
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(737
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:55.50%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Other comprehensive income/(loss) before reclassifications </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>125
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(124
				</td>
				<td valign="bottom" style="width:02.50%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:55.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Amounts reclassified from other comprehensive items </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:55.50%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Other comprehensive income/(loss) </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>125
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(124
				</td>
				<td valign="bottom" style="width:02.50%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:55.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Balance at March&nbsp;31, 2015 </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(262
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(474
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(736
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">9. Commitments and contingencies</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Operating leases</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company leases office space under a noncancelable operating lease through February&nbsp;2019. Rent expense was approximately $0.3 million for the three months ended March&nbsp;31, 2015. The Company also leases certain office equipment under operating leases. Future minimum lease payments as of March&nbsp;31, 2015 are as follows:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;">
			<tr>
				<td valign="top" style="width:80.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">2015 </font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,016&nbsp;
				</td>
				<td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">2016 </font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>946&nbsp;
				</td>
				<td valign="bottom" style="width:01.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">2017 </font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>923&nbsp;
				</td>
				<td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">2018 </font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,035&nbsp;
				</td>
				<td valign="bottom" style="width:01.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">2019 </font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>176&nbsp;
				</td>
				<td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,096&nbsp;
				</td>
				<td valign="bottom" style="width:01.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Other contingencies</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Under various agreements, the Company will be required to pay royalties and milestone payments upon the successful development and commercialization of products. The Company has entered into funding agreements with The Wellcome Trust Limited (Wellcome Trust) for the research and development of small molecule compounds. To the extent that the Company develops and commercializes program intellectual property on a for-profit basis, it may become obligated to pay to Wellcome Trust development and regulatory milestone payments of up to an aggregate of $68.9 million and single-digit royalties on sales of any research program product. The Company&#x2019;s obligation to pay such royalties would continue on a country-by-country basis until the longer of the expiration of the last patent </font><a name="mrllPB12"></a><font style="display: inline;font-size:10pt;">in the program intellectual property in such country covering the research program product and the expiration of market exclusivity of such product in such country.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company has also entered into a collaboration agreement with the SMA Foundation. The Company may become obligated to pay the SMA Foundation single-digit royalties on worldwide net product sales of any collaboration product that we successfully develop and subsequently commercialize or, if the Company outlicenses rights to a collaboration product, a specified percentage of certain payments the Company receives from the licensee. The Company is not obligated to make such payments unless and until annual sales of a collaboration product exceed a designated threshold. The Company&#x2019;s obligation to make such payments would end upon its payment to the SMA Foundation of a specified amount.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company has employment agreements with certain employees that require the funding of a specific level of payments, if certain events, such as a change in control or termination without cause, occur.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Net loss per share<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net loss per share</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:28pt;"><font style="display: inline;font-weight:bold;font-size:10pt;">7.</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;font-weight:bold;font-size:3pt;"></font><font style="display: inline;font-weight:bold;font-size:10pt;">Net loss per share</font></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Basic earnings per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding. Diluted earnings per share is computed by dividing net income (loss) by the weighted-average number of common shares plus the effect of dilutive potential common shares outstanding during the period.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The following tables set forth the computation of basic and diluted net loss per share:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:66.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:29.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">31,</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:66.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;font-size:10pt;">Numerator</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.78%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:66.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Net loss </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(37,915
				</td>
				<td valign="bottom" style="width:02.50%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,098
				</td>
				<td valign="bottom" style="width:02.22%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:66.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;font-size:10pt;">Denominator</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.78%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:66.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Denominator for basic and diluted net loss per share </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>33,067,752
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.78%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,492,487
				</td>
				<td valign="bottom" style="width:02.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:66.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;font-size:10pt;">Net loss per share:</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.78%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:66.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Basic and diluted </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1.15
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)*</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.58
				</td>
				<td valign="bottom" style="width:02.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font><font style="display: inline;font-size:10pt;">*</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">*</font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:3pt;"></font><font style="display: inline;font-size:10pt;">In the three months ended March&nbsp;31, 2015 and 2014, the Company experienced a net loss and therefore did not report any dilutive share impact.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The following table shows historical dilutive common share equivalents outstanding, which are not included in the above historical calculation, as the effect of their inclusion is anti-dilutive during each period.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">As&nbsp;of&nbsp;March&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Stock Options </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,627,833&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,133,830&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Unvested restricted stock </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>364,970&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>748,456&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Total </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,992,803&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,882,286&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for earnings per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock award plan<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock award plan</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock award plan</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:28pt;"><font style="display: inline;font-weight:bold;font-size:10pt;">8.</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;font-weight:bold;font-size:3pt;"></font><font style="display: inline;font-weight:bold;font-size:10pt;">Stock award plan</font></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">On March&nbsp;5, 2013, the Company&#x2019;s Board of Directors approved the 2013 Stock Incentive Plan, which provides for the granting of stock option awards, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards in the aggregate of 739,937 shares of common stock. On March&nbsp;5, 2013, the Board approved a grant of 735,324 shares of restricted stock and 4,613 stock options. There are no additional shares available for issuance under this plan.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In May&nbsp;2013, the Company&#x2019;s Board of Directors and stockholders increased by 2,500,000 the number of shares authorized under the 2009 Equity and Long Term Incentive Plan, which provides for the granting of stock option awards, restricted stock awards, and other stock-based and cash-based awards.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In May&nbsp;2013, the Company&#x2019;s Board of Directors and stockholders approved the 2013 Long Term Incentive Plan, which became effective upon the closing of the Company&#x2019;s IPO.&nbsp;&nbsp;The 2013 Long Term Incentive Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards and other stock-based awards. The number of shares of common stock reserved for issuance under the 2013 Long Term Incentive Plan is the sum of (1)&nbsp;245,000 shares of common stock available for issuance under the Company&#x2019;s 2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan, (2)&nbsp;the number of shares (up to 3,040,444 shares) equal to the sum of the number of shares of common stock subject to outstanding awards under the Company&#x2019;s 1998 Employee, Director and Consultant Stock Option Plan, 2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right plus (3)&nbsp;an annual increase, to be added on the first day of each fiscal year until the expiration of the 2013 Long Term Incentive Plan, equal to the lowest of 2,500,000 shares of common stock, 4% of the number of shares of common stock outstanding on the first day of the fiscal year and an amount determined by the Company&#x2019;s Board of Directors.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">From January&nbsp;1, 2015 through March&nbsp;31, 2015, the Company issued a total of 1,456,550 stock options to various employees.&nbsp;&nbsp;Of those, 93,350 were inducement grants for non-statutory stock options. The inducement grant awards were made pursuant to the NASDAQ inducement grant exception as a material component of our new hires&#x2019; employment compensation.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">A summary of stock option activity is as follows:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Number&nbsp;of</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">options</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Weighted-</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">average</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">exercise</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">price</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Weighted-</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">average</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">remaining</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">contractual</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">term</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Aggregate</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">intrinsic</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">value</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">(in&nbsp;</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">thousands)</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Outstanding at December&nbsp;31, 2014 </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,432,972
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25.00
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Granted </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,456,550
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51.02
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Exercised </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(234,830
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12.86
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Forfeited </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(26,265
				</td>
				<td valign="bottom" style="width:02.50%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>47.52
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Expired </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(594
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>388.53
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Outstanding at March&nbsp;31, 2015 </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,627,833
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>33.60
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">8.9 years</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>140,399
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Vested or Expected to vest at March&nbsp;31, 2015 </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,332,726
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32.74
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">8.9 years</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>133,232
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Exercisable at March&nbsp;31, 2015 </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,037,262
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30.98
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">8.2 years</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>45,137
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The fair value of grants made in the three months ended March&nbsp;31, 2015 was contemporaneously estimated on the date of grant using the following assumptions:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 53.00%;margin-left:126pt;">
			<tr>
				<td valign="bottom" style="width:53.46%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.66%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:40.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Three&nbsp;months&nbsp;</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">ended&nbsp;March&nbsp;</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">31,&nbsp;2015</font></p>
				</td>
				<td valign="bottom" style="width:01.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:53.46%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Risk-free interest rate </font></p>
				</td>
				<td valign="bottom" style="width:04.66%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:40.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">1.54% &#x2014; 1.77%</font></p>
				</td>
				<td valign="bottom" style="width:01.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:53.46%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Expected volatility </font></p>
				</td>
				<td valign="bottom" style="width:04.66%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:40.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">67%-69%</font></p>
				</td>
				<td valign="bottom" style="width:01.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:53.46%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Expected term </font></p>
				</td>
				<td valign="bottom" style="width:04.66%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:40.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">5.50 - 6.11 years</font></p>
				</td>
				<td valign="bottom" style="width:01.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company assumed no expected dividends for all grants. The weighted average grant date fair value of options granted during the three month period ended March&nbsp;31, 2015 was $31.82 per share.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company uses the &#x201C;simplified method&#x201D; to determine the expected term of options. Under this method, the expected term represents the average of the vesting period and the contractual term. The expected volatility of share options was estimated based on a historical volatility analysis of peers that were similar to the Company with respect to industry, stage of life cycle, size, and financial leverage. The risk-free rate of the option is based on U.S. Government Securities Treasury Constant Maturities yields at the date of grant for a term similar to the expected term of the option.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;font-size:10pt;">Restricted Stock Awards</font><font style="display: inline;font-size:10pt;">&#x2014;Restricted stock awards are granted subject to certain restrictions, including in some cases service or time conditions (restricted stock). The grant-date fair value of restricted stock awards, which has been determined based upon the market value of the Company&#x2019;s shares on the grant date, is expensed over the vesting period.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The following table summarizes information on the Company&#x2019;s restricted stock:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:64.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="4" valign="bottom" style="width:32.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Restricted&nbsp;Stock</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Number&nbsp;of</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Shares</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Weighted</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Average&nbsp;</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Grant</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Date&nbsp;Fair&nbsp;</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Value</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">January&nbsp;1, 2015 </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>718,400
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10.72
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:64.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Granted </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Vested </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(350,084
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10.59
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:64.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Forfeited </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,346
				</td>
				<td valign="bottom" style="width:02.50%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10.82
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Unvested at March&nbsp;31, 2015 </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>364,970
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10.85
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company recorded share-based compensation expense in the statement of operations as follows:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:64.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:32.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">31,</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Research and development </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,667&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,944&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:64.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Selling, general and administrative </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,081&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,761&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Total </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,748&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,705&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">As of March&nbsp;31, 2015 there was approximately $70.6 million of total unrecognized compensation cost related to unvested share-based compensation arrangements granted under the 2009 Equity and Long Term Incentive Plan, 2013 Long Term Incentive Plan and equity awards made pursuant to the NASDAQ inducement grant exception for new hires. This cost is expected to be recognized as share-based compensation expense over the weighted average remaining service period of approximately 3.0 years.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Collaboration Revenue<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_CollaborationRevenuesDisclosureAbstract', window );"><strong>Collaboration Revenue</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_CollaborationRevenuesDisclosureTextBlock', window );">Collaboration Revenue</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:23pt;"><font style="display: inline;font-weight:bold;font-size:10pt;">10.</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;font-weight:bold;font-size:3pt;"></font><font style="display: inline;font-weight:bold;font-size:10pt;">Collaboration Revenue</font></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In January&nbsp;2014, the Company announced the initiation of a Phase 1 clinical program in its spinal muscular atrophy collaboration with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc. (Roche) and the Spinal Muscular Atrophy Foundation which triggered a $7.5 million milestone payment from Roche. The Company considered this milestone event substantive because the applicable criteria of its revenue recognition policy would be satisfied and recorded it as collaboration revenue for the three months ended March&nbsp;31, 2014.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_CollaborationRevenuesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">ptct_CollaborationRevenuesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>ptct_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_CollaborationRevenuesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the entire disclosure pertaining to collaboration revenue.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">ptct_CollaborationRevenuesDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>ptct_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2BAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Net loss per share (Details 2)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation</a></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="toggleNextSibling(this);">4,992,803</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="toggleNextSibling(this);">3,882,286</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation</a></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">4,627,833</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">3,133,830</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation</a></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">364,970</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">748,456</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Warrants</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of the Company's outstanding warrants</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The following is a summary of the Company&#x2019;s outstanding warrants as of March&nbsp;31, 2015:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:49.60%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Warrant</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">shares</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Exercise</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">price</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:21.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Expiration</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:49.60%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Common stock </font></p>
				</td>
				<td valign="bottom" style="width:01.52%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,250&nbsp;
				</td>
				<td valign="bottom" style="width:01.52%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.62%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>128.00&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:21.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:49.60%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Common stock </font></p>
				</td>
				<td valign="bottom" style="width:01.52%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.08%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,030&nbsp;
				</td>
				<td valign="bottom" style="width:01.52%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.62%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.68%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>128.00&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:21.14%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">2019 and 2020</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:49.60%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Common stock </font></p>
				</td>
				<td valign="bottom" style="width:01.52%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.08%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>130&nbsp;
				</td>
				<td valign="bottom" style="width:01.52%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.68%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,520.00&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:21.14%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The following is a summary of the Company&#x2019;s outstanding warrants as of December&nbsp;31, 2014:</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:49.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Warrant</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">shares</font></p>
				</td>
				<td valign="bottom" style="width:00.98%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Exercise</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">price</font></p>
				</td>
				<td valign="bottom" style="width:00.98%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:21.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Expiration</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:49.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Common stock </font></p>
				</td>
				<td valign="bottom" style="width:01.96%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,250&nbsp;
				</td>
				<td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>128.00&nbsp;
				</td>
				<td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:21.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:49.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Common stock </font></p>
				</td>
				<td valign="bottom" style="width:01.96%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,030&nbsp;
				</td>
				<td valign="bottom" style="width:00.98%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.94%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.56%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>128.00&nbsp;
				</td>
				<td valign="bottom" style="width:00.98%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:21.14%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">2019 and 2020</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:49.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Common stock </font></p>
				</td>
				<td valign="bottom" style="width:01.96%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>130&nbsp;
				</td>
				<td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.94%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.56%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,520.00&nbsp;
				</td>
				<td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:21.14%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section S99<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 28<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EWNAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Fair value of financial instruments and marketable securities (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities" onclick="toggleNextSibling(this);">$ 243,642</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities" onclick="toggleNextSibling(this);">$ 265,493</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Total</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">243,642</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_EstimateOfFairValueFairValueDisclosureMember<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">265,493</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_EstimateOfFairValueFairValueDisclosureMember<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
        <td class="nump"><a title="us-gaap_WarrantsAndRightsOutstanding[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">229</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WarrantsAndRightsOutstanding<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_EstimateOfFairValueFairValueDisclosureMember<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_WarrantsAndRightsOutstanding[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">188</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WarrantsAndRightsOutstanding<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_EstimateOfFairValueFairValueDisclosureMember<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant other observable inputs (level 2)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">243,642</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">265,493</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant unobservable inputs (level 3)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
        <td class="nump"><a title="us-gaap_WarrantsAndRightsOutstanding[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">$ 229</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WarrantsAndRightsOutstanding<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_WarrantsAndRightsOutstanding[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">$ 188</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WarrantsAndRightsOutstanding<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360136&amp;loc=d3e22054-111558<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (aa)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26610-111562<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EFHAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Consolidated Statements of Comprehensive Loss</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (37,915)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (14,098)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on marketable securities</a></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" onclick="toggleNextSibling(this);">125</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" onclick="toggleNextSibling(this);">10</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation loss</a></td>
        <td class="num"><a title="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" onclick="toggleNextSibling(this);">(124)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
        <td class="num"><a title="us-gaap_ComprehensiveIncomeNetOfTax" onclick="toggleNextSibling(this);">$ (37,914)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ComprehensiveIncomeNetOfTax</span><span></span></td>
        <td class="num"><a title="us-gaap_ComprehensiveIncomeNetOfTax" onclick="toggleNextSibling(this);">$ (14,088)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ComprehensiveIncomeNetOfTax</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35737396<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e557-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569643-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (c)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569643-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (c)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Other comprehensive income (loss) and accumulated other comprehensive items<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive income (loss) and accumulated other comprehensive items</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Other comprehensive income (loss) and accumulated other comprehensive items</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:28pt;"><font style="display: inline;font-weight:bold;font-size:10pt;">4.</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;font-weight:bold;font-size:3pt;"></font><font style="display: inline;font-weight:bold;font-size:10pt;">Other comprehensive income (loss) and accumulated other comprehensive items</font></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Other comprehensive income (loss) includes changes in equity that are excluded from net income (loss), such as unrealized gains and losses on marketable securities.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The following tables summarize other comprehensive income (loss) and the changes in accumulated other comprehensive items for the three months ended March&nbsp;31, 2015:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:55.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Unrealized</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Gains/(Losses)</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">On</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Marketable</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Securities</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Foreign</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Currency</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Translation</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Total</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Accumulated</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Other</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Comprehensive</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Items</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:55.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Balance at December&nbsp;31, 2014 </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(387
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(350
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(737
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:55.50%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Other comprehensive income/(loss) before reclassifications </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>125
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(124
				</td>
				<td valign="bottom" style="width:02.50%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:55.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Amounts reclassified from other comprehensive items </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:55.50%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Other comprehensive income/(loss) </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>125
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(124
				</td>
				<td valign="bottom" style="width:02.50%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:55.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Balance at March&nbsp;31, 2015 </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(262
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(474
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(736
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e689-108580<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669619-108580<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e640-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 17<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e716-108580<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e709-108580<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Reclassification Adjustments<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6522872<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EAAAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Fair value of financial instruments and marketable securities (Details 2) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Marketable securities accounted for as available-for-sale securities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost" onclick="toggleNextSibling(this);">$ 243,904</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost" onclick="toggleNextSibling(this);">$ 265,880</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" onclick="toggleNextSibling(this);">91</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" onclick="toggleNextSibling(this);">87</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" onclick="toggleNextSibling(this);">(353)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</span><span></span></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" onclick="toggleNextSibling(this);">(474)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities" onclick="toggleNextSibling(this);">243,642</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities" onclick="toggleNextSibling(this);">265,493</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Marketable securities accounted for as available-for-sale securities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember]" onclick="toggleNextSibling(this);">19,748</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax[us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember]" onclick="toggleNextSibling(this);">26</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember]" onclick="toggleNextSibling(this);">19,774</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Marketable securities accounted for as available-for-sale securities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">186,810</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">230,379</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax[us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">44</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax[us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">80</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax[us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">(320)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax[us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">(428)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">186,534</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">230,031</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_OtherDebtSecuritiesMember', window );">Government obligations</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Marketable securities accounted for as available-for-sale securities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_OtherDebtSecuritiesMember]" onclick="toggleNextSibling(this);">37,346</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_OtherDebtSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_OtherDebtSecuritiesMember]" onclick="toggleNextSibling(this);">35,501</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_OtherDebtSecuritiesMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax[us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_OtherDebtSecuritiesMember]" onclick="toggleNextSibling(this);">21</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_OtherDebtSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax[us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_OtherDebtSecuritiesMember]" onclick="toggleNextSibling(this);">7</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_OtherDebtSecuritiesMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax[us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_OtherDebtSecuritiesMember]" onclick="toggleNextSibling(this);">(33)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_OtherDebtSecuritiesMember</span><span></span></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax[us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_OtherDebtSecuritiesMember]" onclick="toggleNextSibling(this);">(46)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_OtherDebtSecuritiesMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_OtherDebtSecuritiesMember]" onclick="toggleNextSibling(this);">$ 37,334</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_OtherDebtSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_OtherDebtSecuritiesMember]" onclick="toggleNextSibling(this);">$ 35,462</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis<br>= us-gaap_OtherDebtSecuritiesMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360136&amp;loc=d3e22054-111558<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (aa)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26610-111562<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_OtherDebtSecuritiesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_OtherDebtSecuritiesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.1.9</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>75</ContextCount>
  <ElementCount>179</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>35</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/StatementConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - The Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureCompanys</Role>
      <ShortName>The Company</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of significant accounting policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Fair value of financial instruments and marketable securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecurities</Role>
      <ShortName>Fair value of financial instruments and marketable securities</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Other comprehensive income (loss) and accumulated other comprehensive items</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureOtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItems</Role>
      <ShortName>Other comprehensive income (loss) and accumulated other comprehensive items</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Accounts payable and accrued expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpenses</Role>
      <ShortName>Accounts payable and accrued expenses</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureWarrants</Role>
      <ShortName>Warrants</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Net loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net loss per share</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Stock award plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureStockAwardPlan</Role>
      <ShortName>Stock award plan</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Collaboration Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureCollaborationRevenue</Role>
      <ShortName>Collaboration Revenue</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of significant accounting policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Fair value of financial instruments and marketable securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesTables</Role>
      <ShortName>Fair value of financial instruments and marketable securities (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Other comprehensive income (loss) and accumulated other comprehensive items (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureOtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsTables</Role>
      <ShortName>Other comprehensive income (loss) and accumulated other comprehensive items (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Accounts payable and accrued expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesTables</Role>
      <ShortName>Accounts payable and accrued expenses (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureWarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Net loss per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net loss per share (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Stock award plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureStockAwardPlanTables</Role>
      <ShortName>Stock award plan (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Commitments and contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and contingencies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>40101 - Disclosure - The Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureCompany</Role>
      <ShortName>The Company</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Fair value of financial instruments and marketable securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails</Role>
      <ShortName>Fair value of financial instruments and marketable securities (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Fair value of financial instruments and marketable securities (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails2</Role>
      <ShortName>Fair value of financial instruments and marketable securities (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40303 - Disclosure - Fair value of financial instruments and marketable securities (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails3</Role>
      <ShortName>Fair value of financial instruments and marketable securities (Details 3)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40304 - Disclosure - Fair value of financial instruments and marketable securities (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails4</Role>
      <ShortName>Fair value of financial instruments and marketable securities (Details 4)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Other comprehensive income (loss) and accumulated other comprehensive items (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureOtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsDetails</Role>
      <ShortName>Other comprehensive income (loss) and accumulated other comprehensive items (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Accounts payable and accrued expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails</Role>
      <ShortName>Accounts payable and accrued expenses (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureWarrantsDetails</Role>
      <ShortName>Warrants (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Net loss per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureNetLossPerShareDetails</Role>
      <ShortName>Net loss per share (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Net loss per share (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureNetLossPerShareDetails2</Role>
      <ShortName>Net loss per share (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Stock award plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureStockAwardPlanDetails</Role>
      <ShortName>Stock award plan (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Stock award plan - (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureStockAwardPlanDetails2</Role>
      <ShortName>Stock award plan - (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40803 - Disclosure - Stock award plan (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureStockAwardPlanDetails3</Role>
      <ShortName>Stock award plan (Details 3)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Commitments and contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and contingencies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Collaboration Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DisclosureCollaborationRevenueDetails</Role>
      <ShortName>Collaboration Revenue (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">'Monetary' elements on report '40803 - Disclosure - Stock award plan (Details 3)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '40901 - Disclosure - Commitments and contingencies (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 00100 - Statement - Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2013'</Log>
    <Log type="Info">Process Flow-Through: 00105 - Statement - Consolidated Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 00200 - Statement - Consolidated Statements of Operations</Log>
    <Log type="Info">Process Flow-Through: 00300 - Statement - Consolidated Statements of Comprehensive Loss</Log>
    <Log type="Info">Process Flow-Through: 00400 - Statement - Consolidated Statements of Cash Flows</Log>
  </Logs>
  <InputFiles>
    <File>ptct-20150331.xml</File>
    <File>ptct-20150331.xsd</File>
    <File>ptct-20150331_cal.xml</File>
    <File>ptct-20150331_def.xml</File>
    <File>ptct-20150331_lab.xml</File>
    <File>ptct-20150331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EUPAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and contingencies (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Operating Leases, Rent Expense, Net</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseNet" onclick="toggleNextSibling(this);">$ 300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseNet</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2015</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" onclick="toggleNextSibling(this);">1,016,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2016</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" onclick="toggleNextSibling(this);">946,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2017</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" onclick="toggleNextSibling(this);">923,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2018</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" onclick="toggleNextSibling(this);">1,035,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2019</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" onclick="toggleNextSibling(this);">176,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total future minimum lease payments</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" onclick="toggleNextSibling(this);">4,096,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementProductAgreementMember', window );">Funding agreement | Wellcome trust | Maximum</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Other contingencies</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentAndRegulatoryMilestonePaymentObligations', window );">Development and regulatory milestone payments which the entity may be obligated to pay</a></td>
        <td class="nump"><a title="ptct_DevelopmentAndRegulatoryMilestonePaymentObligations[us-gaap_CounterpartyNameAxis=ptct_WellcomeTrustLimitedMember;us-gaap_RangeAxis=us-gaap_MaximumMember;us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementProductAgreementMember]" onclick="toggleNextSibling(this);">$ 68,900,000</a><span style="display:none;white-space:normal;text-align:left;">ptct_DevelopmentAndRegulatoryMilestonePaymentObligations<br>/ us-gaap_CounterpartyNameAxis<br>= ptct_WellcomeTrustLimitedMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember<br>/ us-gaap_TypeOfArrangementAxis<br>= us-gaap_CollaborativeArrangementProductAgreementMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_DevelopmentAndRegulatoryMilestonePaymentObligations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the development and regulatory milestones payments which the entity may be obligated to pay under certain contractual agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">ptct_DevelopmentAndRegulatoryMilestonePaymentObligations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>ptct_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementProductAgreementMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementProductAgreementMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accounts payable and accrued expenses (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accounts payable and accrued expenses</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of components of accounts payable and accrued expenses</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:66.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">March&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;"></font><font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:66.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Employee compensation, benefits, and related accruals </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,365&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,312&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:66.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Consulting and contracted research </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,691&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,349&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:66.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Professional fees </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,382&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,334&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:66.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Accounts payable </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,139&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,128&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:66.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Other </font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,955&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,998&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,532&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>29,121&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
